-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UVTAKJC50m/7jjNs+LguAW9WtbwggM/BEl+THnzM/EcXuXKU/Rw1Jxl1B1eJ38Dy PKnLylmcSc/u3n5Ai9bqlA== 0000950123-10-019392.txt : 20100301 0000950123-10-019392.hdr.sgml : 20100301 20100301165002 ACCESSION NUMBER: 0000950123-10-019392 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 27 CONFORMED PERIOD OF REPORT: 20100103 FILED AS OF DATE: 20100301 DATE AS OF CHANGE: 20100301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 0209 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03215 FILM NUMBER: 10645237 BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 732-524-2455 MAIL ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 10-K 1 y80744e10vk.htm FORM 10-K e10vk
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-K
 
ANNUAL REPORT PURSUANT TO SECTION 13 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the fiscal year ended January 3, 2010 Commission file number 1-3215
 
JOHNSON & JOHNSON
 
(Exact name of registrant as specified in its charter)
 
     
New Jersey
  22-1024240
(State of incorporation)   (I.R.S. Employer Identification No.)
     
One Johnson & Johnson Plaza
New Brunswick, New Jersey
  08933
(Address of principal executive offices)   (Zip Code)
 
Registrant’s telephone number, including area code: (732) 524-0400
 
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT
 
     
Title of each class
 
Name of each exchange on which registered
 
Common Stock, Par Value $1.00   New York Stock Exchange
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes þ  No o
 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.  Yes o  No þ
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes þ  No o
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes þ  No o
 
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act).
Large accelerated filer  þ     Accelerated filer  o     Non-accelerated filer  o     Smaller reporting company  o
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o  No þ
 
The aggregate market value of the Common Stock held by non-affiliates computed by reference to the price at which the Common Stock was last sold as of the last business day of the registrant’s most recently completed second fiscal quarter was approximately $156 billion.
 
On February 8, 2010 there were 2,751,927,062 shares of Common Stock outstanding.
 
DOCUMENTS INCORPORATED BY REFERENCE
 
     
Parts I, II and III:
  Portions of registrant’s annual report to shareholders for fiscal year 2009 (the “Annual Report”).
Parts I and III:
  Portions of registrant’s proxy statement for its 2010 annual meeting of shareholders filed within 120 days after the close of the registrant’s fiscal year (the “Proxy Statement”).
 


 

             
Item
     
Page
 
 
1.
  Business     1  
      General     1  
      Segments of Business     1  
      Geographic Areas     2  
      Raw Materials     2  
      Patents and Trademarks     2  
      Seasonality     2  
      Competition     3  
      Research and Development     3  
      Environment     3  
      Regulation     3  
      Available Information     4  
1A.
  Risk Factors     4  
1B.
  Unresolved Staff Comments     4  
2.
  Properties     4  
3.
  Legal Proceedings     5  
4.
  Submission of Matters to a Vote of Security Holders     5  
    Executive Officers of the Registrant     5  
 
5.
  Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities     6  
6.
  Selected Financial Data     7  
7.
  Management’s Discussion and Analysis of Financial Condition and Results of Operation     7  
7A.
  Quantitative and Qualitative Disclosures About Market Risk     7  
8.
  Financial Statements and Supplementary Data     7  
9.
  Changes in and Disagreements With Accountants on Accounting and Financial Disclosure     8  
9A.
  Controls and Procedures     8  
9B.
  Other Information     8  
 
10.
  Directors, Executive Officers and Corporate Governance     9  
11.
  Executive Compensation     9  
12.
  Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters     9  
13.
  Certain Relationships and Related Transactions, and Director Independence     10  
14.
  Principal Accountant Fees and Services     10  
 
15.
  Exhibits and Financial Statement Schedules     11  
    Schedule II — Valuation and Qualifying Accounts     12  
    Signatures     13  
    Report of Independent Registered Public Accounting Firm on Financial Statement Schedule     15  
    Exhibit Index     16  
 EX-10.W
 EX-12
 EX-13
 EX-21
 EX-23
 EX-31.A
 EX-31.B
 EX-32.A
 EX-32.B
 EX-99
 EX-101 INSTANCE DOCUMENT
 EX-101 SCHEMA DOCUMENT
 EX-101 CALCULATION LINKBASE DOCUMENT
 EX-101 LABELS LINKBASE DOCUMENT
 EX-101 PRESENTATION LINKBASE DOCUMENT
 EX-101 DEFINITION LINKBASE DOCUMENT


Table of Contents

 
PART I
 
Item 1.  BUSINESS
 
General
 
Johnson & Johnson and its subsidiaries have approximately 115,500 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. Johnson & Johnson is a holding company, which has more than 250 operating companies conducting business in virtually all countries of the world. Johnson & Johnson’s primary focus has been on products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.
 
The Company’s structure is based on the principle of decentralized management. The Executive Committee of Johnson & Johnson is the principal management group responsible for the operations and allocation of the resources of the Company. This Committee oversees and coordinates the activities of the Consumer, Pharmaceutical and Medical Devices and Diagnostics business segments. Each subsidiary within the business segments is, with some exceptions, managed by citizens of the country where it is located.
 
Segments of Business
 
Johnson & Johnson’s operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. Additional information required by this item is incorporated herein by reference to the narrative and tabular (but not the graphic) descriptions of segments and operating results under the captions “Management’s Discussion and Analysis of Results of Operations and Financial Condition” on pages 26 through 35 and Note 18 “Segments of Business and Geographic Areas” under “Notes to Consolidated Financial Statements” on page 55 of the Annual Report, filed as Exhibit 13 to this Report on Form 10-K.
 
Consumer
 
The Consumer segment includes a broad range of products used in the baby care, skin care, oral care, wound care and women’s health care fields, as well as nutritional and over-the-counter pharmaceutical products, and wellness and prevention platforms. The Baby Care franchise includes the JOHNSON’S® Baby line of products. Major brands in the Skin Care franchise include the AVEENO®; CLEAN & CLEAR®; JOHNSON’S® Adult; NEUTROGENA®; RoC®; LUBRIDERM®; Dabao; and Vendôme product lines. The Oral Care franchise includes the LISTERINE® and REACH® oral care lines of products. The Wound Care franchise includes BAND-AID® brand adhesive bandages and PURELL® instant hand sanitizer products. Major brands in the Women’s Health franchise are the CAREFREE® Pantiliners; STAYFREE® sanitary protection products; and Vania Expansion products. The nutritional and over-the-counter lines include SPLENDA®, No Calorie Sweetener; the broad family of TYLENOL® acetaminophen products; SUDAFED® cold, flu and allergy products; ZYRTEC® allergy products; MOTRIN® IB ibuprofen products; and PEPCID® AC Acid Controller from Johnson & Johnson • Merck Consumer Pharmaceuticals Co. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world.
 
Pharmaceutical
 
The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. These products are distributed directly to retailers, wholesalers and health care professionals for prescription use. Key products in the Pharmaceutical segment include: REMICADE® (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases; PROCRIT® (Epoetin alfa, sold outside the U.S. as EPREX®), a biotechnology-derived product that stimulates red blood cell production; LEVAQUIN® (levofloxacin) in the anti-infective field; RISPERDAL® CONSTA® (risperidone), a long-acting injectable for the treatment of schizophrenia; CONCERTA® (methylphenidate HCl), a product for the treatment of attention deficit hyperactivity disorder; ACIPHEX®/PARIET®, a proton pump inhibitor co-marketed with Eisai Inc.; DURAGESIC®/Fentanyl Transdermal (fentanyl transdermal system, sold outside the U.S. as DUROGESIC®), a treatment for chronic pain that offers a novel delivery system; VELCADE® (bortezomib), a product for the treatment for multiple myeloma; PREZISTA® (darunavir) for the treatment of HIV/AIDS patients; and INVEGA® (paliperidone), a once-daily atypical antipsychotic.


Table of Contents

 
Medical Devices and Diagnostics
 
The Medical Devices and Diagnostics segment includes a broad range of products distributed to wholesalers, hospitals and retailers, used principally in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. These products include Cordis’ circulatory disease management products; DePuy’s orthopaedic joint reconstruction, spinal care and sports medicine products; Ethicon’s surgical care, aesthetics and women’s health products; Ethicon Endo-Surgery’s minimally invasive surgical products; LifeScan’s blood glucose monitoring and insulin delivery products; Ortho-Clinical Diagnostics’ professional diagnostic products; and Vistakon’s disposable contact lenses. Distribution to these health care professional markets is done both directly and through surgical supply and other dealers.
 
Geographic Areas
 
The international business of Johnson & Johnson is conducted by subsidiaries located in 59 countries outside the United States, which are selling products in virtually all countries throughout the world. The products made and sold in the international business include many of those described above under “— Segments of Business — Consumer,” “— Pharmaceutical” and “— Medical Devices and Diagnostics.” However, the principal markets, products and methods of distribution in the international business vary with the country and the culture. The products sold in international business include not only those developed in the United States, but also those developed by subsidiaries abroad.
 
Investments and activities in some countries outside the United States are subject to higher risks than comparable U.S. activities because the investment and commercial climate is influenced by restrictive economic policies and political uncertainties.
 
Raw Materials
 
Raw materials essential to Johnson & Johnson’s operating companies’ businesses are generally readily available from multiple sources.
 
Patents and Trademarks
 
Johnson & Johnson and its subsidiaries have made a practice of obtaining patent protection on their products and processes where possible. They own or are licensed under a number of patents relating to their products and manufacturing processes, which in the aggregate are believed to be of material importance to Johnson & Johnson in the operation of its businesses. Sales of the Company’s largest product, REMICADE® (infliximab), accounted for approximately 7% of Johnson & Johnson’s total revenues for fiscal 2009. Accordingly, the patents related to this product are believed to be material to Johnson & Johnson.
 
During 2007 through 2009, RISPERDAL® (risperidone) oral and TOPAMAX® (topiramate) lost basic patent protection and market exclusivity and became subject to generic competition in the United States and international markets. RISPERDAL® oral sales declined by 57.7% and 37.8% in 2009 and 2008, respectively. TOPAMAX® lost market exclusivity in March 2009 and sales declined by 57.9% as compared to 2008. The next significant patent scheduled to expire on December 20, 2010 is for LEVAQUIN® (levofloxacin), which accounted for 2.5% of the Company’s 2009 sales. A pediatric extension for LEVAQUIN® was granted by the U.S. Food and Drug Administration (“FDA”), which extends market exclusivity in the United States through June 20, 2011.
 
Johnson & Johnson’s operating companies have made a practice of selling their products under trademarks and of obtaining protection for these trademarks by all available means. These trademarks are protected by registration in the United States and other countries where such products are marketed. Johnson & Johnson considers these trademarks in the aggregate to be of material importance in the operation of its businesses.
 
Seasonality
 
Worldwide sales do not reflect any significant degree of seasonality; however, spending has been heavier in the fourth quarter of each year than in other quarters. This reflects increased spending decisions, principally for advertising and research and development activity.


2


Table of Contents

 
Competition
 
In all of their product lines, Johnson & Johnson’s operating companies compete with companies both large and small, and both local and global, located throughout the world. Competition exists in all product lines without regard to the number and size of the competing companies involved. Competition in research, involving the development and the improvement of new and existing products and processes, is particularly significant. The development of new and innovative products is important to Johnson & Johnson’s success in all areas of its business. This also includes protecting the Company’s portfolio of intellectual property. The competitive environment requires substantial investments in continuing research and in maintaining sales forces. In addition, the development and maintenance of customer demand for the Company’s consumer products involves significant expenditures for advertising and promotion.
 
Research and Development
 
Research activities represent a significant part of Johnson & Johnson’s subsidiaries’ businesses. Major research facilities are located not only in the United States, but also in Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore and the United Kingdom. The costs of worldwide Company-sponsored research activities relating to the development of new products, improvement of existing products, technical support of products and compliance with governmental regulations for the protection of consumers and patients (excluding purchased in-process research and development charges for fiscal 2008 and 2007), amounted to $7.0 billion, $7.6 billion and $7.7 billion for fiscal years 2009, 2008 and 2007, respectively. These costs are charged directly to expense, or directly against income, in the year in which incurred.
 
Environment
 
Johnson & Johnson’s operating companies are subject to a variety of U.S. and international environmental protection measures. Johnson & Johnson believes that its operations comply in all material respects with applicable environmental laws and regulations. Johnson & Johnson’s compliance with these requirements did not during the past year, and is not expected to, have a material effect upon its capital expenditures, cash flows, earnings or competitive position.
 
Regulation
 
Most of Johnson & Johnson’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation. In the United States, the drug, device, diagnostics and cosmetic industries have long been subject to regulation by various federal and state agencies, primarily as to product safety, efficacy, manufacturing, advertising, labeling and safety reporting. The exercise of broad regulatory powers by the FDA continues to result in increases in the amounts of testing and documentation required for FDA clearance of new drugs and devices and a corresponding increase in the expense of product introduction. Similar trends are also evident in major markets outside of the United States.
 
The costs of human health care have been and continue to be a subject of study, investigation and regulation by governmental agencies and legislative bodies around the world. In the United States, attention has been focused on drug prices and profits and programs that encourage doctors to write prescriptions for particular drugs or recommend, use or purchase particular medical devices. Payers have become a more potent force in the market place and increased attention is being paid to drug and medical device pricing, appropriate drug and medical device utilization and the quality and costs of health care.
 
The regulatory agencies under whose purview Johnson & Johnson’s operating companies operate have administrative powers that may subject those companies to such actions as product withdrawals, recalls, seizure of products and other civil and criminal sanctions. In some cases, Johnson & Johnson’s operating companies may deem it advisable to initiate product recalls.
 
In addition, business practices in the health care industry have come under increased scrutiny, particularly in the United States, by government agencies and state attorneys general, and resulting investigations and prosecutions carry the risk of significant civil and criminal penalties.


3


Table of Contents

Available Information
 
The Company’s main corporate Web site address is www.jnj.com. Copies of Johnson & Johnson’s Quarterly Reports on Form 10-Q, Annual Report on Form 10-K and Current Reports on Form 8-K filed or furnished to the U.S. Securities and Exchange Commission (the “SEC”), and any amendments to the foregoing, will be provided without charge to any shareholder submitting a written request to the Secretary at the principal executive offices of the Company or by calling 1-800-950-5089. All of the Company’s SEC filings are also available on the Company’s Web site at www.investor.jnj.com/governance/materials.cfm, as soon as reasonably practicable after having been electronically filed or furnished to the SEC. All SEC filings are also available at the SEC’s Web site at www.sec.gov. In addition, the written charters of the Audit Committee, the Compensation & Benefits Committee and the Nominating & Corporate Governance Committee of the Board of Directors and the Company’s Principles of Corporate Governance, Policy on Business Conduct for employees and Code of Business Conduct & Ethics for Members of the Board of Directors and Executive Officers are available at the www.investor.jnj.com/governance/materials.cfm Web site address and will be provided without charge to any shareholder submitting a written request, as provided above.
 
Item 1A.  RISK FACTORS
 
Not applicable. Some important factors that could cause the Company’s actual results to differ from the Company’s expectations in any forward-looking statements in this Report are set forth in Exhibit 99 to this Report on Form 10-K.
 
Item 1B.  UNRESOLVED STAFF COMMENTS
 
Not applicable.
 
Item 2.  PROPERTIES
 
Johnson & Johnson and its subsidiaries operate 143 manufacturing facilities occupying approximately 21.4 million square feet of floor space.
 
The manufacturing facilities are used by the industry segments of Johnson & Johnson’s business approximately as follows:
 
         
    Square Feet
 
    (in
 
  Segment
 
thousands)
 
 
Consumer
    6,825  
Pharmaceutical
    6,369  
Medical Devices and Diagnostics
    8,251  
         
Worldwide Total
    21,445  
         
 
Within the United States, 7 facilities are used by the Consumer segment, 12 by the Pharmaceutical segment and 37 by the Medical Devices and Diagnostics segment. Johnson & Johnson’s manufacturing operations outside the United States are often conducted in facilities that serve more than one business segment.
 
The locations of the manufacturing facilities by major geographic areas of the world are as follows:
 
                 
          Square Feet
 
    Number of
    (in
 
Geographic Area
 
Facilities
   
thousands)
 
 
United States
         56       7,489  
Europe
    38       7,336  
Western Hemisphere, excluding U.S.
    16       3,372  
Africa, Asia and Pacific
    33       3,248  
                 
Worldwide Total
    143       21,445  
                 


4


Table of Contents

In addition to the manufacturing facilities discussed above, Johnson & Johnson and its subsidiaries maintain numerous office and warehouse facilities throughout the world. Research facilities are also discussed in Item 1 under “Business — Research and Development.”
 
Johnson & Johnson and its subsidiaries generally seek to own their manufacturing facilities, although some, principally in locations abroad, are leased. Office and warehouse facilities are often leased.
 
Johnson & Johnson’s properties are maintained in good operating condition and repair and are well utilized.
 
For information regarding lease obligations, see Note 16 “Rental Expense and Lease Commitments” under “Notes to Consolidated Financial Statements” on page 53 of the Annual Report, filed as Exhibit 13 to this Report on Form 10-K. Segment information on additions to property, plant and equipment is contained in Note 18 “Segments of Business and Geographic Areas” under “Notes to Consolidated Financial Statements” on page 55 of the Annual Report, filed as Exhibit 13 to this Report on Form 10-K.
 
Item 3.  LEGAL PROCEEDINGS
 
The information set forth in Note 21 “Legal Proceedings” under “Notes to Consolidated Financial Statements” on pages 57 through 63 of the Annual Report is incorporated herein by reference and filed as Exhibit 13 to this Report on Form 10-K.
 
The Company or its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and comparable state laws, in which the primary relief sought is the cost of past and future remediation. While it is not feasible to predict or determine the outcome of these proceedings, in the opinion of the Company, such proceedings would not have a material adverse effect on the results of operations, cash flows or financial position of the Company.
 
Item 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
 
Not applicable.
 
EXECUTIVE OFFICERS OF THE REGISTRANT
 
Listed below are the executive officers of Johnson & Johnson as of February 8, 2010, each of whom, unless otherwise indicated below, has been an employee of the Company or its affiliates and held the position indicated during the past five years. There are no family relationships between any of the executive officers, and there is no arrangement or understanding between any executive officer and any other person pursuant to which the executive officer was selected. At the annual meeting of the Board of Directors, the executive officers are elected by the Board to hold office for one year and until their respective successors are elected and qualified, or until earlier resignation or removal.
 
Information with regard to the directors of the Company, including those of the following executive officers who are directors, is incorporated herein by reference to the material captioned “Election of Directors” in the Proxy Statement.
 
             
Name
 
Age
   
Position
 
Dominic J. Caruso
    52    
Member, Executive Committee; Vice President, Finance; Chief Financial Officer(a)
Russell C. Deyo
    60    
Member, Executive Committee; Vice President, Human Resources and General Counsel(b)
Colleen A. Goggins
    55    
Member, Executive Committee; Worldwide Chairman, Consumer Group(c)
Alex Gorsky
    49    
Member, Executive Committee; Worldwide Chairman, Medical Devices and Diagnostics Group(d)
Sherilyn S. McCoy
    51    
Member, Executive Committee; Worldwide Chairman, Pharmaceuticals Group(e)
William C. Weldon
    61    
Chairman, Board of Directors; Chairman, Executive Committee; Chief Executive Officer


5


Table of Contents

(a) Mr. D. J. Caruso joined the Company in 1999 when the Company acquired Centocor, Inc. At the time of that acquisition, he had been Senior Vice President, Finance of Centocor. Mr. Caruso was named Vice President, Finance of Ortho-McNeil Pharmaceutical, Inc., a subsidiary of the Company, in 2001 and Vice President, Group Finance of the Company’s Medical Devices and Diagnostics Group in 2003. In 2005, Mr. Caruso was named Vice President of the Company’s Group Finance organization. Mr. Caruso became a Member of the Executive Committee and Vice President, Finance and Chief Financial Officer in 2007.
 
(b) Mr. R. C. Deyo joined the Company in 1985 and became Associate General Counsel in 1991. He became a Member of the Executive Committee and Vice President, Administration in 1996 and Vice President, General Counsel in 2004. Mr. Deyo was given the additional responsibility for Human Resources in November 2009.
 
(c) Ms. C. A. Goggins joined the Company in 1981 and held various positions before becoming President of Personal Products Company, a subsidiary of the Company, in 1994. She was named President of Johnson & Johnson Consumer Companies, Inc. in 1995 and Company Group Chairman, North America, Johnson & Johnson Consumer Products in 1998. Ms. Goggins became a Member of the Executive Committee and Worldwide Chairman, Consumer & Personal Care Group in 2001, now known as the Consumer Group.
 
(d) Mr. A. Gorsky joined the Company in 2008 as Company Group Chairman and Worldwide Franchise Chairman for Ethicon, Inc., a subsidiary of the Company. Previously, he was head of the North American pharmaceuticals business at Novartis Pharmaceuticals Corporation from 2004 to 2008. Prior to Novartis, Mr. Gorsky served in various management positions at Johnson & Johnson, including Company Group Chairman for the Company’s pharmaceutical business in Europe, Middle East and Africa and President of Janssen Pharmaceutica Inc. (U.S.), a subsidiary of the Company. In January 2009, he became a Member of the Executive Committee and Worldwide Chairman, Surgical Care Group. In September 2009, Mr. Gorsky became Worldwide Chairman, Medical Devices and Diagnostics Group.
 
(e) Ms. S. S. McCoy joined the Company in 1982 as an Associate Scientist in Research & Development for Personal Products Company, a subsidiary of the Company. She was named Vice President, Research & Development for the Personal Products Worldwide Division of McNEIL-PPC, Inc., a subsidiary of the Company, in 1995, and Vice President, Marketing for its Skin Care franchise in 2000. In 2002, Ms. McCoy became Global President for its Baby and Wound Care franchise. She was named Company Group Chairman and Worldwide Franchise Chairman of Ethicon, Inc., a subsidiary of the Company, in 2005. In 2008 she became a Member of the Executive Committee and Worldwide Chairman, Surgical Care Group. In 2009, she became Worldwide Chairman, Pharmaceuticals Group.
 
PART II
 
Item 5.   MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
 
As of February 8, 2010, there were 185,121 record holders of Common Stock of the Company. Additional information called for by this item is incorporated herein by reference to: the material under the captions “Management’s Discussion and Analysis of Results of Operations and Financial Condition — Liquidity and Capital Resources — Share Repurchase and Dividends” on page 32; “ — Other Information — Common Stock Market Prices” on page 35; Note 17 “Common Stock, Stock Option Plans and Stock Compensation Agreements” under “Notes to Consolidated Financial Statements” on pages 53 and 54; and “Shareholder Return Performance Graphs” on page 67 of the Annual Report, filed as Exhibit 13 to this Report on Form 10-K; and Item 12 “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters — Equity Compensation Plan Information” of this Report on Form 10-K.
 
Issuer Purchases of Equity Securities
 
On July 9, 2007, the Company announced that its Board of Directors approved a stock repurchase program, authorizing the Company to buy back up to $10 billion of the Company’s Common Stock. Share repurchases take place on the open market from time to time based on market conditions. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Any shares acquired will be available for general


6


Table of Contents

corporate purposes. The Company funds the share repurchase program through a combination of available cash and debt. The Company does not expect its triple-A credit rating to be affected by the share repurchase program. As of January 3, 2010, an aggregate of 140,377,700 shares were purchased for a total of $8.9 billion since the inception of the repurchase program announced on July 9, 2007.
 
In addition, Common Stock purchases on the open market are made as part of a systematic plan related to the Company’s compensation programs.
 
The following table provides information with respect to Common Stock purchases by the Company during the fiscal fourth quarter of 2009.
 
                                 
                Total Number
       
                of Shares
    Remaining
 
                Purchased as
    Maximum Number
 
                Part of
    of Shares that
 
    Total Number
    Avg. Price
    Publicly Announced
    May Yet Be Purchased
 
    of Shares
    Paid Per
    Plans or
    Under the Plans
 
Period
  Purchased(1)     Share     Programs     or Programs(2)  
 
September 28, 2009 through October 25, 2010
    984,600     $ 60.53                
October 26, 2009 through November 22, 2009
    3,963,000     $ 59.74                
November 23, 2009 through January 3, 2010
    10,343,500     $ 64.00                
Total
    15,291,100                     16,766,460  
 
 
(1)  During the fiscal fourth quarter of 2009, the Company did not repurchase any shares of the Company’s Common Stock pursuant to the repurchase program that was publicly announced on July 9, 2007. The Company did repurchase an aggregate of 15,291,100 shares in open-market transactions outside of the program.
 
(2)  As of January 3, 2010, based on the closing price of the Company’s Common Stock on the New York Stock Exchange on December 31, 2009 of $64.41 per share.
 
Item 6.  SELECTED FINANCIAL DATA
 
The information called for by this item is incorporated herein by reference to the material under the caption “Summary of Operations and Statistical Data 1999-2009” on page 66 of the Annual Report, filed as Exhibit 13 to this Report on Form 10-K.
 
Item 7.   MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION
 
The information called for by this item is incorporated herein by reference to the narrative and tabular (but not the graphic) material under the caption “Management’s Discussion and Analysis of Results of Operations and Financial Condition” on pages 26 through 35 of the Annual Report, filed as Exhibit 13 to this Report on Form 10-K.
 
Item 7A.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
The information called for by this item is incorporated herein by reference to the material under the caption “Management’s Discussion and Analysis of Results of Operations and Financial Condition — Liquidity and Capital Resources — Financing and Market Risk” on page 32 and Note 1 “Summary of Significant Accounting Policies — Financial Instruments” under “Notes to Consolidated Financial Statements” on page 42 of the Annual Report, filed as Exhibit 13 to this Report on Form 10-K.
 
Item 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
 
The information called for by this item is incorporated herein by reference to the Audited Consolidated Financial Statements and Notes thereto and the material under the caption “Report of Independent Registered Public Accounting Firm” on pages 36 through 65 of the Annual Report, filed as Exhibit 13 to this Report on Form 10-K.


7


Table of Contents

Item 9.   CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
 
Not applicable.
 
Item 9A.   CONTROLS AND PROCEDURES
 
Disclosure Controls and Procedures.  At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. William C. Weldon, Chairman and Chief Executive Officer, and Dominic J. Caruso, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Weldon and Caruso concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were effective.
 
Management’s Report on Internal Control Over Financial Reporting.  Under Section 404 of the Sarbanes-Oxley Act of 2002, management is required to assess the effectiveness of the Company’s internal control over financial reporting as of the end of each fiscal year and report, based on that assessment, whether the Company’s internal control over financial reporting is effective.
 
Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is designed to provide reasonable assurance as to the reliability of the Company’s financial reporting and the preparation of external financial statements in accordance with generally accepted accounting principles.
 
Internal control over financial reporting, no matter how well designed, has inherent limitations. Therefore, internal control over financial reporting determined to be effective can provide only reasonable assurance with respect to financial statement preparation and may not prevent or detect all misstatements. Moreover, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
 
The Company’s management has assessed the effectiveness of the Company’s internal control over financial reporting as of January 3, 2010. In making this assessment, the Company used the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in “Internal Control-Integrated Framework.” These criteria are in the areas of control environment, risk assessment, control activities, information and communication, and monitoring. The Company’s assessment included extensive documenting, evaluating and testing the design and operating effectiveness of its internal control over financial reporting.
 
Based on the Company’s processes and assessment, as described above, management has concluded that, as of January 3, 2010, the Company’s internal control over financial reporting was effective.
 
The effectiveness of the Company’s internal control over financial reporting as of January 3, 2010 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report, which appears in the “Report of Independent Registered Public Accounting Firm” on page 64 of the Annual Report, which is incorporated herein by reference and filed as Exhibit 13 to this Report on Form 10-K.
 
Changes in Internal Control Over Financial Reporting.  During the fiscal quarter ended January 3, 2010, there were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation of such referred to above in this Item 9A that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
 
Item 9B.   OTHER INFORMATION
 
Not applicable.


8


Table of Contents

PART III
 
Item 10.  DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
 
The information called for by this item is incorporated herein by reference to the material under the captions “Election of Directors” and “Stock Ownership and Section 16 Compliance — Section 16(a) Beneficial Ownership Reporting Compliance” and the discussion of the Audit Committee under the caption “Corporate Governance — Board Committees” in the Proxy Statement; and the material under the caption “Executive Officers of the Registrant” in Part I of this Report on Form 10-K.
 
The Company’s Policy on Business Conduct, which covers all employees (including the Chief Executive Officer, Chief Financial Officer and Controller), meets the requirements of the SEC rules promulgated under Section 406 of the Sarbanes-Oxley Act of 2002. The Policy on Business Conduct is available on the Company’s Web site at www.investor.jnj.com/governance/policies.cfm, and copies are available to shareholders without charge upon written request to the Secretary at the Company’s principal executive offices. Any substantive amendment to the Policy on Business Conduct or any waiver of the Policy granted to the Chief Executive Officer, the Chief Financial Officer or the Controller will be posted on the Company’s Web site at www.investor.jnj.com/governance.cfm within five business days (and retained on the Web site for at least one year).
 
In addition, the Company has adopted a Code of Business Conduct & Ethics for Members of the Board of Directors and Executive Officers. The Code of Business Conduct & Ethics for Members of the Board of Directors and Executive Officers is available on the Company’s Web site at www.investor.jnj.com/governance/policies.cfm, and copies are available to shareholders without charge upon written request to the Secretary at the Company’s principal executive offices. Any substantive amendment to the Code or any waiver of the Code granted to any member of the Board of Directors or any executive officer will be posted on the Company’s Web site at www.investor.jnj.com/governance.cfm within five business days (and retained on the Web site for at least one year).
 
Item 11.  EXECUTIVE COMPENSATION
 
The information called for by this item is incorporated herein by reference to the material under the captions “Compensation Discussion and Analysis,” “Executive and Director Compensation” and “Compensation Committee Report” in the Proxy Statement.
 
The material incorporated herein by reference to the material under the caption “Compensation Committee Report” in the Proxy Statement shall be deemed furnished, and not filed, in this Report on Form 10-K and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, as a result of this furnishing, except to the extent that the Registrant specifically incorporates it by reference.
 
Item 12.   SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
 
Additional information called for by this item is incorporated herein by reference to the material under the captions “Stock Ownership and Section 16 Compliance” in the Proxy Statement and Note 17 “Common Stock, Stock Option Plans and Stock Compensation Agreements” under “Notes to Consolidated Financial Statements” on pages 53 and 54 of the Annual Report, filed as Exhibit 13 to this Report on Form 10-K.


9


Table of Contents

Equity Compensation Plan Information
 
The following table provides certain information as of January 3, 2010 concerning the shares of the Company’s Common Stock that may be issued under existing equity compensation plans.
 
                         
    Number of Securities to
    Weighted Average
    Number of Securities
 
    be Issued Upon Exercise of
    Exercise Price of
    Remaining Available for
 
    Outstanding Options,
    Outstanding Options,
    Future Issuance Under
 
Plan Category   Warrants and Rights     Warrants and Rights     Equity Compensation Plans(4)  
 
Equity Compensation Plans Approved by Security Holders(1)
    238,568,739     $ 52.22       139,725,718  
Equity Compensation Plans Not Approved by Security Holders(2)(3)
    474,474       43.06        
Total
    239,043,213       52.20       139,725,718  
 
 
(1)  Included in this category are the following equity compensation plans, which have been approved by the Company’s shareholders: 1995 Stock Option Plan, 2000 Stock Option Plan and 2005 Long-Term Incentive Plan.
 
(2)  Included in this category are 383,124 shares of Common Stock of the Company issuable under various equity compensation plans which were assumed by the Company upon acquisition of the following companies: ALZA Corporation, Scios Inc., and Inverness Medical Technology, Inc. 216,770 of the shares listed as issuable in this category were issued under plans that were approved by the shareholders of these companies prior to the acquisition and the assumption of these plans by the Company. At the time of each of these acquisitions, options to acquire equity of the acquired company were replaced by options to acquire the Common Stock of the Company. No stock options or equity awards of any type have been made under any of these plans since the assumption of these plans by the Company, and no further stock options or other equity awards of any type will be made under any of these plans in the future.
 
The shares that are included in this column that were issued under plans not approved by shareholders of the applicable acquired company are: 131,183 shares issuable under the 1996 Scios Non-Officer Stock Option Plan; and 35,171 shares issuable under warrants under an Inverness Medical plan.
 
(3)  Also included in this category are 91,350 shares of Common Stock of the Company issuable upon the exercise of outstanding stock options under the Company’s Stock Option Plan for Non-Employee Directors. All options outstanding under this plan have fully vested with an expiration period of ten years from the date of grant.
 
(4)  This column excludes shares reflected under the column “Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights.”
 
Item 13.   CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
 
The information called for by this item is incorporated herein by reference to the material under the captions “Transactions with Related Persons” and “Corporate Governance — Director Independence” in the Proxy Statement.
 
Item 14.   PRINCIPAL ACCOUNTANT FEES AND SERVICES
 
The information called for by this item is incorporated herein by reference to the material under the caption “Ratification of Appointment of Independent Registered Public Accounting Firm” in the Proxy Statement.


10


Table of Contents

 
PART IV
 
Item 15.  EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
 
(a) The following documents are filed as part of this report:
 
1. Financial Statements
 
The following Audited Consolidated Financial Statements and Notes thereto and the material under the caption “Report of Independent Registered Public Accounting Firm” on pages 36 through 64 of the Annual Report are incorporated herein by reference and filed as Exhibit 13 to this Report on Form 10-K:
 
Consolidated Balance Sheets at end of Fiscal Years 2009 and 2008
 
Consolidated Statements of Earnings for Fiscal Years 2009, 2008 and 2007
 
Consolidated Statements of Equity for Fiscal Years 2009, 2008 and 2007
 
Consolidated Statements of Cash Flows for Fiscal Years 2009, 2008 and 2007
 
Notes to Consolidated Financial Statements
 
Report of Independent Registered Public Accounting Firm
 
2. Financial Statement Schedules
 
Schedule II — Valuation and Qualifying Accounts
 
Schedules other than those listed above are omitted because they are not required or are not applicable.
 
3. Exhibits Required to be Filed by Item 60l of Regulation S-K
 
The information called for by this item is incorporated herein by reference to the Exhibit Index in this report.


11


Table of Contents

Schedule Of Valuation And Qualifying Accounts Disclosure

 
JOHNSON & JOHNSON AND SUBSIDIARIES
 
 
Fiscal Years Ended January 3, 2010, December 28, 2008 and December 30, 2007
(Dollars in Millions)
 
                                 
    Balance at
                Balance at
 
    Beginning of
                End of
 
    Period     Accruals     Payments/ Other     Period  
 
2009
                               
Accrued Rebates(1)
  $ 1,808       6,584       (6,753 )     1,639  
Accrued Returns
    794       355       (460 )     689  
Accrued Promotions
    356       2,446       (2,373 )     429  
                                 
Subtotal
  $ 2,958       9,385       (9,586 )     2,757  
Reserve for doubtful accounts
    267       110       (44 )     333  
Reserve for cash discounts
    79       1,163       (1,141 )     101  
                                 
Total
  $ 3,304       10,658       (10,771 )     3,191  
                                 
                                 
2008
                               
Accrued Rebates(1)
  $ 1,802       5,578       (5,572 )     1,808  
Accrued Returns
    648       402       (256 )     794  
Accrued Promotions
    578       2,991       (3,213 )     356  
                                 
Subtotal
  $ 3,028       8,971       (9,041 )     2,958  
Reserve for doubtful accounts
    193       101       (27 )     267  
Reserve for cash discounts
    71       905       (897 )     79  
                                 
Total
  $ 3,292     $ 9,977(2 )   $ (9,965 )   $ 3,304  
                                 
                                 
2007
                               
Accrued Rebates(1)
  $ 1,691       5,243       (5,132 )     1,802  
Accrued Returns
    599       395       (346 )     648  
Accrued Promotions
    457       2,908       (2,787 )     578  
                                 
Subtotal
  $ 2,747       8,546       (8,265 )     3,028  
Reserve for doubtful accounts
    160       42       (9 )     193  
Reserve for cash discounts
    62       1,022       (1,013 )     71  
                                 
Total
  $ 2,969       9,610       (9,287 )     3,292  
                                 
 
(1)  Includes reserve for customer rebates of $729 million, $721 million, $710 million at January 3, 2010, December 28, 2008 and December 30, 2007, respectively.
 
(2)  Includes $171 million adjustment related to previously estimated accrued sales reserve.


12


Table of Contents

 
SIGNATURES
 
Pursuant to the requirements of Section 13 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
Date: March 1, 2010
JOHNSON & JOHNSON
(Registrant)
 
  By 
/s/  W. C. Weldon

W. C. Weldon, Chairman, Board of Directors,
and Chief Executive Officer
 
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
 
         
Signature
 
Title
 
Date
 
         
/s/  W. C. Weldon

W. C. Weldon
  Chairman, Board of Directors,
Chief Executive Officer, and Director (Principal Executive Officer)
  March 1, 2010
         
/s/  D. J. Caruso

D. J. Caruso
  Chief Financial Officer (Principal Financial Officer)   March 1, 2010
         
/s/  S. J. Cosgrove

S. J. Cosgrove
  Controller (Principal Accounting Officer)   March 1, 2010
         
/s/  M. S. Coleman

M. S. Coleman
  Director   March 1, 2010
         
/s/  J. G. Cullen

J. G. Cullen
  Director   March 1, 2010
         
/s/  M. M. E. Johns

M. M. E. Johns
  Director   March 1, 2010
         
/s/  A. G. Langbo

A. G. Langbo
  Director   March 1, 2010
         


13


Table of Contents

         
Signature
 
Title
 
Date
 
/s/  S. L. Lindquist

S. L. Lindquist
  Director  
March 1, 2010
/s/  A. M. Mulcahy

A. M. Mulcahy
  Director   March 1, 2010
         
/s/  L. F. Mullin

L. F. Mullin
  Director   March 1, 2010
         
/s/  W. D. Perez

W. D. Perez
  Director   March 1, 2010
         
/s/  C. Prince

C. Prince
  Director   March 1, 2010
         
/s/  D. Satcher

D. Satcher
  Director   March 1, 2010
         


14


Table of Contents

 
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ON
FINANCIAL STATEMENT SCHEDULE
 
To the Board of Directors of
Johnson & Johnson:
 
Our audits of the consolidated financial statements and of the effectiveness of internal control over financial reporting referred to in our report dated March 1, 2010 appearing in the 2009 Annual Report to Shareholders of Johnson & Johnson (which report and consolidated financial statements are incorporated by reference in this Annual Report on Form 10-K) also included an audit of the financial statement schedule listed in Item 15(a)2 of this Form 10-K. In our opinion, this financial statement schedule presents fairly, in all material respects, the information set forth therein when read in conjunction with the related consolidated financial statements.
 
/s/  PricewaterhouseCoopers LLP
PricewaterhouseCoopers LLP
 
New York, New York
March 1, 2010


15


Table of Contents

 
EXHIBIT INDEX
 
         
Reg. S-K
     
Exhibit Table
    Description
Item No.
   
of Exhibit
 
  3 (i)(a)   Restated Certificate of Incorporation dated April 26, 1990 — Incorporated herein by reference to Exhibit 3(a) of the Registrant’s Form 10-K Annual Report for the year ended December 30, 1990.
  3 (i)(b)   Certificate of Amendment to the Restated Certificate of Incorporation of the Company dated May 20, 1992 — Incorporated herein by reference to Exhibit 3(a) of the Registrant’s Form 10-K Annual Report for the year ended January 3, 1993.
  3 (i)(c)   Certificate of Amendment to the Restated Certificate of Incorporation of the Company dated May 21, 1996 — Incorporated herein by reference to Exhibit 3(a)(iii) of the Registrant’s Form 10-K Annual Report for the year ended December 29, 1996.
  3 (i)(d)   Certificate of Amendment to the Restated Certificate of Incorporation of the Company effective May 22, 2001 — Incorporated herein by reference to Exhibit 3 of the Registrant’s Form 10-Q Quarterly Report for the quarter ended July 1, 2001.
  3 (i)(e)   Certificate of Amendment to the Restated Certificate of Incorporation of the Company effective April 27, 2006 — Incorporated herein by reference to Exhibit 3(i) of the Registrant’s Form 10-Q Quarterly Report for the quarter ended April 2, 2006.
  3 (ii)   By-Laws of the Company, as amended effective February 9, 2009 — Incorporated herein by reference to Exhibit 3.1 the Registrant’s Form 8-K Current Report filed February 13, 2009.
  4 (a)   Upon the request of the Securities and Exchange Commission, the Registrant will furnish a copy of all instruments defining the rights of holders of long term debt of the Registrant.
  10 (a)   Stock Option Plan for Non-Employee Directors — Incorporated herein by reference to Exhibit 10(a) of the Registrant’s Form 10-K Annual Report for the year ended December 29, 1996.*
  10 (b)   2000 Stock Option Plan (as amended) — Incorporated herein by reference to Exhibit 10(b) of the Registrant’s Form 10-K Annual Report for the year ended December 29, 2002.*
  10 (c)   1995 Stock Option Plan (as amended) — Incorporated herein by reference to Exhibit 10(b) of the Registrant’s Form 10-K Annual Report for the year ended January 3, 1999.*
  10 (d)   2005 Long-Term Incentive Plan — Incorporated herein by reference to Exhibit 4 of the Registrant’s S-8 Registration Statement filed with the Commission on May 10, 2005 (file no. 333-124785).*
  10 (e)   Form of Stock Option Certificate and Restricted Shares to Non-Employee Directors Certificate under the 2005 Long-Term Incentive Plan — Incorporated herein by reference to Exhibit 10.1 of the Registrant’s Form 10-Q Quarterly Report for the quarter ended July 3, 2005.*
  10 (f)   Form of Restricted Stock Unit Certificate under the 2005 Long-Term Incentive Plan — Incorporated herein by reference to Exhibit 10.1 of the Registrant’s Form 10-Q Quarterly Report for the quarter ended October 2, 2005.*
  10 (g)   Executive Bonus Plan — Incorporated herein by reference to Exhibit 4 of the Registrant’s Form S-8 Registration Statement filed with the Commission on November 8, 2005 (file no. 333-129542).*
  10 (h)   Executive Incentive Plan (as amended) — Incorporated herein by reference to Exhibit 10(f) of the Registrant’s Form 10-K Annual Report for the year ended December 31, 2000.*
  10 (i)   Domestic Deferred Compensation (Certificate of Extra Compensation) Plan — Incorporated herein by reference to Exhibit 10(g) of the Registrant’s Form 10-K Annual Report for the year ended December 28, 2003.*
  10 (j)   Amendments to the Certificate of Extra Compensation Plan effective as of January 1, 2009 — Incorporated herein by reference to Exhibit 10(j) of the Registrant’s Form 10-K Annual Report for the year ended December 28, 2008.*
  10 (k)   2009 Certificates of Long-Term Performance Plan — Incorporated herein by reference to Exhibit 10.1 of the Registrant’s Form 10-Q Quarterly Report for the quarter ended September 27, 2009.*


16


Table of Contents

         
Reg. S-K
     
Exhibit Table
    Description
Item No.
   
of Exhibit
 
  10 (l)   Deferred Fee Plan Directors (as amended) — Incorporated herein by reference to Exhibit 10(h) of the Registrant’s Form 10-K Annual Report for the year ended January 2, 2005.*
  10 (m)   Amendments to the Deferred Fee Plan for Directors effective as of January 1, 2009 — Incorporated herein by reference to Exhibit 10(l) of the Registrant’s Form 10-K Annual Report for the year ended December 28, 2008.*
  10 (n)   Executive Income Deferral Plan (as amended) — Incorporated herein by reference to Exhibit 10(i) of the Registrant’s Form 10-K Annual Report for the year ended December 28, 2003.*
  10 (o)   Amendments to the Executive Income Deferral Plan effective as of January 1, 2009 — Incorporated herein by reference to Exhibit 10(n) of the Registrant’s Form 10-K Annual Report for the year ended December 28, 2008.*
  10 (p)   Excess Savings Plan — Incorporated herein by reference to Exhibit 10(j) of the Registrant’s Form 10-K Annual Report for the year ended December 29, 1996.*
  10 (q)   Amendments to the Johnson & Johnson Excess Savings Plan effective as of January 1, 2009 — Incorporated herein by reference to Exhibit 10(p) of the Registrant’s Form 10-K Annual Report for the year ended December 28, 2008.*
  10 (r)   Excess Benefit Plan (Supplemental Retirement Plan) — Incorporated herein by reference to Exhibit 10(h) of the Registrant’s Form 10-K Annual Report for the year ended January 3, 1993.*
  10 (s)   Amendments to the Excess Benefit Plan of Johnson & Johnson and Affiliated Companies effective as of January 1, 2009 — Incorporated herein by reference to Exhibit 10(r) of the Registrant’s Form 10-K Annual Report for the year ended December 28, 2008.*
  10 (t)   Executive Life Insurance Plan — Incorporated herein by reference to Exhibit 10(i) of the Registrant’s Form 10-K Annual Report for the year ended January 3, 1993.*
  10 (u)   Stock Option Gain Deferral Plan — Incorporated herein by reference to Exhibit 10(m) of the Registrant’s Form 10-K Annual Report for the year ended January 2, 2000.*
  10 (v)   Estate Preservation Plan — Incorporated herein by reference to Exhibit 10(n) of the Registrant’s Form 10-K Annual Report for the year ended January 2, 2000.*
  10 (w)   Summary of compensation arrangements for Named Executive Officers and Directors  — Filed with this document.*
  12     Statement of Computation of Ratio of Earnings to Fixed Charges — Filed with this document.
  13     — Pages 26 through 67 of the Company’s Annual Report to Shareholders for fiscal year 2009 (only those portions of the Annual Report incorporated by reference in this report are deemed “filed”) — Filed with this document.
  21     Subsidiaries — Filed with this document.
  23     Consent of Independent Registered Public Accounting Firm — Filed with this document.
  31 (a)   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act — Filed with this document.
  31 (b)   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act — Filed with this document.
  32 (a)   Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act — Furnished with this document.
  32 (b)   Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act — Furnished with this document.
  99     Cautionary Statement Pursuant to Private Securities Litigation Reform Act of 1995 — “Safe Harbor” for Forward-Looking Statements — Filed with this document.
 
 
* Management contract or compensatory plan.
 
A copy of any of the Exhibits listed above will be provided without charge to any shareholder submitting a written request specifying the desired exhibit(s) to the Secretary at the principal executive offices of the Company.


17

EX-10.W 2 y80744exv10ww.htm EX-10.W exv10ww
EXHIBIT 10(w)
 
Summary of Compensation Arrangements for
Named Executive Officers and Directors
 
Compensation Arrangements for Named Executive Officers
 
Following is a description of the compensation arrangements that have been approved by the Compensation & Benefits Committee of the Board of Directors of Johnson & Johnson (the “Compensation Committee”) on February 8, 2010 for the Company’s Chief Executive Officer, Chief Financial Officer and the other three most highly compensated executive officers in 2009 (the “Named Executive Officers”).
 
Annual Base Salary:
 
The Compensation Committee has approved the following base salaries, effective February 22, 2010, for the Named Executive Officers:
 
         
William C. Weldon
  $ 1,860,000  
Chairman/CEO        
Dominic J. Caruso
  $ 753,900  
Vice President, Finance; CFO        
Russell C. Deyo
  $ 873,100  
Vice President, Human Resources and General Counsel        
Colleen Goggins
  $ 827,200  
Worldwide Chairman, Consumer Group        
Sherilyn S. McCoy
  $ 785,900  
Worldwide Chairman, Pharmaceuticals Group        
 
Annual Performance Bonus:
 
The Compensation Committee has approved the following annual performance bonus payments for performance in 2009 (paid in the form of 85% cash and 15% Company Common Stock as determined by the Compensation Committee):
 
         
Mr. Weldon
  $ 3,600,000  
Mr. Caruso
  $ 1,004,000  
Mr. Deyo
  $ 1,164,000  
Ms. Goggins
  $ 1,007,000  
Ms. McCoy
  $ 1,205,000  
 
Stock Option and Restricted Share Unit Grants:
 
The Compensation Committee has approved the following stock option and Restricted Share Unit (“RSU”) grants under the Company’s 2005 Long-Term Incentive Plan (the “LTI Plan”). The stock options were granted at an exercise price of $62.62, at the “fair market value” (calculated as the average of the high and low prices of the Company’s Common Stock on the New York Stock Exchange) on February 8, 2010. The options will become exercisable on February 9, 2013 and expire on February 7, 2020. The RSUs will vest on February 9, 2013, upon which, the holder, if still employed by the Company on such date, will receive one share of the Company’s Common Stock for each RSU.
 
                 
Mr. Weldon
    586,873 stock options       48,906 RSUs  
Mr. Caruso
    119,770 stock options       9,981 RSUs  
Mr. Deyo
    131,747 stock options       10,979 RSUs  
Ms. Goggins
    134,159 stock options       11,180 RSUs  
Ms. McCoy
    143,724 stock options       11,977 RSUs  


 

Non-Equity Incentive Plan Awards:
 
The Compensation Committee has approved the following non-equity incentive plan awards in recognition of performance during 2009 under the Company’s Certificates of Long-Term Performance (“CLP”) program. Vested awards are not paid out until the earlier of ten years from the date of grant or retirement or other termination of employment. As of the grant date, the defined present value per CLP was $4.69. The CLP unit value will vary over time based on the performance of the Company.
 
                 
Mr. Weldon
    1,471,215       CLPs  
Mr. Caruso
    383,795       CLPs  
Mr. Deyo
    319,830       CLPs  
Ms. Goggins
    383,795       CLPs  
Ms. McCoy
    469,085       CLPs  
 
Due to the change in the planning basis of CLP awards from a vesting-based approach under the Certificates of Long-term Compensation Plan (the “CLC Plan”) to a grant-based approach under the new CLP Plan, which replaced the CLC Plan effective February 2010, certain executives were adversely impacted. The Committee approved selected one-time CLP awards to transition these executives to the new CLP Plan:
 
                 
Mr. Caruso
    148,400       CLPs  
Mr. Deyo
    426,440       CLPs  
Ms. Goggins
    211,430       CLPs  
 
Equity Compensation for Non-Employee Directors
 
Each Non-Employee Director receives non-retainer equity compensation in the first quarter of each year under the LTI Plan in the form of shares of restricted Common Stock having a fair market value of $100,000 on the grant date. Accordingly, each Non-Employee Director was granted 1,596 shares of restricted Common Stock under the LTI Plan on February 8, 2010. The restricted shares will become freely transferable on February 8, 2013.

EX-12 3 y80744exv12.htm EX-12 exv12
EXHIBIT 12
 
JOHNSON & JOHNSON AND SUBSIDIARIES
 
STATEMENT OF COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES(1)
(Dollars in Millions)
 
                                         
    Fiscal Year Ended  
    January 3,
    December 28,
    December 30,
    December 31,
    January 1,
 
    2010     2008     2007     2006     2006  
 
Determination of Earnings:
                                       
Earnings Before Provision for Taxes on Income
  $ 15,755     $ 16,929     $ 13,283     $ 14,587     $ 13,116  
Fixed Charges, less Capitalized Interest
    558       538       397       158       137  
                                         
Total Earnings as Defined
  $ 16,313     $ 17,467     $ 13,680     $ 14,745     $ 13,253  
                                         
Fixed Charges:
                                       
Estimated Interest Portion of Rent Expense
    107       103       101       95       83  
Interest Expensed and Capitalized
    552       583       426       181       165  
                                         
Total Fixed Charges
  $ 659     $ 686     $ 527     $ 276     $ 248  
                                         
Ratio of Earnings to Fixed Charges
    24.75       25.46       25.96       53.42       53.44  
                                         
(1)  The ratio of earnings to fixed charges is computed by dividing the sum of earnings before provision for taxes on income and fixed charges by fixed charges. Fixed charges represent interest expense (before interest is capitalized), amortization of debt discount and an appropriate interest factor on operating leases.

EX-13 4 y80744exv13.htm EX-13 exv13
 

Table of Contents
     
MANAGEMENT’S DISCUSSION AND ANALYSIS
26  
26  
27  
29  
32  
33  
35  
AUDITED CONSOLIDATED FINANCIAL STATEMENTS
36  
37  
38  
39  
40  
64  
65  
SUPPORTING SCHEDULES
66  
67  
JOHNSON & JOHNSON 2009 ANNUAL REPORT

25


Table of Contents

Management’s Discussion and Analysis of Results of Operations and Financial Condition
Organization and Business Segments
DESCRIPTION OF THE COMPANY AND BUSINESS SEGMENTS
Johnson & Johnson and its subsidiaries (the “Company”) have approximately 115,500 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world with the primary focus on products related to human health and well-being.
     The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment includes a broad range of products used in the baby care, skin care, oral care, wound care and women’s health care fields, as well as nutritional and over-the-counter pharmaceutical products. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world. The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. These products are distributed directly to retailers, wholesalers and health care professionals for prescription use. The Medical Devices and Diagnostics segment includes a broad range of products used principally in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. These products include Cordis’ circulatory disease management products; DePuy’s orthopaedic joint reconstruction, spinal care and sports medicine products; Ethicon’s surgical care, aesthetics and women’s health products; Ethicon Endo-Surgery’s minimally invasive surgical products; LifeScan’s blood glucose monitoring and insulin delivery products; Ortho-Clinical Diagnostics’ professional diagnostic products and Vistakon’s disposable contact lenses.
     The Company’s structure is based upon the principle of decentralized management. The Executive Committee of Johnson & Johnson is the principal management group responsible for the operations and allocation of the resources of the Company. This Committee oversees and coordinates the activities of the Consumer, Pharmaceutical and Medical Devices and Diagnostics business segments.
     In all of its product lines, the Company competes with companies both local and global, located throughout the world. Competition exists in all product lines without regard to the number and size of the competing companies involved. Competition in research, involving the development and the improvement of new and existing products and processes, is particularly significant. The development of new and innovative products is important to the Company’s success in all areas of its business. This also includes protecting the Company’s portfolio of intellectual property. The competitive environment requires substantial investments in continuing research and in maintaining sales forces. In addition, the development and maintenance of customer demand for the Company’s consumer products involves significant expenditures for advertising and promotion.
MANAGEMENT’S OBJECTIVES
A primary objective of the Company is to achieve superior levels of capital efficient profitable growth. To accomplish this, the Company’s management operates the business consistent with certain strategic principles that have proven successful over time. To this end, the Company participates in growth areas in human health care and is committed to attaining leadership positions in these growth areas through the development of innovative products and services. New products introduced within the past five years accounted for approximately 25% of 2009 sales. In 2009, $7.0 billion, or 11.3% of sales, was invested in research and development. This investment reflects management’s commitment to the importance of ongoing development of new and differentiated products and services to sustain long-term growth.
     With more than 250 operating companies located in 60 countries, the Company views its principle of decentralized management as an asset and fundamental to the success of a broadly based business. It also fosters an entrepreneurial spirit, combining the extensive resources of a large organization with the ability to react quickly to local market changes and challenges.
     The Company is committed to developing global business leaders who can drive growth objectives. Businesses are managed for the long-term in order to sustain leadership positions and achieve growth that provides an enduring source of value to our shareholders.
     Unifying the management team and the Company’s dedicated employees in achieving these objectives is Our Credo. Our Credo provides a common set of values and serves as a constant reminder of the Company’s responsibilities to its customers, employees, communities and shareholders. The Company believes that these basic principles, along with its overall mission of improving the quality of life for people everywhere, will enable Johnson & Johnson to continue to be among the leaders in the health care industry.
Results of Operations
ANALYSIS OF CONSOLIDATED SALES
In 2009, worldwide sales decreased 2.9% to $61.9 billion, compared to increases of 4.3% in 2008 and 14.6% in 2007. These sales changes consisted of the following:
                         
Sales (decrease)/increase due to:   2009     2008     2007  
     
Volume
    (0.2 )%     1.1       10.1  
Price
    (0.1 )     0.8       1.4  
Currency
    (2.6 )     2.4       3.1  
     
Total
    (2.9 )%     4.3       14.6  
     
Sales by U.S. companies were $30.9 billion in 2009, $32.3 billion in 2008 and $32.4 billion in 2007. This represents a decrease of 4.4% in 2009, a decrease of 0.4% in 2008 and an increase of 9.0% in 2007. Sales by international companies were $31.0 billion in 2009, $31.4 billion in 2008 and $28.7 billion in 2007. This represents a decrease of 1.4% in 2009 and increases of 9.7% and 21.7% in 2008 and 2007, respectively.
JOHNSON & JOHNSON 2009 ANNUAL REPORT

26


Table of Contents

(BAR GRAPH)
     The five-year compound annual growth rates for worldwide, U.S. and international sales were 5.5%, 2.2% and 9.6%, respectively. The ten-year compound annual growth rates for worldwide, U.S. and international sales were 8.5%, 7.1% and 10.1%, respectively.
(BAR GRAPH)
     Sales in Europe experienced a decline of 5.1% including operational growth of 2.1% and a negative impact from currency of 7.2%. Sales in the Western Hemisphere (excluding the U.S.) experienced a decline of 0.3% including operational growth of 8.8% and a negative impact from currency of 9.1%. Sales in the Asia-Pacific, Africa region achieved growth of 4.6%, including operational growth of 4.4% and an increase of 0.2% related to the positive impact of currency.
     In 2009, 2008 and 2007, the Company did not have a customer that represented 10% or more of total consolidated revenues.
     2009 results benefited from the inclusion of a 53rd week. (See Note 1 to the Consolidated Financial Statements for Annual Closing Date details). The Company estimated that the fiscal year 2009 growth rate was enhanced by approximately 0.5%. While the additional week added a few days to sales, it also added a full week’s worth of operating costs; therefore, the net earnings impact was negligible.
(BAR GRAPH)
Analysis of Sales by Business Segments
CONSUMER SEGMENT
Consumer segment sales in 2009 were $15.8 billion, a decrease of 1.6% from 2008 with 2.0% of this change due to operational growth and negative currency impact of 3.6%. U.S. Consumer segment sales were $6.8 billion, a decrease of 1.4%. International sales were $9.0 billion, a decrease of 1.7%, with growth of 4.7% achieved by operations and a decrease of 6.4% resulting from the negative impact of currency fluctuations.
     The Over-the-Counter (OTC) Pharmaceuticals and Nutritionals franchise sales were $5.6 billion, a decrease of 4.5% from 2008. This was primarily due to the negative impact of currency and lower sales of the over-the-counter ZYRTEC® allergy product line related to the initial build of inventory by the trade during the 2008 launch year. This was partially offset by sales growth in the SPLENDA® sweetener product line. The U.S. Food and Drug Administration (FDA) is currently considering certain recommendations made by its advisory committee for reducing the potential for overdose with acetaminophen, the active ingredient in TYLENOL® brand products. The Company has provided the FDA with its own recommendations and will continue to be actively engaged with the FDA on this topic. In December 2009, the Company announced a voluntary recall of all lots of TYLENOL® Arthritis Pain 100 count with EZ-OPEN CAP following reports of an uncharacteristic smell; however, there was an insignificant impact on sales. In January 2010, the Company has undertaken a broader voluntary recall of TYLENOL® and certain OTC products as a precautionary action.
     The Skin Care franchise sales grew by 2.5% to $3.5 billion in 2009. The sales growth was primarily due to the AVEENO®, NEUTROGENA®, and DABAO™ skin care lines. The Baby Care franchise sales were $2.1 billion, a decrease of 4.5% primarily due to the negative impact of currency and lower sales for Babycenter.com as a result of exiting the online retail business, partially offset by growth in the haircare product line. The Women’s Health franchise sales were $1.9 billion, a decrease of 0.8% primarily due to the negative impact of currency partially offset by increased sales associated with the acquisition of a joint venture partner in France in the fiscal
Major Consumer Franchise Sales:
                                         
                            % Change  
(Dollars in Millions)   2009     2008     2007     ’09 vs. ’08     ’08 vs. ’07  
     
OTC Pharmaceuticals & Nutritionals
  $ 5,630       5,894       5,142       (4.5) %     14.6  
Skin Care
    3,467       3,381       3,051       2.5       10.8  
Baby Care
    2,115       2,214       1,982       (4.5 )     11.7  
Women’s Health
    1,895       1,911       1,806       (0.8 )     5.8  
Oral Care
    1,569       1,624       1,488       (3.4 )     9.1  
Wound Care/Other
    1,127       1,030       1,024       9.4       0.6  
     
 
                                       
Total
  $ 15,803       16,054       14,493       (1.6) %     10.8  
     
MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION

27


Table of Contents

first quarter of 2009. Prior to the acquisition of the joint venture partner, sales by the joint venture were not recorded as part of the Company’s sales to customers. The Oral Care franchise sales were $1.6 billion, a decrease of 3.4% due to softness in the category in the U.S., partially offset by growth of LISTERINE® mouthwash outside the U.S. The Wound Care/Other franchise sales grew by 9.4% to $1.1 billion primarily due to the recent acquisitions in the Wellness and Prevention platform and strong sales of PURELL® hand sanitizer.
     Consumer segment sales in 2008 were $16.0 billion, an increase of 10.8% over 2007 with 8.3% of this change due to operational growth and the remaining 2.5% due to positive currency fluctuations. U.S. Consumer segment sales were $6.9 billion, an increase of 8.3%. International sales were $9.1 billion, an increase of 12.8%, with 8.3% as a result of operations and 4.5% due to currency fluctuations over 2007.
PHARMACEUTICAL SEGMENT
Pharmaceutical segment sales in 2009 were $22.5 billion, a decrease of 8.3% from 2008, with an operational decline of 6.1% and the remaining 2.2% due to the negative impact of currency fluctuations. U.S. sales were $13.0 billion, a decrease of 12.1%. International sales were $9.5 billion, a decrease of 2.6%, which included 3.0% operational growth and a decrease of 5.6% resulting from the negative impact of currency fluctuations.
     REMICADE® (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases, achieved sales of $4.3 billion in 2009, with growth of 14.8% over the prior year primarily attributable to strong overall market growth. REMICADE® is competing in a market which is experiencing increased competition due to new entrants and the expansion of indications for existing competitors.
     PROCRIT® (Epoetin alfa) and EPREX® (Epoetin alfa) had combined sales of $2.2 billion in 2009, a decline of 8.7% compared to the prior year. Lower sales of PROCRIT® and EPREX® were due to the declining markets for Erythropoiesis Stimulating Agents (ESAs).
     LEVAQUIN® (levofloxacin)/FLOXIN® (ofloxacin) sales were $1.6 billion, a decline of 2.6% versus the prior year, due to competition in the category. The patent for LEVAQUIN® (levofloxacin) in the U.S. will expire in December 2010. A pediatric extension was granted by the FDA, which extends market exclusivity in the U.S. through June 2011. The expiration of the product patent or loss of market exclusivity is likely to result in a significant reduction in sales.
     RISPERDAL® CONSTA® (risperidone), a long-acting injectable for the treatment of schizophrenia, achieved sales of $1.4 billion in 2009, representing an increase of 8.9% as compared to the prior year. The growth was due to a positive shift from daily therapies to longer-acting RISPERDAL® CONSTA® and the launch of RISPERDAL® CONSTA® in Japan earlier in the year.
     CONCERTA® (methylphenidate HCl), a product for the treatment of attention deficit hyperactivity disorder (ADHD), achieved sales of $1.3 billion in 2009, representing an increase of 6.3% over 2008. Sales results in 2008 were favorably impacted by approximately $115 million related to a change in the estimate of accrued sales reserves related to sales outside the U.S. Although the original CONCERTA® patent expired in 2004, the FDA has not approved any generic version that is substitutable for CONCERTA®. Parties have filed Abbreviated New Drug Applications (ANDAs) for generic versions of CONCERTA®, which are pending and may be approved at any time. An approval would lead to a loss of exclusivity and is likely to result in a significant reduction in sales.
     TOPAMAX® (topiramate), RISPERDAL® (risperidone), and DURAGESIC®/Fentanyl Transdermal (fentanyl transdermal system) experienced sales declines in 2009 of 57.9%, 57.7% and 14.3%, respectively, versus the prior year due to generic competition. Market exclusivity in the U.S. expired for TOPAMAX® (topiramate) in March 2009, RISPERDAL® oral in June 2008 and DURAGESIC® in January 2005.
     ACIPHEX®/PARIET® (rabeprazole sodium) experienced a sales decline of 5.4% due to competition in the category.
     In 2009, Other Pharmaceutical sales were $7.6 billion, representing a growth of 6.6% over the prior year. Contributors to the increase were sales of VELCADE® (bortezomib), a product for the treatment of multiple myeloma; PREZISTA® (darunavir), for the treatment of HIV/AIDS patients; INTELENCE™ (etravirine), for HIV combination therapy and INVEGA® (paliperidone), a once-daily atypical antipsychotic. The growth was partially offset by the impact of a generic version of ORTHO TRI-CYCLEN® LO shipped by a competitor. Subsequently, the generic manufacturer recognized the validity of the patent, paid damages for its infringing sales and ceased further shipments of the product.
     During 2009, the Company received regulatory approval for several new molecular entities (NMEs), including STELARA™ (ustekinumab) in the U.S. and European Union (EU) for the treatment of moderate-to-severe plaque psoriasis; INVEGA® SUSTENNA™ (paliperidone palmitate) extended-release injectable suspension in the U.S. for the acute and maintenance treatment of schizophrenia; SIMPONI™ (golimumab) in the U.S. and EU for the treatment of moderate-to-severe, active rheumatoid arthritis (RA), active and progressive psoriatic arthritis (PsA) and severe, active ankylosing spondylitis (AS); and PRILIGY™ (dapoxetine) in several countries for the on-demand treatment of premature ejaculation. NUCYNTA™ (tapentadol) Immediate Release Tablets, for relief
Major Pharmaceutical Product Revenues:
                                         
                            % Change  
(Dollars in Millions)   2009     2008     2007     ’09 vs. ’08     ’08 vs. ’07  
     
REMICADE® (infliximab)
  $ 4,304       3,748       3,327       14.8 %     12.7  
PROCRIT®/EPREX® (Epoetin alfa)
    2,245       2,460       2,885       (8.7 )     (14.7 )
LEVAQUIN®/FLOXIN® (levofloxacin/ofloxacin)
    1,550       1,591       1,646       (2.6 )     (3.3 )
RISPERDAL® CONSTA® (risperidone)
    1,425       1,309       1,128       8.9       16.0  
CONCERTA® (methylphenidate HCl)
    1,326       1,247       1,028       6.3       21.3  
TOPAMAX® (topiramate)
    1,151       2,731       2,453       (57.9 )     11.3  
ACIPHEX®/PARIET® (rabeprazole sodium)
    1,096       1,158       1,357       (5.4 )     (14.7 )
RISPERDAL® (risperidone)
    899       2,126       3,420       (57.7 )     (37.8 )
DURAGESIC®/Fentanyl Transdermal (fentanyl transdermal system)
    888       1,036       1,164       (14.3 )     (11.0 )
Other Pharmaceuticals
    7,636       7,161       6,458       6.6       10.9  
     
 
                                       
Total
  $ 22,520       24,567       24,866       (8.3) %     (1.2 )
     
JOHNSON & JOHNSON 2009 ANNUAL REPORT

28


Table of Contents

of moderate to severe acute pain, was also launched in the U.S. in 2009.
     The Company also received approvals expanding the indications for several key products, including INVEGA® (paliperidone) extended-release tablets in the U.S. for the acute treatment of schizoaffective disorder; RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment in the U.S. as both monotherapy and adjunctive therapy to lithium or valproate in the maintenance treatment of Bipolar I Disorder, as well as for the treatment of schizophrenia in Japan; PREZISTA® (darunavir) in the EU with low-dose ritonavir as part of combination therapy in treatment-naïve adults, as well as for treatment-experienced pediatric patients with HIV.
     The Company submitted a New Drug Application (NDA) to the FDA for tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older. In addition, the Company also invested in a number of new platforms for growth in Oncology, Alzheimer’s disease and vaccines for the treatment and prevention of influenza and other infectious and non-infectious diseases.
     Pharmaceutical segment sales in 2008 were $24.6 billion, a decrease of 1.2% from 2007, with an operational decline of 3.1% and 1.9% increase due to the positive impact of currency fluctuations. U.S. Pharmaceutical segment sales were $14.9 billion, a decrease of 4.9%. International Pharmaceutical segment sales were $9.7 billion, an increase of 5.1%, which included 0.1% of operational growth and 5.0% related to the positive impact of currency fluctuations.
MEDICAL DEVICES AND DIAGNOSTICS SEGMENT
The Medical Devices and Diagnostics segment achieved sales of $23.6 billion in 2009, representing an increase of 1.9% over the prior year, with operational growth of 4.2% and a negative currency impact of 2.3%. U.S. sales were $11.0 billion, an increase of 4.5% over the prior year. International sales were $12.6 billion, a decrease of 0.2%, with growth of 4.0% from operations and a decrease of 4.2% resulting from the negative impact of currency fluctuations.
     The DePuy franchise achieved sales of $5.4 billion in 2009, a 4.6% increase over the prior year. This was primarily due to growth in the spine, hip and knee product lines. Additionally, new product launches in the Mitek sports medicine product line contributed to the growth.
     The Ethicon Endo-Surgery franchise achieved sales of $4.5 billion in 2009, a 4.8% increase over the prior year. This was attributable to growth in the endoscopy, HARMONIC®, ENSEAL® and Advanced Sterilization product lines.
     The Ethicon franchise achieved sales of $4.1 billion in 2009, a 7.3% increase over the prior year. This was attributable to growth in the sutures, biosurgical and mesh product lines in addition to sales of newly acquired products from the acquisitions of Omrix Biopharmaceuticals, Inc. and Mentor Corporation. The growth was partially offset by the divestiture of the Professional Wound Care business of Ethicon, Inc. in the fiscal fourth quarter of 2008.
     Sales in the Cordis franchise were $2.7 billion, a decline of 10.3% versus the prior year. The decline reflects lower sales of the CYPHER® Sirolimus-eluting Coronary Stent due to increased global competition. The decline was partially offset by growth of the Biosense Webster business.
     The Vision Care franchise achieved sales of $2.5 billion in 2009, a 0.2% increase over prior year primarily related to growth in the Astigmatic contact lens product line offset by the negative impact of currency.
     Sales in the Diabetes Care franchise were $2.4 billion in 2009, a decline of 3.7% versus the prior year. Declines in the LifeScan product line were partially offset by growth of the Animas insulin delivery business resulting from new product launches and continued development in international markets.
     The Ortho-Clinical Diagnostics franchise achieved sales of $2.0 billion in 2009, a 6.6% increase over the prior year primarily attributable to the recent launch of the VITROS® 3600 and 5600 analyzers.
     The Medical Devices and Diagnostics segment achieved sales of $23.1 billion in 2008, representing an increase of 6.4% over the prior year, with operational growth of 3.5% and 2.9% due to a positive impact from currency fluctuations. U.S. sales were $10.5 billion, an increase of 1.0%. International sales were $12.6 billion, an increase of 11.3%, with 5.8% from operations and a positive currency impact of 5.5%.
Analysis of Consolidated Earnings Before Provision for Taxes on Income
Consolidated earnings before provision for taxes on income decreased by $1.1 billion to $15.8 billion in 2009 as compared to the $16.9 billion earned in 2008, a decrease of 6.9%. The decrease was primarily related to lower sales, the negative impact of product mix, lower interest income due to lower rates of interest earned and restructuring charges of $1.2 billion. This was partially offset by lower selling, marketing and administrative expenses due to cost containment efforts across all the businesses. 2008 included purchased in-process research and development (IPR&D) charges of $0.2 billion and increased investment spending in selling, marketing and administrative expenses utilized from the proceeds associated with the divestiture of the Professional Wound Care business of Ethicon, Inc. The increase in 2008 of 27.4% over the $13.3 billion in 2007 was primarily due to lower IPR&D charges of $0.6 billion, gains from divestitures of $0.5 billion and higher litigation gains of $0.5 billion versus restructuring charges of $0.7 billion and the write-down of the NATRECOR® intangible asset of $0.7 billion recorded in 2007. As a percent to sales, consolidated
Major Medical Devices and Diagnostics Franchise Sales*:
                                         
                            % Change  
(Dollars in Millions)   2009     2008     2007     ’09 vs. ’08     ’08 vs. ’07  
     
DEPUY®
  $ 5,372       5,136       4,698       4.6 %     9.3  
ETHICON ENDO-SURGERY®
    4,492       4,286       3,834       4.8       11.8  
ETHICON®
    4,122       3,840       3,603       7.3       6.6  
CORDIS®
    2,679       2,988       3,314       (10.3 )     (9.8 )
Vision Care
    2,506       2,500       2,209       0.2       13.2  
Diabetes Care
    2,440       2,535       2,373       (3.7 )     6.8  
ORTHO-CLINICAL DIAGNOSTICS®
    1,963       1,841       1,705       6.6       8.0  
     
 
                                       
Total
  $ 23,574       23,126       21,736       1.9 %     6.4  
     
 
*   Prior year amounts have been reclassified to conform to current presentation.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION

29


Table of Contents

earnings before provision for taxes on income in 2009 was 25.4% versus 26.5% in 2008.
     The sections that follow highlight the significant components of the changes in consolidated earnings before provision for taxes on income.
Cost of Products Sold and Selling, Marketing and Administrative Expenses: Cost of products sold and selling, marketing and administrative expenses as a percent to sales were as follows:
                         
% of Sales   2009     2008     2007  
     
Cost of products sold
    29.8 %     29.1       29.1  
Percent point increase over the prior year
    0.7             0.9  
Selling, marketing and administrative expenses
    32.0       33.7       33.5  
Percent point (decrease)/increase over the prior year
    (1.7 )     0.2       0.8  
In 2009, cost of products sold as a percent to sales increased primarily due to the continued negative impact of product mix and inventory write-offs associated with the restructuring activity. Additionally, 2008 included some non-recurring positive items. There was a decrease in the percent to sales of selling, marketing and administrative expenses in 2009 primarily due to cost containment efforts across all the businesses and the annualized savings recognized from the 2007 restructuring program. Additionally, 2008 utilized the proceeds associated with the divestiture of the Professional Wound Care business of Ethicon, Inc. to fund increased investment spending.
     In 2008, cost of products sold as a percent to sales remained flat to the prior year. The change in the mix of businesses, with higher sales growth in the Consumer business and a slight sales decline in the Pharmaceutical business, had a negative impact on the cost of products sold as a percent to sales. In 2008, this was offset by manufacturing efficiencies and non-recurring positive items in 2008 and negative items in 2007. There was an increase in the percent to sales of selling, marketing and administrative expenses in 2008 primarily due to the change in the mix of businesses, whereby a greater proportion of sales were attributable to the Consumer segment, which has higher selling, marketing and administrative spending. Additionally, in 2008 the Company utilized the gain associated with the divestiture of the Professional Wound Care business of Ethicon, Inc. to fund increased investment spending. This was partially offset by ongoing cost containment efforts.
     In 2007, there was an increase in the percent to sales of cost of products sold primarily due to the impact of newly acquired consumer brands. There was an increase in the percent to sales of selling, marketing and administrative expenses in 2007 primarily due to the impact of newly acquired consumer brands partially offset by cost containment efforts.
Research and Development expense (excluding purchased in-process research and development charges) by segment of business was as follows:
                                                 
    2009     2008     2007  
(Dollars in Millions)   Amount     % of Sales*     Amount     % of Sales*     Amount     % of Sales*  
     
Consumer
  $ 632       4.0 %     624       3.9       564       3.9  
Pharmaceutical
    4,591       20.4       5,095       20.7       5,265       21.2  
Medical Devices and Diagnostics
    1,763       7.5       1,858       8.0       1,851       8.5  
 
                                         
Total research and development expense
  $ 6,986       11.3 %     7,577       11.9       7,680       12.6  
Percent (decrease)/increase over the prior year
    (7.8 )%             (1.3 )             7.8          
     
 
*   As a percent to segment sales
Research and Development Expense: Research and development activities represent a significant part of the Company’s business. These expenditures relate to the development of new products, improvement of existing products, technical support of products and compliance with governmental regulations for the protection of consumers and patients.
     In 2009 and 2008, the reduction in the Pharmaceutical research and development spending was primarily due to increased efficiencies in Pharmaceutical research and development activities.
Restructuring: In 2009, the Company announced global restructuring initiatives that are expected to generate pre-tax, annual cost savings of $1.4 – $1.7 billion when fully implemented in 2011, with $0.8 – $0.9 billion expected to be achieved in 2010. The associated savings will provide additional resources to invest in new growth platforms; ensure the successful launch of the Company’s many new products and continued growth of the core businesses; and provide flexibility to adjust to the changed and evolving global environment. In the fiscal fourth quarter of 2009 the Company recorded a pre-tax charge of $1.2 billion, of which $113 million is included in cost of products sold.
     The restructuring program announced in 2007 has been completed. See Note 22 to the Consolidated Financial Statements for additional details related to the restructuring.
Purchased In-Process Research and Development: In 2009, in accordance with U.S. GAAP for business combinations, purchased in-process research and development (IPR&D) is no longer expensed but capitalized and tested for impairment. The Company capitalized $1.7 billion of IPR&D in 2009, primarily associated with the acquisitions of Cougar Biotechnology, Inc. and substantially all of the assets and rights of Elan’s Immunotherapy program.
     In 2008, the Company recorded a charge for IPR&D of $181 million before and after tax related to the acquisitions of Amic AB, SurgRx, Inc., HealthMedia, Inc. and Omrix Biopharmaceuticals, Inc. HealthMedia, Inc, a privately held company that creates web-based behavior change interventions, accounted for $7 million before tax of the IPR&D charges and was included in the operating profit of the Consumer segment. The IPR&D charges for all of the following acquisitions were included in the operating profit of the Medical Devices and Diagnostics segment. Amic AB, a Swedish developer of in vitro diagnostic technologies for use in point-of-care and near-patient settings (outside the physical facilities of the clinical laboratory), accounted for $40 million before tax of the IPR&D charges. SurgRx, Inc., a privately held developer of the advanced bipolar tissue sealing system used in the ENSEAL® family of devices, accounted for $7 million before tax of the IPR&D charges. Omrix Biopharmaceuticals, Inc., a fully integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, accounted for $127 million before tax of the IPR&D charges.
     In 2007, the Company recorded a charge for IPR&D of $807 million before and after tax related to the acquisition of Conor Medsystems, Inc. The IPR&D charge was included in the operating profit of the Medical Devices and Diagnostics segment.
JOHNSON & JOHNSON 2009 ANNUAL REPORT

30


Table of Contents

Other (Income) Expense, Net: Other (income) expense, net includes gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson & Johnson Development Corporation, gains and losses on the disposal of property, plant and equipment, currency gains and losses, non-controlling interests, litigation settlements and liabilities and royalty income. The unfavorable change of $0.5 billion in other (income) expense, net from 2009 to 2008 was primarily due to a gain of $0.5 billion from the divestiture of the Professional Wound Care business of Ethicon, Inc. in 2008.
     In 2008, other (income) expense, net included income from net litigation settlements and awards of $0.5 billion and a gain of $0.5 billion from the divestiture of the Professional Wound Care business of Ethicon, Inc. In 2007, other (income) expense, net included a charge of $0.7 billion before tax related to the NATRECOR® intangible asset write-down.
OPERATING PROFIT BY SEGMENT
Operating profits by segment of business were as follows:
                                 
                    Percent of  
                    Segment Sales  
(Dollars in Millions)   2009     2008     2009     2008  
     
Consumer
  $ 2,475       2,674       15.7 %     16.7  
Pharmaceutical
    6,413       7,605       28.5       31.0  
Med Devices and Diagnostics
    7,694       7,223       32.6       31.2  
     
Total (1)
    16,582       17,502       26.8       27.4  
Less: Expenses not allocated to segments (2)
    827       573                  
     
Earnings before provision for taxes on income
  $ 15,755       16,929       25.4 %     26.5  
     
 
(1)   See Note 18 to the Consolidated Financial Statements for more details.
 
(2)   Amounts not allocated to segments include interest (income) expense, non-controlling interests, and general corporate (income) expense.
(BAR GRAPH)
Consumer Segment: In 2009, Consumer segment operating profit decreased 7.4% from 2008. The primary reasons for the decrease in operating profit was $369 million of restructuring charges, partially offset by cost containment initiatives in 2009. In 2008, Consumer segment operating profit increased 17.4% from 2007. Cost synergies, lower integration costs in 2008 related to the acquisition of the Consumer Healthcare business of Pfizer Inc., and other cost containment initiatives contributed to the increased operating profit in 2008.
Pharmaceutical Segment: In 2009, Pharmaceutical segment operating profit decreased 15.7% from 2008. The primary reasons for the decrease in operating profit were $496 million of restructuring charges, $92 million of litigation expense and negative product mix due to the loss of market exclusivity for TOPAMAX® and RISPERDAL® oral. In 2008, Pharmaceutical segment operating profit increased 16.3% from 2007. The primary driver of the improved operating profit in 2008 was due to the restructuring charges of $429 million and $678 million for the NATRECOR® intangible asset write-down recorded in 2007.
Medical Devices and Diagnostics Segment: In 2009, the operating profit in the Medical Devices and Diagnostics segment increased 6.5% from 2008. The improved operating profit was due to $478 million gain from net litigation settlements, favorable product mix, manufacturing efficiencies and cost containment initiatives related to selling, marketing and administrative expenses. This was partially offset by $321 million in restructuring charges. In 2008, the operating profit in the Medical Devices and Diagnostics segment increased 49.1% from 2007. The improved operating profit was the result of the $429 million gain from net litigation settlements, favorable product mix, manufacturing efficiencies and lower IPR&D charges of $174 million in 2008 versus $807 million in 2007. Additionally, $301 million of restructuring charges were recorded in 2007.
Interest (Income) Expense: Interest income in 2009 decreased by $271 million due to lower rates of interest earned despite higher average cash balances. The cash balance, including marketable securities, was $19.4 billion at the end of 2009, and averaged $15.6 billion as compared to the $12.2 billion average cash balance in 2008. The increase in the average cash balance was primarily due to cash generated from operating activities.
     Interest expense in 2009 increased by $16 million due to a higher debt balance. The net debt balance at the end of 2009 was $14.5 billion as compared to $11.9 billion at the end of 2008. The higher average debt balance of $13.5 billion in 2009 versus $12.9 billion in 2008 was primarily related to funding acquisitions and investments and the purchase of the Company’s Common Stock under the ongoing Common Stock repurchase program announced on July 9, 2007.
     Interest income in 2008 decreased by $91 million due to lower rates of interest earned despite higher average cash balances. The cash balance, including marketable securities, was $12.8 billion at the end of 2008, and averaged $12.2 billion as compared to the $6.6 billion average cash balance in 2007. The increase in the average cash balance was primarily due to cash generated from operating activities.
     Interest expense in 2008 increased by $139 million due to a higher debt balance. In the second half of 2007 the Company converted some of its short-term debt to fixed long-term debt at higher interest rates. The net debt balance at the end of 2008 was $11.9 billion as compared to $9.5 billion at the end of 2007. The higher debt balance in 2008 was primarily due to the purchase of the Company’s Common Stock under the ongoing Common Stock repurchase program announced on July 9, 2007 and to fund acquisitions.
     Interest income in 2007 decreased by $377 million due to lower average cash balances. The decline in the average cash balance was primarily due to the acquisition of the Consumer Healthcare business of Pfizer Inc. on December 20, 2006.
     Interest expense in 2007 increased by $233 million as compared to prior year due to a higher average debt balance. The net debt balance at the end of 2007 was $9.5 billion as compared to $6.6 billion at the end of 2006. The higher debt balance in 2007 was due to the debt associated with the acquisition of the Consumer Healthcare business of Pfizer Inc. and the Common Stock repurchase program announced in 2007.
Provision for Taxes on Income: The worldwide effective income tax rate was 22.1% in 2009, 23.5% in 2008 and 20.4% in 2007. The 2009 tax rate decreased as compared to 2008 due to increases in taxable income in lower tax jurisdictions relative to taxable income in higher tax jurisdictions. The 2008 tax rate increased as compared to 2007 due to increases in taxable income in higher tax jurisdictions relative to taxable income in lower jurisdictions. In addition, the
MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION

31


Table of Contents

2007 tax rate benefited from a one-time gain of $267 million related to a business restructuring of certain international subsidiaries.
Liquidity and Capital Resources
LIQUIDITY & CASH FLOWS
Cash and cash equivalents were $15.8 billion at the end of 2009 as compared with $10.8 billion at the end of 2008. The primary sources of cash that contributed to the $5.0 billion increase versus prior year were $16.6 billion of cash generated from operating activities and $2.5 billion net proceeds from long and short-term debt. The major uses of cash were capital spending of $2.4 billion, acquisitions of $2.5 billion, net investment purchases of $2.8 billion, dividends to shareholders of $5.3 billion and the repurchase of common stock, net of proceeds from the exercise of options, of $1.2 billion.
     Cash Flows from operations were $16.6 billion in 2009. The major sources of cash flow were net income of $12.3 billion, adjusted for non-cash charges for depreciation, amortization and stock based compensation of $3.4 billion, restructuring reserves of $1.1 billion and accounts receivable and inventories of $0.5 billion. The remaining changes to operating cash flow were a use of funds of $0.7 billion related to pension plan contributions and decreases in accounts payable partially offset by decreases in other receivables, prepaid expenses and deferred taxes.
     In 2009, the Company continued to have access to liquidity through the commercial paper market. For additional details on borrowings, see Note 7 to the Consolidated Financial Statements.
     The Company anticipates that operating cash flows, existing credit facilities and access to the commercial paper markets will provide sufficient resources to fund operating needs in 2010.
(BAR GRAPH)
FINANCING AND MARKET RISK
The Company uses financial instruments to manage the impact of foreign exchange rate changes on cash flows. Accordingly, the Company enters into forward foreign exchange contracts to protect the value of certain foreign currency assets and liabilities and to hedge future foreign currency transactions primarily related to product costs. Gains or losses on these contracts are offset by the gains or losses on the underlying transactions. A 10% appreciation of the U.S. Dollar from the January 3, 2010 market rates would increase the unrealized value of the Company’s forward contracts by $296 million. Conversely, a 10% depreciation of the U.S. Dollar from the January 3, 2010 market rates would decrease the unrealized value of the Company’s forward contracts by $361 million. In either scenario, the gain or loss on the forward contract would be offset by the gain or loss on the underlying transaction and, therefore, would have no impact on future anticipated earnings and cash flows.
     The Company hedges the exposure to fluctuations in currency exchange rates, and the effect on certain assets and liabilities in foreign currency, by entering into currency swap contracts. A 1% change in the spread between U.S. and foreign interest rates on the Company’s interest rate sensitive financial instruments would either increase or decrease the unrealized value of the Company’s swap contracts by approximately $185 million. In either scenario, at maturity, the gain or loss on the swap contract would be offset by the gain or loss on the underlying transaction and therefore would have no impact on future anticipated cash flows.
     The Company does not enter into financial instruments for trading or speculative purposes. Further, the Company has a policy of only entering into contracts with parties that have at least an “A” (or equivalent) credit rating. The counterparties to these contracts are major financial institutions and there is no significant concentration of exposure with any one counterparty. Management believes the risk of loss is remote.
     The Company has access to substantial sources of funds at numerous banks worldwide. In September 2009, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10 billion, which expires September 23, 2010. Interest charged on borrowings under the credit line agreements is based on either bids provided by banks, the prime rate or London Interbank Offered Rates (LIBOR), plus applicable margins. Commitment fees under the agreement are not material.
     Total borrowings at the end of 2009 and 2008 were $14.5 billion and $11.9 billion, respectively. The increase in borrowings between 2009 and 2008 was a result of financing general corporate purposes and the continuation of the Common Stock repurchase program announced in 2007. In 2009, net cash (cash and current marketable securities, net of debt) was $4.9 billion compared to net cash of $1.0 billion in 2008. Total debt represented 22.3% of total capital (shareholders’ equity and total debt) in 2009 and 21.8% of total capital in 2008. Shareholders’ equity per share at the end of 2009 was $18.37 compared with $15.35 at year-end 2008, an increase of 19.7%.
     Johnson & Johnson continues to be one of a few industrial companies with a Triple A credit rating. A summary of borrowings can be found in Note 7 to the Consolidated Financial Statements.
CONTRACTUAL OBLIGATIONS AND COMMITMENTS
The Company has contractual obligations, primarily lease, debt and unfunded retirement plans, with no other significant obligations. To satisfy these obligations, the Company will use cash from operations. The following table summarizes the Company’s contractual obligations and their aggregate maturities as of January 3, 2010 (see Notes 7, 10 and 16 to the Consolidated Financial Statements for further details):
                                         
    Long-term     Interest on     Unfunded              
    Debt     Debt     Retirement     Operating        
(Dollars in Millions)   Obligations     Obligations     Plans     Leases     Total  
     
2010
  $ 34       469       66       178       747  
2011
    35       465       65       150       715  
2012
    615       442       69       128       1,254  
2013
    507       410       73       103       1,093  
2014
    9       402       76       87       574  
After 2014
    7,057       4,525       474       94       12,150  
     
Total
  $ 8,257       6,713       823       740       16,533  
     
For tax matters, see Note 8 to the Consolidated Financial Statements.
SHARE REPURCHASE AND DIVIDENDS
On July 9, 2007, the Company announced that its Board of Directors approved a stock repurchase program, authorizing the Company to buy back up to $10.0 billion of the Company’s Common Stock. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Any shares acquired will be available for general corporate purposes. The Company funds the share repurchase program through a combination of available cash and debt. As of January 3, 2010, the Company repurchased an
JOHNSON & JOHNSON 2009 ANNUAL REPORT

32


Table of Contents

aggregate of 140.4 million shares of Johnson & Johnson Common Stock under the current repurchase program at a cost of $8.9 billion. In addition, the Company has an annual program to repurchase shares for use in employee stock and incentive plans.
     The Company increased its dividend in 2009 for the 47th consecutive year. Cash dividends paid were $1.930 per share in 2009, compared with dividends of $1.795 per share in 2008 and $1.620 per share in 2007. The dividends were distributed as follows:
                         
    2009     2008     2007  
     
First quarter
  $ 0.460       0.415       0.375  
Second quarter
    0.490       0.460       0.415  
Third quarter
    0.490       0.460       0.415  
Fourth quarter
    0.490       0.460       0.415  
     
Total
  $ 1.930       1.795       1.620  
     
On January 4, 2010, the Board of Directors declared a regular quarterly cash dividend of $0.490 per share, payable on March 9, 2010, to shareholders of record as of February 23, 2010. The Company expects to continue the practice of paying regular cash dividends.
Other Information
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Management’s discussion and analysis of results of operations and financial condition are based on the Company’s consolidated financial statements that have been prepared in accordance with accounting principles generally accepted in the U.S. (GAAP). The preparation of these financial statements requires that management make estimates and assumptions that affect the amounts reported for revenues, expenses, assets, liabilities and other related disclosures. Actual results may or may not differ from these estimates. The Company believes that the understanding of certain key accounting policies and estimates are essential in achieving more insight into the Company’s operating results and financial condition. These key accounting policies include revenue recognition, income taxes, legal and self-insurance contingencies, valuation of long-lived assets, assumptions used to determine the amounts recorded for pensions and other employee benefit plans and accounting for stock options.
Revenue Recognition: The Company recognizes revenue from product sales when goods are shipped or delivered, and title and risk of loss pass to the customer. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded.
     Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates, the largest being the Medicaid rebate provision, are estimated based on contractual terms, historical experience, trend analysis and projected market conditions in the various markets served. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.
     Sales returns are generally estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.
     Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The returns reserve is based on historical return trends by product and by market as a percent to gross sales.
The Company’s sales return reserves are accounted for in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists. Sales return reserves are recorded at full sales value. Sales returns in the Consumer and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices and Diagnostics segment are typically resalable but are not material. The Company rarely exchanges products from inventory for returned products. The sales returns reserve for the total Company has ranged between 1.1% and 1.2% of annual net trade sales during the prior three fiscal reporting years 2007-2009.
     Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the year incurred. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on estimated sales volumes for the incentive period and are recorded as products are sold. The Company also earns service revenue for co-promotion of certain products. For all years presented, service revenues were less than 2% of total revenues and are included in sales to customers. Additionally, these arrangements are evaluated to determine the appropriate amounts to be deferred.
     In addition, the Company enters into collaboration arrangements, which contain multiple revenue generating activities. The revenue for these arrangements is recognized as each activity is performed or delivered, based on the relative fair value. Upfront fees received as part of these arrangements are deferred and recognized as revenue earned over the obligation period.
See Note 1 to the Consolidated Financial Statements for additional disclosures on collaborations.
     Reasonably likely changes to assumptions used to calculate the accruals for rebates, returns and promotions are not anticipated to have a material effect on the financial statements. The Company currently discloses the impact of changes to assumptions in the quarterly or annual filing in which there is a material financial statement impact.
     Below are tables which show the progression of accrued rebates, returns, promotions, reserve for doubtful accounts and reserve for cash discounts by segment of business for the fiscal years ended January 3, 2010 and December 28, 2008.
CONSUMER SEGMENT
                                 
    Balance at                     Balance at  
    Beginning             Payments/     End  
(Dollars in Millions)   of Period     Accruals     Other     of Period  
     
2009
                               
Accrued rebates(1)
  $ 131       380       (390 )     121  
Accrued returns
    115       134       (122 )     127  
Accrued promotions
    202       1,996       (1,926 )     272  
     
Subtotal
  $ 448       2,510       (2,438 )     520  
     
Reserve for doubtful accounts
    110       23       (26 )     107  
Reserve for cash discounts
    22       285       (286 )     21  
     
Total
  $ 580       2,818       (2,750 )     648  
     
2008
                               
Accrued rebates(1)
  $ 217       300       (386 )     131  
Accrued returns
    113       135       (133 )     115  
Accrued promotions
    297       2,369       (2,464 )     202  
     
Subtotal
  $ 627       2,804       (2,983 )     448  
     
Reserve for doubtful accounts
    71       41       (2 )     110  
Reserve for cash discounts
    23       272       (273 )     22  
     
Total
  $ 721       3,117       (3,258 )     580  
     
 
(1)   Includes reserve for customer rebates of $46 million at January 3, 2010 and $73 million at December 28, 2008, recorded as a contra asset.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION

33


Table of Contents

PHARMACEUTICAL SEGMENT
                                 
    Balance at                     Balance at  
    Beginning             Payments/     End  
(Dollars in Millions)   of Period     Accruals     Other     of Period  
     
2009
                               
Accrued rebates(1)
  $ 1,261       3,975       (4,172 )     1,064  
Accrued returns
    490       147       (295 )     342  
Accrued promotions
    107       330       (353 )     84  
     
Subtotal
  $ 1,858       4,452       (4,820 )     1,490  
     
Reserve for doubtful accounts
    48       37       (2 )     83  
Reserve for cash discounts
    23       462       (437 )     48  
     
Total
  $ 1,929       4,951       (5,259 )     1,621  
     
2008
                               
Accrued rebates(1)
  $ 1,249       3,331       (3,319 )     1,261  
Accrued returns
    345       168       (23 )     490  
Accrued promotions
    263       414       (570 )     107  
     
Subtotal
  $ 1,857       3,913       (3,912 )     1,858  
     
Reserve for doubtful accounts
    26       24       (2 )     48  
Reserve for cash discounts
    24       376       (377 )     23  
     
Total
  $ 1,907       4,313 (2)     (4,291 )     1,929  
     
 
(1)   Includes reserve for customer rebates of $372 million at January 3, 2010 and $344 million at December 28, 2008, recorded as a contra asset.
 
(2)   Includes $115 million adjustment related to previously estimated accrued sales reserves.
MEDICAL DEVICES AND DIAGNOSTICS SEGMENT
                                 
    Balance at                     Balance at  
    Beginning             Payments/     End  
(Dollars in Millions)   of Period     Accruals     Other     of Period  
     
2009
                               
Accrued rebates(1)
  $ 416       2,229       (2,191 )     454  
Accrued returns
    189       74       (43 )     220  
Accrued promotions
    47       120       (94 )     73  
     
Subtotal
  $ 652       2,423       (2,328 )     747  
     
Reserve for doubtful accounts
    109       50       (16 )     143  
Reserve for cash discounts
    34       416       (418 )     32  
     
Total
  $ 795       2,889       (2,762 )     922  
     
2008
                               
Accrued rebates(1)
  $ 336       1,947       (1,867 )     416  
Accrued returns
    190       99       (100 )     189  
Accrued promotions
    18       208       (179 )     47  
     
Subtotal
  $ 544       2,254       (2,146 )     652  
     
Reserve for doubtful accounts
    96       36       (23 )     109  
Reserve for cash discounts
    24       257       (247 )     34  
     
Total
  $ 664       2,547 (2)     (2,416 )     795  
     
 
(1)   Includes reserve for customer rebates of $311 million at January 3, 2010 and $304 million at December 28, 2008, recorded as a contra asset.
 
(2)   Includes $56 million adjustment related to previously estimated sales rebate reserve.
Income Taxes: Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on current tax regulations and rates. Changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. Management believes that changes in these estimates would not have a material effect on the Company’s results of operations, cash flows or financial position.
     In 2007, in accordance with U.S. GAAP the Company adopted the standard related to accounting for uncertainty in income taxes. The Codification prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Codification also provides guidance on derecognition, classification and other matters. See Note 8 to the Consolidated Financial Statements for further information regarding income taxes.
     At January 3, 2010 and December 28, 2008, the cumulative amounts of undistributed international earnings were approximately $32.2 billion and $27.7 billion, respectively. The Company intends to continue to reinvest its undistributed international earnings to expand its international operations; therefore, no U.S. tax expense has been recorded with respect to the undistributed portion not intended for repatriation.
Legal and Self Insurance Contingencies: The Company records accruals for various contingencies including legal proceedings and product liability cases as these arise in the normal course of business. The accruals are based on management’s judgment as to the probability of losses and, where applicable, actuarially determined estimates. Additionally, the Company records insurance receivable amounts from third-party insurers when recovery is probable. As appropriate, reserves against these receivables are recorded for estimated amounts that may not be collected from third-party insurers.
Long-Lived and Intangible Assets: The Company assesses changes in economic conditions and makes assumptions regarding estimated future cash flows in evaluating the value of the Company’s property, plant and equipment, goodwill and intangible assets. As these assumptions and estimates may change over time, it may or may not be necessary for the Company to record impairment charges.
Employee Benefit Plans: The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. These plans are based on assumptions for the discount rate, expected return on plan assets, expected salary increases and health care cost trend rates. See Note 10 to the Consolidated Financial Statements for further details on these rates and the effect a rate change would have on the Company’s results of operations.
Stock Based Compensation: The Company recognizes compensation expense associated with the issuance of equity instruments to employees for their services. The fair value of each award is estimated on the date of grant using the Black-Scholes option valuation model and is expensed in the financial statements over the vesting period. The input assumptions used in determining fair value are the expected life, expected volatility, risk-free rate and the dividend yield. See Note 17 to the Consolidated Financial Statements for additional information.
NEW ACCOUNTING PRONOUNCEMENTS
Refer to Note 1 to the Consolidated Financial Statements for recently adopted accounting pronouncements and recently issued accounting pronouncements not yet adopted as of January 3, 2010.
ECONOMIC AND MARKET FACTORS
The Company is aware that its products are used in an environment where, for more than a decade, policymakers, consumers and businesses have expressed concerns about the rising cost of health care. In response to these concerns, the Company has a long-standing policy of pricing products responsibly. For the period 1999-2009, in the United States, the weighted average compound annual growth rate of the Company’s net price increases for health care products
JOHNSON & JOHNSON 2009 ANNUAL REPORT

34


Table of Contents

(prescription and over-the-counter drugs, hospital and professional products) was below the U.S. Consumer Price Index (CPI).
     Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate. The Company will account for operations in Venezuela as highly inflationary in 2010, as the prior three-year cumulative inflation rate has surpassed 100%. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.
     The Company is exposed to fluctuations in currency exchange rates. A 1% change in the value of the U.S. dollar as compared to all foreign currencies in which the Company had sales, income or expense in 2009 would have increased or decreased the translation of foreign sales by $300 million and income by $50 million.
     The Company faces various worldwide health care changes that may continue to result in pricing pressures that include health care cost containment and government legislation relating to sales, promotions and reimbursement.
     Changes in the behavior and spending patterns of purchasers of health care products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing health care insurance coverage, as a result of the current global economic downturn may continue to impact the Company’s businesses.
     The Company also operates in an environment which has become increasingly hostile to intellectual property rights. Generic drug firms have filed Abbreviated New Drug Applications (ANDAs) seeking to market generic forms of most of the Company’s key pharmaceutical products, prior to expiration of the applicable patents covering those products. In the event the Company is not successful in defending the patent claims challenged in ANDA filings, the generic firms will then introduce generic versions of the product at issue, resulting in the potential for substantial market share and revenue losses for that product. For further information see the discussion on “Litigation Against Filers of Abbreviated New Drug Applications” in Note 21 to the Consolidated Financial Statements.
LEGAL PROCEEDINGS
The Company is involved in numerous product liability cases in the United States, many of which concern alleged adverse reactions to drugs and medical devices. The damages claimed are substantial, and while the Company is confident of the adequacy of the warnings and instructions for use which accompany such products, it is not feasible to predict the ultimate outcome of litigation. However, the Company believes that if any liability results from such cases, it will be substantially covered by existing amounts accrued in the Company’s balance sheet under its self-insurance program and by third-party product liability insurance.
     The Company is also involved in a number of patent, trademark and other lawsuits, as well as investigations, incidental to its business. The ultimate legal and financial liability of the Company in respect to all claims, lawsuits and proceedings referred to above cannot be estimated with any certainty. However, in the Company’s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities already accrued in the Company’s balance sheet, is not expected to have a material adverse effect on the Company’s financial condition, although the resolution in any reporting period of one or more of these matters could have a significant impact on the Company’s results of operations and cash flows for that period.
     See Note 21 to the Consolidated Financial Statements for further information regarding legal proceedings.
COMMON STOCK MARKET PRICES
The Company’s common stock is listed on the New York Stock Exchange under the symbol JNJ. The composite market price ranges for Johnson & Johnson common stock during 2009 and 2008 were:
                                 
    2009     2008  
    High     Low     High     Low  
     
First quarter
  $ 61.00       46.25       68.85       61.17  
Second quarter
    56.65       50.12       68.32       63.40  
Third quarter
    62.47       55.71       72.76       63.10  
Fourth quarter
    65.41       58.78       69.86       52.06  
Year-end close   $64.41
  58.56
Cautionary Factors That May Affect Future Results
This Annual Report contains forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and anticipate results based on management’s plans that are subject to uncertainty. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning in conjunction with, among other things, discussions of future operations, financial performance, the Company’s strategy for growth, product development, regulatory approval, market position and expenditures.
     Forward-looking statements are based on current expectations of future events. The Company cannot guarantee that any forward-looking statement will be accurate, although the Company believes that it has been reasonable in its expectations and assumptions. Investors should realize that if underlying assumptions prove inaccurate or that unknown risks or uncertainties materialize, actual results could vary materially from the Company’s expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.
     Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; U.S. and foreign health care reforms and governmental laws and regulations; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; product efficacy or safety concerns resulting in product recalls or regulatory action.
     The Company’s report on Form 10-K for the year ended January 3, 2010 includes, in Exhibit 99, a discussion of additional factors that could cause actual results to differ from expectations. The Company notes these factors as permitted by the Private Securities Litigation Reform Act of 1995.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION

35


Table of Contents

Johnson & Johnson and Subsidiaries
Consolidated Balance Sheets
                 
At January 3, 2010 and December 28, 2008 (Dollars in Millions Except Share and Per Share Data) (Note 1)   2009     2008  
     
Assets
               
Current assets
               
Cash and cash equivalents (Notes 1 and 2)
  $ 15,810       10,768  
Marketable securities (Notes 1 and 2)
    3,615       2,041  
Accounts receivable trade, less allowances for doubtful accounts $333 (2008, $268)
    9,646       9,719  
Inventories (Notes 1 and 3)
    5,180       5,052  
Deferred taxes on income (Note 8)
    2,793       3,430  
Prepaid expenses and other receivables
    2,497       3,367  
     
 
               
Total current assets
    39,541       34,377  
     
 
               
Property, plant and equipment, net (Notes 1 and 4)
    14,759       14,365  
Intangible assets, net (Notes 1 and 5)
    16,323       13,976  
Goodwill (Notes 1 and 5)
    14,862       13,719  
Deferred taxes on income (Note 8)
    5,507       5,841  
Other assets
    3,690       2,634  
     
 
               
Total assets
  $ 94,682       84,912  
     
 
               
Liabilities and Shareholders’ Equity
               
 
               
Current liabilities
               
Loans and notes payable (Note 7)
  $ 6,318       3,732  
Accounts payable
    5,541       7,503  
Accrued liabilities
    5,796       5,531  
Accrued rebates, returns and promotions
    2,028       2,237  
Accrued salaries, wages and commissions
    1,606       1,432  
Accrued taxes on income
    442       417  
     
 
               
Total current liabilities
    21,731       20,852  
     
 
               
Long-term debt (Note 7)
    8,223       8,120  
Deferred taxes on income (Note 8)
    1,424       1,432  
Employee related obligations (Notes 9 and 10)
    6,769       7,791  
Other liabilities
    5,947       4,206  
     
 
Total liabilities
    44,094       42,401  
     
 
               
Shareholders’ equity
               
Preferred stock — without par value
(authorized and unissued 2,000,000 shares)
           
Common stock — par value $1.00 per share (Note 12)
(authorized 4,320,000,000 shares; issued 3,119,843,000 shares)
    3,120       3,120  
Accumulated other comprehensive income (Note 13)
    (3,058 )     (4,955 )
Retained earnings
    70,306       63,379  
     
 
    70,368       61,544  
Less: common stock held in treasury, at cost (Note 12)
(365,522,000 shares and 350,665,000 shares)
    19,780       19,033  
     
 
               
Total shareholders’ equity
    50,588       42,511  
     
 
               
Total liabilities and shareholders’ equity
  $ 94,682       84,912  
     
See Notes to Consolidated Financial Statements
JOHNSON & JOHNSON 2009 ANNUAL REPORT

36


Table of Contents

Johnson & Johnson and Subsidiaries
Consolidated Statements of Earnings
                         
(Dollars in Millions Except Per Share Figures) (Note 1)   2009     2008     2007  
     
Sales to customers
  $ 61,897       63,747       61,095  
     
 
                       
Cost of products sold
    18,447       18,511       17,751  
     
 
                       
Gross profit
    43,450       45,236       43,344  
 
Selling, marketing and administrative expenses
    19,801       21,490       20,451  
Research expense
    6,986       7,577       7,680  
Purchased in-process research and development (Note 20)
          181       807  
Interest income
    (90 )     (361 )     (452 )
Interest expense, net of portion capitalized (Note 4)
    451       435       296  
Other (income) expense, net
    (526 )     (1,015 )     534  
Restructuring (Note 22)
    1,073             745  
     
Earnings before provision for taxes on income
    15,755       16,929       13,283  
Provision for taxes on income (Note 8)
    3,489       3,980       2,707  
     
 
                       
Net earnings
  $ 12,266       12,949       10,576  
     
 
                       
Basic net earnings per share (Notes 1 and 15)
  $ 4.45       4.62       3.67  
Diluted net earnings per share (Notes 1 and 15)
  $ 4.40       4.57       3.63  
 
                       
Cash dividends per share
  $ 1.930       1.795       1.620  
 
                       
Basic average shares outstanding (Notes 1 and 15)
    2,759.5       2,802.5       2,882.9  
Diluted average shares outstanding (Notes 1 and 15)
    2,789.1       2,835.6       2,910.7  
     
See Notes to Consolidated Financial Statements
CONSOLIDATED FINANCIAL STATEMENTS

37


Table of Contents

Johnson & Johnson and Subsidiaries
Consolidated Statements of Equity
                                                 
                            Accumulated                
                            Other             Treasury  
            Comprehensive     Retained     Comprehensive     Common Stock     Stock  
(Dollars in Millions) (Note 1)   Total     Income     Earnings     Income     Issued Amount     Amount  
     
Balance, December 31, 2006
  $ 39,318               49,290       (2,118 )     3,120       (10,974 )
     
 
                                               
Net earnings
    10,576       10,576       10,576                          
Cash dividends paid
    (4,670 )             (4,670 )                        
Employee compensation and stock option plans
    2,311               131                       2,180  
Conversion of subordinated debentures
    9               (4 )                     13  
Repurchase of common stock
    (5,607 )                                     (5,607 )
Adoption of FIN 48
    (19 )             (19 )                        
Other
    (24 )             (24 )                        
Other comprehensive income, net of tax:
                                               
Currency translation adjustment
    786       786               786                  
Unrealized gains on securities
    23       23               23                  
Employee benefit plans
    670       670               670                  
Losses on derivatives & hedges
    (54 )     (54 )             (54 )                
Reclassification adjustment
            (5 )                                
 
                                             
Total comprehensive income
            11,996                                  
 
                                             
 
                                               
                   
Balance, December 30, 2007
  $ 43,319               55,280       (693 )     3,120       (14,388 )
     
Net earnings
    12,949       12,949       12,949                          
Cash dividends paid
    (5,024 )             (5,024 )                        
Employee compensation and stock option plans
    2,180               175                       2,005  
Conversion of subordinated debentures
                  (1 )                     1  
Repurchase of common stock
    (6,651 )                                     (6,651 )
Other comprehensive income, net of tax:
                                               
Currency translation adjustment
    (2,499 )     (2,499 )             (2,499 )                
Unrealized losses on securities
    (59 )     (59 )             (59 )                
Employee benefit plans
    (1,870 )     (1,870 )             (1,870 )                
Gains on derivatives & hedges
    166       166               166                  
Reclassification adjustment
            (27 )                                
 
                                             
Total comprehensive income
            8,660                                  
 
                                             
 
                                               
                   
Balance, December 28, 2008
  $ 42,511               63,379       (4,955 )     3,120       (19,033 )
     
Net earnings
    12,266       12,266       12,266                          
Cash dividends paid
    (5,327 )             (5,327 )                        
Employee compensation and stock option plans
    1,402               25                       1,377  
Conversion of subordinated debentures
    2               (4 )                     6  
Repurchase of common stock
    (2,130 )                                     (2,130 )
Other
    (33 )             (33 )                        
Other comprehensive income, net of tax:
                                               
Currency translation adjustment
    1,363       1,363               1,363                  
Unrealized losses on securities
    (55 )     (55 )             (55 )                
Employee benefit plans
    565       565               565                  
Gains on derivatives & hedges
    24       24               24                  
 
                                             
Total comprehensive income
            14,163                                  
 
                                             
 
                                               
                   
Balance, January 3, 2010
  $ 50,588               70,306       (3,058 )     3,120       (19,780 )
     
See Notes to Consolidated Financial Statements
JOHNSON & JOHNSON 2009 ANNUAL REPORT

38


Table of Contents

Johnson & Johnson and Subsidiaries
Consolidated Statements of Cash Flows
                         
(Dollars in Millions) (Note 1)   2009     2008     2007  
     
Cash flows from operating activities
                       
Net earnings
  $ 12,266       12,949       10,576  
Adjustments to reconcile net earnings to cash flows from operating activities:
                       
Depreciation and amortization of property and intangibles
    2,774       2,832       2,777  
Stock based compensation
    628       627       698  
Purchased in-process research and development
          181       807  
Intangible asset write-down (NATRECOR®)
                678  
Deferred tax provision
    (436 )     22       (1,762 )
Accounts receivable allowances
    58       86       22  
Changes in assets and liabilities, net of effects from acquisitions:
                       
Decrease/(increase) in accounts receivable
    453       (736 )     (416 )
Decrease/(increase) in inventories
    95       (101 )     14  
(Decrease)/increase in accounts payable and accrued liabilities
    (507 )     (272 )     2,642  
Decrease/(increase) in other current and non-current assets
    1,209       (1,600 )     (1,578 )
Increase in other current and non-current liabilities
    31       984       564  
     
 
                       
Net cash flows from operating activities
    16,571       14,972       15,022  
     
 
                       
Cash flows from investing activities
                       
Additions to property, plant and equipment
    (2,365 )     (3,066 )     (2,942 )
Proceeds from the disposal of assets
    154       785       457  
Acquisitions, net of cash acquired (Note 20)
    (2,470 )     (1,214 )     (1,388 )
Purchases of investments
    (10,040 )     (3,668 )     (9,659 )
Sales of investments
    7,232       3,059       7,988  
Other (primarily intangibles)
    (109 )     (83 )     (368 )
     
 
                       
Net cash used by investing activities
    (7,598 )     (4,187 )     (5,912 )
     
 
                       
Cash flows from financing activities
                       
 
                       
Dividends to shareholders
    (5,327 )     (5,024 )     (4,670 )
Repurchase of common stock
    (2,130 )     (6,651 )     (5,607 )
Proceeds from short-term debt
    9,484       8,430       19,626  
Retirement of short-term debt
    (6,791 )     (7,319 )     (21,691 )
Proceeds from long-term debt
    9       1,638       5,100  
Retirement of long-term debt
    (219 )     (24 )     (18 )
Proceeds from the exercise of stock options/excess tax benefits
    882       1,486       1,562  
     
 
                       
Net cash used by financing activities
    (4,092 )     (7,464 )     (5,698 )
     
 
                       
Effect of exchange rate changes on cash and cash equivalents
    161       (323 )     275  
     
Increase in cash and cash equivalents
    5,042       2,998       3,687  
Cash and cash equivalents, beginning of year (Note 1)
    10,768       7,770       4,083  
     
 
Cash and cash equivalents, end of year (Note 1)
  $ 15,810       10,768       7,770  
     
 
                       
Supplemental cash flow data
                       
Cash paid during the year for:
                       
Interest
  $ 533       525       314  
Income taxes
    2,363       4,068       4,099  
 
                       
Supplemental schedule of noncash investing and financing activities
                       
Treasury stock issued for employee compensation and stock option plans, net of cash proceeds
  $ 541       593       738  
Conversion of debt
    2             9  
 
                       
Acquisitions
                       
 
                       
Fair value of assets acquired
  $ 3,345       1,328       1,620  
Fair value of liabilities assumed and non-controlling interests
    (875 )     (114 )     (232 )
     
 
                       
Net cash paid for acquisitions
  $ 2,470       1,214       1,388  
     
See Notes to Consolidated Financial Statements
CONSOLIDATED FINANCIAL STATEMENTS

39


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Summary of Significant Accounting Policies
PRINCIPLES OF CONSOLIDATION
The consolidated financial statements include the accounts of Johnson & Johnson and subsidiaries (the “Company”). Inter-company accounts and transactions are eliminated.
DESCRIPTION OF THE COMPANY AND BUSINESS SEGMENTS
The Company has approximately 115,500 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.
     The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment manufactures and markets a broad range of products used in the baby care, skin care, oral care, wound care and women’s health care fields, as well as nutritional and over-the-counter pharmaceutical products. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world. The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. These products are distributed directly to retailers, wholesalers and health care professionals for prescription use. The Medical Devices and Diagnostics segment includes a broad range of products used principally in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. These products include Cordis’ circulatory disease management products; DePuy’s orthopaedic joint reconstruction, spinal care and sports medicine products; Ethicon’s surgical care, aesthetics and women’s health products; Ethicon Endo-Surgery’s minimally invasive surgical products; LifeScan’s blood glucose monitoring and insulin delivery products; Ortho-Clinical Diagnostics’ professional diagnostic products and Vistakon’s disposable contact lenses.
NEW ACCOUNTING PRONOUNCEMENTS
RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS
During the fiscal fourth quarter of 2009, in accordance with U.S. GAAP, the Company adopted the authoritative guidance for employers’ disclosures about postretirement benefit plan assets to enhance the disclosure regarding the types of assets and associated risks in an employer’s defined benefit pension or other postretirement plan, as well as, events in the economy and markets that could have a significant effect on the value of the plan assets. The adoption of this standard did not have a material impact on the Company’s results of operations, cash flows or financial position. See Note 10 for enhanced disclosures.
     During the fiscal third quarter of 2009, the Company adopted The FASB Accounting Standards CodificationTM (ASC or Codification) and the Hierarchy of Generally Accepted Accounting Principles (GAAP) which establishes the Codification as the sole source for authoritative U.S. GAAP and will supersede all accounting standards in U.S. GAAP, aside from those issued by the SEC. The adoption of the Codification did not have an impact on the Company’s results of operations, cash flows or financial position. Since the adoption of the Accounting Standards Codification (ASC) the Company’s notes to the consolidated financial statements will no longer make reference to Statement of Financial Accounting Standards (SFAS) or other U.S. GAAP pronouncements.
     During the fiscal second quarter of 2009, in accordance with U.S. GAAP, the Company adopted the standards on subsequent events. This pronouncement establishes standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued. See Note 23 for related disclosure.
     During the fiscal first quarter of 2009, in accordance with U.S. GAAP, the Company adopted the standards on business combinations and non-controlling interests in Consolidated Financial Statements. These standards aim to improve, simplify, and converge internationally, the accounting for business combinations and the reporting of non-controlling interests in consolidated financial statements. These standards have an impact on the manner in which the Company accounts for acquisitions beginning in the fiscal year 2009. Significant changes include the capitalization of purchased in-process research and development (IPR&D), expensing of acquisition related restructuring actions and transaction related costs and the recognition of contingent purchase price consideration at fair value at the acquisition date. In addition, changes in accounting for deferred tax asset valuation allowances and acquired income tax uncertainties after the measurement period will be recognized in earnings rather than as an adjustment to the cost of acquisition. This accounting treatment for taxes is applicable to acquisitions that occurred both prior and subsequent to the adoption of the standard. Operating profit attributable to non-controlling interests is reported in Other (Income) Expense, net and the related tax impact to the Provision for Taxes. Additionally, equity attributable to non-controlling interests is recorded in Other Non-Current liabilities. Non-controlling interests as related to the Company’s financial statements are immaterial and therefore, not separately disclosed.
     During the fiscal first quarter of 2009, in accordance with U.S. GAAP, the Company adopted the standard related to disclosures about derivative instruments and hedging activities, which enhanced the disclosure regarding the Company’s derivative and hedging activities. The adoption of this standard did not have a material impact on the Company’s results of operations, cash flows or financial position. See Note 6 for enhanced disclosures.
     During the fiscal first quarter of 2009, in accordance with U.S. GAAP, the Company adopted the standard on collaborative arrangements related to the development and commercialization of intellectual property. This standard addresses the income statement classification of payments made between parties in a collaborative arrangement. The impact of the adoption of this standard related to all collaboration agreements that existed as of January 3, 2010 and December 28, 2008 was immaterial to the Company’s results of operations, cash flows or financial position.
     During the fiscal first quarter of 2009, in accordance with U.S. GAAP, the Company adopted the standard related to defensive intangible assets. This standard applies to acquired intangible assets in situations in which an entity does not intend to actively use the asset but intends to hold the asset to prevent others from obtaining access to the asset, except for intangible assets that are used in research and development activities. The adoption of this standard did not have a material impact on the Company’s results of operations, cash flows or financial position.
RECENTLY ISSUED ACCOUNTING STANDARDS, NOT ADOPTED AS OF JANUARY 3, 2010
The FASB issued guidance and amendments to the criteria for separating consideration in multiple-deliverable revenue arrangements.

40


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The guidance and amendments are expected to: (a) provide principles and application guidance on whether multiple deliverables exist, how the arrangement should be separated, and the consideration allocated; (b) require an entity to allocate revenue in an arrangement using estimated selling prices of deliverables if a vendor does not have vendor-specific objective evidence or third-party evidence of selling price; and (c) eliminate the use of the residual method and require an entity to allocate the revenue using the relative selling price method. The guidance significantly expands the disclosure requirements for multiple-deliverable revenue arrangements. This guidance is effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010. Early adoption is permitted. The Company adopted this guidance in the first fiscal quarter of 2010. The adoption will not have a material impact on the Company’s results of operations, cash flows or financial position; however, it will expand the disclosures for such arrangements.
     The FASB issued a standard to improve financial reporting by enterprises involved with variable interest entities. This statement is effective for the Company beginning with the fiscal year 2010. Earlier application is prohibited. The adoption of this standard will not have a material impact on the Company’s results of operations, cash flows or financial position.
CASH EQUIVALENTS
The Company considers securities with maturities of three months or less, when purchased, to be cash equivalents.
INVESTMENTS
Short-term marketable securities are carried at cost, which approximates fair value. Investments classified as available-for-sale are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Long-term debt securities that the Company has the ability and intent to hold until maturity are carried at amortized cost. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company periodically reviews its investments in equity securities for impairment and adjusts these investments to their fair value when a decline in market value is deemed to be other than temporary. If losses on these securities are considered to be other than temporary, the loss is recognized in earnings.
PROPERTY, PLANT AND EQUIPMENT AND DEPRECIATION
Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:
         
Building and building equipment
  20-40 years
Land and leasehold improvements
  10-20 years
Machinery and equipment
  2-13 years
The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8 years.
     The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.
REVENUE RECOGNITION
The Company recognizes revenue from product sales when the goods are shipped or delivered and title and risk of loss pass to the customer. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded.
     Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates, the largest being the Medicaid rebate provision, are estimated based on contractual terms, historical experience, trend analysis and projected market conditions in the various markets served. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.
     Sales returns are generally estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals. Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods. The Company’s sales return reserves are accounted for in accordance with U.S. GAAP guidance regarding revenue recognition when right of return exists. Sales return reserves are recorded at full sales value. Sales returns in the Consumer and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices and Diagnostics segment are typically resalable but are not material. The Company rarely exchanges products from inventory for returned products. The sales returns reserve for the total Company has ranged between 1.1% and 1.2% of annual net trade sales during the prior three fiscal reporting years 2007-2009.
     Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the year incurred. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. The Company also earns service revenue for co-promotion of certain products and includes it in sales to customers. These arrangements are evaluated to determine the appropriate amounts to be deferred.
SHIPPING AND HANDLING
Shipping and handling costs incurred were $964 million, $1,017 million and $934 million in 2009, 2008 and 2007, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented.
INVENTORIES
Inventories are stated at the lower of cost or market determined by the first-in, first-out method.

41


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
INTANGIBLE ASSETS AND GOODWILL
The authoritative literature on U.S. GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed the annual impairment test for 2009 in the fiscal fourth quarter and no impairment was determined. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if a triggering event occurs.
     Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions. See Note 5 for further details on Intangible Assets and Goodwill.
FINANCIAL INSTRUMENTS
As required by U.S. GAAP all derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.
     The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1) minimize foreign currency exposure’s impact on the Company’s financial performance; (2) protect the Company’s cash flow from adverse movements in foreign exchange rates; (3) ensure the appropriateness of financial instruments; and (4) manage the enterprise risk associated with financial institutions. See Note 6 for additional information on Financial Instruments.
PRODUCT LIABILITY
Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information. The accruals are adjusted periodically as additional information becomes available. As a result of cost and availability factors, effective November 1, 2005, the Company ceased purchasing third-party product liability insurance. Based on the availability of prior coverage, receivables for insurance recoveries related to product liability claims are recorded on an undiscounted basis, when it is probable that a recovery will be realized.
RESEARCH AND DEVELOPMENT
Research and development expenses are expensed as incurred. Upfront and milestone payments made to third-parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third-parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.
     The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations. In general, the income statement presentation for these collaborations is as follows:
         
Nature/Type of Collaboration   Statement of Earnings Presentation  
 
Third-party sale of product
  Sales to customers
Royalties/milestones paid to collaborative partner (post-regulatory approval)*
  Cost of goods sold
Royalties received from collaborative partner
  Other income (expense), net
Upfront payments & milestones paid to collaborative partner (pre-regulatory approval)
  Research expense
Research and development payments to collaborative partner
  Research expense
Research and development payments received from collaborative partner
  Reduction of Research expense
 
*   Milestones are capitalized as intangible assets and amortized to cost of goods sold over the useful life.
ADVERTISING
Costs associated with advertising are expensed in the year incurred and are included in the selling, marketing and administrative expenses. Advertising expenses worldwide, which are comprised of television, radio, print media and Internet advertising, were $2.4 billion in 2009, $2.9 billion in 2008 and $2.7 billion in 2007.
INCOME TAXES
The Company intends to continue to reinvest its undistributed international earnings to expand its international operations; therefore, no U.S. tax expense has been recorded with respect to the undistributed portion not intended for repatriation. At January 3, 2010 and December 28, 2008, the cumulative amount of undistributed international earnings were approximately $32.2 billion and $27.7 billion, respectively.
     Deferred income taxes are recognized for tax consequences of temporary differences by applying enacted statutory tax rates, applicable to future years, to differences between the financial reporting and the tax basis of existing assets and liabilities.
NET EARNINGS PER SHARE
Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.
USE OF ESTIMATES
The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. For instance, in determining annual pension and post-employment benefit costs, the Company estimates the rate of return on plan assets, and the cost of future health care benefits. Actual results may or may not differ from those estimates.

42


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
ANNUAL CLOSING DATE
The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52 weeks, but every five or six years the fiscal year consists of 53 weeks, as was the case in 2009 and will be the case again in 2014.
RECLASSIFICATION
Certain prior period amounts have been reclassified to conform to current year presentation.
2. Cash, Cash Equivalents and Current Marketable Securities
                                                 
    January 3, 2010     December 28, 2008  
    Amortized     Unrealized     Estimated     Amortized     Unrealized     Estimated  
(Dollars in Millions)   Cost     Gains/(Losses)     Fair Value     Cost     Gains/(Losses)     Fair Value  
     
Current Investments
                                               
     
Cash
  $ 2,517             2,517       3,276             3,276  
Government securities and obligations
    13,370       1       13,371       7,486       4       7,490  
Corporate debt securities
    426             426       627       1       628  
Money market funds
    1,890             1,890       813             813  
Time deposits
    1,222             1,222       607             607  
     
Total cash, cash equivalents and current marketable securities
  $ 19,425       1       19,426       12,809       5       12,814  
     
As of January 3, 2010, current marketable securities consist of $3,434 million and $181 million of government securities and obligations and corporate debt securities, respectively.
     As of December 28, 2008, current marketable securities consist of $1,663 million, $342 million and $36 million of government securities and obligations, corporate debt securities and time deposits, respectively.
     Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices in active markets.
     The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an A (or equivalent) credit rating.
3. Inventories
At the end of 2009 and 2008, inventories were comprised of:
                 
(Dollars in Millions)   2009     2008  
     
Raw materials and supplies
  $ 1,144       839  
Goods in process
    1,395       1,372  
Finished goods
    2,641       2,841  
     
 
  $ 5,180       5,052  
     
4. Property, Plant and Equipment
At the end of 2009 and 2008, property, plant and equipment at cost and accumulated depreciation were:
                 
(Dollars in Millions)   2009     2008  
     
Land and land improvements
  $ 714       886  
Buildings and building equipment
    8,863       7,720  
Machinery and equipment
    17,153       15,234  
Construction in progress
    2,521       3,552  
     
 
    29,251       27,392  
Less accumulated depreciation
    14,492       13,027  
     
 
  $ 14,759       14,365  
     
The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in 2009, 2008 and 2007 was $101 million, $147 million and $130 million, respectively.
     Depreciation expense, including the amortization of capitalized interest in 2009, 2008 and 2007, was $2.1 billion, $2.0 billion and $1.9 billion, respectively.
     Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.
5. Intangible Assets and Goodwill
At the end of 2009 and 2008, the gross and net amounts of intangible assets were:
                 
(Dollars in Millions)   2009     2008  
     
Intangible assets with definite lives:
               
Patents and trademarks — gross
  $ 5,697       5,119  
Less accumulated amortization
    2,177       1,820  
     
Patents and trademarks — net
  $ 3,520       3,299  
     
Other intangibles — gross
  $ 7,808       7,376  
Less accumulated amortization
    2,680       2,433  
     
Other intangibles — net
  $ 5,128       4,943  
     
Total intangible assets with definite lives — gross
  $ 13,505       12,495  
Less accumulated amortization
    4,857       4,253  
     
Total intangible assets with definite lives — net
  $ 8,648       8,242  
     
Intangible assets with indefinite lives:
               
Trademarks
  $ 5,938       5,734  
Purchased in-process research and development*
    1,737        
     
Total intangible assets with indefinite lives
  $ 7,675       5,734  
     
Total intangible assets — net
  $ 16,323       13,976  
     
 
*   Purchased in-process research and development will be accounted for as an indefinite-lived intangible asset until the underlying project is completed or abandoned.

43


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Goodwill as of January 3, 2010 and December 28, 2008, as allocated by segment of business is as follows:
                                 
                    Med Dev        
(Dollars in Millions)   Consumer     Pharm     and Diag     Total  
     
Goodwill at December 30, 2007
  $ 8,125       964       5,034       14,123  
     
Acquisitions
    191             286       477  
Currency translation/other
    (842 )     (1 )     (38 )     (881 )
     
Goodwill at December 28, 2008
  $ 7,474       963       5,282       13,719  
     
Acquisitions
          271       401       672  
Currency translation/other*
    600       10       (139 )     471  
     
Goodwill at January 3, 2010
  $ 8,074       1,244       5,544       14,862  
     
 
*   Includes reclassification between segments.
The weighted average amortization periods for patents and trademarks and other intangible assets are 17 years and 28 years, respectively. The amortization expense of amortizable assets for the fiscal years ended January 3, 2010, December 28, 2008 and December 30, 2007 was $675 million, $788 million and $844 million before tax, respectively. Certain patents and intangible assets were written down to fair value during fiscal years 2009, 2008 and 2007, with the resulting charge included in amortization expense.
     The estimated amortization expense for the five succeeding years approximates $700 million before tax, per year. Substantially all of the amortization expense is included in cost of products sold.
6. Fair Value Measurements
During the fiscal first quarter of 2009, in accordance with U.S. GAAP the Company adopted the standard related to disclosures about derivative instruments and hedging activities. This standard requires qualitative disclosures about objectives and strategies for using derivatives, quantitative disclosures about fair value amounts of gain and losses on derivative instruments, and disclosures about credit-risk-related contingent features in derivative agreements.
     The Company uses forward exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of raw materials denominated in foreign currency. The Company also uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. The Company also uses forward exchange contracts to manage its exposure to the variability of cash flows for repatriation of foreign dividends. These contracts are designated as net investment hedges. Additionally, the Company uses forward exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The Company does not enter into derivative financial instruments for trading or speculative purposes, or contain credit risk related contingent features or requirements to post collateral. On an ongoing basis the Company monitors counterparty credit ratings. The Company considers credit non-performance risk to be low, because the Company enters into agreements with commercial institutions that have at least an A (or equivalent) credit rating. As of January 3, 2010, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $21 billion and $4 billion, respectively.
     As required by U.S. GAAP for derivative instruments and hedging activities, all derivative instruments are to be recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.
     The designation as a cash flow hedge is made at the entrance date into the derivative contract. At inception, all derivatives are expected to be highly effective. Changes in the fair value of a derivative that is designated as a cash flow hedge and is highly effective are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction. Gains/losses on net investment hedges are accounted for through the currency translation account and are insignificant. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes in the cash flows of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. Hedge ineffectiveness, if any, is included in current period earnings in other (income) and expense, net, and was insignificant for the fiscal year ended January 3, 2010 and December 28, 2008. Refer to Note 13 for disclosures of movements in Accumulated Other Comprehensive Income.
     As of January 3, 2010, the balance of deferred net gains on derivatives included in accumulated other comprehensive income was $145 million after-tax. For additional information, see Note 13. The Company expects that substantially all of the amount related to foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months excluding interest rate swaps. The amount ultimately realized in earnings will differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.
     The following table is a summary of the activity for the fiscal year ended January 3, 2010 related to designated derivatives as defined in the Codification:
                         
            Gain/(Loss)     Gain/(Loss)  
    Gain/(Loss)     reclassed from     recognized  
    recognized in     Accumulated     in Other  
Cash Flow Hedges   Accumulated     OCI into     Income/  
(Dollars in Millions)   OCI(1)     income(1)     Expense(2)  
     
Foreign exchange contracts
  $ (63 )     (47 )(A)     1  
Foreign exchange contracts
    (173 )     70 (B)     (1 )
Foreign exchange contracts
    5       13 (C)      
Cross currency interest rate swaps
    241       (16 )(D)      
Foreign exchange contracts
    28       (6 )(E)     (12 )
     
Total
  $ 38       14       (12 )
     
 
(1)   Effective portion
 
(2)   Ineffective portion
 
(A)   Included in Sales to customer
 
(B)   Included in Cost of products sold
 
(C)   Included in Research expense
 
(D)   Included in Interest (Income)/Interest Expense, net
 
(E)   Included in Other (Income)/Expense, net
For the fiscal year ended January 3, 2010, a gain of $21 million was recognized in Other (income)/expense, net, relating to foreign exchange contracts not designated as hedging instruments under the Codification.

44


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
     During the fiscal first quarter of 2008, in accordance with U.S. GAAP, the Company adopted the standard related to fair value measurements except for non-financial assets and liabilities recognized or disclosed at fair value on a non-recurring basis, which became effective during the first fiscal quarter of 2009. The effect of adoption on December 29, 2008 of this standard for non-financial assets and liabilities recorded at fair value on a non-recurring basis did not have a material impact on the Company’s financial position and results of operations. This standard defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. During the fiscal first quarter of 2008, the Company adopted the standard related to fair value option for financial assets and financial liabilities. This standard permits the Company to measure certain financial assets and financial liabilities at fair value. The Company assessed the fair value option made available upon adopting this standard, and has elected not to apply the fair value option to any financial instruments that were not already recognized at fair value.
     U.S. GAAP defines fair value as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with level 1 having the highest priority and level 3 having the lowest.
     The fair value of a derivative financial instrument (i.e. forward exchange contract, currency swap) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position.
     The Company also holds equity investments which are classified as level 1 since they are traded in an active exchange market.
During 2009, the Company acquired substantially all of the assets and rights of Elan’s Alzheimer’s Immunotherapy Program through a newly formed company, JANSSEN Alzheimer Immunotherapy (JAI), of which the Company owns 50.1% and Elan owns 49.9%. In addition, the Company purchased approximately 107 million newly issued American Depositary Receipts (ADRs) of Elan, representing 18.4% of Elan’s outstanding ordinary shares. As part of this transaction, the Company paid $885 million to Elan and committed to fund up to $250 million of Elan’s share of research and development spending by JAI. Of this total consideration of $1,135 million, $793 million represents the fair value of the 18.4% investment in Elan based on Elan’s share price in an actively traded market as of the date of this transaction. The IPR&D related to this transaction was $679 million and is associated with bapineuzumab, a potential first-in-class treatment that is being evaluated for slowing the progression of Alzheimer’s Disease. The value of the IPR&D was calculated using cash flow projections discounted for the risk inherent in such projects. Probability of success factors ranging from 40-50% were used to reflect inherent clinical and regulatory risk. The discount rate applied was 26%. The non-controlling interest related to this transaction was $590 million, which the Company has recorded in other non-current liabilities.
     During 2009, the Company entered into a strategic collaboration with Crucell N.V. which will focus on the discovery, development and commercialization of monoclonal antibodies and vaccines for the treatment and prevention of influenza and other infectious and non-infectious diseases. In addition, the Company, through its affiliate, purchased approximately 18% of Crucell’s outstanding ordinary shares for an aggregate purchase price of $448 million. Of the total consideration paid, $329 million represents the fair value of the investment based on Crucell’s share price in an actively traded market as of the date of the transaction with the excess recorded to research and development expense in 2009.
     The Company did not have any other significant financial assets or liabilities which would require revised valuations under this standard that are recognized at fair value.
The Company’s significant financial assets and liabilities measured at fair value as of January 3, 2010 and December 28, 2008 were as follows:
                                         
            Significant                    
    Quoted prices in     other     Significant              
    active markets for     observable     unobservable              
    identical assets     inputs     inputs     2009     2008  
(Dollars in Millions)   Level 1     Level 2     Level 3     Total     Total*  
     
Derivatives designated as hedging instruments:
                                       
Assets:
                                       
Foreign exchange contracts
  $       436             436       1,238  
Cross currency interest rate swaps
          126 **           126       110  
     
Total
          562             562       1,348  
     
Liabilities:
                                       
Foreign exchange contracts
          608             608       1,298  
Cross currency interest rate swaps
          571 ***           571       1,033  
     
Total
          1,179             1,179       2,331  
     
Derivatives not designated as hedging instruments:
                                       
Assets:
                                       
Foreign exchange contracts
          33             33       84  
Liabilities:
                                       
Foreign exchange contracts
          40             40       47  
 
                                       
Other investments
  $ 1,134                   1,134       41  
     
 
*   2008 assets and liabilities are all classified as Level 2 with the exception of other investments of $41 million which are classified as Level 1.
 
**   Includes $119 million of non-current assets.
 
***   Includes $517 million of non-current liabilities.
See Notes 2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.

45


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
7. Borrowings
The components of long-term debt are as follows:
                                 
            Effective             Effective  
(Dollars in Millions)   2009     Rate %     2008     Rate %  
     
6.625% Notes due 2009
                199       6.80  
5.15% Debentures due 2012
  $ 599       5.18 %     599       5.18  
3.80% Debentures due 2013
    500       3.82       500       3.82  
5.55% Debentures due 2017
    1,000       5.55       1,000       5.55  
5.15% Debentures due 2018
    898       5.15       898       5.15  
4.75% Notes due 2019 (1B Euro 1.4382)(2)/(1B Euro 1.4000)(3)
    1,429 (2)     5.35       1,390 (3)     5.35  
3% Zero Coupon Convertible Subordinated Debentures due 2020
    188       3.00       183       3.00  
6.73% Debentures due 2023
    250       6.73       250       6.73  
5.50% Notes due 2024 (500MM GBP1.6189)(2)/(500MM GBP1.4759)(3)
    803 (2)     5.71       731 (3)     5.71  
6.95% Notes due 2029
    294       7.14       294       7.14  
4.95% Debenture due 2033
    500       4.95       500       4.95  
5.95% Notes due 2037
    995       5.99       995       5.99  
5.86% Debentures due 2038
    700       5.86       700       5.86  
Other (Includes Industrial Revenue Bonds)
    101               102          
     
 
    8,257 (4)     5.42 (1)     8,341 (4)     5.46 (1)
Less current portion
    34               221          
     
 
  $ 8,223               8,120          
     
 
(1)   Weighted average effective rate.
 
(2)   Translation rate at January 3, 2010.
 
(3)   Translation rate at December 28, 2008.
 
(4)   The excess of the fair value over the carrying value of debt was $0.8 billion in 2009 and $1.4 billion in 2008.
Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices in active markets.
     The Company has access to substantial sources of funds at numerous banks worldwide. In September 2009, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10 billion which expires September 23, 2010. Interest charged on borrowings under the credit line agreements is based on either bids provided by banks, the prime rate or London Interbank Offered Rates (LIBOR), plus applicable margins. Commitment fees under the agreements are not material.
     On July 28, 2000, ALZA Corporation, a subsidiary of the Company, completed a private offering of the 3% Zero Coupon Convertible Subordinated Debentures, which were issued at a price of $551.26 per $1,000 principal amount at maturity. Under the terms of the 3% Debentures, holders are entitled to convert their debentures into approximately 15.0 million shares of Johnson & Johnson stock at a price of $40.102 per share. Approximately 11.4 million shares have been issued as of January 3, 2010, due to voluntary conversions by note holders. At the option of the holder, the 3% Debentures may be repurchased by the Company on July 28, 2013, at a purchase price equal to the issue price plus accreted original issue discount to such purchase date. The Company, at its option, may also redeem any or all of the 3% Debentures after July 28, 2003 at the issue price plus accreted original issue discount.
     Throughout 2009 the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $6.3 billion at the end of 2009, of which $5.8 billion was borrowed under the Commercial Paper Program. The remainder represents principally local borrowing by international subsidiaries.
     The Company filed a shelf registration with the Securities and Exchange Commission that became effective March 11, 2008 which enables the Company to issue an unlimited aggregate principal amount in debt securities and warrants to purchase debt securities.
     Aggregate maturities of long-term obligations commencing in 2009 are:
                     
(Dollars in Millions)                   After
2010   2011   2012   2013   2014   2014
 
$34
  35   615   507   9   7,057
8. Income Taxes
The provision for taxes on income consists of:
                         
(Dollars in Millions)   2009     2008     2007  
     
Currently payable:
                       
U.S. taxes
  $ 2,410       2,334       2,990  
International taxes
    1,515       1,624       1,479  
     
 
    3,925       3,958       4,469  
     
 
                       
Deferred:
                       
U.S. taxes
    187       126       (722 )
International taxes
    (623 )     (104 )     (1,040 )
     
 
    (436 )     22       (1,762 )
     
 
  $ 3,489       3,980       2,707  
     
A comparison of income tax expense at the U.S. statutory rate of 35% in 2009, 2008 and 2007, to the Company’s effective tax rate is as follows:
                         
(Dollars in Millions)   2009     2008     2007  
     
U.S.
  $ 7,141       6,579       5,237  
International
    8,614       10,350       8,046  
     
Earnings before taxes on income:
  $ 15,755       16,929       13,283  
     
Tax rates:
                       
U.S. statutory rate
    35.0 %     35.0       35.0  
Ireland and Puerto Rico operations
    (5.1 )     (6.8 )     (8.8 )
Research and orphan drug tax credits
    (0.6 )     (0.6 )     (0.8 )
U.S. state and local
    1.8       1.6       2.1  
International subsidiaries excluding Ireland
    (6.7 )     (5.6 )     (7.3 )
U.S. manufacturing deduction
    (0.4 )     (0.4 )     (0.3 )
In-process research and development (IPR&D)
    0.0       0.4       2.1  
U.S. Tax international income
    (1.6 )     (0.5 )     (1.9 )
All other
    (0.3 )     0.4       0.3  
     
Effective tax rate
    22.1 %     23.5       20.4  
     
The Company has subsidiaries manufacturing in Ireland under an incentive tax rate. In addition, the Company has subsidiaries operating in Puerto Rico under various tax incentive grants. The decrease in the 2009 tax rate was primarily due to increases in taxable income in lower tax jurisdictions relative to taxable income in higher tax jurisdictions. The increase in the 2008 tax rate was mainly attributed to increases in taxable income in higher tax jurisdictions relative to taxable income in lower jurisdictions, as well as a business restructuring of certain international subsidiaries in 2007, resulting in a one-time benefit of $267 million, which reduced the 2007 effective tax rate by 2%.

46


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
     Temporary differences and carry forwards for 2009 and 2008 are as follows:
                                 
    2009     2008  
    Deferred Tax     Deferred Tax  
(Dollars in Millions)   Asset     Liability     Asset     Liability  
     
Employee related obligations
  $ 2,153               2,615          
Stock based compensation
    1,291               1,296          
Depreciation
            (661 )             (523 )
Non-deductible intangibles
            (2,377 )             (1,791 )
International R&D capitalized for tax
    1,989               1,914          
Reserves & liabilities
    1,014               688          
Income reported for tax purposes
    648               629          
Net operating loss carryforward international
    615               393          
Miscellaneous international
    1,474       (110 )     964       (251 )
Miscellaneous U.S.
    799               1,828          
     
Total deferred income taxes
  $ 9,983       (3,148 )     10,327       (2,565 )
     
The difference between the net deferred tax on income per the balance sheet and the net deferred tax above is included in taxes on income on the balance sheet. The 2009 and 2008 deferred tax Miscellaneous U.S. includes current year tax receivables. The Company has a wholly-owned international subsidiary which has cumulative net losses. The Company believes that it is more likely than not that the subsidiary will realize future taxable income sufficient to utilize these deferred tax assets.
     The following table summarizes the activity related to unrecognized tax benefits:
                         
(Dollars in Millions)   2009     2008     2007  
     
Beginning of year
  $ 1,978       1,653       1,262  
Increases related to current year tax positions
    555       545       487  
Increases related to prior period tax positions
    203       87       77  
Decreases related to prior period tax positions
    (163 )     (142 )     (117 )
Settlements
    (87 )     (137 )     (14 )
Lapse of statute of limitations
    (83 )     (28 )     (42 )
     
End of year
  $ 2,403       1,978       1,653  
     
The Company had $2.4 billion and $2.0 billion of unrecognized tax benefits, as of January 3, 2010 and December 28, 2008, respectively. All of the unrecognized tax benefits of $2.4 billion at January 3, 2010, if recognized, would affect the Company’s annual effective tax rate. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. The U.S. Internal Revenue Service (IRS) has completed its audit for the tax years through 2002. In other major jurisdictions where the Company conducts business, the years remain open generally back to the year 2002 with some jurisdictions remaining open as far back as 1995. The Company does not expect that the total amount of unrecognized tax benefits will significantly change over the next twelve months. The Company believes that it is possible that within the next twelve months, the IRS may complete its audit of the tax years 2003-2005. The close of the audit may result in the reduction of unrecognized tax benefits. The Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.
     The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. During the fiscal year ended January 3, 2010, the Company recognized $85 million of interest expense and $30 million of interest income with an after-tax impact of $36 million expense. For the fiscal year ended December 28, 2008, the Company recognized $106 million of interest expense with an after-tax impact of $69 million. For the fiscal year ended December 30, 2007, the Company recognized $58 million of interest expense and $42 million of interest income with an after-tax impact of $10 million expense. The total amount of accrued interest was $309 million and $227 million in 2009 and 2008, respectively.
9. Employee Related Obligations
At the end of 2009 and 2008, employee related obligations recorded on the Consolidated Balance Sheet were:
                 
(Dollars in Millions)   2009     2008  
     
Pension benefits
  $ 2,792       4,382  
Postretirement benefits
    2,245       2,217  
Postemployment benefits
    1,504       870  
Deferred compensation
    790       772  
     
Total employee obligations
    7,331       8,241  
Less current benefits payable
    562       450  
     
Employee related obligations — long-term
  $ 6,769       7,791  
     
Prepaid employee related obligations of $266 million and $136 million for 2009 and 2008, respectively, are included in other assets on the consolidated balance sheet.
10. Pensions and Other Benefit Plans

The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides postretirement benefits, primarily health care, to all U.S. retired employees and their dependents.
     Many international employees are covered by government-sponsored programs and the cost to the Company is not significant.
     Retirement plan benefits are primarily based on the employee’s compensation during the last three to five years before retirement and the number of years of service. International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided.
     The Company does not fund retiree health care benefits in advance and has the right to modify these plans in the future.
     The Company uses the date of its consolidated financial statements (January 3, 2010 and December 28, 2008, respectively) as the measurement date for all U.S. and international retirement and other benefit plans.
     In accordance with U.S. GAAP the Company has adopted the recent standards related to employers’ accounting for defined benefit pension and other postretirement plans.

47


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
     Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for 2009, 2008 and 2007 include the following components:
                                                 
    Retirement Plans     Other Benefit Plans  
(Dollars in Millions)   2009     2008     2007     2009     2008     2007  
     
Service cost
  $ 511       545       597     $ 137       142       140  
Interest cost
    746       701       656       174       166       149  
Expected return on plan assets
    (934 )     (876 )     (809 )     (1 )     (2 )     (2 )
Amortization of prior service cost
    13       10       10       (5 )     (4 )     (7 )
Amortization of net transition asset
    1       2       1                    
Recognized actuarial losses
    155       62       186       55       64       66  
Curtailments and settlements
    (11 )     7       5       (1 )            
     
Net periodic benefit cost
  $ 481       451       646     $ 359       366       346  
The net periodic benefit cost attributable to U.S. retirement plans was $286 million, $220 million and $379 million in 2009, 2008 and 2007, respectively.
     Amounts expected to be recognized in net periodic benefit cost in the coming year for the Company’s defined benefit retirement plans and other postretirement plans:
         
(Dollars in Millions)        
 
Amortization of net transition obligation
  $ 1  
Amortization of net actuarial losses
    296  
Amortization of prior service cost
    5  
Unrecognized gains and losses for the U.S. pension plans are amortized over the average remaining future service for each plan. For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S. benefit plans is determined by using a 10% corridor of the greater of the market value of assets or the projected benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service.
     Prior service costs/benefits for the U.S. pension plans are amortized over the remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S. benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment.
     The weighted-average assumptions in the following table represent the rates used to develop the actuarial present value of projected benefit obligation for the year listed and also the net periodic benefit cost for the following year.
                                                 
    Retirement Plans     Other Benefit Plans  
(Dollars in Millions)   2009     2008     2007     2009     2008     2007  
     
U.S. Benefit Plans
                                               
Discount rate
    6.50 %     6.50       6.50       6.50 %     6.50       6.50  
Expected long-term rate of return on plan assets
    9.00       9.00       9.00       9.00       9.00       9.00  
Rate of increase in compensation levels
    4.50       4.50       4.50       4.50       4.50       4.50  
International Benefit Plans
                                               
 
Discount rate
    5.75 %     6.00       5.50       6.75 %     7.25       6.50  
Expected long-term rate of return on plan assets
    8.00       8.00       8.25                    
Rate of increase in compensation levels
    4.00       4.00       4.00       4.75       4.50       4.50  
 
The Company’s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities.
     The expected long-term rate of return on plan assets assumption is determined using a building block approach, considering historical averages and real returns of each asset class. In certain countries, where historical returns are not meaningful, consideration is given to local market expectations of long-term returns.
     The following table displays the assumed health care cost trend rates, for all individuals:
                 
Health Care Plans   2009     2008  
     
Health care cost trend rate assumed for next year
    8.00 %     9.00  
Rate to which the cost trend rate is assumed to decline (ultimate trend)
    5.00 %     5.00  
Year the rate reaches the ultimate trend rate
    2017       2015  
A one-percentage-point change in assumed health care cost trend rates would have the following effect:
                 
    One-Percentage-     One-Percentage-  
(Dollars in Millions)   Point Increase     Point Decrease  
     
Health Care Plans
               
 
Total interest and service cost
  $ 34     $ (28 )
Postretirement benefit obligation
    315       (254 )
 

48


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The following table sets forth information related to the benefit obligation and the fair value of plan assets at year-end 2009 and 2008 for the Company’s defined benefit retirement plans and other postretirement plans:
                                 
    Retirement Plans     Other Benefit Plans  
(Dollars in Millions)   2009     2008     2009     2008  
     
Change in Benefit Obligation
                               
Projected benefit obligation — beginning of year
  $ 11,923       12,002     $ 2,765       2,721  
Service cost
    511       545       137       142  
Interest cost
    746       701       174       166  
Plan participant contributions
    50       60              
Amendments
    3       10             1  
Actuarial losses (gains)
    412       (318 )     51       (124 )
Divestitures & acquisitions
    15             13       (2 )
Curtailments & settlements & restructuring
    (3 )     (2 )     748        
Benefits paid from plan
    (570 )     (535 )     (313 )     (122 )
Effect of exchange rates
    362       (540 )     15       (17 )
     
Projected benefit obligation — end of year*
  $ 13,449       11,923     $ 3,590       2,765  
     
Change in Plan Assets
                               
Plan assets at fair value — beginning of year
  $ 7,677       10,469     $ 17       29  
Actual return (loss) on plan assets
    2,048       (2,787 )     4       (7 )
Company contributions
    1,354       978       308       117  
Plan participant contributions
    50       60              
Settlements
          (1 )            
Benefits paid from plan assets
    (570 )     (535 )     (313 )     (122 )
Effect of exchange rates
    364       (507 )            
     
Plan assets at fair value — end of year
  $ 10,923       7,677     $ 16       17  
     
Funded status at — end of year*
  $ (2,526 )     (4,246 )   $ (3,574 )     (2,748 )
     
Amounts Recognized in the Company’s Balance Sheet consist of the following:
                               
Non-current assets
  $ 266       136     $        
Current liabilities
    (53 )     (45 )     (484 )     (212 )
Non-current liabilities
    (2,739 )     (4,337 )     (3,090 )     (2,536 )
     
Total recognized in the consolidated balance sheet — end of year
  $ (2,526 )     (4,246 )   $ (3,574 )     (2,748 )
     
Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:
                               
Net actuarial loss
  $ 3,415       4,209     $ 924       1,006  
Prior service cost (credit)
    47       43       (23 )     (29 )
Unrecognized net transition obligation
    5       6              
     
Total before tax effects
  $ 3,467       4,258     $ 901       977  
     
Accumulated Benefit Obligations — end of year*
  $ 11,687       10,357                  
     
Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income
                               
Net periodic benefit cost
  $ 481       451     $ 359       366  
     
Net actuarial (gain) loss
    (704 )     3,344       48       60  
Amortization of net actuarial loss
    (134 )     (68 )     (131 )     (65 )
Prior service cost
    3       10             1  
Amortization of prior service cost
    (13 )     (11 )     5       6  
Effect of exchange rates
    57       (102 )     2       (1 )
     
Total recognized in other comprehensive income, before tax
  $ (791 )     3,173     $ (76 )     1  
     
Total recognized in net periodic benefit cost and other comprehensive income
  $ (310 )     3,624     $ 283       367  
     
 
*   The Company does not fund certain plans, as funding is not required. $1.2 billion of the projected benefit obligation and $1.2 billion of the underfunded status for each of the fiscal years 2009 and 2008 relates to the unfunded pension plans. $1.0 billion and $0.9 billion of the accumulated benefit obligation for the fiscal years 2009 and 2008, respectively, relate to these unfunded pension plans.
Plans with accumulated benefit obligations in excess of plan assets consist of the following:
                 
    Retirement Plans  
(Dollars in Millions)   2009     2008  
     
Accumulated benefit obligation
  $ (4,065 )     (9,885 )
Projected benefit obligation
    (4,663 )     (11,379 )
Plan assets at fair value
    2,564       7,021  
     

49


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The following table displays the projected future benefit payments from the Company’s retirement and other benefit plans:
                                                 
(Dollars in Millions)   2010     2011     2012     2013     2014     2015-2019  
     
Projected future benefit payments
                                               
 
Retirement plans
  $ 558       553       582       604       636       3,925  
     
Other benefit plans — gross
  $ 209       198       196       198       197       995  
Medicare rebates
    (9 )                              
     
Other benefit plans — net
  $ 200       198       196       198       197       995  
     
In 2009, the Company contributed $839 million and $515 million to its U.S. and international pension plans, respectively. In addition, the Company funded $500 million to its U.S. plans in the first month of 2010.
     In 2006, Congress passed the Pension Protection Act of 2006. The Act amended the Employee Retirement Income Security Act (ERISA) for plan years beginning after 2007 and established new minimum funding standards for U.S. employer defined benefit plans.
The Company plans to continue to fund its U.S. defined benefit plans to comply with the Act.
     International plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently the Company has several pension plans that are not funded.
     The following table displays the projected future minimum contributions to the Company’s U.S. and international unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future.
                                                 
(Dollars in Millions)   2010     2011     2012     2013     2014     2015-2019  
     
Projected future contributions
                                               
 
Unfunded U.S. retirement plans
  $ 34       36       38       40       44       288  
     
Unfunded International retirement plans
  $ 32       29       31       33       32       186  
 
Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors including local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and other relevant factors including diversification, liquidity of local markets and liquidity of base currency. A majority of the Company’s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds. An asset allocation of 75% equities and 25% fixed income is generally pursued unless local regulations and illiquidity require otherwise.
     The Company’s retirement plan asset allocation at the end of 2009 and 2008 and target allocations for 2010 are as follows:
                         
    Percent of     Target  
    Plan Assets     Allocation  
    2009     2008     2010  
     
U.S. Retirement Plans
                       
Equity securities
    76 %     70 %     75 %
Debt securities
    24       30       25  
     
Total plan assets
    100 %     100 %     100 %
     
International Retirement Plans
                       
Equity securities
    65 %     61 %     65 %
Debt securities
    34       38       34  
Real estate and other
    1       1       1  
     
Total plan assets
    100 %     100 %     100 %
     
The Company’s other benefit plans are unfunded except for U.S. life insurance contract assets of $16 million and $17 million at January 3, 2010 and December 28, 2008, respectively.
     The fair value of Johnson & Johnson common stock directly held in plan assets was $469 million (4.3% of total plan assets) at January 3, 2010 and $416 million (5.4% of total plan assets) at December 28, 2008.
DETERMINATION OF FAIR VALUE
The Plan has an established and well-documented process for determining fair values. Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves.
     While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

50


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
VALUATION HIERARCHY
The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level 1 having the highest priority and Level 3 having the lowest.
A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
     Following is a description of the valuation methodologies used for the investments measured at fair value.
      Short-term investments — Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the Net Asset Value (NAV) provided by the administrator of the fund. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. The NAV is a quoted price in a market that is not active and classified as Level 2.
      Government and agency securities — A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level 1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level 2.
      Debt instruments — A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level 1.
If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level 2. Level 3 debt instruments are priced based on unobservable inputs.
      Equity securities — Common stocks are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all common stock is classified within Level 1 of the valuation hierarchy.
      Commingled funds — The investments are public investment vehicles valued using the NAV provided by the fund administrator. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. Assets in the Level 2 category have a quoted market price in a market that is not active.
      Insurance contracts — The instruments are issued by insurance companies. The fair value is based on negotiated value and the underlying investments held in separate account portfolios as well as considering the credit worthiness of the issuer. The underlying investments are government, asset-backed and fixed income securities. In general, insurance contracts are classified as Level 3 as there are no quoted prices nor other observable inputs for pricing.
      Other assets — Other assets are represented primarily by limited partnerships and real estate investments, as well as commercial loans and commercial mortgages that are not classified as corporate debt. Other assets that are exchange listed and actively traded are classified as Level 1 while inactively traded assets are classified as Level 2. Most limited partnerships represent investments in private equity and similar funds that are valued by the general partners. These, as well as any other assets valued using unobservable inputs, are classified as Level 3.
The following table sets forth the trust investments measured at fair value as of January 3, 2010:
                                 
    Quoted Prices     Significant              
    in Active     Other     Significant        
    Markets for     Observable     Unobservable        
    Identical Assets     Inputs     Inputs        
(Dollars in Millions)   (Level 1)     (Level 2)     (Level 3)     Total Assets  
     
Short-term investment funds
  $ 91       358             449  
Government and agency securities
          1,165             1,165  
Debt instruments
    3       1,145       5       1,153  
Equity securities
    5,068       58       15       5,141  
Commingled funds
          2,673       26       2,699  
Insurance contracts
                32       32  
Other assets
    31       171       82       284  
     
Trust investments at fair value
  $ 5,193       5,570       160       10,923  
     
LEVEL 3 GAINS AND LOSSES
The table below sets forth a summary of changes in the fair value of the Plan’s Level 3 assets for the year ended January 3, 2010:
                                                 
    Debt     Equity     Commingled     Insurance     Other     Total  
(Dollars in Millions)   Instruments     Securities     Funds     Contracts     Assets     Level 3  
     
Balance December 28, 2008
  $ 7       15       15       29       85       151  
Realized gains (losses)
                      3             3  
Unrealized gains (losses)
    2       (2 )     (2 )           (3 )     (5 )
Purchases, sales, issuances and settlements, net
    (4 )     2       13                   11  
     
Balance January 3, 2010
  $ 5       15       26       32       82       160  
     

51


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
11. Savings Plan
The Company has voluntary 401 (k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee’s contributions consistent with the provisions of the plan for which he/she is eligible. Total Company matching contributions to the plans were $163 million, $166 million and $169 million in 2009, 2008 and 2007, respectively.
12. Capital and Treasury Stock
Changes in treasury stock were:
                 
(Amounts in Millions Except Treasury Stock   Treasury Stock
Number of Shares in Thousands)   Shares     Amount  
     
Balance at December 31, 2006
    226,612     $ 10,974  
Employee compensation and stock option plans
    (33,296 )     (2,180 )
Conversion of subordinated debentures
    (194 )     (13 )
Repurchase of common stock
    86,498       5,607  
     
Balance at December 30, 2007
    279,620       14,388  
Employee compensation and stock option plans
    (29,906 )     (2,005 )
Conversion of subordinated debentures
    (19 )     (1 )
Repurchase of common stock
    100,970       6,651  
     
Balance at December 28, 2008
    350,665       19,033  
Employee compensation and stock option plans
    (22,161 )     (1,377 )
Conversion of subordinated debentures
    (96 )     (6 )
Repurchase of common stock
    37,114       2,130  
     
Balance at January 3, 2010
    365,522     $ 19,780  
     
Aggregate shares of Common Stock issued were approximately 3,120 million shares at the end of 2009, 2008 and 2007.
     Cash dividends paid were $1.930 per share in 2009, compared with dividends of $1.795 per share in 2008 and $1.620 per share in 2007.
13. Accumulated Other Comprehensive Income
Components of other comprehensive income/(loss) consist of the following:
                                         
                                    Total  
                            Gains/     Accumulated  
    Foreign     Gains/             (Losses) on     Other  
    Currency     (Losses) on     Employee     Derivatives     Comprehensive  
(Dollars in Millions)   Translation     Securities     Benefit Plans     & Hedges     Income/(Loss)  
     
December 31, 2006
  $ (158 )     61       (2,030 )     9       (2,118 )
2007 changes
                                       
Unrealized gain (loss)
          28             (78 )        
Net amount reclassed to net earnings
          (5 )           24          
Net 2007 changes
    786       23       670       (54 )     1,425  
     
December 30, 2007
  $ 628       84       (1,360 )     (45 )     (693 )
2008 changes
                                       
Unrealized gain (loss)
          (32 )           94          
Net amount reclassed to net earnings
          (27 )           72          
Net 2008 changes
    (2,499 )     (59 )     (1,870 )     166       (4,262 )
     
December 28, 2008
  $ (1,871 )     25       (3,230 )     121       (4,955 )
2009 changes
                                       
Unrealized gain (loss)
          (52 )           38          
Net amount reclassed to net earnings
          (3 )           (14 )        
Net 2009 changes
    1,363       (55 )     565       24       1,897  
     
January 3, 2010
  $ (508 )     (30 )     (2,665 )     145       (3,058 )
     
The tax effect on the unrealized gains/(losses) on the equity securities was income of $14 million in 2009 and expense of $14 million and $46 million in 2008 and 2007, respectively. The tax effect related to employee benefit plans was $302 million, $1,090 million and $349 million in 2009, 2008 and 2007, respectively. The tax effect on the gains/(losses) on derivatives and hedges was expense of $78 million and $70 million in 2009 and 2008, respectively, and income of $24 million in 2007. See Note 6 for additional information relating to derivatives and hedging.
     The currency translation adjustments are not adjusted for income taxes as they relate to permanent investments in international subsidiaries.

52


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
14. International Currency Translation
For translation of its subsidiaries operating in non-U.S. Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency.
     In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. This equity account includes the results of translating all balance sheet assets and liabilities at current exchange rates, except for those located in highly inflationary economies. The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results.
     An analysis of the changes during 2009, 2008 and 2007 for foreign currency translation adjustments is included in Note 13.
     Net currency transaction and translation gains and losses included in other (income) expense were losses of $210 million, $31 million and $23 million in 2009, 2008 and 2007, respectively.
15. Earnings Per Share
The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January 3, 2010, December 28, 2008 and December 30, 2007:
                         
(Shares in Millions Except Per Share Data)   2009     2008     2007  
     
Basic net earnings per share
  $ 4.45       4.62       3.67  
Average shares outstanding — basic
    2,759.5       2,802.5       2,882.9  
Potential shares exercisable under stock option plans
    118.0       179.0       178.6  
Less: shares repurchased under treasury stock method
    (92.0 )     (149.6 )     (154.5 )
Convertible debt shares
    3.6       3.7       3.7  
     
Adjusted average shares outstanding — diluted
    2,789.1       2,835.6       2,910.7  
Diluted net earnings per share
  $ 4.40       4.57       3.63  
     
The diluted net earnings per share calculation includes the dilutive effect of convertible debt that is offset by the related reduction in interest expense of $4 million after-tax for years 2009, 2008 and 2007.
     Diluted net earnings per share excludes 121 million, 59 million and 64 million shares underlying stock options for 2009, 2008 and 2007, respectively, as the exercise price of these options was greater than their average market value, which would result in an anti-dilutive effect on diluted earnings per share.
16. Rental Expense and Lease Commitments
Rentals of space, vehicles, manufacturing equipment and office and data processing equipment under operating leases were approximately $322 million in 2009, $309 million in 2008 and $302 million in 2007.
     The approximate minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year at January 3, 2010 are:
                                               
(Dollars in Millions)                                   After        
2010     2011       2012       2013       2014       2014       Total
 
$178     150       128       103       87       94       740
Commitments under capital leases are not significant.
17. Common Stock, Stock Option Plans and Stock Compensation Agreements
STOCK OPTIONS
At January 3, 2010, the Company had 11 stock-based compensation plans. The shares outstanding are for contracts under the Company’s 1995 and 2000 Stock Option Plans, the 2005 Long-Term Incentive Plan, the 1997 Non-Employee Director’s Plan and the ALZA, Inverness, and Scios Stock Option Plans. During 2009, no options or restricted shares were granted under any of these plans except under the 2005 Long-Term Incentive Plan.
     The compensation cost that has been charged against income for these plans was $628 million, $627 million and $698 million for 2009, 2008 and 2007, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $210 million, $210 million and $238 million for 2009, 2008 and 2007, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods.
     Stock options expire 10 years from the date of grant and vest over service periods that range from six months to five years. All options are granted at the average of the high and low prices of the Company’s common stock on the New York Stock Exchange on the date of grant. Under the 2005 Long-Term Incentive Plan, the Company may issue up to 260 million shares of common stock. Shares available for future grants under the 2005 Long-Term Incentive Plan were 139.7 million at the end of 2009.
     The Company settles employee stock option exercises with treasury shares. Treasury shares are replenished throughout the year for the number of shares used to settle employee stock option exercises.
     The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. Expected volatility represents a blended rate of 4-year daily historical average volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson & Johnson options with a life of 2 years. Historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S. Treasury yield curve in effect at the time of grant.

53


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
     The average fair value of options granted was $8.35, $7.66, and $11.67 in 2009, 2008, and 2007, respectively. The fair value was estimated based on the weighted average assumptions of:
                         
    2009     2008     2007  
     
Risk-free rate
    2.71 %     2.97 %     4.78 %
Expected volatility
    19.5 %     15.0 %     14.7 %
Expected life
  6.0  yrs   6.0  yrs   6.0  yrs  
Dividend yield
    3.30 %     2.90 %     2.50 %
A summary of option activity under the Plan as of January 3, 2010, December 28, 2008, and December 30, 2007 and changes during the years ending on those dates is presented below:
                         
                    Aggregate  
            Weighted     Intrinsic  
    Outstanding     Average     Value  
(Shares in Thousands)   Shares     Exercise Price     (Dollars in Millions)  
     
Shares at December 31, 2006
    242,927     $ 54.57     $ 2,788  
 
                     
Options granted
    26,789       65.61          
Options exercised
    (33,224 )     45.92          
Options canceled/forfeited
    (7,863 )     63.00          
     
Shares at December 30, 2007
    228,629       56.83     $ 2,411  
 
                     
Options granted
    22,428       61.80          
Options exercised
    (30,033 )     50.27          
Options canceled/forfeited
    (5,525 )     61.90          
     
Shares at December 28, 2008
    215,499       58.14     $ 597  
 
                     
Options granted
    21,576       58.32          
Options exercised
    (18,225 )     50.97          
Options canceled/forfeited
    (6,131 )     61.85          
     
Shares at January 3, 2010
    212,719     $ 58.66     $ 1,310  
     
The total intrinsic value of options exercised was $184 million, $506 million, and $625 million in 2009, 2008 and 2007, respectively. The total unrecognized compensation cost was $612 million as of January 3, 2010, $632 million as of December 28, 2008 and $652 million as of December 30, 2007. The weighted average period for this cost to be recognized was 1.16 years, 1.06 years and 1.01 years for 2009, 2008, and 2007, respectively.
     The following table summarizes stock options outstanding and exercisable at January 3, 2010:
                                         
    Outstanding     Exercisable  
(Shares in Thousands)                   Average             Average  
Exercise           Average     Exercise             Exercise  
Price Range   Options     Life (1)   Price     Options     Price  
     
$  7.33 - $28.09
    104       1.5     $ 22.89       104     $ 22.89  
$31.27- $40.08
    131       0.3       35.83       131       35.83  
$41.26- $49.86
    1,024       1.2       47.09       1,024       47.09  
$50.52- $52.11
    17,328       0.8       50.70       17,328       50.70  
$52.13- $53.77
    22,193       3.1       52.22       22,152       52.22  
$53.93- $54.89
    26,155       4.0       53.93       26,156       53.93  
$55.01- $58.25
    26,332       2.1       57.30       26,328       57.30  
$58.33- $65.10
    63,805       7.7       59.48       21,367       58.48  
$65.62- $68.37
    55,647       5.8       65.97       33,759       66.19  
     
 
    212,719       5.0     $ 58.66       148,349     $ 57.26  
     
 
(1)   Average contractual life remaining in years.
Stock options exercisable at December 28, 2008 and December 30, 2007 were 144,962 at an average price of $56.25 and an average life of 5.3 years and 137,310 at an average price of $52.33 and an average life of 5.6 years, respectively.
RESTRICTED SHARE UNITS
The Company grants restricted share units with a vesting period of three years. The Company settles employee stock issuance with treasury shares. Treasury shares are replenished throughout the year for the number of shares used for employee stock issuances.
     A summary of share activity under the Plan as of January 3, 2010:
         
    Outstanding  
(Shares in Thousands)   Shares  
     
Shares at December 31, 2006
    6,885  
Shares granted
    8,029  
Shares issued
    (33 )
Shares canceled/forfeited
    (1,220 )
 
     
Shares at December 30, 2007
    13,661  
Shares granted
    10,105  
Shares issued
    (40 )
Shares canceled/forfeited
    (1,468 )
 
     
Shares at December 28, 2008
    22,258  
Shares granted
    11,172  
Shares issued
    (5,714 )
Shares canceled/forfeited
    (1,392 )
 
     
Shares at January 3, 2010
    26,324  
 
     
The average fair value of the restricted share units granted was $52.79, $56.70 and $60.86 in 2009, 2008 and 2007, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units settled was $308.4 million, $2.5 million and $1.8 million in 2009, 2008 and 2007, respectively.

54


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
18. Segments of Business(1) and Geographic Areas
                         
    Sales to Customers(2)  
(Dollars in Millions)   2009     2008     2007  
     
Consumer —
                       
United States
  $ 6,837       6,937       6,408  
International
    8,966       9,117       8,085  
     
Total
    15,803       16,054       14,493  
     
Pharmaceutical —
                       
United States
    13,041       14,831       15,603  
International
    9,479       9,736       9,263  
     
Total
    22,520       24,567       24,866  
     
Medical Devices and Diagnostics —
                       
United States
    11,011       10,541       10,433  
International
    12,563       12,585       11,303  
     
Total
    23,574       23,126       21,736  
     
Worldwide total
  $ 61,897       63,747       61,095  
     
                                                 
    Operating Profit     Identifiable Assets  
(Dollars in Millions)   2009(5)     2008(6)     2007(7)     2009     2008     2007  
     
Consumer
  $ 2,475       2,674       2,277     $ 24,671       23,765       26,550  
Pharmaceutical
    6,413       7,605       6,540       21,460       19,544       19,780  
Medical Devices and Diagnostics
    7,694       7,223       4,846       22,853       20,779       19,978  
     
Total
    16,582       17,502       13,663       68,984       64,088       66,308  
Less: Expense not allocated to segments(3)
    827       573       380                          
General corporate(4)
                            25,698       20,824       14,646  
     
Worldwide total
  $ 15,755       16,929       13,283     $ 94,682       84,912       80,954  
     
                                                 
    Additions to Property,     Depreciation and  
    Plant & Equipment     Amortization  
(Dollars in Millions)   2009     2008     2007     2009     2008     2007  
     
Consumer
  $ 439       499       504     $ 513       489       472  
Pharmaceutical
    535       920       1,137       922       986       1,033  
Medical Devices and Diagnostics
    1,114       1,251       919       1,124       1,146       1,080  
     
Segments total
    2,088       2,670       2,560       2,559       2,621       2,585  
General corporate
    277       396       382       215       211       192  
     
Worldwide total
  $ 2,365       3,066       2,942     $ 2,774       2,832       2,777  
     
                                                 
    Sales to Customers(2)     Long-Lived Assets(8)  
(Dollars in Millions)   2009     2008     2007     2009     2008     2007  
     
United States
  $ 30,889       32,309       32,444     $ 22,399       21,674       21,685  
Europe
    15,934       16,782       15,644       17,347       14,375       15,578  
Western Hemisphere excluding U.S.
    5,156       5,173       4,681       3,540       3,328       3,722  
Asia-Pacific, Africa
    9,918       9,483       8,326       1,868       1,898       1,261  
     
Segments total
    61,897       63,747       61,095       45,154       41,275       42,246  
General corporate
                            790       785       702  
Other non long-lived assets
                            48,738       42,852       38,006  
     
Worldwide total
  $ 61,897       63,747       61,095     $ 94,682       84,912       80,954  
     
 
(1)   See Note 1 for a description of the segments in which the Company operates.
 
(2)   Export sales are not significant. In 2009, 2008 and 2007, the Company did not have a customer that represented 10% of total revenues.
 
(3)   Amounts not allocated to segments include interest (income) expense, non-controlling interests and general corporate (income) expense.
 
(4)   General corporate includes cash and marketable securities.
 
(5)   Includes $1,186 million of restructuring expense, comprised of $369 million, $496 million, and $321 million for the Consumer, Pharmaceutical, and Medical Devices and Diagnostics segments, respectively. Includes $386 million of fourth quarter net litigation gain, comprised of a $92 million expense in the Pharmaceutical segment and a gain of $478 million in the Medical Devices and Diagnostics segment.
 
(6)   Includes $7 million and $174 million of IPR&D for the Consumer and Medical Devices and Diagnostics segments, respectively. Includes $379 million of fourth quarter net litigation gain, comprised of a $50 million expense in the Consumer segment and a gain of $429 million in the Medical Devices and Diagnostics segment. The Medical Devices and Diagnostics segment also includes $536 million gain on the divestiture of the Professional Wound Care business of Ethicon, Inc.
 
(7)   Includes $745 million of restructuring expense, comprised of $15 million, $429 million, and $301 million for the Consumer, Pharmaceutical, and Medical Devices and Diagnostics segments, respectively. The Medical Devices and Diagnostics segment includes $807 million of IPR&D. The Pharmaceutical segment also includes $678 million for the write-down of the NATRECOR ® intangible asset.
 
(8)   Long-lived assets include property, plant and equipment, net for 2009, 2008 and 2007 of $14,759, $14,365 and $14,185, respectively, and intangible assets and goodwill, net for 2009, 2008 and 2007 of $31,185, $27,695 and $28,763, respectively.

55


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
19. Selected Quarterly Financial Data (unaudited)
Selected unaudited quarterly financial data for the years 2009 and 2008 are summarized below:
                                                                 
    2009     2008  
    First     Second     Third     Fourth     First     Second     Third     Fourth  
(Dollars in Millions Except Per Share Data)   Quarter     Quarter     Quarter     Quarter (1)   Quarter     Quarter (2)   Quarter     Quarter (3)
     
Segment sales to customers
                                                               
Consumer
  $ 3,711       3,854       3,989       4,249       4,064       4,036       4,099       3,855  
Pharmaceutical
    5,780       5,498       5,249       5,993       6,429       6,340       6,113       5,685  
Med Devices & Diagnostics
    5,535       5,887       5,843       6,309       5,701       6,074       5,709       5,642  
     
Total sales
  $ 15,026       15,239       15,081       16,551       16,194       16,450       15,921       15,182  
     
Gross profit
    10,775       10,789       10,647       11,239       11,580       11,699       11,147       10,810  
Earnings before provision for taxes on income
    4,643       4,263       4,245       2,604       4,747       4,375       4,290       3,517  
Net earnings
    3,507       3,208       3,345       2,206       3,598       3,327       3,310       2,714  
     
Basic net earnings per share
  $ 1.27       1.16       1.21       0.80       1.27       1.18       1.19       0.98  
     
Diluted net earnings per share
  $ 1.26       1.15       1.20       0.79       1.26       1.17       1.17       0.97  
     
 
(1)   The fourth quarter of 2009 includes an after-tax charge of $852 million for restructuring and $212 million after-tax of income from net litigation.
 
(2)   The second quarter of 2008 includes an after-tax charge of $40 million for IPR&D.
 
(3)   The fourth quarter of 2008 includes an after-tax charge of $141 million for IPR&D, $229 million after-tax of income from net litigation and $331 million after-tax gain on the divestiture of the Professional Wound Care business of Ethicon, Inc. The gain from the divestiture of the Professional Wound Care business of Ethicon, Inc. was reinvested in the business.
20. Business Combinations and Divestitures
Certain businesses were acquired for $2,470 million in cash and $875 million of liabilities assumed and non-controlling interests during 2009. These acquisitions were accounted for by the purchase method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition.
     The 2009 acquisitions included: Mentor Corporation, a leading supplier of medical products for the global aesthetics market; Cougar Biotechnology, Inc., a development stage biopharmaceutical company with a specific focus on oncology; Finsbury Orthopaedics Limited, a privately held UK-based manufacturer and global distributor of orthopaedic implants; Gloster Europe, a privately held developer of innovative disinfection processes and technologies to prevent healthcare-acquired infections and substantially all of the assets and rights of Elan’s Alzheimer’s Immunotherapy Program through a newly formed company, of which the Company owns 50.1% and Elan owns 49.9%.
     The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $2,940 million and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. Of this amount, approximately $1,737 million has been identified as the value of IPR&D primarily associated with the acquisitions of Cougar Biotechnology, Inc. and substantially all of the assets and rights of Elan’s Alzheimer’s Immunotherapy Program. Additionally, approximately $1,107 million has been identified as the value of other intangible assets, including patents & technology and customer relationships primarily associated with the acquisition of Mentor Corporation.
     The IPR&D related to the acquisition of Cougar Biotechnology, Inc. was $971 million and is associated with abiraterone acetate, a late stage, first-in-class compound for the treatment of prostate cancer. The value of the IPR&D was calculated using cash flow projections discounted for the risk inherent in such projects. Probability of success factors ranging from 60-85% were used to reflect inherent clinical and regulatory risk. The discount rate applied was 23.5%.
Refer to Note 6 for information related to the Elan transaction.
     Certain businesses were acquired for $1,214 million in cash and $114 million of liabilities assumed during 2008. These acquisitions were accounted for by the purchase method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition.
     The 2008 acquisitions included: Amic AB, a privately held Swedish developer of in vitro diagnostic technologies for use in point-of-care and near-patient settings; Beijing Dabao Cosmetics Co., Ltd., a company that sells personal care brands in China; SurgRx, Inc., a privately held developer of the advanced bipolar tissue sealing system used in the ENSEAL® family of devices; HealthMedia, Inc., a privately held company that creates web-based behavior change interventions; LGE Performance Systems, Inc., a privately held company known as Human Performance Institute™, which develops science-based training programs to improve employee engagement and productivity and Omrix Biopharmaceuticals, Inc., a fully integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products.
     The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $891 million and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. Approximately $181 million has been identified as the value of IPR&D associated with the acquisitions of Omrix Biopharmaceuticals, Inc., Amic AB, SurgRx, Inc. and HealthMedia, Inc.
     The IPR&D charge related to the acquisition of Omrix Biopharmaceuticals, Inc. was $127 million and is associated with stand-alone and combination biosurgical technologies used to achieve hemostasis. The value of the IPR&D was calculated using cash flow projections discounted for the risk inherent in such projects. Probability of success factors ranging from 60-90% were used to reflect inherent clinical and regulatory risk. The discount rate applied was 14%. As of the end of the 2008 fiscal year, 97.8% of the outstanding shares of Common Stock of Omrix Biopharmaceuticals,

56


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Inc. had been tendered by stockholders. Excluding shares that were tendered subject to guaranteed delivery procedures, 90.2% of the outstanding shares of Common Stock had been tendered. On December 30, 2008 the Company completed the acquisition of Omrix Biopharmaceuticals, Inc.
     The IPR&D charge related to the acquisition of Amic AB was $40 million and is associated with point-of-care device and 4CAST Chip technologies. The value of the IPR&D was calculated using cash flow projections discounted for the risk inherent in such projects. The discount rate applied was 20%.
     The IPR&D charge related to the acquisition of SurgRx, Inc. was $7 million and is associated with vessel cutting and sealing surgical devices. The value of the IPR&D was calculated using cash flow projections discounted for the risk inherent in such projects. Probability of success factors ranging from 90-95% were used to reflect inherent clinical and regulatory risk. The discount rate applied was 18%.
     The IPR&D charge related to the acquisition of HealthMedia, Inc. was $7 million and is associated primarily with process enhancements to software technology. The value of the IPR&D was calculated using cash flow projections discounted for the risk inherent in such projects. A probability of success factor of 90% was used to reflect inherent risk. The discount rate applied was 14%.
     Certain businesses were acquired for $1,388 million in cash and $232 million of liabilities assumed during 2007. These acquisitions were accounted for by the purchase method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition.
     The 2007 acquisitions included: Conor Medsystems, Inc., a cardiovascular device company, with new drug delivery technology; Robert Reid, Inc., a Japanese orthopedic product distributor; and Maya’s Mom, Inc., a social media company.
     The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $636 million and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. Approximately $807 million has been identified as the value of IPR&D associated with the acquisition of Conor Medsystems, Inc.
     The IPR&D charge related to the acquisition of Conor Medsystems, Inc. was $807 million and is associated with research related to the discovery and application of the stent technology. The value of the IPR&D was calculated using cash flow projections discounted for the risk inherent in such projects. The discount rate applied was 19%.
     Supplemental pro forma information for 2009, 2008 and 2007 in accordance with U.S. GAAP standards related to business combinations, and goodwill and other intangible assets, is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company’s results of operations, cash flows or financial position.
     With the exception of the divestiture of the Professional Wound Care business of Ethicon, Inc., which resulted in a gain of $536 million before tax, and is recorded in other (income) expense, net, in 2008, divestitures in 2009, 2008 and 2007 did not have a material effect on the Company’s results of operations, cash flows or financial position.
Note 21 — Legal Proceedings
PRODUCT LIABILITY
The Company’s subsidiaries are involved in numerous product liability cases in the United States, many of which concern alleged adverse reactions to drugs and medical devices. The damages claimed are substantial, and while the Company is confident of the adequacy of the warnings and instructions for use that accompany such products, it is not feasible to predict the ultimate outcome of litigation. However, the Company believes that if any product liability results from such cases, it will be substantially covered by existing amounts accrued in the Company’s balance sheet and, where available, by third-party product liability insurance.
     Multiple products of Johnson & Johnson subsidiaries are subject to numerous product liability claims and lawsuits. There are a significant number of claimants who have pending lawsuits or claims regarding injuries allegedly due to ORTHO EVRA®, RISPERDAL®, LEVAQUIN®, DURAGESIC®, the CHARITÉ™ Artificial Disc and CYPHER® Stent. These claimants seek substantial compensatory and, where available, punitive damages.
     With respect to RISPERDAL ®, the Attorneys General of eight states and the Office of General Counsel of the Commonwealth of Pennsylvania have filed actions seeking reimbursement of Medicaid or other public funds for RISPERDAL® prescriptions written for off-label use, compensation for treating their citizens for alleged adverse reactions to RISPERDAL®, civil fines or penalties, punitive damages, or other relief. The Attorney General of Texas has joined a qui tam action in that state seeking similar relief. Certain of these actions also seek injunctive relief relating to the promotion of RISPERDAL®. The Attorneys General of more than 40 other states have indicated a potential interest in pursuing similar litigation against the Company’s subsidiary, Janssen Pharmaceutica Inc. (Janssen) (now Ortho-McNeil-Janssen Pharmaceuticals Inc. (OMJPI)), and have obtained a tolling agreement staying the running of the statute of limitations while they inquire into the issues. In addition, there are six cases filed by union health plans seeking damages for alleged overpayments for RISPERDAL®, several of which seek certification as class actions. In the case brought by the Attorney General of West Virginia, based on claims for alleged consumer fraud as to DURAGESIC® as well as RISPERDAL®, Janssen (now OMJPI) was found liable and damages were assessed at $4.5 million. OMJPI has filed an appeal.
     Numerous claims and lawsuits in the United States relating to the drug PROPULSID®, withdrawn from general sale by the Company’s Janssen (now OMJPI) subsidiary in 2000, have been resolved or are currently enrolled in settlement programs with an aggregate cap below $100 million. Similar litigation concerning PROPULSID® is pending in Canada, where a national class action of persons alleging adverse reactions to the drug has been certified and a settlement program instituted with an aggregate cap below $10 million.
AFFIRMATIVE STENT PATENT LITIGATION
In patent infringement actions tried in Delaware Federal District Court in late 2000, Cordis Corporation (Cordis), a subsidiary of Johnson & Johnson, obtained verdicts of infringement and patent validity, and damage awards against Boston Scientific Corporation (Boston Scientific) and Medtronic AVE, Inc. (Medtronic) based on a number of Cordis vascular stent patents. In December 2000, the jury in the damage action against Boston Scientific returned a verdict of $324 million and the jury in the Medtronic action returned a verdict of $271 million. The Court of Appeals for the Federal Circuit has upheld liability in these cases, and on September 30, 2008, the district court entered judgments, including interest, in the amounts of $702 million and $521 million against Boston Scientific and

57


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Medtronic, respectively. Medtronic paid $472 million in October 2008, representing the judgment, net of amounts exchanged in settlement of a number of other litigations between the companies. The net settlement of $472 million was recorded as a credit to other (income) expense, net in the 2008 consolidated statement of earnings. In September 2009, Cordis settled this case with Boston Scientific together with the Kastenhofer/Fontirroche and Ding cases described below, for a net payment of $716 million. As part of that settlement Boston Scientific received a paid up license to the Fontirroche family of patents worldwide and Cordis received a paid license to the Kastenhofer and Ding families of patents worldwide and the parties settled all pending lawsuits worldwide relating to these patents. The receipt of $716 million, less the impact of other litigation matters, resulted in a credit to other (income) expense, net of $386 million in the fiscal fourth quarter of 2009. In addition, in May 2009, Medtronic paid $270 million to settle additional patent infringement claims asserted by Cordis based on its vascular stent patents, which was recorded as a credit to other (income) expense, net in the fiscal second quarter of 2009.
     In January 2003, Cordis filed a patent infringement action against Boston Scientific in Delaware Federal District Court accusing its Express2™, Taxus® and Liberte® stents of infringing the Palmaz patent that expired in November 2005. The Liberte® stent was also accused of infringing Cordis’ Gray patent that expires in 2016. In June 2005, a jury found that the Express2™, Taxus® and Liberte® stents infringed the Palmaz patent and that the Liberte® stent also infringed the Gray patent. On March 31, 2009, the U.S. Court of Appeals for the Federal Circuit affirmed this judgment. The case was remanded to the district court for a trial on damages and willfulness. Cordis also filed a lawsuit in Delaware Federal District Court in October of 2008 alleging that Boston Scientific’s sales of Taxus® and Liberte® after June of 2005 infringes Cordis’ Gray patent. On January 29, 2010, these cases together with the Jang case referred to in the paragraph below, were settled. Under the terms of the settlement, Boston Scientific paid Cordis $1.0 billion on February 1, 2010, and will pay Cordis an additional $725 million plus interest on January 3, 2011. Cordis granted Boston Scientific a paid up worldwide license under the Palmaz and Gray patents and Boston Scientific granted Cordis a paid up worldwide license under the Jang patents for all stents sold by Cordis except the 2.25mm size Cypher.
     Cordis has several pending lawsuits in New Jersey and Delaware Federal District Court against Guidant Corporation (Guidant), Abbott Laboratories, Inc. (Abbott), Boston Scientific and Medtronic alleging that the Xience V™ (Abbott), Promus™ (Boston Scientific) and Endeavor® (Medtronic) drug eluting stents infringe several patents owned by or licensed to Cordis. In one of the cases against Boston Scientific, alleging that sales of their Promus™ stent infringed Wright and Falotico patents, on January 20, 2010 the District Court in Delaware found the Wright/Falotico patent invalid for lack of written description and/or lack of enablement. Cordis intends to appeal this ruling.
PATENT LITIGATION AGAINST VARIOUS JOHNSON & JOHNSON SUBSIDIARIES
The products of various Johnson & Johnson subsidiaries are the subject of various patent lawsuits, the outcomes of which could potentially adversely affect the ability of those subsidiaries to sell those products, or require the payment of past damages and future royalties.
     In July 2005, a jury in Federal District Court in Delaware found that the Cordis CYPHER® Stent infringed Boston Scientific’s Ding ‘536 patent and that the Cordis CYPHER® and BX VELOCITY® Stents also infringed Boston Scientific’s Jang ‘021 patent. The jury also found both of those patents valid. In January 2009, the Court of Appeals for the Federal Circuit held the Ding patent invalid and a judgment in favor of Cordis in that case has been entered. In March 2009, the Court of Appeals for the Federal Circuit upheld the judgment that Cordis’ CYPHER® Stent infringed Boston Scientific’s Jang patent. The case has been remanded for a trial on the issues of damages and willfulness. The Jang case has been dismissed as part of the January 2010 settlement described in the paragraph above relating to the Express2™, Taxus® and Liberte® stents.
     In Germany, Boston Scientific had several actions based on its Ding patents pending against the Cordis CYPHER® Stent. Boston Scientific also had brought actions in Belgium, the Netherlands, Germany, France and Italy under its Kastenhofer patent, which purports to cover two-layer catheters such as those used to deliver the CYPHER® Stent. These cases have been settled as part of the September 2009 settlement described above.
     Trial in Boston Scientific’s U.S. case based on the Kastenhofer patent in Federal District Court in California concluded in October 2007 with a jury finding that the patent was invalid. The jury also found for Cordis on its counterclaim that sale by Boston Scientific of its balloon catheters and stent delivery systems infringe Cordis’ Fontirroche patent. The Court has denied Boston Scientific’s post trial motions. This case was settled as part of the September 2009 settlement described above.
     In May 2008, Centocor, Inc. (Centocor) (now Centocor Ortho Biotech Inc. (COBI)) filed a lawsuit against Genentech, Inc. (Genentech) in U.S. District Court for the Central District of California seeking to invalidate the Cabilly II patent. Prior to filing suit, Centocor had a sublicense under this patent from Celltech (who was licensed by Genentech) for REMICADE® and had been paying royalties to Celltech. Centocor has terminated that sublicense and stopped paying royalties. Genentech has filed a counterclaim alleging that REMICADE® infringes its Cabilly II patents and that the manufacture of REMICADE®, STELARA™, SIMPONI™ and ReoPro® also infringes one of its other patents relating to the purification of antibodies made through recombinant DNA techniques. The court has scheduled a hearing for Summary Judgment Motions in August 2010.
     In April 2009, a bench trial was held before the Federal District Court for the Middle District of Florida on the liability phase of Ciba’s patent infringement lawsuit alleging that Johnson & Johnson Vision Care, Inc.’s (JJVC) ACUVUE® OASYS™ lenses infringe three of their Nicholson patents. In August 2009, the District Court found two of these patents valid and infringed and entered judgment against JJVC. JJVC has appealed that judgment to the Court of Appeals for the Federal Circuit. On March 22, 2010, the District Court will hold a hearing on Ciba’s motion for a permanent injunction. If the judgment is upheld on appeal the Court will schedule another trial to determine damages and willfulness.
     In May 2009, Abbott Biotechnology Ltd. filed a patent infringement lawsuit against Centocor (now COBI) in the United States District Court for the District of Massachusetts. The suit alleges that Centocor’s SIMPONI™ product, a human anti-TNF alpha antibody, infringes Abbott’s ‘394 patent (the Salfeld patent). The case has been stayed pending the resolution of an arbitration filed by Centocor directed to its claim that it is licensed under the ‘394 patent. The arbitration is scheduled for March 2010.
     In August 2009, Abbott GmbH & Co. (Abbott GmbH) and Abbott Bioresearch Center filed a patent infringement lawsuit against COBI in the United States District Court for the District of Massachusetts. The suit alleges that COBI’s STELARA™ product infringes two U.S. patents assigned to Abbott GmbH. In August 2009, COBI filed a complaint for a declaratory judgment of non-infringement and invalidity of the Abbott GmbH patents in the United States District Court for the District of Columbia. On the same date, also in the United States District Court for the District of

58


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Columbia, COBI filed a Complaint for Review of a Patent Interference Decision granting priority of invention on one of the two asserted patents to Abbott GmbH. In August 2009, Abbott GmbH and Abbott Laboratories Limited brought a patent infringement suit in Canada alleging that STELARA™ infringes Abbott GmbH’s Canadian patent. The cases filed by COBI in the District of Columbia have been transferred to the District of Massachusetts.
     In August 2009, Bayer Healthcare LLC filed suit against COBI in Massachusetts District Court alleging infringement by COBI’s SIMPONI™ product of its patent relating to human anti-TNF antibodies. Bayer has also filed suit under its European counterpart to these patents in Germany and the Netherlands.
     In June 2009, Centocor’s (now COBI) lawsuit alleging that Abbott’s HUMIRA anti-TNF alpha product infringes Centocor’s ‘775 patent went to trial in Federal District Court in the Eastern District of Texas. On June 28, 2009 a jury returned a verdict finding the patent valid and willfully infringed, and awarded Centocor damages of approximately $1.7 billion. A bench trial on Abbott’s defenses, of inequitable conduct and prosecution laches, was held in August 2009, and the District Court decided these issues in favor of Centocor. All of Abbott’s post trial motions have been denied except that the District Court granted Abbott’s motion to overturn the jury finding of willfulness. Judgment in the amount of $1.9 billion was entered in favor of Centocor in December 2009 and Abbott has filed an appeal to the Court of Appeals for the Federal Circuit. The Company has not reflected any of the $1.9 billion in its consolidated financial statements. Centocor has also filed a new lawsuit in the Eastern District of Texas seeking damages for infringement of the ‘775 patent attributable to sales of HUMIRA subsequent to the jury verdict in June 2009.
     The following chart summarizes various patent lawsuits concerning products of the Company’s subsidiaries that have yet to proceed to trial:
                         
J&J           Plaintiff/            
Product   Company   Patents   Patent Holder   Court   Trial Date**   Date Filed
     
CYPHER® Stent
  Cordis   Wall   Wall   E.D. TX   Q2/11   11/07
 
CYPHER® Stent
  Cordis   Saffran   Saffran   E.D. TX   Q2/11   10/07
 
Blood Glucose Meters and Strips
  LifeScan   Wilsey   Roche Diagnostics   D. DE   *   11/07
 
REMICADE®, ustekinumab,
  Centocor/COBI   Cabilly II   Genentech   C.D. CA   *   05/08
golimumab, ReoPro®
                       
 
SIMPONI™
  Centocor/COBI   Salfeld   Abbott Laboratories   MA   *   05/09
 
SIMPONI™
  Centocor/COBI   Boyle   Bayer Healthcare   MA   *   08/09
 
STELARA™
  Centocor/COBI   Salfeld   Abbott GmbH   MA/DC   *   08/09
 
*   Trial date to be scheduled.
 
**   Q reflects the Company’s fiscal quarter.
LITIGATION AGAINST FILERS OF ABBREVIATED NEW DRUG APPLICATIONS (ANDAs)
The following chart indicates lawsuits pending against generic firms that filed Abbreviated New Drug Applications (ANDAs) seeking to market generic forms of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement, invalidity and unenforceability of these patents. In the event the subsidiary of the Company involved is not successful in these actions, or the statutory 30-month stay expires before a ruling from the district court is obtained, the firms involved will have the ability, upon FDA approval, to introduce generic versions of the product at issue resulting in very substantial market share and revenue losses for the product of the Company’s subsidiary.
     As noted in the following chart, 30-month stays expired during 2009, and will expire in 2010, 2011 and 2012 with respect to ANDA challenges regarding various products:
                         
Brand Name   Patent/NDA   Generic       Trial   Date   30-Month
Product   Holder   Challenger   Court   Date**   Filed   Stay Expiration
     
CONCERTA®
  McNeil-PPC   Andrx   D. DE   Q4/07   09/05   None
18, 27, 36 and 54 mg controlled release tablet
  ALZA   KUDCO   D. DE   *   01/10   05/12
 
LEVAQUIN® 250, 500, 750 mg tablet
  Ortho-McNeil   Lupin   D. NJ   *   10/06   03/09
 
ORTHO TRI-CYCLEN® LO
  Ortho-McNeil   Watson   D. NJ   *   10/08   03/11
0.18 mg/0.025 mg, 0.215 mg/0.025 mg
and 0.25 mg/0.025 mg
      Sandoz   D. NJ
D. NJ
  *
*
  06/09   10/11
06/12
 
ULTRAM ER® 100, 200, 300 mg tablet
  Ortho-McNeil/Biovail   Par   D. DE   Q2/09   05/07   09/09
 
                  06/07   11/09
 
                  10/07   03/10
 
ULTRAM ER® 100, 200, 300 mg tablet
  Ortho-McNeil/Biovail   Impax   D. DE   Q2/10   08/08   01/11
 
                  11/08   03/11
 
ULTRAM ER® 100, 200, 300 mg tablet
  Ortho-McNeil/Biovail   Paddock   D.DRD. Minn.   *   09/09   01/12
 
ULTRAM ER® 100, 200, 300 mg tablet
  Ortho-McNeil/Biovail   Cipher   D. DE   *   10/09   03/12
 
ULTRAM ER® 100, 200, 300 mg tablet
  Ortho-McNeil/Biovail   Lupin   D. DE   *   01/10   06/12
 
*   Trial date to be scheduled.
 
**   Q reflects the Company’s fiscal quarter.

59


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
     In the action against Barr Pharmaceuticals, Inc. (Barr) (now a wholly-owned subsidiary of Teva Pharmaceutical Industries LTD.) regarding ORTHO TRI-CYCLEN® LO, in January 2008, the Company’s subsidiary Ortho Women’s Health & Urology, a Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), and Barr agreed to a non-binding term sheet to settle the litigation, which settlement discussions are still underway. The trial court postponed the January 2008 trial without setting a new trial date. In June 2009, Barr launched its generic product “at risk” before trial. OMJPI sought a preliminary injunction and recall of Barr product which the Court granted in July 2009. In July 2009, the parties entered into a definitive agreement to settle the lawsuit. Under the terms of the settlement, Barr obtained a release for its sales of its generic product in exchange for an undisclosed royalty payment. Barr also obtained a non-exclusive, royalty-bearing license to re-enter the market on December 31, 2015, or earlier in certain limited circumstances.
     In October 2008, the Company’s subsidiary OMJPI filed suit in Federal District Court in New Jersey against Watson Laboratories, Inc. (Watson) in response to Watson’s ANDA regarding ORTHO TRI-CYCLEN® LO. In June 2009, the Company’s subsidiary OMJPI filed suit in Federal District Court in New Jersey against Sandoz Laboratories, Inc. (Sandoz) in response to Sandoz’s ANDA regarding ORTHO TRI-CYCLEN® LO. The Sandoz and Watson cases have been consolidated.
     In January 2010, the Company’s subsidiary OMJPI filed suit in Federal District Court in New Jersey against Lupin Ltd. and Lupin Pharmaceuticals, Inc. (collectively “Lupin”) in response to Lupin’s ANDA regarding ORTHO TRI-CYCLEN® LO.
     In the action against Barr and AlphaPharm with respect to their ANDA challenges to the RAZADYNE® patent that Janssen (now OMJPI) licenses from Synaptech, Inc. (Synaptech), a four-day non-jury trial was held in the Federal District Court in Delaware in May 2007. In August 2008, the court held that the patent was invalid because it was not enabled. Janssen (OMJPI) and Synaptech have appealed the decision. Since the court’s decision, multiple generic companies have received final approvals for their products and have launched “at risk” pending appeal. Additional generic approvals and launches could occur at any time. In September 2009, the Court of Appeals affirmed the judgment that the patent is invalid.
     In the action by McNEIL-PPC, Inc. (McNeil-PPC) and ALZA Corporation (ALZA) against Andrx Corporation (Andrx) with respect to its ANDA challenge to the CONCERTA® patents, a five-day non-jury trial was held in the Federal District Court in Delaware in December 2007. In March 2009, the court ruled that one CONCERTA® patent would not be infringed by Andrx’s proposed generic product and that the patent was invalid because it was not enabled. The court dismissed without prejudice Andrx’s declaratory judgment suit on a second patent for lack of jurisdiction. McNeil-PPC and ALZA filed an appeal in May 2009. The appeals court heard argument on February 3, 2010. A decision is pending.
     ALZA and OMJPI filed a second suit in Federal District Court in Delaware against Kremers-Urban, LLC and KUDCO Ireland, Ltd. (KUDCO) in January 2010 in response to KUDCO’s ANDA challenge regarding CONCERTA® tablets. In its notice letter, KUDCO contends that two ALZA patents for CONCERTA® are invalid and not infringed by a KUDCO generic.
     In the RAZADYNE® ER cases, a lawsuit was filed against Barr on the RAZADYNE® use patent that Janssen (now OMJPI) licenses from Synaptech in June 2006. In September 2008, the above-discussed Delaware decision invalidating the RAZADYNE® use patent resulted in entry of judgment for Barr on that patent, but the case will be reopened if Janssen (now OMJPI) and Synaptech win on appeal. Barr has received FDA approval of its product and has launched “at risk.” In September 2009, the Federal Circuit affirmed the Delaware decision invalidating the RAZADYNE® use patent. As a result, this case will not be reopened.
     In the action against Lupin Pharmaceuticals, Inc. (Lupin) regarding its ANDA concerning LEVAQUIN®, Lupin contends that the U.S. Patent and Trademark Office improperly granted a patent term extension to the patent that Ortho-McNeil (now Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI)) licenses from Daiichi Pharmaceuticals, Inc. (Daiichi). Lupin alleges that the active ingredient in LEVAQUIN® was the subject of prior marketing, and therefore was not eligible for the patent term extension. Lupin concedes validity and that its product would violate the patent if marketed prior to the expiration of the original patent term. Summary judgment against Lupin was granted in May 2009 and Lupin appealed. Oral argument was held in September 2009. A decision is pending.
     In the ULTRAM® ER actions, Ortho-McNeil Pharmaceutical, Inc. (Ortho-McNeil) (now OMJPI), filed lawsuits (each for different dosages) against Par Pharmaceuticals, Inc. and Par Pharmaceuticals Companies, Inc. (Par) in May, June and October 2007 on two Tramadol ER formulation patents owned by Purdue Pharma Products L.P. (Purdue) and Napp Pharmaceutical Group Ltd. (Napp). OMJPI also filed lawsuits (each for different dosages) against Impax Laboratories, Inc. (Impax) on a Tramadol ER formulation patent owned by Purdue and Napp in August and November 2008. Purdue, Napp and Biovail Laboratories International SRL (Biovail) (the NDA holder) joined as co-plaintiffs in the lawsuits against Par and Impax, but Biovail and OMJPI were subsequently dismissed for lack of standing. The trial against Par took place in April 2009. In August 2009, the Court issued a decision finding the patents-in-suit invalid. Purdue has appealed that decision. The trial against Impax is scheduled for June 2010. In November 2009, the case against Impax was stayed with the consent of all parties. In September and October 2009, respectively, Purdue filed suits against Paddock Laboratories, Inc. (Paddock) and Cipher Pharmaceuticals Inc. (Cipher) on its Tramadol ER formulation patents.
     In January 2010, Purdue filed a suit against Lupin Ltd. (Lupin) on its Tramadol ER formulation patents.
     In September 2009, Centocor Ortho Biotech Products, L.P. (COBI, LP) intervened in an inventorship dispute between Kansas University Center for Research (KUCR) involving certain U.S. government-owned VELCADE® formulation patents. KUCR brought this action against the U.S. government in the District of Kansas seeking to add two Kansas University scientists to the patents. The U.S. government licensed the patents (and their foreign counterparts) to Millennium Pharmaceuticals, Inc., who in turn sublicensed the patents (and their foreign counterparts) to COBI,LP for commercial marketing outside the U.S. If KUCR succeeds in its co-inventorship claim and establishes co-ownership in the U.S. VELCADE® formulation patents, we anticipate that KUCR will initiate actions to establish co-inventorship and co-ownership with respect to the foreign counterpart patents in the countries where COBI, LP has commercial marketing rights. If KUCR in Kansas is successful, this may adversely affect COBI, LP’s license rights in those countries.
AVERAGE WHOLESALE PRICE (AWP) LITIGATION
Johnson & Johnson and several of its pharmaceutical subsidiaries, along with numerous other pharmaceutical companies, are defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Many of these cases, both federal actions and state actions

60


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
removed to federal court, have been consolidated for pre-trial purposes in a Multi-District Litigation (MDL) in Federal District Court in Boston, Massachusetts. The plaintiffs in these cases include classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP.
     The MDL Court identified classes of Massachusetts-only private insurers providing “Medi-gap” insurance coverage and private payers for physician-administered drugs where payments were based on AWP (“Class 2” and “Class 3”), and a national class of individuals who made co-payments for physician-administered drugs covered by Medicare (“Class 1”). A trial of the two Massachusetts-only class actions concluded before the MDL Court in December 2006. In June 2007, the MDL Court issued post-trial rulings, dismissing the Johnson & Johnson defendants from the case regarding all claims of Classes 2 and 3, and subsequently of Class 1 as well. Plaintiffs appealed the Class 1 judgment and, in September 2009, the Court of Appeals vacated the judgment and remanded for further proceedings in the District Court. AWP cases brought by various Attorneys General have proceeded to trial against other manufacturers. One state case against certain of the Company’s subsidiaries has been set for trial in late 2010, and other state cases are likely to be set for trial thereafter.
OTHER
In July 2003, Centocor (now COBI), a Johnson & Johnson subsidiary, received a request that it voluntarily provide documents and information to the criminal division of the U.S. Attorney’s Office, District of New Jersey, in connection with its investigation into various Centocor marketing practices. Subsequent requests for documents have been received from the U.S. Attorney’s Office. Both the Company and Centocor have responded to these requests for documents and information.
     In December 2003, Ortho-McNeil (now OMJPI) received a subpoena from the U.S. Attorney’s Office in Boston, Massachusetts seeking documents relating to the marketing, including alleged off-label marketing, of the drug TOPAMAX® (topiramate). Additional subpoenas for documents have been received, and current and former employees have testified before a grand jury. Discussions are underway in an effort to resolve this matter, but whether agreement can be reached and on what terms is uncertain.
     In January 2004, Janssen (now OMJPI) received a subpoena from the Office of the Inspector General of the U.S. Office of Personnel Management seeking documents concerning sales and marketing of, any and all payments to physicians in connection with sales and marketing of, and clinical trials for, RISPERDAL® (risperidone) from 1997 to 2002. Documents subsequent to 2002 have also been requested. An additional subpoena seeking information about marketing of and adverse reactions to RISPERDAL® was received from the U.S. Attorney’s Office for the Eastern District of Pennsylvania in November 2005. Subpoenas seeking testimony from various witnesses before a grand jury have also been received. Janssen is cooperating in responding to ongoing requests for documents and witnesses. The government is continuing to actively investigate this matter. In February 2010, the government served Civil Investigative Demands seeking additional information relating to sales and marketing of RISPERDAL® and sales and marketing of INVEGA®.
     In September 2004, Ortho Biotech Inc. (Ortho Biotech) (now COBI), received a subpoena from the U.S. Office of Inspector General’s Denver, Colorado field office seeking documents directed to the sales and marketing of PROCRIT® (Epoetin alfa) from 1997 to the present, as well as to dealings with U.S. Oncology Inc., a healthcare services network for oncologists. Ortho Biotech (now COBI) has responded to the subpoena.
     In September 2004, plaintiffs in an employment discrimination litigation initiated against the Company in 2001 in Federal District Court in New Jersey moved to certify a class of all African American and Hispanic salaried employees of the Company and its affiliates in the U.S., who were employed at any time from November 1997 to the present. Plaintiffs seek monetary damages for the period 1997 through the present (including punitive damages) and equitable relief. The Court denied plaintiffs’ class certification motion in December 2006 and their motion for reconsideration in April 2007. Plaintiffs sought to appeal these decisions and, in April 2008, the Court of Appeals ruled that plaintiffs’ appeal of the denial of class certification was untimely. In July 2009, plaintiffs filed a motion for certification of a modified class, which the Company is opposing. Plaintiffs are engaged in further discovery of individual plaintiffs’ claims. The hearing on plaintiffs’ motion for class certification is scheduled for July 2010.
     In March 2005, DePuy Orthopaedics, Inc. (DePuy), a Johnson & Johnson subsidiary, received a subpoena from the U.S. Attorney’s Office, District of New Jersey, seeking records concerning contractual relationships between DePuy and surgeons or surgeons-in-training involved in hip and knee replacement and reconstructive surgery. This investigation was resolved by DePuy and the four other leading suppliers of hip and knee implants in late September 2007 by agreements with the U.S. Attorney’s Office for the District of New Jersey. The settlements included an 18-month Deferred Prosecution Agreement (DPA), acceptance by each company of a monitor to assure compliance with the DPA and, with respect to four of the five companies, payment of settlement monies and entry into five year Corporate Integrity Agreements. DePuy paid $85 million as its settlement. The term of the Monitor-ship under the Deferred Prosecution Agreement concluded on March 27, 2009, and an order dismissing all charges was entered on March 30, 2009.
     In November 2007, the Attorney General of the Commonwealth of Massachusetts issued a Civil Investigative Demand to DePuy seeking information regarding financial relationships between a number of Massachusetts-based orthopedic surgeons and providers and DePuy. DePuy is responding to Massachusetts’ additional requests.
     In July 2005, Scios Inc. (Scios), a Johnson & Johnson subsidiary, received a subpoena from the U.S. Attorney’s Office, District of Massachusetts, seeking documents related to the sales and marketing of NATRECOR®. Scios responded to the subpoena. In early August 2005, Scios was advised that the investigation would be handled by the U.S. Attorney’s Office for the Northern District of California in San Francisco. Additional requests for documents have been received and responded to and former Scios employees have testified before a grand jury in San Francisco. The qui tam complaints were unsealed on February 19, 2009. The U.S. government has intervened in one of the qui tam actions, and filed a complaint against Scios and the Company in June 2009. Scios and Johnson & Johnson have filed a motion to dismiss the qui tam complaint filed by the government, and that motion was denied. The criminal investigation is continuing and discussions are underway in an effort to settle this matter. Whether a settlement can be reached and on what terms is uncertain.
     In September 2005, the Company received a subpoena from the U.S. Attorney’s Office, District of Massachusetts, seeking documents related to sales and marketing of eight drugs to Omnicare, Inc., a manager of pharmaceutical benefits for long-term care facilities. The Johnson & Johnson subsidiaries involved responded to the subpoena. Several employees of the Company’s pharmaceutical subsidiaries have been subpoenaed to testify before a grand jury in connection with this investigation. In April 2009, the Company was served with the complaints in two civil qui tam cases related to

61


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
marketing of prescription drugs to Omnicare, Inc. On January 15, 2010, the government filed a complaint intervening in the cases. The complaint asserts claims under the federal False Claims Act and a related state law claim in connection with the marketing of several drugs to Omnicare.
     In November 2005, Amgen Inc. (Amgen) filed suit against Hoffmann-LaRoche, Inc. (Roche) in the U.S. District Court for the District of Massachusetts seeking a declaration that the Roche product CERA, which Roche has indicated it would seek to introduce into the United States, infringes a number of Amgen patents concerning EPO. Amgen licenses EPO for sale in the United States to Ortho Biotech (now COBI) for non-dialysis indications. Trial in this action concluded in October 2007 with a verdict in Amgen’s favor, finding the patents valid and infringed. The judge issued a preliminary injunction blocking the CERA launch, and subsequently made the injunction permanent. The Federal Circuit upheld the entry of a permanent injunction. This matter has been settled pursuant to an agreement between the parties.
     In February 2006, the Company received a subpoena from the U.S. Securities & Exchange Commission (SEC) requesting documents relating to the participation by several Johnson & Johnson subsidiaries in the United Nations Iraq Oil for Food Program. The subsidiaries are cooperating with the SEC and U.S. Department of Justice (DOJ) in producing responsive documents.
     In February 2007, the Company voluntarily disclosed to the DOJ and the SEC that subsidiaries outside the United States are believed to have made improper payments in connection with the sale of medical devices in two small-market countries, which payments may fall within the jurisdiction of the Foreign Corrupt Practices Act (FCPA). In the course of continuing dialogues with the agencies, other issues potentially rising to the level of FCPA violations in additional markets have been brought to the attention of the agencies by the Company. The Company has provided and will continue to provide additional information to the DOJ and SEC, and will cooperate with the agencies’ reviews of these matters. Law enforcement agencies of a number of other countries are also pursuing investigations of matters voluntarily disclosed by the Company to the DOJ and SEC. Discussions are underway in an effort to resolve these matters, and the Iraq Oil for Food matter referenced above, but whether agreement can be reached and on what terms is uncertain.
     In March 2007, the Company received separate subpoenas from the U.S. Attorney’s Office in Philadelphia, the U.S. Attorney’s Office in Boston and the U.S. Attorney’s Office in San Francisco. The subpoenas relate to investigations by these three offices referenced above concerning, respectively, sales and marketing of RISPERDAL® by Janssen (now OMJPI), TOPAMAX® by Ortho-McNeil (now OMJPI) and NATRECOR® by Scios. The subpoenas request information regarding the Company’s corporate supervision and oversight of these three subsidiaries, including their sales and marketing of these drugs. The Company responded to these requests. In addition, the U.S. Attorney’s Office in Boston has issued subpoenas for grand jury testimony to several employees of Johnson & Johnson.
     In May 2007, the New York State Attorney General issued a subpoena seeking information relating to the marketing and safety of PROCRIT®. The Company is responding to these requests.
     In April 2007, the Company received two subpoenas from the Office of the Attorney General of the State of Delaware. The subpoenas seek documents and information relating to nominal pricing agreements. For purposes of the subpoenas, nominal pricing agreements are defined as agreements under which the Company agreed to provide a pharmaceutical product for less than ten percent of the Average Manufacturer Price for the product. The Company responded to these requests.
     In January 2008, the European Commission (“EC”) began an industry-wide antitrust inquiry concerning competitive conditions within the pharmaceutical sector. Because this is a sector inquiry, it is not based on any specific allegation that the Company has violated EC competition law. The inquiry began with unannounced raids of a substantial number of pharmaceutical companies throughout Europe, including Johnson & Johnson affiliates. In March 2008, the EC issued detailed questionnaires to approximately 100 companies, including Johnson & Johnson affiliates. In November 2008, the EC issued a preliminary report summarizing its findings. The final report was issued on July 8, 2009.
     In March 2008, the Company received a letter request from the Attorney General of the State of Michigan. The request seeks documents and information relating to nominal price transactions. The Company responded to the request and will cooperate with the inquiry.
     In June 2008, the Company received a subpoena from the United States Attorney’s Office for the District of Massachusetts relating to the marketing of biliary stents by the Company’s Cordis subsidiary. Cordis is cooperating in responding to the subpoena.
     In September 2008, Multilan AG (Multilan), an indirect subsidiary of Schering-Plough Corporation, commenced arbitration against Janssen Pharmaceutica NV for an alleged wrongful termination of an agreement relating to payments in connection with termination of certain marketing rights. Multilan seeks declaratory relief, specific performance and damages. This case was recently settled and a charge was recorded to other income (expense), net, in the fiscal fourth quarter of 2009.
     In February 2009, Basilea Pharmaceutica AG (Basilea) brought an arbitration against the Company and various affiliates alleging that the Company breached the 2005 License Agreement for cefto-biprole by, among other things, failing to secure FDA approval of the cSSSI (skin) indication and allegedly failing to properly develop the pneumonia indication. Basilea is seeking to recover damages and a declaration that the Company materially breached the agreement. This matter has been scheduled for an arbitration hearing commencing in June 2010 followed by post-trial submissions.
     In April 2009, the Company received a HIPPA subpoena from the U.S. Attorney’s Office for the District of Massachusetts (Boston) seeking information regarding the Company’s financial relationship with several psychiatrists. The Company is responding to this request.
     In April 2009, Ortho-Clinical Diagnostics, Inc. (OCD) received a grand jury subpoena from the U.S. Department of Justice, Antitrust Division, requesting documents and information for the period beginning September 1, 2000 through the present, pertaining to an investigation of alleged violations of the antitrust laws in the blood reagents industry. The Company is in the process of complying with the subpoena. In the weeks following the public announcement that OCD had received a subpoena from the Antitrust Division, multiple class action complaints were filed. The various cases were consolidated for pre-trial purposes in the Eastern District of Pennsylvania.
     In May 2009, the New Jersey Attorney General issued a subpoena to DePuy Orthopaedics, Inc., seeking information regarding the financial interest of clinical investigators who performed clinical studies for DePuy Orthopaedics, Inc. and DePuy Spine, Inc. The Company is responding to these requests.
     In May 2009, COBI commenced an arbitration proceeding before the American Arbitration Association against Schering-Plough Corporation and its subsidiary Schering-Plough (Ireland) Company (collectively, Schering-Plough). COBI and Schering-Plough are parties to a series of agreements (the Distribution

62


Table of Contents

JOHNSON & JOHNSON
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Agreements) that grant Schering-Plough the exclusive right to distribute the drugs REMICADE® and SIMPONI™ worldwide, except within the United States, Japan, Taiwan, Indonesia, and the People’s Republic of China (including Hong Kong) (the “Territory”). COBI distributes REMICADE® and SIMPONI™, the next generation treatment, within the United States. In the arbitration, COBI seeks a declaration that the agreement and merger between Merck & Co., Inc. (Merck) and Schering-Plough constitutes a change of control under the terms of the Distribution Agreements that permits COBI to terminate the Agreements. The termination of the Distribution Agreements would return to COBI the right to distribute REMICADE® and SIMPONI™ within the Territory. Schering-Plough has filed a response to COBI’s arbitration demand that denies that it has undergone a change of control. The arbitrators have been selected and the matter will be proceeding to arbitration in late September 2010.
     In December 2009, the State of Israel (Sheba Medical Center) filed a lawsuit against three Omrix entities. In the lawsuit, the State claimed that an employee of a government-owned hospital was the inventor on several patents related to fibrin glue technology, that he developed while he was a government employee. The State claims that he had no right to transfer any intellectual property to Omrix because it belongs to the State. The State is seeking damages plus royalty on QUIXIL™ and EVICEL™ or, alternatively, transfer of the patents to the State.
     In recent years the Company has received numerous requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the Company’s policy to cooperate with these inquiries by producing the requested information.
     With respect to all the above matters, the Company and its subsidiaries are vigorously contesting the allegations asserted against them and otherwise pursuing defenses to maximize the prospect of success. The Company and its subsidiaries involved in these matters continually evaluate their strategies in managing these matters and, where appropriate, pursue settlements and other resolutions where those are in the best interest of the Company.
     The Company is also involved in a number of other patent, trademark and other lawsuits incidental to its business. The ultimate legal and financial liability of the Company in respect to all claims, lawsuits and proceedings referred to above cannot be estimated with any certainty. However, in the Company’s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company’s balance sheet, is not expected to have a material adverse effect on the Company’s financial condition, although the resolution in any reporting period of one or more of these matters could have a significant impact on the Company’s results of operations and cash flows for that period.
22. Restructuring
In the fourth quarter of 2009, the Company announced global restructuring initiatives designed to strengthen the Company’s position as one of the world’s leading global health care companies. This program will allow the Company to invest in new growth platforms; ensure the successful launch of its many new products and continued growth of its core businesses; and provide flexibility to adjust to the changed and evolving global environment.
     During the fiscal fourth quarter of 2009, the Company recorded $1.2 billion in related pre-tax charges of which, approximately $830 million of the pre-tax restructuring charges are expected to require cash payments. The $1.2 billion of restructuring charges consists of severance costs of $748 million, asset write-offs of $362 million and $76 million related to leasehold and contract obligations. The $362 million of asset write-offs relate to inventory of $113 million (recorded in cost of products sold), property, plant and equipment of $107 million, intangible assets of $81 million and other assets of $61 million. Additionally, as part of this program the Company plans to eliminate approximately 7,500 positions of which approximately 700 have been eliminated since the restructuring was announced.
     The following table summarizes the severance charges and the associated spending for the fiscal year ended 2009:
                                 
            Asset              
(Dollars in Millions)   Severance     Write-Offs     Other     Total  
     
2009 restructuring charge
  $ 748       362       76       1,186  
Current year activity
    (62 )     (149 )     (28 )     (239 )
     
Reserve balance, January 3, 2010*
  $ 686       213       48       947  
     
 
*   Cash outlays for severance are expected to be substantially paid out over the next 12 to 18 months in accordance with the Company’s plans and local laws.
For additional information on the restructuring as it relates to the segments, see Note 18.
     In the third quarter of 2007, the Company announced restructuring initiatives in an effort to improve its overall cost structure. This action was taken to offset the anticipated negative impacts associated with generic competition in the Pharmaceutical segment and challenges in the drug-eluting stent market. The Company’s Pharmaceuticals segment has reduced its cost base by consolidating certain operations, while continuing to invest in recently launched products and its late-stage pipeline of new products. The Cordis franchise has moved to a more integrated business model to address the market changes underway with drug-eluting stents and to better serve the broad spectrum of its patients’ cardiovascular needs, while reducing its cost base. The Company accelerated steps to standardize and streamline certain aspects of its enterprise-wide functions such as human resources, finance and information technology to support growth across the business, while also leveraging its scale more effectively in areas such as procurement to benefit its operating companies. Additionally, as part of this program the Company eliminated approximately 4,600 positions.
     The Company recorded $745 million in related pre-tax charges during the fiscal third quarter of 2007, of which, approximately $500 million of the pre-tax restructuring charges required cash payments. The $745 million of restructuring charges consists of severance costs of $450 million, asset write-offs of $272 million and $23 million related to leasehold obligations. The $272 million of asset write-offs relate to property, plant and equipment of $166 million, intangible assets of $48 million and other assets of $58 million. The restructuring initiative announced in 2007 has been completed.
23. Subsequent Events
On January 20, 2010, the Company completed the acquisition of Acclarent Inc. for a net purchase
price of approximately $785 million. Acclarent Inc. is a medical technology company dedicated to
designing, developing and commercializing devices that address conditions affecting the ear, nose
and throat.
     The Company has performed an evaluation of subsequent events through March 1, 2010, the date the Company issued these financial statements.

63


Table of Contents

Report of Independent Registered Public Accounting Firm
To the Shareholders and Board of Directors of Johnson & Johnson:
In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of earnings, statements of equity, and statements of cash flows present fairly, in all material respects, the financial position of Johnson & Johnson and its subsidiaries (“the Company”) at January 3, 2010 and December 28, 2008, and the results of their operations and their cash flows for each of the three years in the period ended January 3, 2010 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of January 3, 2010, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company’s management is responsible for these financial statements, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying, “Management’s Report on Internal Control over Financial Reporting.” Our responsibility is to express opinions on these financial statements and on the Company’s internal control over financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.
     As discussed in Note 1 to the Consolidated Financial Statements, the Company changed the manner in which it accounts for business combinations in 2009.
     A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
     Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
(SIGNATURE)
New York, New York
March 1, 2010
JOHNSON & JOHNSON 2009 ANNUAL REPORT

64


Table of Contents

Management’s Report on Internal Control Over Financial Reporting
Under Section 404 of the Sarbanes-Oxley Act of 2002, management is required to assess the effectiveness of the Company’s internal control over financial reporting as of the end of each fiscal year and report, based on that assessment, whether the Company’s internal control over financial reporting is effective.
     Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is designed to provide reasonable assurance as to the reliability of the Company’s financial reporting and the preparation of external financial statements in accordance with generally accepted accounting principles.
     Internal controls over financial reporting, no matter how well designed, have inherent limitations. Therefore, internal control over financial reporting determined to be effective can provide only reasonable assurance with respect to financial statement preparation and may not prevent or detect all misstatements. Moreover, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
     The Company’s management has assessed the effectiveness of the Company’s internal control over financial reporting as of January 3, 2010. In making this assessment, the Company used the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in “Internal Control-Integrated Framework.” These criteria are in the areas of control environment, risk assessment, control activities, information and communication, and monitoring. The Company’s assessment included extensive documenting, evaluating and testing the design and operating effectiveness of its internal controls over financial reporting.
     Based on the Company’s processes and assessment, as described above, management has concluded that, as of January 3, 2010, the Company’s internal control over financial reporting was effective.
     The effectiveness of the Company’s internal control over financial reporting as of January 3, 2010 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report, which appears herein.
     
-s- William C. Weldon
  -s- Dominic J. Caruso
William C. Weldon
  Dominic J. Caruso
Chairman, Board of Directors, and
  Vice President, Finance, and
Chief Executive Officer
  Chief Financial Officer
MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

65


Table of Contents

Summary of Operations and Statistical Data 1999-2009
                                                                                         
(Dollars in Millions Except Per Share Figures)   2009     2008     2007     2006     2005     2004     2003     2002     2001     2000     1999  
     
Sales to customer — U.S.
  $ 30,889       32,309       32,444       29,775       28,377       27,770       25,274       22,455       19,825       17,316       15,532  
Sales to customer— International
    31,008       31,438       28,651       23,549       22,137       19,578       16,588       13,843       12,492       11,856       11,825  
     
Total sales
    61,897       63,747       61,095       53,324       50,514       47,348       41,862       36,298       32,317       29,172       27,357  
     
Cost of products sold
    18,447       18,511       17,751       15,057       14,010       13,474       12,231       10,498       9,622       8,987       8,559  
Selling, marketing and administrative expenses
    19,801       21,490       20,451       17,433       17,211       16,174       14,463       12,520       11,510       10,675       10,182  
Research expense
    6,986       7,577       7,680       7,125       6,462       5,344       4,834       4,094       3,704       3,186       2,821  
Purchased in-process research and development
          181       807       559       362       18       918       189       105       66        
Interest income
    (90 )     (361 )     (452 )     (829 )     (487 )     (195 )     (177 )     (256 )     (456 )     (429 )     (266 )
Interest expense, net of portion capitalized
    451       435       296       63       54       187       207       160       153       204       255  
Other (income) expense, net
    (526 )     (1,015 )     534       (671 )     (214 )     15       (385 )     294       185       (94 )     119  
Restructuring
    1,073             745                                                  
     
 
    46,142       46,818       47,812       38,737       37,398       35,017       32,091       27,499       24,823       22,595       21,670  
     
Earnings before provision for taxes on income
    15,755       16,929       13,283       14,587       13,116       12,331       9,771       8,799       7,494       6,577       5,687  
Provision for taxes on income
    3,489       3,980       2,707       3,534       3,056       4,151       2,923       2,522       2,089       1,813       1,554  
     
Net earnings
    12,266       12,949       10,576       11,053       10,060       8,180       6,848       6,277       5,405       4,764       4,133  
     
Percent of sales to customers
    19.8       20.3       17.3       20.7       19.9       17.3       16.4       17.3       16.7       16.3       15.1  
Diluted net earnings per share of common stock
  $ 4.40       4.57       3.63       3.73       3.35       2.74       2.29       2.06       1.75       1.55       1.34  
Percent return on average shareholders’ equity
    26.4       30.2       25.6       28.3       28.2       27.3       27.1       26.4       24.0       25.3       26.0  
     
Percent increase (decrease) over previous year:
                                                                                       
Sales to customers
    (2.9 )     4.3       14.6       5.6       6.7       13.1       15.3       12.3       10.8       6.6       14.9  
Diluted net earnings per share
    (3.7 )     25.9       (2.7 )     11.3       22.3       19.7       11.2       17.7       12.9       15.7       34.0  
     
Supplementary expense data:
                                                                                       
Cost of materials and services(1)
  $ 27,651       29,346       27,967       22,912       22,328       21,053       18,568       16,540       15,333       14,113       13,922  
Total employment costs
    14,587       14,523       14,571       13,444       12,364       11,581       10,542       8,942       8,153       7,376       6,727  
Depreciation and amortization
    2,774       2,832       2,777       2,177       2,093       2,124       1,869       1,662       1,605       1,592       1,510  
Maintenance and repairs(2)
    567       583       483       506       510       462       395       360       372       327       322  
Total tax expense(3)
    5,052       5,558       4,177       4,857       4,285       5,215       3,890       3,325       2,854       2,517       2,221  
     
Supplementary balance sheet data:
                                                                                       
Property, plant and equipment, net
    14,759       14,365       14,185       13,044       10,830       10,436       9,846       8,710       7,719       7,409       7,155  
Additions to property, plant and equipment
    2,365       3,066       2,942       2,666       2,632       2,175       2,262       2,099       1,731       1,689       1,822  
Total assets
    94,682       84,912       80,954       70,556       58,864       54,039       48,858       40,984       38,771       34,435       31,163  
Long-term debt
    8,223       8,120       7,074       2,014       2,017       2,565       2,955       2,022       2,217       3,163       3,429  
Operating cash flow
    16,571       14,972       15,022       14,248       11,799       11,089       10,571       8,135       8,781       6,889       5,913  
     
Common stock information
                                                                                       
Dividends paid per share
  $ 1.930       1.795       1.620       1.455       1.275       1.095       0.925       0.795       0.700       0.620       0.550  
Shareholders’ equity per share
  $ 18.37       15.35       15.25       13.59       13.01       10.95       9.25       7.79       8.05       6.82       5.73  
Market price per share (year-end close)
  $ 64.41       58.56       67.38       66.02       60.10       63.42       50.62       53.11       59.86       52.53       46.63  
Average shares outstanding (millions) — basic
    2,759.5       2,802.5       2,882.9       2,936.4       2,973.9       2,968.4       2,968.1       2,998.3       3,033.8       2,993.5       2,978.2  
— diluted
    2,789.1       2,835.6       2,910.7       2,961.0       3,002.8       2,992.7       2,995.1       3,049.1       3,089.3       3,075.2       3,090.4  
     
Employees (thousands)
    115.5       118.7       119.2       122.2       115.6       109.9       110.6       108.3       101.8       100.9       99.8  
     
 
(1)   Net of interest and other income.
 
(2)   Also included in cost of materials and services category.
 
(3)   Includes taxes on income, payroll, property and other business taxes.
SUMMARY OF OPERATIONS AND STATISTICAL DATA

66


Table of Contents

Shareholder Return Performance Graphs
Set forth below are line graphs comparing the cumulative total shareholder return on the Company’s Common Stock for periods of five years and ten years ending December 31, 2009, against the cumulative total return of the Standard & Poor’s 500 Stock Index, the Standard & Poor’s Pharmaceutical Index and the Standard & Poor’s Health Care Equipment Index. The graphs and tables assume that $100 was invested on December 31, 2004 and December 31,1999 in each of the Company’s Common Stock, the Standard & Poor’s 500 Stock Index, the Standard & Poor’s Pharmaceutical Index and the Standard & Poor’s Health Care Equipment Index and that all dividends were reinvested.
(PERFORMANCE GRAPH)
                                                                 
 
        2004       2005       2006       2007       2008       2009    
 
Johnson & Johnson
    $ 100.00         96.64         108.67         112.59         103.84         115.55    
 
S&P 500 Index
    $ 100.00         104.91         121.48         128.15         80.74         102.11    
 
S&P Pharmaceutical Index
    $ 100.00         96.64         111.96         117.17         95.85         113.68    
 
S&P Health Care Equipment Index
    $ 100.00         100.05         104.18         109.52         79.25         102.06    
 
(PERFORMANCE GRAPH)
                                                                                                                   
 
        1999       2000       2001       2002       2003       2004       2005       2006       2007       2008       2009    
 
Johnson & Johnson
    $ 100.00         114.20         130.20         119.94         117.41         146.95         142.02         159.69         165.46         152.60         169.81    
 
S&P 500 Index
    $ 100.00         90.92         80.11         62.41         80.31         89.04         93.42         108.17         114.11         71.89         90.92    
 
S&P Pharmaceutical Index
    $ 100.00         136.20         116.39         93.07         101.23         93.71         90.56         104.92         109.80         89.82         106.54    
 
S&P Health Care Equipment Index
    $ 100.00         146.64         139.21         121.61         160.57         180.84         180.93         188.39         198.06         143.31         184.56    
 
SHAREHOLDER RETURN PERFORMANCE GRAPHS

67

EX-21 5 y80744exv21.htm EX-21 exv21
EXHIBIT 21
 
SUBSIDIARIES
 
Johnson & Johnson, a New Jersey corporation, had the domestic and international subsidiaries shown below as of January 3, 2010. Certain U.S. subsidiaries and international subsidiaries are not named because they were not significant in the aggregate. Johnson & Johnson has no parent.
 
     
    Jurisdiction of
Name of Subsidiary
  Organization
 
U.S. Subsidiaries:
   
Advanced Sterilization Products Services Inc. 
  New Jersey
Advanced Technologies and Regenerative Medicine, LLC
  Delaware
ALZA Corporation
  Delaware
ALZA Development Corporation
  California
ALZA Land Management, Inc. 
  Delaware
Animas Corporation
  Delaware
Biosense Webster, Inc. 
  California
Centocor Biologics, LLC
  Pennsylvania
Centocor Ortho Biotech Inc. 
  Pennsylvania
Centocor Ortho Biotech Products, L.P.
  New Jersey
Centocor Ortho Biotech Services LLC
  New Jersey
Centocor Research & Development, Inc. 
  Pennsylvania
CNA Development LLC
  Delaware
Codman & Shurtleff, Inc. 
  New Jersey
Conor Medsystems, LLC
  Delaware
Cordis Corporation
  Florida
Cordis International Corporation
  Delaware
Cordis LLC
  Delaware
Cougar Biotechnology, Inc.
  Delaware
Crescendo Pharmaceuticals Corporation
  Delaware
DePuy, Inc. 
  Delaware
DePuy Mitek, Inc. 
  Massachusetts
DePuy Orthopaedics, Inc. 
  Indiana
DePuy Products, Inc. 
  Indiana
DePuy Spine, Inc. 
  Ohio
DePuy Spine Sales Limited Partnership
  Massachusetts
Diabetes Diagnostics, Inc. 
  Delaware
Ethicon Endo-Surgery, Inc. 
  Ohio
Ethicon Endo-Surgery, LLC
  Delaware
Ethicon Endo-Surgery Services, L.P. 
  Texas
Ethicon, Inc. 
  New Jersey
Ethicon LLC
  Delaware
Global Pharmaceutical Supply Group, LLC
  Pennsylvania
GUH Corporation
  Delaware
Hand Innovations LLC
  Delaware
HealthMedia, Inc. 
  Michigan
Human Performance Institute, Inc.
  Florida
Innovational Holdings, LLC
  Delaware
ISO Holding Corp. 
  Delaware
J&J Holdings (Nevada), Inc. 
  Nevada


 

     
    Jurisdiction of
Name of Subsidiary
  Organization
 
Janssen Alzheimer Immunotherapy Research & Development, LLC
  Delaware
Janssen Ortho LLC
  Delaware
JJHC, LLC
  Delaware
JNJ International Investment LLC
  Delaware
Johnson & Johnson Consumer Companies, Inc. 
  New Jersey
Johnson & Johnson Development Corporation
  New Jersey
Johnson & Johnson Finance Corporation
  New Jersey
Johnson & Johnson Health Care Systems Inc. 
  New Jersey
Johnson & Johnson International
  New Jersey
Johnson & Johnson Japan Inc. 
  New Jersey
Johnson & Johnson • Merck Consumer Pharmaceuticals Co. 
  New Jersey
Johnson & Johnson (Middle East) Inc. 
  New Jersey
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 
  New Jersey
Johnson & Johnson Pharmaceutical Services, LLC
  New Jersey
Johnson & Johnson Sales and Logistics Company, LLC
  New Jersey
Johnson & Johnson Services, Inc. 
  New Jersey
Johnson & Johnson Urban Renewal Associates
  New Jersey
Johnson & Johnson Vision Care, Inc. 
  Florida
Joint Medical Products Corporation
  Delaware
JOM Pharmaceutical Services, Inc.
  Delaware
LifeScan, Inc. 
  California
LifeScan LLC
  Delaware
LifeScan Products, LLC
  Delaware
LuMend, Inc. 
  Delaware
McNeil Consumer Healthcare Latin America LLC
  Delaware
McNeil Healthcare LLC
  Delaware
McNeil LA LLC
  Delaware
McNeil Nutritionals, LLC
  Delaware
McNEIL-PPC, Inc. 
  New Jersey
Mentor Minnesota Inc.
  Delaware
Mentor Texas L.P.
  Delaware
Middlesex Assurance Company Limited
  Vermont
Neutrogena Corporation
  Delaware
Nitinol Development Corporation
  California
Noramco, Inc. 
  Georgia
OMJ Pharmaceuticals, Inc. 
  Delaware
OraPharma, Inc. 
  Delaware
Ortho Biologics LLC
  Delaware
Ortho Biotech Holding LLC 
  Delaware
Ortho-Clinical Diagnostics, Inc. 
  New York
Ortho-McNeil Finance Co. 
  Florida
Ortho-McNeil-Janssen Pharmaceuticals, Inc. 
  Pennsylvania
Patriot Pharmaceuticals, LLC
  Pennsylvania
Rutan Realty LLC
  New Jersey
Scios Inc. 
  Delaware
SurgRx, Inc. 
  Delaware
TERAMed Corporation
  Delaware
Therakos, Inc.
  Florida


 

     
    Jurisdiction of
Name of Subsidiary
  Organization
 
Therapeutic Discovery Corporation
  Delaware
The Tylenol Company
  New Jersey
TransForm Pharmaceuticals, Inc. 
  Delaware
Veridex, LLC
  Delaware
International Subsidiaries:
   
Alza Ireland Limited
  Ireland
Apsis S.A.S. 
  France
Beijing Dabao Cosmetics Co., Ltd. 
  China
Biosense Webster (Israel) Ltd. 
  Israel
Centocor Biologics (Ireland)
  Ireland
Centocor B.V. 
  Netherlands
Cilag Advanced Technologies GmbH
  Switzerland
Cilag AG
  Switzerland
Cilag de Mexico, S. de R.L. de C.V. 
  Mexico
Cilag GmbH International
  Switzerland
Cilag Holding AG
  Switzerland
Cilag Pharmaceuticals GmbH
  Switzerland
Cordis Cashel
  Ireland
Cordis de Mexico, S.A. de C.V. 
  Mexico
Cordis Europa N.V. 
  Netherlands
Cordis Medizinische Apparate GmbH
  Germany
DePuy Ace Sarl
  Switzerland
DePuy France S.A.S.
  France
DePuy International Limited
  United Kingdom
DePuy International (Holdings) Limited
  United Kingdom
DePuy (Ireland)
  Ireland
DePuy Mitek Sarl
  Switzerland
DePuy Motion Sarl
  Switzerland
DePuy Orthopadie GmbH
  Germany
DePuy Spine Sarl
  Switzerland
DePuy UK Holdings Limited
  United Kingdom
EES Holdings de Mexico, S. de R. L. de C. V. 
  Mexico
Ethicon Ireland
  Ireland
Ethicon PR Holdings
  Ireland
Ethicon Sarl
  Switzerland
Ethicon SAS
  France
Ethicon Women’s Health & Urology Sarl
  Switzerland
Ethnor del Istmo S.A. 
  Panama
FMS Future Medical System SA
  Switzerland
Gloster Europe SAS
  France
GMED Health Care Limited
  Ireland
High Wycombe Property Management Limited
  United Kingdom
Janssen Alzheimer Immunotherapy
  Ireland
Janssen Alzheimer Immunotherapy (Holding) Limited
  Ireland
Janssen-Cilag AB
  Sweden
Janssen-Cilag A/S
  Denmark
Janssen-Cilag AG
  Switzerland
Janssen-Cilag B.V. 
  Netherlands


 

     
    Jurisdiction of
Name of Subsidiary
  Organization
 
Janssen-Cilag de Mexico S de R.L. de C.V.
  Mexico
Janssen-Cilag Farmaceutica, Lda. 
  Portugal
Janssen-Cilag Farmaceutica Ltda. 
  Brazil
Janssen-Cilag GmbH
  Germany
Janssen-Cilag Ltd. 
  Thailand
Janssen-Cilag Limited
  United Kingdom
Janssen-Cilag NV
  Belgium
Janssen-Cilag OY
  Finland
Janssen-Cilag Pharmaceutical S.A.C.I. 
  Greece
Janssen-Cilag Pharma GmbH
  Austria
Janssen-Cilag Polska, Sp. z o.o. 
  Poland
Janssen-Cilag Pty. Ltd. 
  Australia
Janssen-Cilag, S.A. 
  Spain
Janssen-Cilag, S.A. de C.V. 
  Mexico
Janssen-Cilag S.A.S. 
  France
Janssen-Cilag S.p.A. 
  Italy
Janssen-Cilag s.r.o
  Czech Republic
Janssen Korea Ltd. 
  Korea
Janssen-Ortho Inc. 
  Canada
Janssen Pharmaceutica NV
  Belgium
Janssen Pharmaceutica (Pty) Limited
  South Africa
Janssen Pharmaceutical K.K. 
  Japan
Janssen Pharmaceutical
  Ireland
J-C HealthCare Ltd. 
  Israel
JHC Nederland B.V. 
  Netherlands
Johnson & Johnson AB
  Sweden
Johnson & Johnson AG
  Switzerland
Johnson & Johnson (China) Investment Co., Ltd. 
  China
Johnson & Johnson (China) Ltd. 
  China
Johnson & Johnson Consumer France SAS
  France
Johnson & Johnson Consumer Healthcare S.r.l. 
  Italy
Johnson & Johnson Consumer Services EAME Ltd. 
  United Kingdom
Johnson & Johnson de Argentina S.A.C.e I. 
  Argentina
Johnson & Johnson de Colombia S.A. 
  Colombia
Johnson & Johnson de Mexico, S.A. de C.V. 
  Mexico
Johnson & Johnson del Ecuador S.A. 
  Ecuador
Johnson & Johnson del Peru S.A. 
  Peru
Johnson & Johnson do Brasil Industria E Comercio de Produtos Para Saude Ltda. 
  Brazil
Johnson & Johnson European Treasury Company
  Ireland
Johnson & Johnson Finance Limited
  United Kingdom
Johnson & Johnson Financial Services GmbH
  Germany
Johnson & Johnson Gesellschaft m.b.H. 
  Austria
Johnson & Johnson GmbH
  Germany
Johnson & Johnson Group Holdings G.m.b.H
  Germany
Johnson & Johnson Hellas S.A. 
  Greece
Johnson & Johnson Hemisferica S.A. 
  Puerto Rico
Johnson & Johnson Holding GmbH
  Germany
Johnson & Johnson (Hong Kong) Limited
  Hong Kong


 

     
    Jurisdiction of
Name of Subsidiary
  Organization
 
Johnson & Johnson Inc. 
  Canada
Johnson & Johnson Industrial Ltda. 
  Brazil
Johnson & Johnson International Financial Services Company
  Ireland
Johnson & Johnson Kft. 
  Hungary
Johnson & Johnson K. K. 
  Japan
Johnson & Johnson Korea, Ltd. 
  Korea
Johnson & Johnson Limitada
  Portugal
Johnson & Johnson Limited
  India
Johnson & Johnson Limited
  United Kingdom
Johnson & Johnson LLC
  Russia
Johnson & Johnson Luxembourg Finance Company Sarl
  Luxembourg
Johnson & Johnson Management Limited
  United Kingdom
Johnson & Johnson Medical B.V. 
  Netherlands
Johnson & Johnson Medical (China) Ltd. 
  China
Johnson & Johnson Medical GmbH
  Germany
Johnson & Johnson Medical Holding S.p.A. 
  Italy
Johnson & Johnson Medical Korea Limited
  Korea
Johnson & Johnson Medical Limited
  United Kingdom
Johnson & Johnson Medical Mexico, S.A. de C.V. 
  Mexico
Johnson & Johnson Medical NV
  Belgium
Johnson & Johnson Medical Products GmbH
  Austria
Johnson & Johnson Medical (Pty) Limited
  South Africa
Johnson & Johnson Medical Pty Ltd. 
  Australia
Johnson & Johnson Medical (Shanghai) Ltd. 
  China
Johnson & Johnson Medical S.p.A. 
  Italy
Johnson & Johnson Medical (Suzhou) Ltd. 
  China
Johnson & Johnson (New Zealand) Limited
  New Zealand
Johnson & Johnson Nordic AB
  Sweden
Johnson & Johnson Pacific Pty. Limited
  Australia
Johnson & Johnson Pakistan (Private) Limited
  Pakistan
Johnson & Johnson (Philippines), Inc. 
  Philippines
Johnson & Johnson Poland Sp. z o.o
  Poland
Johnson & Johnson, Prodaja medicinskih in farmacevtskih izdelkov, d.o.o
  Slovenia
Johnson & Johnson (Proprietary) Limited
  South Africa
Johnson & Johnson Pte. Ltd. 
  Singapore
Johnson & Johnson Pty. Limited
  Australia
Johnson & Johnson S.A. 
  Spain
Johnson & Johnson SDN. BHD. 
  Malaysia
Johnson & Johnson S.E. d.o.o.
  Croatia
Johnson & Johnson S.p.A
  Italy
Johnson & Johnson, s.r.o. 
  Czech Republic
Johnson & Johnson, s.r.o. 
  Slovakia
Johnson & Johnson Swiss Finance Company Limited
  United Kingdom
Johnson & Johnson Taiwan Ltd. 
  Taiwan
Johnson & Johnson (Thailand) Ltd. 
  Thailand
Johnson & Johnson Vision Care (Ireland)
  Ireland
Laboratoires Polive S.N.C. 
  France
Laboratoires Vendome SAS
  France


 

     
    Jurisdiction of
Name of Subsidiary
  Organization
 
Latam International Investment Company
  Ireland
Latam Properties Holdings
  Ireland
Lifescan Canada Ltd. 
  Canada
Lifescan Scotland Limited
  United Kingdom
McNeil AB
  Sweden
McNeil Consumer Healthcare GmbH
  Germany
McNeil Consumer Healthcare, S.L. 
  Spain
McNeil Denmark ApS
  Denmark
McNeil Esbjerg ApS
  Denmark
McNeil GmbH & Co. oHG
  Germany
McNeil Healthcare (UK) Limited
  United Kingdom
McNeil Limited
  United Kingdom
McNeil Manufacturing Pty Ltd
  Australia
McNeil Products Limited
  United Kingdom
McNeil Sante Grand Public, S.A.S. 
  France
McNeil SAS
  France
McNeil Sweden AB
  Sweden
Medos International Sarl
  Switzerland
Medos Sarl
  Switzerland
Mentor Medical Systems C.V. 
  Netherlands
OBTECH Medical Sarl
  Switzerland
OMJ Ireland
  Ireland
OMJ Manufacturing
  Ireland
OMJ PR Holdings
  Ireland
Omrix Biopharmaceuticals Ltd. 
  Israel
Omrix Biopharmaceuticals S.A. 
  Belgium
Ortho-Clinical Diagnostics
  United Kingdom
Ortho-Clinical Diagnostics GmbH
  Germany
Ortho-Clinical Diagnostics K.K. 
  Japan
Ortho-Clinical Diagnostics NV
  Belgium
Ortho-Clinical Diagnostics S.A.S. 
  France
P.T. Johnson & Johnson Indonesia
  Indonesia
Perouse Plastie SAS
  France
Shanghai Johnson & Johnson Pharmaceuticals, Ltd. 
  China
Tasmanian Alkaloids Pty. Ltd. 
  Australia
Tibotec Pharmaceuticals
  Ireland
Tibotec-Virco Comm. VA
  Belgium
Tibotec-Virco Virology BVBA
  Belgium
Turnbuckle Investment Company
  Ireland
Vania Expansion, S.N.C. 
  France
Xian-Janssen Pharmaceutical Ltd. 
  China

EX-23 6 y80744exv23.htm EX-23 exv23
EXHIBIT 23
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-163857, 333-129542, 333-124785, 333-106007, 333-104828, 333-96541, 333-87736, 333-67370, 333-59380, 333-39238, 333-94367, 333-86611, 333-40681, 333-38055, 333-26979, 333-00391, 33-59009, 33-57583, 33-52252, 33-40295, 33-40294, 33-32875) and Form S-3 (No. 333-149632, 333-67020, 333-91349) of Johnson & Johnson of our report dated March 1, 2010 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in the Annual Report to Shareholders, which is incorporated in this Annual Report on Form 10-K. We also consent to the incorporation by reference of our report dated March 1, 2010 relating to the financial statement schedule, which appears in this Form 10-K.
 
/s/  PricewaterhouseCoopers LLP

PricewaterhouseCoopers LLP
 
New York, New York
March 1, 2010

EX-31.A 7 y80744exv31wa.htm EX-31.A exv31wa
EXHIBIT 31(a)
 
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT
 
I, William C. Weldon, certify that:
 
1.  I have reviewed this Annual Report on Form 10-K for the fiscal year ended January 3, 2010 (the “report”) of Johnson & Johnson (the “Company”);
 
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
 
4.  The Company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:
 
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and
 
5.  The Company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):
 
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and
 
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.
 
/s/  William C. Weldon

William C. Weldon
Chief Executive Officer
 
Date: February 17, 2010

EX-31.B 8 y80744exv31wb.htm EX-31.B exv31wb
EXHIBIT 31(b)
 
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT
 
I, Dominic J. Caruso, certify that:
 
1.  I have reviewed this Annual Report on Form 10-K for the fiscal year ended January 3, 2010 (the “report”) of Johnson & Johnson (the “Company”);
 
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
 
4.  The Company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:
 
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and
 
5.  The Company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):
 
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and
 
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.
 
/s/  Dominic J. Caruso
Dominic J. Caruso
Chief Financial Officer
 
Date: February 17, 2010

EX-32.A 9 y80744exv32wa.htm EX-32.A exv32wa
EXHIBIT 32(a)
 
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT
 
The undersigned, William C. Weldon, the Chief Executive Officer of Johnson & Johnson, a New Jersey corporation (the “Company”), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge:
 
(1) the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2010 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and
 
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
/s/  William C. Weldon

William C. Weldon
Chief Executive Officer
 
Dated: February 17, 2010
 
This certification is being furnished to the SEC with this Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.

EX-32.B 10 y80744exv32wb.htm EX-32.B exv32wb
EXHIBIT 32(b)
 
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT
 
The undersigned, Dominic J. Caruso, the Chief Financial Officer of Johnson & Johnson, a New Jersey corporation (the “Company”), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge:
 
(1) the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2010 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and
 
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
/s/  Dominic J. Caruso

Dominic J. Caruso
Chief Financial Officer
 
Dated: February 17, 2010
 
This certification is being furnished to the SEC with this Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.

EX-99 11 y80744exv99.htm EX-99 exv99
EXHIBIT 99
 
CAUTIONARY STATEMENT PURSUANT TO PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995 — “SAFE HARBOR” FOR FORWARD-LOOKING STATEMENTS
 
The Company may from time to time make certain forward-looking statements in publicly-released materials, both written and oral. Forward-looking statements do not relate strictly to historical or current facts and anticipate results based on management’s plans that are subject to uncertainty. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning in conjunction with, among other things, discussions of future operations, financial performance, the Company’s strategy for growth, product development, regulatory approvals, market position and expenditures.
 
Forward-looking statements are based on current expectations of future events. The Company cannot guarantee that any forward-looking statement will be accurate, although the Company believes that it has been reasonable in its expectations and assumptions. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company’s expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements. Furthermore, the Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.
 
Some important factors that could cause the Company’s actual results to differ from the Company’s expectations in any forward-looking statements are as follows:
 
Economic factors, including inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;
 
Competitive factors, including technological advances achieved and patents attained by competitors as well as new products introduced by competitors;
 
Challenges to the Company’s patents by competitors or allegations that the Company’s products infringe the patents of third parties, which could potentially affect the Company’s competitive position and ability to sell the products in question and require the payment of past damages and future royalties. In particular, generic drug firms have filed Abbreviated New Drug Applications seeking to market generic forms of most of the Company’s key pharmaceutical products, prior to expiration of the applicable patents covering those products. In the event that the Company is not successful in defending the resulting lawsuits, generic versions of the product at issue will be introduced, resulting in very substantial market share and revenue losses;
 
Financial distress and bankruptcies experienced by significant customers and suppliers that could impair their ability, as the case may be, to purchase the Company’s products, pay for products previously purchased or meet their obligations to the Company under supply arrangements;
 
Changes in the behavior and spending patterns of purchasers of health care products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing health care insurance coverage, as a result of a prolonged global economic downturn.
 
The impact on political and economic conditions due to terrorist attacks in the U.S. and other parts of the world or U.S. military action overseas, as well as instability in the financial markets which could result from such terrorism or military actions;
 
Interruptions of computer and communication systems, including computer viruses, that could impair the Company’s ability to conduct business and communicate internally and with its customers;
 
Health care changes in the U.S. and other countries resulting in pricing pressures, including the continued consolidation among health care providers, trends toward managed care and health care cost containment, the shift towards governments becoming the primary payers of health care expenses and government laws and regulations relating to sales and promotion, reimbursement and pricing generally;
 
Government laws and regulations, affecting U.S. and international operations, including those relating to securities laws compliance, trade, monetary and fiscal policies, taxes, price controls, regulatory approval of


 

new products, licensing and patent rights, environmental protection, and possible drug reimportation legislation;
 
Competition in research, involving the development and the improvement of new and existing products and processes, is particularly significant and results from time to time in product and process obsolescence. The development of new and improved products is important to the Company’s success in all areas of its business;
 
Challenges and difficulties inherent in product development, including the potential inability to successfully continue technological innovation, complete clinical trials, obtain regulatory approvals in the United States and internationally, gain and maintain market approval of products and the possibility of encountering infringement claims by competitors with respect to patent or other intellectual property rights which can preclude or delay commercialization of a product;
 
Significant litigation adverse to the Company including product liability claims, patent infringement claims and antitrust claims;
 
The health care industry has come under increased scrutiny by government agencies and state attorneys general and resulting investigations and prosecutions carry the risk of significant civil and criminal penalties, including debarment from government business;
 
Product efficacy or safety concerns, whether or not based on scientific evidence, resulting in product withdrawals, recalls, regulatory action on the part of the FDA (or international counterparts) or declining sales;
 
The impact of business combinations, including acquisitions and divestitures, both internally for the Company and externally in the pharmaceutical, medical device and health care industries;
 
The potential impact of climate change concerns on the design, manufacturing, marketing and sale of health care products; and
 
Issuance of new or revised accounting standards by the Financial Accounting Standards Board and the Securities and Exchange Commission.
 
The foregoing list sets forth many, but not all, of the factors that could impact upon the Company’s ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider this list to be a complete statement of all potential risks and uncertainties. The Company has identified the factors on this list as permitted by the Private Securities Litigation Reform Act of 1995.

EX-101.INS 12 jnj-20100103.xml EX-101 INSTANCE DOCUMENT 0000200406 us-gaap:TreasuryStockMember 2008-12-29 2010-01-03 0000200406 us-gaap:TreasuryStockMember 2007-12-31 2008-12-28 0000200406 us-gaap:TreasuryStockMember 2007-01-01 2007-12-30 0000200406 us-gaap:RetainedEarningsMember 2010-01-03 0000200406 us-gaap:CommonStockMember 2010-01-03 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2010-01-03 0000200406 us-gaap:TreasuryStockMember 2010-01-03 0000200406 us-gaap:RetainedEarningsMember 2008-12-28 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2008-12-28 0000200406 us-gaap:TreasuryStockMember 2008-12-28 0000200406 us-gaap:CommonStockMember 2008-12-28 0000200406 us-gaap:RetainedEarningsMember 2007-12-30 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2007-12-30 0000200406 us-gaap:TreasuryStockMember 2007-12-30 0000200406 us-gaap:CommonStockMember 2007-12-30 0000200406 us-gaap:TreasuryStockMember 2006-12-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2006-12-31 0000200406 us-gaap:CommonStockMember 2006-12-31 0000200406 us-gaap:RetainedEarningsMember 2006-12-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2008-12-29 2010-01-03 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2007-12-31 2008-12-28 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2007-01-01 2007-12-30 0000200406 us-gaap:RetainedEarningsMember 2008-12-29 2010-01-03 0000200406 us-gaap:RetainedEarningsMember 2007-12-31 2008-12-28 0000200406 us-gaap:RetainedEarningsMember 2007-01-01 2007-12-30 0000200406 us-gaap:ComprehensiveIncomeMember 2008-12-29 2010-01-03 0000200406 us-gaap:ComprehensiveIncomeMember 2007-12-31 2008-12-28 0000200406 us-gaap:ComprehensiveIncomeMember 2007-01-01 2007-12-30 0000200406 2006-12-31 0000200406 2007-12-31 2008-12-28 0000200406 2007-01-01 2007-12-30 0000200406 2007-12-30 0000200406 2010-01-03 0000200406 2008-12-28 0000200406 2009-06-28 0000200406 2010-02-08 0000200406 2008-12-29 2010-01-03 iso4217:USD xbrli:shares xbrli:shares iso4217:USD <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 1 - us-gaap:SignificantAccountingPoliciesTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <!-- xbrl,ns --> <div align="left"> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"><b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>1. Summary of Significant Accounting Policies</b> </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>PRINCIPLES OF CONSOLIDATION</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The consolidated financial statements include the accounts of Johnson &#038; Johnson and subsidiaries (the &#8220;Company&#8221;). Inter-company accounts and transactions are eliminated. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>DESCRIPTION OF THE COMPANY AND BUSINESS SEGMENTS</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company has approximately 115,500 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment manufactures and markets a broad range of products used in the baby care, skin care, oral care, wound care and women&#8217;s health care fields, as well as nutritional and over-the-counter pharmaceutical products. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world. The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. These products are distributed directly to retailers, wholesalers and health care professionals for prescription use. The Medical Devices and Diagnostics segment includes a broad range of products used principally in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. These products include Cordis&#8217; circulatory disease management products; DePuy&#8217;s orthopaedic joint reconstruction, spinal care and sports medicine products; Ethicon&#8217;s surgical care, aesthetics and women&#8217;s health products; Ethicon Endo-Surgery&#8217;s minimally invasive surgical products; LifeScan&#8217;s blood glucose monitoring and insulin delivery products; Ortho-Clinical Diagnostics&#8217; professional diagnostic products and Vistakon&#8217;s disposable contact lenses. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>NEW ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">During the fiscal fourth quarter of 2009, in accordance with U.S. GAAP, the Company adopted the authoritative guidance for employers&#8217; disclosures about postretirement benefit plan assets to enhance the disclosure regarding the types of assets and associated risks in an employer&#8217;s defined benefit pension or other postretirement plan, as well as, events in the economy and markets that could have a significant effect on the value of the plan assets. The adoption of this standard did not have a material impact on the Company&#8217;s results of operations, cash flows or financial position. See Note 10 for enhanced disclosures. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During the fiscal third quarter of 2009, the Company adopted <i>The FASB Accounting Standards Codification</i><sup style="font-size: 85%; vertical-align: text-top"><i>TM </i></sup><i>(ASC or Codification) and the Hierarchy of Generally Accepted Accounting Principles (GAAP) </i>which establishes the Codification as the sole source for authoritative U.S. GAAP and will supersede all accounting standards in U.S. GAAP, aside from those issued by the SEC. The adoption of the Codification did not have an impact on the Company&#8217;s results of operations, cash flows or financial position. Since the adoption of the Accounting Standards Codification (ASC)&#160;the Company&#8217;s notes to the consolidated financial statements will no longer make reference to Statement of Financial Accounting Standards (SFAS)&#160;or other U.S. GAAP pronouncements. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During the fiscal second quarter of 2009, in accordance with U.S. GAAP, the Company adopted the standards on subsequent events. This pronouncement establishes standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued. See Note 23 for related disclosure. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During the fiscal first quarter of 2009, in accordance with U.S. GAAP, the Company adopted the standards on business combinations and non-controlling interests in Consolidated Financial Statements. These standards aim to improve, simplify, and converge internationally, the accounting for business combinations and the reporting of non-controlling interests in consolidated financial statements. These standards have an impact on the manner in which the Company accounts for acquisitions beginning in the fiscal year 2009. Significant changes include the capitalization of purchased in-process research and development (IPR&#038;D), expensing of acquisition related restructuring actions and transaction related costs and the recognition of contingent purchase price consideration at fair value at the acquisition date. In addition, changes in accounting for deferred tax asset valuation allowances and acquired income tax uncertainties after the measurement period will be recognized in earnings rather than as an adjustment to the cost of acquisition. This accounting treatment for taxes is applicable to acquisitions that occurred both prior and subsequent to the adoption of the standard. Operating profit attributable to non-controlling interests is reported in Other (Income) Expense, net and the related tax impact to the Provision for Taxes. Additionally, equity attributable to non-controlling interests is recorded in Other Non-Current liabilities. Non-controlling interests as related to the Company&#8217;s financial statements are immaterial and therefore, not separately disclosed. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During the fiscal first quarter of 2009, in accordance with U.S. GAAP, the Company adopted the standard related to disclosures about derivative instruments and hedging activities, which enhanced the disclosure regarding the Company&#8217;s derivative and hedging activities. The adoption of this standard did not have a material impact on the Company&#8217;s results of operations, cash flows or financial position. See Note 6 for enhanced disclosures. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During the fiscal first quarter of 2009, in accordance with U.S. GAAP, the Company adopted the standard on collaborative arrangements related to the development and commercialization of intellectual property. This standard addresses the income statement classification of payments made between parties in a collaborative arrangement. The impact of the adoption of this standard related to all collaboration agreements that existed as of January&#160;3, 2010 and December&#160;28, 2008 was immaterial to the Company&#8217;s results of operations, cash flows or financial position. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During the fiscal first quarter of 2009, in accordance with U.S. GAAP, the Company adopted the standard related to defensive intangible assets. This standard applies to acquired intangible assets in situations in which an entity does not intend to actively use the asset but intends to hold the asset to prevent others from obtaining access to the asset, except for intangible assets that are used in research and development activities. The adoption of this standard did not have a material impact on the Company&#8217;s results of operations, cash flows or financial position. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>RECENTLY ISSUED ACCOUNTING STANDARDS, NOT ADOPTED AS OF JANUARY 3, 2010</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The FASB issued guidance and amendments to the criteria for separating consideration in multiple-deliverable revenue arrangements. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The guidance and amendments are expected to: (a)&#160;provide principles and application guidance on whether multiple deliverables exist, how the arrangement should be separated, and the consideration allocated; (b)&#160;require an entity to allocate revenue in an arrangement using estimated selling prices of deliverables if a vendor does not have vendor-specific objective evidence or third-party evidence of selling price; and (c)&#160;eliminate the use of the residual method and require an entity to allocate the revenue using the relative selling price method. The guidance significantly expands the disclosure requirements for multiple-deliverable revenue arrangements. This guidance is effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June&#160;15, 2010. Early adoption is permitted. The Company adopted this guidance in the first fiscal quarter of 2010. The adoption will not have a material impact on the Company&#8217;s results of operations, cash flows or financial position; however, it will expand the disclosures for such arrangements. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The FASB issued a standard to improve financial reporting by enterprises involved with variable interest entities. This statement is effective for the Company beginning with the fiscal year 2010. Earlier application is prohibited. The adoption of this standard will not have a material impact on the Company&#8217;s results of operations, cash flows or financial position. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>CASH EQUIVALENTS</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company considers securities with maturities of three months or less, when purchased, to be cash equivalents. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>INVESTMENTS</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Short-term marketable securities are carried at cost, which approximates fair value. Investments classified as available-for-sale are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Long-term debt securities that the Company has the ability and intent to hold until maturity are carried at amortized cost. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company periodically reviews its investments in equity securities for impairment and adjusts these investments to their fair value when a decline in market value is deemed to be other than temporary. If losses on these securities are considered to be other than temporary, the loss is recognized in earnings. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>PROPERTY, PLANT AND EQUIPMENT AND DEPRECIATION</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="88%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Building and building equipment </div></td> <td>&#160;</td> <td colspan="3" valign="top" align="right" nowrap="nowrap">20-40 years</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Land and leasehold improvements </div></td> <td>&#160;</td> <td colspan="3" valign="top" align="right" nowrap="nowrap">10-20 years</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Machinery and equipment </div></td> <td>&#160;</td> <td colspan="3" valign="top" align="right" nowrap="nowrap">2-13 years</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8&#160;years. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset&#8217;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>REVENUE RECOGNITION</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company recognizes revenue from product sales when the goods are shipped or delivered and title and risk of loss pass to the customer. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates, the largest being the Medicaid rebate provision, are estimated based on contractual terms, historical experience, trend analysis and projected market conditions in the various markets served. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Sales returns are generally estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals. Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company&#8217;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#8217;s sales return reserves are accounted for in accordance with U.S. GAAP guidance regarding revenue recognition when right of return exists. Sales return reserves are recorded at full sales value. Sales returns in the Consumer and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices and Diagnostics segment are typically resalable but are not material. The Company rarely exchanges products from inventory for returned products. The sales returns reserve for the total Company has ranged between 1.1% and 1.2% of annual net trade sales during the prior three fiscal reporting years 2007-2009. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the year incurred. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. The Company also earns service revenue for co-promotion of certain products and includes it in sales to customers. These arrangements are evaluated to determine the appropriate amounts to be deferred. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>SHIPPING AND HANDLING</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Shipping and handling costs incurred were $964&#160;million, $1,017&#160;million and $934&#160;million in 2009, 2008 and 2007, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>INVENTORIES</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Inventories are stated at the lower of cost or market determined by the first-in, first-out method. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>INTANGIBLE ASSETS AND GOODWILL</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The authoritative literature on U.S. GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed the annual impairment test for 2009 in the fiscal fourth quarter and no impairment was determined. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if a triggering event occurs. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions. See Note 5 for further details on Intangible Assets and Goodwill. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>FINANCIAL INSTRUMENTS</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">As required by U.S. GAAP all derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#8217;s impact on the Company&#8217;s financial performance; (2)&#160;protect the Company&#8217;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note 6 for additional information on Financial Instruments. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>PRODUCT LIABILITY</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Accruals for product liability claims are recorded, on an undis-counted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information. The accruals are adjusted periodically as additional information becomes available. As a result of cost and availability factors, effective November&#160;1, 2005, the Company ceased purchasing third-party product liability insurance. Based on the availability of prior coverage, receivables for insurance recoveries related to product liability claims are recorded on an undiscounted basis, when it is probable that a recovery will be realized. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>RESEARCH AND DEVELOPMENT</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Research and development expenses are expensed as incurred. Upfront and milestone payments made to third-parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third-parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#8217;s operations. In general, the income statement presentation for these collaborations is as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="88%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Nature/Type of Collaboration</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Statement of Earnings Presentation</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td colspan="5" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Third-party sale of product </div></td> <td>&#160;</td> <td colspan="3" align="right">Sales to customers</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Royalties/milestones paid to collaborative partner (post-regulatory approval)* </div></td> <td>&#160;</td> <td colspan="3" align="right">Cost of goods sold</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Royalties received from collaborative partner </div></td> <td>&#160;</td> <td colspan="3" align="right">Other income (expense), net</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Upfront payments &#038; milestones paid to collaborative partner (pre-regulatory approval) </div></td> <td>&#160;</td> <td colspan="3" align="right">Research expense</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Research and development payments to collaborative partner </div></td> <td>&#160;</td> <td colspan="3" align="right">Research expense</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Research and development payments received from collaborative partner </div></td> <td>&#160;</td> <td colspan="3" nowrap="nowrap" align="right">Reduction of Research expense</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>*</i></td> <td>&#160;</td> <td><i>Milestones are capitalized as intangible assets and amortized to cost of goods sold over the useful life.</i></td> </tr> </table> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>ADVERTISING</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Costs associated with advertising are expensed in the year incurred and are included in the selling, marketing and administrative expenses. Advertising expenses worldwide, which are comprised of television, radio, print media and Internet advertising, were $2.4&#160;billion in 2009, $2.9&#160;billion in 2008 and $2.7&#160;billion in 2007. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>INCOME TAXES</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company intends to continue to reinvest its undistributed international earnings to expand its international operations; therefore, no U.S. tax expense has been recorded with respect to the undistributed portion not intended for repatriation. At January&#160;3, 2010 and December&#160;28, 2008, the cumulative amount of undistributed international earnings were approximately $32.2&#160;billion and $27.7&#160;billion, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Deferred income taxes are recognized for tax consequences of temporary differences by applying enacted statutory tax rates, applicable to future years, to differences between the financial reporting and the tax basis of existing assets and liabilities. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>NET EARNINGS PER SHARE</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>USE OF ESTIMATES</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. For instance, in determining annual pension and post-employment benefit costs, the Company estimates the rate of return on plan assets, and the cost of future health care benefits. Actual results may or may not differ from those estimates. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>ANNUAL CLOSING DATE</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, as was the case in 2009 and will be the case again in 2014. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>RECLASSIFICATION</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Certain prior period amounts have been reclassified to conform to current year presentation. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 2 - us-gaap:CashAndCashEquivalentsDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>2. Cash, Cash Equivalents and Current Marketable Securities</b> </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="28%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>January 3, 2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>December 28, 2008</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Amortized</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Unrealized</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Estimated</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Amortized</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Unrealized</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Estimated</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Cost</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Gains/(Losses)</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Fair Value</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Cost</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Gains/(Losses)</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Fair Value</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Current Investments</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Cash </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">2,517</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,517</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,276</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,276</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Government securities and obligations </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">13,370</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">13,371</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7,486</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7,490</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Corporate debt securities </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">426</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">426</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">627</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">628</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Money market funds </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,890</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,890</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">813</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">813</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Time deposits </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,222</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,222</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">607</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">607</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Total cash, cash equivalents and current marketable securities </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>19,425</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>1</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>19,426</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>12,809</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>5</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>12,814</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">As of January&#160;3, 2010, current marketable securities consist of $3,434&#160;million and $181&#160;million of government securities and obligations and corporate debt securities, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;As of December&#160;28, 2008, current marketable securities consist of $1,663&#160;million, $342&#160;million and $36&#160;million of government securities and obligations, corporate debt securities and time deposits, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices in active markets. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an A (or equivalent) credit rating. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 3 - us-gaap:InventoryDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>3. Inventories</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">At the end of 2009 and 2008, inventories were comprised of: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="76%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Raw materials and supplies </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">1,144</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">839</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Goods in process </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,395</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,372</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Finished goods </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,641</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,841</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>5,180</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>5,052</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 4 - us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>4. Property, Plant and Equipment</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">At the end of 2009 and 2008, property, plant and equipment at cost and accumulated depreciation were: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="76%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Land and land improvements </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">714</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">886</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Buildings and building equipment </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">8,863</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7,720</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Machinery and equipment </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">17,153</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15,234</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Construction in progress </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,521</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,552</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">29,251</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">27,392</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Less accumulated depreciation </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">14,492</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">13,027</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>14,759</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>14,365</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 0px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in 2009, 2008 and 2007 was $101&#160;million, $147&#160;million and $130&#160;million, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Depreciation expense, including the amortization of capitalized interest in 2009, 2008 and 2007, was $2.1&#160;billion, $2.0&#160;billion and $1.9&#160;billion, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 5 - us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>5. Intangible Assets and Goodwill</b> </div> <div align="left" style="font-size: 10pt; margin-top: 12pt">At the end of 2009 and 2008, the gross and net amounts of intangible assets were: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="76%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Intangible assets with definite lives:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Patents and trademarks &#8212; gross </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">5,697</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,119</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Less accumulated amortization </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,177</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,820</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Patents and trademarks &#8212; net </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>3,520</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>3,299</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Other intangibles &#8212; gross </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">7,808</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7,376</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Less accumulated amortization </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,680</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,433</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Other intangibles &#8212; net </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>5,128</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>4,943</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Total intangible assets with definite lives &#8212; gross </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">13,505</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">12,495</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Less accumulated amortization </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,857</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,253</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Total intangible assets with definite lives &#8212; net </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>8,648</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>8,242</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Intangible assets with indefinite lives:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Trademarks </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">5,938</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,734</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Purchased in-process research and development* </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,737</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Total intangible assets with indefinite lives </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>7,675</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>5,734</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Total intangible assets &#8212; net </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>16,323</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>13,976</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>*</i></td> <td>&#160;</td> <td><i>Purchased in-process research and development will be accounted for as an indefinite-lived intangible asset until the underlying project is completed or abandoned.</i></td> </tr> </table> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Goodwill as of January&#160;3, 2010 and December&#160;28, 2008, as allocated by segment of business is as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="52%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Med Dev</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Consumer</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Pharm</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>and Diag</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Total</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Goodwill at December&#160;30, 2007 </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">8,125</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">964</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,034</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">14,123</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Acquisitions </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">191</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">286</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">477</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Currency translation/other </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(842</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(38</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(881</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" nowrap="nowrap" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Goodwill at December&#160;28, 2008 </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">7,474</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">963</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,282</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">13,719</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Acquisitions </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">271</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">401</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">672</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Currency translation/other* </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">600</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(139</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">471</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Goodwill at January&#160;3, 2010 </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>8,074</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>1,244</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>5,544</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>14,862</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 0px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>*</i></td> <td>&#160;</td> <td><i>Includes reclassification between segments.</i></td> </tr> </table> <div align="left" style="font-size: 10pt; margin-top: 6pt">The weighted average amortization periods for patents and trademarks and other intangible assets are 17&#160;years and 28&#160;years, respectively. The amortization expense of amortizable assets for the fiscal years ended January&#160;3, 2010, December&#160;28, 2008 and December&#160;30, 2007 was $675&#160;million, $788&#160;million and $844&#160;million before tax, respectively. Certain patents and intangible assets were written down to fair value during fiscal years 2009, 2008 and 2007, with the resulting charge included in amortization expense. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The estimated amortization expense for the five succeeding years approximates $700&#160;million before tax, per year. Substantially all of the amortization expense is included in cost of products sold. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 6 - us-gaap:FairValueMeasurementInputsDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>6. Fair Value Measurements</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">During the fiscal first quarter of 2009, in accordance with U.S. GAAP the Company adopted the standard related to disclosures about derivative instruments and hedging activities. This standard requires qualitative disclosures about objectives and strategies for using derivatives, quantitative disclosures about fair value amounts of gain and losses on derivative instruments, and disclosures about credit-risk-related contingent features in derivative agreements. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company uses forward exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of raw materials denominated in foreign currency. The Company also uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. The Company also uses forward exchange contracts to manage its exposure to the variability of cash flows for repatriation of foreign dividends. These contracts are designated as net investment hedges. Additionally, the Company uses forward exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The Company does not enter into derivative financial instruments for trading or speculative purposes, or contain credit risk related contingent features or requirements to post collateral. On an ongoing basis the Company monitors counterparty credit ratings. The Company considers credit non-performance risk to be low, because the Company enters into agreements with commercial institutions that have at least an A (or equivalent) credit rating. As of January&#160;3, 2010, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $21&#160;billion and $4 billion, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;As required by U.S. GAAP for derivative instruments and hedging activities, all derivative instruments are to be recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The designation as a cash flow hedge is made at the entrance date into the derivative contract. At inception, all derivatives are expected to be highly effective. Changes in the fair value of a derivative that is designated as a cash flow hedge and is highly effective are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction. Gains/losses on net investment hedges are accounted for through the currency translation account and are insignificant. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes in the cash flows of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. Hedge ineffectiveness, if any, is included in current period earnings in other (income)&#160;and expense, net, and was insignificant for the fiscal year ended January&#160;3, 2010 and December&#160;28, 2008. Refer to Note 13 for disclosures of movements in Accumulated Other Comprehensive Income. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;As of January&#160;3, 2010, the balance of deferred net gains on derivatives included in accumulated other comprehensive income was $145&#160;million after-tax. For additional information, see Note 13. The Company expects that substantially all of the amount related to foreign exchange contracts will be reclassified into earnings over the next 12&#160;months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18&#160;months excluding interest rate swaps. The amount ultimately realized in earnings will differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The following table is a summary of the activity for the fiscal year ended January&#160;3, 2010 related to designated derivatives as defined in the Codification: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="64%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Gain/(Loss)</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Gain/(Loss)</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Gain/(Loss)</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>reclassed from</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>recognized</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>recognized in</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Accumulated</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>in Other</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Cash Flow Hedges</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Accumulated</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>OCI into</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Income/</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>OCI</b><sup style="font-size: 85%; vertical-align: text-top"><b>(1)</b></sup></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>income</b><sup style="font-size: 85%; vertical-align: text-top"><b>(1)</b></sup></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Expense</b><sup style="font-size: 85%; vertical-align: text-top"><b>(2)</b></sup></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Foreign exchange contracts </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">$</td> <td align="right">(63</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(47</td> <td nowrap="nowrap">)<sup style="font-size: 85%; vertical-align: text-top">(A)</sup></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Foreign exchange contracts </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(173</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">70</td> <td nowrap="nowrap"> <sup style="font-size: 85%; vertical-align: text-top">(B)</sup></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Foreign exchange contracts </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">13</td> <td nowrap="nowrap"> <sup style="font-size: 85%; vertical-align: text-top">(C)</sup></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Cross currency interest rate swaps </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">241</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(16</td> <td nowrap="nowrap">)<sup style="font-size: 85%; vertical-align: text-top">(D)</sup></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Foreign exchange contracts </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">28</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(6</td> <td nowrap="nowrap">)<sup style="font-size: 85%; vertical-align: text-top">(E)</sup></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(12</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" nowrap="nowrap" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Total</b> </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>38</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>14</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>(12</b></td> <td nowrap="nowrap"><b>)</b></td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" nowrap="nowrap" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(1)</i></sup></td> <td>&#160;</td> <td><i>Effective portion</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(2)</i></sup></td> <td>&#160;</td> <td><i>Ineffective portion</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(A)</i></sup></td> <td>&#160;</td> <td><i>Included in Sales to customer</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(B)</i></sup></td> <td>&#160;</td> <td><i>Included in Cost of products sold</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(C)</i></sup></td> <td>&#160;</td> <td><i>Included in Research expense</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(D)</i></sup></td> <td>&#160;</td> <td><i>Included in Interest (Income)/Interest Expense, net</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(E)</i></sup></td> <td>&#160;</td> <td><i>Included in Other (Income)/Expense, net</i></td> </tr> </table> <div align="left" style="font-size: 10pt; margin-top: 6pt">For the fiscal year ended January&#160;3, 2010, a gain of $21&#160;million was recognized in Other (income)/expense, net, relating to foreign exchange contracts not designated as hedging instruments under the Codification. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During the fiscal first quarter of 2008, in accordance with U.S. GAAP, the Company adopted the standard related to fair value measurements except for non-financial assets and liabilities recognized or disclosed at fair value on a non-recurring basis, which became effective during the first fiscal quarter of 2009. The effect of adoption on December&#160;29, 2008 of this standard for non-financial assets and liabilities recorded at fair value on a non-recurring basis did not have a material impact on the Company&#8217;s financial position and results of operations. This standard defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. During the fiscal first quarter of 2008, the Company adopted the standard related to fair value option for financial assets and financial liabilities. This standard permits the Company to measure certain financial assets and financial liabilities at fair value. The Company assessed the fair value option made available upon adopting this standard, and has elected not to apply the fair value option to any financial instruments that were not already recognized at fair value. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;U.S. GAAP defines fair value as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with level 1 having the highest priority and level 3 having the lowest. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The fair value of a derivative financial instrument (i.e. forward exchange contract, currency swap) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company also holds equity investments which are classified as level 1 since they are traded in an active exchange market. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">During 2009, the Company acquired substantially all of the assets and rights of Elan&#8217;s Alzheimer&#8217;s Immunotherapy Program through a newly formed company, JANSSEN Alzheimer Immunotherapy (JAI), of which the Company owns 50.1% and Elan owns 49.9%. In addition, the Company purchased approximately 107&#160;million newly issued American Depositary Receipts (ADRs) of Elan, representing 18.4% of Elan&#8217;s outstanding ordinary shares. As part of this transaction, the Company paid $885&#160;million to Elan and committed to fund up to $250&#160;million of Elan&#8217;s share of research and development spending by JAI. Of this total consideration of $1,135 million, $793&#160;million represents the fair value of the 18.4% investment in Elan based on Elan&#8217;s share price in an actively traded market as of the date of this transaction. The IPR&#038;D related to this transaction was $679&#160;million and is associated with bapineuzumab, a potential first-in-class treatment that is being evaluated for slowing the progression of Alzheimer&#8217;s Disease. The value of the IPR&#038;D was calculated using cash flow projections discounted for the risk inherent in such projects. Probability of success factors ranging from 40-50% were used to reflect inherent clinical and regulatory risk. The discount rate applied was 26%. The non-controlling interest related to this transaction was $590&#160;million, which the Company has recorded in other non-current liabilities. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During 2009, the Company entered into a strategic collaboration with Crucell N.V. which will focus on the discovery, development and commercialization of monoclonal antibodies and vaccines for the treatment and prevention of influenza and other infectious and non-infectious diseases. In addition, the Company, through its affiliate, purchased approximately 18% of Crucell&#8217;s outstanding ordinary shares for an aggregate purchase price of $448&#160;million. Of the total consideration paid, $329&#160;million represents the fair value of the investment based on Crucell&#8217;s share price in an actively traded market as of the date of the transaction with the excess recorded to research and development expense in 2009. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company did not have any other significant financial assets or liabilities which would require revised valuations under this standard that are recognized at fair value. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company&#8217;s significant financial assets and liabilities measured at fair value as of January&#160;3, 2010 and December&#160;28, 2008 were as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="40%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Significant</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Quoted prices in</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>other</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Significant</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>active markets for</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>observable</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>unobservable</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>identical assets</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>inputs</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>inputs</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Level 1</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Level 2</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Level 3</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Total</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Total*</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Derivatives designated as hedging instruments:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Assets:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Foreign exchange contracts </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">436</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">436</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,238</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Cross currency interest rate swaps </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">126</td> <td nowrap="nowrap">**</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">126</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">110</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Total</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>&#8212;</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>562</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>&#8212;</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>562</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>1,348</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Liabilities:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Foreign exchange contracts </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">608</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">608</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,298</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Cross currency interest rate swaps </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">571</td> <td nowrap="nowrap">***</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">571</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,033</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Total</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>&#8212;</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>1,179</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>&#8212;</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>1,179</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>2,331</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Derivatives not designated as hedging instruments:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Assets:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Foreign exchange contracts </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">33</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">33</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">84</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Liabilities:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Foreign exchange contracts </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">40</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">40</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">47</td> <td>&#160;</td> </tr> <tr valign="bottom"><!-- Blank Space --> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Other investments</b> </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">1,134</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,134</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">41</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 0px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>*</i></td> <td>&#160;</td> <td><i>2008 assets and liabilities are all classified as Level 2 with the exception of other investments of $41&#160;million which are classified as Level 1.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>**</i></td> <td>&#160;</td> <td><i>Includes $119&#160;million of non-current assets.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>***</i></td> <td>&#160;</td> <td><i>Includes $517&#160;million of non-current liabilities.</i></td> </tr> </table> <div align="left" style="font-size: 10pt; margin-top: 12pt">See Notes 2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 7 - us-gaap:LongTermDebtTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>7. Borrowings</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The components of long-term debt are as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="52%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Effective</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Effective</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Rate %</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Rate %</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">6.625% Notes due 2009 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">199</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6.80</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">5.15% Debentures due 2012 </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">599</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">5.18</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td>&#160;</td> <td align="right">599</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.18</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">3.80% Debentures due 2013 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">500</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3.82</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">500</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3.82</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">5.55% Debentures due 2017 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,000</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.55</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,000</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.55</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">5.15% Debentures due 2018 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">898</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.15</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">898</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.15</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">4.75% Notes due 2019 (1B Euro 1.4382)<sup style="font-size: 85%; vertical-align: text-top">(2)</sup>/(1B Euro 1.4000)<sup style="font-size: 85%; vertical-align: text-top">(3)</sup> </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">1,429</td> <td nowrap="nowrap"> <sup style="font-size: 85%; vertical-align: text-top">(2)</sup></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.35</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">1,390</td> <td nowrap="nowrap"> <sup style="font-size: 85%; vertical-align: text-top">(3)</sup></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.35</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">3% Zero Coupon Convertible Subordinated Debentures due 2020 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">188</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">183</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3.00</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">6.73% Debentures due 2023 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">250</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6.73</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">250</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6.73</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">5.50% Notes due 2024 (500MM GBP1.6189)<sup style="font-size: 85%; vertical-align: text-top">(2)</sup>/(500MM GBP1.4759)<sup style="font-size: 85%; vertical-align: text-top">(3)</sup> </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">803</td> <td nowrap="nowrap"> <sup style="font-size: 85%; vertical-align: text-top">(2)</sup></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.71</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">731</td> <td nowrap="nowrap"> <sup style="font-size: 85%; vertical-align: text-top">(3)</sup></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.71</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">6.95% Notes due 2029 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">294</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7.14</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">294</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7.14</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">4.95% Debenture due 2033 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">500</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.95</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">500</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.95</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">5.95% Notes due 2037 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">995</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.99</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">995</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.99</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">5.86% Debentures due 2038 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">700</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.86</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">700</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.86</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Other (Includes Industrial Revenue Bonds) </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">101</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">102</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>8,257 </b></td> <td nowrap="nowrap"><sup style="font-size: 85%; vertical-align: text-top"><b>(4)</b></sup></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>5.42 </b></td> <td nowrap="nowrap"><sup style="font-size: 85%; vertical-align: text-top"><b>(1)</b></sup></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>8,341 </b></td> <td nowrap="nowrap"><sup style="font-size: 85%; vertical-align: text-top"><b>(4)</b></sup></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>5.46 </b></td> <td nowrap="nowrap"><sup style="font-size: 85%; vertical-align: text-top"><b>(1)</b></sup></td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Less current portion </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">34</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">221</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>8,223</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>8,120</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(1)</i></sup></td> <td>&#160;</td> <td><i>Weighted average effective rate.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(2)</i></sup></td> <td>&#160;</td> <td><i>Translation rate at January&#160;3, 2010.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(3)</i></sup></td> <td>&#160;</td> <td><i>Translation rate at December&#160;28, 2008.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(4)</i></sup></td> <td>&#160;</td> <td><i>The excess of the fair value over the carrying value of debt was $0.8&#160;billion in 2009 and $1.4&#160;billion in 2008.</i></td> </tr> </table> <div align="left" style="font-size: 10pt; margin-top: 6pt">Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices in active markets. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company has access to substantial sources of funds at numerous banks worldwide. In September&#160;2009, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10&#160;billion which expires September&#160;23, 2010. Interest charged on borrowings under the credit line agreements is based on either bids provided by banks, the prime rate or London Interbank Offered Rates (LIBOR), plus applicable margins. Commitment fees under the agreements are not material. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;On July&#160;28, 2000, ALZA Corporation, a subsidiary of the Company, completed a private offering of the 3% Zero Coupon Convertible Subordinated Debentures, which were issued at a price of $551.26 per $1,000 principal amount at maturity. Under the terms of the 3% Debentures, holders are entitled to convert their debentures into approximately 15.0&#160;million shares of Johnson &#038; Johnson stock at a price of $40.102 per share. Approximately 11.4&#160;million shares have been issued as of January&#160;3, 2010, due to voluntary conversions by note holders. At the option of the holder, the 3% Debentures may be repurchased by the Company on July&#160;28, 2013, at a purchase price equal to the issue price plus accreted original issue discount to such purchase date. The Company, at its option, may also redeem any or all of the 3% Debentures after July&#160;28, 2003 at the issue price plus accreted original issue discount. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Throughout 2009 the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $6.3&#160;billion at the end of 2009, of which $5.8&#160;billion was borrowed under the Commercial Paper Program. The remainder represents principally local borrowing by international subsidiaries. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company filed a shelf registration with the Securities and Exchange Commission that became effective March&#160;11, 2008 which enables the Company to issue an unlimited aggregate principal amount in debt securities and warrants to purchase debt securities. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Aggregate maturities of long-term obligations commencing in 2009 are: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center"><b>After</b></td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="center"><b>2010</b></td> <td>&#160;</td> <td nowrap="nowrap" align="center"><b>2011</b></td> <td>&#160;</td> <td nowrap="nowrap" align="center"><b>2012</b></td> <td>&#160;</td> <td nowrap="nowrap" align="center"><b>2013</b></td> <td>&#160;</td> <td nowrap="nowrap" align="center"><b>2014</b></td> <td>&#160;</td> <td nowrap="nowrap" align="center"><b>2014</b></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td align="center"> <div style="margin-left:15px; text-indent:-15px">$34 </div></td> <td>&#160;</td> <td align="center" valign="top">35</td> <td>&#160;</td> <td align="center" valign="top">615</td> <td>&#160;</td> <td align="center" valign="top">507</td> <td>&#160;</td> <td align="center" valign="top">9</td> <td>&#160;</td> <td align="center" valign="top">7,057</td> </tr> <!-- End Table Body --> </table> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 8 - us-gaap:IncomeTaxDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>8. Income Taxes</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The provision for taxes on income consists of: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="64%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Currently payable: </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">U.S. taxes </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">2,410</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,334</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,990</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">International taxes </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,515</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,624</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,479</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,925</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,958</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,469</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"><!-- Blank Space --> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Deferred: </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">U.S. taxes </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">187</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">126</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(722</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">International taxes </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(623</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(104</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,040</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" nowrap="nowrap" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(436</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">22</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,762</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" nowrap="nowrap" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>3,489</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>3,980</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>2,707</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">A comparison of income tax expense at the U.S. statutory rate of 35% in 2009, 2008 and 2007, to the Company&#8217;s effective tax rate is as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="64%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">U.S. </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">7,141</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,579</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,237</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">International </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">8,614</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10,350</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">8,046</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Earnings before taxes on income: </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">15,755</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">16,929</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">13,283</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Tax rates: </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">U.S. statutory rate </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">35.0</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td>&#160;</td> <td align="right">35.0</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">35.0</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Ireland and Puerto Rico operations </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(5.1</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(6.8</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(8.8</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Research and orphan drug tax credits </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(0.6</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(0.6</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(0.8</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">U.S. state and local </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.8</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.6</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2.1</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">International subsidiaries excluding Ireland </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(6.7</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(5.6</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(7.3</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">U.S. manufacturing deduction </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(0.4</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(0.4</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(0.3</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">In-process research and development (IPR&#038;D) </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.0</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.4</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2.1</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">U.S. Tax international income </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1.6</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(0.5</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1.9</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">All other </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(0.3</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.4</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.3</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Effective tax rate </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">22.1</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td>&#160;</td> <td align="right">23.5</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">20.4</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 0px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company has subsidiaries manufacturing in Ireland under an incentive tax rate. In addition, the Company has subsidiaries operating in Puerto Rico under various tax incentive grants. The decrease in the 2009 tax rate was primarily due to increases in taxable income in lower tax jurisdictions relative to taxable income in higher tax jurisdictions. The increase in the 2008 tax rate was mainly attributed to increases in taxable income in higher tax jurisdictions relative to taxable income in lower jurisdictions, as well as a business restructuring of certain international subsidiaries in 2007, resulting in a one-time benefit of $267&#160;million, which reduced the 2007 effective tax rate by 2%. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 12pt">&#160;&#160;&#160;&#160;&#160;Temporary differences and carry forwards for 2009 and 2008 are as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="52%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>2008</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>Deferred Tax</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>Deferred Tax</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Asset</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Liability</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Asset</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Liability</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Employee related obligations </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">2,153</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,615</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Stock based compensation </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,291</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,296</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Depreciation </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(661</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(523</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Non-deductible intangibles </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2,377</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,791</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">International R&#038;D capitalized for tax </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,989</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,914</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Reserves &#038; liabilities </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,014</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">688</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Income reported for tax purposes </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">648</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">629</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Net operating loss carryforward international </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">615</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">393</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Miscellaneous international </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,474</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(110</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">964</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(251</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Miscellaneous U.S. </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">799</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,828</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Total deferred income taxes </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>9,983</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>(3,148</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>10,327</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>(2,565</b></td> <td nowrap="nowrap"><b>)</b></td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" nowrap="nowrap" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The difference between the net deferred tax on income per the balance sheet and the net deferred tax above is included in taxes on income on the balance sheet. The 2009 and 2008 deferred tax Miscellaneous U.S. includes current year tax receivables. The Company has a wholly-owned international subsidiary which has cumulative net losses. The Company believes that it is more likely than not that the subsidiary will realize future taxable income sufficient to utilize these deferred tax assets. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The following table summarizes the activity related to unrecognized tax benefits: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="64%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Beginning of year </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">1,978</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,653</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,262</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Increases related to current year tax positions </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">555</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">545</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">487</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Increases related to prior period tax positions </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">203</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">87</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">77</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Decreases related to prior period tax positions </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(163</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(142</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(117</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Settlements </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(87</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(137</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(14</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Lapse of statute of limitations </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(83</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(28</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(42</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" nowrap="nowrap" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">End of year </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>2,403</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>1,978</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>1,653</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company had $2.4&#160;billion and $2.0&#160;billion of unrecognized tax benefits, as of January&#160;3, 2010 and December&#160;28, 2008, respectively. All of the unrecognized tax benefits of $2.4&#160;billion at January&#160;3, 2010, if recognized, would affect the Company&#8217;s annual effective tax rate. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. The U.S. Internal Revenue Service (IRS)&#160;has completed its audit for the tax years through 2002. In other major jurisdictions where the Company conducts business, the years remain open generally back to the year 2002 with some jurisdictions remaining open as far back as 1995. The Company does not expect that the total amount of unrecognized tax benefits will significantly change over the next twelve months. The Company believes that it is possible that within the next twelve months, the IRS may complete its audit of the tax years 2003-2005. The close of the audit may result in the reduction of unrecognized tax benefits. The Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. During the fiscal year ended January&#160;3, 2010, the Company recognized $85&#160;million of interest expense and $30&#160;million of interest income with an after-tax impact of $36&#160;million expense. For the fiscal year ended December&#160;28, 2008, the Company recognized $106&#160;million of interest expense with an after-tax impact of $69&#160;million. For the fiscal year ended December&#160;30, 2007, the Company recognized $58&#160;million of interest expense and $42 million of interest income with an after-tax impact of $10&#160;million expense. The total amount of accrued interest was $309&#160;million and $227&#160;million in 2009 and 2008, respectively. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 9 - us-gaap:CompensationRelatedCostsGeneralTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>9. Employee Related Obligations</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">At the end of 2009 and 2008, employee related obligations recorded on the Consolidated Balance Sheet were: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="76%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Pension benefits </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">2,792</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,382</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Postretirement benefits </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,245</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,217</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Postemployment benefits </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,504</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">870</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Deferred compensation </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">790</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">772</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Total employee obligations </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">7,331</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">8,241</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Less current benefits payable </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">562</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">450</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Employee related obligations &#8212; long-term </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>6,769</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>7,791</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Prepaid employee related obligations of $266&#160;million and $136&#160;million for 2009 and 2008, respectively, are included in other assets on the consolidated balance sheet. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 10 - us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>10. Pensions and Other Benefit Plans</b> <br style="font-size: 6pt" /> The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides postretirement benefits, primarily health care, to all U.S. retired employees and their dependents. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Many international employees are covered by government-sponsored programs and the cost to the Company is not significant. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Retirement plan benefits are primarily based on the employee&#8217;s compensation during the last three to five years before retirement and the number of years of service. International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company does not fund retiree health care benefits in advance and has the right to modify these plans in the future. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company uses the date of its consolidated financial statements (January&#160;3, 2010 and December&#160;28, 2008, respectively) as the measurement date for all U.S. and international retirement and other benefit plans. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In accordance with U.S. GAAP the Company has adopted the recent standards related to employers&#8217; accounting for defined benefit pension and other postretirement plans. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans for 2009, 2008 and 2007 include the following components: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="28%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Retirement Plans</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Other Benefit Plans</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Service cost </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">511</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">545</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">597</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">137</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">142</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">140</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Interest cost </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">746</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">701</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">656</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">174</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">166</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">149</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Expected return on plan assets </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(934</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(876</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(809</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Amortization of prior service cost </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">13</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(5</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(4</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(7</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Amortization of net transition asset </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Recognized actuarial losses </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">155</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">62</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">186</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">55</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">64</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">66</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Curtailments and settlements </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(11</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Net periodic benefit cost </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>481</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>451</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>646</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>359</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>366</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>346</b></td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The net periodic benefit cost attributable to U.S. retirement plans was $286&#160;million, $220 million and $379&#160;million in 2009, 2008 and 2007, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Amounts expected to be recognized in net periodic benefit cost in the coming year for the Company&#8217;s defined benefit retirement plans and other postretirement plans: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="88%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td colspan="5" align="left" style="border-top: 0px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Amortization of net transition obligation </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">1</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Amortization of net actuarial losses </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">296</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Amortization of prior service cost </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Unrecognized gains and losses for the U.S. pension plans are amortized over the average remaining future service for each plan. For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S. benefit plans is determined by using a 10% corridor of the greater of the market value of assets or the projected benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Prior service costs/benefits for the U.S. pension plans are amortized over the remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S. benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The weighted-average assumptions in the following table represent the rates used to develop the actuarial present value of projected benefit obligation for the year listed and also the net periodic benefit cost for the following year. </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="28%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Retirement Plans</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Other Benefit Plans</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>U.S. Benefit Plans</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Discount rate </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">6.50</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6.50</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6.50</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">6.50</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6.50</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6.50</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Expected long-term rate of return on plan assets </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">9.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9.00</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Rate of increase in compensation levels </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.50</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.50</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.50</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.50</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.50</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.50</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>International Benefit Plans</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td colspan="25" align="left" style="border-top: 0px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Discount rate </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">5.75</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.50</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">6.75</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7.25</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6.50</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Expected long-term rate of return on plan assets </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">8.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">8.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">8.25</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Rate of increase in compensation levels </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.75</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.50</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.50</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td colspan="25" align="left" style="border-top: 0px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company&#8217;s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The expected long-term rate of return on plan assets assumption is determined using a building block approach, considering historical averages and real returns of each asset class. In certain countries, where historical returns are not meaningful, consideration is given to local market expectations of long-term returns. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The following table displays the assumed health care cost trend rates, for all individuals: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="76%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Health Care Plans</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Health care cost trend rate assumed for next year </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">8.00</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9.00</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Rate to which the cost trend rate is assumed to decline (ultimate trend) </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">5.00</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.00</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Year the rate reaches the ultimate trend rate </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2017</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2015</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">A one-percentage-point change in assumed health care cost trend rates would have the following effect: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="76%">&#160;</td> <td width="5%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="5%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>One-Percentage-</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>One-Percentage-</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Point Increase</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Point Decrease</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Health Care Plans</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td colspan="9" align="left" style="border-top: 0px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Total interest and service cost </div></td> <td>&#160;</td> <td align="right">$</td> <td align="right">34</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right">$</td> <td align="right">(28</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Postretirement benefit obligation </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">315</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(254</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td colspan="9" align="left" style="border-top: 0px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The following table sets forth information related to the benefit obligation and the fair value of plan assets at year-end 2009 and 2008 for the Company&#8217;s defined benefit retirement plans and other postretirement plans: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="52%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>Retirement Plans</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>Other Benefit Plans</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Change in Benefit Obligation</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Projected benefit obligation &#8212; beginning of year </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">11,923</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">12,002</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">2,765</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,721</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Service cost </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">511</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">545</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">137</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">142</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Interest cost </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">746</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">701</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">174</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">166</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Plan participant contributions </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">50</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">60</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Amendments </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">3</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Actuarial losses (gains) </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">412</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(318</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">51</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(124</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Divestitures &#038; acquisitions </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">15</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">13</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Curtailments &#038; settlements &#038; restructuring </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(3</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">748</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Benefits paid from plan </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(570</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(535</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(313</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(122</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Effect of exchange rates </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">362</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(540</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(17</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" nowrap="nowrap" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Projected benefit obligation &#8212; end of year* </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>13,449</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>11,923</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>3,590</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>2,765</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Change in Plan Assets</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Plan assets at fair value &#8212; beginning of year </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">7,677</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10,469</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">17</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">29</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Actual return (loss)&#160;on plan assets </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,048</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2,787</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(7</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Company contributions </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,354</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">978</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">308</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">117</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Plan participant contributions </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">50</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">60</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Settlements </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Benefits paid from plan assets </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(570</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(535</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(313</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(122</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Effect of exchange rates </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">364</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(507</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Plan assets at fair value &#8212; end of year </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>10,923</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>7,677</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>16</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>17</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Funded status at &#8212; end of year* </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>$</b></td> <td align="right"><b>(2,526</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>(4,246</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>$</b></td> <td align="right"><b>(3,574</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>(2,748</b></td> <td nowrap="nowrap"><b>)</b></td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Non-current assets </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">266</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">136</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Current liabilities </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(53</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(45</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(484</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(212</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Non-current liabilities </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2,739</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(4,337</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(3,090</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2,536</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" nowrap="nowrap" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Total recognized in the consolidated balance sheet &#8212; end of year </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>$</b></td> <td align="right"><b>(2,526</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>(4,246</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>$</b></td> <td align="right"><b>(3,574</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>(2,748</b></td> <td nowrap="nowrap"><b>)</b></td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Net actuarial loss </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">3,415</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,209</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">924</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,006</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Prior service cost (credit) </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">47</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">43</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(23</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(29</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Unrecognized net transition obligation </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Total before tax effects </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>3,467</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>4,258</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>901</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>977</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Accumulated Benefit Obligations &#8212; end of year*</b> </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>11,687</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>10,357</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Net periodic benefit cost </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>481</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>451</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>359</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>366</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Net actuarial (gain)&#160;loss </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(704</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,344</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">48</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">60</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Amortization of net actuarial loss </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(134</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(68</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(131</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(65</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Prior service cost </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">3</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Amortization of prior service cost </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(13</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(11</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Effect of exchange rates </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">57</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(102</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" nowrap="nowrap" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Total recognized in other comprehensive income, before tax </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>$</b></td> <td align="right"><b>(791</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>3,173</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>$</b></td> <td align="right"><b>(76</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>1</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Total recognized in net periodic benefit cost and other comprehensive income </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>$</b></td> <td align="right"><b>(310</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>3,624</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>283</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>367</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>*</i></td> <td>&#160;</td> <td><i>The Company does not fund certain plans, as funding is not required. $1.2&#160;billion of the projected benefit obligation and $1.2&#160;billion of the underfunded status for each of the fiscal years 2009 and 2008 relates to the unfunded pension plans. $1.0&#160;billion and $0.9&#160;billion of the accumulated benefit obligation for the fiscal years 2009 and 2008, respectively, relate to these unfunded pension plans.</i></td> </tr> </table> <div align="left" style="font-size: 10pt; margin-top: 6pt">Plans with accumulated benefit obligations in excess of plan assets consist of the following: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="76%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>Retirement Plans</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Accumulated benefit obligation </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">$</td> <td align="right">(4,065</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(9,885</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Projected benefit obligation </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(4,663</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(11,379</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Plan assets at fair value </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,564</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7,021</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The following table displays the projected future benefit payments from the Company&#8217;s retirement and other benefit plans: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="38%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2011</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2012</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2013</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2014</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2015-2019</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Projected future benefit payments</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td colspan="25" align="left" style="border-top: 0px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Retirement plans </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">558</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">553</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">582</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">604</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">636</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,925</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Other benefit plans &#8212; gross </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">209</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">198</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">196</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">198</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">197</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">995</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Medicare rebates </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(9</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Other benefit plans &#8212; net </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">200</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">198</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">196</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">198</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">197</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">995</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">In 2009, the Company contributed $839&#160;million and $515&#160;million to its U.S. and international pension plans, respectively. In addition, the Company funded $500&#160;million to its U.S. plans in the first month of 2010. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In 2006, Congress passed the Pension Protection Act of 2006. The Act amended the Employee Retirement Income Security Act (ERISA)&#160;for plan years beginning after 2007 and established new minimum funding standards for U.S. employer defined benefit plans. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company plans to continue to fund its U.S. defined benefit plans to comply with the Act. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;International plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently the Company has several pension plans that are not funded. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The following table displays the projected future minimum contributions to the Company&#8217;s U.S. and international unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future. </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="38%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2011</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2012</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2013</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2014</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2015-2019</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Projected future contributions</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td colspan="25" align="left" style="border-top: 0px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Unfunded U.S. retirement plans </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">34</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">36</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">38</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">40</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">44</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">288</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Unfunded International retirement plans </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">32</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">29</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">31</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">33</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">32</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">186</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td colspan="25" align="left" style="border-top: 0px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors including local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and other relevant factors including diversification, liquidity of local markets and liquidity of base currency. A majority of the Company&#8217;s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds. An asset allocation of 75% equities and 25% fixed income is generally pursued unless local regulations and illiquidity require otherwise. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company&#8217;s retirement plan asset allocation at the end of 2009 and 2008 and target allocations for 2010 are as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="64%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>Percent of</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Target</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>Plan Assets</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2" style="border-bottom: 0px solid #000000"><b>Allocation</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2010</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>U.S. Retirement Plans</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Equity securities </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">76</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">70</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">75</td> <td nowrap="nowrap">%</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Debt securities </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">24</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">30</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">25</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Total plan assets </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>100</b></td> <td nowrap="nowrap"><b>%</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>100</b></td> <td nowrap="nowrap"><b>%</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>100</b></td> <td nowrap="nowrap"><b>%</b></td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" nowrap="nowrap" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>International Retirement Plans</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Equity securities </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">65</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">61</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">65</td> <td nowrap="nowrap">%</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Debt securities </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">34</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">38</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">34</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Real estate and other </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Total plan assets </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>100</b></td> <td nowrap="nowrap"><b>%</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>100</b></td> <td nowrap="nowrap"><b>%</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>100</b></td> <td nowrap="nowrap"><b>%</b></td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" nowrap="nowrap" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company&#8217;s other benefit plans are unfunded except for U.S. life insurance contract assets of $16&#160;million and $17&#160;million at January&#160;3, 2010 and December&#160;28, 2008, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The fair value of Johnson &#038; Johnson common stock directly held in plan assets was $469&#160;million (4.3% of total plan assets) at January&#160;3, 2010 and $416&#160;million (5.4% of total plan assets) at December&#160;28, 2008. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>DETERMINATION OF FAIR VALUE</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Plan has an established and well-documented process for determining fair values. Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>VALUATION HIERARCHY</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level 1 having the highest priority and Level 3 having the lowest. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">A financial instrument&#8217;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Following is a description of the valuation methodologies used for the investments measured at fair value. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;<b>&#8226;</b>&#160;Short-term investments &#8212; Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the Net Asset Value (NAV)&#160;provided by the administrator of the fund. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. The NAV is a quoted price in a market that is not active and classified as Level 2. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;<b>&#8226;</b>&#160;Government and agency securities &#8212; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level 1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level 2. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;<b>&#8226;</b>&#160;Debt instruments &#8212; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level 1. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt"> If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level 2. Level 3 debt instruments are priced based on unobservable inputs. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;<b>&#8226;</b>&#160;Equity securities &#8212; Common stocks are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all common stock is classified within Level 1 of the valuation hierarchy. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;<b>&#8226;</b>&#160;Commingled funds &#8212; The investments are public investment vehicles valued using the NAV provided by the fund administrator. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. Assets in the Level 2 category have a quoted market price in a market that is not active. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;<b>&#8226;</b>&#160;Insurance contracts &#8212; The instruments are issued by insurance companies. The fair value is based on negotiated value and the underlying investments held in separate account portfolios as well as considering the credit worthiness of the issuer. The underlying investments are government, asset-backed and fixed income securities. In general, insurance contracts are classified as Level 3 as there are no quoted prices nor other observable inputs for pricing. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;<b>&#8226;</b>&#160;Other assets &#8212; Other assets are represented primarily by limited partnerships and real estate investments, as well as commercial loans and commercial mortgages that are not classified as corporate debt. Other assets that are exchange listed and actively traded are classified as Level 1 while inactively traded assets are classified as Level 2. Most limited partnerships represent investments in private equity and similar funds that are valued by the general partners. These, as well as any other assets valued using unobservable inputs, are classified as Level 3. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The following table sets forth the trust investments measured at fair value as of January&#160;3, 2010: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="52%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Quoted Prices</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Significant</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>in Active</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Other</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Significant</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Markets for</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Observable</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Unobservable</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Identical Assets</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Inputs</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Inputs</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>(Level 1)</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>(Level 2)</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>(Level 3)</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Total Assets</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Short-term investment funds </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">91</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">358</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">449</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Government and agency securities </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,165</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,165</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Debt instruments </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">3</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,145</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,153</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Equity securities </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,068</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">58</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,141</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Commingled funds </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,673</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">26</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,699</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Insurance contracts </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">32</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">32</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Other assets </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">31</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">171</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">82</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">284</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Trust investments at fair value</b> </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>5,193</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>5,570</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>160</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>10,923</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>LEVEL 3 GAINS AND LOSSES</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The table below sets forth a summary of changes in the fair value of the Plan&#8217;s Level 3 assets for the year ended January&#160;3, 2010: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="28%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Debt</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Equity</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Commingled</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Insurance</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Other</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Total</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Instruments</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Securities</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Funds</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Contracts</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Assets</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Level 3</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Balance December&#160;28, 2008</b> </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">7</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">29</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">85</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">151</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Realized gains (losses) </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Unrealized gains (losses) </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(3</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(5</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Purchases, sales, issuances and settlements, net </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(4</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">13</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">11</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Balance January&#160;3, 2010</b> </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>5</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>15</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>26</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>32</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>82</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>160</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 11 - jnj:SavingsPlanTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>11. Savings Plan</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company has voluntary 401 (k)&#160;savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee&#8217;s contributions consistent with the provisions of the plan for which he/she is eligible. Total Company matching contributions to the plans were $163&#160;million, $166&#160;million and $169&#160;million in 2009, 2008 and 2007, respectively. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 12 - us-gaap:ScheduleOfTreasuryStockByClassTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>12. Capital and Treasury Stock</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Changes in treasury stock were: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="76%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Amounts in Millions Except Treasury Stock</b></td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 1px solid #000000"><b>Treasury Stock</b></td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Number of Shares in Thousands)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Shares</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Amount</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Balance at December&#160;31, 2006 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">226,612</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">10,974</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Employee compensation and stock option plans </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(33,296</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2,180</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Conversion of subordinated debentures </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(194</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(13</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Repurchase of common stock </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">86,498</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,607</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Balance at December&#160;30, 2007 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">279,620</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">14,388</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Employee compensation and stock option plans </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(29,906</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2,005</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Conversion of subordinated debentures </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(19</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Repurchase of common stock </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">100,970</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,651</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Balance at December&#160;28, 2008 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">350,665</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">19,033</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Employee compensation and stock option plans </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(22,161</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,377</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Conversion of subordinated debentures </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(96</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(6</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Repurchase of common stock </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">37,114</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,130</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Balance at January&#160;3, 2010 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">365,522</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">19,780</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Aggregate shares of Common Stock issued were approximately 3,120&#160;million shares at the end of 2009, 2008 and 2007. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Cash dividends paid were $1.930 per share in 2009, compared with dividends of $1.795 per share in 2008 and $1.620 per share in 2007. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 13 - us-gaap:ComprehensiveIncomeNoteTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>13. Accumulated Other Comprehensive Income</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Components of other comprehensive income/(loss) consist of the following: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="40%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Total</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Gains/</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Accumulated</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Foreign</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Gains/</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>(Losses) on</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Other</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Currency</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>(Losses) on</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Employee</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Derivatives</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Comprehensive</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Translation</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Securities</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Benefit Plans</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>&#038; Hedges</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Income/(Loss)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">December&#160;31, 2006 </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">$</td> <td align="right">(158</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">61</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2,030</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2,118</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">2007 changes </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Unrealized gain (loss) </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">28</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(78</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Net amount reclassed to net earnings </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(5 </td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">24</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Net 2007 changes </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">786</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">23</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">670</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(54</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,425</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">December&#160;30, 2007 </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">628</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">84</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,360</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(45</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(693</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">2008 changes </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Unrealized gain (loss) </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(32</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">94</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Net amount reclassed to net earnings </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(27 </td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">72</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Net 2008 changes </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2,499</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(59</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,870</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">166</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(4,262</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" nowrap="nowrap" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">December&#160;28, 2008 </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">$</td> <td align="right">(1,871</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">25</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(3,230</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">121</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(4,955</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">2009 changes </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Unrealized gain (loss) </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(52</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">38</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Net amount reclassed to net earnings </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(3 </td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(14 </td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Net 2009 changes </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,363</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(55</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">565</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">24</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,897</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">January&#160;3, 2010 </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>$</b></td> <td align="right"><b>(508</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>(30</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>(2,665</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>145</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>(3,058</b></td> <td nowrap="nowrap"><b>)</b></td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" nowrap="nowrap" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The tax effect on the unrealized gains/(losses) on the equity securities was income of $14 million in 2009 and expense of $14&#160;million and $46&#160;million in 2008 and 2007, respectively. The tax effect related to employee benefit plans was $302&#160;million, $1,090&#160;million and $349&#160;million in 2009, 2008 and 2007, respectively. The tax effect on the gains/(losses) on derivatives and hedges was expense of $78&#160;million and $70&#160;million in 2009 and 2008, respectively, and income of $24&#160;million in 2007. See Note 6 for additional information relating to derivatives and hedging. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The currency translation adjustments are not adjusted for income taxes as they relate to permanent investments in international subsidiaries. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 14 - us-gaap:ForeignCurrencyDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>14. International Currency Translation</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">For translation of its subsidiaries operating in non-U.S. Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. This equity account includes the results of translating all balance sheet assets and liabilities at current exchange rates, except for those located in highly inflationary economies. The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;An analysis of the changes during 2009, 2008 and 2007 for foreign currency translation adjustments is included in Note 13. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Net currency transaction and translation gains and losses included in other (income)&#160;expense were losses of $210&#160;million, $31&#160;million and $23&#160;million in 2009, 2008 and 2007, respectively. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 15 - us-gaap:EarningsPerShareTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 6pt"><b>15. Earnings Per Share</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January&#160;3, 2010, December&#160;28, 2008 and December&#160;30, 2007: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="64%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Shares in Millions Except Per Share Data)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Basic net earnings per share </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">4.45</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.62</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3.67</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Average shares outstanding &#8212; basic </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,759.5</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,802.5</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,882.9</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Potential shares exercisable under stock option plans </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">118.0</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">179.0</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">178.6</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Less: shares repurchased under treasury stock method </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(92.0</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(149.6</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(154.5</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Convertible debt shares </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">3.6</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3.7</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3.7</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Adjusted average shares outstanding &#8212; diluted </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,789.1</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,835.6</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,910.7</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Diluted net earnings per share </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">4.40</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.57</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3.63</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 0px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The diluted net earnings per share calculation includes the dilutive effect of convertible debt that is offset by the related reduction in interest expense of $4&#160;million after-tax for years 2009, 2008 and 2007. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Diluted net earnings per share excludes 121&#160;million, 59&#160;million and 64&#160;million shares underlying stock options for 2009, 2008 and 2007, respectively, as the exercise price of these options was greater than their average market value, which would result in an anti-dilutive effect on diluted earnings per share. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 16 - us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>16. Rental Expense and Lease Commitments</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Rentals of space, vehicles, manufacturing equipment and office and data processing equipment under operating leases were approximately $322&#160;million in 2009, $309&#160;million in 2008 and $302 million in 2007. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The approximate minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year at January&#160;3, 2010 are: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" colspan="2"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="1"><b>After</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="center" colspan="1"><b>2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="1"><b>2011</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="1"><b>2012</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="1"><b>2013</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="1"><b>2014</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="1"><b>2014</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="1"><b>Total</b></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td colspan="24" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td align="center">$178</td> <td>&#160;</td> <td>&#160;</td> <td align="center">150</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="center">128</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="center">103</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="center">87</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="center">94</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="center">740</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Commitments under capital leases are not significant. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 17 - us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 6pt"><b>17. Common Stock, Stock Option Plans and Stock Compensation Agreements</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt"><b>STOCK OPTIONS</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">At January&#160;3, 2010, the Company had 11 stock-based compensation plans. The shares outstanding are for contracts under the Company&#8217;s 1995 and 2000 Stock Option Plans, the 2005 Long-Term Incentive Plan, the 1997 Non-Employee Director&#8217;s Plan and the ALZA, Inverness, and Scios Stock Option Plans. During 2009, no options or restricted shares were granted under any of these plans except under the 2005 Long-Term Incentive Plan. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The compensation cost that has been charged against income for these plans was $628&#160;million, $627&#160;million and $698&#160;million for 2009, 2008 and 2007, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $210&#160;million, $210 million and $238&#160;million for 2009, 2008 and 2007, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Stock options expire 10&#160;years from the date of grant and vest over service periods that range from six months to five years. All options are granted at the average of the high and low prices of the Company&#8217;s common stock on the New York Stock Exchange on the date of grant. Under the 2005 Long-Term Incentive Plan, the Company may issue up to 260&#160;million shares of common stock. Shares available for future grants under the 2005 Long-Term Incentive Plan were 139.7&#160;million at the end of 2009. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company settles employee stock option exercises with treasury shares. Treasury shares are replenished throughout the year for the number of shares used to settle employee stock option exercises. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. Expected volatility represents a blended rate of 4-year daily historical average volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson &#038; Johnson options with a life of 2 years. Historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S. Treasury yield curve in effect at the time of grant. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The average fair value of options granted was $8.35, $7.66, and $11.67 in 2009, 2008, and 2007, respectively. The fair value was estimated based on the weighted average assumptions of: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="64%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Risk-free rate </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">2.71</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">2.97</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">4.78</td> <td nowrap="nowrap">%</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Expected volatility </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">19.5</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">15.0</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">14.7</td> <td nowrap="nowrap">%</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Expected life </div></td> <td>&#160;</td> <td colspan="2" nowrap="nowrap" align="right">6.0</td> <td nowrap="nowrap">&#160;yrs</td> <td>&#160;</td> <td colspan="2" nowrap="nowrap" align="right">6.0</td> <td nowrap="nowrap">&#160;yrs</td> <td>&#160;</td> <td colspan="2" nowrap="nowrap" align="right">6.0</td> <td nowrap="nowrap">&#160;yrs</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Dividend yield </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">3.30</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">2.90</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">2.50</td> <td nowrap="nowrap">%</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">A summary of option activity under the Plan as of January&#160;3, 2010, December&#160;28, 2008, and December 30, 2007 and changes during the years ending on those dates is presented below: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="64%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Aggregate</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Weighted</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Intrinsic</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Outstanding</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Average</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Value</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Shares in Thousands)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Shares</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Exercise Price</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>(Dollars in Millions)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares at December&#160;31, 2006 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">242,927</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">54.57</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">2,788</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Options granted </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">26,789</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">65.61</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Options exercised </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(33,224</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">45.92</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Options canceled/forfeited </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(7,863</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">63.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares at December&#160;30, 2007 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">228,629</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">56.83</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">2,411</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Options granted </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">22,428</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">61.80</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Options exercised </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(30,033</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">50.27</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Options canceled/forfeited </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(5,525</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">61.90</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares at December&#160;28, 2008 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">215,499</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">58.14</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">597</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Options granted </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">21,576</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">58.32</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Options exercised </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(18,225</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">50.97</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Options canceled/forfeited </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(6,131</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">61.85</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares at January&#160;3, 2010 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>212,719</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>58.66</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>1,310</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The total intrinsic value of options exercised was $184&#160;million, $506&#160;million, and $625&#160;million in 2009, 2008 and 2007, respectively. The total unrecognized compensation cost was $612&#160;million as of January&#160;3, 2010, $632&#160;million as of December&#160;28, 2008 and $652&#160;million as of December&#160;30, 2007. The weighted average period for this cost to be recognized was 1.16&#160;years, 1.06&#160;years and 1.01&#160;years for 2009, 2008, and 2007, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The following table summarizes stock options outstanding and exercisable at January&#160;3, 2010: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="40%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Outstanding</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>Exercisable</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left" style="border-bottom: 0px solid #000000"><b>(Shares in Thousands)</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Average</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Average</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Exercise</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Average</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Exercise</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Exercise</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Price Range</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Options</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Life</b></td> <td nowrap="nowrap"><sup style="font-size: 85%; vertical-align: text-top"><b>(1)</b></sup></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Price</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Options</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Price</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td colspan="1" align="left" style="border-top: 0px solid #000000">&#160;</td> <td colspan="1" align="left" style="border-top: 0px solid #000000">&#160;</td> <td colspan="19" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">$&#160;&#160;7.33 - $28.09 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">104</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.5</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">22.89</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">104</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">22.89</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">$31.27- $40.08 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">131</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.3</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">35.83</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">131</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">35.83</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">$41.26- $49.86 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,024</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.2</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">47.09</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,024</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">47.09</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">$50.52- $52.11 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">17,328</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.8</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">50.70</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">17,328</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">50.70</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">$52.13- $53.77 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">22,193</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3.1</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">52.22</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">22,152</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">52.22</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">$53.93- $54.89 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">26,155</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.0</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">53.93</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">26,156</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">53.93</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">$55.01- $58.25 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">26,332</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2.1</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">57.30</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">26,328</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">57.30</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">$58.33- $65.10 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">63,805</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7.7</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">59.48</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">21,367</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">58.48</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">$65.62- $68.37 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">55,647</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.8</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">65.97</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">33,759</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">66.19</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>212,719</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>5.0</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>58.66</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>148,349</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>57.26</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(1)</i></sup></td> <td>&#160;</td> <td><i>Average contractual life remaining in years.</i></td> </tr> </table> <div align="left" style="font-size: 10pt; margin-top: 6pt">Stock options exercisable at December&#160;28, 2008 and December&#160;30, 2007 were 144,962 at an average price of $56.25 and an average life of 5.3&#160;years and 137,310 at an average price of $52.33 and an average life of 5.6&#160;years, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>RESTRICTED SHARE UNITS</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company grants restricted share units with a vesting period of three years. The Company settles employee stock issuance with treasury shares. Treasury shares are replenished throughout the year for the number of shares used for employee stock issuances. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;A summary of share activity under the Plan as of January&#160;3, 2010: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="88%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Outstanding</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Shares in Thousands)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Shares</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="3" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares at December&#160;31, 2006 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,885</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Shares granted </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">8,029</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares issued </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(33</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Shares canceled/forfeited </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,220</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares at December&#160;30, 2007 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">13,661</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Shares granted </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">10,105</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares issued </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(40</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Shares canceled/forfeited </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,468</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares at December&#160;28, 2008 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">22,258</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Shares granted </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">11,172</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares issued </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(5,714</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Shares canceled/forfeited </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,392</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares at January&#160;3, 2010 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">26,324</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The average fair value of the restricted share units granted was $52.79, $56.70 and $60.86 in 2009, 2008 and 2007, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units settled was $308.4 million, $2.5&#160;million and $1.8&#160;million in 2009, 2008 and 2007, respectively. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 18 - us-gaap:SegmentReportingDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>18. Segments of Business</b><sup style="font-size: 85%; vertical-align: text-top"><b>(1) </b></sup><b>and Geographic Areas</b> </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="64%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Sales to Customers</b><sup style="font-size: 85%; vertical-align: text-top"><b>(2)</b></sup></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Consumer &#8212; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">United States </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">6,837</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,937</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,408</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">International </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">8,966</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9,117</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">8,085</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Total </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>15,803</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>16,054</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>14,493</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Pharmaceutical &#8212; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">United States </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">13,041</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">14,831</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15,603</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">International </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">9,479</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9,736</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9,263</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Total </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>22,520</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>24,567</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>24,866</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Medical Devices and Diagnostics &#8212; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">United States </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">11,011</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10,541</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10,433</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">International </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">12,563</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">12,585</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">11,303</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Total </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>23,574</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>23,126</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>21,736</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Worldwide total </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>61,897</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>63,747</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>61,095</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="38%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Operating Profit</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Identifiable Assets</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b><sup style="font-size: 85%; vertical-align: text-top"><b>(5)</b></sup></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b><sup style="font-size: 85%; vertical-align: text-top"><b>(6)</b></sup></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b><sup style="font-size: 85%; vertical-align: text-top"><b>(7)</b></sup></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Consumer </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">2,475</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,674</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,277</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">24,671</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">23,765</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">26,550</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Pharmaceutical </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,413</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7,605</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,540</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">21,460</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">19,544</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">19,780</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Medical Devices and Diagnostics </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">7,694</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7,223</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,846</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">22,853</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">20,779</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">19,978</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Total </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">16,582</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">17,502</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">13,663</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">68,984</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">64,088</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">66,308</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Less: Expense not allocated to segments<sup style="font-size: 85%; vertical-align: text-top">(3)</sup> </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">827</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">573</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">380</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">General corporate<sup style="font-size: 85%; vertical-align: text-top">(4)</sup> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">25,698</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">20,824</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">14,646</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Worldwide total </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>15,755</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>16,929</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>13,283</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>94,682</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>84,912</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>80,954</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="38%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10"><b>Additions to Property,</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10"><b>Depreciation and</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Plant &#038; Equipment</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Amortization</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Consumer </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">439</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">499</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">504</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">513</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">489</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">472</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Pharmaceutical </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">535</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">920</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,137</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">922</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">986</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,033</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Medical Devices and Diagnostics </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,114</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,251</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">919</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,124</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,146</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,080</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Segments total </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,088</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,670</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,560</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,559</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,621</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,585</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">General corporate </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">277</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">396</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">382</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">215</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">211</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">192</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Worldwide total </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>2,365</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>3,066</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>2,942</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>2,774</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>2,832</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>2,777</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="38%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Sales to Customers</b><sup style="font-size: 85%; vertical-align: text-top"><b>(2)</b></sup></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Long-Lived Assets</b><sup style="font-size: 85%; vertical-align: text-top"><b>(8)</b></sup></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">United States </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">30,889</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">32,309</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">32,444</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">22,399</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">21,674</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">21,685</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Europe </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">15,934</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">16,782</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15,644</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">17,347</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">14,375</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15,578</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Western Hemisphere excluding U.S. </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,156</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,173</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,681</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,540</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,328</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,722</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Asia-Pacific, Africa </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">9,918</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9,483</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">8,326</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,868</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,898</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,261</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Segments total </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">61,897</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">63,747</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">61,095</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">45,154</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">41,275</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">42,246</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">General corporate </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">790</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">785</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">702</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Other non long-lived assets </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">48,738</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">42,852</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">38,006</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Worldwide total </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>61,897</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>63,747</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>61,095</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>94,682</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>84,912</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>80,954</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="3%"></td> <td width="1%"></td> <td width="96"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(1)</i></sup></td> <td>&#160;</td> <td><i>See Note 1 for a description of the segments in which the Company operates.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(2)</i></sup></td> <td>&#160;</td> <td><i>Export sales are not significant. In 2009, 2008 and 2007, the Company did not have a customer that represented 10% of total revenues.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(3)</i></sup></td> <td>&#160;</td> <td><i>Amounts not allocated to segments include interest (income)&#160;expense, non-controlling interests and general corporate (income)&#160;expense.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(4)</i></sup></td> <td>&#160;</td> <td><i>General corporate includes cash and marketable securities.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(5)</i></sup></td> <td>&#160;</td> <td><i>Includes $1,186&#160;million of restructuring expense, comprised of $369&#160;million, $496&#160;million, and $321&#160;million for the Consumer, Pharmaceutical, and Medical Devices and Diagnostics segments, respectively. Includes $386&#160;million of fourth quarter net litigation gain, comprised of a $92&#160;million expense in the Pharmaceutical segment and a gain of $478&#160;million in the Medical Devices and Diagnostics segment.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(6)</i></sup></td> <td>&#160;</td> <td><i>Includes $7&#160;million and $174&#160;million of IPR&#038;D for the Consumer and Medical Devices and Diagnostics segments, respectively. Includes $379&#160;million of fourth quarter net litigation gain, comprised of a $50&#160;million expense in the Consumer segment and a gain of $429&#160;million in the Medical Devices and Diagnostics segment. The Medical Devices and Diagnostics segment also includes $536&#160;million gain on the divestiture of the Professional Wound Care business of Ethicon, Inc.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(7)</i></sup></td> <td>&#160;</td> <td><i>Includes $745&#160;million of restructuring expense, comprised of $15&#160;million, $429&#160;million, and $301&#160;million for the Consumer, Pharmaceutical, and Medical Devices and Diagnostics segments, respectively. The Medical Devices and Diagnostics segment includes $807&#160;million of IPR&#038;D. The Pharmaceutical segment also includes $678&#160;million for the write-down of the NATRECOR </i><sup style="font-size: 85%; vertical-align: text-top"> <i><sup style="font-size: 85%; vertical-align: text-top">&#174;</sup></i></sup><i> intangible asset.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(8)</i></sup></td> <td>&#160;</td> <td><i>Long-lived assets include property, plant and equipment, net for 2009, 2008 and 2007 of $14,759, $14,365 and $14,185, respectively, and intangible assets and goodwill, net for 2009, 2008 and 2007 of $31,185, $27,695 and $28,763, respectively.</i></td> </tr> </table> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 19 - us-gaap:QuarterlyFinancialInformationTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>19. Selected Quarterly Financial Data (unaudited)</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Selected unaudited quarterly financial data for the years 2009 and 2008 are summarized below: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="20%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="14" style="border-bottom: 1px solid #000000"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="14" style="border-bottom: 1px solid #000000"><b>2008</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>First</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Second</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Third</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Fourth</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>First</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Second</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Third</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Fourth</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions Except Per Share Data)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Quarter</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Quarter</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Quarter</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Quarter</b></td> <td nowrap="nowrap"><sup style="font-size: 85%; vertical-align: text-top"><b>(1)</b></sup></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Quarter</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Quarter</b></td> <td nowrap="nowrap"><sup style="font-size: 85%; vertical-align: text-top"><b>(2)</b></sup></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Quarter</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Quarter</b></td> <td nowrap="nowrap"><sup style="font-size: 85%; vertical-align: text-top"><b>(3)</b></sup></td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="31" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Segment sales to customers </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Consumer </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">3,711</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,854</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,989</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,249</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,064</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,036</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,099</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,855</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Pharmaceutical </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,780</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,498</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,249</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,993</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,429</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,340</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,113</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,685</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Med Devices &#038; Diagnostics </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,535</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,887</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,843</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,309</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,701</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,074</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,709</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,642</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="31" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Total sales </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">15,026</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15,239</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15,081</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">16,551</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">16,194</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">16,450</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15,921</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15,182</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="31" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Gross profit </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">10,775</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10,789</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10,647</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">11,239</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">11,580</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">11,699</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">11,147</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10,810</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Earnings before provision for taxes on income </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,643</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,263</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,245</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,604</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,747</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,375</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,290</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,517</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Net earnings </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,507</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,208</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,345</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,206</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,598</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,327</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,310</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,714</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="31" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Basic net earnings per share </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">1.27</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.16</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.21</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.80</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.27</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.18</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.19</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.98</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="31" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Diluted net earnings per share </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">1.26</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.15</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.20</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.79</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.26</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.17</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.17</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.97</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="31" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(1)</i></sup></td> <td>&#160;</td> <td><i>The fourth quarter of 2009 includes an after-tax charge of $852&#160;million for restructuring and $212&#160;million after-tax of income from net litigation.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(2)</i></sup></td> <td>&#160;</td> <td><i>The second quarter of 2008 includes an after-tax charge of $40&#160;million for IPR&#038;D.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(3)</i></sup></td> <td>&#160;</td> <td><i>The fourth quarter of 2008 includes an after-tax charge of $141&#160;million for IPR&#038;D, $229&#160;million after-tax of income from net litigation and $331&#160;million after-tax gain on the divestiture of the Professional Wound Care business of Ethicon, Inc. The gain from the divestiture of the Professional Wound Care business of Ethicon, Inc. was reinvested in the business.</i></td> </tr> </table> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 20 - us-gaap:BusinessCombinationDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>20. Business Combinations and Divestitures</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Certain businesses were acquired for $2,470&#160;million in cash and $875&#160;million of liabilities assumed and non-controlling interests during 2009. These acquisitions were accounted for by the purchase method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The 2009 acquisitions included: Mentor Corporation, a leading supplier of medical products for the global aesthetics market; Cougar Biotechnology, Inc., a development stage biopharmaceutical company with a specific focus on oncology; Finsbury Orthopaedics Limited, a privately held UK-based manufacturer and global distributor of orthopaedic implants; Gloster Europe, a privately held developer of innovative disinfection processes and technologies to prevent healthcare-acquired infections and substantially all of the assets and rights of Elan&#8217;s Alzheimer&#8217;s Immunotherapy Program through a newly formed company, of which the Company owns 50.1% and Elan owns 49.9%. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $2,940&#160;million and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. Of this amount, approximately $1,737&#160;million has been identified as the value of IPR&#038;D primarily associated with the acquisitions of Cougar Biotechnology, Inc. and substantially all of the assets and rights of Elan&#8217;s Alzheimer&#8217;s Immunotherapy Program. Additionally, approximately $1,107&#160;million has been identified as the value of other intangible assets, including patents &#038; technology and customer relationships primarily associated with the acquisition of Mentor Corporation. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The IPR&#038;D related to the acquisition of Cougar Biotechnology, Inc. was $971&#160;million and is associated with abiraterone acetate, a late stage, first-in-class compound for the treatment of prostate cancer. The value of the IPR&#038;D was calculated using cash flow projections discounted for the risk inherent in such projects. Probability of success factors ranging from 60-85% were used to reflect inherent clinical and regulatory risk. The discount rate applied was 23.5%. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Refer to Note 6 for information related to the Elan transaction. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Certain businesses were acquired for $1,214&#160;million in cash and $114&#160;million of liabilities assumed during 2008. These acquisitions were accounted for by the purchase method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The 2008 acquisitions included: Amic AB, a privately held Swedish developer of in vitro diagnostic technologies for use in point-of-care and near-patient settings; Beijing Dabao Cosmetics Co., Ltd., a company that sells personal care brands in China; SurgRx, Inc., a privately held developer of the advanced bipolar tissue sealing system used in the ENSEAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> family of devices; HealthMedia, Inc., a privately held company that creates web-based behavior change interventions; LGE Performance Systems, Inc., a privately held company known as Human Performance Institute&#8482;, which develops science-based training programs to improve employee engagement and productivity and Omrix Biopharmaceuticals, Inc., a fully integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $891&#160;million and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. Approximately $181&#160;million has been identified as the value of IPR&#038;D associated with the acquisitions of Omrix Biopharmaceuticals, Inc., Amic AB, SurgRx, Inc. and HealthMedia, Inc. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The IPR&#038;D charge related to the acquisition of Omrix Biopharmaceuticals, Inc. was $127&#160;million and is associated with stand-alone and combination biosurgical technologies used to achieve hemostasis. The value of the IPR&#038;D was calculated using cash flow projections discounted for the risk inherent in such projects. Probability of success factors ranging from 60-90% were used to reflect inherent clinical and regulatory risk. The discount rate applied was 14%. As of the end of the 2008 fiscal year, 97.8% of the outstanding shares of Common Stock of Omrix Biopharmaceuticals, Inc. had been tendered by stockholders. Excluding shares that were tendered subject to guaranteed delivery procedures, 90.2% of the outstanding shares of Common Stock had been tendered. On December&#160;30, 2008 the Company completed the acquisition of Omrix Biopharmaceuticals, Inc. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The IPR&#038;D charge related to the acquisition of Amic AB was $40&#160;million and is associated with point-of-care device and 4CAST Chip technologies. The value of the IPR&#038;D was calculated using cash flow projections discounted for the risk inherent in such projects. The discount rate applied was 20%. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The IPR&#038;D charge related to the acquisition of SurgRx, Inc. was $7&#160;million and is associated with vessel cutting and sealing surgical devices. The value of the IPR&#038;D was calculated using cash flow projections discounted for the risk inherent in such projects. Probability of success factors ranging from 90-95% were used to reflect inherent clinical and regulatory risk. The discount rate applied was 18%. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The IPR&#038;D charge related to the acquisition of HealthMedia, Inc. was $7&#160;million and is associated primarily with process enhancements to software technology. The value of the IPR&#038;D was calculated using cash flow projections discounted for the risk inherent in such projects. A probability of success factor of 90% was used to reflect inherent risk. The discount rate applied was 14%. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Certain businesses were acquired for $1,388&#160;million in cash and $232&#160;million of liabilities assumed during 2007. These acquisitions were accounted for by the purchase method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The 2007 acquisitions included: Conor Medsystems, Inc., a cardiovascular device company, with new drug delivery technology; Robert Reid, Inc., a Japanese orthopedic product distributor; and Maya&#8217;s Mom, Inc., a social media company. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $636&#160;million and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. Approximately $807&#160;million has been identified as the value of IPR&#038;D associated with the acquisition of Conor Medsystems, Inc. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The IPR&#038;D charge related to the acquisition of Conor Medsystems, Inc. was $807&#160;million and is associated with research related to the discovery and application of the stent technology. The value of the IPR&#038;D was calculated using cash flow projections discounted for the risk inherent in such projects. The discount rate applied was 19%. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Supplemental pro forma information for 2009, 2008 and 2007 in accordance with U.S. GAAP standards related to business combinations, and goodwill and other intangible assets, is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company&#8217;s results of operations, cash flows or financial position. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;With the exception of the divestiture of the Professional Wound Care business of Ethicon, Inc., which resulted in a gain of $536&#160;million before tax, and is recorded in other (income) expense, net, in 2008, divestitures in 2009, 2008 and 2007 did not have a material effect on the Company&#8217;s results of operations, cash flows or financial position. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 21 - jnj:LegalProceedingsTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>Note 21 &#8212; Legal Proceedings</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt"><b>PRODUCT LIABILITY</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company&#8217;s subsidiaries are involved in numerous product liability cases in the United States, many of which concern alleged adverse reactions to drugs and medical devices. The damages claimed are substantial, and while the Company is confident of the adequacy of the warnings and instructions for use that accompany such products, it is not feasible to predict the ultimate outcome of litigation. However, the Company believes that if any product liability results from such cases, it will be substantially covered by existing amounts accrued in the Company&#8217;s balance sheet and, where available, by third-party product liability insurance. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Multiple products of Johnson &#038; Johnson subsidiaries are subject to numerous product liability claims and lawsuits. There are a significant number of claimants who have pending lawsuits or claims regarding injuries allegedly due to ORTHO EVRA<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, LEVAQUIN<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, DURAGESIC<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, the CHARIT&#201;&#8482; Artificial Disc and CYPHER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> Stent. These claimants seek substantial compensatory and, where available, punitive damages. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;With respect to RISPERDAL <sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, the Attorneys General of eight states and the Office of General Counsel of the Commonwealth of Pennsylvania have filed actions seeking reimbursement of Medicaid or other public funds for RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> prescriptions written for off-label use, compensation for treating their citizens for alleged adverse reactions to RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, civil fines or penalties, punitive damages, or other relief. The Attorney General of Texas has joined a qui tam action in that state seeking similar relief. Certain of these actions also seek injunctive relief relating to the promotion of RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>. The Attorneys General of more than 40 other states have indicated a potential interest in pursuing similar litigation against the Company&#8217;s subsidiary, Janssen Pharmaceutica Inc. (Janssen) (now Ortho-McNeil-Janssen Pharmaceuticals Inc. (OMJPI)), and have obtained a tolling agreement staying the running of the statute of limitations while they inquire into the issues. In addition, there are six cases filed by union health plans seeking damages for alleged overpayments for RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, several of which seek certification as class actions. In the case brought by the Attorney General of West Virginia, based on claims for alleged consumer fraud as to DURAGESIC<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> as well as RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, Janssen (now OMJPI) was found liable and damages were assessed at $4.5&#160;million. OMJPI has filed an appeal. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Numerous claims and lawsuits in the United States relating to the drug PROPULSID<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, withdrawn from general sale by the Company&#8217;s Janssen (now OMJPI) subsidiary in 2000, have been resolved or are currently enrolled in settlement programs with an aggregate cap below $100&#160;million. Similar litigation concerning PROPULSID<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> is pending in Canada, where a national class action of persons alleging adverse reactions to the drug has been certified and a settlement program instituted with an aggregate cap below $10&#160;million. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>AFFIRMATIVE STENT PATENT LITIGATION</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">In patent infringement actions tried in Delaware Federal District Court in late 2000, Cordis Corporation (Cordis), a subsidiary of Johnson &#038; Johnson, obtained verdicts of infringement and patent validity, and damage awards against Boston Scientific Corporation (Boston Scientific) and Medtronic AVE, Inc. (Medtronic) based on a number of Cordis vascular stent patents. In December 2000, the jury in the damage action against Boston Scientific returned a verdict of $324&#160;million and the jury in the Medtronic action returned a verdict of $271&#160;million. The Court of Appeals for the Federal Circuit has upheld liability in these cases, and on September&#160;30, 2008, the district court entered judgments, including interest, in the amounts of $702&#160;million and $521&#160;million against Boston Scientific and Medtronic, respectively. Medtronic paid $472&#160;million in October&#160;2008, representing the judgment, net of amounts exchanged in settlement of a number of other litigations between the companies. The net settlement of $472&#160;million was recorded as a credit to other (income)&#160;expense, net in the 2008 consolidated statement of earnings. In September&#160;2009, Cordis settled this case with Boston Scientific together with the Kastenhofer/Fontirroche and Ding cases described below, for a net payment of $716&#160;million. As part of that settlement Boston Scientific received a paid up license to the Fontirroche family of patents worldwide and Cordis received a paid license to the Kastenhofer and Ding families of patents worldwide and the parties settled all pending lawsuits worldwide relating to these patents. The receipt of $716&#160;million, less the impact of other litigation matters, resulted in a credit to other (income)&#160;expense, net of $386&#160;million in the fiscal fourth quarter of 2009. In addition, in May&#160;2009, Medtronic paid $270&#160;million to settle additional patent infringement claims asserted by Cordis based on its vascular stent patents, which was recorded as a credit to other (income)&#160;expense, net in the fiscal second quarter of 2009. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In January&#160;2003, Cordis filed a patent infringement action against Boston Scientific in Delaware Federal District Court accusing its Express2&#8482;, Taxus<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> and Liberte<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> stents of infringing the Palmaz patent that expired in November&#160;2005. The Liberte<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> stent was also accused of infringing Cordis&#8217; Gray patent that expires in 2016. In June&#160;2005, a jury found that the Express2&#8482;, Taxus<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> and Liberte<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> stents infringed the Palmaz patent and that the Liberte<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> stent also infringed the Gray patent. On March&#160;31, 2009, the U.S. Court of Appeals for the Federal Circuit affirmed this judgment. The case was remanded to the district court for a trial on damages and willfulness. Cordis also filed a lawsuit in Delaware Federal District Court in October of 2008 alleging that Boston Scientific&#8217;s sales of Taxus<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> and Liberte<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> after June of 2005 infringes Cordis&#8217; Gray patent. On January&#160;29, 2010, these cases together with the Jang case referred to in the paragraph below, were settled. Under the terms of the settlement, Boston Scientific paid Cordis $1.0&#160;billion on February&#160;1, 2010, and will pay Cordis an additional $725&#160;million plus interest on January&#160;3, 2011. Cordis granted Boston Scientific a paid up worldwide license under the Palmaz and Gray patents and Boston Scientific granted Cordis a paid up worldwide license under the Jang patents for all stents sold by Cordis except the 2.25mm size Cypher. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Cordis has several pending lawsuits in New Jersey and Delaware Federal District Court against Guidant Corporation (Guidant), Abbott Laboratories, Inc. (Abbott), Boston Scientific and Medtronic alleging that the Xience V&#8482; (Abbott), Promus&#8482; (Boston Scientific) and Endeavor<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> (Medtronic) drug eluting stents infringe several patents owned by or licensed to Cordis. In one of the cases against Boston Scientific, alleging that sales of their Promus&#8482; stent infringed Wright and Falotico patents, on January&#160;20, 2010 the District Court in Delaware found the Wright/Falotico patent invalid for lack of written description and/or lack of enablement. Cordis intends to appeal this ruling. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>PATENT LITIGATION AGAINST VARIOUS JOHNSON &#038; JOHNSON SUBSIDIARIES</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The products of various Johnson &#038; Johnson subsidiaries are the subject of various patent lawsuits, the outcomes of which could potentially adversely affect the ability of those subsidiaries to sell those products, or require the payment of past damages and future royalties. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In July&#160;2005, a jury in Federal District Court in Delaware found that the Cordis CYPHER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> Stent infringed Boston Scientific&#8217;s Ding &#8216;536 patent and that the Cordis CYPHER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> and BX VELOCITY<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> Stents also infringed Boston Scientific&#8217;s Jang &#8216;021 patent. The jury also found both of those patents valid. In January 2009, the Court of Appeals for the Federal Circuit held the Ding patent invalid and a judgment in favor of Cordis in that case has been entered. In March&#160;2009, the Court of Appeals for the Federal Circuit upheld the judgment that Cordis&#8217; CYPHER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> Stent infringed Boston Scientific&#8217;s Jang patent. The case has been remanded for a trial on the issues of damages and willfulness. The Jang case has been dismissed as part of the January&#160;2010 settlement described in the paragraph above relating to the Express2&#8482;, Taxus<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> and Liberte<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> stents. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In Germany, Boston Scientific had several actions based on its Ding patents pending against the Cordis CYPHER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> Stent. Boston Scientific also had brought actions in Belgium, the Netherlands, Germany, France and Italy under its Kastenhofer patent, which purports to cover two-layer catheters such as those used to deliver the CYPHER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> Stent. These cases have been settled as part of the September&#160;2009 settlement described above. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Trial in Boston Scientific&#8217;s U.S. case based on the Kastenhofer patent in Federal District Court in California concluded in October&#160;2007 with a jury finding that the patent was invalid. The jury also found for Cordis on its counterclaim that sale by Boston Scientific of its balloon catheters and stent delivery systems infringe Cordis&#8217; Fontirroche patent. The Court has denied Boston Scientific&#8217;s post trial motions. This case was settled as part of the September&#160;2009 settlement described above. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In May&#160;2008, Centocor, Inc. (Centocor) (now Centocor Ortho Biotech Inc. (COBI)) filed a lawsuit against Genentech, Inc. (Genentech) in U.S. District Court for the Central District of California seeking to invalidate the Cabilly II patent. Prior to filing suit, Centocor had a sublicense under this patent from Celltech (who was licensed by Genentech) for REMICADE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> and had been paying royalties to Celltech. Centocor has terminated that sublicense and stopped paying royalties. Genentech has filed a counterclaim alleging that REMICADE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> infringes its Cabilly II patents and that the manufacture of REMICADE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, STELARA&#8482;, SIMPONI&#8482; and ReoPro<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> also infringes one of its other patents relating to the purification of antibodies made through recombinant DNA techniques. The court has scheduled a hearing for Summary Judgment Motions in August&#160;2010. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In April&#160;2009, a bench trial was held before the Federal District Court for the Middle District of Florida on the liability phase of Ciba&#8217;s patent infringement lawsuit alleging that Johnson &#038; Johnson Vision Care, Inc.&#8217;s (JJVC)&#160;ACUVUE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> OASYS&#8482; lenses infringe three of their Nicholson patents. In August&#160;2009, the District Court found two of these patents valid and infringed and entered judgment against JJVC. JJVC has appealed that judgment to the Court of Appeals for the Federal Circuit. On March&#160;22, 2010, the District Court will hold a hearing on Ciba&#8217;s motion for a permanent injunction. If the judgment is upheld on appeal the Court will schedule another trial to determine damages and willfulness. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In May&#160;2009, Abbott Biotechnology Ltd. filed a patent infringement lawsuit against Centocor (now COBI) in the United States District Court for the District of Massachusetts. The suit alleges that Centocor&#8217;s SIMPONI&#8482; product, a human anti-TNF alpha antibody, infringes Abbott&#8217;s &#8216;394 patent (the Salfeld patent). The case has been stayed pending the resolution of an arbitration filed by Centocor directed to its claim that it is licensed under the &#8216;394 patent. The arbitration is scheduled for March&#160;2010. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In August&#160;2009, Abbott GmbH &#038; Co. (Abbott GmbH) and Abbott Bioresearch Center filed a patent infringement lawsuit against COBI in the United States District Court for the District of Massachusetts. The suit alleges that COBI&#8217;s STELARA&#8482; product infringes two U.S. patents assigned to Abbott GmbH. In August&#160;2009, COBI filed a complaint for a declaratory judgment of non-infringement and invalidity of the Abbott GmbH patents in the United States District Court for the District of Columbia. On the same date, also in the United States District Court for the District of Columbia, COBI filed a Complaint for Review of a Patent Interference Decision granting priority of invention on one of the two asserted patents to Abbott GmbH. In August&#160;2009, Abbott GmbH and Abbott Laboratories Limited brought a patent infringement suit in Canada alleging that STELARA&#8482; infringes Abbott GmbH&#8217;s Canadian patent. The cases filed by COBI in the District of Columbia have been transferred to the District of Massachusetts. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In August&#160;2009, Bayer Healthcare LLC filed suit against COBI in Massachusetts District Court alleging infringement by COBI&#8217;s SIMPONI&#8482; product of its patent relating to human anti-TNF antibodies. Bayer has also filed suit under its European counterpart to these patents in Germany and the Netherlands. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In June&#160;2009, Centocor&#8217;s (now COBI) lawsuit alleging that Abbott&#8217;s HUMIRA anti-TNF alpha product infringes Centocor&#8217;s &#8216;775 patent went to trial in Federal District Court in the Eastern District of Texas. On June&#160;28, 2009 a jury returned a verdict finding the patent valid and willfully infringed, and awarded Centocor damages of approximately $1.7&#160;billion. A bench trial on Abbott&#8217;s defenses, of inequitable conduct and prosecution laches, was held in August&#160;2009, and the District Court decided these issues in favor of Centocor. All of Abbott&#8217;s post trial motions have been denied except that the District Court granted Abbott&#8217;s motion to overturn the jury finding of willfulness. Judgment in the amount of $1.9&#160;billion was entered in favor of Centocor in December&#160;2009 and Abbott has filed an appeal to the Court of Appeals for the Federal Circuit. The Company has not reflected any of the $1.9&#160;billion in its consolidated financial statements. Centocor has also filed a new lawsuit in the Eastern District of Texas seeking damages for infringement of the &#8216;775 patent attributable to sales of HUMIRA subsequent to the jury verdict in June&#160;2009. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The following chart summarizes various patent lawsuits concerning products of the Company&#8217;s subsidiaries that have yet to proceed to trial: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom" style="font-size: 6pt"> <td width="28%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>J&#038;J</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Plaintiff/</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right">&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right">&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Product</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Company</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Patents</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Patent Holder</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Court</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Trial Date**</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Date Filed</b></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" valign="top" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">CYPHER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> Stent </div></td> <td>&#160;</td> <td align="left" valign="top">Cordis </td> <td>&#160;</td> <td align="left" valign="top">Wall </td> <td>&#160;</td> <td align="left" valign="top">Wall </td> <td>&#160;</td> <td align="left" valign="top">E.D. TX </td> <td>&#160;</td> <td align="left" valign="top">Q2/11 </td> <td>&#160;</td> <td align="left" valign="top">11/07</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">CYPHER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> Stent </div></td> <td>&#160;</td> <td align="left" valign="top">Cordis </td> <td>&#160;</td> <td align="left" valign="top">Saffran </td> <td>&#160;</td> <td align="left" valign="top">Saffran </td> <td>&#160;</td> <td nowrap="nowrap" align="left" valign="top">E.D. TX </td> <td>&#160;</td> <td align="left" valign="top">Q2/11 </td> <td>&#160;</td> <td align="left" valign="top">10/07</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">Blood Glucose Meters and Strips </div></td> <td>&#160;</td> <td align="left" valign="top">LifeScan </td> <td>&#160;</td> <td align="left" valign="top">Wilsey </td> <td>&#160;</td> <td nowrap="nowrap" align="left" valign="top">Roche Diagnostics </td> <td>&#160;</td> <td align="left" valign="top">D. DE </td> <td>&#160;</td> <td align="left" valign="top">* </td> <td>&#160;</td> <td align="left" valign="top">11/07</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">REMICADE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, ustekinumab, </div></td> <td>&#160;</td> <td align="left" valign="top">Centocor/COBI </td> <td>&#160;</td> <td nowrap="nowrap" align="left" valign="top">Cabilly II </td> <td>&#160;</td> <td align="left" valign="top">Genentech </td> <td>&#160;</td> <td nowrap="nowrap" align="left" valign="top">C.D. CA </td> <td>&#160;</td> <td align="left" valign="top">* </td> <td>&#160;</td> <td align="left" valign="top">05/08</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">golimumab, ReoPro<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> </div></td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">SIMPONI&#8482; </div></td> <td>&#160;</td> <td align="left" valign="top">Centocor/COBI </td> <td>&#160;</td> <td align="left" valign="top">Salfeld </td> <td>&#160;</td> <td nowrap="nowrap" align="left" valign="top">Abbott Laboratories </td> <td>&#160;</td> <td align="left" valign="top">MA </td> <td>&#160;</td> <td align="left" valign="top">* </td> <td>&#160;</td> <td align="left" valign="top">05/09</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">SIMPONI&#8482; </div></td> <td>&#160;</td> <td align="left" valign="top">Centocor/COBI </td> <td>&#160;</td> <td align="left" valign="top">Boyle </td> <td>&#160;</td> <td align="left" valign="top">Bayer Healthcare </td> <td>&#160;</td> <td align="left" valign="top">MA </td> <td>&#160;</td> <td align="left" valign="top">* </td> <td>&#160;</td> <td align="left" valign="top">08/09</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">STELARA&#8482; </div></td> <td>&#160;</td> <td align="left" valign="top">Centocor/COBI </td> <td>&#160;</td> <td align="left" valign="top">Salfeld </td> <td>&#160;</td> <td align="left" valign="top">Abbott GmbH </td> <td>&#160;</td> <td align="left" valign="top">MA/DC </td> <td>&#160;</td> <td align="left" valign="top">* </td> <td>&#160;</td> <td align="left" valign="top">08/09</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>*</i></td> <td>&#160;</td> <td><i>Trial date to be scheduled.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>**</i></td> <td>&#160;</td> <td><i>Q reflects the Company&#8217;s fiscal quarter.</i></td> </tr> </table> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>LITIGATION AGAINST FILERS OF ABBREVIATED NEW DRUG APPLICATIONS (ANDAs)</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The following chart indicates lawsuits pending against generic firms that filed Abbreviated New Drug Applications (ANDAs) seeking to market generic forms of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement, invalidity and unenforceability of these patents. In the event the subsidiary of the Company involved is not successful in these actions, or the statutory 30-month stay expires before a ruling from the district court is obtained, the firms involved will have the ability, upon FDA approval, to introduce generic versions of the product at issue resulting in very substantial market share and revenue losses for the product of the Company&#8217;s subsidiary. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;As noted in the following chart, 30-month stays expired during 2009, and will expire in 2010, 2011 and 2012 with respect to ANDA challenges regarding various products: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="28%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Brand Name</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Patent/NDA</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Generic</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Trial</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Date</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>30-Month</b></td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Product</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Holder</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Challenger</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Court</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Date**</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Filed</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Stay Expiration</b></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" valign="top" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">CONCERTA<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> </div></td> <td>&#160;</td> <td align="left" valign="top">McNeil-PPC </td> <td>&#160;</td> <td align="left" valign="top">Andrx </td> <td>&#160;</td> <td align="left" valign="top">D. DE </td> <td>&#160;</td> <td align="left" valign="top">Q4/07 </td> <td>&#160;</td> <td align="left" valign="top">09/05 </td> <td>&#160;</td> <td align="left" valign="top">None</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">18, 27, 36 and 54 mg controlled release tablet </div></td> <td>&#160;</td> <td align="left" valign="top">ALZA </td> <td>&#160;</td> <td align="left" valign="top">KUDCO </td> <td>&#160;</td> <td align="left" valign="top">D. DE </td> <td>&#160;</td> <td align="left" valign="top">* </td> <td>&#160;</td> <td align="left" valign="top">01/10 </td> <td>&#160;</td> <td align="left" valign="top">05/12</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td nowrap="nowrap" valign="top"> <div style="margin-left:0px; text-indent:-0px">LEVAQUIN<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> 250, 500, 750 mg tablet </div></td> <td>&#160;</td> <td align="left" valign="top">Ortho-McNeil </td> <td>&#160;</td> <td align="left" valign="top">Lupin </td> <td>&#160;</td> <td align="left" valign="top">D. NJ </td> <td>&#160;</td> <td align="left" valign="top">* </td> <td>&#160;</td> <td align="left" valign="top">10/06 </td> <td>&#160;</td> <td align="left" valign="top">03/09</td> </tr> <tr> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">ORTHO TRI-CYCLEN<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> LO </div></td> <td>&#160;</td> <td align="left" valign="top">Ortho-McNeil </td> <td>&#160;</td> <td align="left" valign="top">Watson </td> <td>&#160;</td> <td align="left" valign="top">D. NJ </td> <td>&#160;</td> <td align="left" valign="top">* </td> <td>&#160;</td> <td align="left" valign="top">10/08 </td> <td>&#160;</td> <td align="left" valign="top">03/11</td> </tr> <tr valign="bottom"> <td nowrap="nowrap" valign="top"> <div style="margin-left:0px; text-indent:-0px">0.18 mg/0.025 mg, 0.215 mg/0.025 mg <br /> and 0.25 mg/0.025 mg </div></td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">Sandoz </td> <td>&#160;</td> <td nowrap="nowrap" align="left" valign="top">D. NJ<br /> D. NJ </td> <td>&#160;</td> <td align="left" valign="top">*<br /> * </td> <td>&#160;</td> <td align="left" valign="top">06/09 </td> <td>&#160;</td> <td align="left" valign="top">10/11<br /> 06/12</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td nowrap="nowrap" valign="top"> <div style="margin-left:0px; text-indent:-0px">ULTRAM ER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> 100, 200, 300 mg tablet </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left" valign="top">Ortho-McNeil/Biovail </td> <td>&#160;</td> <td align="left" valign="top">Par </td> <td>&#160;</td> <td align="left" valign="top">D. DE </td> <td>&#160;</td> <td align="left" valign="top">Q2/09 </td> <td>&#160;</td> <td align="left" valign="top">05/07 </td> <td>&#160;</td> <td align="left" valign="top">09/09</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">&#160; </div></td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">06/07 </td> <td>&#160;</td> <td align="left" valign="top">11/09</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">&#160; </div></td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">10/07 </td> <td>&#160;</td> <td align="left" valign="top">03/10</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">ULTRAM ER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> 100, 200, 300 mg tablet </div></td> <td>&#160;</td> <td align="left" valign="top">Ortho-McNeil/Biovail </td> <td>&#160;</td> <td align="left" valign="top">Impax </td> <td>&#160;</td> <td align="left" valign="top">D. DE </td> <td>&#160;</td> <td align="left" valign="top">Q2/10 </td> <td>&#160;</td> <td align="left" valign="top">08/08 </td> <td>&#160;</td> <td align="left" valign="top">01/11</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">&#160; </div></td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">11/08 </td> <td>&#160;</td> <td align="left" valign="top">03/11</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">ULTRAM ER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> 100, 200, 300 mg tablet </div></td> <td>&#160;</td> <td align="left" valign="top">Ortho-McNeil/Biovail </td> <td>&#160;</td> <td align="left" valign="top">Paddock </td> <td>&#160;</td> <td nowrap="nowrap" align="left" valign="top">D.DRD. Minn. </td> <td>&#160;</td> <td align="left" valign="top"> * </td> <td>&#160;</td> <td align="left" valign="top">09/09 </td> <td>&#160;</td> <td align="left" valign="top">01/12</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">ULTRAM ER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> 100, 200, 300 mg tablet </div></td> <td>&#160;</td> <td align="left" valign="top">Ortho-McNeil/Biovail </td> <td>&#160;</td> <td align="left" valign="top">Cipher </td> <td>&#160;</td> <td align="left" valign="top">D. DE </td> <td>&#160;</td> <td align="left" valign="top">* </td> <td>&#160;</td> <td align="left" valign="top">10/09 </td> <td>&#160;</td> <td align="left" valign="top">03/12</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">ULTRAM ER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> 100, 200, 300 mg tablet </div></td> <td>&#160;</td> <td align="left" valign="top">Ortho-McNeil/Biovail </td> <td>&#160;</td> <td align="left" valign="top">Lupin </td> <td>&#160;</td> <td align="left" valign="top">D. DE </td> <td>&#160;</td> <td align="left" valign="top">* </td> <td>&#160;</td> <td align="left" valign="top">01/10 </td> <td>&#160;</td> <td align="left" valign="top">06/12</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 12pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>*</i></td> <td>&#160;</td> <td><i>Trial date to be scheduled.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>**</i></td> <td>&#160;</td> <td><i>Q reflects the Company&#8217;s fiscal quarter.</i></td> </tr> </table> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In the action against Barr Pharmaceuticals, Inc. (Barr) (now a wholly-owned subsidiary of Teva Pharmaceutical Industries LTD.) regarding ORTHO TRI-CYCLEN<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> LO, in January&#160;2008, the Company&#8217;s subsidiary Ortho Women&#8217;s Health &#038; Urology, a Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), and Barr agreed to a non-binding term sheet to settle the litigation, which settlement discussions are still underway. The trial court postponed the January&#160;2008 trial without setting a new trial date. In June&#160;2009, Barr launched its generic product &#8220;at risk&#8221; before trial. OMJPI sought a preliminary injunction and recall of Barr product which the Court granted in July&#160;2009. In July&#160;2009, the parties entered into a definitive agreement to settle the lawsuit. Under the terms of the settlement, Barr obtained a release for its sales of its generic product in exchange for an undisclosed royalty payment. Barr also obtained a non-exclusive, royalty-bearing license to re-enter the market on December&#160;31, 2015, or earlier in certain limited circumstances. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In October&#160;2008, the Company&#8217;s subsidiary OMJPI filed suit in Federal District Court in New Jersey against Watson Laboratories, Inc. (Watson) in response to Watson&#8217;s ANDA regarding ORTHO TRI-CYCLEN<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> LO. In June&#160;2009, the Company&#8217;s subsidiary OMJPI filed suit in Federal District Court in New Jersey against Sandoz Laboratories, Inc. (Sandoz) in response to Sandoz&#8217;s ANDA regarding ORTHO TRI-CYCLEN<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> LO. The Sandoz and Watson cases have been consolidated. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In January&#160;2010, the Company&#8217;s subsidiary OMJPI filed suit in Federal District Court in New Jersey against Lupin Ltd. and Lupin Pharmaceuticals, Inc. (collectively &#8220;Lupin&#8221;) in response to Lupin&#8217;s ANDA regarding ORTHO TRI-CYCLEN<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> LO. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In the action against Barr and AlphaPharm with respect to their ANDA challenges to the RAZADYNE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> patent that Janssen (now OMJPI) licenses from Synaptech, Inc. (Synaptech), a four-day non-jury trial was held in the Federal District Court in Delaware in May 2007. In August&#160;2008, the court held that the patent was invalid because it was not enabled. Janssen (OMJPI)&#160;and Synaptech have appealed the decision. Since the court&#8217;s decision, multiple generic companies have received final approvals for their products and have launched &#8220;at risk&#8221; pending appeal. Additional generic approvals and launches could occur at any time. In September 2009, the Court of Appeals affirmed the judgment that the patent is invalid. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In the action by McNEIL-PPC, Inc. (McNeil-PPC) and ALZA Corporation (ALZA)&#160;against Andrx Corporation (Andrx) with respect to its ANDA challenge to the CONCERTA<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> patents, a five-day non-jury trial was held in the Federal District Court in Delaware in December 2007. In March&#160;2009, the court ruled that one CONCERTA<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> patent would not be infringed by Andrx&#8217;s proposed generic product and that the patent was invalid because it was not enabled. The court dismissed without prejudice Andrx&#8217;s declaratory judgment suit on a second patent for lack of jurisdiction. McNeil-PPC and ALZA filed an appeal in May&#160;2009. The appeals court heard argument on February&#160;3, 2010. A decision is pending. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;ALZA and OMJPI filed a second suit in Federal District Court in Delaware against Kremers-Urban, LLC and KUDCO Ireland, Ltd. (KUDCO)&#160;in January&#160;2010 in response to KUDCO&#8217;s ANDA challenge regarding CONCERTA<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> tablets. In its notice letter, KUDCO contends that two ALZA patents for CONCERTA<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> are invalid and not infringed by a KUDCO generic. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In the RAZADYNE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> ER cases, a lawsuit was filed against Barr on the RAZADYNE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> use patent that Janssen (now OMJPI) licenses from Synaptech in June 2006. In September&#160;2008, the above-discussed Delaware decision invalidating the RAZADYNE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> use patent resulted in entry of judgment for Barr on that patent, but the case will be reopened if Janssen (now OMJPI) and Synaptech win on appeal. Barr has received FDA approval of its product and has launched &#8220;at risk.&#8221; In September&#160;2009, the Federal Circuit affirmed the Delaware decision invalidating the RAZADYNE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> use patent. As a result, this case will not be reopened. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In the action against Lupin Pharmaceuticals, Inc. (Lupin) regarding its ANDA concerning LEVAQUIN<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, Lupin contends that the U.S. Patent and Trademark Office improperly granted a patent term extension to the patent that Ortho-McNeil (now Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI)) licenses from Daiichi Pharmaceuticals, Inc. (Daiichi). Lupin alleges that the active ingredient in LEVAQUIN<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> was the subject of prior marketing, and therefore was not eligible for the patent term extension. Lupin concedes validity and that its product would violate the patent if marketed prior to the expiration of the original patent term. Summary judgment against Lupin was granted in May&#160;2009 and Lupin appealed. Oral argument was held in September&#160;2009. A decision is pending. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In the ULTRAM<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> ER actions, Ortho-McNeil Pharmaceutical, Inc. (Ortho-McNeil) (now OMJPI), filed lawsuits (each for different dosages) against Par Pharmaceuticals, Inc. and Par Pharmaceuticals Companies, Inc. (Par) in May, June and October&#160;2007 on two Tramadol ER formulation patents owned by Purdue Pharma Products L.P. (Purdue) and Napp Pharmaceutical Group Ltd. (Napp). OMJPI also filed lawsuits (each for different dosages) against Impax Laboratories, Inc. (Impax) on a Tramadol ER formulation patent owned by Purdue and Napp in August and November&#160;2008. Purdue, Napp and Biovail Laboratories International SRL (Biovail) (the NDA holder) joined as co-plaintiffs in the lawsuits against Par and Impax, but Biovail and OMJPI were subsequently dismissed for lack of standing. The trial against Par took place in April&#160;2009. In August&#160;2009, the Court issued a decision finding the patents-in-suit invalid. Purdue has appealed that decision. The trial against Impax is scheduled for June&#160;2010. In November&#160;2009, the case against Impax was stayed with the consent of all parties. In September and October&#160;2009, respectively, Purdue filed suits against Paddock Laboratories, Inc. (Paddock) and Cipher Pharmaceuticals Inc. (Cipher) on its Tramadol ER formulation patents. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In January&#160;2010, Purdue filed a suit against Lupin Ltd. (Lupin) on its Tramadol ER formulation patents. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In September&#160;2009, Centocor Ortho Biotech Products, L.P. (COBI, LP) intervened in an inventorship dispute between Kansas University Center for Research (KUCR)&#160;involving certain U.S. government-owned VELCADE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> formulation patents. KUCR brought this action against the U.S. government in the District of Kansas seeking to add two Kansas University scientists to the patents. The U.S. government licensed the patents (and their foreign counterparts) to Millennium Pharmaceuticals, Inc., who in turn sublicensed the patents (and their foreign counterparts) to COBI,LP for commercial marketing outside the U.S. If KUCR succeeds in its co-inventorship claim and establishes co-ownership in the U.S. VELCADE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> formulation patents, we anticipate that KUCR will initiate actions to establish co-inventorship and co-ownership with respect to the foreign counterpart patents in the countries where COBI, LP has commercial marketing rights. If KUCR in Kansas is successful, this may adversely affect COBI, LP&#8217;s license rights in those countries. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>AVERAGE WHOLESALE PRICE (AWP)&#160;LITIGATION</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Johnson &#038; Johnson and several of its pharmaceutical subsidiaries, along with numerous other pharmaceutical companies, are defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP)&#160;for the drugs at issue. Many of these cases, both federal actions and state actions removed to federal court, have been consolidated for pre-trial purposes in a Multi-District Litigation (MDL)&#160;in Federal District Court in Boston, Massachusetts. The plaintiffs in these cases include classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The MDL Court identified classes of Massachusetts-only private insurers providing &#8220;Medi-gap&#8221; insurance coverage and private payers for physician-administered drugs where payments were based on AWP (&#8220;Class&#160;2&#8221; and &#8220;Class&#160;3&#8221;), and a national class of individuals who made co-payments for physician-administered drugs covered by Medicare (&#8220;Class&#160;1&#8221;). A trial of the two Massachusetts-only class actions concluded before the MDL Court in December&#160;2006. In June&#160;2007, the MDL Court issued post-trial rulings, dismissing the Johnson &#038; Johnson defendants from the case regarding all claims of Classes 2 and 3, and subsequently of Class&#160;1 as well. Plaintiffs appealed the Class&#160;1 judgment and, in September&#160;2009, the Court of Appeals vacated the judgment and remanded for further proceedings in the District Court. AWP cases brought by various Attorneys General have proceeded to trial against other manufacturers. One state case against certain of the Company&#8217;s subsidiaries has been set for trial in late 2010, and other state cases are likely to be set for trial thereafter. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>OTHER</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">In July&#160;2003, Centocor (now COBI), a Johnson &#038; Johnson subsidiary, received a request that it voluntarily provide documents and information to the criminal division of the U.S. Attorney&#8217;s Office, District of New Jersey, in connection with its investigation into various Centocor marketing practices. Subsequent requests for documents have been received from the U.S. Attorney&#8217;s Office. Both the Company and Centocor have responded to these requests for documents and information. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In December&#160;2003, Ortho-McNeil (now OMJPI) received a subpoena from the U.S. Attorney&#8217;s Office in Boston, Massachusetts seeking documents relating to the marketing, including alleged off-label marketing, of the drug TOPAMAX<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> (topiramate). Additional subpoenas for documents have been received, and current and former employees have testified before a grand jury. Discussions are underway in an effort to resolve this matter, but whether agreement can be reached and on what terms is uncertain. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In January&#160;2004, Janssen (now OMJPI) received a subpoena from the Office of the Inspector General of the U.S. Office of Personnel Management seeking documents concerning sales and marketing of, any and all payments to physicians in connection with sales and marketing of, and clinical trials for, RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> (risperidone)&#160;from 1997 to 2002. Documents subsequent to 2002 have also been requested. An additional subpoena seeking information about marketing of and adverse reactions to RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> was received from the U.S. Attorney&#8217;s Office for the Eastern District of Pennsylvania in November&#160;2005. Subpoenas seeking testimony from various witnesses before a grand jury have also been received. Janssen is cooperating in responding to ongoing requests for documents and witnesses. The government is continuing to actively investigate this matter. In February&#160;2010, the government served Civil Investigative Demands seeking additional information relating to sales and marketing of RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> and sales and marketing of INVEGA<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In September&#160;2004, Ortho Biotech Inc. (Ortho Biotech) (now COBI), received a subpoena from the U.S. Office of Inspector General&#8217;s Denver, Colorado field office seeking documents directed to the sales and marketing of PROCRIT<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> (Epoetin alfa) from 1997 to the present, as well as to dealings with U.S. Oncology Inc., a healthcare services network for oncologists. Ortho Biotech (now COBI) has responded to the subpoena. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In September&#160;2004, plaintiffs in an employment discrimination litigation initiated against the Company in 2001 in Federal District Court in New Jersey moved to certify a class of all African American and Hispanic salaried employees of the Company and its affiliates in the U.S., who were employed at any time from November&#160;1997 to the present. Plaintiffs seek monetary damages for the period 1997 through the present (including punitive damages) and equitable relief. The Court denied plaintiffs&#8217; class certification motion in December&#160;2006 and their motion for reconsideration in April&#160;2007. Plaintiffs sought to appeal these decisions and, in April&#160;2008, the Court of Appeals ruled that plaintiffs&#8217; appeal of the denial of class certification was untimely. In July&#160;2009, plaintiffs filed a motion for certification of a modified class, which the Company is opposing. Plaintiffs are engaged in further discovery of individual plaintiffs&#8217; claims. The hearing on plaintiffs&#8217; motion for class certification is scheduled for July&#160;2010. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In March&#160;2005, DePuy Orthopaedics, Inc. (DePuy), a Johnson &#038; Johnson subsidiary, received a subpoena from the U.S. Attorney&#8217;s Office, District of New Jersey, seeking records concerning contractual relationships between DePuy and surgeons or surgeons-in-training involved in hip and knee replacement and reconstructive surgery. This investigation was resolved by DePuy and the four other leading suppliers of hip and knee implants in late September&#160;2007 by agreements with the U.S. Attorney&#8217;s Office for the District of New Jersey. The settlements included an 18-month Deferred Prosecution Agreement (DPA), acceptance by each company of a monitor to assure compliance with the DPA and, with respect to four of the five companies, payment of settlement monies and entry into five year Corporate Integrity Agreements. DePuy paid $85&#160;million as its settlement. The term of the Monitor-ship under the Deferred Prosecution Agreement concluded on March&#160;27, 2009, and an order dismissing all charges was entered on March&#160;30, 2009. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In November&#160;2007, the Attorney General of the Commonwealth of Massachusetts issued a Civil Investigative Demand to DePuy seeking information regarding financial relationships between a number of Massachusetts-based orthopedic surgeons and providers and DePuy. DePuy is responding to Massachusetts&#8217; additional requests. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In July&#160;2005, Scios Inc. (Scios), a Johnson &#038; Johnson subsidiary, received a subpoena from the U.S. Attorney&#8217;s Office, District of Massachusetts, seeking documents related to the sales and marketing of NATRECOR<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>. Scios responded to the subpoena. In early August&#160;2005, Scios was advised that the investigation would be handled by the U.S. Attorney&#8217;s Office for the Northern District of California in San Francisco. Additional requests for documents have been received and responded to and former Scios employees have testified before a grand jury in San Francisco. The qui tam complaints were unsealed on February&#160;19, 2009. The U.S. government has intervened in one of the qui tam actions, and filed a complaint against Scios and the Company in June&#160;2009. Scios and Johnson &#038; Johnson have filed a motion to dismiss the qui tam complaint filed by the government, and that motion was denied. The criminal investigation is continuing and discussions are underway in an effort to settle this matter. Whether a settlement can be reached and on what terms is uncertain. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In September&#160;2005, the Company received a subpoena from the U.S. Attorney&#8217;s Office, District of Massachusetts, seeking documents related to sales and marketing of eight drugs to Omnicare, Inc., a manager of pharmaceutical benefits for long-term care facilities. The Johnson &#038; Johnson subsidiaries involved responded to the subpoena. Several employees of the Company&#8217;s pharmaceutical subsidiaries have been subpoenaed to testify before a grand jury in connection with this investigation. In April&#160;2009, the Company was served with the complaints in two civil qui tam cases related to marketing of prescription drugs to Omnicare, Inc. On January&#160;15, 2010, the government filed a complaint intervening in the cases. The complaint asserts claims under the federal False Claims Act and a related state law claim in connection with the marketing of several drugs to Omnicare. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In November&#160;2005, Amgen Inc. (Amgen) filed suit against Hoffmann-LaRoche, Inc. (Roche) in the U.S. District Court for the District of Massachusetts seeking a declaration that the Roche product CERA, which Roche has indicated it would seek to introduce into the United States, infringes a number of Amgen patents concerning EPO. Amgen licenses EPO for sale in the United States to Ortho Biotech (now COBI) for non-dialysis indications. Trial in this action concluded in October&#160;2007 with a verdict in Amgen&#8217;s favor, finding the patents valid and infringed. The judge issued a preliminary injunction blocking the CERA launch, and subsequently made the injunction permanent. The Federal Circuit upheld the entry of a permanent injunction. This matter has been settled pursuant to an agreement between the parties. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In February&#160;2006, the Company received a subpoena from the U.S. Securities &#038; Exchange Commission (SEC)&#160;requesting documents relating to the participation by several Johnson &#038; Johnson subsidiaries in the United Nations Iraq Oil for Food Program. The subsidiaries are cooperating with the SEC and U.S. Department of Justice (DOJ)&#160;in producing responsive documents. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In February&#160;2007, the Company voluntarily disclosed to the DOJ and the SEC that subsidiaries outside the United States are believed to have made improper payments in connection with the sale of medical devices in two small-market countries, which payments may fall within the jurisdiction of the Foreign Corrupt Practices Act (FCPA). In the course of continuing dialogues with the agencies, other issues potentially rising to the level of FCPA violations in additional markets have been brought to the attention of the agencies by the Company. The Company has provided and will continue to provide additional information to the DOJ and SEC, and will cooperate with the agencies&#8217; reviews of these matters. Law enforcement agencies of a number of other countries are also pursuing investigations of matters voluntarily disclosed by the Company to the DOJ and SEC. Discussions are underway in an effort to resolve these matters, and the Iraq Oil for Food matter referenced above, but whether agreement can be reached and on what terms is uncertain. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In March&#160;2007, the Company received separate subpoenas from the U.S. Attorney&#8217;s Office in Philadelphia, the U.S. Attorney&#8217;s Office in Boston and the U.S. Attorney&#8217;s Office in San Francisco. The subpoenas relate to investigations by these three offices referenced above concerning, respectively, sales and marketing of RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> by Janssen (now OMJPI), TOPAMAX<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> by Ortho-McNeil (now OMJPI) and NATRECOR<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> by Scios. The subpoenas request information regarding the Company&#8217;s corporate supervision and oversight of these three subsidiaries, including their sales and marketing of these drugs. The Company responded to these requests. In addition, the U.S. Attorney&#8217;s Office in Boston has issued subpoenas for grand jury testimony to several employees of Johnson &#038; Johnson. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In May&#160;2007, the New York State Attorney General issued a subpoena seeking information relating to the marketing and safety of PROCRIT<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>. The Company is responding to these requests. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In April&#160;2007, the Company received two subpoenas from the Office of the Attorney General of the State of Delaware. The subpoenas seek documents and information relating to nominal pricing agreements. For purposes of the subpoenas, nominal pricing agreements are defined as agreements under which the Company agreed to provide a pharmaceutical product for less than ten percent of the Average Manufacturer Price for the product. The Company responded to these requests. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In January&#160;2008, the European Commission (&#8220;EC&#8221;) began an industry-wide antitrust inquiry concerning competitive conditions within the pharmaceutical sector. Because this is a sector inquiry, it is not based on any specific allegation that the Company has violated EC competition law. The inquiry began with unannounced raids of a substantial number of pharmaceutical companies throughout Europe, including Johnson &#038; Johnson affiliates. In March&#160;2008, the EC issued detailed questionnaires to approximately 100 companies, including Johnson &#038; Johnson affiliates. In November 2008, the EC issued a preliminary report summarizing its findings. The final report was issued on July&#160;8, 2009. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In March&#160;2008, the Company received a letter request from the Attorney General of the State of Michigan. The request seeks documents and information relating to nominal price transactions. The Company responded to the request and will cooperate with the inquiry. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In June&#160;2008, the Company received a subpoena from the United States Attorney&#8217;s Office for the District of Massachusetts relating to the marketing of biliary stents by the Company&#8217;s Cordis subsidiary. Cordis is cooperating in responding to the subpoena. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In September&#160;2008, Multilan AG (Multilan), an indirect subsidiary of Schering-Plough Corporation, commenced arbitration against Janssen Pharmaceutica NV for an alleged wrongful termination of an agreement relating to payments in connection with termination of certain marketing rights. Multilan seeks declaratory relief, specific performance and damages. This case was recently settled and a charge was recorded to other income (expense), net, in the fiscal fourth quarter of 2009. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In February&#160;2009, Basilea Pharmaceutica AG (Basilea) brought an arbitration against the Company and various affiliates alleging that the Company breached the 2005 License Agreement for cefto-biprole by, among other things, failing to secure FDA approval of the cSSSI (skin)&#160;indication and allegedly failing to properly develop the pneumonia indication. Basilea is seeking to recover damages and a declaration that the Company materially breached the agreement. This matter has been scheduled for an arbitration hearing commencing in June&#160;2010 followed by post-trial submissions. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In April&#160;2009, the Company received a HIPPA subpoena from the U.S. Attorney&#8217;s Office for the District of Massachusetts (Boston) seeking information regarding the Company&#8217;s financial relationship with several psychiatrists. The Company is responding to this request. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In April&#160;2009, Ortho-Clinical Diagnostics, Inc. (OCD)&#160;received a grand jury subpoena from the U.S. Department of Justice, Antitrust Division, requesting documents and information for the period beginning September&#160;1, 2000 through the present, pertaining to an investigation of alleged violations of the antitrust laws in the blood reagents industry. The Company is in the process of complying with the subpoena. In the weeks following the public announcement that OCD had received a subpoena from the Antitrust Division, multiple class action complaints were filed. The various cases were consolidated for pre-trial purposes in the Eastern District of Pennsylvania. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In May&#160;2009, the New Jersey Attorney General issued a subpoena to DePuy Orthopaedics, Inc., seeking information regarding the financial interest of clinical investigators who performed clinical studies for DePuy Orthopaedics, Inc. and DePuy Spine, Inc. The Company is responding to these requests. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In May&#160;2009, COBI commenced an arbitration proceeding before the American Arbitration Association against Schering-Plough Corporation and its subsidiary Schering-Plough (Ireland) Company (collectively, Schering-Plough). COBI and Schering-Plough are parties to a series of agreements (the Distribution Agreements) that grant Schering-Plough the exclusive right to distribute the drugs REMICADE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> and SIMPONI&#8482; worldwide, except within the United States, Japan, Taiwan, Indonesia, and the People&#8217;s Republic of China (including Hong Kong) (the &#8220;Territory&#8221;). COBI distributes REMICADE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> and SIMPONI&#8482;, the next generation treatment, within the United States. In the arbitration, COBI seeks a declaration that the agreement and merger between Merck &#038; Co., Inc. (Merck) and Schering-Plough constitutes a change of control under the terms of the Distribution Agreements that permits COBI to terminate the Agreements. The termination of the Distribution Agreements would return to COBI the right to distribute REMICADE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> and SIMPONI&#8482; within the Territory. Schering-Plough has filed a response to COBI&#8217;s arbitration demand that denies that it has undergone a change of control. The arbitrators have been selected and the matter will be proceeding to arbitration in late September&#160;2010. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In December&#160;2009, the State of Israel (Sheba Medical Center) filed a lawsuit against three Omrix entities. In the lawsuit, the State claimed that an employee of a government-owned hospital was the inventor on several patents related to fibrin glue technology, that he developed while he was a government employee. The State claims that he had no right to transfer any intellectual property to Omrix because it belongs to the State. The State is seeking damages plus royalty on QUIXIL&#8482; and EVICEL&#8482; or, alternatively, transfer of the patents to the State. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In recent years the Company has received numerous requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the Company&#8217;s policy to cooperate with these inquiries by producing the requested information. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;With respect to all the above matters, the Company and its subsidiaries are vigorously contesting the allegations asserted against them and otherwise pursuing defenses to maximize the prospect of success. The Company and its subsidiaries involved in these matters continually evaluate their strategies in managing these matters and, where appropriate, pursue settlements and other resolutions where those are in the best interest of the Company. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company is also involved in a number of other patent, trademark and other lawsuits incidental to its business. The ultimate legal and financial liability of the Company in respect to all claims, lawsuits and proceedings referred to above cannot be estimated with any certainty. However, in the Company&#8217;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#8217;s balance sheet, is not expected to have a material adverse effect on the Company&#8217;s financial condition, although the resolution in any reporting period of one or more of these matters could have a significant impact on the Company&#8217;s results of operations and cash flows for that period. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 22 - us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 6pt"><b>22. Restructuring</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">In the fourth quarter of 2009, the Company announced global restructuring initiatives designed to strengthen the Company&#8217;s position as one of the world&#8217;s leading global health care companies. This program will allow the Company to invest in new growth platforms; ensure the successful launch of its many new products and continued growth of its core businesses; and provide flexibility to adjust to the changed and evolving global environment. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During the fiscal fourth quarter of 2009, the Company recorded $1.2&#160;billion in related pre-tax charges of which, approximately $830&#160;million of the pre-tax restructuring charges are expected to require cash payments. The $1.2&#160;billion of restructuring charges consists of severance costs of $748&#160;million, asset write-offs of $362&#160;million and $76&#160;million related to leasehold and contract obligations. The $362&#160;million of asset write-offs relate to inventory of $113&#160;million (recorded in cost of products sold), property, plant and equipment of $107&#160;million, intangible assets of $81&#160;million and other assets of $61&#160;million. Additionally, as part of this program the Company plans to eliminate approximately 7,500 positions of which approximately 700 have been eliminated since the restructuring was announced. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The following table summarizes the severance charges and the associated spending for the fiscal year ended 2009: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="52%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Asset</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Severance</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Write-Offs</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Other</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Total</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">2009 restructuring charge </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">748</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">362</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">76</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,186</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Current year activity </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(62</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(149</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(28</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(239</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" nowrap="nowrap" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Reserve balance, January&#160;3, 2010* </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">686</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">213</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">48</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">947</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="2%"></td> <td width="1%"></td> <td width="97"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left">*</td> <td>&#160;</td> <td><i>Cash outlays for severance are expected to be substantially paid out over the next 12 to 18&#160;months in accordance with the Company&#8217;s plans and local laws.</i></td> </tr> </table> <div align="left" style="font-size: 10pt; margin-top: 6pt">For additional information on the restructuring as it relates to the segments, see Note 18. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In the third quarter of 2007, the Company announced restructuring initiatives in an effort to improve its overall cost structure. This action was taken to offset the anticipated negative impacts associated with generic competition in the Pharmaceutical segment and challenges in the drug-eluting stent market. The Company&#8217;s Pharmaceuticals segment has reduced its cost base by consolidating certain operations, while continuing to invest in recently launched products and its late-stage pipeline of new products. The Cordis franchise has moved to a more integrated business model to address the market changes underway with drug-eluting stents and to better serve the broad spectrum of its patients&#8217; cardiovascular needs, while reducing its cost base. The Company accelerated steps to standardize and streamline certain aspects of its enterprise-wide functions such as human resources, finance and information technology to support growth across the business, while also leveraging its scale more effectively in areas such as procurement to benefit its operating companies. Additionally, as part of this program the Company eliminated approximately 4,600 positions. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company recorded $745&#160;million in related pre-tax charges during the fiscal third quarter of 2007, of which, approximately $500&#160;million of the pre-tax restructuring charges required cash payments. The $745&#160;million of restructuring charges consists of severance costs of $450&#160;million, asset write-offs of $272&#160;million and $23&#160;million related to leasehold obligations. The $272&#160;million of asset write-offs relate to property, plant and equipment of $166&#160;million, intangible assets of $48&#160;million and other assets of $58&#160;million. The restructuring initiative announced in 2007 has been completed. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 23 - us-gaap:ScheduleOfSubsequentEventsTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>23. Subsequent Events</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">On January&#160;20, 2010, the Company completed the acquisition of Acclarent Inc. for a net purchase<br /> price of approximately $785&#160;million. Acclarent Inc. is a medical technology company dedicated to<br /> designing, developing and commercializing devices that address conditions affecting the ear, nose<br /> and throat. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company has performed an evaluation of subsequent events through March&#160;1, 2010, the date the Company issued these financial statements. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="margin-left: 0%"> <!-- BEGIN PAGE WIDTH --> <!-- XBRL Pagebreak End --> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 24 - us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock--> <div style="margin-left: 0%"> <div style="display: none"> Schedule Of Valuation And Qualifying Accounts Disclosure </div> <br /> <div style="margin-top: 18pt; font-size: 1pt">&#160; </div> <div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #ffffff"> <b><font style="font-family: 'Times New Roman', Times">JOHNSON&#160;&#038; JOHNSON AND SUBSIDIARIES</font></b> </div> <div style="margin-top: 6pt; font-size: 1pt">&#160; </div> <div align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #ffffff"> <b>SCHEDULE&#160;II&#160;&#8212; VALUATION AND QUALIFYING ACCOUNTS</b> </div> <div style="margin-top: 6pt; font-size: 1pt">&#160; </div> <div align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #ffffff"> <b>Fiscal Years Ended January&#160;3, 2010, December&#160;28, 2008 and December&#160;30, 2007</b> </div> <div align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #ffffff"> <b>(Dollars in Millions)</b> </div> <div style="margin-top: 6pt; font-size: 1pt">&#160; </div> <table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #ffffff; text-align: left"> <!-- Table Width Row BEGIN --> <tr style="font-size: 1pt" valign="bottom"> <td width="53%">&#160;</td><!-- colindex=01 type=maindata --> <td width="2%">&#160;</td><!-- colindex=02 type=gutter --> <td width="1%" align="right">&#160;</td><!-- colindex=02 type=lead --> <td width="7%" align="right">&#160;</td><!-- colindex=02 type=body --> <td width="1%" align="left">&#160;</td><!-- colindex=02 type=hang1 --> <td width="3%">&#160;</td><!-- colindex=03 type=gutter --> <td width="1%" align="right">&#160;</td><!-- colindex=03 type=lead --> <td width="5%" align="right">&#160;</td><!-- colindex=03 type=body --> <td width="1%" align="left">&#160;</td><!-- colindex=03 type=hang1 --> <td width="4%">&#160;</td><!-- colindex=04 type=gutter --> <td width="1%" align="right">&#160;</td><!-- colindex=04 type=lead --> <td width="10%" align="right">&#160;</td><!-- colindex=04 type=body --> <td width="1%" align="left">&#160;</td><!-- colindex=04 type=hang1 --> <td width="3%">&#160;</td><!-- colindex=05 type=gutter --> <td width="1%" align="right">&#160;</td><!-- colindex=05 type=lead --> <td width="5%" align="right">&#160;</td><!-- colindex=05 type=body --> <td width="1%" align="left">&#160;</td><!-- colindex=05 type=hang1 --> </tr> <!-- Table Width Row END --> <!-- TableOutputHead --> <tr style="font-size: 8pt" valign="bottom" align="center"> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom"> <b>Balance at<br /> </b> </td> <td> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom"> <b>Balance at<br /> </b> </td> <td> &#160; </td> </tr> <tr style="font-size: 8pt" valign="bottom" align="center"> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom"> <b>Beginning of<br /> </b> </td> <td> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom"> <b>End of<br /> </b> </td> <td> &#160; </td> </tr> <tr style="font-size: 8pt" valign="bottom" align="center"> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000"> <b>Period</b> </td> <td> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000"> <b>Accruals</b> </td> <td> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000"> <b>Payments/ Other</b> </td> <td> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000"> <b>Period</b> </td> <td> &#160; </td> </tr> <tr style="line-height: 3pt; font-size: 1pt"> <td>&#160; </td> </tr> <!-- TableOutputBody --> <tr valign="bottom" style="background: #cceeff"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> 2009 </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Accrued Rebates<sup style="font-size: 85%; vertical-align: top">(1)</sup> </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 1,808 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 6,584 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (6,753 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 1,639 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Accrued Returns </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 794 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 355 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (460 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 689 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Accrued Promotions </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 356 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 2,446 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (2,373 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 429 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="font-size: 1pt"> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Subtotal </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 2,958 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 9,385 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (9,586 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 2,757 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom"> <td align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Reserve for doubtful accounts </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 267 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 110 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (44 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 333 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Reserve for cash discounts </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 79 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 1,163 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (1,141 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 101 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="font-size: 1pt"> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> </tr> <tr valign="bottom"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Total </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 3,304 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 10,658 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (10,771 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 3,191 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="font-size: 1pt"> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> </tr> <tr valign="bottom" style="line-height: 9pt"> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> 2008 </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Accrued Rebates<sup style="font-size: 85%; vertical-align: top">(1)</sup> </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 1,802 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 5,578 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (5,572 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 1,808 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Accrued Returns </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 648 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 402 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (256 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 794 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Accrued Promotions </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 578 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 2,991 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (3,213 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 356 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="font-size: 1pt"> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Subtotal </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 3,028 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 8,971 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (9,041 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 2,958 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom"> <td align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Reserve for doubtful accounts </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 193 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 101 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (27 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 267 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Reserve for cash discounts </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 71 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 905 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (897 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 79 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="font-size: 1pt"> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> </tr> <tr valign="bottom"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Total </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 3,292 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 9,977<sup style="font-size: 85%; vertical-align: top">(2</sup> </td> <td nowrap="nowrap" align="left" valign="bottom"> <sup style="font-size: 85%; vertical-align: top">)</sup> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> (9,965 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 3,304 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="font-size: 1pt"> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> </tr> <tr valign="bottom" style="line-height: 9pt"> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> 2007 </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Accrued Rebates<sup style="font-size: 85%; vertical-align: top">(1)</sup> </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 1,691 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 5,243 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (5,132 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 1,802 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Accrued Returns </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 599 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 395 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (346 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 648 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Accrued Promotions </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 457 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 2,908 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (2,787 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 578 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="font-size: 1pt"> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Subtotal </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 2,747 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 8,546 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (8,265 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 3,028 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom"> <td align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Reserve for doubtful accounts </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 160 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 42 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (9 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 193 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Reserve for cash discounts </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 62 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 1,022 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (1,013 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 71 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="font-size: 1pt"> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> </tr> <tr valign="bottom"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Total </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 2,969 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 9,610 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (9,287 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 3,292 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="font-size: 1pt"> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> </tr> </table> <div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #ffffff"> </div> <div style="font-size: 12pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"> </div> <div style="margin-top: 3pt; font-size: 1pt">&#160; </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="text-align: left"> <tr> <td width="3%"></td> <td width="97%"></td> </tr> <tr valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #ffffff"> <td> <sup style="font-size: 85%; vertical-align: top">(1)</sup>&#160; </td> <td align="left"> Includes reserve for customer rebates of $729&#160;million, $721&#160;million, $710&#160;million at January&#160;3, 2010, December&#160;28, 2008 and December&#160;30, 2007, respectively. </td> </tr> <tr style="line-height: 6pt; font-size: 1pt"> <td>&#160;</td> </tr> <tr valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #ffffff"> <td> <sup style="font-size: 85%; vertical-align: top">(2)</sup>&#160; </td> <td align="left"> Includes $171&#160;million adjustment related to previously estimated accrued sales reserve. </td> </tr> </table> </div> false --01-03 2010-01-03 10-K 0000200406 2751927062 Yes Large Accelerated Filer 156000000000 JOHNSON & JOHNSON No Yes 2237000000 2028000000 3367000000 2497000000 61544000000 70368000000 738000000 593000000 541000000 7503000000 5541000000 9719000000 9646000000 417000000 442000000 5531000000 5796000000 -4955000000 -3058000000 268000000 333000000 678000000 0 0 84912000000 94682000000 34377000000 39541000000 2041000000 3615000000 4083000000 7770000000 10768000000 15810000000 3687000000 2998000000 5042000000 1.62 1.795 1.93 1 1 4320000000 4320000000 3119843000 3119843000 3120000000 3120000000 11996000000 8660000000 14163000000 17751000000 18511000000 18447000000 -19000000 -19000000 9000000 0 2000000 -1762000000 22000000 -436000000 3430000000 2793000000 5841000000 5507000000 1432000000 1424000000 2777000000 2832000000 2774000000 -4670000000 -4670000000 -5024000000 -5024000000 -5327000000 -5327000000 3.67 4.62 4.45 3.63 4.57 4.4 275000000 -323000000 161000000 1432000000 1606000000 13719000000 14862000000 43344000000 45236000000 43450000000 13283000000 16929000000 15755000000 4099000000 4068000000 2363000000 2707000000 3980000000 3489000000 2642000000 -272000000 -507000000 -416000000 -736000000 453000000 14000000 -101000000 95000000 -1578000000 -1600000000 1209000000 564000000 984000000 31000000 13976000000 16323000000 296000000 435000000 451000000 314000000 525000000 533000000 5052000000 5180000000 452000000 361000000 90000000 42401000000 44094000000 84912000000 94682000000 20852000000 21731000000 8120000000 8223000000 -5698000000 -7464000000 -4092000000 -5912000000 -4187000000 -7598000000 15022000000 14972000000 16571000000 1388000000 1214000000 2470000000 1620000000 1328000000 3345000000 -232000000 -114000000 -875000000 2634000000 3690000000 670000000 670000000 670000000 -1870000000 -1870000000 -1870000000 565000000 565000000 565000000 -54000000 -54000000 -54000000 166000000 166000000 166000000 24000000 24000000 24000000 786000000 786000000 786000000 -2499000000 -2499000000 -2499000000 1363000000 1363000000 1363000000 5000000 27000000 23000000 23000000 23000000 -59000000 -59000000 -59000000 -55000000 -55000000 -55000000 4206000000 5947000000 -534000000 1015000000 526000000 368000000 83000000 109000000 5607000000 6651000000 2130000000 4670000000 5024000000 5327000000 1388000000 1214000000 2470000000 9659000000 3668000000 10040000000 2942000000 3066000000 2365000000 7791000000 6769000000 0 0 2000000 2000000 2000000 2000000 0 0 5100000000 1638000000 9000000 7988000000 3059000000 7232000000 457000000 785000000 154000000 19626000000 8430000000 9484000000 1562000000 1486000000 882000000 10576000000 10576000000 10576000000 12949000000 12949000000 12949000000 12266000000 12266000000 12266000000 14365000000 14759000000 22000000 86000000 58000000 18000000 24000000 219000000 21691000000 7319000000 6791000000 7680000000 7577000000 6986000000 807000000 181000000 0 745000000 0 1073000000 63379000000 70306000000 61095000000 63747000000 61897000000 20451000000 21490000000 19801000000 698000000 627000000 628000000 3732000000 6318000000 39318000000 49290000000 3120000000 -2118000000 -10974000000 43319000000 3120000000 -14388000000 -693000000 55280000000 42511000000 3120000000 -19033000000 -4955000000 63379000000 50588000000 -19780000000 -3058000000 3120000000 70306000000 -24000000 -24000000 -33000000 -33000000 9000000 13000000 -4000000 0 -1000000 1000000 2000000 -4000000 6000000 2311000000 131000000 2180000000 2180000000 175000000 2005000000 1402000000 25000000 1377000000 350665000 365522000 19033000000 19780000000 -5607000000 -5607000000 -6651000000 -6651000000 -2130000000 -2130000000 2910700000 2835600000 2789100000 2882900000 2802500000 2759500000 EX-101.SCH 13 jnj-20100103.xsd EX-101 SCHEMA DOCUMENT 0620 - Disclosure - Business Combinations and Divestitures link:presentationLink link:calculationLink link:definitionLink 0701 - Schedule - Valuation and Qualifying Accounts link:presentationLink link:calculationLink link:definitionLink 00 - Document - Document and Company Information link:presentationLink link:calculationLink link:definitionLink 0606 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0619 - Disclosure - Selected Quarterly Financial Data (unaudited) link:presentationLink link:calculationLink link:definitionLink 0612 - Disclosure - Capital and Treasury Stock link:presentationLink link:calculationLink link:definitionLink 0611 - Disclosure - Savings Plan link:presentationLink link:calculationLink link:definitionLink 0602 - Disclosure - Cash, Cash Equivalents and Marketable Securities link:presentationLink link:calculationLink link:definitionLink 0610 - Disclosure - Pensions and Other Benefit Plans link:presentationLink link:calculationLink link:definitionLink 0617 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements link:presentationLink link:calculationLink link:definitionLink 0614 - Disclosure - International Currency Translation link:presentationLink link:calculationLink link:definitionLink 0607 - Disclosure - Borrowings link:presentationLink link:calculationLink link:definitionLink 0609 - Disclosure - Employee Related Obligations link:presentationLink link:calculationLink link:definitionLink 0616 - Disclosure - Rental Expense and Lease Commitments link:presentationLink link:calculationLink link:definitionLink 0604 - Disclosure - Property, Plant and Equipment link:presentationLink link:calculationLink link:definitionLink 03 - Statement - Consolidated Statements of Equity link:presentationLink link:calculationLink link:definitionLink 0623 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 0621 - Disclosure - Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 0622 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 0613 - Disclosure - Accumulated Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0615 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 0618 - Disclosure - Segments of Business and Geographic Areas link:presentationLink link:calculationLink link:definitionLink 0605 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink 0603 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 0608 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0601 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 04 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 02 - Statement - Consolidated Statements of Earnings link:presentationLink link:calculationLink link:definitionLink 011 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 01 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 14 jnj-20100103_cal.xml EX-101 CALCULATION LINKBASE DOCUMENT EX-101.LAB 15 jnj-20100103_lab.xml EX-101 LABELS LINKBASE DOCUMENT EX-101.PRE 16 jnj-20100103_pre.xml EX-101 PRESENTATION LINKBASE DOCUMENT EX-101.DEF 17 jnj-20100103_def.xml EX-101 DEFINITION LINKBASE DOCUMENT GRAPHIC 18 y80744y8074404.gif GRAPHIC begin 644 y80744y8074404.gif M1TE&.#EA.@&2`.8``'1T=.CHZ,_/SW"*DB_O[W]_?Y24E(BKMM;6UHF)B5%14:FIJ;:VMM_?W[FYN=KI[I&1 MD8*"@H6%A4MM=V]O;Y^?GV!Z@7*6H3)UB=G9V?CX^`4%!5&8KOO[^Z'(U/;V M]GAX>/KZ^FEI:=#CZ45%1?'Q\<;>Y;^_OS)B<)"^S//S\_3T]#X^/AIVDD"- MH^SL[*S-U^+N\E"'F#$Q,LO@YXR4EEZ@M)R[Q8V[R/3Y^O#V^,+)S#!<:K74 MW72NP)G#T"Z!FK/2W/[^_H:XR#:(H&2DN+_9X*VMK9:YQ-[L\*VNKLC4V-#7 MVIRPMY"BI[S4V]WEZ!)MB;#0VB)PATM@9Z3(TVRIO`%GA?___R'Y!``````` M+``````Z`9(```?_@`8=@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F-,G^=GI^@ MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>K#S\_%G]I)$ZP*4(E#IT&/>CQ\O/TU@\M?P$` MG2$U]?\`:NLXPFK2LV8`[>S[]\X#(#"*]_T`] M:`!AA@$!,ZPXF1'"P@P'#S"0/4NXL+D#,V+^>>+3TY$(!`B$8L+"RHP.=7_\ MP=#!P8PT?U@:'DV:5)@DJ%.K1AU+Q@R-?T3,$'+DP)^"BS\?P/T'Z.8.>!O\ M9NS/=^GCQS?T69\RLB3,6+)D!HH_+#!L)J!A!H_-1C&(N'(Y\^^ZU,>\S%%^&%&%XS(87/@;*##2"&*"*(&99HXBH;4FAA)V1PV!PH'#A43`#^ ML`("!*`$4)$H3,1PXH]_^+#!D$06N<$6GZ3XWO^*?[3HXG*@V"7*$R3(\D,( M?PSQ5RM+@-/)#02@M(0HG`TS@29HIJGFFI-0\60?+Q3RPIM3&#+GFX1P(F4H M&!@0'1&=.,&;*EUZ@L,,`D!P`9D=`'FB&6_:D.2;3#KY9)0&#"'""!IH\``% M5_D9!P\\5)$&!3BHX,`/.JA`!`!"@&`%$1J0`$%7.O0@@F84:$"$!S4\(`$* M1.AP1`D2T!I3H9T<2H$P)(A`*XYE1M!I3`U(*T&-KOR`XQ]Q./"MH^9`^J2D MGB@)'RB6NH@I!]-5Q0(3XE$0PPP1/($!!"A<%<%(-,W@;0@C$,'#`5$]T<,, M+=`+0`@S.#%!7H=.T$3_"E7P,":S?R`\@PC"C6#`!02(\!MB3U0U!`\B5)'" M*VD8<.`?/Z#0``[^D5N.N2ZBVXFZS57Z9A_O"OP'$>#TF=L@,SQAP`R*23/BGTFXL?#0X!2TP`PEA.%$`"5SUE/NH2%$#_QZ$>N-:" M_P48%*#"#":$??K5)"QA=NL2:```#S/T0(`$%[C-&6(`D%!`$RQX`JBJU(KO M_,$!`C#@#_9F/&T,CD*%.]QREG>I3TC`!-\@2@CRTP`K4.,'5AA/"4RP#_VH MY`@28((%1%``#V@D``4H0``D(!P0BN`":6""EV@(`1%(P`'[N$)^.D$"';!0 M,R,0`0M:H!&P_8$"(<1!#UH0P@[DC!4>(,$0.L`!`7*@`T-HX#8>^)X(4BIQ MS!.C*62``@=0X`\Y0$$6U>A`Y*7KC)]H%X?HR,>-D-$Y9E0>&BOXB1O(J(^( MK..YDN4 MULHGSH`#1,#`H$K`&?,<#72>Z(YFEJ`!*DIF"!20S@08@R/R`,!'(1W-2$O: M,T8.4Y7%9*6?MO2#&1R@<9__H"D8\=4)#)30$QTP72('I)+`$ M)USI<@_PS`0NUPDWQ($)!,#26PD3UT[,M0]U7=)=WP,*#2SJ`"+`@";_4`#8 M>.(`&FA'$U)+``.`YA,.`%T%1`"]#C2!!T`AP@\H`#H'4(<(2-VL63K[A\^& M=ETI3:,OF3"!ZEKWNMC-KG:WR]WN>O>[X`TO>.D@A?*:][SEC<-UA_8!Z\;A M`V]JKW7A^R;LTO=)UKTB(F_`@?[Z][\`#K"`!TS@`AOXP`A.,(+M,+0[_'=H M2/AO_Q#>E('_\H%2`$;"T/Q[VT3>8!`1"GC$\Q6[`84,#@D/&9LB`(=LA>I:4*4)&"!E)3YQBM]$4KGFTW#[ M9)%*/V&`!U3@C:*PY.M\A(]GI,#'KI`!`$#ZB(WH=@3*GZR!#ODXE5V(@7)'866/]%E6I2`*64.,:$CFHH`+"H6$Q"! M"(IGA4Y,8%R)K/.3[MR)/)M4GRCEYY0[<"9`@;$X<`4#;#(`*O"`6QW``C(?T`,LL,D3'/_0`="@^0\32+5] M+(""!U@@!)CIA`Z"S(HTO$QX%UA+B380A'*;^]Q!V,`G-.TB3O_!TTT]:2K[ M'-4_],"M4].,"F10`Z,XH""`^4%)"@T.=O[A`KIH!P0H8`(<=1@'-_@#"F1P M:$^,0#B1^U0^KO-L3@QA'SH`J0YND(;;7J$"L4#Y%ED;@!M.9R4PE'(M%2V^\=F((CRZ!9BQI%$M.8`0";XJL"]X)&41@%U.;``?DF-PA M.J$"%>]$`3@1N120F>E^$L`%W*"11@W/`P;_`P!V](H1.&".!U"!`;!\(IF[ MB.:>8#>'W`UOGR<@T`ZU*Y<4=N<0WCNA=PKQ'>=._C240RUEZ7;B M`IH1NM)EW8D(.``%3TB#XI<^-1V8``/P$?F"`?'FB`2&XP,L@WX-SUN0/ M*9@``.#Q;`",0`4O,[NM4V`?"BCZ]*!(/856'R2;=QKVGM5SE)LT:I'TCA0U M@+DHA#**&LA(!A$G"C4P9W]`@)_0`_HW!/[1`/>'?NGW)NS7>N_Q>D_29/$G M>WM&3#[''AWF@`\XQYH(NKW'A'H?N\&?\TE?[1' M?RJX@C$'_X$AN&DCZ"(6.(,8.'_])'@XR((ZF'',D&'OQ!FKSYH1^!H5(H09O@@99>(2LEX0RN&), MR'-D6&]F>!1H^"1JZ`E:V!QZ(,E6$8GCY1PA50&1DXB*N(B,V(B. M^(B0&(F2V(@(\"9>H(B5^"0(H(A0,#1BH(A#,#2) MJ']TA(B3&(NR.(NTZ(B9Z"*B&#FWR"&;F(B=^":?F(BAJ(BD^"2FF(BHJ#RJ MR(J1XXIU*!%WZ")YV`E[R!Q]V&X]R"$_"(=B"'ASN(&^=&38I/\"-34B/9=@)26`&4!F59@`'QD-Z^0``+M2!\I``4MF544F5 MGD"1SF&1+-F&+JF$@AB'*,B4=-@);>`'#V/B'VAB(@#2(B!-X"@G_"F\IEW!)EZ'`&[PA`P(0:,^8"GSY M)GX9ED%)C4/IAC#)C1[IC6P)CFX)F9&999Z@90Y0`H"3F:JPF4_2F9T`F,PA MF*I'F.YHF/"(F*>DF!-$D\PA"H\)F9()"EJF9<4CFZQ`FRYBFW^`F\NAF^O' MFP/IFP4)G,$DG'SVC43X"<H8FF?YAO)HFB#9E'\P MGG'YGY8&#TX'"@>PG@8Z"NY)(?"IH``ID/:IG?C)G73EG1H8GIX`!B?PHC!Z M`F`@@#@@""#E_V4A\'(A8!M0.).>\*'O$:)XN)*#V9)^J)%'R9%)^0=3H)J0 MJ0#$"24=>@L^ZI0(ZIE#*I1EB9%'^I))^@==4`1B.J9D6@13\`E-ZJ1Q":6, M69-36@M5^@=`ZAQ"*HU$NIM&6IA(>IB>L`!J&I=8@*9_"I=LZ@E\L`"(FJB* MBJ@A=2PE\*B0&JF2.JF46JF6"JD90"F1*@=#DP61NHL4`@616HPN$@61F@5# M,P>1.C2B"JE&,*A^L`"1B@6PJ@"22@6PZ@>0JI4`P:O+<"9L,@EWXB)U0@@J M,#0#4`AN\B1Q0@C+ZB)44`@#,#0I4`A=<*W8FJW7FJR$H`>P"@.%`/\#N6H( MX@JK>>()<(!>Y86%H6`?H$!WJD`4%%"@IB``'&H6"9"O^KJO^7I/:DF(/WJE MMRFB#-JEN8H`G^"G@QJHGI"F?UJHG8``N2H*)P"BHA`2^0=D:9`K)5"P:@JQ?R"QL$JQ%AL*(6$!;N0`-2`"%I`# MT11\51`!/>!&3W`$%3`!XP,"*;"A4S,@$=$!%.`!('`$%#`"%F"OVD!B+C=8 M_-9LLK"S!SF//LL<0.N/0DN?GI`':Y"XBKO_N(F;!)]PM'V:M((ZJ$X+M8,J MM4%ZL31C$R'Q#$V``P)P!3%@=%-C$R#@!HT2$B'1>9;#:#\0$C%``A=@M]K0 M`#8K!"JQ&&SW"GZKG[07N,LQN!7Y"0RPJ,;+`+^4J^QJM+"*L)&[L)/[L*!@ MN7^*N72JN3_`N;(&`1'07S7`%"%1`@(0`A#P1=!VOKE;/'[RNN8';;2;#0%` M=AS0$D_`HY^`!OB;O_J+O\O[![V[I'$*O'T@O&/Y":\ZJ$:0O+#:OY#;"0K[ MITK+I+4ZO1,;"A6;N52[N>>+`Q`@`U?0!!YP!.!;NAS\!(V"`AP0$DR`=.I+ M,Q-P`4W@`+,KL]9`_PT&E`*\RES_NX1**8=R*K#3J:`'_*<)+%?*^[C-B[30 MV[`3_`G4JZ;6^[.B0&)"$'%XRP0`V``5(6,D!H`RH,45`0(5(&,Q(`#^4!%" M$"-Y6<4&6`V^UWP]&0(A,&@FVAP_N,-IV<-K*<`$')@&#*M%[%E'[`D-_`FZ@`6,>\OL)\I.2LIF8,I_4,B'[*2) MW,2>\,1.FIFQ[+N`"\1G`*O(ZPFZK)J\[,O`O,I+2\P1V\AFF,P`'&6TW/\) MS3RHSQS*@*S`@\K`2?R\$!R]3>O*EPO+,HC'B?FOBVFEG/D)X?RGX_P'T0R9 MT[S`2(S*2KS.K"R]3JS-4,C-/%R:/^:RF^]S/?@.5*SN.$ZN-6W>5"_N7I'>:$/>9( M7N:0J=A,_K1.G4@-4%U53#_0=;3IY\KIH&GMREO-R_ M#--)?>?8C.C3C8-EFNI%\`5UGN6+G>D5NNF0V>DDCN`FWM7-_=5T+=SBG>81 M;H:%3.F[;NF]CND_#LY8S<\'_ND)'NI>/>J5CN=^(-UJ7H3![NI,#NNK">3) M+O_4<4G4MZ[@9)[BA;[B'2[?Q_R,UT[JKW[L?Q#DG#[D_ESD\[MQYW5M<[LX>[LN0[MPR[MU/[K4.CO"Z_E[@[OLR[O0TWO M<6GO[R_P[SB;Z"(F_F)(_F.:_6LBZ7M`[FMB[FN([BNF[S M#(_N_*[N-(_MEZ[M<[GT<=GT?_[T@1[UXS[U1G_S2/_Q#C]*U`5>59"K2N!> M>`"K9W!=2E"KZE5==9"K+W!=WCJH<6]=Y?JG,.`&UO7_`KE:!];E!G#O7H.O MIG5O77=/N7E?79,_J(8_`?KE@45?[F=^[N,]\3R_\M0LZHCM^4XNGN2VG@!)UW`;U@ M`.X*"K0/J,*?YZ&O\Q3/]!;_[1@/EQH?EQQ/]?H^](G4*"T!?:+P_'!I^\7. M]00>[WY.Y("^WH)^[X0>_)\__*M?_/+4*+DK`-L$"'^"@GZ%AH>%"(-_18B. M6(M3CH@*BUN3B$B+9YB&#(M&G85&BV:BA2>+IWZ*@PNGD(.2HI6+"*N+N;J[ MO+V^O\#!PL,=?U=I?Q0HNZNM_X*-HK&"LYVU@I>GFH.GP_+S]/7VO<4@!18Z`/($&6$`1B@K]_H@)"ZR3M#S5,[K")0OA'(2:&?QQB M@OA'8B>*?]"YPCA-HRU<(9,J77I/Z#.B+HU>.[CI%$Z=DWCZQ`34Z1]U+`E6 MVXB4J=FS:%59'+024\N7DV)2W685U"FMJ[JN%036K5B89..E'4PXI->VD]Y* M_2.S$TV;DZ[>+957;M(;K:JW>R&HUS.`?1/_ MC1NX(__HV[A1OEZ$^-'LT@9/TTW];?*XRN?V?AV]^`_'3KFC1Q>=N>CFJ<(3 MUBV^^GCKY)>'5H]Z_5U9Z>@+4P^K>>R@QI@>;V]H/"+RBN'Y,B_O_'SZ_V>M MYU=[@+TWEW;$T=>=?=_AMYMX[%GGWB#/80+@A0$JUQLBBI4'WR3R)9A3?3W= M%Y1RL?E&(&V223#;IY)-01BGEE%0B.<:56&9YI0M)`J'EEUPBZ<*76@*1)!=D:CE`DBND MB6681[;IYA@K)#G`G%=RD22>8\#9@IQN^CGFG&8F.>B<2,K_`..BC#;JZ*.0 M1BKII)16:NFEF&:J*5II/(%""DQL*NJHI"HE@`I_Y*"#+S*XX<$!?]QP@01P014])$-N`[RD\8.Z@C1@`+V\ M6(OM'T)$\$2OI>86P06":)#M+@88`,(2'(3@`!-$#,&+%3%,D,(?(8S0A!7U M:G!`"RA4H,.JN]P@P1$J-#"$`1P`4,$N-5P1P`5/<(!"#2PXP8L.#UA0@"`U MA"!"+U<(T$`(?Q100@D$ZQ)!"$?P_Z"H$P74J@L+`OQ03`4E-(`#+W$8((0( M/3P@`@<\A+H+T$+_(0(%)&A0L,$(_Z%P+P`($@(%5P@"`+>ZC"P("W^@[/$N M($0@"*I_(+[+"`+\(A"#H>D``D-@0?X& M<0,1W`!ZD>/%`4)0`PIX(`<`:``'-BD(#EQ!!B`(@1":\`<2M(`760O`T![P M@Q\0(8:YJ$$!./!(&331`I[3A>]JT(\T_L$$=-2%"(Y0`0-*P&*&1WQ`&@K0 M!-_]X0G\TT4N=Q<#'%3!D(NZ'.&.(`(+^(()!6`!!WFVCU[H`P`$ZZ,N+B`! MIE5``@#]GBX@(`$="*$'+"A`"JB5BP#H(&N+:.0N#B"!`L`*!SKHP`IW(804 H%`!952A`,7AQA`+HH(DRX%Z_`/!1@!5`!)KDA4,AR@$)5$X7@0``.S\_ ` end GRAPHIC 19 y80744y8074406.gif GRAPHIC begin 644 y80744y8074406.gif M1TE&.#EA.0&5`.8``+^_O^3DY#GQ]%]?7QUXD]'1T;&QL5B*F;:VMM;6UMG9V2HJ*LC(R)24E`!!5,7%Q7Y^ M?AL;&ZS.V:&AH9&1D8B(B$Q,3+FYN?O[^YB8F%MH:V1D9$!XAX2$A(&!@6V. MF*^OK_CX^+_9X)+`SGEY>5-34_7U]?KZ^HFZR=[>WF]O;X^/C_#P\`4%!>?Q M]//S\[G6WSES@\[.SO3T],K@Y^KJZNWM[>?GYTF`D$)"0MSHH>4ET"-HZNKJVEI:8N+B\C6VUI:6O'W^5F1HG^RPAMQBMCH M[1A=<1118BQ79&QL;&VJO-3FZY_(U%._O[[/3W+_2U]/CZ&:GNEN=L0%E M@@IMBO[^_@%5;=OJ[SZ.IMKI[FRGN0%@>U>>L]#DZGZTQ.[N[BV!FK/&R_7Y M^D1N>Q-MAZ#"S&RFMY&6F&&AM-?H[9VZPZ+)U0%GA0%+8/___R'Y!``````` M+``````Y`94```?_@`R"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F(PI?YR=GI^@ MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMJD`!;J<*18.M\#!PL/$Q<;'H1(```Q_ M`!T'+3#(U-76U]C9K!5.?Q^<(#O:X^3EYN>N)A+>G#L M/_*S*B:@4YF.D%$.6JBC)0B4Q6`":.#A0@Q<^KT1/*!"DX/*-C0\&LEDZ$B_E30 M8$/@0!LSFNIS:$;`R9U8LVKMI$+`4)P@D``1(!#B!!L[0-@(0,&$#P"=_R:Z MJ&"CQ0,;/@Q0"+"UK]^8%3[8`(*#A%<*?R`F:.JUPPD;`KH]K?B!P0L-3ES, M^,NYY=ZD%7X(+ M'TZ\N/$O6WS_@?*!@!`-7BBXZ$`!=88`-IJ(:!(!"@T+&I@\G='SCX.A-92K M!W6#C_OW\./+G\^GA_(=35PPF/`G@@L"($1$P"9#0.%"!B$P86`'G0#1`A10 M%,2)!@"M9R$G[=&GX8;U77C+#B10Y*&%&7)H(GSVU1(%&BRVZ.*+,,:(QASQ M#&$"$B/&0L1Q//;XQ0HTUE+BB2>F2(L;1"9Y`_\L/#BP0WK$1#"$)PC\E*,H M.21YX@91V#*DEAH:.0N28'*XI"L'/`=91L+84$`G"`A@P958EKDAEU[:N:&8 MLI"IYWQGLN)%4P!(0`".PVCP)B=F&``$2#1$*NFDE%9JJ:5[_#F?'7AU'#:"2$H)8``<)EA`@50'.%!`4[XZH`0 MTE4DQ`,"?/#"'W4)(8`/0$#Q9@7.TD`G)UFJ^AZ>0FJ+HBU^>AOH*L^9)P@! MRWW@@`8=(&$##4[8`$(*&DA``@459,#0$0=P``(%)#"K@0@4?&,#!2*\*P-$ M0-A`PA$1]7,`7'\8D$7_!;5DZRVWM'RI*I^QA*OMN*H(%@(",RPTA`9"I,P` M#1IP(D`+'&@`Q`P"/8;`'S5TP(`&!HO70B:`#\`'!'` M"5[0HK&V',_B\:@@PR*RJB2G8L%JG/PL@08,Z`*`$XC91L`/+'^`D[YE"Q"! M$`9O`C.S;T*4=`G;0,4*5@;3P?-$$` M`RI\\X<,$""" M__`)`-W"9@<#7.NQWH@0P`=)>4_!"?)\D!(3!MC_QPZ*SW+\J,F#Q?+TU+Q6 M/.]/T0L&9OX0``'L3A0VV,160$";$_C@``DP0P9PL#C&!?`5`[13`5EQ0#TE M$!CX@<+#8"(*%]1C*P80`<4,8`$)^8]Q?/B@*T)8IA&NHH1V.N&U=/(_3>FP M%3P$DP]5`<0R"7$43&!(9&I5BAFX8(C$*.*?CLB*)&IIB:EH(IB>*(H"V(`# M&8"**5)@-"P*0XMZXN(JJB"&.MKQCGC,HQ[%P`5PX9`/9`R%&2F#F"',@`3\ M"8$(7O:`"B1@3B$X0=HX<0(,$(`$/G"C*^!H)SFJ8O\+70BE*$=)RE*:L@LL M\",.`PD*,QJ@="UX`06:X('!9$``]!)`!1@@$&<10`-STL`L;5`A3:YB`RQ( MIC*7RP07>:\8'-\!('XOR# M;([VA^\9DQ5O:(,\YTG/>MKSGEI8@"VF:`H2:T) MTGTNM9\FG<4&GFI--\A41/K_\@%X#F8C"GA%`SL`Z@&8(H2J%;6=1T7J*91* M55,V59IMI69493'5N)K2JK&@XA]4`(<)O<.FO.&$"J"D5E>PU:ZB?"LM1HK8 M4,XU%G5MK"CQ"HP35,8%)K#2M73!VT`)"O*,20AM*A-;0&20%I1 M#D"UL.TL!T;;VBZ<-K:>95-AKW'8QBIV%HQM[&-A$5G24K85(=!K9S0+BQHP M5#(98`#&:-%;Q/Y6%BLH@W:WR]WN>O>[9.N`@$B>`MA/X&N3M#& M`S)PP#L6]8H$%*!JGJ#-)PYP@!JTMQ0`T"\LAI`"+Z3'`QB`@S1HH84T./C! M$(ZP_X0GW(60DF(%?59R`'S]0KB8+$I++`S6.P@`0[XB5-2L(Y9+.'#2$YR'QJ@!EM@6,E0 MYG"(:T'>QI88%1.@6$$D$($..$&O#+"`$_A3D!>_J2`RL(`%*N(`$)C@)!/X MCHS_@`&;^``'0D@`TWQ0``ML1@5'H`$^<+R9"-"@`S^I@`4"D`(3I*!69IC3 M@$W@`=P(;QFT.'*4-\UD)V_ZTU.F1941>^53<(`??W@3`,2#A!]T,C3M!@)^\B0"99`(0"/_]AY0X@#:'^T,+ M/E&\6'3#*4R8DI$_'>5.U^+)W%9RJ&?QA@:8^]SH3K>ZU]V`Y+3"49Q0-5Q: MTPD6+WK6,H!QJA&PJ`SPFQ,TGD`+,LL)!%#,:,..M\(C)H-E`"#'%>N`"-ZT MJ!1PIQ,>B`4(7A"`S13@`3Z8`0MCH>EP(]G;M`"WR3\\;EFL8>5)KH(K$("3 M5#MCWFQBL0A4@&]]WS/H,7 M)&4"%/<$#3"&]%C(X`@)V%FCCJ#M;>$,$L`!N+P7`<_^`VTBD`#__`F>$RVH08`Y@(%.6(`)'%!&X`&"`C!/BQ2\KAG..W8=;V4;0%WV6=X M[LBU@.`ZHVN0M-[UL(_%VEWO=EC4WO:XWVU(?A_WX,-B^'$O_BN.+_OD*Y_U MMG]]D[^=_0Q+WQ74=[WUKW\0YK/=^:^`/MN_WXKPQWW\Y.^'^<^.?E>H_^SL M9X7[V0[_^,=C_C!7?ZUP?S"7?ZNP?V?7?_Z'#@"X<@+("@2X<@:H"@@(T&.RH(2?YH6G M`(:;!H6F((7<1H:S4'9S%@`@4!&^(0*&EAL[DX:9UGUP:`IR&&5T6`IV^&EX M&`I%$`22.(D0,`HZMB@J8"T,,`U_X!1M:(C;EW(^N(BDT(B; M]HB@``%^$(NR:`66V`F+`@3]XQM"P`0)0`([0`"/4@.XP86R=XBED(A0IHJC MP(I1YHJ?`(NR&(NT*`J7V`D=@&B^40->@``>\`(RP"`%L(4D9_^*GM9]RB@* MS`AESN@)T!B-TQ@*T\8)`O8'/E!MGJ$"&0$"-U$+;LAIIZAVJ2B&W;>.G=". MLS@*(E`K$G`5[C5R,MB/W?:/L6>.`IE]!,D)!BF-HR`#"9`""0`$+Q`!0,`$ M*7`2$H2$$`EEQGAA`5D+Z:AD%_D'&>D'[UB&K9"22K:2HX",XE:1R`<+`V`% M0CF4.F"3KX"32::3HL"327:.H?"2,6>4YX"4)R>1PM>2M`"52!:3JS!U3@! M!0]@`!/P`A^W_XDQX04ZNJ,\VJ,^^J,_J@,>ZI=6\`1`>J1(Z@5R,*1^"0%) M^J0]>J%,RI=&"J4]:B4CNF']&0LZIA4A\``%(&,'<`2H-@ON.:4TZ9RT`)UH M*HOU*0OWV::QJ)^OD*4:MJ6P((Y9X0`3(`/H\G%^6@MG.J7QN:9R&HMO&@MQ M*J=TZ@I3$`>0&JE+L%L($!'85G:Q,*A,6JBSP*9RFJA`>:A^T*BM$`4+<*JH M&DV@H`+U@``RY@`.R0HP,&=X*0H($*N<(`'K)0L@0`(,F(*"V:`I'4)JV2*VU,&U.\0!Z^O\*FCJD MQ!H+QHJFR.H*RHJFS'I,;_"N\$J9HJ!?*2`>9L`$(8`!%!,!.%$`!H`#*I`" M_.$%`2`#/N``3&`EUJIP/L`$*%8!/O$`.,(7`9``Z^`#$8`Q!5`!3+`S`CHE M\14`>9%)IW"K*C!M)R`!)XNKK3"N'EJNL'"N4YJNK;"N4]JNJL`"I20&HX`$ M$R`!&`!R#B`#3"`#N$@#,I`>KB%X9E``$V`!^-`"0_`#\>@%+2`I'>`#&=<" M(=`!!=N-M&$M"1`"_)!X&"`!!9`"F?@'"0EM2("A`F:P M&4;W!\EE#KV+G[_;"L'KH<.K"L7KH<=["LF;6*30:IR``?PQ`9H#`!YI`5Z@ M57"``30D`Q(B'G\@:3A@0SB1``_@!"\@(051$.*1MDF1!6#:'X]2$`7`!!:P MMG_P`+JS>]IPO_.9_[^LL+\8VK^I\+\8&L"F,,"AM+PB<9(Z0K<,7, MF<6IL,7SV<6F\,7S&<;($`&X"@`O4*O)T`DV)`$2ZQMHO)QJC`IL_)YN7`IP M_)YR?`Q=Z@D9X`7!*@H/=%1`0#]?R1E_[)J!?`J#+)VV<,C1FS)R@ M#`LA$!&+!@(5D'$<4`,JP`.;(4%.^PXM8*T,X`,!8``[,`%F(&"VS`D5T/\" MX>H7EPR?O%RLOMS)HCK,KX``6<#`0V`&']!7#/G,\98`<-'(F[`9`HI>G.MX M]>8)9O`VU["AN`6A-4!%;K&KQF"E-.VC0BJG15K3 M3[JDA^JD.GVD<+#0;5JE.JVMIU`!1^`6\_:9-@'2?W``(M`N37L$3L`#&&,T M5NVY:#1G-!!H0#$$)R!#+SP/`-!7?T"<-;:WN\R:/8W.AZK.Y\`$.X``B]8/ M$2"QF^$`'K`#6<"RK##.JEG.YGK.M1#,RPG7YQ#_`"IK$0#A`K7R`'H+"X"- MFIEL"IO,G+\\"H:=G["@!ROPV:!-!+MU`-T@/#O`D,**TX(=LX1-"YO=FHC- M"40@'QM0"D3,"9H9"B#P`#CZ"9F;%RJ`***``]/U!TS`%YP0V;8@`Q8TB@<< M6*G=II5="I=-GV[-J+`PV_%1VZ/@`_OQ"3B`A9^P"3OPR)TP`3CP`"#0>:3@ M!-B(NIU`T;3@!23`0>JDS4X@TZXPV7\YW:10W:Z9V:+PVJD9VW^@W?#!W:+@ M!-L,#ABA`G!1`"?P0IMPKWH-=`F`>J^1`=.&,=R0B^ZEWOV1!0@@`\>Y#A+@ M!(H#`!E@WJS@!!_P`5<4_P+Y@=K1C:;^/0H`WIH"'@H$CIH&CN#;,@HA8"U, MD![=8`9>$!'P:\'2E@%.`+!T%@`>\"AO(:!P00,X:`Z>;`"^=P*N>O(.2- M,PH,LE=C^Q,)L.05,`0X`'3P?7@1(`-5;@97G@)9WK!_P$$D.W2W'#_P?9?O M``2.%+\@@>E\F>.BL..IV>.@\.-_:>!N4!PK(`HU<)(8H`(90`,'\`(I\`(> M4/]#\=T)!N`$!9!)';!U$O`".[`.^&!HV2I!#F#?8RT.&2$.!T"W+R!F-7?I M:RV?;5W8GMX;,B##NJS:;/VIU[VL9LR[^VZH_>[:_Y[PUT#L[JCI^LOIBOKP M$%\-$M^(8$31#. M^VWV@XWV%Z_V:\\)C1RF^Y-QM##R:=KQZ/KQ-YOWC.S_!9(!!VI^XX1:\DE\ M\LF*\6O?R%_V!T"P^))-]ZQM]RB/W8:O]UX``CC!PH*J^6_.^9&/]WDO`AQ$ M`)CE]2UK^IN.^NHJ^9\/#(!O[*&`[*BI[)_`['YIX+=_"KGO^%H,^;6O^L-_ M"\4O^#-+^(6[_,/0_/QN\/ZN_-+_][)?\;1?L[:?_6I-\-7O\=?O^>!O"]3/ M\-;O\-A__IDO_NI/_NQO_NYOIMMO\MT_N-]?_[$/"'Z"@X2%AH96"G^+C(V. MCY!@AY.4A1"0F)F-`Y6=DV&:FC.CI*6FIZBIJJNLK:ZOL+&I5Q>UMK>XN;H7 M([*L(Y[!A%B^JUB[R,FUO;X1_U[/T-'2T]35UM?8V=K;W-W>W\\UX-@+Y>;G MZ.GJY>/M[MPJH?+S]/7V]_1F(?C\_?[_``,*'$BPH,&"$J!``7&PH<.'$"-* MG$AQD9D3BZ``J/($/."^!AD0B&(E.J7,FR93T$)?^(B."RILV;.">J MP/B'Q)"<0(,*'3KO088C)H@J7+3('=T3OHGA`G$(KU` M650@07@(`3-<>%'IA0#M"AX\/("2`+5QCA,L+(II`67*%Z#_6'C`I+@3)RI? M5)8>X`\()EE\'!\OT8R0$`$$_X%BAF4+J"U^'`'P)X'ZE!]PO&@.,'@'R=4T-Y!@0``.S\_ ` end GRAPHIC 20 y80744y8074405.gif GRAPHIC begin 644 y80744y8074405.gif M1TE&.#EA.0&3`.8``,+"PM'1T6:+E_S\_+:VMKFYN61D9)^?GXV-C:&AH::F MIG]_?Y*2DJFIJ9:6EH6%A?GY^=;G[,;&QK^_OYN]R)C"S\G)R2'AX=K:VJ2VNUY>7D!@:>;FYK*RLK"PL'%Q<<_CZ:RLK-34U'IZ>C,S,];6 MUN/CX^OS]@4%!>3DY#X^/O'W^5:'M\>CHZ&AH:$1$1-W=W=C8V%E96=OJ M[[N[N\O+RYK$T;_9X)N;FWQ\?.WM[='DZGF9HT^1I6QL;*V_Q1MWDKG.U527 MJUMI;++2W*/!RM39VX>8G82ROXB;HM_?W^_O[Z^OK[?5WZW/VHRZR%R@M/CZ M^_[^_C6(H8^]S`ELB;O7X86WR#J+HX&UQJZNKN[N[M[>WLK@Y[C5WO;Y^^3O M\]WK\)F>GZ.JK+>\O=WEY^GK[&QN;\#2V`%GA93`STB4J____R'Y!``````` M+``````Y`9,```?_@`X+@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F,&7^=GI^@ MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\"["0@(3'\2)C4;P1=SEYN>M-B,\.A*A"R.I+!WHO0@N-VV= M0O7]_O4<=!SXXV89$```./P)$>]/B@E=.I4`8(%3IWDT`$"`$&!9"1K_7N$( M\2=`@7TA4ZK\!6&$#046>5Q8!P'>'Q(7>-B0(,+&A0L(/+$8,4+'@A(C!C*A MMU*5!GTE'/PIPZ^IU:NS)-C0<0''GQ+1=-Q@^.?"@C\QA%C006-`Q(L7_S9X MT$'"P(4_-AY@/?6@VA\6!1Q\V4NXL*H`Z_X$&7&!KDT=.HK:@,!NQ`NA]+KH MF`!`AX41`0R/$O'I1@K1J%/_&6!AGPT&%U20H$MV1-`_&SCA,''W(KT#(VBT M'%&DC.KCR).7X+KUR`L='3HXCI=`!XCH6EG88.')P(@.(_K^0:%#0?+SZ`L/ M`."`@;L_"ARH.-"$Q(Q.!1@<2+&AC7XOGJB0``,$0-`)##JXD-Z"K-`1P8,0 M1BCAA!1&X!>#P+"@@P<8=GC*"7V$*.*())9H8A]D>/B+"B"IZ&(H()XHXXPH MOOB5!`#:J*,N,=+HXX@INF@"473Q4L-E.V+8X_^//P9)2P1)1"GEE%16:642 M3L3R@0X/#/$"$)Y<.%4HQHWI29F?E#D"`TFR,D<:<,8IYYQTUIG&#[J)K8IRRGMBJCJK`X`!D+&R7E0CMI_5%$!VZ8H,,+ MTBW`@`XI1,'#`/-XX9,%%P2!%`IOJ*:)(EK(.B,7UPZRA;8RAM!MMN":R&TE M%I5P;!$S.,J.`RA,QH,)?YC`PQ\+V.#%;%VH(U."-IS%`W>VE6IJN2;22@NK M"+\:2ZP(BZAP*V5X]4?_!S9,(!`)).R@P@4=F%!"O??FNZ\.;_```L<`-!'P M'P/_4?!Q$!!`PA\0',"`@GY&3.+$LC!8K1D>,-"Q"@TLT MW#Z/.'J7&0`$**=;)$BKTG'>(>[M2M[9WNQ(WPJW/"&&` M!QVNVLO"YK[*W,7B[RL:@@"`.I\]X)-G\T0$,0I]]@?-[0JZ)\ M_ZO,L^(\N.%;;XL&";B``@=,$*""V]\?G>?J(9:_ROG:ID_*!MXSD"A*L(Q. ME*$:$4D=!-[6"@O<[!,0J!8H(O(64WBA1;(8P`$T0`#<:(`!$H05_OK@OP^- M4'\'PU\)1>&!&W"`7J*`B">(D(`_#"0H"`A-+*0""B\,!!0#^>$IF+"#J_!/ M5BLLQ?A0A<)4'+%52?S$`ZI'"AD"\0^WF840/>'#4`11%<:PRA-1%<51+!%0 M343%&`%5QDYD42\(T$\-/#&!("A@`2E(P>YN^(<'I,`+*)@!"KS@C<8EY`$) M*%XGNN"!!N@%`%$@@B<Y)E4(\BP,,Q)WA21()&NA"\?BX@"XDH`E?24`7MF'#%""@@)TP MP0?^``#O"7$")_'A!G[(G2_^X0,D.(L)0))(`?Z!>*A4X?WPE\93N#)0L@@< MOFQX$3I2,)>[Q"*^NB#$`W3A+.R<@0->4*8Y_F$(\>Q$"%+GPRZ4+0KL'$@` M#C`#O9@`0!E8`@-:\X)LU#3G7]X00-T MRS MFAK6BX'_""F--OJ)CC+IHZ7_D.J,5,D!!QA'*D@*H^`,8,>J6%F+S)Z(JNKKAVD35MF\ M7784JRT1:E.+CMC^K+4^>ZTH;*LWV@;C"\`-KG"'2]SB$G<%(UR!<9?+W"]0 M8(0P:*YTA8M<_"EWNL7UIF]/X87N>O>[X`VO>,.+@1%B8+SH3:\7K/JC/*CW MO=\M+_[."U_QHFF[%@2N(E]P`&0^C+*C)6'&!W[5RLH?XKVEJPUT<1!L6$65=A7BP!!*!;[/`PS.'C/;AA M`^YPB7>AS4XH0(X%P0:;``$VL6;C&?Q83[U6,<_ MQ@4,'."`(_S!!7%\CPB7'#32/HG`4=[+B$FX8[L]V7YA)LR89_N')L\HQ)]8 M[G!M)NSF.O<90&7EL]Z3HF<`VS9,SLXT.'TL8?OO&5%(UHE@UZT MG[_,Y4?[(](+8W2.T6QI00.:;IHNVJ<[?0Y,SZ(/;$BUJE?-ZE:[F@UR,'2> M93$'*\VAPL3+M:YWS>M>]UH*(Y2"KX=-[`E4P0_(3K:RE__-[&;[X0[%CK:N M@8T_84N[UWY1`A^VS6T^*($4'`@!"O2QHRZ8^]SH3K>ZUZUN*JCAW?".M[SG M36\U4('=^,YW%WS@['[[&]E9T+?`T;V'$>YAX.S.=K>Y_6U1R*4:I2,U*,#P M[XHS.PRW&(/%-X[L'LCZ>;/0]L*]/8H71!RP!6@#!P)`@!=,H`P*^((*4G`S M!6Q@`C"8P0Q>4,,2$*`-.+C!$3J;$@6P"0)Q5&L4]7MHS M6/WJ6,^ZUK=^AHV*?.$-#X5=.[$!-DW@!5^09`,R$(0!#(`$@WGH$MPP@!`, M@``E"`$$5-"`"2A6)200K%`[^`#_[\F"Z5+W]]-K$?7$]YOJM$B##R9/^+R^8?C`0Z<`@I):CE#R` M!/0*WI6W^`K$.[[9BZ=%XW_/;,C/PO?$5W;P7_'U;H<=%!!HNT,&,,<7$.#U M$.!$#AM0!A"XOA.P[\(#-C``($R@]O]@0@"Z0"]R_,$+2N]]\H&?\?D7WQ;( MM__R7=%\AO\/!C;C$"]``F5@*"E0,S"0`F4``"]@`1!@@%=&?M8'!"Z09/W` M`@M@`C9``BR@(!;008=G?\NV?[$P?")H?"$H@LE&@JS0`W#P@C`(!RBX7>PG M."B0`$&P_TPIJ()^P(*O8(+V-X.PD'_SYX,29PH94#TW\`+`='P\B&Q&V`I` M.']"*']/&(5'V`Q$F'Q8N`I3F'Q5Z`I;2'Q=:`IR8`1HF(9&$&NB,#@U<#.\ MEPO+0`-4!`HX\'>J,8:_5X:I\(7$%X:MH(>.QX>DX`3-EB6B0`(1D0!#D$6[ M,!@;8(&+%(>&(8B)1XBGX(>_!XBL8(E2AXFB8(C,AHBAH(A_D``I4`,PH``W M(`(Y1P)O<``O4`*R>`!?,`-(``$PT`8O!TWW`0`IEU8;L`0W\``X0`,$U``$ M$``EH%(T$%3'X8E-!XJEH(F.QXFK((T<1XV@((K+1HJ@0`(!V,S`` M''$`)*`777`2&L`),U`&$'`#-2`@.&-#7M``'!`47D`OX4?B$/5A_3XB-JJ"-&\>-G^"-R@:.GV"*;@1^*A`"]L%Z77`SKU<""P``'@`` M9?,'46!)&\"/_OA---4)`;``-/`%!ID:#NET"LF##)D*-5EQ$.D)$IEL%.D) M%BE/I]<`$%`"&L"1'@E^+^`"&S!(`Z$@2U!^&[```X`,?W`?$#$!-S``):`` M93`?,XD:._EO/1D*UIAX.8D*9:EXL_"3R!:4G2`"R!135\8!7R`!)2`""K(! MI,$S%4@`1U`M+M"`?[`#+^`.+I!VWC/_`2I`0,=``"[0!"]P`P2T832)D&<) M"FDI=6MY"FW9;YL)EWX@EUE8"J'I;)OY"9W9=)]I"JE)?[*0`W%0F[89!SE0 M80BWF^F&!0A)`;PI`)G=;YA-@9GM,I0"X8@R\8AMB#&T4E"I>A=R57)A[P M!8W3G,<@21@2FQ=WDRKXFJBIF;,P!R9R:Z.``@]$`-R#,SHHD)#8"1S@%Q%Z M>IX`0VX01AG`"1?B=CA30!!00!]@$;F0'PAP$BI`##BV=`(*=0@)H*3`GR,X MH`4Z"AGP`IUS_S9G$9,SP%8*\`(D,1#`.`,;0`(OP``#8'KUX@E?4`)$V@`B M<`!E,$TJX`(JH``%@(P[!P`NH`!M,#*Y(!PB0`\&D`*=@I\-N:*,UZ+XAZ:P M0*`E8J"AX`(6@`!`(`%S:D-#('X.$%.#L0`B,'8#0`,>\'W)Y`E(,`1+T`4J ML`2L>`0TUP4VUPDQ\(PU$`!?H(.Z4`)'L`TD@468:84\N)J>T)H(7^>8)K:JVT-J.B```C@P!:Z?\",U`` MS4@#!^`"1;4`9;`$&>"82S!DO6H"GW5[IR@!+K`[##`8BOAS&P``$J!R"D`" M)3`!Y+8+"`5#!G!RH*J"HMH)I+IQIBH*J+J"JDHB<-I#U>`"`)(;K'$$U4`" M$P!,$;$!R^@Y1T!W7BHX$R`!I0,!$C`!U9`"(Y,;96`2!D("!;`!'U``$B") ML]``J[@-"$!)8J6BVIJF"YFMH5JQ(W*QOC4$"B"DJZ%2/MN);#H+#VMQ$1L* M$PN%I]D/79N0+)JTM1"V#?NU0WBULI"U4Z>T#)L2?+4`7U"B?\`!)>D*:(4# M8X<>9GNM0>BV(GBVJ?"AGC"A.`,!2#H092#_/_M4-@C@K]_D`BUTN>_W!0'0(N(7>IEYM,+GO-6ZM,U0 M`!.`N#)D`AS@5-=[F,7Z!23``--4!@S``)=A>@C`BCEI:N`D` M@LO+OECKOCOXMLV0`!F0`(D4$?3B`"6@0`0-1_XZNMP'E:`%O8&1[V[D2O+84;+3PRPPDBP/=Q0FI0[(J M4'O$HP)^40(0<`0"^P5'L(#>V@E>D0)X]T^,VP34,#+->(`20``B*AK0B[0X M";CZ=QQ\]W/HIQ++N9O(R8/*&,CH@K;/R[RNP+;_MK43)\F0[)(&8`"*M0%!$`07)<06C,;_ MJ<9%F,FF0`+DQQUC"@$@@*EI^\.?2[:1+,NH#'W<02K9DZ(+&[A^2X6FS(6W M7`H#P`#%$SJ<\;ZCW+ZTK,R^/,RC@`!_5TM^Y,QK/+9I'+JV/,P(P`('8/\> M!^`!!?">%?S,M>`'9I#.ZKS.[-S.[FP&EOP)9PS-GT`#N=8)8URUV8C)K#`% MG??/`+UPN5D+28`&!GW0")W0"KW0:'`&]*R%_+P*_AS0%-UY`TT+%5#1&MUM M8O#0S'`%:Q#2(CW2)%W2)KT&)W`+$[W1&GW1LY#1+*W1'>W1P`#3,4W1,UT+ M*WW3`.W2LF#3//W/.4W3O0#403UR0ST+.WW4`FT+1LW4W);41*T+3PW5?"#5 ML;#45LT'/AT+50W56#W5M_#53!W6KZ#55MW5L$#61VW68HW16[UP;MT*:`W5 M:OT*;!W4<_W67AW7'*W2?LUM=^T*>\W7>!W_V-MVV*I0UTP]V*U0V#?- MV(C-"I(=TY2-"HY]U)!MV8I]U6*-7:(]7`+PV0(PVM*%!I]M!ZC-7*6MV*?= MVL"ESWQ]V2R=V:>PV4'=V:M@VQN-VUDX`S!D`D'`0R_]V"@TNU'S]%C3P`M==X'']X)Z0X!N=X:2P MX9U'XI7]"2J.U!?NUR@^_PHO+MV8.(M[=39?>,^;N$[_MDS+@HY M'M5`'N3U'>-Q7>2A<.2+G>2U`.6@/>3;K>0&+N5P+>0Z3>18/N):7N%+;N48 M_N5;S>)`3N5HSN,5[>2@H.9A+N)GSN1;[>8N_N.OP`'UM>=\WN=^_N>`'NC= M)0:?O06"'EYL3M%X<.C?1>B*;>B`7@8>8`*47NF6?NF8GNF:ONF_NF@ M'NJBCNE6T`*F?NJHGNJJONHM8`6CWNFL'NNR?NIZ\.J;7NJSGNNI[NJVKDQQ M_NO`'NS"C@H$@`)C.NS(;@HNP!U>,-_)_NR?4``_]``YY0NNF@`&`@#`!<'H M4/FC_;4:`*`!=8@.2.FQ5X:\M/W67P""(1#BNX`"5UI4+J"H55$/TCP$V*`` M'@`!0E#&YO`!@^0`#;`!/$`##^"(24X"Q"0>OD!,*-"$/.L/H<,`0T!)?^%? MYH"ZG7![#$9,6EX&,9``)L!7]E!3.L0"]W4.M\$9'%`$18#PYL!0`H4#-D`` M"*![80X!S10,_K0`"C(!\7<.H7,`-(``%O"Z^HD.,Z`!&S\`.Y``!^!/T*X+ M!O`&7A`\93!^__``1H9DMP?`O%P..U".2,`F9=`VH#7UMK`!46``(^,%W%X/ <+A`#Q^X^0=`Y_F`!!F`"!E)'G*OV@*\+@0``.S\_ ` end GRAPHIC 21 y80744y8074407.gif GRAPHIC begin 644 y80744y8074407.gif M1TE&.#EA.0&6`.8``*FIJ;&QL1UYE*^OKZ&AH?KZ^H6%A145%<+"PLG?YXJZ MR?W]_6)B8I65E7Y^?I&1D0,#`X^/CUJ=LL7%Q9^?GX&!@?;V]HF)B9F9F9>[ MQU-34_CX^#T]/>;FYO/S\U:6J;O7X7IZ>J#'U?#P\.'AX>KJZD-#0^KS]?+R M\F]O;\_/S^/CX^3DY-;G[3,S,UY>7K2TM$U-375U==K:VFN8IKJZNK>WM[:V MMLC(R-+2TLO+RX&UQM34U*2DI&AH:"PL+.WM[:W/VZ>GI[V]O7&LOINOP?'V^6QL;-_?W[^_O^_O[VBGNJ?+UY;!SUR@M)K$T2V!FO[^_H6WR`UO MC&RGN4"-H[Z^ON[N[M[>WE*:L,_CZ66DM^/N\HNROHNKMY^HJT:1J)FQNLK4 MUX:AJX&7GW.AK]CBY:ZXO'NFL_G[_&VHN@%GA93`STB4J____R'Y!``````` M+``````Y`98```?_@`T1@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F+/7^=GI^@ MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>M9S!_)1@86;C!PL/$Q:8%QK M)`8R?PQ2"`;-U]C9VIT%!@<0)CFR'36='"&J/TD_*`%@0-)\(UB M8$+,B@L>M$#84DS?GQDF.*AHJ.T$F#XX<^K)`!305.(7`P4`&LB$O9&@9X.G`/A@0_](T MT&$@C8<++XK\L:'N`8X*+#1`\+$DGX,%,<1XV`?TFLV>D"/K_-EX&`((.#R9 M,/$GGH\D&L28F!(AR1`5$'Y,X<&@B@L.7`\P3?*BLPL?$(2<.2`D1A).G3K6 M,''``XAA&3X(&N`(!!9C^4<`6 M(GGB0;H%H"#&*!KX4$`)S*5RKBE;A/OLOIY$*^U.W<+2Q;^2@2!,$KL$$X`) M+TR1`@G\1HR+OP3C%/#_*P-7W)/!$G?L\2T45WRQ*QEKO!/'KZQPP$RFZ&`" M<_H*`T2Z']<,[4TF`WQ+R3GCA+(K:4#`,BE-#&8`!\3@:?/2HH1,\,BM\-SS MSZUD`4$/#40U0<(]%/8'/$V8VTD.#U#@P1\6$/#`!#:@8$03!#3@=@,L;2%$ M!.+,$$`:#P0@!@805`$QTX1WXO2_4+,B=`//]B'`WYPF==P@`"R^\,6S`ZKV`=1X;D#'$`#9SO"#USP"2TD`0)/](`'?/.#!&E`';0IP.;^P`%K'.T/ MI?G!#V[0`XQLX0`PL,!$`."=(5#@CGC,HQ[WR,<^^O&/@`RD(/4(AP[F1`Z# M'&0&#-D'1"92CS;XPPHFH`-D6&`&/Z@"*%:``!TDRO\"$YC`")8PO@X`;@L\ M,%84.A>%/XAA!EJ8P1^`((X%J*"`('*'B\1`LR'>C)%'1$42";;$5@@)::K8 MPA2GD(0*^'(&9?E##%[P@DCZ,A1%7%$P3S',?Q6S%6=KA05JZ$L+J&`?&K@F M*;*IHFV:HIO2^J8ZLW%.,K[``.2G9*G*5S5@0F,(F&=:`+$ M=D$4(:`@%@5H@"P_H0)=>F(7=#P%"61$BWJ28`$VT*0^#9=!#?J3%``5DT!) M80,8B`$-V!'%DSI!`F,%:$IG*%G<@"0$:Z MSY+V[*2C2.F*5CH*9_[!`\S_2$,->H`I"N"@![+LP-EN^H`)3#(6AL` MB$,&)-!""!9P!AO8`&+A_(,2.E``=&2AIW\8`EMJD`4@8$`,."B'8'F[`2S\ M`0N1E)<%$B6#%3!U&)F5#%1%(545=1846^@IAS34B4:1]P\#$,)/R3NEVNCE MJCW00HA^VX$7""%F._Q##5;P6T_X(%P_-\7E<8 MV?74_V8[^-U/B($H?QCOD\S[I![88+VL_0-'26`$^6:8+0M``$?_L-0`E*"_ MG9#7'W[:@)DLP+F"K0`P#ABE+1"@ITKHY8FJM:TB&_E:3YB84W.VW5!T5SP5 M_L0%"J/A\GJB"#J8`-U`C)0L_>$,77-`!TS\VR9,``KOO5$-(GMB3P3@3@XH M[@.:(`3T"%8&/+"!`CLQ`"@$H%E1B(JFGAR>("@9F!/68)0_02@+L,0=$S57 M#;00KBTHB!FR#-L?2,!5";+$`L82;KIPD#!0?R('`YCN+`$P.&98UP(]R(*Q M+%@``*!G!OD;-",-#;(EFZS)H"!TP6:Q@8<.4$G9D>/]MBPA#!MB?4#9D M%OU@4$F[)\RNA;.G98MK\X3:U2;5IL>SR)GEJXASANG91[%N?66;<9 M">YU)WO7AS8DM#W1;@_:&WW]QLF[91'OR:2;<THN1`PSL@W@P6.HLJJ[MJS\MZ^_;>C&0^@<88'CL^#ZZOM&N1+4G MC3$>D$%N94%V#`!;S*^`YB M_!4/WV#2*>SX8(R@"048@.B%&(N^P_OOO`N\-SO/+],3'/7K4WT\6;\OUSL< M]D:4?4!I_RS;9WSQM"@Y[W5MR,N[(O,LTKU*QVZ&YCO?#&TH10F.$+/AHS3Q MVE;`&+;/_>Y[__O@ISB_Z3T+!?#A_.CG`Q-&\;=!/-WZ_\0^+9#P!3_8__[X MS[_^]^\%Y4^U_.F'?NLG"C5@47\P`H\E0=RP=YY0``JR+IT`@=Q0;;[W"O2W M?QB8@?C7?YNG:``8@.HW"C-E+A6``PV`!@0``&<``%&``350`@,@6G]@`#<@ M!`8P!`=$_P$3@`&!=@%YQ505Z`H7J(%$J'\<6'D>*`OF!X(#&`II]@B`59D`4C`%P/9H:L@(9J2(1L"'>- M%PM+&(!-"`H+(`.3%@`%4`%:4`3AQ6%V(N`J*N(@9V(A\YX:E]WS.%WVDH&J=D$\-F"@;4'VA8`'(-E*OJ`JQ*(O\ MYW_>!7_B)G^SD(S*F'^T6'JVZ(RI@`.BMXW^(W@*'HXU_]!&1".YFB. M`U-%$"PE@+ M+S:(")F0"KF0#-F069`!.Q"1$CF1%%F1%MD'#IF1&3D'$K".&>@&&AF2"BD" MC$0%(MF0[A`$^X<$HS``%&``S6)>PG!)?P`4MS"4'OF4KM"7?HE_"C`+49E_4QG_"FRQ!1BP`":@93E``A-0`Z2F%9LH M!2%0`S5@`R6@!:36`0T0!?=0!&3CA?*E`T50B']``*&4!B2@`P"@C=>P5#)@ M(K1@F(=I?X!I"X*YCH39"KS9FXDI"XN)?XT)"J(W!`HR)1P"!`%@`Z)W`S/& M$LV"7A8PG4(P`*8R`$6@!43!%O(%(EZH!)X`!*`H>M?0`U50!"804[O9F_CW MF[40G-,XG*Q0G(=YG+&0G/>WG)]@B-"I!6DB!J(7(EK`$E4(`^@Q``&`.S5P M!EM00&PQ!`L:(FQA7ACP4>S9#`4P!#4P!3H5"_SIE_8Y?_5'G_:GGZMPHC_I MG[``H/8GH!?U_PGH0`((T)T$T%)M@@`%E#`P$`!B*`0C4`1$^@=]`UH1$``5 M@``6<`$LL`LUP%8S@`$!T``MA0TE$`+H80LPZI$I&HTKRJ(NJ@IANHXR^@I/ MH`9N^J9J8*,?-P(&P("SD*;3.*:R@)_*>*:I@*?*N*;8Z!V`*HMZ&@M\*HM^ MB@J%NHB".JB-T:AJ>*BPD*B+N*BG(*EI^*BL<`(M\*F@V@)Z0`ID^0<+8(#. M(#:CH$MIH`(".0K%:#.:6H24:H%E2I^8:@JS2H2T%=0$`*-)0H.-42[JH&U*H2WVINY6@K3FH&]J@J_RA/!&O\*)&!K M&1$-"U`#7\H#`+!#QN(!!&!=*T`!Q@)<0R4&1V$!`U`8UE4G[K`U"694`S`! M>PDJVPJ40GFMAYFMI%"P^]>MJ?"M.Q&NH*`")+!#/``#SO4V-_")-K`$UC`` M:%`$)5`..9`%T4"OGM``"]`#)$``=R$&"*`"`6($.#`#)5`$35`#"-`#/(`H M'<.P?WFP+-JBMP"T^>>PJ`"Q.B&Q530"G--6T5`%6O!A,O`N`1*PV8E<-^!< M*-L)9J0%0I`%8,46,[NL4ULB!$!I/SNT?E"M9XBP?JFPHV"TB#D+2IL33.L) M7(@!;.%,H.5**8`,.P1$P*$#G``070L6?_#_MU:["\BJ+R*E+P!@G1)#M_?G MMHD(MT19M&R+M*=PMSB1MPG6"56`'7JA!0Y@`$O0`3)@`)Q0#NM:`1W@`!?@ M3.70"0[@`/%1E090`05D`%#P!\TB!2U$`CF0NA-``+5;JOQBN;XIM$,KMZ+@ MO'[@N:8`NGT@NI":J6R+N;"HN8/)N4-KO:6P`2=PONA[`@.[O=K:O=!KIN++ MHN3+OL9`O=Z+C.`KG/%+G_.;#`7@#A:@!0C@#@Y(;'8JJ^X;F/F;G_MKG"YB MGAF&`%M0`P.[PC`,`!WTF4J,`!&\%BFU&G)D`-V"*8)#)P+W*>L[)?].PL'5,RQW+)24?_+ MIDH`_@BVKC2&!I`PCZD%$6"'/:`O3S%^``NQ`"#L`)KAL%9[``%6```2`%,N!@Q0``]BS-0WN_J6"I:BB]H4"] MV5P>&)`#!>``IWPB*2`#&/`"^UR8_:RB;(O3H*#3-0-*-7!XSI(_$7"[\SG3 MJHRM`>V1.[V]15`.6B'3+$K3J:X`J^ MX&3=WM;-WN00)?'=FPUN"DP@`'"8X1J>?F5P"Q+@!"`>XB(^XB1>XCLPWYV` M`S(P=+00!P+PXC`>XS(^_^,TK@8#CN$;GN,@V.&V$`8Z_N/H)P$H[@E3\*RS MX.-`_N-.<.-)_N,\7@M(WN0;+N3S;00U,`0,L+ZM$.52GN%+?@L7WN4;_N2T MP.5B'H!4SMXCT%)'[0IF?N;H]^6V$.9PON.W\.9UGN9#?N=U#H)R7@MTWN?H M1^9'+NCII^=[#N6&'N=,ONA\0.BR@.=PCNB)7NB._N>T$.B&#NFQ(.EG3NF5 MWNF.S@>8/@N:+NB<#@N>+N:@'NJOL.I=7NJR<.I]GNJO/NJM[NI;/NJR'@NT M7N>V[N:XKNMESNN-ONC!ONN.GNO$K@JP+N6]#@N_#N?)S@K/WN3,WNRH<.U) M'O_MKS#M9U[MJ\#M0)[MVFX*Y*[DQ[[I?+[LYZ[JQ@[F.([L[;[HYO[NHY#N M.N[MK@#N8B[NSC[L^*[LB\[OK>#O70[PJ:#O.7[O`P\*#+_A!L\*""_E"K_M M`O\*-A!T'-_Q'O_Q(!_R(C_R)%_R)G_R*%_R:?GP+*_;)8`#L=KR+(\`/H`# M4Q#S,H_O^4,`")7S/K]42\#B/B_S^2,%3SCT+7\!S)`"%XST+#\"4S`%,>WT M5&\,"U`$4R`.1I!R4MT80J`!MPL#4_!VC5$`2O`"LN04+W#?50\+14``>T(" MCK8%+X#SS0`#*CL6K('/E-L8#=`$:."L?Y]W/]CVL5"HI\'UM^I:'@80+B,0 M`23P`D=0`0Q&$]W0"0]@`]W1`#UO^+`P5%F`81K0YMDP5']0`=W`(SRY#5LP M5!1``#7@`/#9^9[O"@;P4'2U:5;E'?GS^#W0)DU7&0N0/U50#@6P`0[0];7O M"CUP`040`RR!^.6!`.@Y!3-0`R24K#2!`1.P!<*<86N__+)PKAW:":9R(EK0 7TZXT!$BJY=A0`#V``>Y``%HI#($``#L_ ` end GRAPHIC 22 y80744y8074408.gif GRAPHIC begin 644 y80744y8074408.gif M1TE&.#EA.0&4`.8``*&AH:FIJ965E?;V]H2GL?KZ^O+R\H&"@OCX^$R4JH6% MA>_O[V2*ED-#0W%Q<6EI:75U=7IZ>NKJZKFYN?3T]/#P\++2W"XN+D]/3[:V MMH^/C^?GYV)B8C,S,U555>+BXN7EY61D9%E961%KA=;6UN3DY%]Y@.SL[,+" MPIR#@X%%149B8F(J*BI&1D::FIM'1T4:(G-/3 MTPP,#+&QL8>'AXR,C#\_/Y.3DQ45%39YC(B8J+C(V.CY"1DI.4E9:7F)F:C&%_GI^@ MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XMQN>'T`#N<#!PL/$Q<;'I5)4?R!6 M`%_(T=+3P04E$KAHV-34&G\N*&8[W.3EYJ8[.%A8%RNS5F)_`5@DY\?>:`T8 M`/;]_M):L(1P440%BP6RL'#YLT'`KW_"O,T(8@`:Q(L8;S7`L8T&EB(Y0@QI M\,6`&0T-/$SXXR"``QHQ,/!X,"8"E@XI6F"0D`*"#AYLS*RXP@-"A)4967G; MT6+#D*10H[+RP>.3!"P:-&!I<`7+C`Q8,H10\><"%A8I="B0@>,+%RP8_[IT MP3+F"!8G3K"L$$%E@0HJ+:2F"OQ'`X0:@A,K!O7WTP%&C@@0@FB,0I8GC0`141 M5%#870W$4$`!;%!!Q0,&.###'P,\T,$#5J10&!4'Z,23`Q2L@4$86N'*;L"@@,4$8TR`@_\6.3;IY!\[`BFEE$*>8L`- M*YCA"1?+B#+`!#>(0L$"9!I@0``?C(*&,A4ZYYRA%"-2""Q85L$"@ M?QA0P!^#>+J`,LVL,0)#:#P`0\K89`#+PYVH,,? M$1R1Q04*_!%$%CRP\&BO]$[S*[`^7BH*5:$L(4`&.$2P!!8N2#'!H"QH@`-L MGARZS@FNIJ!0%C@8X,/_%QXY`00.1GBR0`09=#4`!@M3@84!(JA`0P/SUNNR M,??BJZ$3C@`,,'I98E6L,^0/#%!JXZL8P0*J#@@1,/L(## M`TZ`&D,'ZBR``09_O/4$"[#I^O+8P\0LL[ZA=(6")[]<@,$8*A17`AV$L8##3AQP``H63%$ M_PHU6.&$!]X^L/80-'PRPQ`/D9!<`3(X(4(&GN@P#@`D'T20$0M`$%U3$#RCXHQ$L MHA/6PXX72.BC!,",A3W:'"XR!RP9@F(#+FA!K4P!!`.8`@7M\X0!QD#$,8RJ M%B#XW@?<88Y1>6H!"#C&"F'H!Q<6@X:5LJ$ML)@G+?X!/.O``:A(,08LB"8+ M31C%UC[Q%D2AD!9S68`'6%`8KE%C!EGX@PYZP`7$&&.*,+0B,;B()R_2@I"6 M,H5'(!"$%7@C5&/P81HJ8(8-^-`,.9"``50`@5\4X/\#N]";'8NG@3"$80`( M\*$!!E```Z#A`[7:P#8,@(`!?"!0GI+"\&J`@@*DS"0+&!4%*/"'!4S2$Q+8 M0*`H\`)BQ@(-WK#"!G9(#$"R4)!EHZ(?##D+1&:O%%C#E2>NIH(.`&$%16%! M!U!@@`OD@`-_:F`#6,"""(B2C5@)@P0H\(`!:JL-&V(!!E:0A@APYD,<.$*J MK/"'%5!+9PL8`@?:X(.[D.`"-G*`Y"[P!2IL(`47P)L9PD"%O]0C%MY0@&&8 M]$=M8E,8W@S6(+6I17Z!H@LY($'R!N5.%6#@!`H)`W+"8(`>!`$"6+CGEA!U M@#_H4@0L,,!8@`.&1Q0).,$'WL)"%^Y) M'0],)P`NP`$`G-"!!2S!@4/Z1$VDZ-(74I&;LHCIC[1HD%"0``85O4+0K'"! M,BY$!=!(`QM4H`ZE%B\&8]B&;=86QS\X`0,RP((*5("%)42K>'_`P>'B2)0_ M7($L"U`K6S]$N]%.36(^"($/4?J'%J2!!A8IAC5)^-)@"#9?5Z2I*:R`A7$9 MYP\LR,)P%$NH/WC`HZ2![!],5P.)6?8M:_48:1]0FN']H0-7F`$6@D!$`YSV M+7_P05,9U]K7%A,+`3##9T>SD,*U@8@G^(,08A`W6=1C`AKH`C6%,5P*%A<8 MQXUA_W+_:HH%2`TO.#B!"AI@&>IN2+6Q=5W"+#,$DWV7'=%"@4%IEX&Y9,$# M..@""7#@@0ATZ[U)/2ORR%J5`V#!"A_``;-PP#725$`%/!A"C3WP@`-$3C8- MQMZ#D$$33*1F3P#A`1Z`P`J*\(`PXU4P49;9E&>HW"O#$+"D"%HP M.IO"5J0:7ZO&7*NSB658!.$(80J&G8]8ZU7<&EBYWN*N8?^Z[&('Z-B52G8M MJKS-";\:%1E8``A(@0#\.>8/2A@`>]-PZE:L``"[_<2;/D&"#TC`!:A``PV( MG2-HYTG:AVPVA/4=BA0`H``[H/>\-U-?K.ZUZ.0P".C.``S2*!6!%\`KGZ!<(7_(8K&V6T!TG!+ M3X"`FM/\0P&3"Q"UBR3^8(0VB2@,(CIB3C/?5VBR$-2RHK44' MS,D;1W@`#3BP6[_`008Q^(-H6AX/;^@`)ORP`@2D4!P92"$&Q!+T$+JP@0[D MX(@RV`$-/"`/'00@CT*G^!\$(`7_!Y!@#!C0P`NN(!=/F*'B`M+XE#@>6(_K M&N2B<,(GL%Z/.>QJ`7G\@P(*,/:$EQT(Y[(N`E+/-05,H%9AP)\O]08*AD'C M"J.2`@D"#XT!:"$"7!B#-R1P!3?\QQ.2:Y+DI43Y6%`=ZB34(L(]@75(=>'S M!=VB?$_G:E$'?12D12NP!-0G=M:'?<;1+MQ7=A_P%`601^07 M*N_!#W_P`8<#`GDT2G_``:TD`M:U"XC&>T]0!'^P!/H'(J,B`X@A!4K@=%34 M?%-G>(B'.$%4%`6(V(B. M6(A1H$TC\(B4V(B12$63>(B,XFRN4`!%](F@&(JB.(JD2$3+!R1)4(JJN(I% ME``TQ8JP.(JN2$5;0(ISPHFR,'/(<(H_8H,#@H/3!HRXZ`I=P'(##B`OPIW-_0`*'LXQR:(#8(W6_J(/1*`N/]`*+KO!\#EE#$!F1\LALWOAQ])B1BB&1/$*1 MK6"1]1B0ID`'9["2+$D'($D.(EE%``F-%YE%J%`%?9"3.ED%I5```*`!37`= MI-`Q)P"/GA``GY`!*<`%;]0*80`$-R`!!;!@=1*3),D*)LF1'TD*.*F3.6K1`<)V=*]6*5,SF0-=E%-^F57TD*09!\GD`" M&E4#-]!_YZ(%!N`$"F``,9!W:DE]$9!@N1!81``P0D`\$&FQMI7,+8<1T)"O.YDZ40`?6P`4&P`VA@ MC6(0`VA@!7.C_T9(T*:9T*9]XV0?U&0KRY@!- M8``?8%4W(`8B\`5IT@D2``$;0`-#,`<#\"9=$(A=$``70F8.(`/I5P$1$`,& M@$*=8`1'@`)CT`D%,`1/L`)'0`0DL`&=8^S2J(GFH-;^9*I4`"F5*S& M>JS(FJS*NJQ;H$U(L*S0&JW(:@/:M`72>JW02JVTZ`;*&DIW$`?@&O^N=U`* M174`/]@*V``QJ+`",J``.TH*J><8*I4")!!$Q#``P9&O^KJO_-JO_OJOS4I% M2/"O!%NP_*JM,+0%!KNP!(NP+*2P_KHK28"*I1!IQ01YI[`02'<*8]!4H6*4 MN1(*5THJA6(,$I`FTM"K^_:KP0"CE-,P6PG`"HFG$N``LZ%CZ-"@M&@LE16HI7GLG/;(W4K"B``AW^@ MJ`4G`"W`!A#Z`=`@`3)``S#0-88[!FNU$(FZCUN2D&:P!`#0`V`H``=0`-"P M`$/3M5RP+?*0`P$@!!,`!Z9B"Q`Z!U61NB.ZLL&ZNJY+L:2P`RY`I8>CMR2P M`PO@``70%-`@!44``EQC(0O0@@OA$UIP1"<0`;>D!2\P`_`'A@/`!4);3-5; M*!KZ!#&0!@<0!!N``08`!QYK"T%``JB[B^6+ON?KD;5*"J_+([$["BCP!95[ M!0'P>ANH`$"`!B@$_P`TX`9_``3S1A%I$@0#(`.1RP&?,`!+<`"=``0RL`8G M<`,]L#:22A@GD'Y_$,5_,+DOX`E,4@(G90LOP`'BQ+;7-)>E:JMC6@HG[`KP(^O4`!^")&J M>\=EG,',KG,,JF#,J6G,BH#!&JW+JGO,J7_,K^$,O.Q[JY7,JV3`VX?(.\O,NS MW,O3\,O=.,S"S,K$S`W&7)&Z#,S(O,Q@3%QB?*ID7*;2;`_-7)+/?,S*G/_- MY!NFUSS&BES+RPQ!(10)B@A#%I3.B#!"F.C.AP#/,&1"BM"4X*R0;0NW-NFV M@Y7/H5`";9:R=OS(WTS+KIS-8S`$8S3-#E;-<3O.UIS/.^``5\!2("S.Y9S0 MB(S-^7P`1%```Q3.^RS1$;W1'@W.,<`D1^!,#BUE$-W/_&R7`.T))\`&.B`` M!*W1F&S.!NW3-?W2JA;3-#W3M1G4,%G0K9S2(GS02!T,VXR5W>S,P?S4N!#5 MJY"5*$W.5BW4N$;41VW4[]G5)!W&LBG3)HW69(V-9NW/R.76$K;6&5W26SW1 M/JW4GPS4@XW7@'T+>YW_"GW=U(1]V+20V*BPV!W- MU8Y]U8)-RM'LS8U=V;'`R2K)DJ`=VJ*]DDQP/56MV8;=RUQ0B:Q=B>O,0HS8 MB'M``&=:V[9-`%]PB?7G=!]\MWN&=V9.X`9^X`@.!7E@ MVO3-R!K@`>56"OJ]WWW0WVU="@#>W0*NS!.^WZ7]W-)<`'QGW12.W'^@W"6N MDQM.V!W^WA\.WB^9`0$@_P"E>]XIGI,63LVGD.'8O>*IW>+I_>+R_9(ED`%3 M2^(WGN,/O>,W#M\,SN%-+N0-_M1`WMU*#M-,?N,^_M>?4.78+>5.+==>SMQ7 M/M19GN);3MF@,.;'#>:;3=Q1?N+;W>1I;M>AP.;9_>1O+N9QCN):KN<_'N<@ M[MAX;MME_M5G7N)U?M*B4.BU[>;1#=B.KMYRSMXH2N>`SN6>,.EX">F:3NA] M/N=_/NB<;N*#?MBESM^5[M_MC>FD+N@PCM2ICN.K?N%K`..L5GNEJSMFZ M?NC(9IMHSNMVON:P/N2R'NJ6_@D\SMR+KM:-?NQ3GNQ)7NLZ;J:CGNO2'N9K M_?_KUK[DV#[LKU[M@]X&2]-]J`!88)9&N`&`R"1Q/9@`."G9L-7LGH/ M#".N`8CQP_V`O$"``BT0`D?PN.9``H_T,T-``CFP:(\?#`6G`?4@`%)\#C/@ M0SFT`VL@`<%K#VOP(=:U@0=@,*4?#`AJMF9@!B-N#RD0`&B0!0-PF/K5#V@P M>@9PC220!86\^[90`&^_"TKJ#VF@E/7P`@"0`BAK#Q(0`RGP"R3`9[D0"``[ ` end GRAPHIC 23 y80744y8074409.gif GRAPHIC begin 644 y80744y8074409.gif M1TE&.#EA`0$<`.8``&5E9?/S\\+"PNCHZ,[.SC(R,G]_?Y:6EC4U-3X^/M;6 MUBDI*=G9V79V=B`@(,S,S%555=34U.;FYH*"@L#`P*"@H+R\O./CX]+2TBXN M+I*2DD='1[JZNAT='08&!A45%8B(B+BXN%Y>7JVMK7)R<@X.#@H*"IZ>GIB8 MF(^/CW1T=&%A87IZ>M#0T(N+BZBHJ**BHGQ\?&YN;DY.3LG)R;"PL!$1$&IJ M:K2TM(Z.CJJJJD1$1%-34VQL;"0D)+*RLB8F)DM+2X2$A&-C8TI*2H"`@%A8 M6,;&QCL[.Z2DI%Q<7'!P<#@X.#HZ.@("`O?W]_W]_?O[^_[^_OGY^;^_O_S\ M_/KZ^O7U]?CX^+>WM^_O[_;V]M_?W_3T],7%Q>OKZ]O;V^7EY>'AX=W=W>WM M[?'Q\>SL[+Z^OM[>WN3DY-K:VO#P\.#@X-SDI5?;0L>3R^$7A8-.;LF)1\J#0U:!28> M!;ZL7WA!&*[6U]C983P=)48<""5SV>36%"4E;9T8"1ZSE'$[)BL30PXW?VDP M!1Y-(E$<+JCQ,BB,F`$5^(FH4ZZAPX>MV&BP`>&!)#H>1$#<6$D-@"XK;E4Z ML\*/'S24]NP8X@+,EQ@GUZRPX:/"FS*?WI#(F(:CSY\-U1PHX://((Q&@'($ M,\&#`W6<7GCPX\'.I#(@/C0@(\C`20$?2*SB],7+V#]A?G0QP%6IV[>?_["8 MF''V#XHN).`V/)/"#]Y.7@"8K-)6T)9V?&A!-43G=(4,"E$@J`R9KR@HT-(5XW^G)&`8D.'X"`1VR/<3*&21E8,$@$4USA@04B M@;%#:Z'H\4$"[@DB@`=;F*%?)6L84$$E89A!0'Z$D-!%.GJIX8`#=WS8RAL& MD`!$$QW(8($9#7B`$B=TE%3""+^`]F!V7@PP@?\-.90'"FP)$.)&`EU$(",E M!VXP"!@$C&%!/3FH44D9#OBQ14]P">!'`TJ5A9-#<@"0@!05!""(=@X4V)$& M?MB@P21>$-&%@R78\$$S53P@"I2#*)!#%R>@J)08>G*"AA\%H&'`!DUTT<\, M1Q0V"1I=A#;;EJ(ZY,43'NP!U!DR<)8J)5^\.8FDN*#A`0NT6E$%IW[Q.@D; M"73@A00C@(`#&@K@R@FC`1A@@PD5W,*`#]!T`@8&(/`640X)W%+&&8,$X(8+ M*YC@5PD+B*#!"'"4D6$E#?CEA$AJ5/#$`BF@28@%,Q#IBAHE/%$7)6&DD8:' MKJB@K@>G4N)%$0@4`-7_("#H4.DF@4),:Q(9..<'$)4(80-XV'CQ@`E`AZX`'P0`L-4)G6!0QA!9&3& M_Q<)B!"'`UWP0(8%F*_!PA`%0/'!![/)<;@(%Q>B01)K/!`=*/HPP:ZP(1*Z*%,42)$$)IA/=A$;4*]NQ-H1@;#/X!@ M5PM,W0X6X`?KA:$!)K#9'[PB@RLT\3HKZ()H:,,:/Y@@#=I)@!O^0(<"]*`I M$`O`#%E`@RE$#8Q*2*$<6%M`MS>5'`H"#'2TBAA\`,^-"8*.)O$!&.+@ M@T9ZP0!*>$P"GG`&,W@``&?_`(,VK><&Z/TA`"0PI@B!(:2Y.">5'$E!]2U`0LTH01C-(,#.D"`_T%!<:``C08P8`(' MV(D0>B"E#N8UB+KV\QHY3>LD&/"R1/H4%M0;`QGN@M9-C-,$`0C#:A`PAPDX M35Y7X,(7!+"6/XQ@*H`K`Q.7((@[9&$P<@C#'40&A%7&808F$8$,O#D]/ZP` M#`\HDU_0$`8[<*\)6""$`E`(!QRL2`:)_<7_B$,(S574.G^8@PA*`)W'_H$I MR;,!_PM24*HN/*$!#G`'6AB`5!O8H`-)0(M4NM`!!QS`J.R!`5F_4`,3`($! M8Q%`!EB:`!D8P``IP(,@<'E;:^0V8N+I@@#LFT-+,O$)&+B!R'PZ"4CBDPQY MP.42!%"F/\WA0F6`@`=Z$(:Z+L!*$0`@#00Q`B8B``-A"$`5_+(F2<"!J'YH M0A_PX!P3F&8+(5AS(`X$T9`)T$%XC<"@B"#=!'%10\A@`V\`L" M:#`K49`!!OL"IPX0=^,8S$`(+#A!*/\`FAX/3*>#^$(4\/\"A@$4``%BT$,* MGD`]#^"@`!_H%),'48<"T!`,8#!`%YI`@Z9ZP"A:GD!.CQF")Z!U#PSPLPE" M.0?!4.@//C!!#"#)`C(0H);C]E827#``TK'&`SN83CM,X(,$Q*#`59C*7&[3 M`8&]P76N>C#M3""$'33!`TM(B`=&D((/`+HK?O!!`W:AA.3Y90MHB!@/@&"" MEED`#A.``!I6(88.],D(8L)I&@+LB0&8QMBL``,T=2N("MB@`.02PT?VI44, M#-$$#`C`VBH%AAH,@2II^`+R-(I4#Z2A#39`P`!R:@(C=*I4V%[;81=!/?>B M00IA$<,+#HO"3+7@M80[P`)*(`3_.'SA`DL4@HZWI(#W=<$$.+#3<$U@`T5\ M``+"'`0<0*"("=#@"U\80:PY/F9!M"&.'2`!&K1.%;2*+@Q>0+$@"(`&F8U& M`4W8P1BSD5/WCJ4-34C`305Z@`9$`<9V8P$+Y@.&G3P!!!6H``ARD!'T&:"; MW.O"%#HE`T,1(`S`]0->"0`"]<`;N`08,,`;_5V"V0@YK$'UU0%N^P0<,%P4>(`01N!XNF`5Z M(`@Q\`$UD%)D$0!\,`8,P`9G40?-PX.4\E-O\`"F\X01R$LFD`1`(=TJ!?:H5%=($5UN(=\V(>\MV2`YX>".(B$2`EEH`6>`@.U5HB,V(AP ,*`83H`J.:`V!```[ ` end GRAPHIC 24 y80744y8074402.gif GRAPHIC begin 644 y80744y8074402.gif M1TE&.#EAD@`8`.8``,C(R,;&QB8F)NCHZ+R\O-#0T+FYN#@X,'! MP:BHJ)"0D(R,C'9V=IZ>GM;6UC$Q,9>7EZ:FIK2TM+JZNIN;F\K*RMC8V,[. MSD)"0JZNKMK:VJRLK'Q\?`H*"L/#PWEY>=34U&!@8'AX>)J:FCP\/%I:6M[> MWE)24HB(B&YN;HZ.CFAH:(J*BEA86"$A(0$!`8*"@I.3D[&QL38V-EY>7J*B MHD!`0*"@H("`@+*RLBHJ*F1D9'Y^?CX^/AX>'A45%9B8F&MK:QD9&7%Q<69F M9JJJJE145'1T=(:&ADQ,3(2$A')R3DY$1$1.OKZY65E=+2TO+R M\KZ^OMSWM^7EY>SL[/___R'Y!``````` M+`````"2`!@```?_@'^"@X2%A!0J6H:+C(V.CY"1DI.4E8->#29\EIR=GI^@ MEGXG2&*AIZBIJH\043%8'PN#6A5?J[>K96FA6FUHE`]!2!=;#BJ"7Q$FII!= M9;C0C018-*!C-1UADF)%$3N*?S@$?V51'PJ+*"L7@VD]+=!?"BTG-]%_%$$U M7IYJ0U=D*"&QD6?0`1-F"M1XM4&+@@.#V)@@^%$Z0PA/$!%[/L0HX>&$%1,0_XC0<$$`RS\,8CRXI44"#`."Q+SX M!,?-(BXZ8@C`X(F.@`F@SFC8T"#&ASUDEB"0,^C"$C,\(/SAXB"&!RZK_\!, MP?%+D`^LG-`\D+*IT!8H7NTXTL)@!B,*6`"`^N+$1XD8$>PP"&)@2[LJ`$XT M$!0B1@^5J3#4"#$(S$4SG!;P:!"PT)D1,8AD;(0B0@P*BRP0:>WIRX@68SZ, M4/!B1$%"4QHT,:)(QH8%%@X,5;S806B%5C:,*+S[$ M,=2E017>G;:L&/&`B`H%.!(5>J!AQ`DP?X"`10NVJ#)'%`Q8)L@&`C!0R183 M"&"#`@#B,X0@7J@00Q0%-**%#$O@X,(B,F@`'R=;C%"%%;'<0`0ZA=P!V0JV MF`&$!^"D`D853!`"0!!*5*+'"#`$4,@)0@CR0/\,5/#V10:*";*%$35H(`$A M72C@@0!`U`&*%R?P0$00%#@0!3.%)!&#?EYH$`)<@DP`#RA!7##36\M0@; M'^`EQ@]4=#$(!D",$T<5$6308R4-/`&G(`4@=4H!1)AW0!!6:!.&#$!8@.8? M2^(PP"PG1#'&`E7L\DD!MFD0PQL(R"+(#`+@]@<-,!CVAQP:!'''(&L0L0`` M)BQ1P0)1-$"`#$Y%\H`))Z8BD6`$1.'!%F5-<(',I"LP$.`'1A5!%_*&!%"P7,88$1*JT1Q8B#M!&! M#%LDH,$X@I21Q`ECT!#"&S&,,'F%`A/)C'$!2``0SVA0\D6"L*;5``#"3`A9+\ M800._,`:%O4$`/F@05A;1!<^X"=#K"`ME#``#!Y@E!X8P"L6F,,?NM`!//S! M"CVH`0F.M80&A*$/XD%"#9[P`!)8H!'DP8(,V&`9/F"A!$Y(%POB!0D"M($1 M4C"!"4"P"#AX[`+/@)CB'($`)<1Q$0.XDB0X,`(>O(`*+"0N&Y&`*+!QF,AD 4Q!;BH($ES$"(R71$$5@@B$```#L_ ` end GRAPHIC 25 y80744y8074403.gif GRAPHIC begin 644 y80744y8074403.gif M1TE&.#EAB0`S`.8``)J:FN+BXA45%7AX>)"0D(*"@O'Q\8"`@')RGI[FYN=/3TRLK M*W1T=#HZ.JBHJ*.CHYV=G3T]/34U-6!@8,+"PIRD9&1E145$1$1$E)24M+2U)24OW]_?O[^_?W M]_/S\_GY^?KZ^MO;VX2$A/7U]?CX^/;V]N'AX?[^_H6%A6MK:]75U6IJ:NSL M[,3$Q+&QL=SCH MZ.[N[M_?W[>WM_+R\JZNKJ^OK\[.SEY>7L7%Q>GIZ>KJZK:VMK"PL-C8V*6E MI>_O[]34U-;6UK^_O_3T].#@X,_/S^OKZ^WM[=W=W='1T?___R'Y!``````` M+`````")`#,```?_@'^"@X2%AH>(B8J+C(V&)Q$1CI.4E9:7F(UO!4LS-)F@ MH:*CDT0)#`%_70.DK:ZOETQ4+(,==K"XN;J"$E'3H-^@)B#N#CH0YP(`%$H*DNK0@5$3*`XB"#+30@H:0$Q,%HBRH M@A$3&03\_C3I@*7DH!P9GA@J4\)#!`4I72[Z4N#(("(#&EBJ8F6+ME=%1G1) MM`1&B7HZ%:FY0FA!`DH!N`SH,,)',EP;LBCR8B&*@:B'(!`@E$"+HR(F_X`4 M4&($C(T]NM!D,$+HB))"*H1>?>GC(Y%1C:,%O5D@8V)EQ`(^K*!.:(W6JC0 M&60D@IE^8<>(Q9)1-=A\M81$@B``5!WRA00__#)($K'!@P1`)/C42`MA MC/)0(@[H\`8B2L#Q1QKW&:);#<`5]@<526#V5A##5"&#(@HT`)*'%*0P1TYH M9=!``9144-(9#8!@H"!CI"`!7J\PL08743@0TO\!$DA`00E7-7(%#/Z]I<(N M2/QXR`PX;-$7`0PX2(@9)ESDB)B".(%!!2!PL!XH1@@@C", M%MQ0!P_B_9'$:X,T$8$`(?RQQ0T<5.>"`&82T@$S@_110QN&H%$#`RI0^M84 MA&&P5BM`@,9(&",4LL<$(+@01`$7Q&'#"Q)@44$0!%Q%1PT"0,!$!#?)M!&-0/$H,%.I0P#3$#S""B MRRA'G&'3`BU%!<"HXQ?2$2-F4!#%$AAD,3)::5C>/B%;B$&C($TX`04D4`,$ M[&!_)QA`]O:W!*BH1`DE"$(0&`"`/B2H?7D8POWV1P@[2&`#(!C`!!(P!0=R M$$A"B,X)5SB),8S`5"R,82("L`$YR/"&B##"")R%PQXZS0+'\6$/T<`&&PJQ MATT8P)R.>$,HD"!*3+PA`3`011S>00Q'J2(+W8"`_6CQA$F@0:2^>$(`W(*, :*_2"_M"X/R.LD8WMPT"`X+@_+J`-C8$``#L_ ` end GRAPHIC 26 y80744y8074410.gif GRAPHIC begin 644 y80744y8074410.gif M1TE&.#EA80+_`.8``'U]?>/CX^_O[\[.SL7>Y9V=G;R\O(JYR*RLK-/3TS$Q M,2A_FK+2VU976.+N\L/#P[2TM/3Y^NOS]H.#@XV-C6RGN:2DI/S]_924E/CX M^/3T]$-#0_'Q\3F)H2^#G:JTN,C4V-[>WIC"SFYN;J?+UIFBI;G$R(N3E@`` M`.GJZG-S6QR==#;P\P1HAM+DZJ6OLW=Y>:^X MO&^INV27IIZIK(:/DB)I?PHM.-;G[&AH:9_&TM?CZ!,Z1O;Z^ZG!R6!F:`=K MB-KG[$]/3\C(R&AN<6:DMUZ?L]OJ[N[U]PT-#:_0VB$A(;W)SEY?7]#CZ0]O MC(>'B&]W>6BFN=GI[;FYE*(F-[K\/___R'Y!``````` M+`````!A`O\```?_@']M*(2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@ MH:*CI`H"?ZBIJG\"K:ZOL+&RL[2UMK>XN;J[LD`BO,#!PKIX0L/'R,=">,G- MSKA`*<_3U+`@U=C48JO0X:[ M)[)DMWXF4ZH:J++E07$)!LCDD(K/@PRH!$1$QP<"!(ON!F``=P&"AI9_,G1Y MH4(`!@4&'E`H,"(#!!544Z3BB-0DR*XB28(-B7)L2)9F/;X,-XB0A500_U"\ M_=/`QBES$`8-NLL.P)MN``K\88$"`E(^`(:B&F$@59<4&U#1F?N':UJ%7R\C M%*NY8-G.!=&")K@6'(H"(4+03+7!5(+"YT*@B*/A`H)W?KLI`(!*8]<);PS_ M8?S'KP4-D?\@H+!UW6B"F9_OXRQ=W^?J^D1CSU?:6P`4&!#@5,6B#8#6?R;8 ML$'GCX4W;=X\X+"AP)L$J#"@T)IJ0N0$;P1`@1D;M-%%%VTH<(%_?P`80&Y^ MQ1>`"BBT$4<`\L5!Q1\%1$;%>LQUA`$%C1'WAP8OA*``*A8H5IESV^4378SO M4$>C.U]4,<"-]&C'8SO==9-`?#:T<08+!13PP/]P;;3!PADV1(5""`,8P,(; M#0B@@`T`^`9`&ZN,L.(`4WYIP0OFZ9>`F'^0&4)N!IQQ1AM47!G'`+(90(<- M%YC1Q1DHL("`#?P5E$("X1G&6``/I3A"`A=TL2,JEOW8SHR6FF-CIN%PD``$ M&`"0&%^0$R4T&`P20@`TC(/#&&RHT:(.';9AA!@I64E'7!EIVH0H= M*(RWV)AEKFA?:B@,P*:;N0W010,6_K';'WD"RH(-".A'8!O"+=2%&1/@5,"G MHKX5P`@`6'!!:\XI_[KC:JK")#$'Q>\\4+! M"L11G`+\7;"!&7]L`.S_M:D8^P2O##@O01GT*G*'`!G1LK25OJNRJ@`).$FO&("%S.+)L`ZC-=FX6JE#M M!F]0T#(5*/#V70,8;'#&:#M#K8K/4`?]XP6"*FTT!@/0M`0$HOIK>"I/&RYU M*B%0T`4`@Z^2@06-#4;!!.(-,$$!9XAG0>BJ7*4"!$FD@`$=?%#`P1EO)5`` M!QQ0D(+MN.M^AF`&H&Y`8PG0\3L%%J6@-RHLT('ZP:`5?OD?B#>M>(PZ%6`T M_P!T0,""L96Q00'YVV/>/C>;OX^=]I=W__/WSVGP:='[3O8`HR>)@`%$!;O+ M90YJ\9.?=.AG./OQ#'^:24&^^"$.C,'P,$`'ZV=\"F)5"$G2%ATTSX+Q2J)`D!0(#C^`6YHYP# M)1P0%04\"+4:_NR&.+R,#G_&PWOY4"0:,$`!ABBJ"1@@!.@[HC_^\`!1S=!P M3N19`C$0AS:VL70U.:,J$+"BC+W`#%00P`!BQA,%R'$5$*@C*O8(%'`,H(TC M*``349&$`9#*(U/D617I=<6$>`I41IN`!1X0`J:YH_\L'%!:`<+(LS0*+(%T M@!D*='4;58R`8MR@`)@&^88-B"D$&GOD..#VC0*@0!4:G,=G*`>`2341AU#TY2DND"\6_"$`%AM< M"""``!?*,A6^+)3&>K(C`!4$Z M!]?(W1F1F"Y\P8HN,%"M$%-X3_I#"AJS3U?Q(0$!@(`PZ1%)@4$35=+41PJ( M-CX*M),@G\F`*#\HPG"BX!1V4P"O9I8@:RG`:M*;I:W:@`&<:*P--BC,J[84 MF=;0"0-MH-87*Y34!&3@#>O_L8$&?#D8%&!U2@.P`;4*H*4-H"!T$$W!URKV M-1MD0*=5XO#7'\9!QNX M*Y[!K(=?[P583@D6'1S0(A?)9SZ^!N0ZH4P,&L$IV9O&MC%R)"$0A`[QS M%4/RXDU9ZS5C5FP$)T+!!MH(`+@)X#1W1$7>N/J&"?PAF&=SHUK)QMC"O(%B M#T!!_P/:*-+D+K>NL.1J=$GJS/=5-U/7'8?^,,DO3?YOD0JYSA^X.=)2DG<< MD[6!0PCT!]=R``%M&`"@W"O4`5@@!$,BT7Q+2Z`D?.F^J+`!%2[``4XVZ[\% MP,!]E`D!W!*76"$@D``H.K8Y3FEFJ(%-``+`![DHQ08!X!N&4:'A*4FWP^W[ ML*5"_`T)=LMH%L1@2U0<@IDVS93_LNDI9(D"&^Q(/S8HCPUTRN-46*`M"@A` M+EE+K$6#R9:,16H;4O3DC9E5OTG@ZIQ0H-,07*E)IL!8@UV((`YTH=#@^H/5 MZ*`Q4C,WP[_8F)>"1<4K%E4A!?\&Z'M!,0-\X4`G M4R$`BU2;%4F`MBJ`Z)LDW$4`..&#P4ZA`6-E(`3CW#(KQI,"WVC[#QS@PP74 M#43^<`!]WGY7!L8C`#"B(@,!H,GPYGTB(VH[WV\6H:]Y!.PDA"!IAQV`$= M09=F7RPWQ`>`B=,+ZZ6Z80:8(X#_U1TE"73`@!$'"#L^3,";YPS,P30P`0Q@ MK[&/9;Q[*(/#MY4C^HSYG-]F\TH%8;H,(&7O#6$30@ M,G2O>("N^9`CRG$N@UK6@E<`-H0P;XH``5W2:5*VZ-8&KR!Q6\@([P M?D/Z=]0%%=0G/0N#`6:P?=L3?9DR?=*1!&>P/J5W0MU` M!0Z#"FH5'G6T`8^V(P6@`%?U`&90`+=5`!;!!\$Q(`)F`?,%`&9`!PKP%`ZC M@@\H/P9H_RD(.!H384UD5X!ZQPT78`'?MW(6R`T`T`#_]@9#80`V<"(*,`!O MT!B!\P)OT%P;H`*.E0*Q9@%U9`,19D[VUR8&X($-`C%1E(,_LH.=P0=TT$5G MX'>7TWV#,8%&&%GAD`+W\5:[,4HV0`$JL")/X86;A`!T-`)&I(?`AP!\T`8% M,"X9@%GV@1]/(2QU52MIV'4E]'6&$T,`<`)``$)T>`'K0P>%4BKBERDW-"`" ML"]#D0!4($,(@P$JP'FLDPIHURYMHH46H0%T,#NH0`$/<#`&8`:G*(J:N$.< M^#,!P'<3\`!E@`\*1(<-(BHYPRFI:"E0I'(BD4&9J'#+*#"JH_]$&@%L/$*- M?U"*)4/>4<.H5(N%8B'`YD]R4A%X5@J&9`\Z7*,#+EQ0?@-_0@`%/@C M`'DC`CF1'5&0-'*0)2$`1&B-I-214?>1WL`!#[F.V%&2-'*2*)D0*ADC+!D2 M?59!90>43\EU M45DJ3K$OHU4O1_D^Z)@*`T!`V.B57YD2/[D=05D0"N@X&'"#W""3\X.56?F& M&`!^.>F6;UD2<8D=C`399S(Z6Y':>) MFOF@FM+!FO0@`'P'`!"@``QY`!C!P!_W@!R)`G-\00YNY';>)'?'3`W;PGO`9G_(YG_19 MG_9YG_B9G_"Y<=%I4M.I&4D``8YC`8L9F_\"!4=P!*AP`0L``PX*`P>P!&RP M`F00`^;9#1RT1,TYF=W``POPH2`:HB(ZHB1:HB9ZHBB:HB#*GV$I'1Q$=2.I M*9V9*6NP`PT*_P,=D`H[$`4>H`8B<`-+P`!SX*!J<*'<$$/861WK61WQ(P=( M\*10&J52.J546J56>J58FJ50RJ*6^9]FL98LA)P`:HP`,/"@-D4#,W MX$G]<`1$X*`K8*2JT(J)0:>:L:32D9O/N6LMVAGV")/TH)T)L0-(,*0PH*!_ M$`9D(`-IX`528)XHT0,R``->8`XQ]$=*ZIQ]ZAG]^5=>BA0)P(!TH*GM0*CZ M$`$$(`(PL@)I*@*IT`1X6A8.`*OF$%ZCQ(X@=`,B8*N=&H^?2EVAFA(9\`". M4P#>.`^H2@]2D`8=4`,P@`1A@`HQ(`,KL`-&``5B)(0',*PH)XLQHO^GFA$! M1A`$"Z`&XY`"8:0!Q_@.*?``[=JN0(2,?SH6*?"2(HFG8SH6;'`$(J"M?T`` MX.F@1"`%TA6$W`D#1#"L&B`J\Z>>[7,!1V"N'XH$-R`.TZ,*N)0/"3`!G1-+ MW"``S^>9P=IQWAH2'=M%R5H/RUH..U"I#GH`J,`&'K``:7`$9GJPJQ`!0>"@ M-5!#C04`20H:XCH6!(`$(2H"EXJQ*K>Q]0`!G*<*S$EM(UN`)2MS)ZL021"T M[8*3ISJC"B$%.V`%.IJF09`*^KJMJQ`&.4"PBOH-N!JNAC.Q(.H!!W"QJQ@" M:58`=1("5)`T2S("+6(!2=`%&&`!&7`&B3?_`0+P`"8(KAJ%B-A"*LS1<^(C M;H)+!TO2+A@@&"K0N614>0!P`8B2-+"Y0%<+=UF+$`RA1$PY'6!+$%"P`G$* M`S6`/0R`!%8@`@3@F-I$DQ<0`U&0!A<[3,H&L3QS`0R``R#:`0?@!R'$M!B@ M%>Y56&TB&`O#(1E@!L(T`N\2'@:`'X;H:*:+@E);'!:QEBZ)+;RA&`[3!4!A M!CBQ23IV8-Q8';SY'+[YF&^8&&*:#Z@:!G+@!5;``ZAP`U'PH`N+"F%`@/\@ M==PI`;OD9YOZ+Q?``U90MSO@!*N0MR'2.1L[`(*!7QPR&!HB`!D(*E^D'*VT MO@W[L,%8,1H8!R++_[XE7%<-$@?>"TON)1/V>XZI^WFK"Q`9$)SXF!"$N@.U M"Z&IT`$K$`,$H!+HZ`8D<*%!N[*=4;0$60%U:P?0RPW120P`(JT!@R9;@9D`+F%`!+,A`1'[0O^@ M'D%G>N`!#SH'J4`"SGL$$IP6U,@``TNVWA"T]WL96IP039#!(*H&2^`-;(`$ M#IH#OPJLW*P0S=A%PQ@25^0'#+`#.&"K-.N@9.`!7^QVOOL'#`"SOKH*:'?$ MSU'/!.$$.]`!(%H!!'"A-T#.,N`&`4V8AWR`B3P/<:-$0UL0/D0",`L#9XL* M.Y`#O)NS"U31?^`&,K``_RD^'BL='OT/4'``(OVA.,``#HP*3K`",KO2!-G2 M.OC2[9`!7$NX)F$O7&`$,;``-6,$#UH#.'`C%^``!$`"5H`$:L``JOP-0`Y.="C<*`S*@VN_``R(0`SC0U"1JK7S] MH52]SM[@``VZ`#Z-"F_RR42[';S*W$CPVN'@!HCJ`1R,"K5MV^F`U6NHU>7@ MDEUD`%&-$$?0`0^*KJAP`#O@!A,-H'YP!%YP`':P`L\MHG"]`R+``$[``Q$` M!49@!\_M`7;@`M*M"A+@S\1ML*KPDJBM$L:-#A(@`DC;UT8PU]X@`?0-`VI@ MRG]PWNC-#^H]C^P]#BQ0_S04L-@B<0`)'`4+L`.6;1)LX`0,D-QJ$.(CZ@$K M8`<'0`($X`=N.D870``'0.0+0-61N@H.T+,X.JVI((%I-QH=7@XW8`2<7;$B M<-WAP``UL`-:'KTMCA"XW1EL2%'[\CM@$09!L`)F;A9L30([,.8EV@$X$`-> MX`1TJF(2.\HA&@0,<-UA0*%1O&TOF5CT#!K*Z^?.2PYZX-,3SN9M#E,O;I`Q M_@T:P#^U61)A<`#V_0=^$+LF$0&9;05^3J)&;@4NT`-`O15)&09>(.4>D`;E MC3!@R^4Q"A9?'@[S7;ZI`^T.-W:/DEX2._#8,J"HWKZ@?M#6`"[@)5K@!RX%)/Z[ MXW"<5O#@.4`"$I`$:0`#47``[\("=IBG8Z&\S%NQSVL..$"P7O#L>6B(-%_S M-G_S.)_S.K_S/-_S-E_O._?I*QGJJA``_?MX74')41`$'H2J-R`%0:X&`RZB M1H[D#+#I`)&<-W``L;[CPNN@:IZ.Y(/%J=T53^[G'K`#%R\./$`&"_#HX!`_ MV3T^=%_W=G_W>)_W>L\OV"Z[!/#W@!_X@@_X;G``@W__^(B?^(J_^(S?^(WO M!@S@^(Q?!?M2!)$O^9B?^0M@^('/`&Z0^8I_!"00`YPM`Z9_^J@O`X!^`)\/ M^JY/^$?@^EZP`JE?NYM,`&(@*ECP^KS/^"[0^\#?UDB`^D$0^Z\?`\:_^#$/ M#G._]\[__-`/_7U/<4(/E$2?`L%YT"GAH9S\#2'&!H6?!A+_YVD@`D?`!;?^ M7>F_MD>P\@L@`SSJ'#]^#A&`!"L`"#=_@X2%AH-&AXJ+C(V. MCY"1DI.4E$LDE9F:FXX]#IQ_9W0``!@AH)L2.V0P1$>,#CV1;'(,(C$X'0N[ MO+L>014')`0.%ZC'(1MO*DF@_UPB0;T=.UA4``C'V7]RVI%)1W:\TTN51PLP M,#N4B=WM[N^9'*>1E_#VJ)Z;&1"D`!8"]QRM0`SJ-%,229L,,,'P@8!!C:<^8-A0YQY?^H=W6HH7Z84&$A- M>,"U4(56#!S%(G3#B2TU.2?Z6F'G``,)91T]&*G`V)\)(U$,Z';#2P>"Z/80 M").W$$V.#JST,KC)"SHUC(DVWKSU`94"*?X$`""`!0`#"4;\&:!ZD%;.1;U2 M>C"!%/^%T%SQ#F*S(W,C!PYSR96&XP`!*'YA$\)@9O"@.('G"=A@`\.[&QX0 MPY`Q#9`#1EQL M!*$A!8QD`W\IHF!#3`Y&\(<`<6P0("IA#`1##3!$P4L07LC(%7CNL($3+VDX MD1PE1^!PS'J,4&#``_)1T!YN&!@`P00P7D`%`@CP\0<$!1A`AP9_/)`E'6(. M8H`!C!1PXB8"*!!'?@B>5D!^?S3H6GISVB/A(PF,`@`%_&W_Q0,2Z-3`QB-) M,!"-##+\$LPPQ00ZR`#4M?:'2"/!.0@"="3JFHP`J/@?CCD$04$=/NP15P`>P<:$X(%5''P!P?4 MN@DG!QPD@&%I;Y)+1^>/HAN-X,RDH$!_5C0YE90 M`+7=`<$:<@$/%?02@Q2/:IH``KCU&=VF-J`0Q[F,+"%C%X$%0)@$`Y!2Q1$[ M]+H`#B+X$3`\N:(B@0A(_&B$B95`$404/1H+"K**T%'`?Q.(JG&X(X`4`@40 M\!GN'R_\.)CQGT!R%S7^0`*]ZX8$#',0>GJM$$D30*]%I(P@>\,Z3)-$@ZRBM"V@Z MVB$NT#L+7O^@04=3EK;^(#P!"(^$;SI#3)J3O??`B!YN:R$GMC>(#%B@'PAX MH5$<(:844.$/5`#(`[HP%0T.(@#&>("< M`'`*!.2G`(.9$O!(.`@Y,8,#3`/-U6RX//#)$!+8>V0E:)B`L`"`#@,X64!N M<(`Y!$6-AG#``'=A!P(LR8A'"8`";.`X.`8F41#``)]0`<5!F/`-#=A?-@R@ M`QXM0$B%@((7X"*.6H&2$V!\!!M(L`)>K"!(J)!#!\C@0W>,SA#_6MO3:G2' M@"1@(`/P(\09+``F8Z3`=?-+03:3PX+\9(LL"7"=>P2@.P,(`!M\"*@#2D*L*^CD(`5,%A!`F]`@I;M(@A&X%P1_1:0<38L52.9QQD4@`(S MZ+`;M?R#!0(#K6QD@`(ZT`(1%Q$&D(DL""+H@28ID4Q&7,`-F%L`$D1@'E`P M0`;HZ,`[KNG/HB(NAD:-1+TT4"%2E)0K$5A!#0"XP2,X=`$K0.I$90(!)IX+ M5&UPI#U".M*1//48^`(`?Z#@Q<)Y`0<3R0$#CCF)FE:UF;XX0%LU00""(`&8 MW2!J4@?K(*T2EA&#PAHIZ#!+HT`!@%"0_Z`B"'!5#[A@IG]`938^J("2JB`P M7^.@`N['D9!F@`HV>`%F,R$`"EQR(1[PP%X)L3*1><`*>-.$70M!`+SJY`!T MU402S@$P>`CVL$GM)W(/(2$$Y(MB1A$!$:+0DT8<(:<>Z.(C-'N,P:&@#2!! M@*H:$]*`3$VM04#'`B2[B('%8"(K`&XE=OL'`N1T`0=@+RA\(X'J&G>Y`/Y3 M@#MAG@!8<@)G6.T[G*`C&%2@O4?8VRXZ<(">JH6BF4B``MHP`AB](#`-,P`& MG%B6\NKG#*8"A0!J@P$EZ&@!4O@A"=(0%P]4P`VZ@41-OY$#<>S@@,=8H"MJ MM!F2D;1!/@-X0QL: M,"<3$T(%;;"!?-!*B@1`82`U>(4W"+"#JRX@"`>P:S)YH$6=Q&`HVKB!%6C6 M`?W^U\B'1?*`>_`%YY(BAWE)@@R0$.-#`'$R3JB$EAEA`!7!"`->3G&@S#P( MQJ$@:=G0P$"3<($5E$^!#%##1((PUT8D<`F209*%C^$'1L&`#)2329$1G3U% M`_@"(&BR6KGB@F#_`3F'",,!>A$$T'!&SY:;,`>@@5T^&8W,E`;#5X` M"35`'24NX(1I4R2_AB"2!"H0ER0I>!.+"NY0_SW8@#_2<`DP@`510&?5,EA72;7X_8B4\(UD8*2$R()!Z!9 M##%\$@`Z# M$8;O!=TXX/B`.L+Q5_H'+QP_,\$?_GH(<'Q`_X$$Q]?-PX>O=P'Y7%,<8($> MBUYTG4$@!'ZA84#\0(08',*^XJ"J)-3_0HM7&HE;MUQ==R!\D6ZD0&(BP`H< M@@I'D`-QL0`=(`)QL0)R]@XDP",PL`#W=G?6A1@>0`A1A@X<(@'9T2B`Q@"( M(0.$@`.(X6P8B`ZZ<00>2`AG01`+J'3H`&A+D((`5WZ:D@(#X'?LUP\4X$>> M1PCRUPYL`%&%TQ6P=P"@!PEEM0%^\6$C`0(U1`$;H$\`-H"#L`&!<82:$``L M9@A>L(#9$`$>L@L@LO\+2%"![Q`!&(@#AF=-CB"#!/&!@Q""Z3`()$@0-7"" M/#@(+$@0+H@8,3B#@U"#(D@(.`@#.CB(\W)^C<$!`U!PR@9X"#```N!R;YA[[\``D[,9QQ4!2_",2]!3$@"-2Z`;"P&-39`9S@B- M0`8%U&@B34"-XT.-TDB-.>8'U)@924"-[:8IE%@40"=T1,=^%&`!J)$"AI>$ MQQ`&.$!%2-!N?)83'K`#M[@(+!`'9K!F8/A=R\$7+Q0`9_`%=F=D7O@']P+_ M:=G`!P-U,@=`!BN0,-E``,)X#PQ@;<_&&?Z&BZ/F@T9Q.P-`)G]7=(+W`"RP M*I.@CZB0!-E1`S%@(J+4*W'W'@50`+IDA6_@%PW`1$(Y`?8Q"-@V8!4)#X[6 ME-EV#@GE>S-Q#V(T!T$`DBBIDO[TCNZ@`2%P!DTUA!-0`!"0`'6(6*!H$H3@ M!$C@7RM#;000`H=C!B-A!H2@ER.Q/QI@!AO0;;\QD5`9A8^@-F?U%8^F"`Y@ ME0N`E3IF#S>0!N@0!=4$&RD)EA`BEJAP`0*0`!80DT57A`DP>OCPEJ#``T3P M:EUCB%D`1B MR)N&Z9N(V0@8A0)<6`D"0`JDA48Q,(SS90\DL!WMR!EPL%H`D`(:H$3?Q`<@ ML3,!$#2V]`\BYCLUL3`6N6[,TH/P`)KJ5W!#>"CV.`#X6!/T*0E24()DL`,2 M\``CD`>^U0);T%&#<`'FYBD7``$0H)P(`9:_.0@$@@(;X(F54"$3@)J&<`1P MF`G,"0D1L!&6(YE%<0;OZ?\(`+`D&+`DX5(JMC0_O5,`#P!I+(``HI("!I`" M(7"G0/@/X@(F,?$L$!`3>1H:N",:26`!(S`8&F.H&0!.%A`:N^F.Z2D)2<`' M`R"/-SJ3"6"3/*J:F0`$6I"!;G`!&@`&+=`*$"@"MZFD\]$%*@",VM";7;B@ MC9`"9W"@F1`"3G6'*Q&F--4-#H`#:B"E,J&F`#`!8D4($$`%`?(9LZ@T`G"B M,"(`E8H`U-(``Y``#7*H7O,T<&(&#Q`"+Y!#=!`*UVH!)Z4\`V"6%Z!:.V.M M05A([\JI+'`&7,.B,@H*&5"6%M">8J$[`X",6]&C]S$($K1*8#`$?R`%B8<. M,M#_&U3Q!@I@J_:`JP*HJT5Q0P#@I8,P:.B@ZDIH0F@@PC^Q'!Q8P`**Z&0I["'JI`%<0!4L0`(%A!CVV`/S9 M`C3`&1R+7%5Z"!1@`PKPK)'0/:?1"!=P``2ALC&7#0F(#KUW(JSQ`@`P`U@@ M"8F$<6;0#+MY3X7`LQ<``'P0`D#['$*;()27'UYS-'OB'Q?`M`+@M'9Z-.5$ MM%5;9BI;/3!YHUES!B'@J[#1HU7Q1H-P!B[2`C0C`V$@_V8MT(8+L`,@\+5; M$;>)YK&.D`&!06:;T*BD8+R$8!E$<`>ZE0U19@7*:@^T.!(CP`=,YPCU\0#K M"@#Q.734$KF$R;,:0`$!,)0LVCLL"@#MFP+KH@&FP`(A8``[8P`<8*?861H( MIS3X&P+Z6P!G,`!UBIZ-4!IW:G#MIY8#P`=:>B+;`P%T`#\(8&JB$@(VD(<, MT`17H`5M:`6+MQG(2UASJQ^FAFJ;8!I[ZP@D4&EBJ@U6D)D"D@$8,Q+44F1, M5E*C*28&@!^'<#N%P"=D80#NFQ](/!^;\CE``"F`&M"L)KG4;D@`%%5I7G.`%]HG/*FA,`"9M`%+Y0"#;`!3B1:V.`)`\`X;[`_956;-00="L`!WG<$W#>! M8UH4@/QY`@+#B[D(;'`.*R#(@U#-2VJ?,,!Z`H*_!\<",'+)F+P95P`#+>`2 M/E`'?JD`4E))GC8((>!E\!.KW;:0?C*@"E!Q?*%$7951\Q$81Q.KSOLT3.07 MWM4&2>#_";2)`M"2`LA\A#]%!-4%<5AE2NARS4:UPHP@`%0Y"6'!)9"P!DJ' M!(8V;]<&I(!;%`A@!HAK`9[GPXT@:NU\#Z>J'5&`I&"0!\,P!M\V)H%A07P0 M&/(+H'M)".;6!@0X$E^#1%^CNR/QBG]@:@+JEVW@88&1`9X0G#:`%2%PRL%4 M`52D!LSD,A8*&R)=5"2M"`7`.*U4"1T#`-OLF(>14)$@SB)`N,0*&\'9!@7P M444FOXNPNCWM#GV`&',@`T!A`UO0(S5`!"W0`F"P`PP@!T/`.#806N8F;E:( M;A3`.`W]`*@-$@%PFPH`$AH`AF\0(&AF`]V&`*UH07\0`JND_QJ>0"$C\*"% M$&4^635QL%50D4TJS2S0A!<,*.$0GT!_\#@YW-AH(`">")+0XG(0"?V5(`(?"* M<@(!%&">.YX)Y]<#9[@"<1"!AM84W[0`5-%\>\P M`.:&`ET.WH]@'0E0$KSZ!UF+`8-AM&HENS1_TO>./S,=,R3@!4;P$(\HO%2T M(T@0`U[``#RP[,<0-Q'P[8%^9V0N21;/=1@/"73,V/;"8CJN"!V9`S#-S80@ M!VD.&V)CE(_`SCTO$_DN=3^^`VD0$=K!"T`5!46.9T>P!!;^B87#V2XP*V=O M]1@NMUG_"'&L<7JN%Z2@[HBUG`K1D2]](FF%Z@\@O83`]FT?$&_?#2TE`CNP M`C*`5T1NZ-P1!#$@`G(@=U[!`^S/U/?-0_L=ARYIY?B-<%`P$`0;021^8)4RX)ISD@$8]08\ MOPB:#PA_@H.$A8:'B(F*BXR-CH^.2R20E)6*84M.3D.RM1IF2D"T2F48AX M6"`CRH(=N>0I5.1KH<-&Q.2E,(=B0B4#`/\`)-C%@QJ,'=@,,+"C=6V\HW;C M*8TW`D6;`98P:N3%QBJV(_^0Y#V4044<`!@RZ"J[N/),M9;7]7"0F1W>SN#V MQ@N@09>`"9`E!Q-!"\8*PY93-#"WH?1DT+@58LX=;#-O8Y]_[Q+M,!HDP1N! M^?$0*H:$SBDPV#!G@Q=EX=B![R3?W7K^^#ROV<,";-@8@"_>=(<`*F19Y#*IFCFB,(9`08,'(\UUD(J`&` M``(%C'6;(G2@8`,"@R2`WP;&_:&"A^D)\D`Y<1`2!PIO/#`(!--A,,@%^"E@ MVQ\6M-$&B()D,"(A&/B5XA\"E&-&=OX5B$B`3C(47I0&FC2;7PLVDD%&!023 M36<)C#`"`$<"<]TA;>0G"``4G2&(!A0U,$@7%(4@2`A-#7(E"K:=09%%?R2Q M`76#($`1D"G@AP)+@E!`40K8-4DE(5!.:@B!E@Y"G#P)-+"!C)0T"``+$'9V MQJ`H.&7,F89,AX*@QGQJHNX>3V043FO@J/NQTQ. M0G,A'F<;LJ4C*Y1`.6]DJ0B%D(5;&009C4H'!AS(?#-_'$^:'0\"MIK-"!_L[<*R6>/@ MUX;$[*"]L`4%//A``1D*`D$!%KR;07)_`)E(>O\92);`P80\8`$"%I3X=-14 MNCTIW%'*[4X&%KP@N2,H>0TV6AH@D*LY2P;."!71G$RO:N"^,)8`DH^P2)<# M`&;`UG]`8.P?%[/]!^A1BDXEZ4Z:GA?>%K[.MU?FFJ/J.H(+@CN1GH-+1W+` M#R+\'PE@`"GP%#3=Y003L&``!!BLKO`@&D!`!Z1\"("_!H"!KQ4(>DZ27I2H M=\`#(24%","<(KPR`;L]8F\SR0`&,D*!`'2!`CLZ&R-8T(7E_6$$%KE`>@H0 M`I<91P`;B(,,60(!$*D@`WQ(009:1#SC32`#QQL$O0:1`CXDH45T*$`2!O"` M)`Q10`@LD`*=Q$`H.K#_*(KR%R-2D)'57=`L'+`/``H@--LQ(@D&D$H%"7@& MP%```4W45_#^0($"((`"(1!`#7GXA^+](8@AD-P3_\"!&K[@#XD;P8644;VU MI6V*!:KB?ZPG#P'\R1$4;!XD,.@2/E``/S;0HCS"1PA@T>M4DM&8'-6'R`0( M0``7*,`#+B"\'OXQ/8%47P@M8(`D`"MQ5$C!*ST'-4<^#9("DB34KC@318&* M$2'H8B4X^9``8*`OWEL(*0W00F"IX`P!*``&;*1*0:1/$,(S``8$8``!8"`$ M9Y!3EUB```T`4G(L*!L$W]*P`-*$X(,4.M8`Q-$"AX`*0T\(`#O M$\0`2%,:DQ+"I1!H6@;.P()EP%(0'U6909W7-LZP;:'B:6A>$B#-3-!NC6=4!!-?G**,L1D=)[P M0GQ$I*8',>9&T1'2?U`=`E2E2-!HH*",6.Q^[(P=/%=+NF;AK04+42XR#]H= M2?#*GI2K:/$.@@-``E:EG1Q$1.X+U(]6);BZI,I.?YI>73KSC;K`:[1`H`$% MN$`*>@RI6+[`L*H6#ZN%X^K`DL"'*SC_:<`$1I==Y9N8D/%RK-K$CU7GVE5Q`;&0<" M'C;@`5R`5!EX9EX@H((E:6!]<4C`G_%'B)-S)^6\63EH6FZ7K@!@`E4M!+QU M84T`C&"^=D%L(3A*B&(G=A%=40`&+D"'"7QR`-*F4-OI?"VCIDWNG:&[25PZ MZT'0'`#G3<3>*\$'#*A``6V(`WB+(OB;(@+5AU>$`"C0!3>E(`4D6M_B)D]4 MN.<&\YG1?''\9EA&.P/OF5T'5%*BM<#'_B4)\++#V*<`.V&`C!NPF]NSXWO< M`-\RPE\(GLQQ2$0P%?3)/VW2.HN"M[+^^2X)P`CH0*H4%/_`-A=`0/W>0?F. M6?YIWU<9X:<0&F`KOB4(28`:ZR1ZX=!6&6$`&C`!"E!M,]%Z\!<,7M3&`:)$$ MSK!XB#!ZC*"",&<#=.!S:/&",.@0,B@<--@9-CA7(5@96F=:A2`88D<(/J@( MGX!H=.!--.$:X&##Y$@T4((C`<`4G$(5X@(@C$!>U)\:V&$ M7B@/2?@;2Y@99*A83[@8YP*'#N*&O'`!7>,ULO$&%&@6=GB'[I"'O+&'EM&' M9V&&Z&8.TF8(L\>&L(>"EC`.7V'_0+A!2DVP!*9XBJB8BJJXBJS8BJ[XBK`8 MB[*HBK`1&F`8/6+X,91H%I:X$(6&`%)H",AA"&\X"(4&`%V@``K@19U!2CWA M$]`8C=(XC=18C=9XC=B8C=8H`NL`B;DAB96QBUO1BV=Q&L\`>\5(*]RC*"B0 M5I;AC-H8C_(XC_18C]'(C>K@C;@!CHLACDA!C@]Q`:>'/,-HA94@;Y"Q)XFV M&/!HCP[YD!!9C_@8#OH(&OR8%_Y8%`#I$`6@*Z'W)ER2)6\8'5RB`2&`'\SH M@HSPC/M0`R[9&J$`%*;@#_)(!$C0`2QY"DC`#=&8"AT`D_PP$#`9D=DXD;;8 M>[FH,U/R_SE_F!F.8@[(TS68`(U$(`)I>0,'8`HRP`-^X``,P!Q$693=>(L)E)14 MLY0WLY%AA1_]9@@1.$8&Z0B>A(P*8`9AL`,1L`+=@`-VN00X0`9R(`)] MZ9?Y")A2))AO0Y@T8YAF(2KO,GHI4"&3182@T9"F8`1>L)/1&`-LL`(7(`-( MX`<2L)8Y\!Q0(`-!P``'L)8P$`1_``K1.`<7L`*?:0HUP`/H"?^-,J";,&`$ M]?F;U6B4QE"1G7&1=I&1E]&4W[&80[1WT?2`J-(&5]F,6>D3#'`#4'`!.'`+ M!\`<H\`KH61)H4!@H:?F(.;2@(`;"# M@J!9*I@1ST1=WV&E,-`!`!%X`!00`!2>Z!-"X`B4A!3#PF0AA"K@@`W^P`D1``(/@!S#``R)P MG[CI!3Q`J[BIK,LZJ&P#K6*F,4+0N>;=XF[=ZN[=\V[=^ M^[>`&[B"J[=>`+&/1+;38[;<8K&\\91#A!(3(`:%`(K/H$EJ*[*,P`":N[F< MV[F>^[F@&[JB.[JD6[JF^[GD&IQ">E2**S*,BQM"0BA`E1%/(`ZB\@)FP$A4 M0DI^T+N^^[O`&[S".[S$6[S&>[S(F[S"6XO_*;9UA;@+U+H\\[JX<26U`VD9 M81NHDS0P\UE.PKO*&[[B.[[D6[[!R[S-ZKR,!;U4)+U60[V@(0!40/\%(015 MV<,!W$-QKM(BN\L(YON_`!S`_XN^2:N^J\:^D>2^<0._W-$Z]1&2%\`F6S@I MX"O`%GS!&/R[!!RVJWMY"EPZ#)P;20`!^_>D20,`W[4P"[D?%?R[--"[-'`" M3``$OOO"&7S#PJL$)2##0O"[4\`$3]"["[6(`% M?@`')^`'3-`$6>`'0A#$2:RZA,K$"N7$#40SO`48<,!!KK*(_Z'%8MR[=1"\ M8US&CMR[:]R[8Q#&9B#'ECP#2)S'%&G`XL;_QUWEQU9$,Q"0)D&##13P``9P M21^#R'[`Q4H0!TRP!$)0Q*W\R(_,!!_`QDSP!32P`7Y0`B60!5-@`E-`RQJL MQ`CER7<%RI,$Q;AQ7[8A!\MP=DDJ9Y;"REP\`U50`D1L`HELRV3\`7/\N]S\ M!`W@!TL``FK,!%B0!4,`O!O,"TI;&4R[%4Z+A,XL'.*R4RM<((B\!%P?\S>"LQQ&KS([%S,OD/`BP`=#@/%H, M!%-`!7[0`'B@!"=0!R<@!'B`!@>=P2;0`$,P!&A<`KV+!U3@QKU;!5/@!R?P M`2<0QKX;S\/!R2B'_]&OI=$,E<^Y$0#UQC9:/`4ET,-E`,SO_`%#P`1P\-(8 MC`Q9=8`,;T,_]NPAYO=@7O-?#8-1OU]9W]M9?%=>P:P(/ M>LW^R]B6C1OIR!]WW=FJ;;R.70E]G1=_712!K1NE#1JG MS<*;O=JZC;RM30FO;1>Q/1.SC8>UW1FWK;6*O=O*7;R]K8$=#("C#5E$==QT MF]R_"P=,T-/H+,Y;G<96_;L@\-7=_04?8,-^4`930`--P-E`P`0-#;P-#?\$ M6'#6()#)%;W)S^V!T1U;TXU56HP',Z`$N2S'NTS1-#`#0_`#`^X'8S`%Q=R[ M5#`%3Q#'35`$53#AC/T%8_`%V@R\<.#+?N#.BVS)FGR4>SRD^QU=_4U46LP$ MQASB[^T',0S)OCL&/JS3/_`%4T#119#6>(T%#5W'OEL&)V#3?A#$3-#*9ZW6 M%GVX*.X\@WT6U,T=6EP&8V#D;QS1?H`%33#C%U[C,U`$2-P%9UT%$TW+3X#E M7$W1(?Z[3T`#1EX$>%`'(*#=)=Z\^3V&*9YGQ9T94YX=B/P%6%`'0@`$,X`% M`*`$/R#C#5#D2^"[)@`"<(`&33#),!S#-ISFB\W_YD+N!R!@TT:.!UA`8S]< M!&7M!\W]"+^]%L$-$\.M%WUN&7^.'7=-`U-0!"\,!U20Y#,^O$]@Z`W-!"#` MS@Z]X%S]!&+=YF)!HN-!S;^Y3[^R[X+`FN,!GCP MX/=MXA?]Y&P3Y68QZU7J[7X`[7&@TT_P`G7P!4,PZL8.R6/P`\E>!7&`!CW\ MQAN_Y'D-`C^@TW8NT37Y$M,\&EC\%N!\+^1VLNMW*D>"9#-?=BN M&3+/&S1?\[I]__,0D?,SN/-QU_,L]_.+$?2Y,?1$K]I&GVI(KX1* M_WM,/W=.GQ=03YF*,/5BC^K67GDNSY3<#M4*/_:[7?6+L.IHT>HO\>J/V/5V M\?71N?9LO]INGQ97KX=9[WU;GWEVOQ9X#Z'6O>]88,-=7@+)+@13\`%E3)`/=G(?'[BK`OETG_PU-_Z&N[C-##B(``(330G?GA9?H@-B$5?8S]9BG!U16A^ M)3-8-&-%+UE99D.(HJ.DI::GB%^'B"9,<*%^)TU92DRG-W^YNKN\O;ZY2R2_ MP\3%QL?(QCT.RQ()(@^"4*7Z&*&Q(%=47*B!&S3"12%3_4S1?JAP<]1%<2)IH M?95,RS97RK9L6\)M*W-N6IO$2`E!]*$*$ZA+X@!8`I244$1$^\41$GCIP()0 MI5:=3$I)$5A^(`XAM$0HD(YHA.0D5;;;6;LTUZ*&^7;U2[FN8=:-O1+O,%)8 M?LR@@FA&ECI#L$R!,W84;U%%]A[$4F1&1RQ[X0ALZ@?$!\K8_>0^<0(J(3]/ MFL.:4J90D55DQ9VF?5(U^Y&MWXN$+7_D[/KB;/_*SK^___\-E<;->OB1Q$R! MX<2'X#;T+J4N5:OZ!I2Y6`BC@#1*4:NJIJ*9J*@\BJ.KJJ[#&*NNLM*)*@!2UYJKK MKKR:*@4!O08K[+"E\N``L<@F2^L1RC;K;*HH@\L8HMA)A0 MG+]F1=OFTU!'+35:I`#QP[M3V%P/4$J@=U@_B)A1AKX^0W5H'6@T\,43^8!0 MA0GDUC%&'.1B=\*G1-/`Q%1(-V&S1^HY/?7@A!=N>#*E#+%;;\[I(X@"<@D453UPWQ0F'%#;_RM>$X)&.)=MR MOODJHY=^.B%"$5W5"?7X@9ZV/1&$2'!U@+`\:``=(0!"=@B)%4%\#.B(]>XR"$#LYU`PVY8=W_

CE[P@Q,"(0/4.$$ M9@"""9A8A[>1:P--7-ID`/"$+F1E=<7!0BB>.(-/O3`9`%"``70Q`1\V(!<# MT%T`B4C(0AI2)$/"2G]&=XJOS0E^_\G```4@\`<^="$7./S#`RSPPT-Z\I.@ MY,:0WA7"?I'"A8^$I#&2H`$,#*``?Z``+/]@A@3\004!Z&0H=\G+7MXFE<"$ M$3(L:88)U!`#.P0>%0"@.UW2`0!=T-T$5#`"!/P!`ET`P`AT@0`%W(@"5.@" M+.E`36LB()LJ^`,&!-/,&X5`!0!X00`"()@1!"`)+X#F'C,`@`DD\T88T*;N M,#`"%>CN#-GL@@8@`(`\AD!'`8#G"S(@@'QV88DSU@,!Q<[2#$[-Q1D0D`$5 M"+9'!I@`!#X;6DTR]`54L*627L""/_YA`/PCZBT%H``Z3$"W/3H#+CWZ!P", M]7\#H$`N"F#5'FG@!6K-!1_,8`!*_N$%?^C?"#C9H0(48*NY4,$`#&L!"JC@ MH1/0'6;7BQW-.N,T#_!I`EB;SC^,E@*<-"R-QMO763:@M=7-@$W_WZ"D.%#2 MMK@M@&Y5D(`&)"$$V.U1`C9P@0`0U[@J^%T"E'L!!=BU1]7\@X[ M);9`)AV$T`L@(*RW/(-A$4`!`9AA`QNP+'MW'*#`Y8(%]%OJ'SL<59T.M0#W M>P--372&B?XAL7\@!/$UIU`+I$,UJ*.X+1)J.^-!O""&@KUK`IH MK`_E:@#N]J@+U@7``*X)@!10X0JE(J_$\%-]71`S;04!9P`)V4I<(( M]MC0?CJ(`PI8IC7!N>S;9I,"_VNH4A7-Z&[?,1P2D$(N`M`[G?XA!+G,10ID MJPMSIXC GRAPHIC 27 y80744y8074411.gif GRAPHIC begin 644 y80744y8074411.gif M1TE&.#EA8@+]`.8```("`KV]OY82$ MA+74W2A_FNOS]J2DI,/#PU]?7[2TM*;*UG]_?T]/3YO$T(R,C/CX^)24E/W] M_IFCIO3Y^BZ"G/3T]-_?W\G5V>[N[CDY.;K&RO'Q\6YN;HJ3EN+BXN#M\;_9 MX'-S<^;FYJNUN>KJZB8F)DJ3J3>(H1I28V1D9-G9V6%Y@'2MOGN#AE-35%F< ML4!`0&2CMOO\_$&-I<+-T0%GA1QXDU*8K;2_PW^SPM#0MMBFYT=]CE MZO'V^-3@Y8>(B5QB9.7P\Q5SC\_CZ=+DZLK@YM3FZY6>H8^8FV^INVNFN8:. MDF>EN'1\?J6OLP1HAI^IK&AH:/GZ^UJ%D=;G[+;,TUA96:[/V4E46&%G:15I M@F=O<=39VP9JB$%S@AH:&DE*2C`P,.[U]T5&1EE>8'!W>1!PC-?CZ+"ZOW^( MBU^@M,C(R`5@>P@_3];6UMO;VVR@KQ]MA#%^E/'U]M[K\/___R'Y!``````` M+`````!B`OT```?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@ MH:*0)A"FIZBIJJNLK:ZOL+&RL[2L,3&UN;J[O+V^O\#!PL/$Q<;'R+\=C1X4 MSL_0T=+3U-76U]C9VMO'4;>+ET3CFZ11M:NKEY.[B\/'=[?3=[/?< M\_K9_/W7VH`81;"@048HO!PDU&0AH04;'`IJTD#BGX86,4H<$%%B@HH2-3H4 MN1`%2(LH4V)",2`C2H@93RXD>9"F08X6/[K<*=&DRI\J`TABR=,AS)`R:Z*T M61"GQZ0&F1*4.LJGHP`3!CD@@:$0`0@C!$6`8$)2$ALVNE:R0`&1CC\&_V*H MD(@@1AH+?VS$:!.61`PU81&``1-!$-&0+SN.A%J0JBC'H9PZU(FX:$G&AW`` M`"#(31H(+=2\%70``-X1:6)D@'0AQ&>[JRF16'-H#8$_`2AXD)A"!HEE92-$ M0(`73XP_6SJTOO#G\,C$,2TKM2AY(>51*M8`",$<,BCOGZPRPC"$LPD`#G`# MJ$/(1@L9!`!X`"'\[8@'"!YDN%#G0@#F?\2'@"!X_(&'`7^`$(`.><@@`P(J MF(!`'@8BJ*`.L_W!0@`(('A`&D.8H,(#(#PPEPGL=1!!`,M\8@$$60VBP`%; ML/='""S$2((,S;54F41'+29=5"A5=]!UHEBPV?]Z?P!A06'/620>(_']X0`` MAZD00(`/-Z81B$0X*`>""2TD`8` M:^@)P`5UWIEA&RUH=T`,`*0Q`0%IU.'F'R3PE08.+4`0"@%@J(7`%G_$@."- M'B0AR`0']#AD04'.A-DHX'G2:B=&&H3D)A@`X,9B"T`:D@ M.(3E7+`6I5K3JH\M5:3_8M913$D>2PXQ"`9MI.?!DGA!W)/&A%09@7Q_7``` M`75,,(%0>3P*P:3,'H!!&EM\UN9M@Z@!`,!_N(NGG1.L`4*U'AB=80HMI`!` M5FG8FX8!>`"`@+K&,HM#@9YL@4,,%LBP+0D/Z&!#"FKLI@`86RA@F(]1`HGQ MQ*=.=7%.*#-R`!@0M,CQ9C$:HAT`I9KLT+"*5`E"F!?4&N<@;9+PAP4M%&C` M""U,<$&E/Q-2[1988W!!#&NH(/71?R2]M'RHJ_YN!UJS,/4?+8AY;P9Z'GVJQ=117]"LDHR@&0"6"Y+$ M_QH0['8(#P@DKOAECU3YAP)JWEY(Y0F&$%H+'A"J!NA5%S)!&@!,`PAJ%1IS M(4UI3".@T/"T!BZD80T4Z%Q>%,4H!"4!/1HJ4QN4!@I<1>)AT[%;=*2WOH/$ M:GO6&T0&$$``9*F@!9L1ER`Z,#Q#O(H3-]P$XQ+1`?/]004(\"$A=&`"9&7@ M`&G[0P<>P`(0L("(1!,$"U84&SS@(0,>R``(YK+%_7C@+5;$HA;GLL01-/$/ M7*A#'D;@`>9/;(BY@@N$=CO\S@U`.)#"B)`!XK#&- MA*0J5SFW2XJBDHUQI"9R.,N]/44160.`&I#U+``HK!(8@6&B[G@R5AJ3CG9$ M)1Y'6+=F+N2$!$%2!E0PO`L:75(?)#I@(T2H@)X)@AXY M%9%,<(H0*:X,!2TS`4U`GH1=FQF0P2#P@$Y,%!,?O<0.#^&K)0GT`ATZA#,& M`0(P;&8-&4C:)-R'B$`-XG^-@,!F0'0(/#B@A@=I*"8?*B02GO.9?PR%`=80 M`Q:09DF'_$X?]^F(X5`*`0C_<"KE^F>(E8XJ#0]X@*AD*@F:'L*F7\UIHXP% M-$*00(:+,Z<^%P)+/494JIE8C($`; MW$"``AC(P`5#@``3D(`"-BB,5_^0+F"U+G<4N,U8*,"MHD6`4W4`@PW2$Q^V M9"4#;(%`J0*E`A*`80USLBP%DJ`#`Z2@#GTM6FZC9B4;@(&)>N+4%H3B@+$B M8`@/F``"+NO9EB$J%'G:L*D9@(!9/H4[38#!A+*4VL5"RW_@&W M:X@`;O,4@G+>]1-U914_+Q%22_2X$A6E1(0&,8(UZ7(04FM!5.=Z7HTFEJJ+ MI0T!O'4C$H3N#W7`,&KQ79:`QB8LX:LX%030DTO M455UX^OE51-7>ID@1G`XN`;2H?^D`(@0^XD?4V*D-:4-@><2`F[U;\$(J%5^ MVU((.2,@S)P)P=?:\0?TKFQ%`@8-;IUH`PSRE,$6B!F0=D MNR'@X6##ED^Z'+"%H=6I5SA(@IY>K`:?8A64@[C9'VKE@#J\[``I`$&ZNC*I M_W4;7(X.=R8B+=AE:C??W+V)N1-1*_X.PL@U5L2])0UT@IA`#6#X5B,P$#X$ M#-P";R%`&Y+P@'9@H"T*D)M8ZC1?*UDN`.6U``Y(,`&Y4W&PX"@&IKJ[ZX@1$&`(DS,RE?^0AQ3L:!%+[_DA@)N"L%C: M(48.\4)W3Q">/[GI486U>T7LJ1O\O[Z MX1DWOH'_$O0G"0$8"2>4:7_B5YN1=)?0?M-'"!GP)K_B?A&S!/E7@?K7 M=`3Q>1+U?Y,P@*-T,2P`!M5F,$NR?GE0!X%E"0SH48F`1>O'@NIE@3)H";XG M@9.&-_LG_PK\(0>$<``DH`"V]P>^D0)29UE;0$\L0`)NX%DCD`(<-@@Z(&%X MP1%%5V*"8`*N$3Z>L()\U'F7@``A0`$(@FJ'P'P&$80SN'/:QW3<5U08&`IO MTB@S)$PE\P?? M\X98>8`!9A-K.%!HY:5D+O=T!'`>!X`:`D6+IV:+ST=)_>=1T[A-$N$K!?,' M&>!2=H9DFU&'\L0E*P,`T6@@>P(&L?$Y`&`G018*C5A/BF",`("&/'805](" M[+&-05,R(W,`QU-4,8( MMB$((Y-W(>!2>#`!94F(D>)2`>`U[;4%%-DL<%%B2;<&#H`!(:!3S-580;F/ M1YD)15EJ`?F!HW!!:8!Y$V%+DS&8C^#_';$F=5OI="!IB8Z@!M(W,G^@`W@P M!**AF9RI`US@@Q"@(,\&*12P##%0,!$'`BUP`0ZD'QZ``6L0%@I@*7WIESDX M"H'I?W\)"J%@.^25G(^``>65+>W5E%/9)>,)`AY0H$XU`@>@51D@`U?4,E*G``I%GI!@ MGC!X@Y8DGYD`9@KP@A[X"%CY"5HIB8Z@`]K1`OG8@3JX)%IH&(SY"4`EH>7) MCS:(BY2&H9*P_S5I('V(T*&.\*%;V**(]`@N1S@B&@H1$`,3$$4F":,R2*%> MV88U^H:4`&^*P*.-X*.=$*+$V0B#HVE;^I5,2IY.ZH@^EXO#=PG?HX"'8*6, M@*6JF-`(%IX$^ARJG2>)0/P"P%18W$XRN(:*J>BJJ1M)Z5D)XX]*M5 MB@G)N'I!"I^=.I0Z(#1\8I^=$``I0``O.@BG"JSDI*I?RJH7*JB,P/\":D!9 MA(FHBSF4%_`].J>KBJ6MM,BM<6JAL324+-!-6W"MC@"JBN"FFP"GT@H)\P96 M_WH)$K)(B+`!-&"L[FH0\#JPZ/F/Q3J4UL0D`$BK*"2L%9L)";89%)((.B`! M+^`#"K&P:=BP&2NO=J6HA%"%AIJO%AM-"KNCHT<)!HB8A9`!"_`##,``/E`! MCK`$)Q"T0CNT1%NT1GNT2)NT2KNT01NSXH:QDT"L\^>T-B0)*H`Z*8"ORVJN M\0FNBG!KU>6R&>HK'5L(2Q`$'+"S+T`%%-@(.["S)NW M<$L#UV>R*%JIK7JF_A,U6LNN#L&OC$BUA1#_4@]Y+`*I"2:``0:[`1*0M@S` M`5.P`7OZMGK;N9[[N:`;MWR;JC)ZGOX8?$%7"(V[9/%ZN!#;KXI[J),P2(3X MN*$@`)S+`"[@(WLJ`17PN\`;O,([O,1;O,9[O,B;O+^+`GU;NA4*J-_JJN?% MN@Y+?(GJM8A@`GO2FK9+LQ!`O0V0`W#[`@LP/-E*LJODMX;KK?.*H0](/HMX MLJ[;3@>A`UY0`2=@"2;P`)/YJ99@@/[$!A7P`FI;`$EQON@+2>K;O>R;LD!' M`&O3(AG0OZV[;MP/\"*F$W%X$@`!A`0$^M1L>8`(.4"H7 M0``.P)P$$`"HN+\(\()9>P@&D!4@D,O,00(^12$R("$(T@$.0`!S`1]0PO\" M^!&_V_K"9(JR.N82:&=E1!;(_6C&]/L(:AP&!6`%<@RW+D`%%;``?O"B&I$` M04#`._O!(+%:MWPP M`2`W%H!5!P`",1``29`>,3`<]\``61$#"!``'I,"#D#3K>,` M'=(!)$#(Z2%=%UV!CRRVY@QZ&7$!!"FXHX"XF<"`&;S!'3RW'/`#-%`!"="V M>:Q"3?#/FU*+@V0N8%#JPQE%-MSM` M`RQ\$1Z[`'+L`BI,J9#``S#0`W#``.0["9"*`0Z@`Y$G`QX3U\*MW$(A`PJ@ M`I82`;0A^B"7'V@A<(`&Y.P4I+M$M;(%#O;4K M#MX%42V;409^WMD[7@D-S;-Q.]55[:\([0A0<-8!70"QK9";(=;PS0A00`5$ M0`0^X`)AH.@3>MF=KH9U#@EW#E**2^H`8.K)[J&I+@FM;;D^\`(W$`0+P,[? MQ_\(&U`!`"<$L%MRX(2,_`EC`` MKKVS/F`'=S#>#(]&F`ZW4_`!'L0)6:_U087S%1S#.Q__-B:U\ER_"#&."'X@ MO@&]`(;P]EZ<"5P`[C[0`YJ_`T\`5!H!!:CL`BCPD(6\(B8A-BHV. MAUX%.PR4.T$NE`QT"88J)"0&CZ*&*(*CIZBIJJNLK:DH`ZZMC+*L"QNUJTVF MN84=&!@LB;2]J,3%HP.XKFP%_R^4+P5+CPF\R(_'UX07!%5!DY0^##L5;-J- MI:,8"NSM[N_P\?+S]/7V[1CGVK#ZCMG]AVX!5+3KG!H``$(,&TB082)EK3*$ MX9")RI%1U1P>^J<-!T(P&19,\E&`BR$#>`:F$V5A@LN7,&/*G$FSILV;.%]: MT"B+'T]"'!T*_#FHH+86"-,L)%J4Z2"(JP3\R.1"`*J,3(,B2X-PS:`,3L(< MLH$P!<"5CR(@6,NVK=NW<./*G4NW+ML(/Y%PY#!T&/GR\"(*BLH36H4-_ MCEU80/\9A#7ZSA;`%4`+VH?SU#^?WPZ[/^",H-JBBT M\EU\Q/VC@P7YJ.?>@D1EH(`P?W2`"`@0_@$?3_J=0Q^&]JWB0!HA2.A/@=4M MX\@&-&3"@00ZN#(@AC]UX(%T&>[3(8,X%F/`%B%8X`$%+?RA0`H6("`D"2X- M6!09XN#!+#6`X,84.<%@^#_X8`#(@Y2AR)U M/)KC*AC(8-8%'7BE0$I_9$!"BSB,8&$L,9X'P`1,2>D0E;58"4&61'&Q0`$" M+`$E3UR2\A\E-P28RXM3\J2`E0'0L@9"26@49R,.!*"#"8,08,`%H?P10`0@ MC$=("AYXH$*$%IA@P$XF6*""`004DFXB:TVZB@Q;@/'M'UX-D<($!JB@P"!# MI+3D0"8@!4`;A`20`@:WZJ/J?62>@D$+.'@`ZT\5<.`#!SO0$41@NR1\3JZ# M'.$,-,(5`^RJ/"&`4`LRT&*E0G`V+"2G@V!P0"$!D/?'F_L2HH`,_')!@*1; MB!KM'RR`X,#-?WC@P`1&JH``T#)(_^>!2>XF/V'M(2DZP`! M&5B0APRPUSG"OC:;@($*DF>-2`9X!##!S5Y]Y=467&2P1HO_#I2!"//>Z>I7 M#H2@@,>R+#P0JZMD8+0Q/X5!"0<%5)###A3=;3<'+M`0AA<7R<+E`+N.X\0Y M)]^GY05X0#LY*A[X5!T<`((47"`?`5``M@HA'1V@JG2#B`#J5(>!:JWN@JM# MEW36$H%[0?\@'PA(`:!\9X@(A``'"/L:"6S0!D(A0`UMV%/SML=`CZ2!4Q&P MTIYZH3V`<"\5.CA6&E0W"L6U0GP,X,`"B)&!)3PA#`6X0?K4!XT?4*$`"X@? M*JRC`QI,40)O0T;^:!@WXBSK$0'(0PJ$,8(8D"=GBH"=S0:1`BXX@%!_(,'W MTK4N::V+@W@``0@0A8$A5(B$A;``U@CAO1%BBA`SO,8(6B*Q;.C@`-%36=H& M<0$2X"`)B+)%&*>$.$1H$@!V*J)#=""!\05(*SHX00(D4``:W&!PZGO!#Z90 M``DDP`^+1`1$-I"=\7$'(&/T(5,ND(0TM,%_/SEC(NIP`!DHH`/_$2"`"AY@ M@2&``(X,#``(#)`L$(1K7$TS%[K4A4%I/0`!)A@"`O3%@@?(X`#SA!TB#1'* M4T02&1/XR`7DHP*RK&%>.43(#E71P_R4\A`'L!(>5T+9@1R@#BU:;2$^BQ`(&:`%:7@L(4:KC=(^X@'7G,5IDYA:U0ZD`4U8 M@/FF*`X7<.(GN26MEI@2W.&Z5Q5@56\M6`"&$+0MCZ!-JL3^0-W$O=6R`$C# M;\&G,+O&M#Q$68(`PK"QVVHDO=5=KTX3^]X*%R*^K@A`I1"M"1+;0JZ@!/ M#J?*`E9*Y:0?<0`(@,'%VC79EUC4B".G0M/]\#.4`0U94/M:$:*N108,ZY0% MK,!*%EQU(S(`!H3@0+$F`P>Q:UTBI^BZ%[:V,YA_S6U$!/L1*H@`T!`1AAZ\ MX`2IVD``(+##`U@@`#+%=L,NH&:$0#L73OA2$$21[5/@6A_7OC>E/3W_"O1Q MX.#H_@,4#G[P'1"B8@PO`"'HP'`./&$0;*@X!PA1@(K3@!`&/[BOH/`"AO_` M;Q`_^,<'\8.*7QR1WV[$!7HCU4(\@0D]Z,$9?,63#&$@H`OE<7<1WX MGHYKX84(&RH>"P@@\C M"-2Q@I'`(`KIVVX,H``=X`D M&"Q/AX(+N"`-R$#]@PA+P`1$8!4:50A>D'8]D%$*,X`>8"4D`&4=\H,(@2I_ MM@JJ1PE3H`O91Q3;MWC=AWDMR&TO^!4LIFI_P`4_D'.PEPU<,`59P`!P=@UM ME00`$#&$,$BN$&41L/\&6]!5`H<*2P"`4Q!O(U*`VL>"EZ>"!"<*';`H=H(' M>6(G[O8ZC6(!>4(>'L@3_H,!TC<(*O`F,"=^[](;:F`(9=<#@-<4AA`X%)@` M)LA0H?AA:),&6&@,>LAOJC``4\$`4^!@IV!YHB!YVO"$:YB`#`%UA%!!?Q!* M!"`Q_@-'I$8(07@!"J`#K\(3ZX)#C9`` M/N`"4%`,`Q`$5.`%=H@(7&`E!,-CSA%NAQ1AJ-``I\$`.0"+L=B$Z)6*$^-T M??@(&#!1JZ,S@4(>&;`N>30(C`(!`T0>)O`Z0(,'!E`')G``>K*0".`]",#_ M.A>P%J'@`6N1`2S`*7B0!R2`%^2A`VI!*`^P*!?@C%Y5A8/``BF0!!Z3`!B% M9HJPA3V0!;3&#(3%`$S``#<0!HC3&\FH"\-Q@;ZQ7_(U"AO0BC]0COD8>:%8 MB_AXAP,W8:=@`22@.B\D#,D2`-*R!4JY!080`1X(`3>3#R"0`1F`*B1@)->R M.I(C+1?0(NE!`,)@`B.0+B80`>MT0>L2A`X@,1+C-7@@04;(>U%H"$N`DST` M>ZN@`Q63"3^9"3?05C)@`T,02M@4`5"I6L,Q=`@AB1\H"AL`@##I_4)S6(B@W$X0$^9=_L$X#B4$:FE1#L$'6 M.8FR()HC6@@58&[BER$#0($HD(W+%@:MR``N0&NWP`8+0`.X]`+N0R8"$R3Q M>0@1,`'^Z(Z.L`160`GZ&8=2:8"PJ3\K.`K7DD`70'[O1`!#X`'@M%P->C1# M\``1L"\32IS&&0#-$@&7"/^6!H``!R2FF)0$`\1'CQ*$#R`M#F`"*3!`B/F, MLE!O+1`]*"!U9V"#IG8*#7`Q"U".+94)T<`+S.$'%6`%LN4"!0"*B@`!'1B+ M`)IEB;`!2\H`/T!Y_.D(_BE&G;H(N*@2B,,"T7,!)B`B=8E\O>@+G#0(L=HB M(J(#TI$\?Z`#+:("'1!*L`HE*J`ZL)J%OVH"'L9),Q(AT,*KCS@I#3@$:0(H MUIAS/'BHHR!W/>`"?.8'.:`B00!G4J(#*%`_XS,%]W,(&9`'2BD#:]`"L`:: MOSHD_$=&BL`%`.@"JLEC]L@3MAAK5^E]4^AK#<@->$D(87`&/6`%`3H*&5`! M#JO_B89P!.B9"4$@GH6@/0VP`/'HJ#2@'.ZI%,,@",PEI%*:"/S**U.YAPYQ MJH<3I?HZH`<+:BYI"`LP!;2*5U&Q`TS0KG^P!!VWKEK15GX@`3F`2Y:*`F-8 MLMPI"!YA;Z:%"`TPK@Q@!1SKI"4(I04+(U,J"B-08P)TI@/[U8Z<>P[!QEP`@$=LL`/F9H+*!068@',Y MYP/=\0BN2PBP*U(W>EM-9KA1F`'QN(GV^:1Y:+F[NX_):R1;D$8@=#H*``)B M&HD9@`$C@`'U>KW7$&RG)")TD',N\)F+-0`A&X`,4+XFF+X,]`1%JR(W4`&X M8"HPXP`ML`;U";:,A+6CFK]*Y[4"2B!A^PB9:X3I$H2K`P(*L!:BLS6GJ,`+ M[+F),)!#H#,%D`4]P`#T:+S^%@3IPP%!@&Y+0`5G0(%VVPL;@`+?8#?^/^(O&^ML(,WPTO@D"26``!G``%\##/CQ9 MN0"&<$#%KSD*2S"W290#Z2<1A'`"%="S;'8-2Q`&4\"TK($+83QP1Q`$E.`" M7J"X77N_QUNU-KN_?T##?V`!(]`Y(."7'3H"!&0!"9S'N4!F.J`"/5L^]2@* M.F!1`-((.K"%/R"CT_6R0%0!ZII$!3`')7S"?)@B>$.[I=G"G/S"*/S)C=`! MT%(MHW-`@XDH`6`!,G"E@^!\KEP,9&9#BL>$7SHS*VY MQO4KA0B=T$!,"$0(`.0A`6XW@K6,"$]`!>D3#(5!#0PV$W]U(;M`N+P`F>\TO9;V="L_]LPG=F:G0H; M\`+?6KF=@LN5(-FRL`$Z^`-)O#UAI@,-,`!/5`!\A3ZT?3&Y[=N1J]JU0+GF M;-F7"]S!K0BH1I\,5`&^7,L+,,\[H,[(L`%4,'5^3$K](-U>\`1_70%!0`?/ M(-?<';/>+0O@[=`N;2/D3=:)X`&]@27\;`P)@+7C4`[](!%`.>!Y?>#-O-M? MW=N>+-8)3JV>JP)B10(G0`?IMPI^X-/C\\0.X0=A@`O80;H:*-XLS.$#W2`@ M\`6K.MXA[BY@%0!M0`$L<`,Y5]JIL`1,3%M6L-YN\P=;9Q'V;>-L[-4Y'A[G M$@%),`$*4,X!GHL$_>/P-=.#('<,\/_@B<`&C8L:+D#FR'`+7E"Q+^#F&4[E M+]W=+JP-,A(!&#`3^N3A8#X*)H``BB<>X'R8OY612EDHSE((J@R'#W"D+,`H MAA``R,P[5!8!K5S>VVC$3+#=_;GFHHIEQ88+?I!VGZYL!KWJ>/[,N4"]:-H2 M?DX`+K&@7\ZJHD!D+<"99(%*A)!08HPT4PN0&(`0%$#37-%\GX,0-MRAR:Z4 MO7Y?`;`R1#2UYM>2E/@`\]H[EM;.IY`!">!%F9`#MQ"\K;L,;'`#60"QJG[K M`9UI&"X@828C=9!-"B`3"D``$5`''H`H!^02H379F)T((880DF(`O0&??^"> M`*`ZTVZ[A"#_5B;[!Z()`&\2I+L(=(/P,H004`B!1VN#$#8P9I1H*FN@.DNP MDW("!4QLF6&`->:>",S!!14@GO%>:V'NLW:N#FX[P\&D02B,PM00)8"KK`0*32M::$(306-M+")`S\H/P`%82 M?/6V!82@26D`30+S5'Z*")!S\K`EW``4%M"">@KC_PC4K\$ZKB!PY+_P1KO=H: M?H3P'OC\Y`%\?N_X3@`/H`(T_@<-4`%&(.O@_.[2+.8,$DE-``<7C=5/4,%T MH-PZC_>(T)0YEP5+Z%^_WW_![^J#P*4.0/@Q00`!(`-K*0K-O[&MIW-ZX!(6 MP/3`#PA_@H.$A8:'B(4H#8F-CH^0D9*3E)66A"@#AA>"1PP]606).@M6'`P, M'#0).HU-E["#"QN)!4P].URQATV,NY:OO\#"E@.TQ),)#1'8YL2X)L-SX]H"B"2^(]9#,3#AG(KNZ3B_"P%ZV#VO/Y^H>9A!TQ(2S\ MH2/N!R(="::@2F4%13M'P?8EFI4H0Y@7W?_@]9*8*")'0QX_$C(FLI")%5HP M*)@VS8*#"`94Z&HTH`*-'ZH$Z=AQ+DN%031N]4`C[8#(D"7_R(/4P0()#((. MI-CB0%`=,"DPX/LS8="(`(T0>/AC0A")0P<4D$B!)ZG;1OT&.0!`UT08.!@/ M":"SD$&.)Y*0EJ08Z4D88AO?_A%\5+$@DDE9(&`Y#0."!R`:'6D21I2@`N=Z MN!@4Q`45"1D%-5FRPX<9"Q,4C/C(^./21T/*#B+`@E``L",(##HK"`2"L&.% M_R%.2(<%>_8<2X\K:"[=/'^6:"HDP$7?'*DCU>9(^-&`3U:BPTK\=KQ$]_L@ M?QSA@&6U`#)'"6K_(%2``8`"B"SP0U]3_#C)@_F4YX@$1(CSP@F[L.<6D_-@"8]\^W10 MWS0.?.&+(0O8`=LILX$1G/PER0VB>_4'%%`4L,$"QXBD290\,I*G/LK$4 ML"83?3XRP@0C(!"`C`8(%P`!>,QD5H<(2#6A`Q=$\*<'F"I'W(9#C#6(#@$@ M0(`!^4J:PH0\LNJ.JW^`UD,.@FRP`%^HJ")`E=+]ZH@?.Q"10)7QEL3N+S/O MTBPR(`00C30.]"M(`A<)]0)0/0AXPP(:&?+%'N*,MNY;*#!QQ@XQ.Q*`#"DL M^D<;8&%8"'/&Y;'AA`@BG-R_F0KBP89_[/N'!Q0+=T%5&N?3CP-KD("".#XL MD0$*1Y9,@Y+KI7S,)$X,PL;A2U9-FW0UQW+S+_]?L82!#-[\O,"Y/?@PB!]^ M[",8`FB0@87H'Y%"CB`5)!!A(P0@$,$6?["0P@,6S'Z`UX2`?1P&$1@<@`(! M0&#V'VQQF'9U"AC@``()!A!#W((,83#;=?^2B0IT`6"'.&'HV1<-!R)F."Q< M^,"!K(T[%GGACDU.S_"58??'!D'`(4H"`_R00QA>\!='!),!#$BC+&$@D#O> MYP@O"(L!NU**XP[!`JW]@1GXJ$>Q."&(#,R$!9\"`0LRX,%V7$`%&>`@!^^! MA]E("H4ZT,$*09B]C0W``]T30P]>X)V2!>%.-#O?)6C`M\.T3S$,'$;\&!<+ M+D"K?NTXPA3@P+<_*,/_?8C(PTJ2`()P,(!PL4CB(8YP@RR((PMM&L3K:LC& M-O8C!2UH0P%.@8H7%(!]"Q2B)1JPK1X0H5N0.);,("<=^4TB9["1QL1VM3=Q M<*`"&;@B$A/Q`&G,X1-^+``3+R%&0VP@'$2X0>(P,<$VFG(ZFO!"`0+'@`&! M45EZM`07:'`&-!VQ/81<8BPN\``#2@,#!M#&"3*2/@84(".2Q"4B+C"H":R@ MCQS8I!+=`1A!7"0,`A3$&D_)3<>@H`GN@D/)*B#-/#I&99580+8"4\I\9.`) M@+Q2(&B''URP)G&<[!`!198C\*#(#`U"`#L` M8IR$L0$ZG&MHCMCF(7CG"-W$`E.#6-4A;`320["A"6A-JUK7FE8GP*`'=O@> M';[)UKK:]:YV#0->]\K7O5;@"7T-;!.VE047)`"OX1.L8M,:AL,V00*A.0-= M77`.!@1AL9C5*V8WR]8%`#:P3D"!!G8V`0*(X+--B!HH7%``U*Y5`G3EK&PU MB]0B``P)0A^?]H0,&&XL,M/L`@O(FK`CJ+MVJBP&P&$!V;>O-1\LJ MB37$U0Y[T$`=>M.8-U@^`P(J@,COZ4BH>3C"#`Z+5D@"`(,/F M\^\\&O""&[B"SX;(@!_F^)`PB(,(.S!B(=S3R``-X@D+*)]"W?+H#!R`M`J@ M]!\:P)-SL/01FGX<)`(@#2@/X@1[FG<00U!D6Y"1^T)^C'J&U](1/`Q80!`881,+B8,`- MCKJD>2;B`!^>]`IUT%#1O"P9X!8&DV0DC:'_0`9%Z&S,W*' M-Z$1]#("*?"`"I(0@?9F:@O,/4['!96S]K(CY#KR*I>++?C<&3YW0H]`>2>` M[>P9``+`,PX$0"`5$#A`(%O`@P=PT`Z.ZZ+>D%!F@V8$7"*'T M1"PA?(,0%B@8L+I`3J)\&;A[#ZIYA`HXH?/K]GHA+I"OECQ@!%P(`PW4>`.' M5"+@`Y0$"U:BJ'#SA`A3D'='*J&#?G)``@^'.')S]AMM&/\@>-(-0`$`! M$&`/$P`"_L=@(3`")/('$%`6'#,(7`![0&!M@F!B-!`&-[8L&=`$%5!H1'`,>\,$-C5WI;9A;X<'7S(!26!M?V`D M69`%VP%WWY=V&A8)E30!&-5!5%!4.Y!0.!8)2]`M3D`#!!8)$><(#^!5A9`Q M:>88>)`&*3`;'P@!T_4'..`!/#(!TY6"AM`!#T``0%=:^Z5P@Q%_E\!MXG`& MU82#AP-9E853O/(+_N(QXK`#!Z?_?HLA?6_S80J``/C0;^+P;Y8`?N]!"W&#&S!!7P`I3X&#Z0!1QP1U\H#`T0!BY`1=LG M""Z0!0Q``TW0"ITT"23!<2R!`!ME!4WSC)'@BG,6"1T0#0JP%81`1JSXA*QV M=T[CBUX8C-R4+T,``6#Q@2P`!B8P`5`6`S!!`=KDCX;P>CI#&2YX`#"8AC+( M$2B0&D\0+_UT#E0P"$X`)]DV#P.0&OW1`TC3"POPD)QJ9&0N0%W\@ M10_U"P#Y_S24D"`_=9)_P`;ER`N.0$1^A&+(\(L0>8<@8`&W(P@&P`DZ0B$J M@`$8X$*&&`D^MR\MB`!U8$$*:7N02`RT&`1!`#*?D77$Q902H0-'R`%9R`A- MD`#GY@,^^`<"T%B/-@D=8`)X4%W4$`$J<`02T&\*-`]+Z2#L%P'2H%R'D`%6 MZ0)).8J&X`>^P`4[0`.:N`M:N95I9@*T]PAI>6`V,FTLD01N68V\%TLB<01W M=P;EXP13(`&K272]B0+98H2A`8J"(%QGX`,OD"U<`%M00).-T)@'\``1D"A` M=XH.TW"3>)GPD)EX4@DC`!L*0(>%D`$5(!0,,'6]4]0:?\)K>F:^`D7 M("D)O*2(E($!;_D0]2@)M[<^-4$#-V!3@U!VJR@()Q`:3/`Y M"]`$<9"="$!:E`$F4RN_ENP@<';^B0 M^7FCL#";301FBTAX*C"@D5"@^V`3:210DX0(4$!U/_`"U?0$H>$#S>``71`: M1"$-,S`#;^82`9`'(&`,$L``9Y)[&HHE@E3[P`P^Q!,6G#QXV`7/@4AN``N(ZKN1:KN9ZKNB: MKNJZKNS:KNYZKG,)AZKZ"QG@44)YB@=`K?-`JUEBJYN(19*RJ]K)G;^*3R\1 M``;@`2.08LA9`%-P`[+B!#T`!U30BY;JK\:R"P2W#G(:!L>ZK5WR1-Y:4301 M&B9[LBB;LBJ[LBS;LB[[LBX[K_+J/N#E4[%A*0DZ\"5&`0D-0!"AP!$9H$72H``1\(L#`+-@ M&[9B.[9DB[(RFZH`FP$J,(724(4N!`_\JA$]:XWS40[:R:;DH0P@7<`!L M6UH/D&*7$+<+)+@QN`_V]B=XN[<&8`(CX+<_N;-*2;H%(@Q,M0X;]0X240>D MI6^.:QXG>P8,(!0^X!V1U1H!X@*`'RL1H+HJLL MZ(N[Q-`!X^6?U$```8`'^`"DCPN[NU"_YQ@+31$;([=^\Y`!D89/#Y!-`1P: M=!`$7A`$/4#!/4`'&\`Y+Y`!.X!I#>4#_>$#>$8$6<`Y.4"#?J1\F'8"[49C MO^=(QWH#=L<$[6?"*YO"B*"C`5D1^0)TP/2VE!##B#'#2$RXSI.Z=7"[I.EH M0!P+0IRYPB`#^`2Z*.D.7L*X)*M&+@6YH4'_!$\0!)XC+!](!+Q\#G+L`W"@`WYFQR>+Q_Q@ MS/\JD#I"&;I&R8<@R#S[O9FJ`A%@L_B$'S3\%O.+F82,")V$IF-(E+,F-VUB/@*R(6LS2)]"8\<1N[`3-*`.=F\"RP0>PZ@THJ`SB:KSJ,\ M4QP0Q589!N9V`\U7_P$5D`42$,]_X,]4[&\"@+(NP`4;T``Z\`0"-C3;X@,+ MX-`]>`)44%45G;(9K49EO;^5<`$L;#FPZLS03#,D'9?7J7(XO+4ZG`>*7--) ML[CR][@%340[$#H(=[)(O8H;P`4+8(LB@VC:9[+@D1TT`(H^LR7OT"!UFPIQ?+6,%/< M'>11R>UI0C?$>]W2)@KA].I+LNC)[G>I[GQN9E1P)6>M+7.OCLNG_4EP@`)[^Z:`>ZJ(^ZJ1> MZJ9^ZJB>ZJH^ZM;MYY$>TQ%HLP@`T@-TX^#EQR\H<&*N&&2>S//``B\&E]>M MEAV-`0?0W'GL4A`-.LS>[,[^[-`>[=(^[=1>[=9^[=".[';VY^F;%-4W#0'0 MZK5:$AD@`]2FPX2]H+O^%KV>L?L@R3]UNUAB`CZ%`-J>[)"P[-B^[_S>[_[^ M[\Y^[_'`[7HM$AT0>TE`TT=!TJ97&2(PJ"P]YC=>Z?FPL2LW[(W@1"U!ZV[^ M"/H.\"`?\B+O[P(O"0>NF>=D!DLN[(#Z$?=$B#K@PX"^[M`]\1B?#\X1&VV^ MR(F`!SYU+S;J\<\^`#P`_SI"H`4K,`#,7O0CW_38+@1`$/5*W^QQ(`2@PP,? MP.Q(D.U3KDQTQDL[4X5Y/;JF*P.QAP#\)?/='O&\;O,\KP_CYVDK-![&P;@< MKW?Y_NQ"4`.@8#O19 MJ>QZ/_A5\.R#7_BZ_^Q2$.U84`)%X`=C0/1O$`=1$.TE/[-4COF,XP%+GN[1 M/`\&0&T!T""IC^1LS^ZH7Q)2>_."0!^8W"JT[^Q[#SI%(`=^0/2@D_N[W_Y^ M4/\"6B`%BM_L)2`$P5\"0(`%6%`$4P\(?H*#.G^&AXB)BHN'*`.,D)&2B4V3 MEI>)"QN)7'43GPH1&9B830VDEB`$GQ,8+(N5J+*,L;.VAP.;M[<)I[NVM;^3 M(*"OP88/"J`&H\***+Z2.H.#0C5^45)5*R(K@M?4X>+CY.7FY^)`WR8**1=15HX96$X($.M"'0N?*C83*7,236H\KOBA,,"/"!Q, M%0N=3#DHDF\BX@BI-D^0E`$?M!@I096CU;J&[E[ERDA'!%8*Z@S>!?&71%86 M#HQ$;9'Q20P"PR2"7=)$<-MZ'((885(+.X"?A@G_P%TF! M+4%WRX"R=-`,F%&-Q;T_R!JPN7GVVNL3(!`!W5Q"(F'(B:I9)(D"F.B M7#D*I&(D'4P4V`-<`!/A)194"[HP001N(B: MD:W5J>FF/]UY2YYM,?I+GY/\%1:1&L$)"1<8?I*$;H,NBJ*C;T&J)XH?H(AI MG)SVZBLUGMH"JE:B[D+J)!<@`!NL-JJZB`?'I16L6PL6>PNM;=D:JJP+[JJ( MG+^&2X]XC0%;U2-BHGBL)2J`]0D!:TE"*",@'(J!![]8"\RLP/'H[%7ZQMKM MOX?(&?^'"!]4`T1/]/#`@Q'G"'%9-1.+ZX<4UPT`,7GEDB.'%N::ANYPZO8[ MBPZF(A?!2_(2K,,#!B;QP`4"(%J4H$%1?D0M!7Q82'&UQ>_YP8/0W@RBQ=`@?Z!U3T#05\-F@DPK MR[``E^P,"\JN>8";E/R[$BL$)%ISM?PNJ'/<@`\\4S@K@#Q("?`I/88@20OR M!E--@3=&'!^4(`P`:^1K@0;@J01I@^2F"`0"_'_>'R#C/'!Q%4\ MK4X43&D0A;B/"P&>/8L+L@(0IJ->`MN"2.:'VZC`7;S<`F5@Y2,9:H0'$^*)Q'BE0-[APL&#.72F"G-X@Q_&(`0AM``,5Z`<%J96A@$4 M@2D\P`)[1!BN.,R#!^#A`=7\H(2TB4$$2)@#/#10@@P*8GKO'"7D.(U(+\8R`(! M`"!'GF@)0DYBB1]IXB`%6*3D_0%<_UZ3`A#&>(4.;I$<532C((J`!!Y(T`_P M$!=.@B:(,B2,&G*(G!^P`(0/>&,J1F!=#D661-3T\!8CB,!",&"1U/AB;RPDBY()(CBL11,=_B,T0@:05S*$$1(%8#;91`"U$0PB>I,8=L2`9I4A-$ M%)JVPE^=SP]RJ.;W4KDY]GQ@C$<#60E..W%(8!%D*I!'R`=@X0).$N M.D`[ULJ1BR3HAAP)28=N*J*3H5Q%[3DR']51+KF$#6Z$&2F5OL6@!4&H0`PI MKRA.QZ5(!?\1_$AQ3R?FLRT9^!,H`FE3DA;4I-E"J3)]^J8%)O6KE5DJ)IJ: M4MAA%282L0`!@EA5.M[LK,/3:D+=VC.6@O6N=IIC6VT)5Y@(0*Y#769;@"H0 MH1*3JUIAJ/+PRMA.Z15-9JT68`]K56/VE8F3=091([%92"CVD8T-;3G$>@FR M;C6R8LKLWRK[T\LF4K7Y$FQB[1H.K1$-.U5`FE&4T#3*E2":4XG"TQHK!*') M-"<:R%@4J/:!X\ZT(*:=*U\EB]B1*M&UR(0M;61[E<\B::+CNEA1)K9%IPSB M@]C(QW`9B[&C;,P/1IB#%AKC-"SP8P[L"QE-JPN3C.)(NR_B+DS_"/L/PVI6 MP(2A[2`^,(>.09,:EU0E>M71M-SZ(0Y1F`,_>``$+<1A!4A#(7XU%0?P>+&4 ME+M<8H"P7OU"MZ:0Q2AV_\M??"Z(P,XP\&KI>BD%#V(%-@@;%M3PO2M\0`AJ MP$(9PN:'(DA!`X\+IQ;U\6_O0/POFKLH!D'5K+D(*SBE MTU;I#AEZK@3N$$)1>-`9]LS)R^A47),;HX7KQ"$.4HCA>DJS7SUK!B/M4^+.#RO;].#_P6CI><:D&[*I"NM*2-$SH9Q5$_8 M.LR#5Y+ZQ;'."*K)$FWI7M75U0ZLX?@\"!%((0IG-L(5O#>'&F#ADM1`KR`6 MW>NF14$)?@BVI+U&;$U-30Z*"6&\DWN%RPAA*G&8PPIDR>92NUDNT];LJX^7 M;3+9N;`+3V##2S3K"T?TR()8N7#E/C9>G402;GMOW6;DR(TC9X:H">3JY89?4A! MTUAL6G[%$9H0M9+68CPE%L(&FG&`:0%6"+[PAT_\XN?@!L5/OO*7SWSAYZ#Y MT(^^\I\O_>I+G_K6S_[RL:_][@^?^][W/OC#K_WQD]_ZYC__]=7O?3H M(PW;Q.@UQSE&PKX=Q`"4$'`YP)<^?C`U/R$$+489H[$^U*`!NZ,90,`#FB,.`MC_;HQ-C#U$WY6#DDS!D9`:;7G>Z1P`=,2=ATXA$18A$9XA$C8@7)2 M`FY`"`!#A!/BK8!F,P.C2$3D`@@)+F93AP/>X# M%/&E!35P7'*@6PJH`>@S6IA@`#&``1F0!P1``!'P!QD`%BP3$Q28A(18B(9X MB(B8B*0`+G%0`YE1`W&0/6,P`$B&!1&E;O'6/I>Q0>.P@J!T&2Q&AE5$&C@! M2C%E/7Y0!@"('2O0&6FC!6BF#\\6"9ZP%W\@)!X0(&`0`'C0!HTPB(H8C,(X MC,18C'4!28"6..US#>BF:^6S`N`@!/"F@BM4_P6;$8I%48:D^#E"45SF4T[B M1'*0YFSU<0D/,`1)8`@I@`!XX(=@8`CW8@A":(ST6(_V>(_"^%U:``1S(`)" M<`5``(UO(`?-N$F^%0=7\%Y:``]$`7HUP&)(L)`B\`8!^9!4Z&5J\#&6!A2A M]$$?5801O4`;IP0,@LP)C4`8@Y'\7`U&S&`G[A`'M:`@0\`=O^0=L@I,^69=V M>9=X*1*`#)H`#?Z`&!@`"(=`,5@%` M)N`W>;`6,A"(I%"9A\"9AC`">-`,7"`#J.(,>5@C?^`!@0@">=`,'3!,MG`! M,N`B.C";G>DW'G!$NY`!,K`6'K`6+,!6'L!6PL`%EVD(4;46(*`AAY`!MO,+ M'8`'`'0!>)`E?I@'+M(!(``"(G4+O,DR>;B:K7D(%_"8`()E`C MVKF=7W<(T2E(>1"('2`#`)0!)D"67&7=7;F," M6Q`#`?`'$6`!&"`H'8`!%K">.`D"-A`#?S`$%DJ3%$``*9".;>``)(`!J$#_ M`@0P!"GP!R2@``I``G_P`!#@`"&@`RH``0A@`S?I#$/@`#_Z!V!``%M``!!* M`@ZP!1<`!BW`G[LP`C'@`#:`GR4*`3?YHI_P!T4Z!#0I#&Z0I`[0F!B@HG*9 M`@1``;<(DUOP#TA*`@CP!S%@`2D0I@2@HFIP"`30`O\0`&Z*`RQP`&J``&T@ M3!20I&]:I`30EKNI!@X`!@B0`84:I7^``"HJHW]``&[0H\)0HRF@`']P`#%` M`(S9H3!*DP%@`1:0!J@Y"P?@IC9@"&U0IV'J`6#@`!3P$NA(`!PJ#*V@`$,` MH3H:`C1C`0J``2U:!S8@J(FREXWG4/!3!T[*"(Z@_P,Z,`$7$`*&0`(C@*87 MD`(FP*$=T**DD"4C@`,7P*$9``$7H`:"X@"&::0=L*;.D"47L`5UL*O:V@:% M0"D=``'1:@L94`@.,+`/F@T)V[0#,>T*)M\!($4`?A.@HA@"HJ@*:[8)U#\*H`""8IB+U:R,%9^18!43 MD`%M<``'8`/7*@,/``;EZO\!#_"JLJ`0)H"B?V!$HYH'QOJ@C5D0&(``"$"X M*6``H^H`*.JO&3$")/"M@I(!(2`#1EJX->(`$NL,.A`*$:"X;QF7$?``?V"K M87I'"O``#O"F?R"LXOH`*Y,"()"RSM`!MRJN'>JNZF@":B"G&.H,*1`!`ZN. M!G"GE[JCG3JZ_V"A?R"R#^L`!C"Z*1!$&*"IN]`!'.H`BNL&?W"T_^F+!*`& M8-"'_X``$IL"H]`N#R"N*?``!&!$&."I!NJV"JI#-/FM)/".H)H";WFO*;"K MI!`!,FH"HVNXHX`'(JJX#>L,`<"A[JN.!X"MEUJY_WH+C2I6F* MG%OPNCH0`^R+"0>@I+!*K;YHI1UJ``[@J2:@O\(0`7'I`7=Z`220`7CKHJQK MN0+AIL@0I@\0`Y"J`Q?`F%7\#_<["BP@HRS`F#CP$ELP`H6@`S&\"ZM@"""0 MR1V`K9G[!S9@`A&PARU0R$,+!FTIQ7+I`'?[GYFLRT=\_PL1(*YX\*J8_`<4 M0#,DH`,>*Y?&3"`QX`]@@"\3@"\QP`4A.PJ4*PR0"BLF\*LFX(M#T(?*^P?B MRL:[4,&'4+^%^P`=8*DXX"(>8+%XG,=)MIV08XX`"CX*T" M<0`M@-(PG0(X``%$$@$:S;H530'1/`L=4-,4D(X88-$:<@`4$*NWJ`9M\,VW ML`8G39,LV0;XZEMH`;U20'JJYNSX`%$C:(. M4-8:X@$X4*)_L*UM$-2VT`)376/7-M"2AA`!3LT[&3`$L(D)$>#5%-".%B#2 M^'*N.+`%A7#4:O"YOZ#1%,"A)@`!:D#8#XL#.*"XG5J:S&K0O8+0B]``[]>< ?B#`;A9V7KOW:L$V/;C+:I+TIIAW;N)W;NKW;@0``.S\_ ` end XML 28 R19.xml IDEA: Accumulated Other Comprehensive Income 1.0.0.3 false Accumulated Other Comprehensive Income false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 us-gaap_ComprehensiveIncomeNoteAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false No definition available. false 3 1 us-gaap_ComprehensiveIncomeNoteTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 13 - us-gaap:ComprehensiveIncomeNoteTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>13. Accumulated Other Comprehensive Income</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Components of other comprehensive income/(loss) consist of the following: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="40%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Total</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Gains/</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Accumulated</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Foreign</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Gains/</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>(Losses) on</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Other</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Currency</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>(Losses) on</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Employee</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Derivatives</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Comprehensive</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Translation</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Securities</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Benefit Plans</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>&#038; Hedges</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Income/(Loss)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">December&#160;31, 2006 </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">$</td> <td align="right">(158</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">61</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2,030</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2,118</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">2007 changes </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Unrealized gain (loss) </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">28</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(78</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Net amount reclassed to net earnings </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(5 </td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">24</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Net 2007 changes </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">786</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">23</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">670</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(54</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,425</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">December&#160;30, 2007 </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">628</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">84</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,360</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(45</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(693</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">2008 changes </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Unrealized gain (loss) </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(32</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">94</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Net amount reclassed to net earnings </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(27 </td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">72</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Net 2008 changes </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2,499</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(59</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,870</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">166</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(4,262</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" nowrap="nowrap" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">December&#160;28, 2008 </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">$</td> <td align="right">(1,871</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">25</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(3,230</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">121</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(4,955</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">2009 changes </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Unrealized gain (loss) </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(52</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">38</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Net amount reclassed to net earnings </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(3 </td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(14 </td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Net 2009 changes </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,363</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(55</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">565</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">24</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,897</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">January&#160;3, 2010 </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>$</b></td> <td align="right"><b>(508</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>(30</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>(2,665</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>145</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>(3,058</b></td> <td nowrap="nowrap"><b>)</b></td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" nowrap="nowrap" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The tax effect on the unrealized gains/(losses) on the equity securities was income of $14 million in 2009 and expense of $14&#160;million and $46&#160;million in 2008 and 2007, respectively. The tax effect related to employee benefit plans was $302&#160;million, $1,090&#160;million and $349&#160;million in 2009, 2008 and 2007, respectively. The tax effect on the gains/(losses) on derivatives and hedges was expense of $78&#160;million and $70&#160;million in 2009 and 2008, respectively, and income of $24&#160;million in 2007. See Note 6 for additional information relating to derivatives and hedging. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The currency translation adjustments are not adjusted for income taxes as they relate to permanent investments in international subsidiaries. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 29 R29.xml IDEA: Subsequent Events 1.0.0.3 false Subsequent Events false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 jnj_SubsequentEventsAbstract jnj false na duration string Subsequent Events. false false false false false true false false false 1 false false 0 0 false false Subsequent Events. false 3 1 us-gaap_ScheduleOfSubsequentEventsTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 23 - us-gaap:ScheduleOfSubsequentEventsTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>23. Subsequent Events</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">On January&#160;20, 2010, the Company completed the acquisition of Acclarent Inc. for a net purchase<br /> price of approximately $785&#160;million. Acclarent Inc. is a medical technology company dedicated to<br /> designing, developing and commercializing devices that address conditions affecting the ear, nose<br /> and throat. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company has performed an evaluation of subsequent events through March&#160;1, 2010, the date the Company issued these financial statements. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="margin-left: 0%"> <!-- BEGIN PAGE WIDTH --> <!-- XBRL Pagebreak End --> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 30 R11.xml IDEA: Intangible Assets and Goodwill 1.0.0.3 false Intangible Assets and Goodwill false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 jnj_IntangibleAssetsAndGoodwillAbstract jnj false na duration string Intangible Assets And Goodwill. false false false false false true false false false 1 false false 0 0 false false Intangible Assets And Goodwill. false 3 1 us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 5 - us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>5. Intangible Assets and Goodwill</b> </div> <div align="left" style="font-size: 10pt; margin-top: 12pt">At the end of 2009 and 2008, the gross and net amounts of intangible assets were: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="76%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Intangible assets with definite lives:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Patents and trademarks &#8212; gross </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">5,697</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,119</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Less accumulated amortization </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,177</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,820</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Patents and trademarks &#8212; net </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>3,520</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>3,299</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Other intangibles &#8212; gross </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">7,808</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7,376</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Less accumulated amortization </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,680</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,433</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Other intangibles &#8212; net </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>5,128</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>4,943</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Total intangible assets with definite lives &#8212; gross </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">13,505</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">12,495</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Less accumulated amortization </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,857</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,253</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Total intangible assets with definite lives &#8212; net </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>8,648</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>8,242</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Intangible assets with indefinite lives:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Trademarks </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">5,938</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,734</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Purchased in-process research and development* </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,737</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Total intangible assets with indefinite lives </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>7,675</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>5,734</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Total intangible assets &#8212; net </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>16,323</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>13,976</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>*</i></td> <td>&#160;</td> <td><i>Purchased in-process research and development will be accounted for as an indefinite-lived intangible asset until the underlying project is completed or abandoned.</i></td> </tr> </table> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Goodwill as of January&#160;3, 2010 and December&#160;28, 2008, as allocated by segment of business is as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="52%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Med Dev</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Consumer</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Pharm</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>and Diag</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Total</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Goodwill at December&#160;30, 2007 </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">8,125</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">964</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,034</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">14,123</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Acquisitions </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">191</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">286</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">477</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Currency translation/other </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(842</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(38</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(881</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" nowrap="nowrap" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Goodwill at December&#160;28, 2008 </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">7,474</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">963</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,282</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">13,719</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Acquisitions </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">271</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">401</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">672</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Currency translation/other* </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">600</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(139</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">471</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Goodwill at January&#160;3, 2010 </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>8,074</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>1,244</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>5,544</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>14,862</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 0px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>*</i></td> <td>&#160;</td> <td><i>Includes reclassification between segments.</i></td> </tr> </table> <div align="left" style="font-size: 10pt; margin-top: 6pt">The weighted average amortization periods for patents and trademarks and other intangible assets are 17&#160;years and 28&#160;years, respectively. The amortization expense of amortizable assets for the fiscal years ended January&#160;3, 2010, December&#160;28, 2008 and December&#160;30, 2007 was $675&#160;million, $788&#160;million and $844&#160;million before tax, respectively. Certain patents and intangible assets were written down to fair value during fiscal years 2009, 2008 and 2007, with the resulting charge included in amortization expense. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The estimated amortization expense for the five succeeding years approximates $700&#160;million before tax, per year. Substantially all of the amortization expense is included in cost of products sold. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 31 R10.xml IDEA: Property, Plant and Equipment 1.0.0.3 false Property, Plant and Equipment false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 us-gaap_PropertyPlantAndEquipmentAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false No definition available. false 3 1 us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 4 - us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>4. Property, Plant and Equipment</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">At the end of 2009 and 2008, property, plant and equipment at cost and accumulated depreciation were: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="76%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Land and land improvements </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">714</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">886</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Buildings and building equipment </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">8,863</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7,720</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Machinery and equipment </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">17,153</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15,234</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Construction in progress </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,521</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,552</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">29,251</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">27,392</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Less accumulated depreciation </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">14,492</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">13,027</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>14,759</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>14,365</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 0px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in 2009, 2008 and 2007 was $101&#160;million, $147&#160;million and $130&#160;million, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Depreciation expense, including the amortization of capitalized interest in 2009, 2008 and 2007, was $2.1&#160;billion, $2.0&#160;billion and $1.9&#160;billion, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 32 R30.xml IDEA: Valuation and Qualifying Accounts 1.0.0.3 false Valuation and Qualifying Accounts false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 jnj_ValuationAndQualifyingAccountsAbstract jnj false na duration string Valuation and qualifying accounts. false false false false false true false false false 1 false false 0 0 false false Valuation and qualifying accounts. false 3 1 us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 24 - us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock--> <div style="margin-left: 0%"> <div style="display: none"> Schedule Of Valuation And Qualifying Accounts Disclosure </div> <br /> <div style="margin-top: 18pt; font-size: 1pt">&#160; </div> <div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #ffffff"> <b><font style="font-family: 'Times New Roman', Times">JOHNSON&#160;&#038; JOHNSON AND SUBSIDIARIES</font></b> </div> <div style="margin-top: 6pt; font-size: 1pt">&#160; </div> <div align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #ffffff"> <b>SCHEDULE&#160;II&#160;&#8212; VALUATION AND QUALIFYING ACCOUNTS</b> </div> <div style="margin-top: 6pt; font-size: 1pt">&#160; </div> <div align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #ffffff"> <b>Fiscal Years Ended January&#160;3, 2010, December&#160;28, 2008 and December&#160;30, 2007</b> </div> <div align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #ffffff"> <b>(Dollars in Millions)</b> </div> <div style="margin-top: 6pt; font-size: 1pt">&#160; </div> <table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #ffffff; text-align: left"> <!-- Table Width Row BEGIN --> <tr style="font-size: 1pt" valign="bottom"> <td width="53%">&#160;</td><!-- colindex=01 type=maindata --> <td width="2%">&#160;</td><!-- colindex=02 type=gutter --> <td width="1%" align="right">&#160;</td><!-- colindex=02 type=lead --> <td width="7%" align="right">&#160;</td><!-- colindex=02 type=body --> <td width="1%" align="left">&#160;</td><!-- colindex=02 type=hang1 --> <td width="3%">&#160;</td><!-- colindex=03 type=gutter --> <td width="1%" align="right">&#160;</td><!-- colindex=03 type=lead --> <td width="5%" align="right">&#160;</td><!-- colindex=03 type=body --> <td width="1%" align="left">&#160;</td><!-- colindex=03 type=hang1 --> <td width="4%">&#160;</td><!-- colindex=04 type=gutter --> <td width="1%" align="right">&#160;</td><!-- colindex=04 type=lead --> <td width="10%" align="right">&#160;</td><!-- colindex=04 type=body --> <td width="1%" align="left">&#160;</td><!-- colindex=04 type=hang1 --> <td width="3%">&#160;</td><!-- colindex=05 type=gutter --> <td width="1%" align="right">&#160;</td><!-- colindex=05 type=lead --> <td width="5%" align="right">&#160;</td><!-- colindex=05 type=body --> <td width="1%" align="left">&#160;</td><!-- colindex=05 type=hang1 --> </tr> <!-- Table Width Row END --> <!-- TableOutputHead --> <tr style="font-size: 8pt" valign="bottom" align="center"> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom"> <b>Balance at<br /> </b> </td> <td> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom"> <b>Balance at<br /> </b> </td> <td> &#160; </td> </tr> <tr style="font-size: 8pt" valign="bottom" align="center"> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom"> <b>Beginning of<br /> </b> </td> <td> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom"> <b>End of<br /> </b> </td> <td> &#160; </td> </tr> <tr style="font-size: 8pt" valign="bottom" align="center"> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000"> <b>Period</b> </td> <td> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000"> <b>Accruals</b> </td> <td> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000"> <b>Payments/ Other</b> </td> <td> &#160; </td> <td> &#160; </td> <td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #000000"> <b>Period</b> </td> <td> &#160; </td> </tr> <tr style="line-height: 3pt; font-size: 1pt"> <td>&#160; </td> </tr> <!-- TableOutputBody --> <tr valign="bottom" style="background: #cceeff"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> 2009 </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Accrued Rebates<sup style="font-size: 85%; vertical-align: top">(1)</sup> </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 1,808 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 6,584 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (6,753 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 1,639 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Accrued Returns </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 794 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 355 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (460 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 689 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Accrued Promotions </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 356 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 2,446 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (2,373 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 429 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="font-size: 1pt"> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Subtotal </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 2,958 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 9,385 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (9,586 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 2,757 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom"> <td align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Reserve for doubtful accounts </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 267 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 110 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (44 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 333 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Reserve for cash discounts </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 79 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 1,163 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (1,141 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 101 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="font-size: 1pt"> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> </tr> <tr valign="bottom"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Total </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 3,304 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 10,658 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (10,771 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 3,191 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="font-size: 1pt"> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> </tr> <tr valign="bottom" style="line-height: 9pt"> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> 2008 </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Accrued Rebates<sup style="font-size: 85%; vertical-align: top">(1)</sup> </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 1,802 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 5,578 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (5,572 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 1,808 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Accrued Returns </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 648 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 402 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (256 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 794 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Accrued Promotions </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 578 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 2,991 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (3,213 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 356 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="font-size: 1pt"> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Subtotal </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 3,028 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 8,971 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (9,041 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 2,958 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom"> <td align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Reserve for doubtful accounts </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 193 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 101 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (27 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 267 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Reserve for cash discounts </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 71 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 905 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (897 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 79 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="font-size: 1pt"> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> </tr> <tr valign="bottom"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Total </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 3,292 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 9,977<sup style="font-size: 85%; vertical-align: top">(2</sup> </td> <td nowrap="nowrap" align="left" valign="bottom"> <sup style="font-size: 85%; vertical-align: top">)</sup> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> (9,965 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 3,304 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="font-size: 1pt"> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> </tr> <tr valign="bottom" style="line-height: 9pt"> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> 2007 </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Accrued Rebates<sup style="font-size: 85%; vertical-align: top">(1)</sup> </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 1,691 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 5,243 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (5,132 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 1,802 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Accrued Returns </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 599 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 395 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (346 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 648 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Accrued Promotions </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 457 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 2,908 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (2,787 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 578 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="font-size: 1pt"> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Subtotal </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 2,747 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 8,546 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (8,265 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 3,028 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom"> <td align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Reserve for doubtful accounts </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 160 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 42 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (9 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 193 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Reserve for cash discounts </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 62 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 1,022 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (1,013 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 71 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="font-size: 1pt"> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td style="border-top: 1px solid #000000"> &#160; </td> <td> &#160; </td> </tr> <tr valign="bottom"> <td nowrap="nowrap" align="left" valign="bottom"> <div style="text-indent: -10pt; margin-left: 10pt"> Total </div> </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> $ </td> <td nowrap="nowrap" align="right" valign="bottom"> 2,969 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 9,610 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> (9,287 </td> <td nowrap="nowrap" align="left" valign="bottom"> ) </td> <td> &#160; </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> <td nowrap="nowrap" align="right" valign="bottom"> 3,292 </td> <td nowrap="nowrap" align="left" valign="bottom"> &#160; </td> </tr> <tr valign="bottom" style="font-size: 1pt"> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> <td> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td style="border-top: 3px double #000000"> &#160; </td> <td> &#160; </td> </tr> </table> <div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #ffffff"> </div> <div style="font-size: 12pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"> </div> <div style="margin-top: 3pt; font-size: 1pt">&#160; </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="text-align: left"> <tr> <td width="3%"></td> <td width="97%"></td> </tr> <tr valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #ffffff"> <td> <sup style="font-size: 85%; vertical-align: top">(1)</sup>&#160; </td> <td align="left"> Includes reserve for customer rebates of $729&#160;million, $721&#160;million, $710&#160;million at January&#160;3, 2010, December&#160;28, 2008 and December&#160;30, 2007, respectively. </td> </tr> <tr style="line-height: 6pt; font-size: 1pt"> <td>&#160;</td> </tr> <tr valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #ffffff"> <td> <sup style="font-size: 85%; vertical-align: top">(2)</sup>&#160; </td> <td align="left"> Includes $171&#160;million adjustment related to previously estimated accrued sales reserve. </td> </tr> </table> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 33 R8.xml IDEA: Cash, Cash Equivalents and Marketable Securities 1.0.0.3 false Cash, Cash Equivalents and Marketable Securities false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false No definition available. false 3 1 us-gaap_CashAndCashEquivalentsDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 2 - us-gaap:CashAndCashEquivalentsDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>2. Cash, Cash Equivalents and Current Marketable Securities</b> </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="28%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>January 3, 2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>December 28, 2008</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Amortized</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Unrealized</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Estimated</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Amortized</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Unrealized</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Estimated</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Cost</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Gains/(Losses)</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Fair Value</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Cost</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Gains/(Losses)</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Fair Value</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Current Investments</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Cash </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">2,517</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,517</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,276</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,276</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Government securities and obligations </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">13,370</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">13,371</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7,486</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7,490</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Corporate debt securities </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">426</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">426</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">627</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">628</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Money market funds </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,890</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,890</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">813</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">813</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Time deposits </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,222</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,222</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">607</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">607</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Total cash, cash equivalents and current marketable securities </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>19,425</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>1</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>19,426</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>12,809</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>5</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>12,814</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">As of January&#160;3, 2010, current marketable securities consist of $3,434&#160;million and $181&#160;million of government securities and obligations and corporate debt securities, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;As of December&#160;28, 2008, current marketable securities consist of $1,663&#160;million, $342&#160;million and $36&#160;million of government securities and obligations, corporate debt securities and time deposits, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices in active markets. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an A (or equivalent) credit rating. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 34 R22.xml IDEA: Rental Expense and Lease Commitments 1.0.0.3 false Rental Expense and Lease Commitments false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 us-gaap_LeasesOperatingAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false No definition available. false 3 1 us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 16 - us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>16. Rental Expense and Lease Commitments</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Rentals of space, vehicles, manufacturing equipment and office and data processing equipment under operating leases were approximately $322&#160;million in 2009, $309&#160;million in 2008 and $302 million in 2007. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The approximate minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year at January&#160;3, 2010 are: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" colspan="2"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="1"><b>After</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="center" colspan="1"><b>2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="1"><b>2011</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="1"><b>2012</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="1"><b>2013</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="1"><b>2014</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="1"><b>2014</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="1"><b>Total</b></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td colspan="24" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td align="center">$178</td> <td>&#160;</td> <td>&#160;</td> <td align="center">150</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="center">128</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="center">103</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="center">87</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="center">94</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="center">740</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Commitments under capital leases are not significant. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 35 R18.xml IDEA: Capital and Treasury Stock 1.0.0.3 false Capital and Treasury Stock false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 us-gaap_TreasuryStockNoteDisclosureAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false No definition available. false 3 1 us-gaap_ScheduleOfTreasuryStockByClassTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 12 - us-gaap:ScheduleOfTreasuryStockByClassTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>12. Capital and Treasury Stock</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Changes in treasury stock were: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="76%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Amounts in Millions Except Treasury Stock</b></td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 1px solid #000000"><b>Treasury Stock</b></td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Number of Shares in Thousands)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Shares</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Amount</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Balance at December&#160;31, 2006 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">226,612</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">10,974</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Employee compensation and stock option plans </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(33,296</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2,180</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Conversion of subordinated debentures </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(194</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(13</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Repurchase of common stock </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">86,498</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,607</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Balance at December&#160;30, 2007 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">279,620</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">14,388</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Employee compensation and stock option plans </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(29,906</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2,005</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Conversion of subordinated debentures </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(19</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Repurchase of common stock </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">100,970</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,651</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Balance at December&#160;28, 2008 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">350,665</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">19,033</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Employee compensation and stock option plans </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(22,161</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,377</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Conversion of subordinated debentures </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(96</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(6</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Repurchase of common stock </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">37,114</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,130</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Balance at January&#160;3, 2010 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">365,522</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">19,780</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Aggregate shares of Common Stock issued were approximately 3,120&#160;million shares at the end of 2009, 2008 and 2007. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Cash dividends paid were $1.930 per share in 2009, compared with dividends of $1.795 per share in 2008 and $1.620 per share in 2007. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 36 R12.xml IDEA: Fair Value Measurements 1.0.0.3 false Fair Value Measurements false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 jnj_FairValueMeasurementsAbstract jnj false na duration string Fair Value Measurements false false false false false true false false false 1 false false 0 0 false false Fair Value Measurements false 3 1 us-gaap_FairValueMeasurementInputsDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 6 - us-gaap:FairValueMeasurementInputsDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>6. Fair Value Measurements</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">During the fiscal first quarter of 2009, in accordance with U.S. GAAP the Company adopted the standard related to disclosures about derivative instruments and hedging activities. This standard requires qualitative disclosures about objectives and strategies for using derivatives, quantitative disclosures about fair value amounts of gain and losses on derivative instruments, and disclosures about credit-risk-related contingent features in derivative agreements. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company uses forward exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of raw materials denominated in foreign currency. The Company also uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. The Company also uses forward exchange contracts to manage its exposure to the variability of cash flows for repatriation of foreign dividends. These contracts are designated as net investment hedges. Additionally, the Company uses forward exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The Company does not enter into derivative financial instruments for trading or speculative purposes, or contain credit risk related contingent features or requirements to post collateral. On an ongoing basis the Company monitors counterparty credit ratings. The Company considers credit non-performance risk to be low, because the Company enters into agreements with commercial institutions that have at least an A (or equivalent) credit rating. As of January&#160;3, 2010, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $21&#160;billion and $4 billion, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;As required by U.S. GAAP for derivative instruments and hedging activities, all derivative instruments are to be recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The designation as a cash flow hedge is made at the entrance date into the derivative contract. At inception, all derivatives are expected to be highly effective. Changes in the fair value of a derivative that is designated as a cash flow hedge and is highly effective are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction. Gains/losses on net investment hedges are accounted for through the currency translation account and are insignificant. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes in the cash flows of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. Hedge ineffectiveness, if any, is included in current period earnings in other (income)&#160;and expense, net, and was insignificant for the fiscal year ended January&#160;3, 2010 and December&#160;28, 2008. Refer to Note 13 for disclosures of movements in Accumulated Other Comprehensive Income. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;As of January&#160;3, 2010, the balance of deferred net gains on derivatives included in accumulated other comprehensive income was $145&#160;million after-tax. For additional information, see Note 13. The Company expects that substantially all of the amount related to foreign exchange contracts will be reclassified into earnings over the next 12&#160;months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18&#160;months excluding interest rate swaps. The amount ultimately realized in earnings will differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The following table is a summary of the activity for the fiscal year ended January&#160;3, 2010 related to designated derivatives as defined in the Codification: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="64%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Gain/(Loss)</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Gain/(Loss)</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Gain/(Loss)</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>reclassed from</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>recognized</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>recognized in</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Accumulated</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>in Other</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Cash Flow Hedges</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Accumulated</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>OCI into</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Income/</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>OCI</b><sup style="font-size: 85%; vertical-align: text-top"><b>(1)</b></sup></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>income</b><sup style="font-size: 85%; vertical-align: text-top"><b>(1)</b></sup></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Expense</b><sup style="font-size: 85%; vertical-align: text-top"><b>(2)</b></sup></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Foreign exchange contracts </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">$</td> <td align="right">(63</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(47</td> <td nowrap="nowrap">)<sup style="font-size: 85%; vertical-align: text-top">(A)</sup></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Foreign exchange contracts </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(173</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">70</td> <td nowrap="nowrap"> <sup style="font-size: 85%; vertical-align: text-top">(B)</sup></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Foreign exchange contracts </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">13</td> <td nowrap="nowrap"> <sup style="font-size: 85%; vertical-align: text-top">(C)</sup></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Cross currency interest rate swaps </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">241</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(16</td> <td nowrap="nowrap">)<sup style="font-size: 85%; vertical-align: text-top">(D)</sup></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Foreign exchange contracts </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">28</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(6</td> <td nowrap="nowrap">)<sup style="font-size: 85%; vertical-align: text-top">(E)</sup></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(12</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" nowrap="nowrap" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Total</b> </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>38</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>14</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>(12</b></td> <td nowrap="nowrap"><b>)</b></td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" nowrap="nowrap" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(1)</i></sup></td> <td>&#160;</td> <td><i>Effective portion</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(2)</i></sup></td> <td>&#160;</td> <td><i>Ineffective portion</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(A)</i></sup></td> <td>&#160;</td> <td><i>Included in Sales to customer</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(B)</i></sup></td> <td>&#160;</td> <td><i>Included in Cost of products sold</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(C)</i></sup></td> <td>&#160;</td> <td><i>Included in Research expense</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(D)</i></sup></td> <td>&#160;</td> <td><i>Included in Interest (Income)/Interest Expense, net</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(E)</i></sup></td> <td>&#160;</td> <td><i>Included in Other (Income)/Expense, net</i></td> </tr> </table> <div align="left" style="font-size: 10pt; margin-top: 6pt">For the fiscal year ended January&#160;3, 2010, a gain of $21&#160;million was recognized in Other (income)/expense, net, relating to foreign exchange contracts not designated as hedging instruments under the Codification. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During the fiscal first quarter of 2008, in accordance with U.S. GAAP, the Company adopted the standard related to fair value measurements except for non-financial assets and liabilities recognized or disclosed at fair value on a non-recurring basis, which became effective during the first fiscal quarter of 2009. The effect of adoption on December&#160;29, 2008 of this standard for non-financial assets and liabilities recorded at fair value on a non-recurring basis did not have a material impact on the Company&#8217;s financial position and results of operations. This standard defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. During the fiscal first quarter of 2008, the Company adopted the standard related to fair value option for financial assets and financial liabilities. This standard permits the Company to measure certain financial assets and financial liabilities at fair value. The Company assessed the fair value option made available upon adopting this standard, and has elected not to apply the fair value option to any financial instruments that were not already recognized at fair value. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;U.S. GAAP defines fair value as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with level 1 having the highest priority and level 3 having the lowest. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The fair value of a derivative financial instrument (i.e. forward exchange contract, currency swap) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company also holds equity investments which are classified as level 1 since they are traded in an active exchange market. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">During 2009, the Company acquired substantially all of the assets and rights of Elan&#8217;s Alzheimer&#8217;s Immunotherapy Program through a newly formed company, JANSSEN Alzheimer Immunotherapy (JAI), of which the Company owns 50.1% and Elan owns 49.9%. In addition, the Company purchased approximately 107&#160;million newly issued American Depositary Receipts (ADRs) of Elan, representing 18.4% of Elan&#8217;s outstanding ordinary shares. As part of this transaction, the Company paid $885&#160;million to Elan and committed to fund up to $250&#160;million of Elan&#8217;s share of research and development spending by JAI. Of this total consideration of $1,135 million, $793&#160;million represents the fair value of the 18.4% investment in Elan based on Elan&#8217;s share price in an actively traded market as of the date of this transaction. The IPR&#038;D related to this transaction was $679&#160;million and is associated with bapineuzumab, a potential first-in-class treatment that is being evaluated for slowing the progression of Alzheimer&#8217;s Disease. The value of the IPR&#038;D was calculated using cash flow projections discounted for the risk inherent in such projects. Probability of success factors ranging from 40-50% were used to reflect inherent clinical and regulatory risk. The discount rate applied was 26%. The non-controlling interest related to this transaction was $590&#160;million, which the Company has recorded in other non-current liabilities. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During 2009, the Company entered into a strategic collaboration with Crucell N.V. which will focus on the discovery, development and commercialization of monoclonal antibodies and vaccines for the treatment and prevention of influenza and other infectious and non-infectious diseases. In addition, the Company, through its affiliate, purchased approximately 18% of Crucell&#8217;s outstanding ordinary shares for an aggregate purchase price of $448&#160;million. Of the total consideration paid, $329&#160;million represents the fair value of the investment based on Crucell&#8217;s share price in an actively traded market as of the date of the transaction with the excess recorded to research and development expense in 2009. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company did not have any other significant financial assets or liabilities which would require revised valuations under this standard that are recognized at fair value. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company&#8217;s significant financial assets and liabilities measured at fair value as of January&#160;3, 2010 and December&#160;28, 2008 were as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="40%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Significant</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Quoted prices in</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>other</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Significant</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>active markets for</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>observable</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>unobservable</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>identical assets</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>inputs</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>inputs</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Level 1</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Level 2</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Level 3</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Total</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Total*</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Derivatives designated as hedging instruments:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Assets:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Foreign exchange contracts </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">436</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">436</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,238</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Cross currency interest rate swaps </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">126</td> <td nowrap="nowrap">**</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">126</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">110</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Total</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>&#8212;</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>562</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>&#8212;</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>562</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>1,348</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Liabilities:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Foreign exchange contracts </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">608</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">608</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,298</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Cross currency interest rate swaps </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">571</td> <td nowrap="nowrap">***</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">571</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,033</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Total</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>&#8212;</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>1,179</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>&#8212;</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>1,179</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>2,331</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Derivatives not designated as hedging instruments:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Assets:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Foreign exchange contracts </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">33</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">33</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">84</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Liabilities:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Foreign exchange contracts </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">40</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">40</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">47</td> <td>&#160;</td> </tr> <tr valign="bottom"><!-- Blank Space --> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Other investments</b> </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">1,134</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,134</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">41</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 0px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>*</i></td> <td>&#160;</td> <td><i>2008 assets and liabilities are all classified as Level 2 with the exception of other investments of $41&#160;million which are classified as Level 1.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>**</i></td> <td>&#160;</td> <td><i>Includes $119&#160;million of non-current assets.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>***</i></td> <td>&#160;</td> <td><i>Includes $517&#160;million of non-current liabilities.</i></td> </tr> </table> <div align="left" style="font-size: 10pt; margin-top: 12pt">See Notes 2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 37 R3.xml IDEA: Consolidated Balance Sheets (Parenthetical) 1.0.0.3 false Consolidated Balance Sheets (Parenthetical) (USD $) In Millions, except Share data false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 false 2 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 3 1 us-gaap_AssetsCurrentAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false 2 false false 0 0 false false No definition available. false 4 2 us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false 1 true true 333000000 333 false false 2 true true 268000000 268 false false No definition available. No authoritative reference available. false 5 1 us-gaap_StockholdersEquityAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false 2 false false 0 0 false false No definition available. false 6 2 us-gaap_PreferredStockNoParValue us-gaap true na instant decimal No definition available. false false false false false false false false false 1 false true 0 0 false false 2 false true 0 0 false false No definition available. No authoritative reference available. false 7 2 us-gaap_PreferredStockSharesAuthorized us-gaap true na instant shares No definition available. false false false false false false false false false 1 false true 2000000 2000000.00 false false 2 false true 2000000 2000000.00 false false No definition available. No authoritative reference available. false 8 2 us-gaap_PreferredStockSharesIssued us-gaap true na instant shares No definition available. false false false false false false false false false 1 false true 2000000 2000000.00 false false 2 false true 2000000 2000000.00 false false No definition available. No authoritative reference available. false 9 2 us-gaap_CommonStockParOrStatedValuePerShare us-gaap true na instant decimal No definition available. false false false false false false false false false 1 false true 1 1 false false 2 false true 1 1 false false No definition available. No authoritative reference available. false 10 2 us-gaap_CommonStockSharesAuthorized us-gaap true na instant shares No definition available. false false false false false false false false false 1 false true 4320000000 4320000000.00 false false 2 false true 4320000000 4320000000.00 false false No definition available. No authoritative reference available. false 11 2 us-gaap_CommonStockSharesIssued us-gaap true na instant shares No definition available. false false false false false false false false false 1 false true 3119843000 3119843000.00 false false 2 false true 3119843000 3119843000.00 false false No definition available. No authoritative reference available. false 12 2 us-gaap_TreasuryStockShares us-gaap true na instant shares No definition available. false false false false false false false false false 1 false true 365522000 365522000.00 false false 2 false true 350665000 350665000.00 false false No definition available. No authoritative reference available. false false 2 10 false Millions NoRounding UnKnown false true XML 38 R14.xml IDEA: Income Taxes 1.0.0.3 false Income Taxes false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 us-gaap_IncomeTaxExpenseBenefitAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false No definition available. false 3 1 us-gaap_IncomeTaxDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 8 - us-gaap:IncomeTaxDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>8. Income Taxes</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The provision for taxes on income consists of: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="64%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Currently payable: </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">U.S. taxes </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">2,410</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,334</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,990</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">International taxes </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,515</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,624</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,479</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,925</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,958</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,469</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"><!-- Blank Space --> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Deferred: </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">U.S. taxes </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">187</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">126</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(722</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">International taxes </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(623</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(104</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,040</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" nowrap="nowrap" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(436</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">22</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,762</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" nowrap="nowrap" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>3,489</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>3,980</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>2,707</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">A comparison of income tax expense at the U.S. statutory rate of 35% in 2009, 2008 and 2007, to the Company&#8217;s effective tax rate is as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="64%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">U.S. </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">7,141</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,579</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,237</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">International </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">8,614</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10,350</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">8,046</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Earnings before taxes on income: </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">15,755</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">16,929</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">13,283</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Tax rates: </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">U.S. statutory rate </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">35.0</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td>&#160;</td> <td align="right">35.0</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">35.0</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Ireland and Puerto Rico operations </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(5.1</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(6.8</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(8.8</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Research and orphan drug tax credits </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(0.6</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(0.6</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(0.8</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">U.S. state and local </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.8</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.6</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2.1</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">International subsidiaries excluding Ireland </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(6.7</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(5.6</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(7.3</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">U.S. manufacturing deduction </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(0.4</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(0.4</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(0.3</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">In-process research and development (IPR&#038;D) </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.0</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.4</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2.1</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">U.S. Tax international income </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1.6</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(0.5</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1.9</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">All other </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(0.3</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.4</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.3</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Effective tax rate </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">22.1</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td>&#160;</td> <td align="right">23.5</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">20.4</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 0px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company has subsidiaries manufacturing in Ireland under an incentive tax rate. In addition, the Company has subsidiaries operating in Puerto Rico under various tax incentive grants. The decrease in the 2009 tax rate was primarily due to increases in taxable income in lower tax jurisdictions relative to taxable income in higher tax jurisdictions. The increase in the 2008 tax rate was mainly attributed to increases in taxable income in higher tax jurisdictions relative to taxable income in lower jurisdictions, as well as a business restructuring of certain international subsidiaries in 2007, resulting in a one-time benefit of $267&#160;million, which reduced the 2007 effective tax rate by 2%. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 12pt">&#160;&#160;&#160;&#160;&#160;Temporary differences and carry forwards for 2009 and 2008 are as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="52%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>2008</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>Deferred Tax</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>Deferred Tax</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Asset</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Liability</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Asset</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Liability</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Employee related obligations </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">2,153</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,615</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Stock based compensation </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,291</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,296</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Depreciation </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(661</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(523</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Non-deductible intangibles </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2,377</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,791</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">International R&#038;D capitalized for tax </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,989</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,914</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Reserves &#038; liabilities </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,014</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">688</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Income reported for tax purposes </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">648</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">629</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Net operating loss carryforward international </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">615</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">393</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Miscellaneous international </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,474</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(110</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">964</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(251</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Miscellaneous U.S. </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">799</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,828</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Total deferred income taxes </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>9,983</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>(3,148</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>10,327</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>(2,565</b></td> <td nowrap="nowrap"><b>)</b></td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" nowrap="nowrap" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The difference between the net deferred tax on income per the balance sheet and the net deferred tax above is included in taxes on income on the balance sheet. The 2009 and 2008 deferred tax Miscellaneous U.S. includes current year tax receivables. The Company has a wholly-owned international subsidiary which has cumulative net losses. The Company believes that it is more likely than not that the subsidiary will realize future taxable income sufficient to utilize these deferred tax assets. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The following table summarizes the activity related to unrecognized tax benefits: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="64%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Beginning of year </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">1,978</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,653</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,262</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Increases related to current year tax positions </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">555</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">545</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">487</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Increases related to prior period tax positions </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">203</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">87</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">77</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Decreases related to prior period tax positions </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(163</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(142</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(117</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Settlements </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(87</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(137</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(14</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Lapse of statute of limitations </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(83</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(28</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(42</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" nowrap="nowrap" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">End of year </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>2,403</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>1,978</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>1,653</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company had $2.4&#160;billion and $2.0&#160;billion of unrecognized tax benefits, as of January&#160;3, 2010 and December&#160;28, 2008, respectively. All of the unrecognized tax benefits of $2.4&#160;billion at January&#160;3, 2010, if recognized, would affect the Company&#8217;s annual effective tax rate. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. The U.S. Internal Revenue Service (IRS)&#160;has completed its audit for the tax years through 2002. In other major jurisdictions where the Company conducts business, the years remain open generally back to the year 2002 with some jurisdictions remaining open as far back as 1995. The Company does not expect that the total amount of unrecognized tax benefits will significantly change over the next twelve months. The Company believes that it is possible that within the next twelve months, the IRS may complete its audit of the tax years 2003-2005. The close of the audit may result in the reduction of unrecognized tax benefits. The Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. During the fiscal year ended January&#160;3, 2010, the Company recognized $85&#160;million of interest expense and $30&#160;million of interest income with an after-tax impact of $36&#160;million expense. For the fiscal year ended December&#160;28, 2008, the Company recognized $106&#160;million of interest expense with an after-tax impact of $69&#160;million. For the fiscal year ended December&#160;30, 2007, the Company recognized $58&#160;million of interest expense and $42 million of interest income with an after-tax impact of $10&#160;million expense. The total amount of accrued interest was $309&#160;million and $227&#160;million in 2009 and 2008, respectively. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 39 R15.xml IDEA: Employee Related Obligations 1.0.0.3 false Employee Related Obligations false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 us-gaap_LaborAndRelatedExpenseAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false No definition available. false 3 1 us-gaap_CompensationRelatedCostsGeneralTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 9 - us-gaap:CompensationRelatedCostsGeneralTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>9. Employee Related Obligations</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">At the end of 2009 and 2008, employee related obligations recorded on the Consolidated Balance Sheet were: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="76%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Pension benefits </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">2,792</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,382</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Postretirement benefits </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,245</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,217</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Postemployment benefits </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,504</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">870</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Deferred compensation </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">790</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">772</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Total employee obligations </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">7,331</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">8,241</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Less current benefits payable </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">562</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">450</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Employee related obligations &#8212; long-term </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>6,769</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>7,791</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Prepaid employee related obligations of $266&#160;million and $136&#160;million for 2009 and 2008, respectively, are included in other assets on the consolidated balance sheet. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 40 R24.xml IDEA: Segments of Business and Geographic Areas 1.0.0.3 false Segments of Business and Geographic Areas false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 jnj_SegmentsOfBusinessAndGeographicAreasAbstract jnj false na duration string Segments Of Business And Geographic Areas. false false false false false true false false false 1 false false 0 0 false false Segments Of Business And Geographic Areas. false 3 1 us-gaap_SegmentReportingDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 18 - us-gaap:SegmentReportingDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>18. Segments of Business</b><sup style="font-size: 85%; vertical-align: text-top"><b>(1) </b></sup><b>and Geographic Areas</b> </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="64%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Sales to Customers</b><sup style="font-size: 85%; vertical-align: text-top"><b>(2)</b></sup></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Consumer &#8212; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">United States </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">6,837</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,937</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,408</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">International </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">8,966</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9,117</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">8,085</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Total </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>15,803</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>16,054</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>14,493</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Pharmaceutical &#8212; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">United States </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">13,041</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">14,831</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15,603</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">International </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">9,479</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9,736</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9,263</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Total </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>22,520</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>24,567</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>24,866</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Medical Devices and Diagnostics &#8212; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">United States </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">11,011</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10,541</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10,433</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">International </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">12,563</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">12,585</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">11,303</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Total </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>23,574</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>23,126</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>21,736</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Worldwide total </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>61,897</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>63,747</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>61,095</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="38%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Operating Profit</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Identifiable Assets</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b><sup style="font-size: 85%; vertical-align: text-top"><b>(5)</b></sup></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b><sup style="font-size: 85%; vertical-align: text-top"><b>(6)</b></sup></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b><sup style="font-size: 85%; vertical-align: text-top"><b>(7)</b></sup></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Consumer </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">2,475</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,674</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,277</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">24,671</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">23,765</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">26,550</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Pharmaceutical </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,413</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7,605</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,540</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">21,460</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">19,544</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">19,780</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Medical Devices and Diagnostics </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">7,694</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7,223</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,846</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">22,853</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">20,779</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">19,978</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Total </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">16,582</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">17,502</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">13,663</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">68,984</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">64,088</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">66,308</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Less: Expense not allocated to segments<sup style="font-size: 85%; vertical-align: text-top">(3)</sup> </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">827</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">573</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">380</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">General corporate<sup style="font-size: 85%; vertical-align: text-top">(4)</sup> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">25,698</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">20,824</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">14,646</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Worldwide total </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>15,755</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>16,929</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>13,283</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>94,682</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>84,912</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>80,954</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="38%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10"><b>Additions to Property,</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10"><b>Depreciation and</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Plant &#038; Equipment</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Amortization</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Consumer </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">439</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">499</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">504</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">513</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">489</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">472</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Pharmaceutical </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">535</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">920</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,137</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">922</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">986</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,033</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Medical Devices and Diagnostics </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,114</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,251</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">919</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,124</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,146</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,080</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Segments total </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,088</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,670</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,560</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,559</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,621</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,585</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">General corporate </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">277</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">396</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">382</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">215</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">211</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">192</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Worldwide total </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>2,365</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>3,066</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>2,942</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>2,774</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>2,832</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>2,777</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="38%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="4%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Sales to Customers</b><sup style="font-size: 85%; vertical-align: text-top"><b>(2)</b></sup></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Long-Lived Assets</b><sup style="font-size: 85%; vertical-align: text-top"><b>(8)</b></sup></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">United States </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">30,889</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">32,309</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">32,444</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">22,399</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">21,674</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">21,685</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Europe </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">15,934</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">16,782</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15,644</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">17,347</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">14,375</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15,578</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Western Hemisphere excluding U.S. </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,156</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,173</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,681</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,540</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,328</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,722</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Asia-Pacific, Africa </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">9,918</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9,483</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">8,326</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,868</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,898</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,261</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Segments total </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">61,897</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">63,747</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">61,095</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">45,154</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">41,275</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">42,246</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">General corporate </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">790</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">785</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">702</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Other non long-lived assets </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">48,738</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">42,852</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">38,006</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Worldwide total </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>61,897</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>63,747</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>61,095</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>94,682</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>84,912</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>80,954</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="3%"></td> <td width="1%"></td> <td width="96"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(1)</i></sup></td> <td>&#160;</td> <td><i>See Note 1 for a description of the segments in which the Company operates.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(2)</i></sup></td> <td>&#160;</td> <td><i>Export sales are not significant. In 2009, 2008 and 2007, the Company did not have a customer that represented 10% of total revenues.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(3)</i></sup></td> <td>&#160;</td> <td><i>Amounts not allocated to segments include interest (income)&#160;expense, non-controlling interests and general corporate (income)&#160;expense.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(4)</i></sup></td> <td>&#160;</td> <td><i>General corporate includes cash and marketable securities.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(5)</i></sup></td> <td>&#160;</td> <td><i>Includes $1,186&#160;million of restructuring expense, comprised of $369&#160;million, $496&#160;million, and $321&#160;million for the Consumer, Pharmaceutical, and Medical Devices and Diagnostics segments, respectively. Includes $386&#160;million of fourth quarter net litigation gain, comprised of a $92&#160;million expense in the Pharmaceutical segment and a gain of $478&#160;million in the Medical Devices and Diagnostics segment.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(6)</i></sup></td> <td>&#160;</td> <td><i>Includes $7&#160;million and $174&#160;million of IPR&#038;D for the Consumer and Medical Devices and Diagnostics segments, respectively. Includes $379&#160;million of fourth quarter net litigation gain, comprised of a $50&#160;million expense in the Consumer segment and a gain of $429&#160;million in the Medical Devices and Diagnostics segment. The Medical Devices and Diagnostics segment also includes $536&#160;million gain on the divestiture of the Professional Wound Care business of Ethicon, Inc.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(7)</i></sup></td> <td>&#160;</td> <td><i>Includes $745&#160;million of restructuring expense, comprised of $15&#160;million, $429&#160;million, and $301&#160;million for the Consumer, Pharmaceutical, and Medical Devices and Diagnostics segments, respectively. The Medical Devices and Diagnostics segment includes $807&#160;million of IPR&#038;D. The Pharmaceutical segment also includes $678&#160;million for the write-down of the NATRECOR </i><sup style="font-size: 85%; vertical-align: text-top"> <i><sup style="font-size: 85%; vertical-align: text-top">&#174;</sup></i></sup><i> intangible asset.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(8)</i></sup></td> <td>&#160;</td> <td><i>Long-lived assets include property, plant and equipment, net for 2009, 2008 and 2007 of $14,759, $14,365 and $14,185, respectively, and intangible assets and goodwill, net for 2009, 2008 and 2007 of $31,185, $27,695 and $28,763, respectively.</i></td> </tr> </table> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 41 R20.xml IDEA: International Currency Translation 1.0.0.3 false International Currency Translation false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 us-gaap_ForeignCurrencyTranslationAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false No definition available. false 3 1 us-gaap_ForeignCurrencyDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 14 - us-gaap:ForeignCurrencyDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>14. International Currency Translation</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">For translation of its subsidiaries operating in non-U.S. Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. This equity account includes the results of translating all balance sheet assets and liabilities at current exchange rates, except for those located in highly inflationary economies. The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;An analysis of the changes during 2009, 2008 and 2007 for foreign currency translation adjustments is included in Note 13. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Net currency transaction and translation gains and losses included in other (income)&#160;expense were losses of $210&#160;million, $31&#160;million and $23&#160;million in 2009, 2008 and 2007, respectively. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 42 R4.xml IDEA: Consolidated Statements of Earnings 1.0.0.3 false Consolidated Statements of Earnings (USD $) In Millions, except Per Share data false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 false 2 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 false 3 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 us-gaap_IncomeStatementAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. false 3 1 us-gaap_SalesRevenueGoodsNet us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 true true 61897000000 61897 false false 2 true true 63747000000 63747 false false 3 true true 61095000000 61095 false false No definition available. No authoritative reference available. true 4 1 us-gaap_CostOfGoodsSold us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true 18447000000 18447 false false 2 false true 18511000000 18511 false false 3 false true 17751000000 17751 false false No definition available. No authoritative reference available. true 5 1 us-gaap_GrossProfit us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true 43450000000 43450 false false 2 false true 45236000000 45236 false false 3 false true 43344000000 43344 false false No definition available. No authoritative reference available. false 6 1 us-gaap_SellingGeneralAndAdministrativeExpense us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true 19801000000 19801 false false 2 false true 21490000000 21490 false false 3 false true 20451000000 20451 false false No definition available. No authoritative reference available. false 7 1 us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true 6986000000 6986 false false 2 false true 7577000000 7577 false false 3 false true 7680000000 7680 false false No definition available. No authoritative reference available. false 8 1 us-gaap_ResearchAndDevelopmentInProcess us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true 0 0 false false 2 false true 181000000 181 false false 3 false true 807000000 807 false false No definition available. No authoritative reference available. false 9 1 us-gaap_InvestmentIncomeInterest us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true -90000000 -90 false false 2 false true -361000000 -361 false false 3 false true -452000000 -452 false false No definition available. No authoritative reference available. false 10 1 us-gaap_InterestExpense us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true 451000000 451 false false 2 false true 435000000 435 false false 3 false true 296000000 296 false false No definition available. No authoritative reference available. false 11 1 us-gaap_OtherNonoperatingIncomeExpense us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true -526000000 -526 false false 2 false true -1015000000 -1015 false false 3 false true 534000000 534 false false No definition available. No authoritative reference available. false 12 1 us-gaap_RestructuringCharges us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true 1073000000 1073 false false 2 false true 0 0 false false 3 false true 745000000 745 false false No definition available. No authoritative reference available. true 13 1 us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true 15755000000 15755 false false 2 false true 16929000000 16929 false false 3 false true 13283000000 13283 false false No definition available. No authoritative reference available. false 14 1 us-gaap_IncomeTaxExpenseBenefit us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true 3489000000 3489 false false 2 false true 3980000000 3980 false false 3 false true 2707000000 2707 false false No definition available. No authoritative reference available. true 15 1 us-gaap_ProfitLoss us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 true true 12266000000 12266 false false 2 true true 12949000000 12949 false false 3 true true 10576000000 10576 false false No definition available. No authoritative reference available. true 16 1 us-gaap_EarningsPerShareBasic us-gaap true na duration decimal No definition available. false false false false false false false false true 1 true true 4.45 4.45 false false 2 true true 4.62 4.62 false false 3 true true 3.67 3.67 false false No definition available. No authoritative reference available. false 17 1 us-gaap_EarningsPerShareDiluted us-gaap true na duration decimal No definition available. false false false false false false false false true 1 true true 4.4 4.4 false false 2 true true 4.57 4.57 false false 3 true true 3.63 3.63 false false No definition available. No authoritative reference available. false 18 1 us-gaap_CommonStockDividendsPerShareCashPaid us-gaap true na duration decimal No definition available. false false false false false false false false true 1 true true 1.93 1.93 false false 2 true true 1.795 1.795 false false 3 true true 1.62 1.62 false false No definition available. No authoritative reference available. false 19 1 us-gaap_WeightedAverageNumberOfSharesOutstandingBasic us-gaap true na duration shares No definition available. false false false false false false false false false 1 false true 2759500000 2759.5 false false 2 false true 2802500000 2802.5 false false 3 false true 2882900000 2882.9 false false No definition available. No authoritative reference available. false 20 1 us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding us-gaap true na duration shares No definition available. false false false false false false false false false 1 false true 2789100000 2789.1 false false 2 false true 2835600000 2835.6 false false 3 false true 2910700000 2910.7 false false No definition available. No authoritative reference available. false false 3 19 false Millions HundredThousands NoRounding false true XML 43 R27.xml IDEA: Legal Proceedings 1.0.0.3 false Legal Proceedings false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 jnj_LegalProceedingsAbstract jnj false na duration string Legal Proceedings. false false false false false true false false false 1 false false 0 0 false false Legal Proceedings. false 3 1 jnj_LegalProceedingsTextBlock jnj false na duration string Legal Proceedings. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 21 - jnj:LegalProceedingsTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>Note 21 &#8212; Legal Proceedings</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt"><b>PRODUCT LIABILITY</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company&#8217;s subsidiaries are involved in numerous product liability cases in the United States, many of which concern alleged adverse reactions to drugs and medical devices. The damages claimed are substantial, and while the Company is confident of the adequacy of the warnings and instructions for use that accompany such products, it is not feasible to predict the ultimate outcome of litigation. However, the Company believes that if any product liability results from such cases, it will be substantially covered by existing amounts accrued in the Company&#8217;s balance sheet and, where available, by third-party product liability insurance. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Multiple products of Johnson &#038; Johnson subsidiaries are subject to numerous product liability claims and lawsuits. There are a significant number of claimants who have pending lawsuits or claims regarding injuries allegedly due to ORTHO EVRA<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, LEVAQUIN<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, DURAGESIC<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, the CHARIT&#201;&#8482; Artificial Disc and CYPHER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> Stent. These claimants seek substantial compensatory and, where available, punitive damages. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;With respect to RISPERDAL <sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, the Attorneys General of eight states and the Office of General Counsel of the Commonwealth of Pennsylvania have filed actions seeking reimbursement of Medicaid or other public funds for RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> prescriptions written for off-label use, compensation for treating their citizens for alleged adverse reactions to RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, civil fines or penalties, punitive damages, or other relief. The Attorney General of Texas has joined a qui tam action in that state seeking similar relief. Certain of these actions also seek injunctive relief relating to the promotion of RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>. The Attorneys General of more than 40 other states have indicated a potential interest in pursuing similar litigation against the Company&#8217;s subsidiary, Janssen Pharmaceutica Inc. (Janssen) (now Ortho-McNeil-Janssen Pharmaceuticals Inc. (OMJPI)), and have obtained a tolling agreement staying the running of the statute of limitations while they inquire into the issues. In addition, there are six cases filed by union health plans seeking damages for alleged overpayments for RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, several of which seek certification as class actions. In the case brought by the Attorney General of West Virginia, based on claims for alleged consumer fraud as to DURAGESIC<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> as well as RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, Janssen (now OMJPI) was found liable and damages were assessed at $4.5&#160;million. OMJPI has filed an appeal. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Numerous claims and lawsuits in the United States relating to the drug PROPULSID<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, withdrawn from general sale by the Company&#8217;s Janssen (now OMJPI) subsidiary in 2000, have been resolved or are currently enrolled in settlement programs with an aggregate cap below $100&#160;million. Similar litigation concerning PROPULSID<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> is pending in Canada, where a national class action of persons alleging adverse reactions to the drug has been certified and a settlement program instituted with an aggregate cap below $10&#160;million. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>AFFIRMATIVE STENT PATENT LITIGATION</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">In patent infringement actions tried in Delaware Federal District Court in late 2000, Cordis Corporation (Cordis), a subsidiary of Johnson &#038; Johnson, obtained verdicts of infringement and patent validity, and damage awards against Boston Scientific Corporation (Boston Scientific) and Medtronic AVE, Inc. (Medtronic) based on a number of Cordis vascular stent patents. In December 2000, the jury in the damage action against Boston Scientific returned a verdict of $324&#160;million and the jury in the Medtronic action returned a verdict of $271&#160;million. The Court of Appeals for the Federal Circuit has upheld liability in these cases, and on September&#160;30, 2008, the district court entered judgments, including interest, in the amounts of $702&#160;million and $521&#160;million against Boston Scientific and Medtronic, respectively. Medtronic paid $472&#160;million in October&#160;2008, representing the judgment, net of amounts exchanged in settlement of a number of other litigations between the companies. The net settlement of $472&#160;million was recorded as a credit to other (income)&#160;expense, net in the 2008 consolidated statement of earnings. In September&#160;2009, Cordis settled this case with Boston Scientific together with the Kastenhofer/Fontirroche and Ding cases described below, for a net payment of $716&#160;million. As part of that settlement Boston Scientific received a paid up license to the Fontirroche family of patents worldwide and Cordis received a paid license to the Kastenhofer and Ding families of patents worldwide and the parties settled all pending lawsuits worldwide relating to these patents. The receipt of $716&#160;million, less the impact of other litigation matters, resulted in a credit to other (income)&#160;expense, net of $386&#160;million in the fiscal fourth quarter of 2009. In addition, in May&#160;2009, Medtronic paid $270&#160;million to settle additional patent infringement claims asserted by Cordis based on its vascular stent patents, which was recorded as a credit to other (income)&#160;expense, net in the fiscal second quarter of 2009. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In January&#160;2003, Cordis filed a patent infringement action against Boston Scientific in Delaware Federal District Court accusing its Express2&#8482;, Taxus<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> and Liberte<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> stents of infringing the Palmaz patent that expired in November&#160;2005. The Liberte<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> stent was also accused of infringing Cordis&#8217; Gray patent that expires in 2016. In June&#160;2005, a jury found that the Express2&#8482;, Taxus<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> and Liberte<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> stents infringed the Palmaz patent and that the Liberte<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> stent also infringed the Gray patent. On March&#160;31, 2009, the U.S. Court of Appeals for the Federal Circuit affirmed this judgment. The case was remanded to the district court for a trial on damages and willfulness. Cordis also filed a lawsuit in Delaware Federal District Court in October of 2008 alleging that Boston Scientific&#8217;s sales of Taxus<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> and Liberte<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> after June of 2005 infringes Cordis&#8217; Gray patent. On January&#160;29, 2010, these cases together with the Jang case referred to in the paragraph below, were settled. Under the terms of the settlement, Boston Scientific paid Cordis $1.0&#160;billion on February&#160;1, 2010, and will pay Cordis an additional $725&#160;million plus interest on January&#160;3, 2011. Cordis granted Boston Scientific a paid up worldwide license under the Palmaz and Gray patents and Boston Scientific granted Cordis a paid up worldwide license under the Jang patents for all stents sold by Cordis except the 2.25mm size Cypher. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Cordis has several pending lawsuits in New Jersey and Delaware Federal District Court against Guidant Corporation (Guidant), Abbott Laboratories, Inc. (Abbott), Boston Scientific and Medtronic alleging that the Xience V&#8482; (Abbott), Promus&#8482; (Boston Scientific) and Endeavor<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> (Medtronic) drug eluting stents infringe several patents owned by or licensed to Cordis. In one of the cases against Boston Scientific, alleging that sales of their Promus&#8482; stent infringed Wright and Falotico patents, on January&#160;20, 2010 the District Court in Delaware found the Wright/Falotico patent invalid for lack of written description and/or lack of enablement. Cordis intends to appeal this ruling. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>PATENT LITIGATION AGAINST VARIOUS JOHNSON &#038; JOHNSON SUBSIDIARIES</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The products of various Johnson &#038; Johnson subsidiaries are the subject of various patent lawsuits, the outcomes of which could potentially adversely affect the ability of those subsidiaries to sell those products, or require the payment of past damages and future royalties. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In July&#160;2005, a jury in Federal District Court in Delaware found that the Cordis CYPHER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> Stent infringed Boston Scientific&#8217;s Ding &#8216;536 patent and that the Cordis CYPHER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> and BX VELOCITY<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> Stents also infringed Boston Scientific&#8217;s Jang &#8216;021 patent. The jury also found both of those patents valid. In January 2009, the Court of Appeals for the Federal Circuit held the Ding patent invalid and a judgment in favor of Cordis in that case has been entered. In March&#160;2009, the Court of Appeals for the Federal Circuit upheld the judgment that Cordis&#8217; CYPHER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> Stent infringed Boston Scientific&#8217;s Jang patent. The case has been remanded for a trial on the issues of damages and willfulness. The Jang case has been dismissed as part of the January&#160;2010 settlement described in the paragraph above relating to the Express2&#8482;, Taxus<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> and Liberte<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> stents. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In Germany, Boston Scientific had several actions based on its Ding patents pending against the Cordis CYPHER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> Stent. Boston Scientific also had brought actions in Belgium, the Netherlands, Germany, France and Italy under its Kastenhofer patent, which purports to cover two-layer catheters such as those used to deliver the CYPHER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> Stent. These cases have been settled as part of the September&#160;2009 settlement described above. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Trial in Boston Scientific&#8217;s U.S. case based on the Kastenhofer patent in Federal District Court in California concluded in October&#160;2007 with a jury finding that the patent was invalid. The jury also found for Cordis on its counterclaim that sale by Boston Scientific of its balloon catheters and stent delivery systems infringe Cordis&#8217; Fontirroche patent. The Court has denied Boston Scientific&#8217;s post trial motions. This case was settled as part of the September&#160;2009 settlement described above. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In May&#160;2008, Centocor, Inc. (Centocor) (now Centocor Ortho Biotech Inc. (COBI)) filed a lawsuit against Genentech, Inc. (Genentech) in U.S. District Court for the Central District of California seeking to invalidate the Cabilly II patent. Prior to filing suit, Centocor had a sublicense under this patent from Celltech (who was licensed by Genentech) for REMICADE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> and had been paying royalties to Celltech. Centocor has terminated that sublicense and stopped paying royalties. Genentech has filed a counterclaim alleging that REMICADE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> infringes its Cabilly II patents and that the manufacture of REMICADE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, STELARA&#8482;, SIMPONI&#8482; and ReoPro<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> also infringes one of its other patents relating to the purification of antibodies made through recombinant DNA techniques. The court has scheduled a hearing for Summary Judgment Motions in August&#160;2010. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In April&#160;2009, a bench trial was held before the Federal District Court for the Middle District of Florida on the liability phase of Ciba&#8217;s patent infringement lawsuit alleging that Johnson &#038; Johnson Vision Care, Inc.&#8217;s (JJVC)&#160;ACUVUE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> OASYS&#8482; lenses infringe three of their Nicholson patents. In August&#160;2009, the District Court found two of these patents valid and infringed and entered judgment against JJVC. JJVC has appealed that judgment to the Court of Appeals for the Federal Circuit. On March&#160;22, 2010, the District Court will hold a hearing on Ciba&#8217;s motion for a permanent injunction. If the judgment is upheld on appeal the Court will schedule another trial to determine damages and willfulness. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In May&#160;2009, Abbott Biotechnology Ltd. filed a patent infringement lawsuit against Centocor (now COBI) in the United States District Court for the District of Massachusetts. The suit alleges that Centocor&#8217;s SIMPONI&#8482; product, a human anti-TNF alpha antibody, infringes Abbott&#8217;s &#8216;394 patent (the Salfeld patent). The case has been stayed pending the resolution of an arbitration filed by Centocor directed to its claim that it is licensed under the &#8216;394 patent. The arbitration is scheduled for March&#160;2010. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In August&#160;2009, Abbott GmbH &#038; Co. (Abbott GmbH) and Abbott Bioresearch Center filed a patent infringement lawsuit against COBI in the United States District Court for the District of Massachusetts. The suit alleges that COBI&#8217;s STELARA&#8482; product infringes two U.S. patents assigned to Abbott GmbH. In August&#160;2009, COBI filed a complaint for a declaratory judgment of non-infringement and invalidity of the Abbott GmbH patents in the United States District Court for the District of Columbia. On the same date, also in the United States District Court for the District of Columbia, COBI filed a Complaint for Review of a Patent Interference Decision granting priority of invention on one of the two asserted patents to Abbott GmbH. In August&#160;2009, Abbott GmbH and Abbott Laboratories Limited brought a patent infringement suit in Canada alleging that STELARA&#8482; infringes Abbott GmbH&#8217;s Canadian patent. The cases filed by COBI in the District of Columbia have been transferred to the District of Massachusetts. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In August&#160;2009, Bayer Healthcare LLC filed suit against COBI in Massachusetts District Court alleging infringement by COBI&#8217;s SIMPONI&#8482; product of its patent relating to human anti-TNF antibodies. Bayer has also filed suit under its European counterpart to these patents in Germany and the Netherlands. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In June&#160;2009, Centocor&#8217;s (now COBI) lawsuit alleging that Abbott&#8217;s HUMIRA anti-TNF alpha product infringes Centocor&#8217;s &#8216;775 patent went to trial in Federal District Court in the Eastern District of Texas. On June&#160;28, 2009 a jury returned a verdict finding the patent valid and willfully infringed, and awarded Centocor damages of approximately $1.7&#160;billion. A bench trial on Abbott&#8217;s defenses, of inequitable conduct and prosecution laches, was held in August&#160;2009, and the District Court decided these issues in favor of Centocor. All of Abbott&#8217;s post trial motions have been denied except that the District Court granted Abbott&#8217;s motion to overturn the jury finding of willfulness. Judgment in the amount of $1.9&#160;billion was entered in favor of Centocor in December&#160;2009 and Abbott has filed an appeal to the Court of Appeals for the Federal Circuit. The Company has not reflected any of the $1.9&#160;billion in its consolidated financial statements. Centocor has also filed a new lawsuit in the Eastern District of Texas seeking damages for infringement of the &#8216;775 patent attributable to sales of HUMIRA subsequent to the jury verdict in June&#160;2009. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The following chart summarizes various patent lawsuits concerning products of the Company&#8217;s subsidiaries that have yet to proceed to trial: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom" style="font-size: 6pt"> <td width="28%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>J&#038;J</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Plaintiff/</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right">&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right">&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Product</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Company</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Patents</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Patent Holder</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Court</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Trial Date**</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Date Filed</b></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" valign="top" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">CYPHER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> Stent </div></td> <td>&#160;</td> <td align="left" valign="top">Cordis </td> <td>&#160;</td> <td align="left" valign="top">Wall </td> <td>&#160;</td> <td align="left" valign="top">Wall </td> <td>&#160;</td> <td align="left" valign="top">E.D. TX </td> <td>&#160;</td> <td align="left" valign="top">Q2/11 </td> <td>&#160;</td> <td align="left" valign="top">11/07</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">CYPHER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> Stent </div></td> <td>&#160;</td> <td align="left" valign="top">Cordis </td> <td>&#160;</td> <td align="left" valign="top">Saffran </td> <td>&#160;</td> <td align="left" valign="top">Saffran </td> <td>&#160;</td> <td nowrap="nowrap" align="left" valign="top">E.D. TX </td> <td>&#160;</td> <td align="left" valign="top">Q2/11 </td> <td>&#160;</td> <td align="left" valign="top">10/07</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">Blood Glucose Meters and Strips </div></td> <td>&#160;</td> <td align="left" valign="top">LifeScan </td> <td>&#160;</td> <td align="left" valign="top">Wilsey </td> <td>&#160;</td> <td nowrap="nowrap" align="left" valign="top">Roche Diagnostics </td> <td>&#160;</td> <td align="left" valign="top">D. DE </td> <td>&#160;</td> <td align="left" valign="top">* </td> <td>&#160;</td> <td align="left" valign="top">11/07</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">REMICADE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, ustekinumab, </div></td> <td>&#160;</td> <td align="left" valign="top">Centocor/COBI </td> <td>&#160;</td> <td nowrap="nowrap" align="left" valign="top">Cabilly II </td> <td>&#160;</td> <td align="left" valign="top">Genentech </td> <td>&#160;</td> <td nowrap="nowrap" align="left" valign="top">C.D. CA </td> <td>&#160;</td> <td align="left" valign="top">* </td> <td>&#160;</td> <td align="left" valign="top">05/08</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">golimumab, ReoPro<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> </div></td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">SIMPONI&#8482; </div></td> <td>&#160;</td> <td align="left" valign="top">Centocor/COBI </td> <td>&#160;</td> <td align="left" valign="top">Salfeld </td> <td>&#160;</td> <td nowrap="nowrap" align="left" valign="top">Abbott Laboratories </td> <td>&#160;</td> <td align="left" valign="top">MA </td> <td>&#160;</td> <td align="left" valign="top">* </td> <td>&#160;</td> <td align="left" valign="top">05/09</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">SIMPONI&#8482; </div></td> <td>&#160;</td> <td align="left" valign="top">Centocor/COBI </td> <td>&#160;</td> <td align="left" valign="top">Boyle </td> <td>&#160;</td> <td align="left" valign="top">Bayer Healthcare </td> <td>&#160;</td> <td align="left" valign="top">MA </td> <td>&#160;</td> <td align="left" valign="top">* </td> <td>&#160;</td> <td align="left" valign="top">08/09</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">STELARA&#8482; </div></td> <td>&#160;</td> <td align="left" valign="top">Centocor/COBI </td> <td>&#160;</td> <td align="left" valign="top">Salfeld </td> <td>&#160;</td> <td align="left" valign="top">Abbott GmbH </td> <td>&#160;</td> <td align="left" valign="top">MA/DC </td> <td>&#160;</td> <td align="left" valign="top">* </td> <td>&#160;</td> <td align="left" valign="top">08/09</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>*</i></td> <td>&#160;</td> <td><i>Trial date to be scheduled.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>**</i></td> <td>&#160;</td> <td><i>Q reflects the Company&#8217;s fiscal quarter.</i></td> </tr> </table> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>LITIGATION AGAINST FILERS OF ABBREVIATED NEW DRUG APPLICATIONS (ANDAs)</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The following chart indicates lawsuits pending against generic firms that filed Abbreviated New Drug Applications (ANDAs) seeking to market generic forms of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement, invalidity and unenforceability of these patents. In the event the subsidiary of the Company involved is not successful in these actions, or the statutory 30-month stay expires before a ruling from the district court is obtained, the firms involved will have the ability, upon FDA approval, to introduce generic versions of the product at issue resulting in very substantial market share and revenue losses for the product of the Company&#8217;s subsidiary. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;As noted in the following chart, 30-month stays expired during 2009, and will expire in 2010, 2011 and 2012 with respect to ANDA challenges regarding various products: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="28%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Brand Name</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Patent/NDA</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Generic</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Trial</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Date</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>30-Month</b></td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Product</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Holder</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Challenger</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Court</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Date**</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Filed</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>Stay Expiration</b></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" valign="top" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">CONCERTA<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> </div></td> <td>&#160;</td> <td align="left" valign="top">McNeil-PPC </td> <td>&#160;</td> <td align="left" valign="top">Andrx </td> <td>&#160;</td> <td align="left" valign="top">D. DE </td> <td>&#160;</td> <td align="left" valign="top">Q4/07 </td> <td>&#160;</td> <td align="left" valign="top">09/05 </td> <td>&#160;</td> <td align="left" valign="top">None</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">18, 27, 36 and 54 mg controlled release tablet </div></td> <td>&#160;</td> <td align="left" valign="top">ALZA </td> <td>&#160;</td> <td align="left" valign="top">KUDCO </td> <td>&#160;</td> <td align="left" valign="top">D. DE </td> <td>&#160;</td> <td align="left" valign="top">* </td> <td>&#160;</td> <td align="left" valign="top">01/10 </td> <td>&#160;</td> <td align="left" valign="top">05/12</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td nowrap="nowrap" valign="top"> <div style="margin-left:0px; text-indent:-0px">LEVAQUIN<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> 250, 500, 750 mg tablet </div></td> <td>&#160;</td> <td align="left" valign="top">Ortho-McNeil </td> <td>&#160;</td> <td align="left" valign="top">Lupin </td> <td>&#160;</td> <td align="left" valign="top">D. NJ </td> <td>&#160;</td> <td align="left" valign="top">* </td> <td>&#160;</td> <td align="left" valign="top">10/06 </td> <td>&#160;</td> <td align="left" valign="top">03/09</td> </tr> <tr> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">ORTHO TRI-CYCLEN<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> LO </div></td> <td>&#160;</td> <td align="left" valign="top">Ortho-McNeil </td> <td>&#160;</td> <td align="left" valign="top">Watson </td> <td>&#160;</td> <td align="left" valign="top">D. NJ </td> <td>&#160;</td> <td align="left" valign="top">* </td> <td>&#160;</td> <td align="left" valign="top">10/08 </td> <td>&#160;</td> <td align="left" valign="top">03/11</td> </tr> <tr valign="bottom"> <td nowrap="nowrap" valign="top"> <div style="margin-left:0px; text-indent:-0px">0.18 mg/0.025 mg, 0.215 mg/0.025 mg <br /> and 0.25 mg/0.025 mg </div></td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">Sandoz </td> <td>&#160;</td> <td nowrap="nowrap" align="left" valign="top">D. NJ<br /> D. NJ </td> <td>&#160;</td> <td align="left" valign="top">*<br /> * </td> <td>&#160;</td> <td align="left" valign="top">06/09 </td> <td>&#160;</td> <td align="left" valign="top">10/11<br /> 06/12</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td nowrap="nowrap" valign="top"> <div style="margin-left:0px; text-indent:-0px">ULTRAM ER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> 100, 200, 300 mg tablet </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left" valign="top">Ortho-McNeil/Biovail </td> <td>&#160;</td> <td align="left" valign="top">Par </td> <td>&#160;</td> <td align="left" valign="top">D. DE </td> <td>&#160;</td> <td align="left" valign="top">Q2/09 </td> <td>&#160;</td> <td align="left" valign="top">05/07 </td> <td>&#160;</td> <td align="left" valign="top">09/09</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">&#160; </div></td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">06/07 </td> <td>&#160;</td> <td align="left" valign="top">11/09</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">&#160; </div></td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">10/07 </td> <td>&#160;</td> <td align="left" valign="top">03/10</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">ULTRAM ER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> 100, 200, 300 mg tablet </div></td> <td>&#160;</td> <td align="left" valign="top">Ortho-McNeil/Biovail </td> <td>&#160;</td> <td align="left" valign="top">Impax </td> <td>&#160;</td> <td align="left" valign="top">D. DE </td> <td>&#160;</td> <td align="left" valign="top">Q2/10 </td> <td>&#160;</td> <td align="left" valign="top">08/08 </td> <td>&#160;</td> <td align="left" valign="top">01/11</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">&#160; </div></td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">&#160;</td> <td>&#160;</td> <td align="left" valign="top">11/08 </td> <td>&#160;</td> <td align="left" valign="top">03/11</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">ULTRAM ER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> 100, 200, 300 mg tablet </div></td> <td>&#160;</td> <td align="left" valign="top">Ortho-McNeil/Biovail </td> <td>&#160;</td> <td align="left" valign="top">Paddock </td> <td>&#160;</td> <td nowrap="nowrap" align="left" valign="top">D.DRD. Minn. </td> <td>&#160;</td> <td align="left" valign="top"> * </td> <td>&#160;</td> <td align="left" valign="top">09/09 </td> <td>&#160;</td> <td align="left" valign="top">01/12</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">ULTRAM ER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> 100, 200, 300 mg tablet </div></td> <td>&#160;</td> <td align="left" valign="top">Ortho-McNeil/Biovail </td> <td>&#160;</td> <td align="left" valign="top">Cipher </td> <td>&#160;</td> <td align="left" valign="top">D. DE </td> <td>&#160;</td> <td align="left" valign="top">* </td> <td>&#160;</td> <td align="left" valign="top">10/09 </td> <td>&#160;</td> <td align="left" valign="top">03/12</td> </tr> <tr style="font-size: 5pt"><!-- Blank Space --> <td>&#160;</td> </tr> <tr valign="bottom"> <td valign="top"> <div style="margin-left:0px; text-indent:-0px">ULTRAM ER<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> 100, 200, 300 mg tablet </div></td> <td>&#160;</td> <td align="left" valign="top">Ortho-McNeil/Biovail </td> <td>&#160;</td> <td align="left" valign="top">Lupin </td> <td>&#160;</td> <td align="left" valign="top">D. DE </td> <td>&#160;</td> <td align="left" valign="top">* </td> <td>&#160;</td> <td align="left" valign="top">01/10 </td> <td>&#160;</td> <td align="left" valign="top">06/12</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 12pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>*</i></td> <td>&#160;</td> <td><i>Trial date to be scheduled.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>**</i></td> <td>&#160;</td> <td><i>Q reflects the Company&#8217;s fiscal quarter.</i></td> </tr> </table> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In the action against Barr Pharmaceuticals, Inc. (Barr) (now a wholly-owned subsidiary of Teva Pharmaceutical Industries LTD.) regarding ORTHO TRI-CYCLEN<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> LO, in January&#160;2008, the Company&#8217;s subsidiary Ortho Women&#8217;s Health &#038; Urology, a Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), and Barr agreed to a non-binding term sheet to settle the litigation, which settlement discussions are still underway. The trial court postponed the January&#160;2008 trial without setting a new trial date. In June&#160;2009, Barr launched its generic product &#8220;at risk&#8221; before trial. OMJPI sought a preliminary injunction and recall of Barr product which the Court granted in July&#160;2009. In July&#160;2009, the parties entered into a definitive agreement to settle the lawsuit. Under the terms of the settlement, Barr obtained a release for its sales of its generic product in exchange for an undisclosed royalty payment. Barr also obtained a non-exclusive, royalty-bearing license to re-enter the market on December&#160;31, 2015, or earlier in certain limited circumstances. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In October&#160;2008, the Company&#8217;s subsidiary OMJPI filed suit in Federal District Court in New Jersey against Watson Laboratories, Inc. (Watson) in response to Watson&#8217;s ANDA regarding ORTHO TRI-CYCLEN<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> LO. In June&#160;2009, the Company&#8217;s subsidiary OMJPI filed suit in Federal District Court in New Jersey against Sandoz Laboratories, Inc. (Sandoz) in response to Sandoz&#8217;s ANDA regarding ORTHO TRI-CYCLEN<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> LO. The Sandoz and Watson cases have been consolidated. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In January&#160;2010, the Company&#8217;s subsidiary OMJPI filed suit in Federal District Court in New Jersey against Lupin Ltd. and Lupin Pharmaceuticals, Inc. (collectively &#8220;Lupin&#8221;) in response to Lupin&#8217;s ANDA regarding ORTHO TRI-CYCLEN<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> LO. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In the action against Barr and AlphaPharm with respect to their ANDA challenges to the RAZADYNE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> patent that Janssen (now OMJPI) licenses from Synaptech, Inc. (Synaptech), a four-day non-jury trial was held in the Federal District Court in Delaware in May 2007. In August&#160;2008, the court held that the patent was invalid because it was not enabled. Janssen (OMJPI)&#160;and Synaptech have appealed the decision. Since the court&#8217;s decision, multiple generic companies have received final approvals for their products and have launched &#8220;at risk&#8221; pending appeal. Additional generic approvals and launches could occur at any time. In September 2009, the Court of Appeals affirmed the judgment that the patent is invalid. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In the action by McNEIL-PPC, Inc. (McNeil-PPC) and ALZA Corporation (ALZA)&#160;against Andrx Corporation (Andrx) with respect to its ANDA challenge to the CONCERTA<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> patents, a five-day non-jury trial was held in the Federal District Court in Delaware in December 2007. In March&#160;2009, the court ruled that one CONCERTA<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> patent would not be infringed by Andrx&#8217;s proposed generic product and that the patent was invalid because it was not enabled. The court dismissed without prejudice Andrx&#8217;s declaratory judgment suit on a second patent for lack of jurisdiction. McNeil-PPC and ALZA filed an appeal in May&#160;2009. The appeals court heard argument on February&#160;3, 2010. A decision is pending. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;ALZA and OMJPI filed a second suit in Federal District Court in Delaware against Kremers-Urban, LLC and KUDCO Ireland, Ltd. (KUDCO)&#160;in January&#160;2010 in response to KUDCO&#8217;s ANDA challenge regarding CONCERTA<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> tablets. In its notice letter, KUDCO contends that two ALZA patents for CONCERTA<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> are invalid and not infringed by a KUDCO generic. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In the RAZADYNE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> ER cases, a lawsuit was filed against Barr on the RAZADYNE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> use patent that Janssen (now OMJPI) licenses from Synaptech in June 2006. In September&#160;2008, the above-discussed Delaware decision invalidating the RAZADYNE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> use patent resulted in entry of judgment for Barr on that patent, but the case will be reopened if Janssen (now OMJPI) and Synaptech win on appeal. Barr has received FDA approval of its product and has launched &#8220;at risk.&#8221; In September&#160;2009, the Federal Circuit affirmed the Delaware decision invalidating the RAZADYNE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> use patent. As a result, this case will not be reopened. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In the action against Lupin Pharmaceuticals, Inc. (Lupin) regarding its ANDA concerning LEVAQUIN<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>, Lupin contends that the U.S. Patent and Trademark Office improperly granted a patent term extension to the patent that Ortho-McNeil (now Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI)) licenses from Daiichi Pharmaceuticals, Inc. (Daiichi). Lupin alleges that the active ingredient in LEVAQUIN<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> was the subject of prior marketing, and therefore was not eligible for the patent term extension. Lupin concedes validity and that its product would violate the patent if marketed prior to the expiration of the original patent term. Summary judgment against Lupin was granted in May&#160;2009 and Lupin appealed. Oral argument was held in September&#160;2009. A decision is pending. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In the ULTRAM<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> ER actions, Ortho-McNeil Pharmaceutical, Inc. (Ortho-McNeil) (now OMJPI), filed lawsuits (each for different dosages) against Par Pharmaceuticals, Inc. and Par Pharmaceuticals Companies, Inc. (Par) in May, June and October&#160;2007 on two Tramadol ER formulation patents owned by Purdue Pharma Products L.P. (Purdue) and Napp Pharmaceutical Group Ltd. (Napp). OMJPI also filed lawsuits (each for different dosages) against Impax Laboratories, Inc. (Impax) on a Tramadol ER formulation patent owned by Purdue and Napp in August and November&#160;2008. Purdue, Napp and Biovail Laboratories International SRL (Biovail) (the NDA holder) joined as co-plaintiffs in the lawsuits against Par and Impax, but Biovail and OMJPI were subsequently dismissed for lack of standing. The trial against Par took place in April&#160;2009. In August&#160;2009, the Court issued a decision finding the patents-in-suit invalid. Purdue has appealed that decision. The trial against Impax is scheduled for June&#160;2010. In November&#160;2009, the case against Impax was stayed with the consent of all parties. In September and October&#160;2009, respectively, Purdue filed suits against Paddock Laboratories, Inc. (Paddock) and Cipher Pharmaceuticals Inc. (Cipher) on its Tramadol ER formulation patents. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In January&#160;2010, Purdue filed a suit against Lupin Ltd. (Lupin) on its Tramadol ER formulation patents. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In September&#160;2009, Centocor Ortho Biotech Products, L.P. (COBI, LP) intervened in an inventorship dispute between Kansas University Center for Research (KUCR)&#160;involving certain U.S. government-owned VELCADE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> formulation patents. KUCR brought this action against the U.S. government in the District of Kansas seeking to add two Kansas University scientists to the patents. The U.S. government licensed the patents (and their foreign counterparts) to Millennium Pharmaceuticals, Inc., who in turn sublicensed the patents (and their foreign counterparts) to COBI,LP for commercial marketing outside the U.S. If KUCR succeeds in its co-inventorship claim and establishes co-ownership in the U.S. VELCADE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> formulation patents, we anticipate that KUCR will initiate actions to establish co-inventorship and co-ownership with respect to the foreign counterpart patents in the countries where COBI, LP has commercial marketing rights. If KUCR in Kansas is successful, this may adversely affect COBI, LP&#8217;s license rights in those countries. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>AVERAGE WHOLESALE PRICE (AWP)&#160;LITIGATION</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Johnson &#038; Johnson and several of its pharmaceutical subsidiaries, along with numerous other pharmaceutical companies, are defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP)&#160;for the drugs at issue. Many of these cases, both federal actions and state actions removed to federal court, have been consolidated for pre-trial purposes in a Multi-District Litigation (MDL)&#160;in Federal District Court in Boston, Massachusetts. The plaintiffs in these cases include classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The MDL Court identified classes of Massachusetts-only private insurers providing &#8220;Medi-gap&#8221; insurance coverage and private payers for physician-administered drugs where payments were based on AWP (&#8220;Class&#160;2&#8221; and &#8220;Class&#160;3&#8221;), and a national class of individuals who made co-payments for physician-administered drugs covered by Medicare (&#8220;Class&#160;1&#8221;). A trial of the two Massachusetts-only class actions concluded before the MDL Court in December&#160;2006. In June&#160;2007, the MDL Court issued post-trial rulings, dismissing the Johnson &#038; Johnson defendants from the case regarding all claims of Classes 2 and 3, and subsequently of Class&#160;1 as well. Plaintiffs appealed the Class&#160;1 judgment and, in September&#160;2009, the Court of Appeals vacated the judgment and remanded for further proceedings in the District Court. AWP cases brought by various Attorneys General have proceeded to trial against other manufacturers. One state case against certain of the Company&#8217;s subsidiaries has been set for trial in late 2010, and other state cases are likely to be set for trial thereafter. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>OTHER</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">In July&#160;2003, Centocor (now COBI), a Johnson &#038; Johnson subsidiary, received a request that it voluntarily provide documents and information to the criminal division of the U.S. Attorney&#8217;s Office, District of New Jersey, in connection with its investigation into various Centocor marketing practices. Subsequent requests for documents have been received from the U.S. Attorney&#8217;s Office. Both the Company and Centocor have responded to these requests for documents and information. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In December&#160;2003, Ortho-McNeil (now OMJPI) received a subpoena from the U.S. Attorney&#8217;s Office in Boston, Massachusetts seeking documents relating to the marketing, including alleged off-label marketing, of the drug TOPAMAX<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> (topiramate). Additional subpoenas for documents have been received, and current and former employees have testified before a grand jury. Discussions are underway in an effort to resolve this matter, but whether agreement can be reached and on what terms is uncertain. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In January&#160;2004, Janssen (now OMJPI) received a subpoena from the Office of the Inspector General of the U.S. Office of Personnel Management seeking documents concerning sales and marketing of, any and all payments to physicians in connection with sales and marketing of, and clinical trials for, RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> (risperidone)&#160;from 1997 to 2002. Documents subsequent to 2002 have also been requested. An additional subpoena seeking information about marketing of and adverse reactions to RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> was received from the U.S. Attorney&#8217;s Office for the Eastern District of Pennsylvania in November&#160;2005. Subpoenas seeking testimony from various witnesses before a grand jury have also been received. Janssen is cooperating in responding to ongoing requests for documents and witnesses. The government is continuing to actively investigate this matter. In February&#160;2010, the government served Civil Investigative Demands seeking additional information relating to sales and marketing of RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> and sales and marketing of INVEGA<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In September&#160;2004, Ortho Biotech Inc. (Ortho Biotech) (now COBI), received a subpoena from the U.S. Office of Inspector General&#8217;s Denver, Colorado field office seeking documents directed to the sales and marketing of PROCRIT<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> (Epoetin alfa) from 1997 to the present, as well as to dealings with U.S. Oncology Inc., a healthcare services network for oncologists. Ortho Biotech (now COBI) has responded to the subpoena. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In September&#160;2004, plaintiffs in an employment discrimination litigation initiated against the Company in 2001 in Federal District Court in New Jersey moved to certify a class of all African American and Hispanic salaried employees of the Company and its affiliates in the U.S., who were employed at any time from November&#160;1997 to the present. Plaintiffs seek monetary damages for the period 1997 through the present (including punitive damages) and equitable relief. The Court denied plaintiffs&#8217; class certification motion in December&#160;2006 and their motion for reconsideration in April&#160;2007. Plaintiffs sought to appeal these decisions and, in April&#160;2008, the Court of Appeals ruled that plaintiffs&#8217; appeal of the denial of class certification was untimely. In July&#160;2009, plaintiffs filed a motion for certification of a modified class, which the Company is opposing. Plaintiffs are engaged in further discovery of individual plaintiffs&#8217; claims. The hearing on plaintiffs&#8217; motion for class certification is scheduled for July&#160;2010. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In March&#160;2005, DePuy Orthopaedics, Inc. (DePuy), a Johnson &#038; Johnson subsidiary, received a subpoena from the U.S. Attorney&#8217;s Office, District of New Jersey, seeking records concerning contractual relationships between DePuy and surgeons or surgeons-in-training involved in hip and knee replacement and reconstructive surgery. This investigation was resolved by DePuy and the four other leading suppliers of hip and knee implants in late September&#160;2007 by agreements with the U.S. Attorney&#8217;s Office for the District of New Jersey. The settlements included an 18-month Deferred Prosecution Agreement (DPA), acceptance by each company of a monitor to assure compliance with the DPA and, with respect to four of the five companies, payment of settlement monies and entry into five year Corporate Integrity Agreements. DePuy paid $85&#160;million as its settlement. The term of the Monitor-ship under the Deferred Prosecution Agreement concluded on March&#160;27, 2009, and an order dismissing all charges was entered on March&#160;30, 2009. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In November&#160;2007, the Attorney General of the Commonwealth of Massachusetts issued a Civil Investigative Demand to DePuy seeking information regarding financial relationships between a number of Massachusetts-based orthopedic surgeons and providers and DePuy. DePuy is responding to Massachusetts&#8217; additional requests. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In July&#160;2005, Scios Inc. (Scios), a Johnson &#038; Johnson subsidiary, received a subpoena from the U.S. Attorney&#8217;s Office, District of Massachusetts, seeking documents related to the sales and marketing of NATRECOR<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>. Scios responded to the subpoena. In early August&#160;2005, Scios was advised that the investigation would be handled by the U.S. Attorney&#8217;s Office for the Northern District of California in San Francisco. Additional requests for documents have been received and responded to and former Scios employees have testified before a grand jury in San Francisco. The qui tam complaints were unsealed on February&#160;19, 2009. The U.S. government has intervened in one of the qui tam actions, and filed a complaint against Scios and the Company in June&#160;2009. Scios and Johnson &#038; Johnson have filed a motion to dismiss the qui tam complaint filed by the government, and that motion was denied. The criminal investigation is continuing and discussions are underway in an effort to settle this matter. Whether a settlement can be reached and on what terms is uncertain. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In September&#160;2005, the Company received a subpoena from the U.S. Attorney&#8217;s Office, District of Massachusetts, seeking documents related to sales and marketing of eight drugs to Omnicare, Inc., a manager of pharmaceutical benefits for long-term care facilities. The Johnson &#038; Johnson subsidiaries involved responded to the subpoena. Several employees of the Company&#8217;s pharmaceutical subsidiaries have been subpoenaed to testify before a grand jury in connection with this investigation. In April&#160;2009, the Company was served with the complaints in two civil qui tam cases related to marketing of prescription drugs to Omnicare, Inc. On January&#160;15, 2010, the government filed a complaint intervening in the cases. The complaint asserts claims under the federal False Claims Act and a related state law claim in connection with the marketing of several drugs to Omnicare. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In November&#160;2005, Amgen Inc. (Amgen) filed suit against Hoffmann-LaRoche, Inc. (Roche) in the U.S. District Court for the District of Massachusetts seeking a declaration that the Roche product CERA, which Roche has indicated it would seek to introduce into the United States, infringes a number of Amgen patents concerning EPO. Amgen licenses EPO for sale in the United States to Ortho Biotech (now COBI) for non-dialysis indications. Trial in this action concluded in October&#160;2007 with a verdict in Amgen&#8217;s favor, finding the patents valid and infringed. The judge issued a preliminary injunction blocking the CERA launch, and subsequently made the injunction permanent. The Federal Circuit upheld the entry of a permanent injunction. This matter has been settled pursuant to an agreement between the parties. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In February&#160;2006, the Company received a subpoena from the U.S. Securities &#038; Exchange Commission (SEC)&#160;requesting documents relating to the participation by several Johnson &#038; Johnson subsidiaries in the United Nations Iraq Oil for Food Program. The subsidiaries are cooperating with the SEC and U.S. Department of Justice (DOJ)&#160;in producing responsive documents. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In February&#160;2007, the Company voluntarily disclosed to the DOJ and the SEC that subsidiaries outside the United States are believed to have made improper payments in connection with the sale of medical devices in two small-market countries, which payments may fall within the jurisdiction of the Foreign Corrupt Practices Act (FCPA). In the course of continuing dialogues with the agencies, other issues potentially rising to the level of FCPA violations in additional markets have been brought to the attention of the agencies by the Company. The Company has provided and will continue to provide additional information to the DOJ and SEC, and will cooperate with the agencies&#8217; reviews of these matters. Law enforcement agencies of a number of other countries are also pursuing investigations of matters voluntarily disclosed by the Company to the DOJ and SEC. Discussions are underway in an effort to resolve these matters, and the Iraq Oil for Food matter referenced above, but whether agreement can be reached and on what terms is uncertain. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In March&#160;2007, the Company received separate subpoenas from the U.S. Attorney&#8217;s Office in Philadelphia, the U.S. Attorney&#8217;s Office in Boston and the U.S. Attorney&#8217;s Office in San Francisco. The subpoenas relate to investigations by these three offices referenced above concerning, respectively, sales and marketing of RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> by Janssen (now OMJPI), TOPAMAX<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> by Ortho-McNeil (now OMJPI) and NATRECOR<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> by Scios. The subpoenas request information regarding the Company&#8217;s corporate supervision and oversight of these three subsidiaries, including their sales and marketing of these drugs. The Company responded to these requests. In addition, the U.S. Attorney&#8217;s Office in Boston has issued subpoenas for grand jury testimony to several employees of Johnson &#038; Johnson. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In May&#160;2007, the New York State Attorney General issued a subpoena seeking information relating to the marketing and safety of PROCRIT<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>. The Company is responding to these requests. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In April&#160;2007, the Company received two subpoenas from the Office of the Attorney General of the State of Delaware. The subpoenas seek documents and information relating to nominal pricing agreements. For purposes of the subpoenas, nominal pricing agreements are defined as agreements under which the Company agreed to provide a pharmaceutical product for less than ten percent of the Average Manufacturer Price for the product. The Company responded to these requests. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In January&#160;2008, the European Commission (&#8220;EC&#8221;) began an industry-wide antitrust inquiry concerning competitive conditions within the pharmaceutical sector. Because this is a sector inquiry, it is not based on any specific allegation that the Company has violated EC competition law. The inquiry began with unannounced raids of a substantial number of pharmaceutical companies throughout Europe, including Johnson &#038; Johnson affiliates. In March&#160;2008, the EC issued detailed questionnaires to approximately 100 companies, including Johnson &#038; Johnson affiliates. In November 2008, the EC issued a preliminary report summarizing its findings. The final report was issued on July&#160;8, 2009. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In March&#160;2008, the Company received a letter request from the Attorney General of the State of Michigan. The request seeks documents and information relating to nominal price transactions. The Company responded to the request and will cooperate with the inquiry. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In June&#160;2008, the Company received a subpoena from the United States Attorney&#8217;s Office for the District of Massachusetts relating to the marketing of biliary stents by the Company&#8217;s Cordis subsidiary. Cordis is cooperating in responding to the subpoena. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In September&#160;2008, Multilan AG (Multilan), an indirect subsidiary of Schering-Plough Corporation, commenced arbitration against Janssen Pharmaceutica NV for an alleged wrongful termination of an agreement relating to payments in connection with termination of certain marketing rights. Multilan seeks declaratory relief, specific performance and damages. This case was recently settled and a charge was recorded to other income (expense), net, in the fiscal fourth quarter of 2009. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In February&#160;2009, Basilea Pharmaceutica AG (Basilea) brought an arbitration against the Company and various affiliates alleging that the Company breached the 2005 License Agreement for cefto-biprole by, among other things, failing to secure FDA approval of the cSSSI (skin)&#160;indication and allegedly failing to properly develop the pneumonia indication. Basilea is seeking to recover damages and a declaration that the Company materially breached the agreement. This matter has been scheduled for an arbitration hearing commencing in June&#160;2010 followed by post-trial submissions. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In April&#160;2009, the Company received a HIPPA subpoena from the U.S. Attorney&#8217;s Office for the District of Massachusetts (Boston) seeking information regarding the Company&#8217;s financial relationship with several psychiatrists. The Company is responding to this request. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In April&#160;2009, Ortho-Clinical Diagnostics, Inc. (OCD)&#160;received a grand jury subpoena from the U.S. Department of Justice, Antitrust Division, requesting documents and information for the period beginning September&#160;1, 2000 through the present, pertaining to an investigation of alleged violations of the antitrust laws in the blood reagents industry. The Company is in the process of complying with the subpoena. In the weeks following the public announcement that OCD had received a subpoena from the Antitrust Division, multiple class action complaints were filed. The various cases were consolidated for pre-trial purposes in the Eastern District of Pennsylvania. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In May&#160;2009, the New Jersey Attorney General issued a subpoena to DePuy Orthopaedics, Inc., seeking information regarding the financial interest of clinical investigators who performed clinical studies for DePuy Orthopaedics, Inc. and DePuy Spine, Inc. The Company is responding to these requests. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In May&#160;2009, COBI commenced an arbitration proceeding before the American Arbitration Association against Schering-Plough Corporation and its subsidiary Schering-Plough (Ireland) Company (collectively, Schering-Plough). COBI and Schering-Plough are parties to a series of agreements (the Distribution Agreements) that grant Schering-Plough the exclusive right to distribute the drugs REMICADE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> and SIMPONI&#8482; worldwide, except within the United States, Japan, Taiwan, Indonesia, and the People&#8217;s Republic of China (including Hong Kong) (the &#8220;Territory&#8221;). COBI distributes REMICADE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> and SIMPONI&#8482;, the next generation treatment, within the United States. In the arbitration, COBI seeks a declaration that the agreement and merger between Merck &#038; Co., Inc. (Merck) and Schering-Plough constitutes a change of control under the terms of the Distribution Agreements that permits COBI to terminate the Agreements. The termination of the Distribution Agreements would return to COBI the right to distribute REMICADE<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> and SIMPONI&#8482; within the Territory. Schering-Plough has filed a response to COBI&#8217;s arbitration demand that denies that it has undergone a change of control. The arbitrators have been selected and the matter will be proceeding to arbitration in late September&#160;2010. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In December&#160;2009, the State of Israel (Sheba Medical Center) filed a lawsuit against three Omrix entities. In the lawsuit, the State claimed that an employee of a government-owned hospital was the inventor on several patents related to fibrin glue technology, that he developed while he was a government employee. The State claims that he had no right to transfer any intellectual property to Omrix because it belongs to the State. The State is seeking damages plus royalty on QUIXIL&#8482; and EVICEL&#8482; or, alternatively, transfer of the patents to the State. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In recent years the Company has received numerous requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the Company&#8217;s policy to cooperate with these inquiries by producing the requested information. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;With respect to all the above matters, the Company and its subsidiaries are vigorously contesting the allegations asserted against them and otherwise pursuing defenses to maximize the prospect of success. The Company and its subsidiaries involved in these matters continually evaluate their strategies in managing these matters and, where appropriate, pursue settlements and other resolutions where those are in the best interest of the Company. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company is also involved in a number of other patent, trademark and other lawsuits incidental to its business. The ultimate legal and financial liability of the Company in respect to all claims, lawsuits and proceedings referred to above cannot be estimated with any certainty. However, in the Company&#8217;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#8217;s balance sheet, is not expected to have a material adverse effect on the Company&#8217;s financial condition, although the resolution in any reporting period of one or more of these matters could have a significant impact on the Company&#8217;s results of operations and cash flows for that period. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false Legal Proceedings. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 44 R16.xml IDEA: Pensions and Other Benefit Plans 1.0.0.3 false Pensions and Other Benefit Plans false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 us-gaap_GeneralDiscussionOfPensionAndOtherPostretirementBenefitsAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false No definition available. false 3 1 us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 10 - us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>10. Pensions and Other Benefit Plans</b> <br style="font-size: 6pt" /> The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides postretirement benefits, primarily health care, to all U.S. retired employees and their dependents. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Many international employees are covered by government-sponsored programs and the cost to the Company is not significant. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Retirement plan benefits are primarily based on the employee&#8217;s compensation during the last three to five years before retirement and the number of years of service. International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company does not fund retiree health care benefits in advance and has the right to modify these plans in the future. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company uses the date of its consolidated financial statements (January&#160;3, 2010 and December&#160;28, 2008, respectively) as the measurement date for all U.S. and international retirement and other benefit plans. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In accordance with U.S. GAAP the Company has adopted the recent standards related to employers&#8217; accounting for defined benefit pension and other postretirement plans. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans for 2009, 2008 and 2007 include the following components: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="28%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Retirement Plans</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Other Benefit Plans</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Service cost </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">511</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">545</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">597</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">137</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">142</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">140</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Interest cost </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">746</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">701</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">656</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">174</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">166</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">149</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Expected return on plan assets </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(934</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(876</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(809</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Amortization of prior service cost </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">13</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(5</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(4</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(7</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Amortization of net transition asset </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Recognized actuarial losses </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">155</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">62</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">186</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">55</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">64</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">66</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Curtailments and settlements </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(11</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Net periodic benefit cost </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>481</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>451</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>646</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>359</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>366</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>346</b></td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The net periodic benefit cost attributable to U.S. retirement plans was $286&#160;million, $220 million and $379&#160;million in 2009, 2008 and 2007, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Amounts expected to be recognized in net periodic benefit cost in the coming year for the Company&#8217;s defined benefit retirement plans and other postretirement plans: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="88%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td colspan="5" align="left" style="border-top: 0px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Amortization of net transition obligation </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">1</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Amortization of net actuarial losses </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">296</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Amortization of prior service cost </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Unrecognized gains and losses for the U.S. pension plans are amortized over the average remaining future service for each plan. For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S. benefit plans is determined by using a 10% corridor of the greater of the market value of assets or the projected benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Prior service costs/benefits for the U.S. pension plans are amortized over the remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S. benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The weighted-average assumptions in the following table represent the rates used to develop the actuarial present value of projected benefit obligation for the year listed and also the net periodic benefit cost for the following year. </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="28%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Retirement Plans</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Other Benefit Plans</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>U.S. Benefit Plans</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Discount rate </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">6.50</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6.50</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6.50</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">6.50</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6.50</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6.50</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Expected long-term rate of return on plan assets </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">9.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9.00</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Rate of increase in compensation levels </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.50</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.50</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.50</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.50</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.50</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.50</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>International Benefit Plans</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td colspan="25" align="left" style="border-top: 0px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Discount rate </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">5.75</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.50</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">6.75</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7.25</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6.50</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Expected long-term rate of return on plan assets </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">8.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">8.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">8.25</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Rate of increase in compensation levels </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.75</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.50</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.50</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td colspan="25" align="left" style="border-top: 0px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company&#8217;s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The expected long-term rate of return on plan assets assumption is determined using a building block approach, considering historical averages and real returns of each asset class. In certain countries, where historical returns are not meaningful, consideration is given to local market expectations of long-term returns. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The following table displays the assumed health care cost trend rates, for all individuals: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="76%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Health Care Plans</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Health care cost trend rate assumed for next year </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">8.00</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9.00</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Rate to which the cost trend rate is assumed to decline (ultimate trend) </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">5.00</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.00</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Year the rate reaches the ultimate trend rate </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2017</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2015</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">A one-percentage-point change in assumed health care cost trend rates would have the following effect: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="76%">&#160;</td> <td width="5%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="5%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>One-Percentage-</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>One-Percentage-</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Point Increase</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Point Decrease</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Health Care Plans</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td colspan="9" align="left" style="border-top: 0px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Total interest and service cost </div></td> <td>&#160;</td> <td align="right">$</td> <td align="right">34</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right">$</td> <td align="right">(28</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Postretirement benefit obligation </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">315</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(254</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td colspan="9" align="left" style="border-top: 0px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The following table sets forth information related to the benefit obligation and the fair value of plan assets at year-end 2009 and 2008 for the Company&#8217;s defined benefit retirement plans and other postretirement plans: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="52%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>Retirement Plans</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>Other Benefit Plans</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Change in Benefit Obligation</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Projected benefit obligation &#8212; beginning of year </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">11,923</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">12,002</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">2,765</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,721</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Service cost </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">511</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">545</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">137</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">142</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Interest cost </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">746</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">701</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">174</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">166</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Plan participant contributions </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">50</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">60</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Amendments </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">3</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Actuarial losses (gains) </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">412</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(318</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">51</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(124</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Divestitures &#038; acquisitions </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">15</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">13</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Curtailments &#038; settlements &#038; restructuring </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(3</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">748</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Benefits paid from plan </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(570</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(535</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(313</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(122</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Effect of exchange rates </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">362</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(540</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(17</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" nowrap="nowrap" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Projected benefit obligation &#8212; end of year* </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>13,449</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>11,923</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>3,590</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>2,765</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Change in Plan Assets</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Plan assets at fair value &#8212; beginning of year </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">7,677</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10,469</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">17</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">29</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Actual return (loss)&#160;on plan assets </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,048</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2,787</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(7</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Company contributions </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,354</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">978</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">308</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">117</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Plan participant contributions </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">50</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">60</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Settlements </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Benefits paid from plan assets </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(570</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(535</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(313</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(122</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Effect of exchange rates </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">364</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(507</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Plan assets at fair value &#8212; end of year </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>10,923</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>7,677</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>16</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>17</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Funded status at &#8212; end of year* </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>$</b></td> <td align="right"><b>(2,526</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>(4,246</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>$</b></td> <td align="right"><b>(3,574</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>(2,748</b></td> <td nowrap="nowrap"><b>)</b></td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Non-current assets </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">266</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">136</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Current liabilities </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(53</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(45</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(484</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(212</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Non-current liabilities </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2,739</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(4,337</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(3,090</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2,536</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" nowrap="nowrap" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Total recognized in the consolidated balance sheet &#8212; end of year </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>$</b></td> <td align="right"><b>(2,526</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>(4,246</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>$</b></td> <td align="right"><b>(3,574</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>(2,748</b></td> <td nowrap="nowrap"><b>)</b></td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Net actuarial loss </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">3,415</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,209</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">924</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,006</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Prior service cost (credit) </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">47</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">43</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(23</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(29</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Unrecognized net transition obligation </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Total before tax effects </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>3,467</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>4,258</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>901</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>977</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Accumulated Benefit Obligations &#8212; end of year*</b> </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>11,687</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>10,357</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Net periodic benefit cost </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>481</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>451</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>359</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>366</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Net actuarial (gain)&#160;loss </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(704</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,344</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">48</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">60</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Amortization of net actuarial loss </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(134</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(68</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(131</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(65</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Prior service cost </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">3</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Amortization of prior service cost </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(13</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(11</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Effect of exchange rates </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">57</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(102</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" nowrap="nowrap" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Total recognized in other comprehensive income, before tax </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>$</b></td> <td align="right"><b>(791</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>3,173</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>$</b></td> <td align="right"><b>(76</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>1</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Total recognized in net periodic benefit cost and other comprehensive income </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left"><b>$</b></td> <td align="right"><b>(310</b></td> <td nowrap="nowrap"><b>)</b></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>3,624</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>283</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>367</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>*</i></td> <td>&#160;</td> <td><i>The Company does not fund certain plans, as funding is not required. $1.2&#160;billion of the projected benefit obligation and $1.2&#160;billion of the underfunded status for each of the fiscal years 2009 and 2008 relates to the unfunded pension plans. $1.0&#160;billion and $0.9&#160;billion of the accumulated benefit obligation for the fiscal years 2009 and 2008, respectively, relate to these unfunded pension plans.</i></td> </tr> </table> <div align="left" style="font-size: 10pt; margin-top: 6pt">Plans with accumulated benefit obligations in excess of plan assets consist of the following: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="76%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>Retirement Plans</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Accumulated benefit obligation </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">$</td> <td align="right">(4,065</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(9,885</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Projected benefit obligation </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(4,663</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(11,379</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Plan assets at fair value </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,564</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7,021</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The following table displays the projected future benefit payments from the Company&#8217;s retirement and other benefit plans: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="38%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2011</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2012</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2013</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2014</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2015-2019</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Projected future benefit payments</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td colspan="25" align="left" style="border-top: 0px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Retirement plans </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">558</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">553</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">582</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">604</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">636</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,925</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Other benefit plans &#8212; gross </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">209</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">198</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">196</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">198</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">197</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">995</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Medicare rebates </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(9</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Other benefit plans &#8212; net </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">200</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">198</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">196</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">198</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">197</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">995</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">In 2009, the Company contributed $839&#160;million and $515&#160;million to its U.S. and international pension plans, respectively. In addition, the Company funded $500&#160;million to its U.S. plans in the first month of 2010. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In 2006, Congress passed the Pension Protection Act of 2006. The Act amended the Employee Retirement Income Security Act (ERISA)&#160;for plan years beginning after 2007 and established new minimum funding standards for U.S. employer defined benefit plans. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company plans to continue to fund its U.S. defined benefit plans to comply with the Act. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;International plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently the Company has several pension plans that are not funded. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The following table displays the projected future minimum contributions to the Company&#8217;s U.S. and international unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future. </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="38%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2011</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2012</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2013</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2014</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2015-2019</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Projected future contributions</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td colspan="25" align="left" style="border-top: 0px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Unfunded U.S. retirement plans </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">34</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">36</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">38</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">40</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">44</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">288</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Unfunded International retirement plans </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">32</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">29</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">31</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">33</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">32</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">186</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td colspan="25" align="left" style="border-top: 0px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors including local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and other relevant factors including diversification, liquidity of local markets and liquidity of base currency. A majority of the Company&#8217;s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds. An asset allocation of 75% equities and 25% fixed income is generally pursued unless local regulations and illiquidity require otherwise. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company&#8217;s retirement plan asset allocation at the end of 2009 and 2008 and target allocations for 2010 are as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="64%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="6%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>Percent of</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Target</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>Plan Assets</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2" style="border-bottom: 0px solid #000000"><b>Allocation</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2010</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>U.S. Retirement Plans</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Equity securities </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">76</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">70</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">75</td> <td nowrap="nowrap">%</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Debt securities </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">24</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">30</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">25</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Total plan assets </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>100</b></td> <td nowrap="nowrap"><b>%</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>100</b></td> <td nowrap="nowrap"><b>%</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>100</b></td> <td nowrap="nowrap"><b>%</b></td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" nowrap="nowrap" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>International Retirement Plans</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Equity securities </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">65</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">61</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">65</td> <td nowrap="nowrap">%</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Debt securities </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">34</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">38</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">34</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Real estate and other </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Total plan assets </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>100</b></td> <td nowrap="nowrap"><b>%</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>100</b></td> <td nowrap="nowrap"><b>%</b></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>100</b></td> <td nowrap="nowrap"><b>%</b></td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" nowrap="nowrap" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company&#8217;s other benefit plans are unfunded except for U.S. life insurance contract assets of $16&#160;million and $17&#160;million at January&#160;3, 2010 and December&#160;28, 2008, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The fair value of Johnson &#038; Johnson common stock directly held in plan assets was $469&#160;million (4.3% of total plan assets) at January&#160;3, 2010 and $416&#160;million (5.4% of total plan assets) at December&#160;28, 2008. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>DETERMINATION OF FAIR VALUE</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Plan has an established and well-documented process for determining fair values. Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>VALUATION HIERARCHY</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level 1 having the highest priority and Level 3 having the lowest. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">A financial instrument&#8217;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Following is a description of the valuation methodologies used for the investments measured at fair value. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;<b>&#8226;</b>&#160;Short-term investments &#8212; Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the Net Asset Value (NAV)&#160;provided by the administrator of the fund. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. The NAV is a quoted price in a market that is not active and classified as Level 2. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;<b>&#8226;</b>&#160;Government and agency securities &#8212; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level 1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level 2. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;<b>&#8226;</b>&#160;Debt instruments &#8212; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level 1. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt"> If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level 2. Level 3 debt instruments are priced based on unobservable inputs. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;<b>&#8226;</b>&#160;Equity securities &#8212; Common stocks are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all common stock is classified within Level 1 of the valuation hierarchy. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;<b>&#8226;</b>&#160;Commingled funds &#8212; The investments are public investment vehicles valued using the NAV provided by the fund administrator. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. Assets in the Level 2 category have a quoted market price in a market that is not active. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;<b>&#8226;</b>&#160;Insurance contracts &#8212; The instruments are issued by insurance companies. The fair value is based on negotiated value and the underlying investments held in separate account portfolios as well as considering the credit worthiness of the issuer. The underlying investments are government, asset-backed and fixed income securities. In general, insurance contracts are classified as Level 3 as there are no quoted prices nor other observable inputs for pricing. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;<b>&#8226;</b>&#160;Other assets &#8212; Other assets are represented primarily by limited partnerships and real estate investments, as well as commercial loans and commercial mortgages that are not classified as corporate debt. Other assets that are exchange listed and actively traded are classified as Level 1 while inactively traded assets are classified as Level 2. Most limited partnerships represent investments in private equity and similar funds that are valued by the general partners. These, as well as any other assets valued using unobservable inputs, are classified as Level 3. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The following table sets forth the trust investments measured at fair value as of January&#160;3, 2010: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="52%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Quoted Prices</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Significant</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>in Active</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Other</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Significant</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Markets for</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Observable</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Unobservable</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Identical Assets</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Inputs</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Inputs</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>(Level 1)</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>(Level 2)</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>(Level 3)</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Total Assets</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Short-term investment funds </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">91</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">358</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">449</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Government and agency securities </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,165</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,165</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Debt instruments </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">3</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,145</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,153</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Equity securities </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,068</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">58</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,141</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Commingled funds </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,673</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">26</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,699</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Insurance contracts </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">32</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">32</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Other assets </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">31</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">171</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">82</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">284</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Trust investments at fair value</b> </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>5,193</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>5,570</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>160</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>10,923</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>LEVEL 3 GAINS AND LOSSES</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The table below sets forth a summary of changes in the fair value of the Plan&#8217;s Level 3 assets for the year ended January&#160;3, 2010: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="28%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Debt</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Equity</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Commingled</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Insurance</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Other</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Total</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Instruments</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Securities</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Funds</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Contracts</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Assets</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Level 3</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Balance December&#160;28, 2008</b> </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">7</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">29</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">85</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">151</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Realized gains (losses) </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Unrealized gains (losses) </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(2</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(3</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(5</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Purchases, sales, issuances and settlements, net </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(4</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">13</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">11</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Balance January&#160;3, 2010</b> </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>5</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>15</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>26</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>32</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>82</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>160</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="23" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 45 R28.xml IDEA: Restructuring 1.0.0.3 false Restructuring false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 us-gaap_RestructuringChargesAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false No definition available. false 3 1 us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 22 - us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 6pt"><b>22. Restructuring</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">In the fourth quarter of 2009, the Company announced global restructuring initiatives designed to strengthen the Company&#8217;s position as one of the world&#8217;s leading global health care companies. This program will allow the Company to invest in new growth platforms; ensure the successful launch of its many new products and continued growth of its core businesses; and provide flexibility to adjust to the changed and evolving global environment. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During the fiscal fourth quarter of 2009, the Company recorded $1.2&#160;billion in related pre-tax charges of which, approximately $830&#160;million of the pre-tax restructuring charges are expected to require cash payments. The $1.2&#160;billion of restructuring charges consists of severance costs of $748&#160;million, asset write-offs of $362&#160;million and $76&#160;million related to leasehold and contract obligations. The $362&#160;million of asset write-offs relate to inventory of $113&#160;million (recorded in cost of products sold), property, plant and equipment of $107&#160;million, intangible assets of $81&#160;million and other assets of $61&#160;million. Additionally, as part of this program the Company plans to eliminate approximately 7,500 positions of which approximately 700 have been eliminated since the restructuring was announced. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The following table summarizes the severance charges and the associated spending for the fiscal year ended 2009: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="52%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Asset</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Severance</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Write-Offs</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Other</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Total</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">2009 restructuring charge </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">748</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">362</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">76</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,186</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Current year activity </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(62</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(149</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(28</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(239</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" nowrap="nowrap" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Reserve balance, January&#160;3, 2010* </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">686</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">213</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">48</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">947</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="2%"></td> <td width="1%"></td> <td width="97"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left">*</td> <td>&#160;</td> <td><i>Cash outlays for severance are expected to be substantially paid out over the next 12 to 18&#160;months in accordance with the Company&#8217;s plans and local laws.</i></td> </tr> </table> <div align="left" style="font-size: 10pt; margin-top: 6pt">For additional information on the restructuring as it relates to the segments, see Note 18. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;In the third quarter of 2007, the Company announced restructuring initiatives in an effort to improve its overall cost structure. This action was taken to offset the anticipated negative impacts associated with generic competition in the Pharmaceutical segment and challenges in the drug-eluting stent market. The Company&#8217;s Pharmaceuticals segment has reduced its cost base by consolidating certain operations, while continuing to invest in recently launched products and its late-stage pipeline of new products. The Cordis franchise has moved to a more integrated business model to address the market changes underway with drug-eluting stents and to better serve the broad spectrum of its patients&#8217; cardiovascular needs, while reducing its cost base. The Company accelerated steps to standardize and streamline certain aspects of its enterprise-wide functions such as human resources, finance and information technology to support growth across the business, while also leveraging its scale more effectively in areas such as procurement to benefit its operating companies. Additionally, as part of this program the Company eliminated approximately 4,600 positions. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company recorded $745&#160;million in related pre-tax charges during the fiscal third quarter of 2007, of which, approximately $500&#160;million of the pre-tax restructuring charges required cash payments. The $745&#160;million of restructuring charges consists of severance costs of $450&#160;million, asset write-offs of $272&#160;million and $23&#160;million related to leasehold obligations. The $272&#160;million of asset write-offs relate to property, plant and equipment of $166&#160;million, intangible assets of $48&#160;million and other assets of $58&#160;million. The restructuring initiative announced in 2007 has been completed. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 46 R9.xml IDEA: Inventories 1.0.0.3 false Inventories false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 us-gaap_InventoryNetAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false No definition available. false 3 1 us-gaap_InventoryDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 3 - us-gaap:InventoryDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>3. Inventories</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">At the end of 2009 and 2008, inventories were comprised of: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="76%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Raw materials and supplies </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">1,144</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">839</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Goods in process </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,395</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,372</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Finished goods </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,641</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,841</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>5,180</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>5,052</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="7" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 47 R6.xml IDEA: Consolidated Statements of Cash Flows 1.0.0.3 false Consolidated Statements of Cash Flows (USD $) In Millions false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 false 2 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 false 3 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 3 1 us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. false 4 2 us-gaap_ProfitLoss us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 true true 12266000000 12266 false false 2 true true 12949000000 12949 false false 3 true true 10576000000 10576 false false No definition available. No authoritative reference available. false 5 2 us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. false 6 3 us-gaap_DepreciationDepletionAndAmortization us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true 2774000000 2774 false false 2 false true 2832000000 2832 false false 3 false true 2777000000 2777 false false No definition available. No authoritative reference available. false 7 3 us-gaap_ShareBasedCompensation us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true 628000000 628 false false 2 false true 627000000 627 false false 3 false true 698000000 698 false false No definition available. No authoritative reference available. false 8 3 us-gaap_ResearchAndDevelopmentInProcess us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true 0 0 false false 2 false true 181000000 181 false false 3 false true 807000000 807 false false No definition available. No authoritative reference available. false 9 3 us-gaap_AmortizationOfIntangibleAssets us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true 0 0 false false 2 false true 0 0 false false 3 false true 678000000 678 false false No definition available. No authoritative reference available. false 10 3 us-gaap_DeferredIncomeTaxExpenseBenefit us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true -436000000 -436 false false 2 false true 22000000 22 false false 3 false true -1762000000 -1762 false false No definition available. No authoritative reference available. false 11 3 us-gaap_ProvisionForDoubtfulAccounts us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true 58000000 58 false false 2 false true 86000000 86 false false 3 false true 22000000 22 false false No definition available. No authoritative reference available. false 12 2 us-gaap_IncreaseDecreaseInOperatingCapitalAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. false 13 3 us-gaap_IncreaseDecreaseInAccountsReceivable us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true 453000000 453 false false 2 false true -736000000 -736 false false 3 false true -416000000 -416 false false No definition available. No authoritative reference available. false 14 3 us-gaap_IncreaseDecreaseInInventories us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true 95000000 95 false false 2 false true -101000000 -101 false false 3 false true 14000000 14 false false No definition available. No authoritative reference available. false 15 3 us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true -507000000 -507 false false 2 false true -272000000 -272 false false 3 false true 2642000000 2642 false false No definition available. No authoritative reference available. false 16 3 us-gaap_IncreaseDecreaseInOtherOperatingAssets us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true 1209000000 1209 false false 2 false true -1600000000 -1600 false false 3 false true -1578000000 -1578 false false No definition available. No authoritative reference available. false 17 3 us-gaap_IncreaseDecreaseInOtherOperatingLiabilities us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true 31000000 31 false false 2 false true 984000000 984 false false 3 false true 564000000 564 false false No definition available. No authoritative reference available. true 18 2 us-gaap_NetCashProvidedByUsedInOperatingActivities us-gaap true na duration monetary No definition available. false false false false false false false false false 1 false true 16571000000 16571 false false 2 false true 14972000000 14972 false false 3 false true 15022000000 15022 false false No definition available. No authoritative reference available. true 19 1 us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. false 20 2 us-gaap_PaymentsToAcquirePropertyPlantAndEquipment us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true -2365000000 -2365 false false 2 false true -3066000000 -3066 false false 3 false true -2942000000 -2942 false false No definition available. No authoritative reference available. false 21 2 us-gaap_ProceedsFromSaleOfProductiveAssets us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true 154000000 154 false false 2 false true 785000000 785 false false 3 false true 457000000 457 false false No definition available. No authoritative reference available. false 22 2 us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true -2470000000 -2470 false false 2 false true -1214000000 -1214 false false 3 false true -1388000000 -1388 false false No definition available. No authoritative reference available. false 23 2 us-gaap_PaymentsToAcquireInvestments us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true -10040000000 -10040 false false 2 false true -3668000000 -3668 false false 3 false true -9659000000 -9659 false false No definition available. No authoritative reference available. false 24 2 us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true 7232000000 7232 false false 2 false true 3059000000 3059 false false 3 false true 7988000000 7988 false false No definition available. No authoritative reference available. false 25 2 us-gaap_PaymentsForProceedsFromOtherInvestingActivities us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true -109000000 -109 false false 2 false true -83000000 -83 false false 3 false true -368000000 -368 false false No definition available. No authoritative reference available. true 26 2 us-gaap_NetCashProvidedByUsedInInvestingActivities us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true -7598000000 -7598 false false 2 false true -4187000000 -4187 false false 3 false true -5912000000 -5912 false false No definition available. No authoritative reference available. true 27 1 us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. false 28 2 us-gaap_PaymentsOfOrdinaryDividends us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true -5327000000 -5327 false false 2 false true -5024000000 -5024 false false 3 false true -4670000000 -4670 false false No definition available. No authoritative reference available. false 29 2 us-gaap_PaymentsForRepurchaseOfCommonStock us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true -2130000000 -2130 false false 2 false true -6651000000 -6651 false false 3 false true -5607000000 -5607 false false No definition available. No authoritative reference available. false 30 2 us-gaap_ProceedsFromShortTermDebt us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true 9484000000 9484 false false 2 false true 8430000000 8430 false false 3 false true 19626000000 19626 false false No definition available. No authoritative reference available. false 31 2 us-gaap_RepaymentsOfShortTermDebt us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true -6791000000 -6791 false false 2 false true -7319000000 -7319 false false 3 false true -21691000000 -21691 false false No definition available. No authoritative reference available. false 32 2 us-gaap_ProceedsFromIssuanceOfLongTermDebt us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true 9000000 9 false false 2 false true 1638000000 1638 false false 3 false true 5100000000 5100 false false No definition available. No authoritative reference available. false 33 2 us-gaap_RepaymentsOfLongTermDebt us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true -219000000 -219 false false 2 false true -24000000 -24 false false 3 false true -18000000 -18 false false No definition available. No authoritative reference available. false 34 2 us-gaap_ProceedsFromStockOptionsExercised us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true 882000000 882 false false 2 false true 1486000000 1486 false false 3 false true 1562000000 1562 false false No definition available. No authoritative reference available. true 35 2 us-gaap_NetCashProvidedByUsedInFinancingActivities us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true -4092000000 -4092 false false 2 false true -7464000000 -7464 false false 3 false true -5698000000 -5698 false false No definition available. No authoritative reference available. true 36 1 us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true 161000000 161 false false 2 false true -323000000 -323 false false 3 false true 275000000 275 false false No definition available. No authoritative reference available. true 37 1 us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease us-gaap true na duration monetary No definition available. false false false false false false false false false 1 false true 5042000000 5042 false false 2 false true 2998000000 2998 false false 3 false true 3687000000 3687 false false No definition available. No authoritative reference available. false 38 1 us-gaap_CashAndCashEquivalentsAtCarryingValue us-gaap true debit instant monetary No definition available. false false false false false false true false false 1 false true 10768000000 10768 false false 2 false true 7770000000 7770 false false 3 false true 4083000000 4083 false false No definition available. No authoritative reference available. false 39 1 us-gaap_CashAndCashEquivalentsAtCarryingValue us-gaap true debit instant monetary No definition available. false false false false false false false true false 1 false true 15810000000 15810 false false 2 false true 10768000000 10768 false false 3 false true 7770000000 7770 false false No definition available. No authoritative reference available. false 41 2 jnj_CashPaidDuringYearForAbstract jnj false na duration string Cash paid during the year for. false false false false false true false false false 1 false false 0 0 false false 2 false false 0 0 false false 3 false false 0 0 false false Cash paid during the year for. false 42 3 us-gaap_InterestPaidNet us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true 533000000 533 false false 2 false true 525000000 525 false false 3 false true 314000000 314 false false No definition available. No authoritative reference available. false 43 3 us-gaap_IncomeTaxesPaid us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true 2363000000 2363 false false 2 false true 4068000000 4068 false false 3 false true 4099000000 4099 false false No definition available. No authoritative reference available. false 44 2 us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. false 45 3 jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds jnj false credit instant monetary Treasury stock issued for employee compensation and stock option plans, net of cash proceeds. false false false false false false false false false 1 false true 541000000 541 false false 2 false true 593000000 593 false false 3 false true 738000000 738 false false Treasury stock issued for employee compensation and stock option plans, net of cash proceeds. No authoritative reference available. false 46 3 us-gaap_DebtConversionOriginalDebtAmount us-gaap true credit instant monetary No definition available. false false false false false false false false false 1 false true 2000000 2 false false 2 false true 0 0 false false 3 false true 9000000 9 false false No definition available. No authoritative reference available. false 47 1 jnj_AcquisitionsAbstract jnj false na duration string Acquisitions. false false false false false true false false false 1 false false 0 0 false false 2 false false 0 0 false false 3 false false 0 0 false false Acquisitions. false 48 2 us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired us-gaap true debit instant monetary No definition available. false false false false false false false false false 1 false true 3345000000 3345 false false 2 false true 1328000000 1328 false false 3 false true 1620000000 1620 false false No definition available. No authoritative reference available. false 49 2 us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed us-gaap true credit instant monetary No definition available. false false false false false false false false false 1 false true -875000000 -875 false false 2 false true -114000000 -114 false false 3 false true -232000000 -232 false false No definition available. No authoritative reference available. true 50 2 us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed us-gaap true debit instant monetary No definition available. false false false false false false false false false 1 true true 2470000000 2470 false false 2 true true 1214000000 1214 false false 3 true true 1388000000 1388 false false No definition available. No authoritative reference available. true false 3 47 false Millions UnKnown UnKnown false true XML 48 R5.xml IDEA: Consolidated Statements of Equity 1.0.0.3 true Consolidated Statements of Equity (USD $) In Millions false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 false 2 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 false 3 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 2 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap true credit instant monetary No definition available. false false false false false false true false false 1 true true 42511000000 42511 false false 2 true true 43319000000 43319 false false 3 true true 39318000000 39318 false false No definition available. No authoritative reference available. false 3 2 us-gaap_ProfitLoss us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true 12266000000 12266 false false 2 false true 12949000000 12949 false false 3 false true 10576000000 10576 false false No definition available. No authoritative reference available. false 4 2 us-gaap_DividendsCommonStockCash us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true -5327000000 -5327 false false 2 false true -5024000000 -5024 false false 3 false true -4670000000 -4670 false false No definition available. No authoritative reference available. false 5 2 us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true 1402000000 1402 false false 2 false true 2180000000 2180 false false 3 false true 2311000000 2311 false false No definition available. No authoritative reference available. false 6 2 us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true 2000000 2 false false 2 false true 0 0 false false 3 false true 9000000 9 false false No definition available. No authoritative reference available. false 7 2 us-gaap_TreasuryStockValueAcquiredCostMethod us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true -2130000000 -2130 false false 2 false true -6651000000 -6651 false false 3 false true -5607000000 -5607 false false No definition available. No authoritative reference available. false 8 2 us-gaap_CumulativeEffectOfInitialAdoptionOfFIN48 us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false false 0 0 false false 2 false false 0 0 false false 3 false true -19000000 -19 false false No definition available. No authoritative reference available. false 9 2 us-gaap_StockholdersEquityOther us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true -33000000 -33 false false 2 false false 0 0 false false 3 false true -24000000 -24 false false No definition available. No authoritative reference available. false 10 2 us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease us-gaap true na duration monetary No definition available. false false false false false false false false false 1 false true 1363000000 1363 false false 2 false true -2499000000 -2499 false false 3 false true 786000000 786 false false No definition available. No authoritative reference available. false 11 2 us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true -55000000 -55 false false 2 false true -59000000 -59 false false 3 false true 23000000 23 false false No definition available. No authoritative reference available. false 12 2 us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecrease us-gaap true na duration monetary No definition available. false false false false false false false false false 1 false true 565000000 565 false false 2 false true -1870000000 -1870 false false 3 false true 670000000 670 false false No definition available. No authoritative reference available. false 13 2 us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecrease us-gaap true na duration monetary No definition available. false false false false false false false false false 1 false true 24000000 24 false false 2 false true 166000000 166 false false 3 false true -54000000 -54 false false No definition available. No authoritative reference available. true 16 2 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap true credit instant monetary No definition available. false false false false false false false true false 1 false true 50588000000 50588 false false 2 false true 42511000000 42511 false false 3 false true 43319000000 43319 false false No definition available. No authoritative reference available. false 17 0 na true na na na No definition available. false true false false false false false false false 1 false false 0 0 false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. No authoritative reference available. false 18 2 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap true credit instant monetary No definition available. false false false false false false true false false 1 false true 63379000000 63379 false false 2 false true 55280000000 55280 false false 3 false true 49290000000 49290 false false No definition available. No authoritative reference available. false 19 2 us-gaap_ProfitLoss us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true 12266000000 12266 false false 2 false true 12949000000 12949 false false 3 false true 10576000000 10576 false false No definition available. No authoritative reference available. false 20 2 us-gaap_DividendsCommonStockCash us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true -5327000000 -5327 false false 2 false true -5024000000 -5024 false false 3 false true -4670000000 -4670 false false No definition available. No authoritative reference available. false 21 2 us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true 25000000 25 false false 2 false true 175000000 175 false false 3 false true 131000000 131 false false No definition available. No authoritative reference available. false 22 2 us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true -4000000 -4 false false 2 false true -1000000 -1 false false 3 false true -4000000 -4 false false No definition available. No authoritative reference available. false 24 2 us-gaap_CumulativeEffectOfInitialAdoptionOfFIN48 us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false false 0 0 false false 2 false false 0 0 false false 3 false true -19000000 -19 false false No definition available. No authoritative reference available. false 25 2 us-gaap_StockholdersEquityOther us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true -33000000 -33 false false 2 false false 0 0 false false 3 false true -24000000 -24 false false No definition available. No authoritative reference available. false 32 2 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap true credit instant monetary No definition available. false false false false false false false true false 1 false true 70306000000 70306 false false 2 false true 63379000000 63379 false false 3 false true 55280000000 55280 false false No definition available. No authoritative reference available. false 33 0 na true na na na No definition available. false true false false false false false false false 1 false false 0 0 false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. No authoritative reference available. false 34 2 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap true credit instant monetary No definition available. false false false false false false true false false 1 false true -4955000000 -4955 false false 2 false true -693000000 -693 false false 3 false true -2118000000 -2118 false false No definition available. No authoritative reference available. false 42 2 us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease us-gaap true na duration monetary No definition available. false false false false false false false false false 1 false true 1363000000 1363 false false 2 false true -2499000000 -2499 false false 3 false true 786000000 786 false false No definition available. No authoritative reference available. false 43 2 us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true -55000000 -55 false false 2 false true -59000000 -59 false false 3 false true 23000000 23 false false No definition available. No authoritative reference available. false 44 2 us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecrease us-gaap true na duration monetary No definition available. false false false false false false false false false 1 false true 565000000 565 false false 2 false true -1870000000 -1870 false false 3 false true 670000000 670 false false No definition available. No authoritative reference available. false 45 2 us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecrease us-gaap true na duration monetary No definition available. false false false false false false false false false 1 false true 24000000 24 false false 2 false true 166000000 166 false false 3 false true -54000000 -54 false false No definition available. No authoritative reference available. true 48 2 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap true credit instant monetary No definition available. false false false false false false false true false 1 false true -3058000000 -3058 false false 2 false true -4955000000 -4955 false false 3 false true -693000000 -693 false false No definition available. No authoritative reference available. false 49 0 na true na na na No definition available. false true false false false false false false false 1 false false 0 0 false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. No authoritative reference available. false 50 2 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap true credit instant monetary No definition available. false false false false false false true false false 1 false true 3120000000 3120 false false 2 false true 3120000000 3120 false false 3 false true 3120000000 3120 false false No definition available. No authoritative reference available. false 64 2 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap true credit instant monetary No definition available. false false false false false false false true false 1 false true 3120000000 3120 false false 2 false true 3120000000 3120 false false 3 false true 3120000000 3120 false false No definition available. No authoritative reference available. false 65 0 na true na na na No definition available. false true false false false false false false false 1 false false 0 0 false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. No authoritative reference available. false 66 2 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap true credit instant monetary No definition available. false false false false false false true false false 1 false true -19033000000 -19033 false false 2 false true -14388000000 -14388 false false 3 false true -10974000000 -10974 false false No definition available. No authoritative reference available. false 69 2 us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true 1377000000 1377 false false 2 false true 2005000000 2005 false false 3 false true 2180000000 2180 false false No definition available. No authoritative reference available. false 70 2 us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true 6000000 6 false false 2 false true 1000000 1 false false 3 false true 13000000 13 false false No definition available. No authoritative reference available. false 71 2 us-gaap_TreasuryStockValueAcquiredCostMethod us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false true -2130000000 -2130 false false 2 false true -6651000000 -6651 false false 3 false true -5607000000 -5607 false false No definition available. No authoritative reference available. false 80 2 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap true credit instant monetary No definition available. false false false false false false false true false 1 false true -19780000000 -19780 false false 2 false true -19033000000 -19033 false false 3 false true -14388000000 -14388 false false No definition available. No authoritative reference available. false 81 0 na true na na na No definition available. false true false false false false false false false 1 false false 0 0 false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. No authoritative reference available. false 83 2 us-gaap_ProfitLoss us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true 12266000000 12266 false false 2 false true 12949000000 12949 false false 3 false true 10576000000 10576 false false No definition available. No authoritative reference available. false 90 2 us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease us-gaap true na duration monetary No definition available. false false false false false false false false false 1 false true 1363000000 1363 false false 2 false true -2499000000 -2499 false false 3 false true 786000000 786 false false No definition available. No authoritative reference available. false 91 2 us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 false true -55000000 -55 false false 2 false true -59000000 -59 false false 3 false true 23000000 23 false false No definition available. No authoritative reference available. false 92 2 us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecrease us-gaap true na duration monetary No definition available. false false false false false false false false false 1 false true 565000000 565 false false 2 false true -1870000000 -1870 false false 3 false true 670000000 670 false false No definition available. No authoritative reference available. false 93 2 us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecrease us-gaap true na duration monetary No definition available. false false false false false false false false false 1 false true 24000000 24 false false 2 false true 166000000 166 false false 3 false true -54000000 -54 false false No definition available. No authoritative reference available. true 94 2 us-gaap_OtherComprehensiveIncomeReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax us-gaap true debit duration monetary No definition available. false false false false false false false false false 1 false false 0 0 false false 2 false true -27000000 -27 false false 3 false true -5000000 -5 false false No definition available. No authoritative reference available. true 95 2 us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest us-gaap true credit duration monetary No definition available. false false false false false false false false false 1 true true 14163000000 14163 false false 2 true true 8660000000 8660 false false 3 true true 11996000000 11996 false false No definition available. No authoritative reference available. true false 3 46 false Millions UnKnown UnKnown false true XML 49 R23.xml IDEA: Common Stock, Stock Option Plans and Stock Compensation Agreements 1.0.0.3 false Common Stock, Stock Option Plans and Stock Compensation Agreements false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 us-gaap_ShareBasedCompensationAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false No definition available. false 3 1 us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 17 - us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 6pt"><b>17. Common Stock, Stock Option Plans and Stock Compensation Agreements</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt"><b>STOCK OPTIONS</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">At January&#160;3, 2010, the Company had 11 stock-based compensation plans. The shares outstanding are for contracts under the Company&#8217;s 1995 and 2000 Stock Option Plans, the 2005 Long-Term Incentive Plan, the 1997 Non-Employee Director&#8217;s Plan and the ALZA, Inverness, and Scios Stock Option Plans. During 2009, no options or restricted shares were granted under any of these plans except under the 2005 Long-Term Incentive Plan. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The compensation cost that has been charged against income for these plans was $628&#160;million, $627&#160;million and $698&#160;million for 2009, 2008 and 2007, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $210&#160;million, $210 million and $238&#160;million for 2009, 2008 and 2007, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Stock options expire 10&#160;years from the date of grant and vest over service periods that range from six months to five years. All options are granted at the average of the high and low prices of the Company&#8217;s common stock on the New York Stock Exchange on the date of grant. Under the 2005 Long-Term Incentive Plan, the Company may issue up to 260&#160;million shares of common stock. Shares available for future grants under the 2005 Long-Term Incentive Plan were 139.7&#160;million at the end of 2009. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company settles employee stock option exercises with treasury shares. Treasury shares are replenished throughout the year for the number of shares used to settle employee stock option exercises. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. Expected volatility represents a blended rate of 4-year daily historical average volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson &#038; Johnson options with a life of 2 years. Historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S. Treasury yield curve in effect at the time of grant. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The average fair value of options granted was $8.35, $7.66, and $11.67 in 2009, 2008, and 2007, respectively. The fair value was estimated based on the weighted average assumptions of: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="64%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Risk-free rate </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">2.71</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">2.97</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">4.78</td> <td nowrap="nowrap">%</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Expected volatility </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">19.5</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">15.0</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">14.7</td> <td nowrap="nowrap">%</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Expected life </div></td> <td>&#160;</td> <td colspan="2" nowrap="nowrap" align="right">6.0</td> <td nowrap="nowrap">&#160;yrs</td> <td>&#160;</td> <td colspan="2" nowrap="nowrap" align="right">6.0</td> <td nowrap="nowrap">&#160;yrs</td> <td>&#160;</td> <td colspan="2" nowrap="nowrap" align="right">6.0</td> <td nowrap="nowrap">&#160;yrs</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Dividend yield </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">3.30</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">2.90</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">2.50</td> <td nowrap="nowrap">%</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">A summary of option activity under the Plan as of January&#160;3, 2010, December&#160;28, 2008, and December 30, 2007 and changes during the years ending on those dates is presented below: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="64%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Aggregate</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Weighted</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Intrinsic</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Outstanding</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Average</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Value</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Shares in Thousands)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Shares</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Exercise Price</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>(Dollars in Millions)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares at December&#160;31, 2006 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">242,927</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">54.57</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">2,788</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Options granted </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">26,789</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">65.61</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Options exercised </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(33,224</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">45.92</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Options canceled/forfeited </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(7,863</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">63.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares at December&#160;30, 2007 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">228,629</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">56.83</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">2,411</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Options granted </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">22,428</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">61.80</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Options exercised </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(30,033</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">50.27</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Options canceled/forfeited </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(5,525</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">61.90</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares at December&#160;28, 2008 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">215,499</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">58.14</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">597</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Options granted </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">21,576</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">58.32</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Options exercised </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(18,225</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">50.97</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Options canceled/forfeited </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(6,131</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">61.85</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares at January&#160;3, 2010 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>212,719</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>58.66</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>1,310</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The total intrinsic value of options exercised was $184&#160;million, $506&#160;million, and $625&#160;million in 2009, 2008 and 2007, respectively. The total unrecognized compensation cost was $612&#160;million as of January&#160;3, 2010, $632&#160;million as of December&#160;28, 2008 and $652&#160;million as of December&#160;30, 2007. The weighted average period for this cost to be recognized was 1.16&#160;years, 1.06&#160;years and 1.01&#160;years for 2009, 2008, and 2007, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The following table summarizes stock options outstanding and exercisable at January&#160;3, 2010: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="40%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"><b>Outstanding</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>Exercisable</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left" style="border-bottom: 0px solid #000000"><b>(Shares in Thousands)</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Average</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Average</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Exercise</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Average</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Exercise</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Exercise</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Price Range</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Options</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Life</b></td> <td nowrap="nowrap"><sup style="font-size: 85%; vertical-align: text-top"><b>(1)</b></sup></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Price</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Options</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Price</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td colspan="1" align="left" style="border-top: 0px solid #000000">&#160;</td> <td colspan="1" align="left" style="border-top: 0px solid #000000">&#160;</td> <td colspan="19" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">$&#160;&#160;7.33 - $28.09 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">104</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.5</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">22.89</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">104</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">22.89</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">$31.27- $40.08 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">131</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.3</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">35.83</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">131</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">35.83</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">$41.26- $49.86 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,024</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.2</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">47.09</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,024</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">47.09</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">$50.52- $52.11 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">17,328</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.8</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">50.70</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">17,328</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">50.70</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">$52.13- $53.77 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">22,193</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3.1</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">52.22</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">22,152</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">52.22</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">$53.93- $54.89 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">26,155</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.0</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">53.93</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">26,156</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">53.93</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">$55.01- $58.25 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">26,332</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2.1</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">57.30</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">26,328</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">57.30</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">$58.33- $65.10 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">63,805</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7.7</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">59.48</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">21,367</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">58.48</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">$65.62- $68.37 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">55,647</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.8</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">65.97</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">33,759</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">66.19</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>212,719</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>5.0</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>58.66</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>148,349</b></td> <td>&#160;</td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>57.26</b></td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="19" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(1)</i></sup></td> <td>&#160;</td> <td><i>Average contractual life remaining in years.</i></td> </tr> </table> <div align="left" style="font-size: 10pt; margin-top: 6pt">Stock options exercisable at December&#160;28, 2008 and December&#160;30, 2007 were 144,962 at an average price of $56.25 and an average life of 5.3&#160;years and 137,310 at an average price of $52.33 and an average life of 5.6&#160;years, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>RESTRICTED SHARE UNITS</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company grants restricted share units with a vesting period of three years. The Company settles employee stock issuance with treasury shares. Treasury shares are replenished throughout the year for the number of shares used for employee stock issuances. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;A summary of share activity under the Plan as of January&#160;3, 2010: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="88%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Outstanding</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Shares in Thousands)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Shares</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="3" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares at December&#160;31, 2006 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,885</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Shares granted </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">8,029</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares issued </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(33</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Shares canceled/forfeited </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,220</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares at December&#160;30, 2007 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">13,661</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Shares granted </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">10,105</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares issued </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(40</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Shares canceled/forfeited </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,468</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares at December&#160;28, 2008 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">22,258</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Shares granted </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">11,172</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares issued </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(5,714</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Shares canceled/forfeited </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,392</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Shares at January&#160;3, 2010 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">26,324</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The average fair value of the restricted share units granted was $52.79, $56.70 and $60.86 in 2009, 2008 and 2007, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units settled was $308.4 million, $2.5&#160;million and $1.8&#160;million in 2009, 2008 and 2007, respectively. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 50 defnref.xml IDEA: XBRL DOCUMENT No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Treasury stock issued for employee compensation and stock option plans, net of cash proceeds. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Savings Plan No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Sum of the amounts paid in advance for capitalized costs that will be expensed and charged against earnings within one year or the normal operating cycle if longer. Other receivables include current assets not separately disclosed due to materiality considerations. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Shareholders' Equity Before Deduction Of Treasury Stock. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Legal Proceedings. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. XML 51 R21.xml IDEA: Earnings Per Share 1.0.0.3 false Earnings Per Share false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 us-gaap_EarningsPerShareAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false No definition available. false 3 1 us-gaap_EarningsPerShareTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 15 - us-gaap:EarningsPerShareTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 6pt"><b>15. Earnings Per Share</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January&#160;3, 2010, December&#160;28, 2008 and December&#160;30, 2007: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="64%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Shares in Millions Except Per Share Data)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2007</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Basic net earnings per share </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">4.45</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.62</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3.67</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Average shares outstanding &#8212; basic </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,759.5</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,802.5</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,882.9</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Potential shares exercisable under stock option plans </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">118.0</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">179.0</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">178.6</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Less: shares repurchased under treasury stock method </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(92.0</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(149.6</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(154.5</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Convertible debt shares </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">3.6</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3.7</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3.7</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Adjusted average shares outstanding &#8212; diluted </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,789.1</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,835.6</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,910.7</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Diluted net earnings per share </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">4.40</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.57</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3.63</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="11" align="left" style="border-top: 0px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The diluted net earnings per share calculation includes the dilutive effect of convertible debt that is offset by the related reduction in interest expense of $4&#160;million after-tax for years 2009, 2008 and 2007. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Diluted net earnings per share excludes 121&#160;million, 59&#160;million and 64&#160;million shares underlying stock options for 2009, 2008 and 2007, respectively, as the exercise price of these options was greater than their average market value, which would result in an anti-dilutive effect on diluted earnings per share. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 52 R13.xml IDEA: Borrowings 1.0.0.3 false Borrowings false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false No definition available. false 3 1 us-gaap_LongTermDebtTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 7 - us-gaap:LongTermDebtTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>7. Borrowings</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The components of long-term debt are as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="52%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Effective</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Effective</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Rate %</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>2008</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Rate %</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">6.625% Notes due 2009 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">199</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6.80</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">5.15% Debentures due 2012 </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">599</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">5.18</td> <td nowrap="nowrap">%</td> <td>&#160;</td> <td>&#160;</td> <td align="right">599</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.18</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">3.80% Debentures due 2013 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">500</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3.82</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">500</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3.82</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">5.55% Debentures due 2017 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,000</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.55</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,000</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.55</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">5.15% Debentures due 2018 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">898</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.15</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">898</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.15</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">4.75% Notes due 2019 (1B Euro 1.4382)<sup style="font-size: 85%; vertical-align: text-top">(2)</sup>/(1B Euro 1.4000)<sup style="font-size: 85%; vertical-align: text-top">(3)</sup> </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">1,429</td> <td nowrap="nowrap"> <sup style="font-size: 85%; vertical-align: text-top">(2)</sup></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.35</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">1,390</td> <td nowrap="nowrap"> <sup style="font-size: 85%; vertical-align: text-top">(3)</sup></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.35</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">3% Zero Coupon Convertible Subordinated Debentures due 2020 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">188</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3.00</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">183</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3.00</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">6.73% Debentures due 2023 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">250</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6.73</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">250</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6.73</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">5.50% Notes due 2024 (500MM GBP1.6189)<sup style="font-size: 85%; vertical-align: text-top">(2)</sup>/(500MM GBP1.4759)<sup style="font-size: 85%; vertical-align: text-top">(3)</sup> </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">803</td> <td nowrap="nowrap"> <sup style="font-size: 85%; vertical-align: text-top">(2)</sup></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.71</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">731</td> <td nowrap="nowrap"> <sup style="font-size: 85%; vertical-align: text-top">(3)</sup></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.71</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">6.95% Notes due 2029 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">294</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7.14</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">294</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">7.14</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">4.95% Debenture due 2033 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">500</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.95</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">500</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4.95</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">5.95% Notes due 2037 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">995</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.99</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">995</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.99</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">5.86% Debentures due 2038 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">700</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.86</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">700</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5.86</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Other (Includes Industrial Revenue Bonds) </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">101</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">102</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>8,257 </b></td> <td nowrap="nowrap"><sup style="font-size: 85%; vertical-align: text-top"><b>(4)</b></sup></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>5.42 </b></td> <td nowrap="nowrap"><sup style="font-size: 85%; vertical-align: text-top"><b>(1)</b></sup></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>8,341 </b></td> <td nowrap="nowrap"><sup style="font-size: 85%; vertical-align: text-top"><b>(4)</b></sup></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right"><b>5.46 </b></td> <td nowrap="nowrap"><sup style="font-size: 85%; vertical-align: text-top"><b>(1)</b></sup></td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Less current portion </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">34</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">221</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td align="left"><b>$</b></td> <td align="right"><b>8,223</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right"><b>8,120</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="15" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(1)</i></sup></td> <td>&#160;</td> <td><i>Weighted average effective rate.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(2)</i></sup></td> <td>&#160;</td> <td><i>Translation rate at January&#160;3, 2010.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(3)</i></sup></td> <td>&#160;</td> <td><i>Translation rate at December&#160;28, 2008.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(4)</i></sup></td> <td>&#160;</td> <td><i>The excess of the fair value over the carrying value of debt was $0.8&#160;billion in 2009 and $1.4&#160;billion in 2008.</i></td> </tr> </table> <div align="left" style="font-size: 10pt; margin-top: 6pt">Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices in active markets. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company has access to substantial sources of funds at numerous banks worldwide. In September&#160;2009, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10&#160;billion which expires September&#160;23, 2010. Interest charged on borrowings under the credit line agreements is based on either bids provided by banks, the prime rate or London Interbank Offered Rates (LIBOR), plus applicable margins. Commitment fees under the agreements are not material. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;On July&#160;28, 2000, ALZA Corporation, a subsidiary of the Company, completed a private offering of the 3% Zero Coupon Convertible Subordinated Debentures, which were issued at a price of $551.26 per $1,000 principal amount at maturity. Under the terms of the 3% Debentures, holders are entitled to convert their debentures into approximately 15.0&#160;million shares of Johnson &#038; Johnson stock at a price of $40.102 per share. Approximately 11.4&#160;million shares have been issued as of January&#160;3, 2010, due to voluntary conversions by note holders. At the option of the holder, the 3% Debentures may be repurchased by the Company on July&#160;28, 2013, at a purchase price equal to the issue price plus accreted original issue discount to such purchase date. The Company, at its option, may also redeem any or all of the 3% Debentures after July&#160;28, 2003 at the issue price plus accreted original issue discount. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Throughout 2009 the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $6.3&#160;billion at the end of 2009, of which $5.8&#160;billion was borrowed under the Commercial Paper Program. The remainder represents principally local borrowing by international subsidiaries. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company filed a shelf registration with the Securities and Exchange Commission that became effective March&#160;11, 2008 which enables the Company to issue an unlimited aggregate principal amount in debt securities and warrants to purchase debt securities. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Aggregate maturities of long-term obligations commencing in 2009 are: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> <td width="5%">&#160;</td> <td width="7%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions)</b></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center"><b>After</b></td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="center"><b>2010</b></td> <td>&#160;</td> <td nowrap="nowrap" align="center"><b>2011</b></td> <td>&#160;</td> <td nowrap="nowrap" align="center"><b>2012</b></td> <td>&#160;</td> <td nowrap="nowrap" align="center"><b>2013</b></td> <td>&#160;</td> <td nowrap="nowrap" align="center"><b>2014</b></td> <td>&#160;</td> <td nowrap="nowrap" align="center"><b>2014</b></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td colspan="11" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td align="center"> <div style="margin-left:15px; text-indent:-15px">$34 </div></td> <td>&#160;</td> <td align="center" valign="top">35</td> <td>&#160;</td> <td align="center" valign="top">615</td> <td>&#160;</td> <td align="center" valign="top">507</td> <td>&#160;</td> <td align="center" valign="top">9</td> <td>&#160;</td> <td align="center" valign="top">7,057</td> </tr> <!-- End Table Body --> </table> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 53 R26.xml IDEA: Business Combinations and Divestitures 1.0.0.3 false Business Combinations and Divestitures false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 jnj_BusinessCombinationsAndDivestituresAbstract jnj false na duration string Business Combinations and Divestitures. false false false false false true false false false 1 false false 0 0 false false Business Combinations and Divestitures. false 3 1 us-gaap_BusinessCombinationDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 20 - us-gaap:BusinessCombinationDisclosureTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>20. Business Combinations and Divestitures</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Certain businesses were acquired for $2,470&#160;million in cash and $875&#160;million of liabilities assumed and non-controlling interests during 2009. These acquisitions were accounted for by the purchase method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The 2009 acquisitions included: Mentor Corporation, a leading supplier of medical products for the global aesthetics market; Cougar Biotechnology, Inc., a development stage biopharmaceutical company with a specific focus on oncology; Finsbury Orthopaedics Limited, a privately held UK-based manufacturer and global distributor of orthopaedic implants; Gloster Europe, a privately held developer of innovative disinfection processes and technologies to prevent healthcare-acquired infections and substantially all of the assets and rights of Elan&#8217;s Alzheimer&#8217;s Immunotherapy Program through a newly formed company, of which the Company owns 50.1% and Elan owns 49.9%. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $2,940&#160;million and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. Of this amount, approximately $1,737&#160;million has been identified as the value of IPR&#038;D primarily associated with the acquisitions of Cougar Biotechnology, Inc. and substantially all of the assets and rights of Elan&#8217;s Alzheimer&#8217;s Immunotherapy Program. Additionally, approximately $1,107&#160;million has been identified as the value of other intangible assets, including patents &#038; technology and customer relationships primarily associated with the acquisition of Mentor Corporation. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The IPR&#038;D related to the acquisition of Cougar Biotechnology, Inc. was $971&#160;million and is associated with abiraterone acetate, a late stage, first-in-class compound for the treatment of prostate cancer. The value of the IPR&#038;D was calculated using cash flow projections discounted for the risk inherent in such projects. Probability of success factors ranging from 60-85% were used to reflect inherent clinical and regulatory risk. The discount rate applied was 23.5%. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Refer to Note 6 for information related to the Elan transaction. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Certain businesses were acquired for $1,214&#160;million in cash and $114&#160;million of liabilities assumed during 2008. These acquisitions were accounted for by the purchase method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The 2008 acquisitions included: Amic AB, a privately held Swedish developer of in vitro diagnostic technologies for use in point-of-care and near-patient settings; Beijing Dabao Cosmetics Co., Ltd., a company that sells personal care brands in China; SurgRx, Inc., a privately held developer of the advanced bipolar tissue sealing system used in the ENSEAL<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> family of devices; HealthMedia, Inc., a privately held company that creates web-based behavior change interventions; LGE Performance Systems, Inc., a privately held company known as Human Performance Institute&#8482;, which develops science-based training programs to improve employee engagement and productivity and Omrix Biopharmaceuticals, Inc., a fully integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $891&#160;million and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. Approximately $181&#160;million has been identified as the value of IPR&#038;D associated with the acquisitions of Omrix Biopharmaceuticals, Inc., Amic AB, SurgRx, Inc. and HealthMedia, Inc. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The IPR&#038;D charge related to the acquisition of Omrix Biopharmaceuticals, Inc. was $127&#160;million and is associated with stand-alone and combination biosurgical technologies used to achieve hemostasis. The value of the IPR&#038;D was calculated using cash flow projections discounted for the risk inherent in such projects. Probability of success factors ranging from 60-90% were used to reflect inherent clinical and regulatory risk. The discount rate applied was 14%. As of the end of the 2008 fiscal year, 97.8% of the outstanding shares of Common Stock of Omrix Biopharmaceuticals, Inc. had been tendered by stockholders. Excluding shares that were tendered subject to guaranteed delivery procedures, 90.2% of the outstanding shares of Common Stock had been tendered. On December&#160;30, 2008 the Company completed the acquisition of Omrix Biopharmaceuticals, Inc. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The IPR&#038;D charge related to the acquisition of Amic AB was $40&#160;million and is associated with point-of-care device and 4CAST Chip technologies. The value of the IPR&#038;D was calculated using cash flow projections discounted for the risk inherent in such projects. The discount rate applied was 20%. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The IPR&#038;D charge related to the acquisition of SurgRx, Inc. was $7&#160;million and is associated with vessel cutting and sealing surgical devices. The value of the IPR&#038;D was calculated using cash flow projections discounted for the risk inherent in such projects. Probability of success factors ranging from 90-95% were used to reflect inherent clinical and regulatory risk. The discount rate applied was 18%. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The IPR&#038;D charge related to the acquisition of HealthMedia, Inc. was $7&#160;million and is associated primarily with process enhancements to software technology. The value of the IPR&#038;D was calculated using cash flow projections discounted for the risk inherent in such projects. A probability of success factor of 90% was used to reflect inherent risk. The discount rate applied was 14%. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Certain businesses were acquired for $1,388&#160;million in cash and $232&#160;million of liabilities assumed during 2007. These acquisitions were accounted for by the purchase method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The 2007 acquisitions included: Conor Medsystems, Inc., a cardiovascular device company, with new drug delivery technology; Robert Reid, Inc., a Japanese orthopedic product distributor; and Maya&#8217;s Mom, Inc., a social media company. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $636&#160;million and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. Approximately $807&#160;million has been identified as the value of IPR&#038;D associated with the acquisition of Conor Medsystems, Inc. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The IPR&#038;D charge related to the acquisition of Conor Medsystems, Inc. was $807&#160;million and is associated with research related to the discovery and application of the stent technology. The value of the IPR&#038;D was calculated using cash flow projections discounted for the risk inherent in such projects. The discount rate applied was 19%. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Supplemental pro forma information for 2009, 2008 and 2007 in accordance with U.S. GAAP standards related to business combinations, and goodwill and other intangible assets, is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company&#8217;s results of operations, cash flows or financial position. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;With the exception of the divestiture of the Professional Wound Care business of Ethicon, Inc., which resulted in a gain of $536&#160;million before tax, and is recorded in other (income) expense, net, in 2008, divestitures in 2009, 2008 and 2007 did not have a material effect on the Company&#8217;s results of operations, cash flows or financial position. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 54 R1.xml IDEA: Document and Company Information 1.0.0.3 false Document and Company Information (USD $) In Billions, except Share data false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 false 2 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 false 3 $ false false USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 2 0 jnj_DocumentAndCompanyInformationAbstract jnj false na duration string Document and Company Information [Abstract] false false false false false true false false false 1 false false 0 0 false false 2 false false 0 0 false false 3 false false 0 0 false false Document and Company Information [Abstract] false 3 1 dei_EntityRegistrantName dei false na duration normalizedstring No definition available. false false false false false false false false false 1 false false 0 0 JOHNSON & JOHNSON JOHNSON & JOHNSON false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. No authoritative reference available. false 4 1 dei_EntityCentralIndexKey dei false na duration na No definition available. false false false false false false false false false 1 false false 0 0 0000200406 0000200406 false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. No authoritative reference available. false 5 1 dei_DocumentType dei false na duration na No definition available. false false false false false false false false false 1 false false 0 0 10-K 10-K false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. No authoritative reference available. false 6 1 dei_DocumentPeriodEndDate dei false na duration date No definition available. false false false false false false false false false 1 false false 0 0 2010-01-03 2010-01-03 false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. No authoritative reference available. false 7 1 dei_AmendmentFlag dei false na duration na No definition available. false false false false false false false false false 1 false false 0 0 false false false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. No authoritative reference available. false 8 1 dei_CurrentFiscalYearEndDate dei false na duration monthday No definition available. false false false false false false false false false 1 false false 0 0 --01-03 --01-03 false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. No authoritative reference available. false 9 1 dei_EntityWellKnownSeasonedIssuer dei false na duration na No definition available. false false false false false false false false false 1 false false 0 0 Yes Yes false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. No authoritative reference available. false 10 1 dei_EntityVoluntaryFilers dei false na duration na No definition available. false false false false false false false false false 1 false false 0 0 No No false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. No authoritative reference available. false 11 1 dei_EntityCurrentReportingStatus dei false na duration na No definition available. false false false false false false false false false 1 false false 0 0 Yes Yes false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. No authoritative reference available. false 12 1 dei_EntityFilerCategory dei false na duration na No definition available. false false false false false false false false false 1 false false 0 0 Large Accelerated Filer Large Accelerated Filer false false 2 false false 0 0 false false 3 false false 0 0 false false No definition available. No authoritative reference available. false 13 1 dei_EntityPublicFloat dei false credit instant monetary No definition available. false false false false false false false false false 1 false false 0 0 false false 2 false false 0 0 false false 3 true true 156000000000 156 false false No definition available. No authoritative reference available. false 14 1 dei_EntityCommonStockSharesOutstanding dei false na instant shares No definition available. false false false false false false false false false 1 false false 0 0 false false 2 false true 2751927062 2751927062.00 false false 3 false false 0 0 false false No definition available. No authoritative reference available. false false 3 13 false Billions NoRounding UnKnown false true XML 55 R2.xml IDEA: Consolidated Balance Sheets 1.0.0.3 false Consolidated Balance Sheets (USD $) In Millions false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 false 2 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 4 2 us-gaap_AssetsCurrentAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false 2 false false 0 0 false false No definition available. false 5 3 us-gaap_CashAndCashEquivalentsAtCarryingValue us-gaap true debit instant monetary No definition available. false false false false false false false false false 1 true true 15810000000 15810 false false 2 true true 10768000000 10768 false false No definition available. No authoritative reference available. false 6 3 us-gaap_AvailableForSaleSecuritiesCurrent us-gaap true debit instant monetary No definition available. false false false false false false false false false 1 false true 3615000000 3615 false false 2 false true 2041000000 2041 false false No definition available. No authoritative reference available. false 7 3 us-gaap_AccountsReceivableNetCurrent us-gaap true debit instant monetary No definition available. false false false false false false false false false 1 false true 9646000000 9646 false false 2 false true 9719000000 9719 false false No definition available. No authoritative reference available. false 8 3 us-gaap_InventoryNet us-gaap true debit instant monetary No definition available. false false false false false false false false false 1 false true 5180000000 5180 false false 2 false true 5052000000 5052 false false No definition available. No authoritative reference available. false 9 3 us-gaap_DeferredTaxAssetsNetCurrent us-gaap true debit instant monetary No definition available. false false false false false false false false false 1 false true 2793000000 2793 false false 2 false true 3430000000 3430 false false No definition available. No authoritative reference available. false 10 3 jnj_PrepaidExpensesAndOtherReceivables jnj false debit instant monetary Sum of the amounts paid in advance for capitalized costs that will be expensed and charged against earnings within one year... false false false false false false false false false 1 false true 2497000000 2497 false false 2 false true 3367000000 3367 false false Sum of the amounts paid in advance for capitalized costs that will be expensed and charged against earnings within one year or the normal operating cycle if longer. Other receivables include current assets not separately disclosed due to materiality considerations. No authoritative reference available. true 11 3 us-gaap_AssetsCurrent us-gaap true debit instant monetary No definition available. false false false false false false false false false 1 false true 39541000000 39541 false false 2 false true 34377000000 34377 false false No definition available. No authoritative reference available. true 12 2 us-gaap_PropertyPlantAndEquipmentNet us-gaap true debit instant monetary No definition available. false false false false false false false false false 1 false true 14759000000 14759 false false 2 false true 14365000000 14365 false false No definition available. No authoritative reference available. false 13 2 us-gaap_IntangibleAssetsNetExcludingGoodwill us-gaap true debit instant monetary No definition available. false false false false false false false false false 1 false true 16323000000 16323 false false 2 false true 13976000000 13976 false false No definition available. No authoritative reference available. false 14 2 us-gaap_Goodwill us-gaap true debit instant monetary No definition available. false false false false false false false false false 1 false true 14862000000 14862 false false 2 false true 13719000000 13719 false false No definition available. No authoritative reference available. false 15 2 us-gaap_DeferredTaxAssetsNetNoncurrent us-gaap true debit instant monetary No definition available. false false false false false false false false false 1 false true 5507000000 5507 false false 2 false true 5841000000 5841 false false No definition available. No authoritative reference available. false 16 2 us-gaap_OtherAssetsNoncurrent us-gaap true debit instant monetary No definition available. false false false false false false false false false 1 false true 3690000000 3690 false false 2 false true 2634000000 2634 false false No definition available. No authoritative reference available. true 17 2 us-gaap_Assets us-gaap true debit instant monetary No definition available. false false false false false false false false false 1 false true 94682000000 94682 false false 2 false true 84912000000 84912 false false No definition available. No authoritative reference available. true 19 2 us-gaap_LiabilitiesCurrentAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false 2 false false 0 0 false false No definition available. false 20 3 us-gaap_ShortTermBorrowings us-gaap true credit instant monetary No definition available. false false false false false false false false false 1 false true 6318000000 6318 false false 2 false true 3732000000 3732 false false No definition available. No authoritative reference available. false 21 3 us-gaap_AccountsPayableCurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false 1 false true 5541000000 5541 false false 2 false true 7503000000 7503 false false No definition available. No authoritative reference available. false 22 3 us-gaap_AccruedLiabilitiesCurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false 1 false true 5796000000 5796 false false 2 false true 5531000000 5531 false false No definition available. No authoritative reference available. false 23 3 jnj_AccruedRebatesReturnsAndPromotions jnj false credit instant monetary Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items... false false false false false false false false false 1 false true 2028000000 2028 false false 2 false true 2237000000 2237 false false Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs. No authoritative reference available. false 24 3 us-gaap_EmployeeRelatedLiabilitiesCurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false 1 false true 1606000000 1606 false false 2 false true 1432000000 1432 false false No definition available. No authoritative reference available. false 25 3 us-gaap_AccruedIncomeTaxesCurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false 1 false true 442000000 442 false false 2 false true 417000000 417 false false No definition available. No authoritative reference available. true 26 3 us-gaap_LiabilitiesCurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false 1 false true 21731000000 21731 false false 2 false true 20852000000 20852 false false No definition available. No authoritative reference available. true 27 2 us-gaap_LongTermDebtNoncurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false 1 false true 8223000000 8223 false false 2 false true 8120000000 8120 false false No definition available. No authoritative reference available. false 28 2 us-gaap_DeferredTaxLiabilitiesNoncurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false 1 false true 1424000000 1424 false false 2 false true 1432000000 1432 false false No definition available. No authoritative reference available. false 29 2 us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false 1 false true 6769000000 6769 false false 2 false true 7791000000 7791 false false No definition available. No authoritative reference available. false 30 2 us-gaap_OtherLiabilitiesNoncurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false 1 false true 5947000000 5947 false false 2 false true 4206000000 4206 false false No definition available. No authoritative reference available. true 31 2 us-gaap_Liabilities us-gaap true credit instant monetary No definition available. false false false false false false false false false 1 false true 44094000000 44094 false false 2 false true 42401000000 42401 false false No definition available. No authoritative reference available. true 32 2 us-gaap_StockholdersEquityAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false 2 false false 0 0 false false No definition available. false 33 3 us-gaap_PreferredStockValue us-gaap true credit instant monetary No definition available. false false false false false false false false false 1 false true 0 0 false false 2 false true 0 0 false false No definition available. No authoritative reference available. false 34 3 us-gaap_CommonStockValue us-gaap true credit instant monetary No definition available. false false false false false false false false false 1 false true 3120000000 3120 false false 2 false true 3120000000 3120 false false No definition available. No authoritative reference available. false 35 3 us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax us-gaap true credit instant monetary No definition available. false false false false false false false false false 1 false true -3058000000 -3058 false false 2 false true -4955000000 -4955 false false No definition available. No authoritative reference available. false 36 3 us-gaap_RetainedEarningsAccumulatedDeficit us-gaap true credit instant monetary No definition available. false false false false false false false false false 1 false true 70306000000 70306 false false 2 false true 63379000000 63379 false false No definition available. No authoritative reference available. true 37 3 jnj_ShareholdersEquityBeforeDeductionOfTreasuryStock jnj false credit instant monetary Shareholders' Equity Before Deduction Of Treasury Stock. false false false false false false false false false 1 false true 70368000000 70368 false false 2 false true 61544000000 61544 false false Shareholders' Equity Before Deduction Of Treasury Stock. No authoritative reference available. false 38 3 us-gaap_TreasuryStockValue us-gaap true debit instant monetary No definition available. false false false false false false false false false 1 false true 19780000000 19780 false false 2 false true 19033000000 19033 false false No definition available. No authoritative reference available. true 39 3 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap true credit instant monetary No definition available. false false false false false false false false false 1 false true 50588000000 50588 false false 2 false true 42511000000 42511 false false No definition available. No authoritative reference available. true 40 2 us-gaap_LiabilitiesAndStockholdersEquity us-gaap true credit instant monetary No definition available. false false false false false false false false false 1 true true 94682000000 94682 false false 2 true true 84912000000 84912 false false No definition available. No authoritative reference available. true false 2 36 false Millions UnKnown UnKnown false true XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 1.0.0.3 true Sheet 00 - Document - Document and Company Information Document and Company Information R1.xml false Sheet 01 - Statement - Consolidated Balance Sheets Consolidated Balance Sheets R2.xml false Sheet 011 - Statement - Consolidated Balance Sheets (Parenthetical) Consolidated Balance Sheets (Parenthetical) R3.xml false Sheet 02 - Statement - Consolidated Statements of Earnings Consolidated Statements of Earnings R4.xml false Sheet 03 - Statement - Consolidated Statements of Equity Consolidated Statements of Equity R5.xml false Sheet 04 - Statement - Consolidated Statements of Cash Flows Consolidated Statements of Cash Flows R6.xml false Sheet 0601 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies R7.xml false Sheet 0602 - Disclosure - Cash, Cash Equivalents and Marketable Securities Cash, Cash Equivalents and Marketable Securities R8.xml false Sheet 0603 - Disclosure - Inventories Inventories R9.xml false Sheet 0604 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment R10.xml false Sheet 0605 - Disclosure - Intangible Assets and Goodwill Intangible Assets and Goodwill R11.xml false Sheet 0606 - Disclosure - Fair Value Measurements Fair Value Measurements R12.xml false Sheet 0607 - Disclosure - Borrowings Borrowings R13.xml false Sheet 0608 - Disclosure - Income Taxes Income Taxes R14.xml false Sheet 0609 - Disclosure - Employee Related Obligations Employee Related Obligations R15.xml false Sheet 0610 - Disclosure - Pensions and Other Benefit Plans Pensions and Other Benefit Plans R16.xml false Sheet 0611 - Disclosure - Savings Plan Savings Plan R17.xml false Sheet 0612 - Disclosure - Capital and Treasury Stock Capital and Treasury Stock R18.xml false Sheet 0613 - Disclosure - Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income R19.xml false Sheet 0614 - Disclosure - International Currency Translation International Currency Translation R20.xml false Sheet 0615 - Disclosure - Earnings Per Share Earnings Per Share R21.xml false Sheet 0616 - Disclosure - Rental Expense and Lease Commitments Rental Expense and Lease Commitments R22.xml false Sheet 0617 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements Common Stock, Stock Option Plans and Stock Compensation Agreements R23.xml false Sheet 0618 - Disclosure - Segments of Business and Geographic Areas Segments of Business and Geographic Areas R24.xml false Sheet 0619 - Disclosure - Selected Quarterly Financial Data (unaudited) Selected Quarterly Financial Data (unaudited) R25.xml false Sheet 0620 - Disclosure - Business Combinations and Divestitures Business Combinations and Divestitures R26.xml false Sheet 0621 - Disclosure - Legal Proceedings Legal Proceedings R27.xml false Sheet 0622 - Disclosure - Restructuring Restructuring R28.xml false Sheet 0623 - Disclosure - Subsequent Events Subsequent Events R29.xml false Sheet 0701 - Schedule - Valuation and Qualifying Accounts Valuation and Qualifying Accounts R30.xml false Book All Reports All Reports 1 37 5 0 3 142 false false BalanceAsOf_08Feb2010 1 BalanceAsOf_31Dec2006_Accumulated_Other_Comprehensive_Income_Member 1 BalanceAsOf_03Jan2010_Retained_Earnings_Member 1 BalanceAsOf_28Dec2008_Treasury_Stock_Member 1 TwelveMonthsEnded_28Dec2008_Retained_Earnings_Member 4 BalanceAsOf_30Dec2007_Treasury_Stock_Member 1 BalanceAsOf_28Dec2008 46 TwelveMonthsEnded_30Dec2007_Accumulated_Other_Comprehensive_Income_Member 4 TwelveMonthsEnded_30Dec2007_Treasury_Stock_Member 3 TwelveMonthsEnded_28Dec2008_Accumulated_Other_Comprehensive_Income_Member 4 TwelveMonthsEnded_03Jan2010_Treasury_Stock_Member 3 BalanceAsOf_30Dec2007_Common_Stock_Member 1 BalanceAsOf_30Dec2007 7 TwelveMonthsEnded_30Dec2007_Comprehensive_Income_Member 7 BalanceAsOf_28Dec2008_Common_Stock_Member 1 BalanceAsOf_03Jan2010_Treasury_Stock_Member 1 BalanceAsOf_31Dec2006_Treasury_Stock_Member 1 BalanceAsOf_30Dec2007_Accumulated_Other_Comprehensive_Income_Member 1 TwelveMonthsEnded_03Jan2010_Retained_Earnings_Member 5 BalanceAsOf_03Jan2010_Common_Stock_Member 1 BalanceAsOf_28Dec2008_Retained_Earnings_Member 1 BalanceAsOf_03Jan2010_Accumulated_Other_Comprehensive_Income_Member 1 BalanceAsOf_30Dec2007_Retained_Earnings_Member 1 BalanceAsOf_31Dec2006_Retained_Earnings_Member 1 TwelveMonthsEnded_03Jan2010_Accumulated_Other_Comprehensive_Income_Member 4 BalanceAsOf_03Jan2010 46 TwelveMonthsEnded_30Dec2007 58 BalanceAsOf_31Dec2006 2 TwelveMonthsEnded_28Dec2008 56 TwelveMonthsEnded_28Dec2008_Comprehensive_Income_Member 7 December-29-2008_January-03-2010 91 TwelveMonthsEnded_30Dec2007_Retained_Earnings_Member 6 TwelveMonthsEnded_03Jan2010_Comprehensive_Income_Member 6 BalanceAsOf_31Dec2006_Common_Stock_Member 1 TwelveMonthsEnded_28Dec2008_Treasury_Stock_Member 3 BalanceAsOf_28Jun2009 1 BalanceAsOf_28Dec2008_Accumulated_Other_Comprehensive_Income_Member 1 true true EXCEL 57 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls MT,\1X*&Q&N$`````````````````````/@`#`/[_"0`&```````````````# M`````0``````````$```)P$```$```#^____```````````"`````P```/__ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M_______________________]_____O____W____]____!0````8````'```` M"`````D````*````"P````P````-````#@````\````0````$0```!(````3 M````%````!4````6````%P```!@````9````&@```!L````<````'0```!X` M```?````(````"$````B````(P```"0````E````)@```"<````H````*0`` M`"H````K````+````"T````N````+P```#`````Q````,@```#,````T```` M-0```#8````W````.````#D````Z````.P```#P````]````/@```#\```!` M````00```$(```!#````1````$4```!&````1P```$@```!)````2@```$L` M``!,````30```$X```!/````4````%$```!2````4P```%0```!5````5@`` M`%<```!8````60```%H```!;````7````%T```!>````7P```&````!A```` M8@```&,```!D````90```&8```!G````:````&D```!J````:P```&P```!M M````;@```&\```!P````<0```'(```!S````=````'4```!V````=P```'@` M``!Y````>@```'L```!\````?0```'X```!_````@````%(`;P!O`'0`(`!% M`&X`=`!R`'D````````````````````````````````````````````````` M```````````6``4`__________\"```````````````````````````````` M`````````%!Q)'F)N````GP```*````"A M````H@```*,```"D````I0```*8```"G````J````*D```"J````JP```*P` M``"M````K@```*\```"P````L0```+(```"S````M````+4```"V````MP`` M`+@```"Y````N@```+L```"\````O0```+X```"_````P````,$```#"```` MPP```,0```#%````Q@```,<```#(````R0```,H```#+````S````,T```#. M````SP```-````#1````T@```-,```#4````U0```-8```#7````V````-D` M``#:````VP```-P```#=````W@```-\```#@````X0```.(```#C````Y``` M`.4```#F````YP```.@```#I````Z@```.L```#L````[0```.X```#O```` M\````/$```#R````\P```/0```#U````]@```/<```#X````^0```/H```#[ M````_````/T```#^````_P`````!```!`0```@$```,!```$`0``!0$```8! M```'`0``"`$```D!```*`0``"P$```P!```-`0``#@$```\!```0`0``$0$` M`!(!```3`0``%`$``!4!```6`0``%P$``!@!```9`0``&@$``!L!```<`0`` M'0$``!X!```?`0``(`$``"$!```B`0``(P$``"0!```E`0``)@$``/[____^ M_____O______________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M_____________________________________________________PD($``` M!@4`1AC-!\&````&`@``X0`"`+`$P0`"````X@```%P`<``'``!S!$$`!@`>``$B`"0` M(@`C`"P`(P`C`#``7P`I`#L`6P!2`&4`9`!=`%P`*``@`"(`)``B`",`+``C M`",`,`!<`"``*0`>!$,`!P`?``$B`"0`(@`C`"P`(P`C`#``+@`P`#``7P`I M`#L`7``H`"``(@`D`"(`(P`L`",`(P`P`"X`,``P`%P`(``I`!X$30`(`"0` M`2(`)``B`",`+``C`",`,``N`#``,`!?`"D`.P!;`%(`90!D`%T`7``H`"`` M(@`D`"(`(P`L`",`(P`P`"X`,``P`%P`(``I`!X$<0`J`#8``5\`*``B`"0` M(@`J`"``(P`L`",`(P`P`%\`*0`[`%\`*``B`"0`(@`J`"``7``H`"``(P`L M`",`(P`P`%P`(``I`#L`7P`H`"(`)``B`"H`(``B`"T`(@!?`"D`.P!?`"@` M(`!``%\`(``I`!X$7P`I`"T``5\`*``J`"``(P`L`",`(P`P`%\`*0`[`%\` M*``J`"``7``H`"``(P`L`",`(P`P`%P`(``I`#L`7P`H`"H`(``B`"T`(@!? M`"D`.P!?`"@`(`!``%\`(``I`!X$@0`L`#X``5\`*``B`"0`(@`J`"``(P`L M`",`(P`P`"X`,``P`%\`*0`[`%\`*``B`"0`(@`J`"``7``H`"``(P`L`",` M(P`P`"X`,``P`%P`(``I`#L`7P`H`"(`)``B`"H`(``B`"T`(@`_`#\`7P`I M`#L`7P`H`"``0`!?`"``*0`>!&\`*P`U``%?`"@`*@`@`",`+``C`",`,``N M`#``,`!?`"D`.P!?`"@`*@`@`%P`*``@`",`+``C`",`,``N`#``,`!<`"`` M*0`[`%\`*``J`"``(@`M`"(`/P`_`%\`*0`[`%\`*``@`$``7P`@`"D`'@0C M`*0`#P`!)``C`"P`(P`C`#``.P`H`"0`(P`L`",`(P`P`"D`'@0?`*4`#0`! M(P`L`",`(P`P`#L`*``C`"P`(P`C`#``*0`>!"\`I@`5``$D`",`+``C`",` M,``N`",`(P`[`"@`)``C`"P`(P`C`#``+@`C`",`*0`>!"L`IP`3``$C`"P` M(P`C`#``+@`C`",`.P`H`",`+``C`",`,``N`",`(P`I`.``%```````]?\@ M``````````````#`(.``%``!````]?\@``#T``````````!!(.``%``!```` M]?\@``#T``````````!!(.``%``"````]?\@``#T``````````!!(.``%``" M````]?\@``#T``````````!!(.``%```````]?\@``#T``````````!!(.`` M%```````]?\@``#T``````````!!(.``%```````]?\@``#T``````````!! M(.``%```````]?\@``#T``````````!!(.``%```````]?\@``#T```````` M``!!(.``%```````]?\@``#T``````````!!(.``%```````]?\@``#T```` M``````!!(.``%```````]?\@``#T``````````!!(.``%```````]?\@``#T M``````````!!(.``%```````]?\@``#T``````````!!(.``%````````0`@ M``````````````#`(.``%``!`"L`]?\@``#X``````````!!(.``%``!`"D` M]?\@``#X``````````!!(.``%``!`"P`]?\@``#X``````````!!(.``%``! M`"H`]?\@``#X``````````!!(.``%``!``D`]?\@``#X``````````!!(.`` M%``%`````0`@```(``````````#`(.``%``%`````0`H```8``````````#` M(.``%``%`````0`J```8``````````#`(.``%````````0`H```0```````` M``#`(.``%```````"0`@``````````````#`(.``%```````"0`H```0```` M``````#`(.``%```````"0`(```0``````````#`(.``%````*0``0`@```$ M``````````#`(.``%````*4``0`@```$``````````#`(.``%``&`*4``0`@ M```,``````````#`(.``%``&`*0``0`@```,``````````#`(.``%````*8` M`0`@```$``````````#`(.``%````*<``0`@```$``````````#`(.``%``& M`````0`@```(``````````#`(.``%``%`````0`H``!8``````````0I(.`` M%````````0`@``!```````````0I(),"!```@`#_DP($`!"``_^3`@0`$8`& M_Y,"!``2@`3_DP($`!.`!_^3`@0`%(`%_V`!`@```(4`1@!MXP$````?`40` M;P!C`'4`;0!E`&X`=``@`&$`;@!D`"``0P!O`&T`<`!A`&X`>0`@`$D`;@!F M`&\`<@!M`&$`=`!I`&\`A0`^`*KG`0```!L!0P!O`&X``!\9`@````L!20!N M`'8`90!N`'0`;P!R`&D`90!S`(4`0@`2&P(````=`5``<@!O`'``90!R`'0` M>0`L`"``4`!L`&$`;@!T`"``80!N`&0`(`!%`'$`=0!I`'``;0!E`&X`=`"% M`$0`!1T"````'@%)`&X`=`!A`&X`9P!I`&(`;`!E`"``00!S`',`90!T`',` M(`!A`&X`9``@`$<`;P!O`&0`=P!I`&P`;`"%`#8`^!X"````%P%&`&$`:0!R M`"``5@!A`&P`=0!E`"``30!E`&$`0!E`&4` M(`!2`&4`;`!A`'0`90!D`"``3P!B`&P`:0!G`&$`=`!I`&\`;@!S`(4`1@#$ M)@(````?`5``90!N`',`:0!O`&X`0`@`%0`<@!A`&X``!P`&4`;@!S`&4` M(`!A`&X`9``@`$P`90!A`',`90`@`$,`;P!M`&T`:0!T`(4`1@!I-`(````? M`4,`;P!M`&T`;P!N`"``4P!T`&\`8P!K`"P`(`!3`'0`;P!C`&L`(`!/`'`` M=`!I`&\`;@`@`%``;`!A`&X`A0!&`%PV`@```!\!4P!E`&<`;0!E`&X`=`!S M`"``;P!F`"``0@!U`',`:0!N`&4`0`@`$8`:0!N`&$`;@!C`&D`80!L`"``1`!A`(4`1@!".@(````?`4(` M=0!S`&D`;@!E`',```@`$L`90!Y``H``3``,``P`#`` M,@`P`#``-``P`#8`#0`!1`!O`&,`=0!M`&4`;@!T`"``5`!Y`'``90`$``$Q M`#``+0!+`!@``40`;P!C`'4`;0!E`&X`=``@`%``90!R`&D`;P!D`"``10!N M`&0`(`!$`&$`=`!E``H``3(`,``Q`#``+0`P`#$`+0`P`#,`#@`!00!M`&4` M;@!D`&T`90!N`'0`(`!&`&P`80!G``4``68`80!L`',`90`<``%#`'4`<@!R M`&4`;@!T`"``1@!I`',`8P!A`&P`(`!9`&4`80!R`"``10!N`&0`(`!$`&$` M=`!E``<``2T`+0`P`#$`+0`P`#,`(0`!10!N`'0`:0!T`'D`(`!7`&4`;`!L M`"T`:P!N`&\`=P!N`"``4P!E`&$`0`@ M`$8`:0!L`&4`<@!S``(``4X`;P`?``%%`&X`=`!I`'0`>0`@`$,`=0!R`'(` M90!N`'0`(`!2`&4`<`!O`'(`=`!I`&X`9P`@`%,`=`!A`'0`=0!S`!4``44` M;@!T`&D`=`!Y`"``1@!I`&P`90!R`"``0P!A`'0`90!G`&\`<@!Y`!<``4P` M80!R`&<`90`@`$$`8P!C`&4`;`!E`'(`80!T`&4`9``@`$8`:0!L`&4`<@`3 M``%%`&X`=`!I`'0`>0`@`%``=0!B`&P`:0!C`"``1@!L`&\`80!T`"<``44` M;@!T`&D`=`!Y`"``0P!O`&T`;0!O`&X`(`!3`'0`;P!C`&L`+``@`%,`:`!A M`'(`90!S`"``3P!U`'0`0!A`&(`;`!E`!,``4$`8P!C`'(`=0!E`&0`(`!L`&D`80!B`&D` M;`!I`'0`:0!E`',`)P`!00!C`&,`<@!U`&4`9``@`'(`90!B`&$`=`!E`',` M+``@`'(`90!T`'4`<@!N`',`(`!A`&X`9``@`'``<@!O`&T`;P!T`&D`;P!N M`',`)P`!00!C`&,`<@!U`&4`9``@`',`80!L`&$`<@!I`&4`0`@`',`=`!O`&,` M:P!4``%,`&4``!P`&4`;@!S`&4`+``@ M`&X`90!T`"``;P!F`"``<`!O`'(`=`!I`&\`;@`@`&,`80!P`&D`=`!A`&P` M:0!Z`&4`9``@`"@`3@!O`'0`90`@`#0`*0`;``%/`'0`:`!E`'(`(``H`&D` M;@!C`&\`;0!E`"D`(`!E`'@`<`!E`&X`0!E`&4`(`!C`&\`;0!P`&4`;@!S`&$`=`!I`&\`;@`@`&$` M;@!D`"``0`@`'0`<@!A`&X`0`@ M`%,`=`!O`&,`:P`@`$$`;0!O`'4`;@!T`!0``4,`;P!M`'``<@!E`&@`90!N M`',`:0!V`&4`(`!)`&X`8P!O`&T`90`;``%2`&4`8P!L`&$`0`@`&D`;@!V`&4``!E`'(`8P!I`',`90`@`&\`9@`@`',`=`!O`&,` M:P`@`&\`<`!T`&D`;P!N`',`+P!E`'@`8P!E`',`0`@`',` M=`!O`&,`:P`@`&D`0!E M`&4`(`!C`&\`;0!P`&4`;@!S`&$`=`!I`&\`;@`@`&$`;@!D`"``0`@`&\`9@`@`%,`:0!G`&X`:0!F`&D`8P!A`&X`=``@`$$`8P!C`&\` M=0!N`'0`:0!N`&<`(`!0`&\`;`!I`&,`:0!E`',`+@`!,0`R`"``30!O`&X` M=`!H`',`(`!%`&X`9`!E`&0`#0`*`$H`80!N`"X`(``P`#,`+``@`#(`,``Q M`#``#0`*`%4`4P!$`"``+P`@`',`:`!A`'(`90!S``T`"@`U``%3`'4`;0!M M`&$`<@!Y`"``;P!F`"``4P!I`&<`;@!I`&8`:0!C`&$`;@!T`"``00!C`&,` M;P!U`&X`=`!I`&X`9P`@`%``;P!L`&D`8P!I`&4`0`@ M`&\`9@`@`%,`:0!G`&X`:0!F`&D`8P!A`&X`=``@`$$`8P!C`&\`=0!N`'0` M:0!N`&<`(`!0`&\`;`!I`&,`:0!E`',`(``@``T`#0!0`%(`20!.`$,`20!0 M`$P`10!3`"``3P!&`"``0P!/`$X`4P!/`$P`20!$`$$`5`!)`$\`3@`@`"`` M#0`-`%0`:`!E`"``8P!O`&X`0`@`&@`80!S`"``80!P`'``<@!O`'@`:0!M M`&$`=`!E`&P`>0`@`#$`,0`U`"P`-0`P`#``(`!E`&T`<`!L`&\`>0!E`&4` M0`@`&8`;P!C`'4`@!E`&0`(`!I`&X`=`!O`"``=`!H`'(`90!E`"`` M8@!U`',`:0!N`&4`0`@`&,`80!R`&4`+``@`',`:P!I`&X` M(`!C`&$`<@!E`"P`(`!O`'(`80!L`"``8P!A`'(`90`L`"``=P!O`'4`;@!D M`"``8P!A`'(`90`@`&$`;@!D`"``=P!O`&T`90!N`',`(`!H`&4`80!L`'0` M:``@`&,`80!R`&4`(`!F`&D`90!L`&0`0`L`"``;P!N`&,`;P!L`&\`9P!Y`"P`(`!P`&$`:0!N M`"``;0!A`&X`80!G`&4`;0!E`&X`=``L`"``=0!R`&\`;`!O`&<`>0`@`&$` M;@!D`"``=@!I`'(`;P!L`&\`9P!Y`"X`(`!4`&@`90!S`&4`(`!P`'(`;P!D M`'4`8P!T`',`(`!A`'(`90`@`&0`:0!S`'0`<@!I`&(`=0!T`&4`9``@`&0` M:0!R`&4`8P!T`&P`>0`@`'0`;P`@`'(`90!T`&$`:0!L`&4`<@!S`"P`(`!W M`&@`;P!L`&4`0`@`&D`;@`@`'0`:`!E`"``<`!R`&\`9@!E`',`0`@`'``:`!Y`',`:0!C`&D`80!N`',`+``@`&X` M=0!R`',`90!S`"P`(`!T`&@`90!R`&$`<`!I`',`=`!S`"P`(`!H`&\`0!S`"``;0!I`&X`:0!M`&$`;`!L`'D` M(`!I`&X`=@!A`',`:0!V`&4`(`!S`'4`<@!G`&D`8P!A`&P`(`!P`'(`;P!D M`'4`8P!T`',`.P`@`$P`:0!F`&4`4P!C`&$`;@!S`"``8@!L`&\`;P!D`"`` M9P!L`'4`8P!O`',`90`@`&T`;P!N`&D`=`!O`'(`:0!N`&<`(`!A`&X`9``@ M`&D`;@!S`'4`;`!I`&X`(`!D`&4`;`!I`'8`90!R`'D`(`!P`'(`;P!D`'4` M8P!T`',`.P`@`$\`<@!T`&@`;P`M`$,`;`!I`&X`:0!C`&$`;``@`$0`:0!A M`&<`;@!O`',`=`!I`&,`0`@`&$` M9`!O`'``=`!E`&0`(`!T`&@`90`@`&$`=0!T`&@`;P!R`&D`=`!A`'0`:0!V M`&4`(`!G`'4`:0!D`&$`;@!C`&4`(`!F`&\`<@`@`&4`;0!P`&P`;P!Y`&4` M<@!S`"``9`!I`',`8P!L`&\`0!E`'(`0`@`&$`9`!O`'``=`!E`&0`(`!4`&@`90`@`$8` M00!3`$(`(`!!`&,`8P!O`'4`;@!T`&D`;@!G`"``4P!T`&$`;@!D`&$`<@!D M`',`(`!#`&\`9`!I`&8`:0!C`&$`=`!I`&\`;@!4`$T`(``H`$$`4P!#`"`` M;P!R`"``0P!O`&0`:0!F`&D`8P!A`'0`:0!O`&X`*0`@`&$`;@!D`"``=`!H M`&4`(`!(`&D`90!R`&$`<@!C`&@`>0`@`&\`9@`@`$<`90!N`&4`<@!A`&P` M;`!Y`"``00!C`&,`90!P`'0`90!D`"``00!C`&,`;P!U`&X`=`!I`&X`9P`@ M`%``<@!I`&X`8P!I`'``;`!E`',`(``H`$<`00!!`%``*0`@`'<`:`!I`&,` M:``@`&4`0`L`"``4`!L`&$`;@!T`"``80!N`&0`(`!% M`'$`=0!I`'``;0!E`&X`=``H``%0`'(`;P!P`&4`<@!T`'D`+``@`%``;`!A M`&X`=``@`&$`;@!D`"``10!Q`'4`:0!P`&T`90!N`'0`(`!;`$$`8@!S`'0` M<@!A`&,`=`!=`.$$`2``(``-``T`#0`T`"X`(`!0`'(`;P!P`&4`<@!T`'D` M+``@`%``;`!A`&X`=``@`&$`;@!D`"``10!Q`'4`:0!P`&T`90!N`'0`(``@ M``T`#0!!`'0`(`!T`&@`90`@`&4`;@!D`"``;P!F`"``,@`P`#``.0`@`&$` M;@!D`"``,@`P`#``.``L`"``<`!R`&\`<`!E`'(`=`!Y`"P`(`!P`&P`80!N M`'0`(`!A`&X`9``@`&4`<0!U`&D`<`!M`&4`;@!T`"``80!T`"``8P!O`',` M=``@`&$`;@!D`"``80!C`&,`=0!M`'4`;`!A`'0`90!D`"``9`!E`'``<@!E M`&,`:0!A`'0`:0!O`&X`(`!W`&4`<@!E`#H`(``@``T`#0`-``D`(``)``D` M(``)``D`(``)``D`(``)``T`#0`)`"@`1`!O`&P`;`!A`'(`0`@`&,`80!P`&D`=`!A`&P`:0!Z`&4``!P`&4`;@!S`&4`(`!A`',`(`!P`&$`<@!T`"``;P!F`"``=`!H`&4` M(`!C`&\``!P`&4`;@!S`&4`+``@`&D`;@!C`&P`=0!D`&D`;@!G`"``=`!H`&4`(`!A M`&T`;P!R`'0`:0!Z`&$`=`!I`&\`;@`@`&\`9@`@`&,`80!P`&D`=`!A`&P` M:0!Z`&4`9``@`&D`;@!T`&4`<@!E`',`=``@`&D`;@`@`#(`,``P`#D`+``@ M`#(`,``P`#@`(`!A`&X`9``@`#(`,``P`#<`+``@`'<`80!S`"``)``R`"X` M,0!B`&D`;`!L`&D`;P!N`"P`(``D`#(`+@`P`&(`:0!L`&P`:0!O`&X`(`!A M`&X`9``@`"0`,0`N`#D`8@!I`&P`;`!I`&\`;@`L`"``<@!E`',`<`!E`&,` M=`!I`'8`90!L`'D`+@`@`"``#0`-`%4`<`!O`&X`(`!R`&4`=`!I`'(`90!M M`&4`;@!T`"``;P!R`"``;P!T`&@`90!R`"``9`!I`',`<`!O`',`80!L`"`` M;P!F`"``<`!R`&\`<`!E`'(`=`!Y`"P`(`!P`&P`80!N`'0`(`!A`&X`9``@ M`&4`<0!U`&D`<`!M`&4`;@!T`"P`(`!T`&@`90`@`&,`;P!S`'0`0`N`"``5`!H`&4`(`!D`&D`9@!F`&4` M<@!E`&X`8P!E`"P`(`!I`&8`(`!A`&X`>0`L`"``8@!E`'0`=P!E`&4`;@`@ M`'0`:`!E`"``;@!E`'0`(`!A`',```%) M`&X`=`!A`&X`9P!I`&(`;`!E`"``00!S`',`90!T`',`(`!A`&X`9``@`$<` M;P!O`&0`=P!I`&P`;``I``%)`&X`=`!A`&X`9P!I`&(`;`!E`"``00!S`',` M90!T`',`(`!A`&X`9``@`$<`;P!O`&0`=P!I`&P`;``@`%L`00!B`',`=`!R M`&$`8P!T`%T`]PH!(``@``T`#0`-`#4`+@`@`$D`;@!T`&$`;@!G`&D`8@!L M`&4`(`!!`',`@!A`'0`:0!O`&X`(``@ M``D`"0`@``D`,@`L`#$`-P`W`"``"0`)`"``"0`)`#$`+``X`#(`,``@``D` M#0`-``D`(``)``T`#0`-`%``80!T`&4`;@!T`',`(`!A`&X`9``@`'0`<@!A M`&0`90!M`&$`<@!K`',`(``@`&X`90!T`"``(``)``D`)``@``D`,P`L`#4` M,@`P`"``"0`)`"``"0`)`#,`+``R`#D`.0`@``D`#0`-``D`(``)``T`#0`- M`$\`=`!H`&4`<@`@`&D`;@!T`&$`;@!G`&D`8@!L`&4`@!A`'0`:0!O`&X`(``@``D`"0`@``D`-``L`#@`-0`W`"``"0`)`"`` M"0`)`#0`+``R`#4`,P`@``D`#0`-``D`(``)``T`#0`-`%0`;P!T`&$`;``@ M`&D`;@!T`&$`;@!G`&D`8@!L`&4`(`!A`',`0`@`'0`<@!A`&X`@!A`'0`:0!O M`&X`(`!P`&4`<@!I`&\`9`!S`"``9@!O`'(`(`!P`&$`=`!E`&X`=`!S`"`` M80!N`&0`(`!T`'(`80!D`&4`;0!A`'(`:P!S`"``80!N`&0`(`!O`'0`:`!E M`'(`(`!I`&X`=`!A`&X`9P!I`&(`;`!E`"``80!S`',`90!T`',`(`!A`'(` M90`@`#$`-P!Y`&4`80!R`',`(`!A`&X`9``@`#(`.`!Y`&4`80!R`',`+``@ M`'(`90!S`'``90!C`'0`:0!V`&4`;`!Y`"X`(`!4`&@`90`@`&$`;0!O`'(` M=`!I`'H`80!T`&D`;P!N`"``90!X`'``90!N`',`90`@`&\`9@`@`&$`;0!O M`'(`=`!I`'H`80!B`&P`90`@`&$`0!E`&$`<@!S`"``90!N`&0`90!D`"``2@!A M`&X`=0!A`'(`>0`S`"P`(``R`#``,0`P`"P`(`!$`&4`8P!E`&T`8@!E`'(` M,@`X`"P`(``R`#``,``X`"``80!N`&0`(`!$`&4`8P!E`&T`8@!E`'(`,P`P M`"P`(``R`#``,``W`"``=P!A`',`(``D`#8`-P`U`&T`:0!L`&P`:0!O`&X` M+``@`"0`-P`X`#@`;0!I`&P`;`!I`&\`;@`@`&$`;@!D`"``)``X`#0`-`!M M`&D`;`!L`&D`;P!N`"``8@!E`&8`;P!R`&4`(`!T`&$`>``L`"``<@!E`',` M<`!E`&,`=`!I`'8`90!L`'D`+@`@`$,`90!R`'0`80!I`&X`(`!P`&$`=`!E M`&X`=`!S`"``80!N`&0`(`!I`&X`=`!A`&X`9P!I`&(`;`!E`"``80!S`',` M90!T`',`(`!W`&4`<@!E`"``=P!R`&D`=`!T`&4`;@`@`&0`;P!W`&X`(`!T M`&\`(`!F`&$`:0!R`"``=@!A`&P`=0!E`"``9`!U`'(`:0!N`&<`(`!F`&D` M`!P`&4`;@!S`&4` M+@`@`"``#0`-`%0`:`!E`"``90!S`'0`:0!M`&$`=`!E`&0`(`!A`&T`;P!R M`'0`:0!Z`&$`=`!I`&\`;@`@`&4`>`!P`&4`;@!S`&4`(`!F`&\`<@`@`'0` M:`!E`"``9@!I`'8`90`@`',`=0!C`&,`90!E`&0`:0!N`&<`(`!Y`&4`80!R M`',`(`!A`'``<`!R`&\`>`!I`&T`80!T`&4`0!E M`&$`<@`N`"``4P!U`&(`0`@`&$`;`!L`"`` M;P!F`"``=`!H`&4`(`!A`&T`;P!R`'0`:0!Z`&$`=`!I`&\`;@`@`&4`>`!P M`&4`;@!S`&4`(`!I`',`(`!I`&X`8P!L`'4`9`!E`&0`(`!I`&X`(`!C`&\` M0`@`&$` M9`!O`'``=`!E`&0`(`!T`&@`90`@`',`=`!A`&X`9`!A`'(`9``@`'(`90!L M`&$`=`!E`&0`(`!T`&\`(`!D`&D``!C`&@`80!N`&<`90`@`&,`;P!N`'0`<@!A`&,`=`!S M`"``=`!O`"``;0!A`&X`80!G`&4`(`!I`'0``!P`&\`0`N`"``5`!H`&4`(`!# M`&\`;0!P`&$`;@!Y`"``80!L`',`;P`@`'4`0!P`&4`0`@`&$`;`!S`&\`(`!U`',`90!S`"``9@!O`'(`=P!A`'(`9``@`&4` M>`!C`&@`80!N`&<`90`@`#P`'"`!8P!O`&X`=`!R`&$`8P!T`',`(`!T`&\` M(`!M`&$`;@!A`&<`90`@`&D`=`!S`"``90!X`'``;P!S`'4`<@!E`"``=`!O M`"``=`!H`&4`(`!V`&$`<@!I`&$`8@!I`&P`:0!T`'D`(`!O`&8`(`!C`&$` M0`@`'4`0`@`&$`0`@`&0`;P!E`',`(`!N`&\`=``@`&4`;@!T M`&4`<@`@`&D`;@!T`&\`(`!D`&4`<@!I`'8`80!T`&D`=@!E`"``9@!I`&X` M80!N`&,`:0!A`&P`(`!I`&X`0`@`&,`<@!E`&0`:0!T M`"``<@!A`'0`:0!N`&<``!C`&@`80!N`&<` M90`@`&,`;P!N`'0`<@!A`&,`=`!S`"``80!N`&0`(`!C`'(`;P!S`',`(`!C M`'4`<@!R`&4`;@!C`'D`(`!I`&X`=`!E`'(`90!S`'0`(`!R`&$`=`!E`"`` M0`@ M`%4`+@!3`"X`(`!'`$$`00!0`"``9@!O`'(`(`!D`&4`<@!I`'8`80!T`&D` M=@!E`"``:0!N`',`=`!R`'4`;0!E`&X`=`!S`"``80!N`&0`(`!H`&4`9`!G M`&D`;@!G`"``80!C`'0`:0!V`&D`=`!I`&4`0!P M`&4`(`!O`&8`(`!H`&4`9`!G`&4`(`!T`'(`80!N`',`80!C`'0`:0!O`&X` M+@`@`"``#0`-`%0`:`!E`"``9`!E`',`:0!G`&X`80!T`&D`;P!N`"``80!S M`"``80`@`&,`80!S`&@`(`!F`&P`;P!W`"``:`!E`&0`9P!E`"``:0!S`"`` M;0!A`&0`90`@`&$`=``@`'0`:`!E`"``90!N`'0`<@!A`&X`8P!E`"``9`!A M`'0`90`@`&D`;@!T`&\`(`!T`&@`90`@`&0`90!R`&D`=@!A`'0`:0!V`&4` M(`!C`&\`;@!T`'(`80!C`'0`+@`@`$$`=``@`&D`;@!C`&4`<`!T`&D`;P!N M`"P`(`!A`&P`;``@`&0`90!R`&D`=@!A`'0`:0!V`&4`0!I`&X`9P`@`'0`<@!A`&X`0`@`'0`<@!A`&X`0`@`&@`80!S`"``80!C`&,`90!S`',`(`!T`&\`(`!S`'4`8@!S`'0` M80!N`'0`:0!A`&P`(`!S`&\`=0!R`&,`90!S`"``;P!F`"``9@!U`&X`9`!S M`"``80!T`"``;@!U`&T`90!R`&\`=0!S`"``8@!A`&X`:P!S`"``=P!O`'(` M;`!D`'<`:0!D`&4`+@`@`$D`;@`@`%,`90!P`'0`90!M`&(`90!R`#(`,``P M`#D`+``@`'0`:`!E`"``0P!O`&T`<`!A`&X`>0`@`',`90!C`'4`<@!E`&0` M(`!A`"``;@!E`'<`(``S`#8`-``M`&0`80!Y`"``0P!R`&4`9`!I`'0`(`!& M`&$`8P!I`&P`:0!T`'D`+@`@`%0`;P!T`&$`;``@`&,`<@!E`&0`:0!T`"`` M80!V`&$`:0!L`&$`8@!L`&4`(`!T`&\`(`!T`&@`90`@`$,`;P!M`'``80!N M`'D`(`!A`'``<`!R`&\`>`!I`&T`80!T`&4`0`@`&(`80!N`&L`0`R M`#@`+``@`#(`,``P`#``+``@`$$`3`!:`$$`(`!#`&\`<@!P`&\`<@!A`'0` M:0!O`&X`+``@`&$`(`!S`'4`8@!S`&D`9`!I`&$`<@!Y`"``;P!F`"``=`!H M`&4`(`!#`&\`;0!P`&$`;@!Y`"P`(`!C`&\`;0!P`&P`90!T`&4`9``@`&$` M(`!P`'(`:0!V`&$`=`!E`"``;P!F`&8`90!R`&D`;@!G`"``;P!F`"``=`!H M`&4`(``S`"4`(`!:`&4`<@!O`"``0P!O`'4`<`!O`&X`(`!#`&\`;@!V`&4` M<@!T`&D`8@!L`&4`(`!3`'4`8@!O`'(`9`!I`&X`80!T`&4`9``@`$0`90!B M`&4`;@!T`'4`<@!E`',`+``@`'<`:`!I`&,`:``@`'<`90!R`&4`(`!I`',` M`!I`&T`80!T`&4`;`!Y`"``,0`U`"X`,`!M`&D` M;`!L`&D`;P!N`"``0`@`#$`,0`N`#0` M;0!I`&P`;`!I`&\`;@`@`',`:`!A`'(`90!S`"``:`!A`'8`90`@`&(`90!E M`&X`(`!I`',`0`@`&,`;P!N`'8`90!R`',`:0!O`&X`0`@`&X`;P!T`&4` M(`!H`&\`;`!D`&4`<@!S`"X`(`!!`'0`(`!T`&@`90`@`&\`<`!T`&D`;P!N M`"``;P!F`"``=`!H`&4`(`!H`&\`;`!D`&4`<@`L`"``=`!H`&4`(``S`"4` M(`!$`&4`8@!E`&X`=`!U`'(`90!S`"``;0!A`'D`(`!B`&4`(`!R`&4`<`!U M`'(`8P!H`&$``!E`',`%P`!20!N`&,`;P!M`&4`(`!4 M`&$`>`!E`',`(`!;`$$`8@!S`'0`<@!A`&,`=`!=`(`,`2``(``-``T`#0`X M`"X`(`!)`&X`8P!O`&T`90`@`%0`80!X`&4`0`@`'`` M80!Y`&$`8@!L`&4`.@`@`"``"0`)`"``"0`)`"``"0`)`"``"0`)`"``"0`) M`"``"0`)``T`#0`-`%4`+@!3`"X`(`!T`&$`>`!E`',`(``@``D`"0`D`"`` M"0`R`"P`-``Q`#``(``)``D`(``)``D`,@`L`#,`,P`T`"``"0`)`"``"0`) M`#(`+``Y`#D`,``@``D`#0`-``T`20!N`'0`90!R`&X`80!T`&D`;P!N`&$` M;``@`'0`80!X`&4``!E`',`(``@``D`"0`@``D`,0`X M`#<`(``)``D`(``)``D`,0`R`#8`(``)``D`(``)``D`*``W`#(`,@`@``D` M*0`@`"``#0`-``T`20!N`'0`90!R`&X`80!T`&D`;P!N`&$`;``@`'0`80!X M`&4``!E`',`(`!O`&X`(`!I`&X`8P!O`&T`90`Z`"``(``)``D`)``@ M``D`,0`U`"P`-P`U`#4`(``)``D`(``)``D`,0`V`"P`.0`R`#D`(``)``D` M(``)``D`,0`S`"P`,@`X`#,`(``)``T`#0`)`"``"0`-``T`#0!4`&$`>``@ M`'(`80!T`&4```@`&,`<@!E`&0`:0!T`',`(``@``D`"0`@``D` M*``P`"X`-@`@``D`*0`@``D`"0`@``D`*``P`"X`-@`@``D`*0`@``D`"0`@ M``D`*``P`"X`.``@``D`*0`@`"``#0`-``T`50`N`%,`+@`@`',`=`!A`'0` M90`@`&$`;@!D`"``;`!O`&,`80!L`"``(``)``D`(``)`#$`+@`X`"``"0`) M`"``"0`)`#$`+@`V`"``"0`)`"``"0`)`#(`+@`Q`"``"0`-``T`#0!)`&X` M=`!E`'(`;@!A`'0`:0!O`&X`80!L`"````@`'(`80!T`&4`(``@``D`"0`@``D`,@`R`"X`,0`@``D`)0`@``D`"0`@ M``D`,@`S`"X`-0`@``D`"0`@``D`"0`R`#``+@`T`"``"0`-``T`"0`@``D` M#0`-`%0`:`!E`"``0P!O`&T`<`!A`&X`>0`@`&@`80!S`"``0`@`&@`80!S M`"````@`&D`;@!C`&4`;@!T`&D`=@!E`"`` M9P!R`&$`;@!T`',`+@`@`%0`:`!E`"``9`!E`&,`<@!E`&$`0`@`&0`=0!E`"``=`!O`"``:0!N`&,`<@!E M`&$``!A`&(`;`!E`"``:0!N`&,`;P!M`&4` M(`!I`&X`(`!L`&\`=P!E`'(`(`!T`&$`>``@`&H`=0!R`&D``!A`&(` M;`!E`"``:0!N`&,`;P!M`&4`(`!I`&X`(`!H`&D`9P!H`&4`<@`@`'0`80!X M`"``:@!U`'(`:0!S`&0`:0!C`'0`:0!O`&X```@ M`'(`80!T`&4`(`!W`&$```@`&H`=0!R`&D``!A`&(`;`!E`"``:0!N`&,`;P!M`&4` M(`!I`&X`(`!L`&\`=P!E`'(`(`!J`'4`<@!I`',`9`!I`&,`=`!I`&\`;@!S M`"P`(`!A`',`(`!W`&4`;`!L`"``80!S`"``80`@`&(`=0!S`&D`;@!E`',` M``@``D`"0`@``D`1`!E`&8` M90!R`'(`90!D`"``5`!A`'@`(``)``T`#0`)`"@`1`!O`&P`;`!A`'(`0!E`&4`(`!R`&4`;`!A`'0`90!D`"``;P!B`&P`:0!G M`&$`=`!I`&\`;@!S`"``(``)``D`)``@``D`,@`L`#$`-0`S`"``"0`)`"`` M"0`)`"``"0`)`"``"0`)`#(`+``V`#$`-0`@``D`"0`@``D`"0`@``D`#0`- M``T`4P!T`&\`8P!K`"``8@!A`',`90!D`"``8P!O`&T`<`!E`&X`/``;(`%S M`&$`=`!I`&\`;@`@`"``"0`)`"``"0`Q`"P`,@`Y`#$`(``)``D`(``)``D` M(``)``D`(``)``D`,0`L`#(`.0`V`"``"0`)`"``"0`)`"``"0`-``T`#0!$ M`&4`<`!R`&4`8P!I`&$`=`!I`&\`;@`@`"``"0`)`"``"0`)`"``"0`)`"`` M"0`H`#8`-@`Q`"``"0`I`"``"0`)`"``"0`)`"``"0`)`"``"0`H`#4`,@`S M`"``"0`I`"``(``-``T`#0!.`&\`;@`M`&0`90!D`'4`8P!T`&D`8@!L`&4` M(`!I`&X`=`!A`&X`9P!I`&(`;`!E`',`(``@``D`"0`@``D`"0`@``D`"0`@ M``D`*``R`"P`,P`W`#<`(``)`"D`(``)``D`(``)``D`(``)``D`(``)`"@` M,0`L`#<`.0`Q`"``"0`I`"``(``-``T`#0!)`&X`=`!E`'(`;@!A`'0`:0!O M`&X`80!L`"``4@!$`"``8P!A`'``:0!T`&$`;`!I`'H`90!D`"``9@!O`'(` M(`!T`&$`>``@`"``"0`)`"``"0`Q`"P`.0`X`#D`(``)``D`(``)``D`(``) M``D`(``)``D`,0`L`#D`,0`T`"``"0`)`"``"0`)`"``"0`-``T`#0!2`&4` M``@`'``=0!R`'``;P!S`&4`0!E`&4`(`!R`&4`;`!A`'0`90!D`"``;P!B`&P` M:0!G`&$`=`!I`&\`;@!S`"``(`!L`&\`;@!G`"T`=`!E`'(`;0`@`"``"0`) M`"0`(``)`#8`+``W`#8`.0`@``D`"0`@``D`"0`W`"P`-P`Y`#$`(``)``T` M#0`)`"``"0`-``T`4`!R`&4`<`!A`&D`9``@`&4`;0!P`&P`;P!Y`&4`90`@ M`'(`90!L`&$`=`!E`&0`(`!O`&(`;`!I`&<`80!T`&D`;P!N`',`(`!O`&8` M(``D`#(`-@`V`&T`:0!L`&P`:0!O`&X`(`!A`&X`9``@`"0`,0`S`#8`;0!I M`&P`;`!I`&\`;@`@`&8`;P!R`"``,@`P`#``.0`@`&$`;@!D`"``,@`P`#`` M.``L`"``<@!E`',`<`!E`&,`=`!I`'8`90!L`'D`+``@`&$`<@!E`"``:0!N M`&,`;`!U`&0`90!D`"``:0!N`"``;P!T`&@`90!R`"``80!S`',`90!T`',` M(`!O`&X`(`!T`&@`90`@`&,`;P!N`',`;P!L`&D`9`!A`'0`90!D`"``8@!A M`&P`80!N`&,`90`@`',`:`!E`&4`=``N`"``(``@`"```5``90!N`',`:0!O M`&X`0!E`&4`0`@`&@`90!A`&P`=`!H M`"``8P!A`'(`90`L`"``=`!O`"``80!L`&P`(`!5`"X`4P`N`"``<@!E`'0` M:0!R`&4`9``@`&4`;0!P`&P`;P!Y`&4`90!S`"``80!N`&0`(`!T`&@`90!I M`'(`(`!D`&4`<`!E`&X`9`!E`&X`=`!S`"X`(``@``T`#0!-`&$`;@!Y`"`` M:0!N`'0`90!R`&X`80!T`&D`;P!N`&$`;``@`&4`;0!P`&P`;P!Y`&4`90!S M`"``80!R`&4`(`!C`&\`=@!E`'(`90!D`"``8@!Y`"``9P!O`'8`90!R`&X` M;0!E`&X`=``M`',`<`!O`&X`0!E`&4` M0!E`&$`<@!S`"``8@!E`&8`;P!R`&4`(`!R`&4`=`!I`'(`90!M`&4`;@!T M`"``80!N`&0`(`!T`&@`90`@`&X`=0!M`&(`90!R`"``;P!F`"``>0!E`&$` M<@!S`"``;P!F`"``0`@`&0`;P!E`',`(`!N`&\`=``@`&8`=0!N`&0`(`!R M`&4`=`!I`'(`90!E`"``:`!E`&$`;`!T`&@`(`!C`&$`<@!E`"``8@!E`&X` M90!F`&D`=`!S`"``:0!N`"``80!D`'8`80!N`&,`90`@`&$`;@!D`"``:`!A M`',`(`!T`&@`90`@`'(`:0!G`&@`=``@`'0`;P`@`&T`;P!D`&D`9@!Y`"`` M=`!H`&4`0`@`&@`80!S`"``80!D`&\`<`!T M`&4`9``@`'0`:`!E`"``<@!E`&,`90!N`'0`(`!S`'0`80!N`&0`80!R`&0` M0!E`'(`@!A`'0`:0!O`&X`(`!O`&8`(`!P M`'(`:0!O`'(`(`!S`&4`<@!V`&D`8P!E`"``8P!O`',`=``@`"``"0`)`"`` M"0`Q`#,`(``)``D`(``)``D`,0`P`"``"0`)`"``"0`)`#$`,``@``D`"0`@ M``D`"0`H`#4`(``)`"D`(``)``D`(``)`"@`-``@``D`*0`@``D`"0`@``D` M*``W`"``"0`I`"``(``-``T`#0!!`&T`;P!R`'0`:0!Z`&$`=`!I`&\`;@`@ M`&\`9@`@`&X`90!T`"``=`!R`&$`;@!S`&D`=`!I`&\`;@`@`&$`0!E`&4`0`@`&$`<@!E`"``80!M`&\`<@!T`&D`>@!E M`&0`(`!O`'8`90!R`"``=`!H`&4`(`!A`'8`90!R`&$`9P!E`"``;`!I`&8` M90`@`&4`>`!P`&4`8P!T`&$`;@!C`'D`+@`@`%0`:`!E`"``80!M`&\`<@!T M`&D`>@!A`'0`:0!O`&X`(`!O`&8`(`!G`&$`:0!N`',`(`!A`&X`9``@`&P` M;P!S`',`90!S`"``9@!O`'(`(`!T`&@`90`@`&\`=`!H`&4`<@`@`%4`+@!3 M`"X`(`!B`&4`;@!E`&8`:0!T`"``<`!L`&$`;@!S`"``:0!S`"``9`!E`'0` M90!R`&T`:0!N`&4`9``@`&(`>0`@`'4`0`@`&@` M80!S`"``=@!O`&P`=0!N`'0`80!R`'D`(``T`#``,0`@`"@`:P`I`',`80!V M`&D`;@!G`',`(`!P`&P`80!N`',`(`!D`&4`0`@`&T`80!T`&,`:`!E`',` M(`!A`"``<`!E`'(`8P!E`&X`=`!A`&<`90`@`&\`9@`@`&4`80!C`&@`(`!E M`&T`<`!L`&\`>0!E`&4`0`@`%,`=`!O`&,`:P`@`%L`00!B`',` M=`!R`&$`8P!T`%T`'04!(``@``T`#0`-`#$`,@`N`"``0P!A`'``:0!T`&$` M;``@`&$`;@!D`"``5`!R`&4`80!S`'4`<@!Y`"``4P!T`&\`8P!K`"``(``- M``T`0P!H`&$`;@!G`&4`0`@`',` M=`!O`&,`:P`@`'<`90!R`&4`.@`@`"``#0`-``T`"0`@``D`"0`@``D`"0`@ M``D`"0`@``D`#0`-``D`*`!!`&T`;P!U`&X`=`!S`"``:0!N`"``30!I`&P` M;`!I`&\`;@!S`"``10!X`&,`90!P`'0`(`!4`'(`90!A`',`=0!R`'D`(`!3 M`'0`;P!C`&L`(``)``D`5`!R`&4`80!S`'4`<@!Y`"``4P!T`&\`8P!K`"`` M(``-``T`"0!.`'4`;0!B`&4`<@`@`&\`9@`@`%,`:`!A`'(`90!S`"``:0!N M`"``5`!H`&\`=0!S`&$`;@!D`',`*0`@``D`"0!3`&@`80!R`&4``!I`&T`80!T`&4`;`!Y`"``,P`L M`#$`,@`P`&T`:0!L`&P`:0!O`&X`(`!S`&@`80!R`&4`@!E`&0`(`!G`&$`:0!N`"``*`!L`&\`0`S`"P`(``R`#``,0`P`"``(``)``D`)``@``D`*``U`#``.``@ M``D`*0`@``D`"0`@``D`*``S`#``(``)`"D`(``)``D`(``)`"@`,@`L`#8` M-@`U`"``"0`I`"``"0`)`"``"0`Q`#0`-0`@``D`"0`@``D`"0`H`#,`+``P M`#4`.``@``D`*0`@`"``#0`-``D`(``)``T`#0!4`&@`90`@`'0`80!X`"`` M90!F`&8`90!C`'0`(`!O`&X`(`!T`&@`90`@`'4`;@!R`&4`80!L`&D`>@!E M`&0`(`!G`&$`:0!N`',`+P`H`&P`;P!S`',`90!S`"D`(`!O`&X`(`!T`&@` M90`@`&4`<0!U`&D`=`!Y`"``0!E`&4`(`!B`&4`;@!E`&8`:0!T`"``<`!L`&$`;@!S`"``=P!A M`',`(``D`#,`,``R`&T`:0!L`&P`:0!O`&X`+``@`"0`,0`L`#``.0`P`&T` M:0!L`&P`:0!O`&X`(`!A`&X`9``@`"0`,P`T`#D`;0!I`&P`;`!I`&\`;@`@ M`&D`;@`@`#(`,``P`#D`+``@`#(`,``P`#@`(`!A`&X`9``@`#(`,``P`#<` M+``@`'(`90!S`'``90!C`'0`:0!V`&4`;`!Y`"X`(`!4`&@`90`@`'0`80!X M`"``90!F`&8`90!C`'0`(`!O`&X`(`!T`&@`90`@`&<`80!I`&X``!P`&4`;@!S`&4` M(`!O`&8`(``D`#<`.`!M`&D`;`!L`&D`;P!N`"``80!N`&0`(``D`#<`,`!M M`&D`;`!L`&D`;P!N`"``:0!N`"``,@`P`#``.0`@`&$`;@!D`"``,@`P`#`` M.``L`"``<@!E`',`<`!E`&,`=`!I`'8`90!L`'D`+``@`&$`;@!D`"``:0!N M`&,`;P!M`&4`(`!O`&8`(``D`#(`-`!M`&D`;`!L`&D`;P!N`"``:0!N`"`` M,@`P`#``-P`N`"``4P!E`&4`(`!.`&\`=`!E`"``-@`@`&8`;P!R`"``80!D M`&0`:0!T`&D`;P!N`&$`;``@`&D`;@!F`&\`<@!M`&$`=`!I`&\`;@`@`'(` M90!L`&$`=`!I`&X`9P`@`'0`;P`@`&0`90!R`&D`=@!A`'0`:0!V`&4`0`@`%0`<@!A`&X`0`@`%0`<@!A`&X`0`@`&$`8P!C`&\`=0!N`'0`(`!I`&X`8P!L M`'4`9`!E`',`(`!T`&@`90`@`'(`90!S`'4`;`!T`',`(`!O`&8`(`!T`'(` M80!N`',`;`!A`'0`:0!N`&<`(`!A`&P`;``@`&(`80!L`&$`;@!C`&4`(`!S M`&@`90!E`'0`(`!A`',``!C`&@`80!N M`&<`90`@`'(`80!T`&4`0`@ M`&D`;@!F`&P`80!T`&D`;P!N`&$`<@!Y`"``90!C`&\`;@!O`&T`:0!E`',` M+@`@`%0`:`!E`"``=`!R`&$`;@!S`&P`80!T`&D`;P!N`"``;P!F`"``8@!A M`&P`80!N`&,`90`@`',`:`!E`&4`=``@`&$`8P!C`&\`=0!N`'0`0`@ M`&4`8P!O`&X`;P!M`&D`90!S`"``80!R`&4`(`!R`&4`9@!L`&4`8P!T`&4` M9``@`&D`;@`@`'0`:`!E`"``;P!P`&4`<@!A`'0`:0!N`&<`(`!R`&4`0`@`'0`<@!A`&X``!E`'(`8P!I`',`80!B`&P` M90`@`'4`;@!D`&4`<@`@`',`=`!O`&,`:P`@`&\`<`!T`&D`;P!N`"``<`!L M`&$`;@!S`"``(``)``D`(``)`#$`,0`X`"X`,``@``D`"0`@``D`"0`Q`#<` M.0`N`#``(``)``D`(``)``D`,0`W`#@`+@`V`"``"0`-``T`#0!,`&4`0`@`',`=`!O`&,`:P`@`&T`90!T M`&@`;P!D`"``(``)``D`(``)`"@`.0`R`"X`,``@``D`*0`@``D`"0`@``D` M*``Q`#0`.0`N`#8`(``)`"D`(``)``D`(``)`"@`,0`U`#0`+@`U`"``"0`I M`"``(``-``T`#0!#`&\`;@!V`&4`<@!T`&D`8@!L`&4`(`!D`&4`8@!T`"`` M``@`&8`;P!R M`"``>0!E`&$`<@!S`"``,@`P`#``.0`L`"``,@`P`#``.``@`&$`;@!D`"`` M,@`P`#``-P`N`"``(``-``T`1`!I`&P`=0!T`&4`9``@`&X`90!T`"``90!A M`'(`;@!I`&X`9P!S`"``<`!E`'(`(`!S`&@`80!R`&4`(`!E`'@`8P!L`'4` M9`!E`',`(``Q`#(`,0!M`&D`;`!L`&D`;P!N`"P`(``U`#D`;0!I`&P`;`!I M`&\`;@`@`&$`;@!D`"``-@`T`&T`:0!L`&P`:0!O`&X`(`!S`&@`80!R`&4` M0`L`"``80!S M`"``=`!H`&4`(`!E`'@`90!R`&,`:0!S`&4`(`!P`'(`:0!C`&4`(`!O`&8` M(`!T`&@`90!S`&4`(`!O`'``=`!I`&\`;@!S`"``=P!A`',`(`!G`'(`90!A M`'0`90!R`"``=`!H`&$`;@`@`'0`:`!E`&D`<@`@`&$`=@!E`'(`80!G`&4` M(`!M`&$`<@!K`&4`=``@`'8`80!L`'4`90`L`"``=P!H`&D`8P!H`"``=P!O M`'4`;`!D`"``<@!E`',`=0!L`'0`(`!I`&X`(`!A`&X`(`!A`&X`=`!I`"T` M9`!I`&P`=0!T`&D`=@!E`"``90!F`&8`90!C`'0`(`!O`&X`(`!D`&D`;`!U M`'0`90!D`"``90!A`'(`;@!I`&X`9P!S`"``<`!E`'(`(`!S`&@`80!R`&4` M+@`@`"``(``D``%2`&4`;@!T`&$`;``@`$4`>`!P`&4`;@!S`&4`(`!A`&X` M9``@`$P`90!A`',`90`@`$,`;P!M`&T`:0!T`&T`90!N`'0``!P`&4`;@!S`&4`(`!A`&X`9``@`$P`90!A`',`90`@ M`$,`;P!M`&T`:0!T`&T`90!N`'0`0!S`"``,0`Y`#D` M-0`@`&$`;@!D`"``,@`P`#``,``@`%,`=`!O`&,`:P`@`$\`<`!T`&D`;P!N M`"``4`!L`&$`;@!S`"P`(`!T`&@`90`@`#(`,``P`#4`(`!,`&\`;@!G`"T` M5`!E`'(`;0`@`$D`;@!C`&4`;@!T`&D`=@!E`"``4`!L`&$`;@`L`"``=`!H M`&4`(``Q`#D`.0`W`"``3@!O`&X`+0!%`&T`<`!L`&\`>0!E`&4`(`!$`&D` M<@!E`&,`=`!O`'(```@`&T`;P!N`'0`:`!S`"``=`!O`"``9@!I`'8`90`@`'D` M90!A`'(`0`@`',`90!T`'0`;`!E`',`(`!E`&T`<`!L`&\`>0!E`&4`(`!S`'0` M;P!C`&L`(`!O`'``=`!I`&\`;@`@`&4`>`!E`'(`8P!I`',`90!S`"``=P!I M`'0`:``@`'0`<@!E`&$`0`@`',`:`!A`'(`90!S`"X`(`!4`'(` M90!A`',`=0!R`'D`(`!S`&@`80!R`&4`0!E`&$`<@`@`&8`;P!R`"``=`!H`&4`(`!N`'4`;0!B`&4`<@`@`&\`9@`@ M`',`:`!A`'(`90!S`"``=0!S`&4`9``@`'0`;P`@`',`90!T`'0`;`!E`"`` M90!M`'``;`!O`'D`90!E`"``0`@`'(`90!P`'(`90!S`&4`;@!T`',`(`!A`"``8@!L`&4`;@!D M`&4`9``@`'(`80!T`&4`(`!O`&8`(``T`"T`>0!E`&$`<@`@`&0`80!I`&P` M>0`@`&@`:0!S`'0`;P!R`&D`8P!A`&P`(`!A`'8`90!R`&$`9P!E`"``=@!O M`&P`80!T`&D`;`!I`'0`>0`@`'(`80!T`&4`+``@`&$`;@!D`"``80`@`#4` M+0!W`&4`90!K`"``80!V`&4`<@!A`&<`90`@`&D`;0!P`&P`:0!E`&0`(`!V M`&\`;`!A`'0`:0!L`&D`=`!Y`"``<@!A`'0`90`@`&(`80!S`&4`9``@`&\` M;@`@`&$`=``M`'0`:`!E`"T`;0!O`&X`90!Y`"``=`!R`&$`9`!E`&0`(`!* M`&\`:`!N`',`;P!N`"``(`!*`&\`:`!N`',`;P!N`"``;P!P`'0`:0!O`&X` M0`@`'D`:0!E`&P`9``@`&,`=0!R`'8`90`@ M`&D`;@`@`&4`9@!F`&4`8P!T`"``80!T`"``=`!H`&4`(`!T`&D`;0!E`"`` M;P!F`"``9P!R`&$`;@!T`"X`(``@`"``(``@`"``#0`-`%0`:`!E`"``80!V M`&4`<@!A`&<`90`@`&8`80!I`'(`(`!V`&$`;`!U`&4`(`!O`&8`(`!O`'`` M=`!I`&\`;@!S`"``9P!R`&$`;@!T`&4`9``@`'<`80!S`"``)``X`"X`,P`U M`"P`(``D`#<`+@`V`#8`+``@`&$`;@!D`"``)``Q`#$`+@`V`#<`(`!I`&X` M(``R`#``,``Y`"P`(``R`#``,``X`"P`(`!A`&X`9``@`#(`,``P`#<`+``@ M`'(`90!S`'``90!C`'0`:0!V`&4`;`!Y`"X`(`!4`&@`90`@`&8`80!I`'(` M(`!V`&$`;`!U`&4`(`!W`&$``!P`&4`8P!T`&4`9``@`'8`;P!L`&$`=`!I`&P`:0!T`'D`(``@ M``D`"0`@``D`,0`Y`"X`-0`@``D`)0`@``D`"0`@``D`,0`U`"X`,``@``D` M)0`@``D`"0`@``D`,0`T`"X`-P`@``D`)0`@`"``#0`-``T`10!X`'``90!C M`'0`90!D`"``;`!I`&8`90`@`"``"0`)`#8`+@`P`"``"0!Y`'(`0!R`',`(``)``D`-@`N`#``(``)`'D`<@!S`"``"0`- M``T`#0!$`&D`=@!I`&0`90!N`&0`(`!Y`&D`90!L`&0`(``@``D`"0`@``D` M,P`N`#,`,``@``D`)0`@``D`"0`@``D`,@`N`#D`,``@``D`)0`@``D`"0`@ M``D`,@`N`#4`,``@``D`)0`@`"``(``@`"``#0`-`$$`(`!S`'4`;0!M`&$` M<@!Y`"``;P!F`"``;P!P`'0`:0!O`&X`(`!A`&,`=`!I`'8`:0!T`'D`(`!U M`&X`9`!E`'(`(`!T`&@`90`@`%``;`!A`&X`(`!A`',`(`!O`&8`(`!*`&$` M;@!U`&$`<@!Y`#,`+``@`#(`,``Q`#``+``@`$0`90!C`&4`;0!B`&4`<@`R M`#@`+``@`#(`,``P`#@`+``@`&$`;@!D`"``1`!E`&,`90!M`&(`90!R`"`` M,P`P`"P`(``R`#``,``W`"``80!N`&0`(`!C`&@`80!N`&<`90!S`"``9`!U M`'(`:0!N`&<`(`!T`&@`90`@`'D`90!A`'(``!P`&4` M;@!S`&4`(`!N`&\`=``@`&$`;`!L`&\`8P!A`'0`90!D`"``=`!O`"``0`L`"``"0`)`"``"0!$`&4`<`!R M`&4`8P!I`&$`=`!I`&\`;@`@`&$`;@!D`"``"0`-``T`"0`@``D`4`!L`&$` M;@!T`"``(`!%`'$`=0!I`'``;0!E`&X`=``@``D`"0`@``D`00!M`&\`<@!T M`&D`>@!A`'0`:0!O`&X`(``)``T`#0`)`"@`1`!O`&P`;`!A`'(`0`@`$8`:0!N`&$`;@!C`&D`80!L M`"``1`!A`'0`80`@`"@`=0!N`&$`=0!D`&D`=`!E`&0`*0`X``%3`&4`;`!E M`&,`=`!E`&0`(`!1`'4`80!R`'0`90!R`&P`>0`@`$8`:0!N`&$`;@!C`&D` M80!L`"``1`!A`'0`80`@`"@`=0!N`&$`=0!D`&D`=`!E`&0`*0`@`%L`00!B M`',`=`!R`&$`8P!T`%T`K`@!(``@``T`#0`-`#$`.0`N`"``4P!E`&P`90!C M`'0`90!D`"``40!U`&$`<@!T`&4`<@!L`'D`(`!&`&D`;@!A`&X`8P!I`&$` M;``@`$0`80!T`&$`(``H`'4`;@!A`'4`9`!I`'0`90!D`"D`(``@``T`#0!3 M`&4`;`!E`&,`=`!E`&0`(`!U`&X`80!U`&0`:0!T`&4`9``@`'$`=0!A`'(` M=`!E`'(`;`!Y`"``9@!I`&X`80!N`&,`:0!A`&P`(`!D`&$`=`!A`"``9@!O M`'(`(`!T`&@`90`@`'D`90!A`'(`@!E`&0`(`!B`&4`;`!O M`'<`.@`@`"``#0`-``T`"0`@``D`"0`@``D`"0`@``D`"0`@``D`"0`@``D` M"0`@``D`"0`@``D`"0`@``D`"0`@``D`"0`@``D`"0`@``D`"0`@``D`"0`@ M``D`"0`@``D`"0`@``D`"0`@``D`#0`-``D`(``)`#(`,``P`#D`(``)``D` M(``)`#(`,``P`#@`(``)``T`#0`)`"``"0!&`&D`<@!S`'0`(``)``D`(``) M`%,`90!C`&\`;@!D`"``"0`)`"``"0!4`&@`:0!R`&0`(``)``D`(``)`$8` M;P!U`'(`=`!H`"``"0`)`"``"0!&`&D`<@!S`'0`(``)``D`(``)`%,`90!C M`&\`;@!D`"``"0`)`"``"0!4`&@`:0!R`&0`(``)``D`(``)`$8`;P!U`'(` M=`!H`"``"0`-``T`"0`H`$0`;P!L`&P`80!R`',`(`!I`&X`(`!-`&D`;`!L M`&D`;P!N`',`(`!%`'@`8P!E`'``=``@`%``90!R`"``4P!H`&$`<@!E`"`` M1`!A`'0`80`I`"``"0`)`%$`=0!A`'(`=`!E`'(`(``)``D`(``)`%$`=0!A M`'(`=`!E`'(`(``)``D`(``)`%$`=0!A`'(`=`!E`'(`(``)``D`(``)`%$` M=0!A`'(`=`!E`'(`(``)`"@`,0`I`"``"0`)`%$`=0!A`'(`=`!E`'(`(``) M``D`(``)`%$`=0!A`'(`=`!E`'(`(``)`"@`,@`I`"``"0`)`%$`=0!A`'(` M=`!E`'(`(``)``D`(``)`%$`=0!A`'(`=`!E`'(`(``)`"@`,P`I`"``(``- M``T`"0`@``D`#0`-``T`4P!E`&<`;0!E`&X`=``@`',`80!L`&4``!E`',`(`!O`&X`(`!I`&X`8P!O`&T`90`@`"``"0`)`"`` M"0`T`"P`-@`T`#,`(``)``D`(``)``D`-``L`#(`-@`S`"``"0`)`"``"0`) M`#0`+``R`#0`-0`@``D`"0`@``D`"0`R`"P`-@`P`#0`(``)``D`(``)``D` M-``L`#<`-``W`"``"0`)`"``"0`)`#0`+``S`#<`-0`@``D`"0`@``D`"0`T M`"P`,@`Y`#``(``)``D`(``)``D`,P`L`#4`,0`W`"``"0`-``T`#0!.`&4` M=``@`&4`80!R`&X`:0!N`&<```@`&,`:`!A`'(`9P!E`"``;P!F`"``)``T`#``;0!I`&P`;`!I M`&\`;@`@`&8`;P!R`"``20!0`%(`1``N`"``(``-``T`#0`)`"@`,P`I`"`` M"0`)`%0`:`!E`"``9@!O`'4`<@!T`&@`(`!Q`'4`80!R`'0`90!R`"``;P!F M`"``,@`P`#``.``@`&D`;@!C`&P`=0!D`&4```@`&<`80!I`&X`(`!O`&X`(`!T`&@`90`@`&0`:0!V`&4`0`@`'<`:0!T`&@`(`!A`"``0`@`&@`90!L`&0`(`!5 M`$L`+0!B`&$`0`@`'(`90!S`&D`9`!U`&$`;``@`'(`90!C`&\`<@!D`&4`9``@`'0`;P`@ M`&<`;P!O`&0`=P!I`&P`;``N`"``3P!F`"``=`!H`&D``!I`&T`80!T`&4`;`!Y`"``)``Q`"P`-P`S M`#<`;0!I`&P`;`!I`&\`;@`@`&@`80!S`"``8@!E`&4`;@`@`&D`9`!E`&X` M=`!I`&8`:0!E`&0`(`!A`',`(`!T`&@`90`@`'8`80!L`'4`90`@`&\`9@`@ M`$D`4`!2`$0`(`!P`'(`:0!M`&$`<@!I`&P`>0`@`&$`0`L`"``20!N`&,`+@`@`&$`;@!D`"``0`@`&$`;`!L`"``;P!F`"``=`!H`&4`(`!A`',`@!H`&4`:0!M`&4`<@!S`"``20!M`&T`=0!N`&\`=`!H`&4`<@!A`'`` M>0`@`%``<@!O`&<`<@!A`&T`+@`@`$$`9`!D`&D`=`!I`&\`;@!A`&P`;`!Y M`"P`(`!A`'``<`!R`&\`>`!I`&T`80!T`&4`;`!Y`"``)``Q`"P`,0`P`#<` M;0!I`&P`;`!I`&\`;@`@`&@`80!S`"``8@!E`&4`;@`@`&D`9`!E`&X`=`!I M`&8`:0!E`&0`(`!A`',`(`!T`&@`90`@`'8`80!L`'4`90`@`&\`9@`@`&\` M=`!H`&4`<@`@`&D`;@!T`&$`;@!G`&D`8@!L`&4`(`!A`',`0`L`"``20!N`&,`+@`@`'<`80!S`"``)``Y`#<`,0!M`&D` M;`!L`&D`;P!N`"``80!N`&0`(`!I`',`(`!A`',`0`@`&\`9@`@`',`=0!C`&,`90!S`',`(`!F`&$`8P!T`&\` M<@!S`"``<@!A`&X`9P!I`&X`9P`@`&8`<@!O`&T`(``V`#``+0`X`#4`)0`@ M`'<`90!R`&4`(`!U`',`90!D`"``=`!O`"``<@!E`&8`;`!E`&,`=``@`&D` M;@!H`&4`<@!E`&X`=``@`&,`;`!I`&X`:0!C`&$`;``@`&$`;@!D`"``<@!E M`&<`=0!L`&$`=`!O`'(`>0`@`'(`:0!S`&L`+@`@`%0`:`!E`"``9`!I`',` M8P!O`'4`;@!T`"``<@!A`'0`90`@`&$`<`!P`&P`:0!E`&0`(`!W`&$`0`L`"``<@!E M`',`=0!L`'0```L`"``20!N`&,`+@`L`"``80`@`'`` M<@!I`'8`80!T`&4`;`!Y`"``:`!E`&P`9``@`&0`90!V`&4`;`!O`'``90!R M`"``;P!F`"``=`!H`&4`(`!A`&0`=@!A`&X`8P!E`&0`(`!B`&D`<`!O`&P` M80!R`"``=`!I`',`0`@`'0`:`!A`'0`(`!C M`'(`90!A`'0`90!S`"``=P!E`&(`+0!B`&$`0`@`&\` M9@`@`'0`:`!E`"``=P!A`'(`;@!I`&X`9P!S`"``80!N`&0`(`!I`&X`0`@`&4`>`!I`',`=`!I`&X`9P`@`&$`;0!O`'4` M;@!T`',`(`!A`&,`8P!R`'4`90!D`"``:0!N`"``=`!H`&4`(`!#`&\`;0!P M`&$`;@!Y`',`(`!B`&$`;`!A`&X`8P!E`"``0`@`&$`;@!D`"P`(`!W`&@`90!R`&4`(`!A`'8`80!I`&P`80!B`&P` M90`L`"``<`!U`&X`:0!T`&D`=@!E`"``9`!A`&T`80!G`&4`0!S`"``1P!E M`&X`90!R`&$`;``@`&\`9@`@`&4`:0!G`&@`=``@`',`=`!A`'0`90!S`"`` M80!N`&0`(`!T`&@`90`@`$\`9@!F`&D`8P!E`"``;P!F`"``1P!E`&X`90!R M`&$`;``@`$,`;P!U`&X`0`@`$<` M90!N`&4`<@!A`&P`(`!O`&8`(`!4`&4`>`!A`',`(`!H`&$`0!S`"``1P!E`&X`90!R`&$`;``@`&\`9@`@`&T`;P!R M`&4`(`!T`&@`80!N`"``-``P`"``;P!T`&@`90!R`"``0!M`&4`;@!T`',`(`!F`&\`<@`@`%(`20!3 M`%``10!2`$0`00!,`"P`(`!S`&4`=@!E`'(`80!L`"``;P!F`"``=P!H`&D` M8P!H`"``0`@`&D` M;@`@`#(`,``P`#``+``@`&@`80!V`&4`(`!B`&4`90!N`"``<@!E`',`;P!L M`'8`90!D`"``;P!R`"``80!R`&4`(`!C`'4`<@!R`&4`;@!T`&P`>0`@`&4` M;@!R`&\`;`!L`&4`9``@`&D`;@`@`',`90!T`'0`;`!E`&T`90!N`'0`(`!P M`'(`;P!G`'(`80!M`',`(`!W`&D`=`!H`"``80!N`"``80!G`&<`<@!E`&<` M80!T`&4`(`!C`&$`<``@`&(`90!L`&\`=P`@`"0`,0`P`#``;0!I`&P`;`!I M`&\`;@`N`"``4P!I`&T`:0!L`&$`<@`@`&P`:0!T`&D`9P!A`'0`:0!O`&X` M(`!C`&\`;@!C`&4`<@!N`&D`;@!G`"``4`!2`$\`4`!5`$P`4P!)`$0`(`!I M`',`(`!P`&4`;@!D`&D`;@!G`"``:0!N`"``0P!A`&X`80!D`&$`+``@`'<` M:`!E`'(`90`@`&$`(`!N`&$`=`!I`&\`;@!A`&P`(`!C`&P`80!S`',`(`!A M`&,`=`!I`&\`;@`@`&\`9@`@`'``90!R`',`;P!N`',`(`!A`&P`;`!E`&<` M:0!N`&<`(`!A`&0`=@!E`'(`0`@`&\`9@`@`$H`;P!H`&X`0`@`&X`90!W`"``<`!R`&\`9`!U`&,`=`!S`"`` M80!N`&0`(`!C`&\`;@!T`&D`;@!U`&4`9``@`&<`<@!O`'<`=`!H`"``;P!F M`"``:0!T`',`(`!C`&\`<@!E`"``8@!U`',`:0!N`&4``!I`&(`:0!L`&D`=`!Y M`"``=`!O`"``80!D`&H`=0!S`'0`(`!T`&\`(`!T`&@`90`@`&,`:`!A`&X` M9P!E`&0`(`!A`&X`9``@`&4`=@!O`&P`=@!I`&X`9P`@`&<`;`!O`&(`80!L M`"``90!N`'8`:0!R`&\`;@!M`&4`;@!T`"X`(``@``T`#0!$`'4`<@!I`&X` M9P`@`'0`:`!E`"``9@!I`',`8P!A`&P`(`!F`&\`=0!R`'0`:``@`'$`=0!A M`'(`=`!E`'(`(`!O`&8`(``R`#``,``Y`"P`(`!T`&@`90`@`$,`;P!M`'`` M80!N`'D`(`!R`&4`8P!O`'(`9`!E`&0`(``D`#$`+@`R`&(`:0!L`&P`:0!O M`&X`(`!I`&X`(`!R`&4`;`!A`'0`90!D`"``<`!R`&4`+0!T`&$`>``@`&,` M:`!A`'(`9P!E`',`(`!O`&8`(`!W`&@`:0!C`&@`+``@`&$`<`!P`'(`;P!X M`&D`;0!A`'0`90!L`'D`(``D`#@`,P`P`&T`:0!L`&P`:0!O`&X`(`!O`&8` M(`!T`&@`90`@`'``<@!E`"T`=`!A`'@`(`!R`&4`0!M M`&4`;@!T`',`+@`@`%0`:`!E`"``)``Q`"X`,@!B`&D`;`!L`&D`;P!N`"`` M;P!F`"``<@!E`',`=`!R`'4`8P!T`'4`<@!I`&X`9P`@`&,`:`!A`'(`9P!E M`',`(`!C`&\`;@!S`&D`0`L`"``<`!L`&$`;@!T`"``80!N`&0` M(`!E`'$`=0!I`'``;0!E`&X`=``@`&\`9@`@`"0`,0`P`#<`;0!I`&P`;`!I M`&\`;@`L`"``:0!N`'0`80!N`&<`:0!B`&P`90`@`&$`0`L`"``80!S`"``<`!A`'(`=``@ M`&\`9@`@`'0`:`!I`',`(`!P`'(`;P!G`'(`80!M`"``=`!H`&4`(`!#`&\` M;0!P`&$`;@!Y`"``<`!L`&$`;@!S`"``=`!O`"``90!L`&D`;0!I`&X`80!T M`&4`(`!A`'``<`!R`&\`>`!I`&T`80!T`&4`;`!Y`"``-P`L`#4`,``P`"`` M<`!O`',`:0!T`&D`;P!N`',`(`!O`&8`(`!W`&@`:0!C`&@`(`!A`'``<`!R M`&\`>`!I`&T`80!T`&4`;`!Y`"``-P`P`#``(`!H`&$`=@!E`"``8@!E`&4` M;@`@`&4`;`!I`&T`:0!N`&$`=`!E`&0`(`!S`&D`;@!C`&4`(`!T`&@`90`@ M`'(`90!S`'0`<@!U`&,`=`!U`'(`:0!N`&<`(`!W`&$`0`@`&$`;@!N M`&\`=0!N`&,`90!D`"``<@!E`',`=`!R`'4`8P!T`'4`<@!I`&X`9P`@`&D` M;@!I`'0`:0!A`'0`:0!V`&4`0`@`'<`:0!T`&@`(`!D`'(`=0!G`"T`90!L M`'4`=`!I`&X`9P`@`',`=`!E`&X`=`!S`"``80!N`&0`(`!T`&\`(`!B`&4` M=`!T`&4`<@`@`',`90!R`'8`90`@`'0`:`!E`"``8@!R`&\`80!D`"``0`@`&$`8P!C M`&4`;`!E`'(`80!T`&4`9``@`',`=`!E`'``0`@`&4`;`!I M`&T`:0!N`&$`=`!E`&0`(`!A`'``<`!R`&\`>`!I`&T`80!T`&4`;`!Y`"`` M-``L`#8`,``P`"``<`!O`',`:0!T`&D`;P!N`',`+@`@`"``#0`-`%0`:`!E M`"``0P!O`&T`<`!A`&X`>0`@`'(`90!C`&\`<@!D`&4`9``@`"0`-P`T`#4` M;0!I`&P`;``1``%3`'4`8@!S`&4`<0!U`&4`;@!T`"``10!V`&4`;@!T`',` M'``!4P!U`&(`0`@`"0` M-P`X`#4`;0!I`&P`;`!I`&\`;@`N`"``00!C`&,`;`!A`'(`90!N`'0`(`!) M`&X`8P`N`"``:0!S`"``80`@`&T`90!D`&D`8P!A`&P`(`!T`&4`8P!H`&X` M;P!L`&\`9P!Y`"``8P!O`&T`<`!A`&X`>0`@`&0`90!D`&D`8P!A`'0`90!D M`"``=`!O`"``9`!E`',`:0!G`&X`:0!N`&<`+``@`&0`90!V`&4`;`!O`'`` M:0!N`&<`(`!A`&X`9``@`&,`;P!M`&T`90!R`&,`:0!A`&P`:0!Z`&D`;@!G M`"``9`!E`'8`:0!C`&4`0`@`&@`80!S`"``<`!E M`'(`9@!O`'(`;0!E`&0`(`!A`&X`(`!E`'8`80!L`'4`80!T`&D`;P!N`"`` M;P!F`"``0!I`&X`9P`@`$$`8P!C`&\`=0!N`'0`0`S`"P`(``R`#``,0`P`"P` M(`!$`&4`8P!E`&T`8@!E`'(`,@`X`"P`(``R`#``,``X`"``80!N`&0`(`!$ M`&4`8P!E`&T`8@!E`'(`,P`P`"P`(``R`#``,``W`"``(``-``T`(``H`$0` M;P!L`&P`80!R`',`(`!I`&X`(`!-`&D`;`!L`&D`;P!N`',`*0`@`"``#0`- M``T`"0`@``D`"0`@``D`"0`@``D`"0`@``D`"0`@``D`"0`@``D`"0`@``D` M"0`@``D`#0`-``D`(``@`"``"0`@`$(`80!L`&$`;@!C`&4`(`!A`'0`(``@ M`"``"0`)`"``(``@``D`"0`@`"``(``)``D`(``@`"``"0`)`"``(``@``D` M(`!"`&$`;`!A`&X`8P!E`"``80!T`"``(``@``D`#0`-``D`(``@`"``"0`@ M`$(`90!G`&D`;@!N`&D`;@!G`"``;P!F`"``(``@``D`"0`@`"``(``)``D` M(``@`"``"0`)`"``(``@``D`"0`@`"``(``)`"``10!N`&0`(`!O`&8`(``@ M`"``"0`-``T`"0`@`"``(``)`"``4`!E`'(`:0!O`&0`(``@``D`"0`@`"`` M(``)`"``00!C`&,`<@!U`&$`;`!S`"``(``)``D`(``@`"``"0`@`%``80!Y M`&T`90!N`'0``````@#_`````````0\`"`(0`!\````" M`/\````````!#P#]``H``````!<`&P```/T`"@`!````%P`<````_0`*``$` M`0`7`!T```#]``H``0`"`!<`'@```/T`"@`"````%@`?````_0`*``,````8 M`"````"]`!(``P`!`!P``.'.0!P```C%0`(`_0`*``0````8`"$```"]`!(` M!``!`!T``#ZL0!T``.2?0`(`_0`*``4````8`"(```"]`!(`!0`!`!T``-?" M0!T`@/O"0`(`_0`*``8````8`",```"]`!(`!@`!`!T``#RT0!T``+RS0`(` M_0`*``<````8`"0```"]`!(`!P`!`!T``-*E0!T``,RJ0`(`_0`*``@````8 M`"4```"]`!(`"``!`!X``(*C0!X``$ZJ0`(`_0`*``D````8`"8```"]`!(` M"0`!`!X`H$[C0!X`(,G@0`(`_0`*``H````8`"<```"]`!(`"@`!`!T`@-/, M0!T`@`[,0`(`_0`*``L````8`"@```"]`!(`"P`!`!T`@.'/0!T``$S+0`(` M_0`*``P````8`"D```"]`!(`#``!`!T```?-0!T`@,O*0`(`_0`*``T````8 M`"0```"]`!(`#0`!`!T``(.U0!T``-&V0`(`_0`*``X````8`"H```"]`!(` M#@`!`!X``-2L0!X``)2D0`(`_0`*``\````8`"L```"]`!(`#P`!`!X`H!WW M0!X``+OT0`(`_0`*`!`````6`"P```#]``H`$0```!@`+0```+T`$@`1``$` M'0``KKA`'0``**U``@#]``H`$@```!@`+@```+T`$@`2``$`'0``I;5`'0`` M3[U``@#]``H`$P```!@`+P```+T`$@`3``$`'0``I+9`'0``F[5``@#]``H` M%````!@`,````+T`$@`4``$`'0``L)]`'0``>J%``@#]``H`%0```!@`,0`` M`+T`$@`5``$`'0``&)E`'0``8)9``@#]``H`%@```!@`,@```+T`$@`6``$` M'@``H'M`'@``$'I``@#]``H`%P```!@`,P```+T`$@`7``$`'@#`.-5`'@`` M7=1``@#]``H`&````!@`-````+T`$@`8``$`'0"`#\!`'0``N+]``@#]``H` M&0```!@`)````+T`$@`9``$`'0``0)9`'0``8)9``@#]``H`&@```!@`-0`` M`+T`$@`:``$`'0``<;I`'0``;[Y``@#]``H`&P```!@`-@```+T`$@`;``$` M'@``.[=`'@``;K!``@#]``H`'````!@`-P```+T`$@`<``$`'@#`A^5`'@`@ MM.1``@#]``H`'0```!8`.````/T`"@`>````&``Y````O0`2`!X``0`=```` M```=```````"`/T`"@`?````&``Z````O0`2`!\``0`=``!@J$`=``!@J$`" M`-<`1`"N!@``;`(.`"H`#@`D`"0`)``D`"0`)``D`"0`)``D`"0`)``D``X` M)``D`"0`)``D`"0`)``D`"0`)``D`"0`#@`D``@"$``@`````@#_```````` M`0\`"`(0`"$````"`/\````````!#P`(`A``(@````(`_P````````$/``@" M$``C`````@#_`````````0\`"`(0`"0````"`/\````````!#P`(`A``)0`` M``(`_P````````$/`/T`"@`@````&``[````O0`2`"```0`=``#DI\`=``!; ML\`"`/T`"@`A````&``\````O0`2`"$``0`>`"`J\4`>`&#R[D`"`/T`"@`B M````&``]````O0`2`"(``0`=```N\4`=```-[D`"`/T`"@`C````&``^```` MO0`2`",``0`>``!1TT`>`$"6TD`"`/T`"@`D````&``_````O0`2`"0``0`> M`("SZ$`>`.#!Y$`"`/T`"@`E````&`!`````O0`2`"4``0`?`*`=]T`?``"[ M]$`"`-<`$`!0`0``9``D`"0`)``D`"0`/@(2`+8``````$`````````````` M`*``!`!D`&0`'0`/``,````````!`````````.\`!@```#<````*````"0@0 M```&$`!&&,T'P8````8"```+`A0````````````,`````````,_T`0`-``(` M`0`,``(`9``/``(``0`1``(````0``@`_*GQTDUB4#]?``(``0`J``(````K M``(```""``(``0"```@````````````E`@0```#_`($``@#!!!0````5```` M@P`"````A``"````H0`B``D`9``!``$``0!&`%@"6`(```````#@/P`````` M`.`_`0!5``(`"`!]``P``````+8\#P````0`?0`,``$``@"V&`\````$`'T` M#``#`/\`)`D/````!````@X```````P```````,````(`A``````````_P`` M``````$/``@"$``!`````@#_`````````0\`"`(0``(``````/\````````! M#P`(`A```P````(`_P````````$/``@"$``$``````#_`````````0\`"`(0 M``4````"`/\````````!#P`(`A``!@````(`_P````````$/``@"$``'```` M`@#_`````````0\`"`(0``@````"`/\````````!#P`(`A``"0````(`_P`` M``````$/``@"$``*`````@#_`````````0\`"`(0``L````"`/\````````! M#P#]``H``````!<`00```/T`"@`!````%P!"````_0`*``$``0`7`!T```#] M``H``0`"`!<`'@```/T`"@`"````%@`?````_0`*``,````8`$,```"]`!(` M`P`!`!P``-!T0!P``,!P0`(`_0`*``0````6`#@```#]``H`!0```!@`1``` M`+T`$@`%``$`'0``````'0```````@#]``H`!@```!@`10```+T`$@`&``$` M'0"`A#Y!'0"`A#Y!`@#]``H`!P```!@`1@```+T`$@`'``$`'0"`A#Y!'0"` MA#Y!`@#]``H`"````!@`1P```+T`$@`(``$`'0```/`_'0```/`_`@#]``H` M"0```!@`2`````,"#@`)``$`'0````"`WQ?P00,"#@`)``(`'0````"`WQ?P M0?T`"@`*````&`!)`````P(.``H``0`=`````->@/N=!`P(.``H``@`=```` M`->@/N=!_0`*``L````8`$H```"]`!(`"P`!`!T`0K$E5QT`HN2:4P(`UP`< M`(`"``#<``X`*@`.`"0`#@`D`"0`)``D`#(`,@`^`A(`M@``````0``````` M````````H``$`&0`9``=``\``P````````$`````````[P`&````-P````H` M```)"!````80`$88S0?!@```!@(```L"%````````````!4`````````*OL! M``T``@`!``P``@!D``\``@`!`!$``@```!``"`#\J?'236)0/U\``@`!`"H` M`@```"L``@```((``@`!`(``"````````````"4"!````/\`@0`"`,$$%``` M`!4```"#``(```"$``(```"A`"(`"0!D``$``0`!`$8`6`)8`@```````.`_ M````````X#\!`%4``@`(`'T`#```````MCP/````!`!]``P``0`#`+88#P`` M``0`?0`,``0`_P`D"0\````$```"#@``````%0``````!`````@"$``````` M``#_`````````0\`"`(0``$````#`/\````````!#P`(`A```@``````_P`` M``````$/``@"$``#`````P#_`````````0\`"`(0``0````#`/\````````! M#P`(`A``!0````,`_P````````$/``@"$``&`````P#_`````````0\`"`(0 M``<````#`/\````````!#P`(`A``"`````,`_P````````$/``@"$``)```` M`P#_`````````0\`"`(0``H````#`/\````````!#P`(`A``"P````,`_P`` M``````$/``@"$``,`````P#_`````````0\`"`(0``T````#`/\````````! M#P`(`A``#@````,`_P````````$/``@"$``/`````P#_`````````0\`"`(0 M`!`````#`/\````````!#P`(`A``$0````,`_P````````$/``@"$``2```` M`P#_`````````0\`"`(0`!,````#`/\````````!#P`(`A``%`````,`_P`` M``````$/`/T`"@``````%P!+````_0`*``$````7`$P```#]``H``0`!`!<` M`@```/T`"@`!``(`%P!-````_0`*``$``P`7`$X```#]``H``@```!8`3P`` M`/T`"@`#````&`!0````O0`8``,``0`?`"`Y[D`?`&`@[T`?`.#4[4`#`/T` M"@`$````&`!1````O0`8``0``0`>`,`#TD`>`,`3TD`>`,!5T4`#`/T`"@`% M````&`!2````O0`8``4``0`=`$`WY4`=`(`6YD`=```JY4`#`/T`"@`&```` M&`!3````O0`8``8``0`=`$!6TT`=`(#\U$`=`,#XTT`#`/T`"@`'````&`!4 M````O0`8``<``0`=``!*NT`=``"9O4`=````OD`#`/T`"@`(````&`!5```` MO0`8``@``0`=```````=``"@9D`=```XB4`#`/T`"@`)````&`!6````O0`8 M``D``0`=``"`5L`=``"0=L`=``!`?,`#`/T`"@`*````&`!7````O0`8``H` M`0`=```P?$`=```P>T`=``"```#$ MD$`>```````>``!(AT`#`/T`"@`-````&`!:````O0`8``T``0`=`(#%SD`= M`$"(T$`=`(#QR4`#`/T`"@`.````&`!;````O0`8``X``0`>``!"JT`>```8 MKT`>```FI4`#`/T`"@`/````&`!<````O0`8``\``0`?``#UQT`?`(!*R4`? M``"HQ$`#`/T`"@`0````&`!=````O0`8`!```0`@``'0>T`@``'@?$`@``'P M=D`#`/T`"@`1````&`!>`````P(.`!$``0`@`)J9F9F9F1%`O0`2`!$``@`@ M``&0?$`@``&P=D`#`/T`"@`2````&`!?````O0`8`!(``0`@``$@:$`@``%P M9D`@``%`9$`#`/T`"@`3````&`!@````O0`8`!,``0`A``"/I4`A``#EI4`A M`(F8$4$#`/T`"@`4````&`!A````O0`8`!0``0`A`/D%$4$A`*%.$4$A`/G# M$4$#`-<`+@#X!```D`$.`#@`#@`J`"H`*@`J`"H`*@`J`"H`*@`J`"H`*@`J M`"H`-@`J`"H`/@(2`+8``````$```````````````*``!`!D`&0`'0`/``,` M```````!`````````.\`!@```#<````*````"0@0```&$`!&&,T'P8````8" M```+`A@````````````P`````````!4$`@`I"`(`#0`"``$`#``"`&0`#P`" M``$`$0`"````$``(`/RI\=)-8E`_7P`"``$`*@`"````*P`"````@@`"``$` M@``(````````````)0($````_P"!``(`P004````%0```(,``@```(0``@`` M`*$`(@`)`&0``0`!``$`1@!8`E@"````````X#\```````#@/P$`50`"``@` M?0`,``````"V/`\````$`'T`#``!``,`MA@/````!`!]``P`!`#_`"0)#P`` M``0```(.```````P```````$````"`(0`````````/\````````!#P`(`A`` M`0````,`_P````````$/``@"$``"`````P#_`````````0\`"`(0``,````# M`/\````````!#P`(`A``!`````,`_P````````$/``@"$``%`````P#_```` M`````0\`"`(0``8````#`/\````````!#P`(`A``!P````,`_P````````$/ M``@"$``(`````P#_`````````0\`"`(0``D````#`/\````````!#P`(`A`` M"@````,`_P````````$/``@"$``+`````P#_`````````0\`"`(0``P````# M`/\````````!#P`(`A``#0````,`_P````````$/``@"$``.`````P#_```` M`````0\`"`(0``\````#`/\````````!#P`(`A``$`````,`_P````````$/ M``@"$``1`````P#_`````````0\`"`(0`!(````#`/\````````!#P`(`A`` M$P````,`_P````````$/``@"$``4`````P#_`````````0\`"`(0`!4````# M`/\````````!#P`(`A``%@````,`_P````````$/``@"$``7`````P#_```` M`````0\`"`(0`!@````#`/\````````!#P`(`A``&0````,`_P````````$/ M``@"$``:`````P#_`````````0\`"`(0`!L````#`/\````````!#P`(`A`` M'`````,`_P````````$/``@"$``=`````P#_`````````0\`"`(0`!X````# M`/\````````!#P`(`A``'P````,`_P````````$/`/T`"@``````%P!B```` M_0`*``$````7`!P```#]``H``0`!`!<``@```/T`"@`!``(`%P!-````_0`* M``$``P`7`$X```#]``H``@```!@`8P```+T`&``"``$`'`#@P>1`'`#@)N5` M'`#`,N-``P#]``H``P```!@`7````+T`&``#``$`'0``]<=`'0"`2LE`'0`` MJ,1``P#]``H`!````!@`9````+T`&``$``$`'0``S[3`'0``H+/`'0``/K+` M`P#]``H`!0```!@`90```+T`&``%``$`'0``Z)5`'0``"*%`'0``#J)``P#] M``H`!@```!@`9@```+T`&``&``$`'0````!`'0``````'0```")``P#]``H` M!P```!@`9P```+T`&``'``$`'0``I*#`'0``^[G`'0``Y[7``P#]``H`"``` M`!@`:````'X""@`(``,`'0```#/`_0`*``D````8`&D```!^`@H`"0`!`!T` M`(!`P'X""@`)``,`'0```#C`_0`*``H````8`&H```"]`!@`"@`!`!T``$R5 M0!T``(:CP!T``)"(0`,`_0`*``L````8`&L```"]`!@`"P`!`!T``(!+P!T` M`(!-P!T````W0`,`_0`*``P````8`&P```"]`!@`#``!`!T``*B!0!T``#B= MP!T``/"$0`,`_0`*``T````8`&T```"]`!@`#0`!`!X````X0!X``,!D0!X` M``!+P`,`_0`*``X````8`&X```"]`!@`#@`!`!T`@+/H0!T`X,'D0!T`X";E M0`,`_0`*``\````C`&\```"^``P`#P`!`"0`)``D``,`_0`*`!`````8`&,` M``"]`!@`$``!`!T`8/+N0!T``/[J0!T`0!'H0`,`_0`*`!$````8`%P```"] M`!@`$0`!`!T``/7'0!T`@$K)0!T``*C$0`,`_0`*`!(````8`&0```"]`!@` M$@`!`!T``,^TP!T``*"SP!T``#ZRP`,`_0`*`!,````8`&4```"]`!@`$P`! M`!T````Y0!T``.!E0!T``&!@0`,`_0`*`!0````8`&8```"]`!@`%``!`!T` M```0P!T```#POQT````0P`,`_0`*`!4````8`&@```!^`@H`%0`#`!T````S MP/T`"@`6````&`!I````?@(*`!8``0`=``"`0,!^`@H`%@`#`!T````XP/T` M"@`7````&`!N````O0`8`!<``0`=`"`J\4`=`&#R[D`=``#^ZD`#`/T`"@`8 M````(P!P````O@`,`!@``0`D`"0`)``#`/T`"@`9````&`!C````O0`8`!D` M`0`=``!;L\`=``"HA<`=``",H,`#`/T`"@`:````&`!J````O0`8`!H``0`= M``!,E4`=``"&H\`=``"0B$`#`/T`"@`;````&`!K````O0`8`!L``0`=``"` M2\`=``"`3<`=````-T`#`/T`"@`<````&`!L````O0`8`!P``0`=``"H@4`= M```XG<`=``#PA$`#`/T`"@`=````&`!M````O0`8`!T``0`>````.$`>``#` M9$`>````2\`#`/T`"@`>````&`!N````O0`8`!X``0`=``#DI\`=``!;L\`= M``"HA<`#`/T`"@`?````(P!Q````O@`,`!\``0`D`"0`)``#`-<`1`!R!P`` M;`(.`#@`*@`J`"H`*@`J`"H`'``J`"H`*@`J`"H`*@`>`"H`*@`J`"H`*@`< M`"H`*@`>`"H`*@`J`"H`*@`J``@"$``@`````P#_`````````0\`"`(0`"$` M```#`/\````````!#P`(`A``(@````,`_P````````$/``@"$``C`````P#_ M`````````0\`"`(0`"0````#`/\````````!#P`(`A``)0````,`_P`````` M``$/``@"$``F`````P#_`````````0\`"`(0`"<````#`/\````````!#P`( M`A``*`````,`_P````````$/``@"$``I`````P#_`````````0\`"`(0`"H` M```#`/\````````!#P`(`A``*P````,`_P````````$/``@"$``L`````P#_ M`````````0\`"`(0`"T````#`/\````````!#P`(`A``+@````,`_P`````` M``$/``@"$``O`````P#_`````````0\`_0`*`"`````8`&,```"]`!@`(``! M`!T``&"H0!T``&"H0!T``&"H0`,`_0`*`"$````8`&X```"]`!@`(0`!`!T` M`&"H0!T``&"H0!T``&"H0`,`_0`*`"(````C`'(```"^``P`(@`!`"0`)``D M``,`_0`*`",````8`&,```"]`!@`(P`!`!T`0);2P!T``!K,P!T``&_%P`,` M_0`*`"0````8`&4```"]`!@`)``!`!T``(250!T``%2?0!T```BA0`,`_0`* M`"4````8`&8```"]`!@`)0`!`!T````80!T```#P/QT````J0`,`_0`*`"8` M```8`&<```"]`!@`)@`!`!T``*2@P!T``/NYP!T``.>UP`,`_0`*`"<````8 M`&X```"]`!@`)P`!`!T``%'3P!T`0);2P!T``!K,P`,`_0`*`"@````C`',` M``"^``P`*``!`"0`)``D``,`_0`*`"D````8`%P```"]`!@`*0`!`!T``/7' M0!T`@$K)0!T``*C$0`,`_0`*`"H````8`&H```"]`!@`*@`!`!T``$R50!T` M`(:CP!T``)"(0`,`_0`*`"L````8`&L```"]`!@`*P`!`!T``(!+P!T``(!- MP!T````W0`,`_0`*`"P````8`&P```"]`!@`+``!`!T``*B!0!T``#B=P!T` M`/"$0`,`_0`*`"T````8`&T```"]`!@`+0`!`!X````X0!X``,!D0!X```!+ MP`,`_0`*`"X````8`'0````!`@8`+@`!`"(`O0`2`"X``@`>````.\`>```` M%,`#`/T`"@`O````&`!U````O0`8`"\``0`?`("IRT`?``#JP$`?``!NQT`# M`-<`)`#,`P``+`$J`"H`'@`J`"H`*@`J`"H`'@`J`"H`*@`J`"H`+@`^`A(` MM@``````0```````````````H``$`&0`9``=``\``P````````$````````` M[P`&````-P````H````)"!````80`$88S0?!@```!@(```L"&``````````` M`#$`````````OA`"`-`4`@`-``(``0`,``(`9``/``(``0`1``(````0``@` M_*GQTDUB4#]?``(``0`J``(````K``(```""``(``0"```@````````````E M`@0```#_`($``@#!!!0````5````@P`"````A``"````H0`B``D`9``!``$` M`0!&`%@"6`(```````#@/P```````.`_`0!5``(`"`!]``P``````+8\#P`` M``0`?0`,``$``P"V&`\````$`'T`#``$`/\`)`D/````!````@X``````#$` M``````0````(`A``````````_P````````$/``@"$``!`````P#_```````` M`0\`"`(0``(``````/\````````!#P`(`A```P````,`_P````````$/``@" M$``$``````#_`````````0\`"`(0``4````#`/\````````!#P`(`A``!@`` M``,`_P````````$/``@"$``'`````P#_`````````0\`"`(0``@````#`/\` M```````!#P`(`A``"0````,`_P````````$/``@"$``*`````P#_```````` M`0\`"`(0``L``````/\````````!#P`(`A``#`````,`_P````````$/``@" M$``-`````P#_`````````0\`"`(0``X````#`/\````````!#P`(`A``#P`` M``,`_P````````$/``@"$``0`````P#_`````````0\`"`(0`!$````#`/\` M```````!#P`(`A``$@``````_P````````$/``@"$``3`````P#_```````` M`0\`"`(0`!0````#`/\````````!#P`(`A``%0````,`_P````````$/``@" M$``6`````P#_`````````0\`"`(0`!<````#`/\````````!#P`(`A``&``` M``,`_P````````$/``@"$``9`````P#_`````````0\`"`(0`!H``````/\` M```````!#P`(`A``&P````,`_P````````$/``@"$``<`````P#_```````` M`0\`"`(0`!T````#`/\````````!#P`(`A``'@````,`_P````````$/``@" M$``?`````P#_`````````0\`_0`*```````7`'8```#]``H``0```!<`'``` M`/T`"@`!``$`%P`"````_0`*``$``@`7`$T```#]``H``0`#`!<`3@```/T` M"@`"````%@!W````_0`*``,````8`%P```"]`!@``P`!`!P``/7'0!P`@$K) M0!P``*C$0`,`_0`*``0````6`'@```#]``H`!0```!@`>0```+T`&``%``$` M'0``K*5`'0``(*9`'0``LJ5``P#]``H`!@```!@`>@```+T`&``&``$`'0`` MH(-`'0``F(-`'0``T(5``P#]``H`!P```!@`>P```+T`&``'``$`'0`````` M'0``H&9`'0``.(E``P#]``H`"````!@`?````+T`&``(``$`'0``````'0`` M````'0``,(5``P#]``H`"0```!@`?0```+T`&``)``$`'0``0'O`'0```#9` M'0``B)O``P#]``H`"@```!@`?@```+T`&``*``$`'0```$U`'0``@%5`'0`` M`#9``P#]``H`"P```!8`?P```/T`"@`,````&`"`````O0`8``P``0`=``!0 M?$`=````A\`=````>L`#`/T`"@`-````&`"!````O0`8``T``0`=``#`5T`= M``!`6<`=````+$`#`/T`"@`.````&`""````O0`8``X``0`=``"P?\`=```` M<<`=``"DI$`#`/T`"@`/````&`"#````O0`8``\``0`=``#DDD`=````F<`= M``"HF,`#`/T`"@`0````&`"$````O0`8`!```0`>````/T`>``#`CD`>``"@ M@4`#`/T`"@`1````&`"%````O0`8`!$``0`>`,`NT$`>```^S4`>``!7S4`# M`/T`"@`2````%@"&````_0`*`!,````8`(<```"]`!@`$P`!`!T``'JBP!T` M`/2GP!T``/RFP`,`_0`*`!0````8`(@```"]`!@`%``!`!T``$!C0!T``(B( M0!T``)!\0`,`_0`*`!4````8`(D```"]`!@`%0`!`!T``$RCP!T``/B2P!T` M`+"5P`,`_0`*`!8````8`(H```"]`!@`%@`!`!T``)S#P!T``*BLP!T`@-W" MP`,`_0`*`!<````8`(L```"]`!@`%P`!`!T``$"\0!T``.:G0!T``#2_0`,` M_0`*`!@````8`(P```"]`!@`&``!`!X``$!;P!X``,!4P!X```!WP`,`_0`* M`!D````8`(T```"]`!@`&0`!`!X``*Z]P!X``%NPP!X``!BWP`,`_0`*`!H` M```6`(X```#]``H`&P```!@`CP```+T`&``;``$`'0``S[3`'0``H+/`'0`` M/K+``P#]``H`'````!@`9P```+T`&``<``$`'0``I*#`'0``^[G`'0``Y[7` M`P#]``H`'0```!@`D````+T`&``=``$`'0``AL)`'0``=\!`'0"`*M-``P#] M``H`'@```!@`D0```+T`&``>``$`'0``A[K`'0``E[S`'0#`+M7``P#]``H` M'P```!@`D@```+T`&``?``$`'0```")`'0``F)E`'0``[+-``P#7`$0`)@<` M`&P"#@`X``X`*@`.`"H`*@`J`"H`*@`J``X`*@`J`"H`*@`J`"H`#@`J`"H` M*@`J`"H`*@`J``X`*@`J`"H`*@`(`A``(`````,`_P````````$/``@"$``A M`````P#_`````````0\`"`(0`"(````#`/\````````!#P`(`A``(P````,` M_P````````$/``@"$``D`````P#_`````````0\`"`(0`"4````#`/\````` M```!#P`(`A``)@````,`_P````````$/``@"$``G``````#_`````````0\` M"`(0`"@````#`/\````````!#P`(`A``*0````,`_P````````$/``@"$``J M``````#_`````````0\`"`(0`"L````#`/\````````!#P`(`A``+`````,` M_P````````$/``@"$``M``````#_`````````0\`"`(0`"X````#`/\````` M```!#P`(`A``+P````,`_P````````$/``@"$``P`````P#_`````````0\` M_0`*`"`````8`),```"]`!@`(``!`!T``&!KP!T````XP!T````RP`,`_0`* M`"$````8`)0```"]`!@`(0`!`!X``)"+0!X``#B70!X``&B80`,`_0`*`"(` M```8`)4```"]`!@`(@`!`!X``/BOP!X``"B]P!X``$*VP`,`_0`*`",````8 M`)8```"]`!@`(P`!`!X``"!D0!X``#!TP!X``#!Q0`,`_0`*`"0````8`)<` M``"]`!@`)``!`!T``+*S0!T``&RG0!T``,ZL0`,`_0`*`"4````8`)@```"] M`!@`)0`!`!T```C%0!T``%J^0!T``.:O0`,`_0`*`"8````8`)D```"]`!@` M)@`!`!T``.'.0!T```C%0!T``%J^0`,`_0`*`"<````6`)H```#]``H`*``` M`!@`FP```+T`&``H``$`'0``J(!`'0``:(!`'0``H'-``P#]``H`*0```!@` MG````+T`&``I``$`'0``=J)`'0``R*]`'0```[!``P#]``H`*@```!8`G0`` M`/T`"@`K````&`">````O0`8`"L``0`=``#H@$`=``"(@D`=```0AT`#`/T` M"@`L````&`"?````O0`8`"P``0`=`````$`=```````=````(D`#`/T`"@`M M````%@"@````_0`*`"X````8`*$```"]`!@`+@`!`!T``"*J0!T``,"40!T` M`%"90`,`_0`*`"\````8`*(```"]`!@`+P`!`!X``%B+P!X``(! XML 58 R25.xml IDEA: Selected Quarterly Financial Data (unaudited) 1.0.0.3 false Selected Quarterly Financial Data (unaudited) false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 us-gaap_SelectedQuarterlyFinancialInformationAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false No definition available. false 3 1 us-gaap_QuarterlyFinancialInformationTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 19 - us-gaap:QuarterlyFinancialInformationTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>19. Selected Quarterly Financial Data (unaudited)</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Selected unaudited quarterly financial data for the years 2009 and 2008 are summarized below: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="20%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="14" style="border-bottom: 1px solid #000000"><b>2009</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="14" style="border-bottom: 1px solid #000000"><b>2008</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>First</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Second</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Third</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Fourth</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>First</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Second</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Third</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Fourth</b></td> <td>&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>(Dollars in Millions Except Per Share Data)</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Quarter</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Quarter</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Quarter</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Quarter</b></td> <td nowrap="nowrap"><sup style="font-size: 85%; vertical-align: text-top"><b>(1)</b></sup></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Quarter</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Quarter</b></td> <td nowrap="nowrap"><sup style="font-size: 85%; vertical-align: text-top"><b>(2)</b></sup></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Quarter</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Quarter</b></td> <td nowrap="nowrap"><sup style="font-size: 85%; vertical-align: text-top"><b>(3)</b></sup></td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="31" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Segment sales to customers </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Consumer </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">3,711</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,854</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,989</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,249</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,064</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,036</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,099</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,855</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Pharmaceutical </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,780</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,498</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,249</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,993</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,429</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,340</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,113</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,685</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Med Devices &#038; Diagnostics </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,535</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,887</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,843</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,309</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,701</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,074</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,709</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">5,642</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="31" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Total sales </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">15,026</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15,239</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15,081</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">16,551</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">16,194</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">16,450</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15,921</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">15,182</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="31" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Gross profit </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">10,775</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10,789</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10,647</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">11,239</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">11,580</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">11,699</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">11,147</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10,810</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Earnings before provision for taxes on income </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,643</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,263</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,245</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,604</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,747</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,375</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,290</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,517</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Net earnings </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,507</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,208</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,345</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,206</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,598</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,327</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,310</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,714</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="31" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Basic net earnings per share </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">1.27</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.16</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.21</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.80</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.27</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.18</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.19</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.98</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="31" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Diluted net earnings per share </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">1.26</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.15</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.20</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.79</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.26</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.17</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1.17</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.97</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td>&#160;</td> <td>&#160;</td> <td colspan="31" align="left" style="border-top: 3px double #000000">&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(1)</i></sup></td> <td>&#160;</td> <td><i>The fourth quarter of 2009 includes an after-tax charge of $852&#160;million for restructuring and $212&#160;million after-tax of income from net litigation.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(2)</i></sup></td> <td>&#160;</td> <td><i>The second quarter of 2008 includes an after-tax charge of $40&#160;million for IPR&#038;D.</i></td> </tr> <tr style="font-size: 3pt"> <td>&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><sup style="font-size: 85%; vertical-align: text-top"><i>(3)</i></sup></td> <td>&#160;</td> <td><i>The fourth quarter of 2008 includes an after-tax charge of $141&#160;million for IPR&#038;D, $229&#160;million after-tax of income from net litigation and $331&#160;million after-tax gain on the divestiture of the Professional Wound Care business of Ethicon, Inc. The gain from the divestiture of the Professional Wound Care business of Ethicon, Inc. was reinvested in the business.</i></td> </tr> </table> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 59 R7.xml IDEA: Summary of Significant Accounting Policies 1.0.0.3 false Summary of Significant Accounting Policies false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract us-gaap true na duration string No definition available. false false false false false true false false false 1 false false 0 0 false false No definition available. false 3 1 us-gaap_SignificantAccountingPoliciesTextBlock us-gaap true na duration string No definition available. false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 1 - us-gaap:SignificantAccountingPoliciesTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <!-- xbrl,ns --> <div align="left"> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"><b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>1. Summary of Significant Accounting Policies</b> </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>PRINCIPLES OF CONSOLIDATION</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The consolidated financial statements include the accounts of Johnson &#038; Johnson and subsidiaries (the &#8220;Company&#8221;). Inter-company accounts and transactions are eliminated. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>DESCRIPTION OF THE COMPANY AND BUSINESS SEGMENTS</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company has approximately 115,500 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment manufactures and markets a broad range of products used in the baby care, skin care, oral care, wound care and women&#8217;s health care fields, as well as nutritional and over-the-counter pharmaceutical products. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world. The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. These products are distributed directly to retailers, wholesalers and health care professionals for prescription use. The Medical Devices and Diagnostics segment includes a broad range of products used principally in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. These products include Cordis&#8217; circulatory disease management products; DePuy&#8217;s orthopaedic joint reconstruction, spinal care and sports medicine products; Ethicon&#8217;s surgical care, aesthetics and women&#8217;s health products; Ethicon Endo-Surgery&#8217;s minimally invasive surgical products; LifeScan&#8217;s blood glucose monitoring and insulin delivery products; Ortho-Clinical Diagnostics&#8217; professional diagnostic products and Vistakon&#8217;s disposable contact lenses. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>NEW ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">During the fiscal fourth quarter of 2009, in accordance with U.S. GAAP, the Company adopted the authoritative guidance for employers&#8217; disclosures about postretirement benefit plan assets to enhance the disclosure regarding the types of assets and associated risks in an employer&#8217;s defined benefit pension or other postretirement plan, as well as, events in the economy and markets that could have a significant effect on the value of the plan assets. The adoption of this standard did not have a material impact on the Company&#8217;s results of operations, cash flows or financial position. See Note 10 for enhanced disclosures. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During the fiscal third quarter of 2009, the Company adopted <i>The FASB Accounting Standards Codification</i><sup style="font-size: 85%; vertical-align: text-top"><i>TM </i></sup><i>(ASC or Codification) and the Hierarchy of Generally Accepted Accounting Principles (GAAP) </i>which establishes the Codification as the sole source for authoritative U.S. GAAP and will supersede all accounting standards in U.S. GAAP, aside from those issued by the SEC. The adoption of the Codification did not have an impact on the Company&#8217;s results of operations, cash flows or financial position. Since the adoption of the Accounting Standards Codification (ASC)&#160;the Company&#8217;s notes to the consolidated financial statements will no longer make reference to Statement of Financial Accounting Standards (SFAS)&#160;or other U.S. GAAP pronouncements. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During the fiscal second quarter of 2009, in accordance with U.S. GAAP, the Company adopted the standards on subsequent events. This pronouncement establishes standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued. See Note 23 for related disclosure. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During the fiscal first quarter of 2009, in accordance with U.S. GAAP, the Company adopted the standards on business combinations and non-controlling interests in Consolidated Financial Statements. These standards aim to improve, simplify, and converge internationally, the accounting for business combinations and the reporting of non-controlling interests in consolidated financial statements. These standards have an impact on the manner in which the Company accounts for acquisitions beginning in the fiscal year 2009. Significant changes include the capitalization of purchased in-process research and development (IPR&#038;D), expensing of acquisition related restructuring actions and transaction related costs and the recognition of contingent purchase price consideration at fair value at the acquisition date. In addition, changes in accounting for deferred tax asset valuation allowances and acquired income tax uncertainties after the measurement period will be recognized in earnings rather than as an adjustment to the cost of acquisition. This accounting treatment for taxes is applicable to acquisitions that occurred both prior and subsequent to the adoption of the standard. Operating profit attributable to non-controlling interests is reported in Other (Income) Expense, net and the related tax impact to the Provision for Taxes. Additionally, equity attributable to non-controlling interests is recorded in Other Non-Current liabilities. Non-controlling interests as related to the Company&#8217;s financial statements are immaterial and therefore, not separately disclosed. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During the fiscal first quarter of 2009, in accordance with U.S. GAAP, the Company adopted the standard related to disclosures about derivative instruments and hedging activities, which enhanced the disclosure regarding the Company&#8217;s derivative and hedging activities. The adoption of this standard did not have a material impact on the Company&#8217;s results of operations, cash flows or financial position. See Note 6 for enhanced disclosures. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During the fiscal first quarter of 2009, in accordance with U.S. GAAP, the Company adopted the standard on collaborative arrangements related to the development and commercialization of intellectual property. This standard addresses the income statement classification of payments made between parties in a collaborative arrangement. The impact of the adoption of this standard related to all collaboration agreements that existed as of January&#160;3, 2010 and December&#160;28, 2008 was immaterial to the Company&#8217;s results of operations, cash flows or financial position. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;During the fiscal first quarter of 2009, in accordance with U.S. GAAP, the Company adopted the standard related to defensive intangible assets. This standard applies to acquired intangible assets in situations in which an entity does not intend to actively use the asset but intends to hold the asset to prevent others from obtaining access to the asset, except for intangible assets that are used in research and development activities. The adoption of this standard did not have a material impact on the Company&#8217;s results of operations, cash flows or financial position. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>RECENTLY ISSUED ACCOUNTING STANDARDS, NOT ADOPTED AS OF JANUARY 3, 2010</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The FASB issued guidance and amendments to the criteria for separating consideration in multiple-deliverable revenue arrangements. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The guidance and amendments are expected to: (a)&#160;provide principles and application guidance on whether multiple deliverables exist, how the arrangement should be separated, and the consideration allocated; (b)&#160;require an entity to allocate revenue in an arrangement using estimated selling prices of deliverables if a vendor does not have vendor-specific objective evidence or third-party evidence of selling price; and (c)&#160;eliminate the use of the residual method and require an entity to allocate the revenue using the relative selling price method. The guidance significantly expands the disclosure requirements for multiple-deliverable revenue arrangements. This guidance is effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June&#160;15, 2010. Early adoption is permitted. The Company adopted this guidance in the first fiscal quarter of 2010. The adoption will not have a material impact on the Company&#8217;s results of operations, cash flows or financial position; however, it will expand the disclosures for such arrangements. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The FASB issued a standard to improve financial reporting by enterprises involved with variable interest entities. This statement is effective for the Company beginning with the fiscal year 2010. Earlier application is prohibited. The adoption of this standard will not have a material impact on the Company&#8217;s results of operations, cash flows or financial position. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>CASH EQUIVALENTS</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company considers securities with maturities of three months or less, when purchased, to be cash equivalents. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>INVESTMENTS</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Short-term marketable securities are carried at cost, which approximates fair value. Investments classified as available-for-sale are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Long-term debt securities that the Company has the ability and intent to hold until maturity are carried at amortized cost. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company periodically reviews its investments in equity securities for impairment and adjusts these investments to their fair value when a decline in market value is deemed to be other than temporary. If losses on these securities are considered to be other than temporary, the loss is recognized in earnings. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>PROPERTY, PLANT AND EQUIPMENT AND DEPRECIATION</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="88%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Building and building equipment </div></td> <td>&#160;</td> <td colspan="3" valign="top" align="right" nowrap="nowrap">20-40 years</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Land and leasehold improvements </div></td> <td>&#160;</td> <td colspan="3" valign="top" align="right" nowrap="nowrap">10-20 years</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Machinery and equipment </div></td> <td>&#160;</td> <td colspan="3" valign="top" align="right" nowrap="nowrap">2-13 years</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8&#160;years. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset&#8217;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>REVENUE RECOGNITION</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company recognizes revenue from product sales when the goods are shipped or delivered and title and risk of loss pass to the customer. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates, the largest being the Medicaid rebate provision, are estimated based on contractual terms, historical experience, trend analysis and projected market conditions in the various markets served. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Sales returns are generally estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals. Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company&#8217;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#8217;s sales return reserves are accounted for in accordance with U.S. GAAP guidance regarding revenue recognition when right of return exists. Sales return reserves are recorded at full sales value. Sales returns in the Consumer and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices and Diagnostics segment are typically resalable but are not material. The Company rarely exchanges products from inventory for returned products. The sales returns reserve for the total Company has ranged between 1.1% and 1.2% of annual net trade sales during the prior three fiscal reporting years 2007-2009. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the year incurred. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. The Company also earns service revenue for co-promotion of certain products and includes it in sales to customers. These arrangements are evaluated to determine the appropriate amounts to be deferred. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>SHIPPING AND HANDLING</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Shipping and handling costs incurred were $964&#160;million, $1,017&#160;million and $934&#160;million in 2009, 2008 and 2007, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>INVENTORIES</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Inventories are stated at the lower of cost or market determined by the first-in, first-out method. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>INTANGIBLE ASSETS AND GOODWILL</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The authoritative literature on U.S. GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed the annual impairment test for 2009 in the fiscal fourth quarter and no impairment was determined. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if a triggering event occurs. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions. See Note 5 for further details on Intangible Assets and Goodwill. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>FINANCIAL INSTRUMENTS</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">As required by U.S. GAAP all derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#8217;s impact on the Company&#8217;s financial performance; (2)&#160;protect the Company&#8217;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note 6 for additional information on Financial Instruments. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>PRODUCT LIABILITY</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Accruals for product liability claims are recorded, on an undis-counted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information. The accruals are adjusted periodically as additional information becomes available. As a result of cost and availability factors, effective November&#160;1, 2005, the Company ceased purchasing third-party product liability insurance. Based on the availability of prior coverage, receivables for insurance recoveries related to product liability claims are recorded on an undiscounted basis, when it is probable that a recovery will be realized. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>RESEARCH AND DEVELOPMENT</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Research and development expenses are expensed as incurred. Upfront and milestone payments made to third-parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third-parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#8217;s operations. In general, the income statement presentation for these collaborations is as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="88%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> <td width="5%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Nature/Type of Collaboration</b></td> <td>&#160;</td> <td nowrap="nowrap" align="right" colspan="2"><b>Statement of Earnings Presentation</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr style="font-size: 1px"> <td colspan="5" align="left" style="border-top: 1px solid #000000">&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Third-party sale of product </div></td> <td>&#160;</td> <td colspan="3" align="right">Sales to customers</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Royalties/milestones paid to collaborative partner (post-regulatory approval)* </div></td> <td>&#160;</td> <td colspan="3" align="right">Cost of goods sold</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Royalties received from collaborative partner </div></td> <td>&#160;</td> <td colspan="3" align="right">Other income (expense), net</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Upfront payments &#038; milestones paid to collaborative partner (pre-regulatory approval) </div></td> <td>&#160;</td> <td colspan="3" align="right">Research expense</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Research and development payments to collaborative partner </div></td> <td>&#160;</td> <td colspan="3" align="right">Research expense</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Research and development payments received from collaborative partner </div></td> <td>&#160;</td> <td colspan="3" nowrap="nowrap" align="right">Reduction of Research expense</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td width="1%"></td> <td width="1%"></td> <td width="98"></td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left"><i>*</i></td> <td>&#160;</td> <td><i>Milestones are capitalized as intangible assets and amortized to cost of goods sold over the useful life.</i></td> </tr> </table> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>ADVERTISING</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Costs associated with advertising are expensed in the year incurred and are included in the selling, marketing and administrative expenses. Advertising expenses worldwide, which are comprised of television, radio, print media and Internet advertising, were $2.4&#160;billion in 2009, $2.9&#160;billion in 2008 and $2.7&#160;billion in 2007. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>INCOME TAXES</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company intends to continue to reinvest its undistributed international earnings to expand its international operations; therefore, no U.S. tax expense has been recorded with respect to the undistributed portion not intended for repatriation. At January&#160;3, 2010 and December&#160;28, 2008, the cumulative amount of undistributed international earnings were approximately $32.2&#160;billion and $27.7&#160;billion, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">&#160;&#160;&#160;&#160;&#160;Deferred income taxes are recognized for tax consequences of temporary differences by applying enacted statutory tax rates, applicable to future years, to differences between the financial reporting and the tax basis of existing assets and liabilities. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>NET EARNINGS PER SHARE</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>USE OF ESTIMATES</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. For instance, in determining annual pension and post-employment benefit costs, the Company estimates the rate of return on plan assets, and the cost of future health care benefits. Actual results may or may not differ from those estimates. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>ANNUAL CLOSING DATE</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, as was the case in 2009 and will be the case again in 2014. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>RECLASSIFICATION</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Certain prior period amounts have been reclassified to conform to current year presentation. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false No definition available. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 60 R17.xml IDEA: Savings Plan 1.0.0.3 false Savings Plan false 1 $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 jnj_SavingsPlanAbstract jnj false na duration string Savings Plan false false false false false true false false false 1 false false 0 0 false false Savings Plan false 3 1 jnj_SavingsPlanTextBlock jnj false na duration string Savings Plan false false false false false false false false false 1 false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 11 - jnj:SavingsPlanTextBlock--> <div style="font-family: Helvetica,Arial,sans-serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>11. Savings Plan</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company has voluntary 401 (k)&#160;savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee&#8217;s contributions consistent with the provisions of the plan for which he/she is eligible. Total Company matching contributions to the plans were $163&#160;million, $166&#160;million and $169&#160;million in 2009, 2008 and 2007, respectively. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false Savings Plan No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true -----END PRIVACY-ENHANCED MESSAGE-----